<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Hypoxia‐inducible factor stabilisers for the anaemia of chronic kidney disease - Natale, P - 2022 | Cochrane Library</title> <meta content="Hypoxia‐inducible factor stabilisers for the anaemia of chronic kidney disease - Natale, P - 2022 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013751.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Hypoxia‐inducible factor stabilisers for the anaemia of chronic kidney disease - Natale, P - 2022 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013751.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD013751.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Hypoxia‐inducible factor stabilisers for the anaemia of chronic kidney disease" name="citation_title"/> <meta content="Patrizia Natale" name="citation_author"/> <meta content="Suetonia C Palmer" name="citation_author"/> <meta content="University of Otago Christchurch" name="citation_author_institution"/> <meta content="Allison Jaure" name="citation_author"/> <meta content="Elisabeth M Hodson" name="citation_author"/> <meta content="Marinella Ruospo" name="citation_author"/> <meta content="University of Bari" name="citation_author_institution"/> <meta content="Tess E Cooper" name="citation_author"/> <meta content="Deirdre Hahn" name="citation_author"/> <meta content="The Children's Hospital at Westmead" name="citation_author_institution"/> <meta content="Valeria M Saglimbene" name="citation_author"/> <meta content="Jonathan C Craig" name="citation_author"/> <meta content="Giovanni FM Strippoli" name="citation_author"/> <meta content="giovanni.strippoli@uniba.it" name="citation_author_email"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="8" name="citation_issue"/> <meta content="10.1002/14651858.CD013751.pub2" name="citation_doi"/> <meta content="2022" name="citation_date"/> <meta content="2022/08/25" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013751.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013751.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013751.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="*Anemia [drug therapy, etiology]; *Cardiovascular Diseases; Cause of Death; Fatigue; Hypoxia; Iron [therapeutic use]; *Renal Insufficiency, Chronic [therapy]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013751.pub2&amp;doi=10.1002/14651858.CD013751.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013751.pub2&amp;doi=10.1002/14651858.CD013751.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013751.pub2&amp;doi=10.1002/14651858.CD013751.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013751.pub2&amp;doi=10.1002/14651858.CD013751.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013751.pub2&amp;doi=10.1002/14651858.CD013751.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013751.pub2&amp;doi=10.1002/14651858.CD013751.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013751.pub2&amp;doi=10.1002/14651858.CD013751.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013751.pub2&amp;doi=10.1002/14651858.CD013751.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013751.pub2&amp;doi=10.1002/14651858.CD013751.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013751.pub2&amp;doi=10.1002/14651858.CD013751.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013751.pub2&amp;doi=10.1002/14651858.CD013751.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013751.pub2&amp;doi=10.1002/14651858.CD013751.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013751.pub2&amp;doi=10.1002/14651858.CD013751.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013751.pub2&amp;doi=10.1002/14651858.CD013751.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013751.pub2&amp;doi=10.1002/14651858.CD013751.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013751.pub2&amp;doi=10.1002/14651858.CD013751.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013751.pub2&amp;doi=10.1002/14651858.CD013751.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013751.pub2&amp;doi=10.1002/14651858.CD013751.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013751.pub2&amp;doi=10.1002/14651858.CD013751.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013751.pub2&amp;doi=10.1002/14651858.CD013751.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013751.pub2&amp;doi=10.1002/14651858.CD013751.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013751.pub2&amp;doi=10.1002/14651858.CD013751.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013751.pub2&amp;doi=10.1002/14651858.CD013751.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774054000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774081000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000"}};Liferay.authToken="na56WA6j";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD013751\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD013751\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013751\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013751\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1559916434000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANT","ko","pt","ms","hr","fa","fr"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD013751.pub2",title:"Hypoxia\\u2010inducible factor stabilisers for the anaemia of chronic kidney disease",firstPublishedDate:"Aug 25, 2022 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Kidney and Transplant Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738735355000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=na56WA6j&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD013751.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD013751.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD013751.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD013751.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD013751.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD013751.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD013751.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD013751.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD013751.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD013751.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;초록&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;쉬운 말 요약&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pt&quot;,&quot;title&quot;:&quot;Resumo para leigos&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;淺顯易懂的口語結論&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD013751.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD013751.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD013751.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD013751.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>4010 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD013751.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013751.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013751.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013751.pub2/full#CD013751-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013751.pub2/full#CD013751-sec-0119"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013751.pub2/full#CD013751-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013751.pub2/full#CD013751-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013751.pub2/full#CD013751-sec-0014"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013751.pub2/full#CD013751-sec-0015"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013751.pub2/full#CD013751-sec-0040"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013751.pub2/full#CD013751-sec-0113"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD013751.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013751.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013751.pub2/appendices#CD013751-sec-0124"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013751.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013751.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD013751.pub2/media/CDSR/CD013751/supinfo/CD013751StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD013751.pub2/media/CDSR/CD013751/supinfo/CD013751StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013751.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013751.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013751.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD013751.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD013751.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD013751.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2022 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD013751.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Hypoxia‐inducible factor stabilisers for the anaemia of chronic kidney disease</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013751.pub2/information#CD013751-cr-0004">Patrizia Natale</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013751.pub2/information#CD013751-cr-0005">Suetonia C Palmer</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013751.pub2/information#CD013751-cr-0006">Allison Jaure</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013751.pub2/information#CD013751-cr-0007">Elisabeth M Hodson</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013751.pub2/information#CD013751-cr-0008">Marinella Ruospo</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013751.pub2/information#CD013751-cr-0009">Tess E Cooper</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013751.pub2/information#CD013751-cr-0010">Deirdre Hahn</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013751.pub2/information#CD013751-cr-0011">Valeria M Saglimbene</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013751.pub2/information#CD013751-cr-0012">Jonathan C Craig</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013751.pub2/information#CD013751-cr-0013"><i class="icon corresponding-author fa fa-envelope"></i>Giovanni FM Strippoli</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD013751.pub2/information/en#CD013751-sec-0131">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 25 August 2022 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD013751.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD013751.pub2">https://doi.org/10.1002/14651858.CD013751.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD013751-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD013751-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD013751-abs-0013">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD013751-abs-0009">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD013751-abs-0011">Français</a> </li> <li class="section-language"> <a class="" href="full/ko#CD013751-abs-0004">한국어</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD013751-abs-0001" lang="en"> <section id="CD013751-sec-0001"> <h3 class="title" id="CD013751-sec-0001">Background</h3> <p>Anaemia occurs in chronic kidney disease (CKD) and is more prevalent with lower levels of kidney function. Anaemia in CKD is associated with death related to cardiovascular (CV) disease and infection. Established treatments include erythropoiesis‐stimulating agents (ESAs), iron supplementation and blood transfusions. Oral hypoxia‐inducible factors (HIF) stabilisers are now available to manage anaemia in people with CKD. </p> </section> <section id="CD013751-sec-0002"> <h3 class="title" id="CD013751-sec-0002">Objectives</h3> <p>We aimed to assess the benefits and potential harms of HIF stabilisers for the management of anaemia in people with CKD. </p> </section> <section id="CD013751-sec-0003"> <h3 class="title" id="CD013751-sec-0003">Search methods</h3> <p>We searched the Cochrane Kidney and Transplant Register of Studies up to 22 November 2021 through contact with the Information Specialist using search terms relevant to our review. Studies in the Register are identified through searches of CENTRAL, MEDLINE, EMBASE, conference proceedings, the International Clinical Trials Register (ICTRP) Search Portal, and ClinicalTrials.gov. </p> </section> <section id="CD013751-sec-0004"> <h3 class="title" id="CD013751-sec-0004">Selection criteria</h3> <p>Randomised and quasi‐randomised studies evaluating hypoxia‐inducible factors stabilisers compared to placebo, standard care, ESAs or iron supplementation in people with CKD were included. </p> </section> <section id="CD013751-sec-0005"> <h3 class="title" id="CD013751-sec-0005">Data collection and analysis</h3> <p>Five authors independently extracted data and assessed the risk of bias. Treatment estimates were summarised using random effects pair‐wise meta‐analysis and expressed as a relative risk (RR) or mean difference (MD), with a corresponding 95% confidence interval (CI). Evidence certainty was assessed using GRADE. </p> </section> <section id="CD013751-sec-0006"> <h3 class="title" id="CD013751-sec-0006">Main results</h3> <p>We included 51 studies randomising 30,994 adults. These studies compared HIF stabilisers to either placebo or an ESA. </p> <p>Compared to placebo, HIF stabiliser therapy had uncertain effects on CV death (10 studies, 1114 participants): RR 3.68, 95% CI 0.19 to 70.21; very low certainty evidence), and nonfatal myocardial infarction (MI) (3 studies, 822 participants): RR 1.29, 95% CI 0.31 to 5.36; I² = 0%; very low certainty evidence), probably decreases the proportion of patients requiring blood transfusion (8 studies, 4329 participants): RR 0.51, 95% CI 0.44 to 0.60; I² = 0%; moderate certainty evidence), and increases the proportion of patients reaching the target haemoglobin (Hb) (10 studies, 5102 participants): RR 8.36, 95% CI 6.42 to 10.89; I² = 37%; moderate certainty evidence). </p> <p>Compared to ESAs, HIF stabiliser therapy may make little or no difference to CV death (17 studies, 10,340 participants): RR 1.05, 95% CI 0.88 to 1.26; I² = 0%; low certainty evidence), nonfatal MI (7 studies, 7765 participants): RR 0.91, 95% CI 0.76 to 1.10; I² = 0%; low certainty evidence), and nonfatal stroke (5 studies, 7285 participants): RR 1.06, 95% CI 0.71 to 1.56; I² = 8%; low certainty evidence), and had uncertain effects on fatigue (2 studies, 3471 participants): RR 0.80, 95% CI 0.56 to 1.16; I² = 0%; very low certainty evidence). HIF stabiliser therapy probably decreased the proportion of patients requiring blood transfusion (11 studies, 10,786 participants): RR 0.87, 95% CI 0.76 to 1.00; I² = 25%; moderate certainty evidence), but may make little or no difference on the proportion of patients reaching the target Hb (14 studies, 4601 participants): RR 1.00, 95% CI 0.93 to 1.07; I² = 70%; low certainty evidence), compared to ESA. </p> <p>The effect of HIF stabilisers on hospitalisation for heart failure, peripheral arterial events, loss of unassisted dialysis vascular access patency, access intervention, cancer, infection, pulmonary hypertension and diabetic nephropathy was uncertain. </p> <p>None of the included studies reported life participation. Adverse events were rarely and inconsistently reported. </p> </section> <section id="CD013751-sec-0007"> <h3 class="title" id="CD013751-sec-0007">Authors' conclusions</h3> <p>HIF stabiliser management of anaemia had uncertain effects on CV death, fatigue, death (any cause), CV outcomes, and kidney failure compared to placebo or ESAs. Compared to placebo or ESAs, HIF stabiliser management of anaemia probably decreased the proportion of patients requiring blood transfusions, and probably increased the proportion of patients reaching the target Hb when compared to placebo. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD013751-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD013751-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD013751-abs-0014">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD013751-abs-0010">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD013751-abs-0012">Français</a> </li> <li class="section-language"> <a class="" href="full/hr#CD013751-abs-0008">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ko#CD013751-abs-0005">한국어</a> </li> <li class="section-language"> <a class="" href="full/ms#CD013751-abs-0007">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pt#CD013751-abs-0006">Português</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD013751-abs-0003">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD013751-abs-0002" lang="en"> <h3>Are hypoxia‐inducible factor stabilisers effective for management of anaemia among people with chronic kidney disease? </h3> <p><b>What is the issue?</b> </p> <p>Anaemia (reduced levels of circulating red blood cells) is common in people with chronic kidney disease (CKD). Anaemia is linked to cardiovascular disease, infection and death. Hypoxia‐inducible factors (HIF) stabilisers have now become available to manage anaemia and can be taken by mouth, thus avoiding injections. </p> <p><b>What did we do?</b> </p> <p>We evaluated whether HIF stabilisers are beneficial for children and adults with CKD to manage anaemia. We evaluated all clinical studies for hypoxia‐inducible factor stabilisers and summarised the results. We evaluated how certain we could be about the evidence related to hypoxia‐inducible factors stabiliser using a system called "GRADE". </p> <p><b>What did we find?</b> </p> <p>We included 51 studies randomising 30,994 adult patients. Patients in the studies were given a HIF stabiliser, a sugar pill (placebo), or erythropoietin treatment. The treatment they got was decided by random chance. The studies were generally short‐term (over a few weeks). There were no studies in children or people who had received a kidney transplant. </p> <p>HIF stabilisers decreased blood transfusions for people with CKD when compared to placebo or erythropoietin treatment. HIF stabilisers increased the number of patients reaching their haemoglobin target level when compared to placebo. HIF stabilisers have uncertain effects on life expectancy and the chance of heart disease in people with CKD. </p> <p><b>Conclusions</b> </p> <p>HIF stabilisers decreased the need for a blood transfusion for people with CKD and increased the number of patients reaching their haemoglobin target level. We are not sure whether hypoxia‐inducible factor stabilisers have any impact on life expectancy or life quality in people with CKD when compared to a placebo or other treatments for anaemia. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD013751-sec-0119" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD013751-sec-0119"></div> <h3 class="title" id="CD013751-sec-0120">Implications for practice</h3> <section id="CD013751-sec-0120"> <p>HIF stabilisers have uncertain effects on CV death, fatigue, death (any cause), nonfatal MI, nonfatal stroke, and kidney failure compared with placebo or ESA in people with CKD. HIF stabiliser management of anaemia probably decreases the proportion of patients requiring blood transfusion compared with placebo or ESA. HIF stabilisers probably increase the proportion of patients reaching their Hb target compared to placebo. There is scant evidence to inform decision‐making in children and kidney transplant recipients. Adverse events were rarely and inconsistently provided. </p> </section> <h3 class="title" id="CD013751-sec-0121">Implications for research</h3> <section id="CD013751-sec-0121"> <p>In the near future, well‐designed and adequately powered RCTs will be included to assess the benefits and harms of HIF stabilisers to treat anaemia in all stages of CKD, including people requiring any form of dialysis and kidney transplant recipients. The potential use of oral HIF stabilisers for anaemia may lead to higher compliance with the treatment in people with CKD and reduce the need for blood transfusion, although unwanted side effects could be a major concern in this population. Future real‐world experience studies will assess the effects of HIF stabiliser regimen on the progression of CKD, and blood pressure and define the proper dose in people with and without iron supplementation. Future studies will evaluate whether HIF stabiliser effects are dependent on the CKD stage. </p> <p>Our review has identified several ongoing and promising RCTs that could help to increase our knowledge and confidence in the findings, focusing on important outcomes, such as death and CV events. Further research is likely to change the estimated effects of treatments for anaemia in CKD and provide relevant information on HRQoL and patient‐reported outcomes (including life participation and fatigue). Larger studies should be conducted in PD to address specific outcomes related to this population, including PD infection and PD technique longevity. </p> <p>Future HIF stabiliser studies compared with standard care or iron supplementation will increase our certainty of the evidence based on the paucity of evidence in CKD. </p> <p>Evaluation of cost‐effectiveness for HIF stabilisers in the treatment of anaemia would assist decision‐making by policy‐makers and health care providers in this population. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD013751-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD013751-sec-0008"></div> <div class="table" id="CD013751-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Hypoxia‐inducible factor (HIF) stabilisers versus placebo for people with chronic kidney disease (CKD)</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>HIF stabilisers versus placebo for people with CKD</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population</b>: people with CKD (including HD and PD) </p> <p><b>Settings</b>: multinational </p> <p><b>Intervention</b>: HIF stabilisers </p> <p><b>Comparison</b>: placebo </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>No. of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>HIF stabilisers</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Cardiovascular death</b> </p> <p>Median follow‐up:</p> <p>16 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Low risk population (CKD)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 3.68</b> </p> <p>(0.19 to 70.21)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>1114 (10)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low</b><sup>1,2,3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Studies were not designed to measure effects of HIF stabiliser management of anaemia on CV death compared with placebo in CKD and HD </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>No events</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>3/607**</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>High risk population (HD)</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>No events</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>No events</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Fatigue</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No studies reported this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Life participation</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No studies reported this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Nonfatal myocardial</b> </p> <p><b>infarction</b> </p> <p>Median follow‐up:</p> <p>24 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Low risk population (CKD)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.29</b> </p> <p>(0.31 to</p> <p>5.36)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>822 (3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low</b><sup>1,2,4</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>The effects of HIF stabiliser management of anaemia on nonfatal MI were uncertain compared with placebo in CKD </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>8 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>2 more per 1000</b> </p> <p>(from 6 fewer</p> <p>to 35 more)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Nonfatal stroke</b> </p> <p>Median follow‐up:</p> <p>21 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Low risk population (CKD)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>228 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low</b><sup>1,2,4</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Studies were not designed to measure effects of HIF stabiliser management of anaemia on nonfatal stroke compared with placebo in CKD </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>No events</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>No events</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Proportion of patients requiring blood transfusion</b> </p> <p>Median follow‐up:</p> <p>18 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Low risk population (CKD)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.51</b> (0.44 to 0.60) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>4329 (8)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝<br/><b>moderate</b><sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>HIF stabiliser management of anaemia probably decreases the proportion of patients requiring blood transfusion compared to placebo in CKD and HD </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>200 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>96 fewer per 1000</b><br/>(from 112 fewer to 80 fewer) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>High risk population (HD)</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>214 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>169 fewer per 1000</b><br/>(206 fewer to 30 more) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Proportion reaching target haemoglobin</b> </p> <p>Median follow‐up:</p> <p>16 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Low risk population (CKD)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 8.36</b> (6.42 to 10.89) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>5102 (10)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝<br/><b>moderate</b><sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>HIF stabiliser management of anaemia probably increases the proportion of patients reaching their Hb target compared to placebo in CKD and HD </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>83 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>594 more per 1000</b><br/>(424 more to 821 more) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>High risk population (CKD and HD)</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>No events</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>63/141**</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p>** Event rate derived from the raw data. A 'per thousand' rate is non‐informative in view of the scarcity of evidence and zero events in the control group </p> <p><b>HD:</b> haemodialysis; <b>PD:</b> peritoneal dialysis; <b>CI</b> : confidence interval; <b>RR</b>: risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Evidence certainty was downgraded by one level due to study limitations. Some studies had unclear risks for sequence generation and/or allocation concealment and the majority or all of them were not blinded (participant/investigator and/or outcomes assessor). All studies reported sources of funding </p> <p><sup>2</sup> Evidence certainty was downgraded by one level due to imprecision </p> <p><sup>3</sup> Evidence certainty was downgraded by one level due to indirectness in the study population </p> <p><sup>4</sup> Evidence certainty was downgraded by one level due to imprecision (optimal information size was not met and the included studies reported zero events) </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD013751-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Hypoxia‐inducible factor (HIF) stabilisers versus erythropoiesis‐stimulating agent (ESA) for people with chronic kidney disease (CKD)</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>HIF stabilisers versus ESA for people with CKD</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population</b>: people with CKD (including HD and PD) </p> <p><b>Settings</b>: multinational </p> <p><b>Intervention</b>: HIF stabilisers </p> <p><b>Comparison</b>: ESA </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>No. of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>ESA</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>HIF stabilisers</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Cardiovascular death</b> </p> <p>Median follow‐up:</p> <p>28 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Low risk population (CKD)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 1.05</b> </p> <p>(0.88 to 1.26)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>10,340 (17)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/><b>low</b><sup>1,2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>HIF stabiliser management of anaemia may have little or no difference on CV death compared with ESA in CKD </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>34 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>6 more per 1000</b><br/>(from 3 fewer </p> <p>to 18 more)</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>High risk population (HD and PD)</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>77 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>3 fewer per 1000</b><br/>(from 19 fewer </p> <p>to 17 more)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Fatigue</b> </p> <p>Median follow‐up:</p> <p>57 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Low risk population (CKD)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.80</b> </p> <p>(0.56 to 1.16)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>3471 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low</b><sup>1,2,3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>HIF stabiliser management of anaemia had uncertain effects on fatigue compared with ESA in CKD </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>36 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>7 fewer per 1000</b><br/>(from 16 fewer </p> <p>to 6 more)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Life participation</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No studies reported this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Nonfatal</b> </p> <p><b>myocardial</b> </p> <p><b>infarction</b> </p> <p>Median follow‐up:</p> <p>26 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Low risk population (CKD)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.91</b> </p> <p>(0.76 to 1.10)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>7765 (7)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/><b>low</b><sup>1,2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>HIF stabiliser management of anaemia may have little or no difference on nonfatal MI compared with ESA in CKD, HD and PD </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>46 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>3 more per 1000</b><br/>(from 9 fewer </p> <p>to 18 more)</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>High risk population (HD and PD)</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>80 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>16 fewer per 1000</b><br/>(from 30 fewer to 2 more) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Nonfatal stroke</b> </p> <p>Median follow‐up:</p> <p>28 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Low risk population (CKD)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 1.06</b> </p> <p>(0.71 to 1.56)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>7285 (5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/><b>low</b><sup>1,2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>HIF stabiliser management of anaemia may have little or no difference on nonfatal stroke compared with ESA in CKD, HD and PD </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>10 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>5 more per 1000</b><br/>(from 1 fewer </p> <p>to 16 more)</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>High risk population (HD)</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>24 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>5 fewer per 1000</b><br/>(from 12 fewer to 8 more) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Proportion of patients requiring blood transfusion</b> </p> <p>Median follow‐up:</p> <p>52 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Low risk population (CKD)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.87</b> (0.76 to 1.00) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>10786 (11)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝<br/><b>moderate</b><sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>HIF stabiliser management of anaemia probably decreases the proportion of patients requiring blood transfusion compared to ESA in CKD, HD and PD </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>121 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>4 fewer per 1000</b><br/>(19 fewer to 16 more) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>High risk population (HD)</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>154 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>31 fewer per 1000</b><br/>(55 fewer to 2 more) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Proportion reaching target haemoglobin</b> </p> <p>Median follow‐up:</p> <p>27 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Low risk population (CKD)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 1.00</b> (0.93 to 1.07) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>4601 (14)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/><b>low</b><sup>1,2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>HIF stabiliser management of anaemia may have little or no difference on the proportion of patients reaching their Hb target compared to ESA in CKD, HD and PD </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>793 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>16 more per 1000</b><br/>(79 fewer to 127 more) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>High risk population (HD and PD)</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>540 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>11 fewer per 1000</b><br/>(49 fewer to 32 more) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% CI is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>HD:</b> haemodialysis; <b>PD:</b> peritoneal dialysis; <b>CI</b> : confidence interval; <b>RR</b>: risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Evidence certainty was downgraded by one level due to study limitations. Some studies had unclear risks for sequence generation and/or allocation concealment and the majority or all of them were not blinded (participant/investigator and/or outcomes assessor). All studies reported sources of funding </p> <p><sup>2</sup> Evidence certainty was downgraded by one level due to imprecision </p> <p><sup>3</sup> Evidence certainty was downgraded by one level because similar studies assessed the outcomes </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD013751-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD013751-sec-0009"></div> <section id="CD013751-sec-0010"> <h3 class="title" id="CD013751-sec-0010">Description of the condition</h3> <p>Chronic kidney disease (CKD), reduced kidney function or structural changes in kidney tissue lasting longer than three months, affects approximately 0.7 billion people globally with 20 million additional people affected each year (<a href="./references#CD013751-bbs2-0098" title="GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017 [Erratum in: Lancet. 2019 Jun 22;393(10190):e44]. Lancet2018;392(10159):1789-858. [MEDLINE: 30496104]">Global Burden of Disease 2017</a>). Reduced kidney function and raised levels of albumin in the urine are important risk factors for cardiovascular (CV) disease. CKD increases CV risk approximately two‐ to four‐fold in excess of traditional CV risk factors (<a href="./references#CD013751-bbs2-0096" title="GansevoortRT , Correa-RotterR , HemmelgarnBR , JafarTH , HeerspinkHJ , MannJF , et al. Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention. Lancet2013;382(9889):339-52. [MEDLINE: 23727170]">Gansevoort 2013</a>). CKD is associated with fatigue (<a href="./references#CD013751-bbs2-0110" title="MathiasSD , BlumSI , SikiricaV , JohansenKL , ColwellHH , OkoroT . Symptoms and impacts in anemia of chronic kidney disease. Journal of Patient-Reported Outcomes2020;4(1):64. [MEDLINE: 32728779]">Mathias 2020</a>) and lower quality of life (QoL), and incurred 61.3 million disability‐affected years worldwide in 2017 (<a href="./references#CD013751-bbs2-0097" title="GBD Chronic Kidney Disease Collaboration. Global, regional, and national burden of chronic kidney disease, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet2020;395(10225):709-33. [MEDLINE: 32061315]">GBD Kidney Disease 2017</a>; <a href="./references#CD013751-bbs2-0098" title="GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017 [Erratum in: Lancet. 2019 Jun 22;393(10190):e44]. Lancet2018;392(10159):1789-858. [MEDLINE: 30496104]">Global Burden of Disease 2017</a>; <a href="./references#CD013751-bbs2-0122" title="WyldML , MortonRL , CalytonP , WongMG , JardineM , PolkinghorneK , et al. The impact of progressive chronic kidney disease on health-related quality of life: A 12-year community cohort study. Quality of Life Research2019;28(8):2081-90. [MEDLINE: 30937731]">Wyld 2019</a>). </p> <p>Anaemia (reduced levels of circulating red blood cells (RBC)) occurs as a result of the progression of CKD due to impaired kidney erythropoietin secretion, lower absorption of iron, macrophage sequestration of iron by uraemic inflammation, and shortened RBC survival (<a href="./references#CD013751-bbs2-0092" title="BabittJL , LinHY . Mechanisms of anemia in CKD. Journal of the American Society of Nephrology2012;23(10):1631-4. [MEDLINE: 22935483]">Babitt 2012</a>). Anaemia is a critically important outcome for people with CKD (<a href="./references#CD013751-bbs2-0119" title="SONG Initiative. The SONG Handbook Version 1.0. www.songinitiative.org/reports-and-publications/2017.">SONG 2017</a>) and may worsen the impact of CKD on health‐related (HR) QoL including decreased work productivity (<a href="./references#CD013751-bbs2-0120" title="vanHaalenH , JacksonJ , SpinowitzB , MilliganG , MoonR . Impact of chronic kidney disease and anemia on health-related quality of life and work productivity: analysis of multinational real-world data. BMC Nephrology2020;21(1):88. [MEDLINE: 32143582]">van Haalen 2020</a>). Anaemia prevalence is higher at lower levels of kidney function, affecting one in five people with moderate CKD (estimated glomerular filtration rate (eGFR) 30 to 59 mL/min/1.73 m²) (<a href="./references#CD013751-bbs2-0094" title="El-AchkarTM , OhmitSE , McCulloghPA , CrookED , BrownWW , GrimmR , et al. Higher prevalence of anemia with diabetes mellitus in moderate kidney insufficiency: The Kidney Early Evaluation Program. Kidney International2005;67(4):1483-8. [MEDLINE: 15780101]">El‐Achkar 2005</a>). Anaemia in CKD is associated with increased death, including death related to CV disease and infection (<a href="./references#CD013751-bbs2-0109" title="MaJZ , EbbenJ , XiaH , CollinsAJ . Hematocrit level and associated mortality in hemodialysis patients. Journal of the American Society of Nephrology1999;10(3):610-9. [MEDLINE: 10073612]">Ma 1999</a>). </p> </section> <section id="CD013751-sec-0011"> <h3 class="title" id="CD013751-sec-0011">Description of the intervention</h3> <p>Treatments for anaemia caused by CKD include erythropoiesis‐stimulating agents (ESAs), iron supplementation and blood transfusion. Clinical practice guidelines suggest that iron deficiency is corrected prior to initiation of ESA therapy, minimising RBC transfusions especially to avoid allosensitization, except when rapid correction of anaemia is required (<a href="./references#CD013751-bbs2-0104" title="Kidney Disease: Improving Global Outcomes (KDIGO) Anemia Work Group. KDIGO clinical practice guideline for anemia in chronic kidney disease. Kidney International Supplements2012;2(4):279-335. [https://kdigo.org/wp-content/uploads/2016/10/KDIGO-2012-Anemia-Guideline-English.pdf]">KDIGO Clinical Practice Guideline Anemia 2012</a>). ESAs to target higher haemoglobin (Hb) levels (&gt; 130 g/L) in people with CKD increase the risk of death and adverse CV events (<a href="./references#CD013751-bbs2-0112" title="PhrommintikulA , HaasSJ , ElsikM , KrumH . Mortality and target haemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin: a meta-analysis. Lancet2007;369(9559):381-8. [MEDLINE: 17276778]">Phrommuntikul 2007</a>), leading to clinical practice guidance that suggests ESA therapy is used to avoid Hb concentrations below 90 g/L (<a href="./references#CD013751-bbs2-0104" title="Kidney Disease: Improving Global Outcomes (KDIGO) Anemia Work Group. KDIGO clinical practice guideline for anemia in chronic kidney disease. Kidney International Supplements2012;2(4):279-335. [https://kdigo.org/wp-content/uploads/2016/10/KDIGO-2012-Anemia-Guideline-English.pdf]">KDIGO Clinical Practice Guideline Anemia 2012</a>). Hypoxia‐inducible factors (HIF) are promising orally administered drugs to treat anaemia in people with CKD (<a href="./references#CD013751-bbs2-0101" title="HaaseVH . Hypoxia-inducible factor-prolyl hydroxylase inhibitors in the treatment of anemia of chronic kidney disease. Kidney Int Suppl (2011)2021;11(1):8-25. doi: 10.1016/j.kisu.2020.12.002.">Haase 2021</a>). </p> </section> <section id="CD013751-sec-0012"> <h3 class="title" id="CD013751-sec-0012">How the intervention might work</h3> <p>HIF are transcription factors present in cells formed through binding of HIF‐α and β subunits (<a href="./references#CD013751-bbs2-0118" title="SemenzaGL . Oxygen sensing, homeostasis, and disease [Erratum in: N Engl J Med. 2011 Sep 8;365(10):968]. New England Journal of Medicine2011;365(6):537-47. [MEDLINE: 21830968]">Semenza 2011</a>). The HIF‐β subunit is expressed constitutively, while the HIF‐α subunit is regulated through hydroxylation at proline residues by HIF‐prolyl‐hydroxylases. During tissue hypoxia, the HIF‐prolyl‐hydroxylase is inhibited, stabilising HIF‐1 and HIF‐2, which act to up‐regulate expression of many genes, including those that promote erythropoiesis and angiogenesis as well as metabolic processes. HIF stabilisers inhibit HIF‐prolyl‐hydroxylase activity and stimulate erythropoiesis in people with CKD (<a href="./references#CD013751-bbs2-0093" title="BernhardtWM , WiesenerMS , ScigallaP , ChouJ , SchmeiderRE , GünzlerV , et al. Inhibition of prolyl hydroxylases increases erythropoietin production in ESRD. Journal of the American Society of Nephrology2010;21(12):2151-6. [MEDLINE: 21115615]">Bernhardt 2010</a>). </p> <p>Oral HIF stabilisers correct anaemia in people with CKD in a dose‐dependent manner (<a href="./references#CD013751-bbs2-0113" title="ProvenzanoR , BesarabA , SunCH , DiamondSA , DurhamJH , CangianoJL , et al. Oral hypoxia-inducible factor prolyl hydroxylase inhibitor Roxadustat (FG-4592) for the treatment of anemia in patients with CKD. Clinical Journal of The American Society of Nephrology: CJASN2016;11(6):982-91. [MEDLINE: 27094610]">Provenzano 2016c</a>). HIF suppresses hepcidin production, which is the main regulator of systemic iron homeostasis (<a href="./references#CD013751-bbs2-0111" title="NemethE , GanzT . The role of hepcidin in iron metabolism. Acta Haematologica2009;122(2-3):78–86. [MEDLINE: 19907144]">Nemeth 2009</a>), enabling ferroportin stabilisation and promoting intestinal uptake and iron mobilisation from the reticuloendothelial system (<a href="./references#CD013751-bbs2-0108" title="LiuQ , DavidoffO , NissK , HaaseVH . Hypoxia-inducible factor regulates hepcidin via erythropoietin-induced erythropoiesis. Journal of Clinical Investigation2012;122(12):4635–44. [MEDLINE: 23114598]">Liu 2012</a>; <a href="./references#CD013751-bbs2-0114" title="RenassiaC , PeyssonnauxP . New insights into the links between hypoxia and iron homeostasis. Current Opinion in Hematology2019;26(3):125-30. [MEDLINE: 30855332]">Renassia 2019</a>; <a href="./references#CD013751-bbs2-0117" title="SchwartzAJ , DasNK , RamakrishnanSK , Jain C JurkovicMT , WuJ , et al. Hepatic hepcidin/intestinal HIF-2α axis maintains iron absorption during iron deficiency and overload. Journal of Clinical Investigation2019;129(1):336-48. [MEDLINE: 30352047]">Schwartz 2019</a>). Although HIF stabilisation has potentially pleiotropic cellular effects, changes is vascular endothelial growth factor (VEG‐F) have not been seen at doses used in randomised controlled trials (RCTs). Potential adverse consequences of HIF stabiliser treatment include tumour activity and angiogenesis (<a href="./references#CD013751-bbs2-0106" title="LaGoryEL , GiacciaAJ . The ever expanding role of HIF in tumour and stromal biology. Nature Cell Biology2016;18(4):356-65. [MEDLINE: 27027486]">LaGory 2016</a>). HIF stabilisers provide a potential oral therapy for sustained correction of anaemia in CKD, less dependent on iron (particularly intravenous (IV) supplementation. Although oral treatment adherence in a dialysis setting is still not clearly defined among nephrologists, oral HIF stabiliser therapy may be more acceptable to patients, including the potential to avoid the known adverse consequences of treatments with ESAs and blood transfusions. Several HIF stabilisers are available including roxadustat, vadadustat, daprodustat, desidustat, enarodustat and molidustat. </p> </section> <section id="CD013751-sec-0013"> <h3 class="title" id="CD013751-sec-0013">Why it is important to do this review</h3> <p>Evidence for HIF stabilisers to treat anaemia in people with CKD is emerging in RCTs. With data presented from phase 2 studies for competitive HIF stabilisers and preliminary data from phase 3 studies on roxadustat in patients requiring dialysis, sufficient evidence was available to determine the efficacy and safety of HIF stabilisers compared to other treatment strategies, including ESAs therapy. This Cochrane review evaluated the benefits and potential harms of HIF stabilisers in CKD and provide a summary of the certainty of available evidence for decision‐makers including clinicians, patients, and policy‐makers. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD013751-sec-0014" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD013751-sec-0014"></div> <p>We aimed to assess the benefits and potential harms of HIF stabilisers for the management of anaemia in people with CKD. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD013751-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD013751-sec-0015"></div> <section id="CD013751-sec-0016"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD013751-sec-0017"> <h4 class="title">Types of studies</h4> <p>All RCTs and quasi‐RCTs (RCTs in which treatment allocation was obtained by alternation, use of alternate medical records, date of birth or other predictable methods) looking at the effects of HIF stabilisers versus other anaemia therapies, placebo or standard care in people with CKD were included. </p> </section> <section id="CD013751-sec-0018"> <h4 class="title">Types of participants</h4> <section id="CD013751-sec-0019"> <h5 class="title">Inclusion criteria</h5> <p>Adults and children with CKD were included. We defined CKD as those who are receiving any form of kidney replacement therapy (KRT), have a functioning kidney transplant, have impaired kidney function defined as a reduced eGFR &lt; 60 mL/min/1.73 m², or the presence of other markers of kidney damage such as proteinuria (KDOQI stages 1‐5) (<a href="./references#CD013751-bbs2-0105" title="Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney International Supplements2013;3(1):1-150. [https://kdigo.org/guidelines/ckd-evaluation-and-management/]">KDIGO Clinical Practice Guideline CKD 2012</a>), or elevated serum creatinine (SCr) (&gt; 120 mmol/L), or as defined by study authors. </p> </section> </section> <section id="CD013751-sec-0020"> <h4 class="title">Types of interventions</h4> <p>We evaluated the following treatment comparisons:</p> <p> <ol id="CD013751-list-0001"> <li> <p>HIF stabiliser versus placebo</p> </li> <li> <p>HIF stabiliser versus standard care</p> </li> <li> <p>HIF stabiliser versus ESA</p> </li> <li> <p>HIF stabiliser versus iron supplementation</p> </li> </ol> </p> <p>We evaluated HIF stabiliser therapy given orally at any frequency. We included RCTs regardless of the target Hb used to guide dose and frequency. </p> <p>We investigated studies comparing different doses and phase 1 and 2 studies using subgroup analysis. </p> <p>We excluded studies assessing head‐to‐head comparisons of HIF stabilisers.</p> <p>We excluded studies with follow‐up of less than eight weeks.</p> </section> <section id="CD013751-sec-0021"> <h4 class="title">Types of outcome measures</h4> <p>We did not exclude studies based on non‐reporting of outcomes of interest.</p> <p>The outcomes selected included the relevant <a href="http://songinitiative.org/" target="_blank">SONG core outcome sets</a> as specified by the Standardised Outcomes in Nephrology initiative (<a href="./references#CD013751-bbs2-0119" title="SONG Initiative. The SONG Handbook Version 1.0. www.songinitiative.org/reports-and-publications/2017.">SONG 2017</a>). </p> <section id="CD013751-sec-0022"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD013751-list-0002"> <li> <p>CV death</p> </li> <li> <p>Life participation</p> </li> <li> <p>Fatigue</p> </li> </ul> </p> </section> <section id="CD013751-sec-0023"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD013751-list-0003"> <li> <p>CV disease (nonfatal myocardial infarction (MI), nonfatal stroke, peripheral arterial event, hospitalisation for heart failure (HF)) </p> </li> <li> <p>Proportion of patients requiring blood transfusion</p> </li> <li> <p>Vascular access (including vascular access failure, early thrombosis (&lt; eight weeks), loss of unassisted patency (combined data for stenosis/occlusions), access failure to attain suitability for dialysis, and need for access intervention (combined data for surgically or by radiological guided angioplasty)) </p> </li> <li> <p>Cancer</p> </li> <li> <p>Kidney failure</p> </li> <li> <p>Infection</p> </li> <li> <p>Graft health (including graft loss, graft function, acute rejection and chronic rejection)</p> </li> <li> <p>Peritoneal dialysis (PD) infection</p> </li> <li> <p>PD failure</p> </li> <li> <p>Proportion of patients reaching the target Hb</p> </li> <li> <p>Adverse events (including pulmonary hypertension<b>,</b> deterioration of diabetic retinopathy, kidney and liver cysts and hyperkalaemia) </p> </li> </ul> </p> </section> </section> </section> <section id="CD013751-sec-0024"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD013751-sec-0025"> <h4 class="title">Electronic searches</h4> <p>We searched the <a href="http://kidneyandtransplant.cochrane.org/cochrane-kidney-and-transplant-specialised-register" target="_blank">Cochrane Kidney and Transplant Register of Studies</a> up to 22 November 2021 through contact with the Information Specialist using search terms relevant to our review. The Register contains studies identified from the following sources. </p> <p> <ol id="CD013751-list-0004"> <li> <p>Monthly searches of the Cochrane Central Register of Controlled Trials (CENTRAL)</p> </li> <li> <p>Weekly searches of MEDLINE OVID SP</p> </li> <li> <p>Searches of kidney and transplant journals and the proceedings and abstracts from major kidney and transplant conferences </p> </li> <li> <p>Searching the current year of EMBASE OVID SP</p> </li> <li> <p>Weekly current awareness alerts for selected kidney and transplant journals</p> </li> <li> <p>Searches of the International Clinical Trials Register (ICTRP) Search Portal and ClinicalTrials.gov</p> </li> </ol> </p> <p>Studies contained in the Register are identified through searches of CENTRAL, MEDLINE, and EMBASE based on the scope of Cochrane Kidney and Transplant. Details of search strategies and a list of handsearched journals, conference proceedings and current awareness alerts are available on the <a href="https://kidneyandtransplant.cochrane.org/cochrane-kidney-and-transplant-specialised-register" target="_blank">Cochrane Kidney and Transplant website</a>. </p> <p>See <a href="./appendices#CD013751-sec-0125">Appendix 1</a> for search terms used in strategies for this review. </p> </section> <section id="CD013751-sec-0026"> <h4 class="title">Searching other resources</h4> <p> <ol id="CD013751-list-0005"> <li> <p>Reference lists of review articles, relevant studies, and clinical practice guidelines</p> </li> <li> <p>Contacting relevant individuals/organisations seeking information about unpublished or incomplete studies </p> </li> <li> <p>Grey literature sources (e.g. abstracts, dissertations, and theses), in addition to those already included in the Cochrane Kidney and Transplant Register of Studies, were also searched </p> </li> </ol> </p> </section> </section> <section id="CD013751-sec-0027"> <h3 class="title" id="CD013751-sec-0027">Data collection and analysis</h3> <section id="CD013751-sec-0028"> <h4 class="title">Selection of studies</h4> <p>The search strategies described were used to obtain titles and abstracts of studies that may be relevant to the review. The titles and abstracts were screened by five authors (PN, EH, MR, DH, VS) working independently, who discarded studies that were not applicable, however, studies and reviews that might include relevant data or information on studies were retained initially. Five authors (PN, EH, MR, DH, VS) independently assessed retrieved abstracts and, if necessary, the full text of these studies to determine which studies satisfy the inclusion criteria. Disagreements were resolved in consultation with another author (SP). </p> </section> <section id="CD013751-sec-0029"> <h4 class="title">Data extraction and management</h4> <p>Data extraction was carried out independently by five authors (PN, EH, MR, DH, VS) using standard data extraction forms. Disagreements were resolved in consultation with another author (SC). Studies reported in non‐English language journals were translated before assessment. Where more than one publication of one study existed, reports were grouped together, and the publication with the most complete data were used in the analyses. Where relevant outcomes were only published in earlier versions these data were used. Any discrepancy between published versions was highlighted. </p> </section> <section id="CD013751-sec-0030"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Five authors (PN, EH, MR, DH, VS) independently assessed the following items using the risk of bias assessment tool (<a href="./references#CD013751-bbs2-0103" title="HigginsJP , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.1 (updated September 2020). Cochrane, 2020. Available from www.training.cochrane.org/handbook.">Higgins 2020</a>) (see <a href="./appendices#CD013751-sec-0126">Appendix 2</a>). </p> <p> <ul id="CD013751-list-0006"> <li> <p>Was there adequate sequence generation (selection bias)?</p> </li> <li> <p>Was allocation adequately concealed (selection bias)?</p> </li> <li> <p>Was knowledge of the allocated interventions adequately prevented during the study?</p> <ul id="CD013751-list-0007"> <li> <p>Participants and personnel (performance bias)</p> </li> <li> <p>Outcome assessors (detection bias)</p> </li> </ul> </li> <li> <p>Were incomplete outcome data adequately addressed (attrition bias)?</p> </li> <li> <p>Are the study reports free of suggestion of selective outcome reporting (reporting bias)? </p> </li> <li> <p>Was the study free of other problems that could put it at risk of bias?</p> </li> </ul> </p> </section> <section id="CD013751-sec-0031"> <h4 class="title">Measures of treatment effect</h4> <p>For dichotomous outcomes (death, CV disease, blood transfusion, vascular access, cancer, hospitalisation for HF, kidney failure, infection, graft health, PD infection, PD failure, proportion reaching Hb target, adverse events) results were expressed as risk ratio (RR) with 95% confidence intervals (CI). Where continuous scales of measurement were used to assess the effects of treatment (life participation, fatigue) the mean difference (MD) was used, or the standardised mean difference (SMD) if different scales have been used. Studies analysing change scores were included in meta‐analyses together with studies including endpoint outcome data. Missing standard deviations were imputed. </p> </section> <section id="CD013751-sec-0032"> <h4 class="title">Unit of analysis issues</h4> <p>For cross‐over studies, we extracted data for the end of the first period of treatment.</p> </section> <section id="CD013751-sec-0033"> <h4 class="title">Dealing with missing data</h4> <p>We requested any further information required from the original author by written correspondence (e.g. emailing corresponding author/s) and any relevant information obtained in this manner were included in the review. Evaluation of important numerical data such as screened, randomised patients, as well as intention‐to‐treat, as‐treated and per‐protocol population, were carefully performed. Attrition rates, for example, drop‐outs, losses to follow‐up and withdrawals were investigated. Issues of missing data and imputation methods (e.g., last‐observation‐carried‐forward) were critically appraised (<a href="./references#CD013751-bbs2-0103" title="HigginsJP , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.1 (updated September 2020). Cochrane, 2020. Available from www.training.cochrane.org/handbook.">Higgins 2020</a>). </p> </section> <section id="CD013751-sec-0034"> <h4 class="title">Assessment of heterogeneity</h4> <p>We first assessed the heterogeneity by visual inspection of the forest plot. We quantified statistical heterogeneity using the I² statistic, which describes the percentage of total variation across studies due to heterogeneity rather than sampling error (<a href="./references#CD013751-bbs2-0102" title="HigginsJP , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta-analyses. BMJ2003;327(7414):557-60. [MEDLINE: 12958120]">Higgins 2003</a>). A guide to the interpretation of I² values was as follows. </p> <p> <ul id="CD013751-list-0008"> <li> <p>0% to 40%: might not be important</p> </li> <li> <p>30% to 60%: may represent moderate heterogeneity</p> </li> <li> <p>50% to 90%: may represent substantial heterogeneity</p> </li> <li> <p>75% to 100%: considerable heterogeneity.</p> </li> </ul> </p> <p>The importance of the observed value of I² depends on the magnitude and direction of treatment effects and the strength of evidence for heterogeneity (e.g. P‐value from the Chi² test or a CI for I²) (<a href="./references#CD013751-bbs2-0103" title="HigginsJP , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.1 (updated September 2020). Cochrane, 2020. Available from www.training.cochrane.org/handbook.">Higgins 2020</a>). </p> </section> <section id="CD013751-sec-0035"> <h4 class="title">Assessment of reporting biases</h4> <p>If possible, funnel plots were used to assess the potential existence of small study bias (<a href="./references#CD013751-bbs2-0103" title="HigginsJP , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.1 (updated September 2020). Cochrane, 2020. Available from www.training.cochrane.org/handbook.">Higgins 2020</a>). We planned to generate funnel plots if at least 10 studies examining the same treatment comparison were included in the review and comment on whether any asymmetry in the funnel plot was due to publication bias or methodological or clinical heterogeneity of the studies. </p> </section> <section id="CD013751-sec-0036"> <h4 class="title">Data synthesis</h4> <p>Data were pooled using the random‐effects model, but the fixed‐effect model was also used to ensure the robustness of the model chosen and susceptibility to outliers. </p> </section> <section id="CD013751-sec-0037"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We used subgroup analyses to explore possible sources of heterogeneity. Heterogeneity among participants could be related to the stage of kidney disease (stage 3‐5 not requiring KRT, dialysis, kidney transplant) and the presence of comorbidities (CV disease, diabetes). Heterogeneity in treatments could be related to a prior agent(s) used, the Hb target during therapy, the type, and the frequency and the duration of therapy. Adverse effects were tabulated and assessed with descriptive techniques, as they were likely to be different for the various agents used. Where possible, the risk difference (RD) with 95% CI was calculated for each adverse effect, either compared to no treatment or another agent. Studies comparing different doses and phase 1 and 2 studies were investigated using subgroup analysis. </p> </section> <section id="CD013751-sec-0038"> <h4 class="title">Sensitivity analysis</h4> <p>We planned to perform sensitivity analyses to explore the influence of the following factors on effect size: </p> <p> <ul id="CD013751-list-0009"> <li> <p>Repeating the analysis, excluding unpublished studies</p> </li> <li> <p>Repeating the analysis taking into account the risk of bias, as specified</p> </li> <li> <p>Repeating the analysis, excluding any very long or large studies to establish how much they dominate the results </p> </li> <li> <p>Repeating the analysis excluding studies using the following filters: diagnostic criteria, language of publication, source of funding (industry versus other), and country. </p> </li> </ul> </p> </section> <section id="CD013751-sec-0039"> <h4 class="title">Summary of findings and assessment of the certainty of the evidence</h4> <p>We presented the main results of the review in 'Summary of findings' tables. These tables present key information concerning the certainty of the evidence, the magnitude of the effects of the interventions examined, and the sum of the available data for the main outcomes (<a href="./references#CD013751-bbs2-0115" title="SchünemannHJ , HigginsJP , VistGE , GlasziouP , AklEA , SkoetzN , et al. Chapter 14: Completing ‘Summary of findings’ tables and grading the certainty of the evidence. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.1 (updated September 2020). Cochrane, 2020. www.training.cochrane.org/handbook.">Schunemann 2020a</a>). The 'Summary of findings' tables also included an overall grading of the evidence related to each of the main outcomes using the GRADE (Grades of Recommendation, Assessment, Development and Evaluation) approach (<a href="./references#CD013751-bbs2-0099" title="GuyattGH , OxmanAD , VistGE , KunzR , Falck-YtterY , Alonso-CoelloP , et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ2008;336(7650):924-6. [MEDLINE: 18436948]">GRADE 2008</a>; <a href="./references#CD013751-bbs2-0100" title="GuyattG , OxmanAD , AklEA , KunzR , VistG , BrozekJ , et al. GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. Journal of Clinical Epidemiology2011;64(4):383-94. [MEDLINE: 21195583]">GRADE 2011</a>). The GRADE approach defines the certainty of a body of evidence as the extent to which one can be confident that an estimate of effect or association is close to the true quantity of specific interest. This was assessed by three authors (PN, EH, MR). The certainty of a body of evidence involves consideration of the within‐trial risk of bias (methodological quality), directness of evidence, heterogeneity, the precision of effect estimates and risk of publication bias (<a href="./references#CD013751-bbs2-0116" title="SchünemannHJ , VistGE , HigginsJP , SantessoN , DeeksJJ , GlasziouP , et al. Chapter 15: Interpreting results and drawing conclusions. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.1 (updated September 2020). Cochrane, 2020. Available from www.training.cochrane.org/handbook.">Schunemann 2020b</a>). We reported the following outcomes in the 'Summary of findings' tables. </p> <p> <ul id="CD013751-list-0010"> <li> <p>CV death</p> </li> <li> <p>Fatigue</p> </li> <li> <p>Life participation</p> </li> <li> <p>Nonfatal MI</p> </li> <li> <p>Nonfatal stroke</p> </li> <li> <p>Proportion of patients requiring blood transfusion</p> </li> <li> <p>Proportion of patients reaching the target Hb</p> </li> </ul> </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD013751-sec-0040" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD013751-sec-0040"></div> <section id="CD013751-sec-0041"> <h3 class="title">Description of studies</h3> <p>See <a href="./references#CD013751-sec-0138" title="">Characteristics of included studies</a>; <a href="./references#CD013751-sec-0139" title="">Characteristics of excluded studies</a>; <a href="./references#CD013751-sec-0141" title="">Characteristics of ongoing studies</a> </p> <section id="CD013751-sec-0042"> <h4 class="title">Results of the search</h4> <p>After searching the Specialised Register,  we identified 173 records. After screening titles, abstracts, and undertaking full‐text review, 51 studies (117 records) were included, and 31 studies (47 records) were excluded. Eight ongoing studies were identified (<a href="./references#CD013751-bbs2-0084" title="NCT03446612. Anemia study in chronic kidney disease (CKD) : erythropoiesis via a novel prolyl hydroxylase inhibitor (PHI) daprodustat -forearm blood flow (ASCEND-FBF) [A randomized, repeat dose, open label, parallel group, multi-center study to evaluate the effect of daprodustat compared to darbepoetin alfa on forearm blood flow in participants with anemia of chronic kidney disease that are not dialysis dependent]. www.clinicaltrials.gov/show/NCT03446612 (first received 27 February 2018). ">ASCEND‐FBF 2018</a>; <a href="./references#CD013751-bbs2-0085" title="KansagraK . Desidustat in the treatment of anemia in chronic kidney disease (CKD) [A phase 3, multicenter, multicountry, open-label, randomized, active-controlled clinical trial to evaluate the efficacy and safety of desidustat versus darbepoetin for the treatment of anemia in patients with chronic kidney disease (CKD) who are not on dialysis.]. ctri.nic.in/Clinicaltrials/showallp.php?mid1=33329&amp;EncHid=&amp;userName=CTRI/2019/06/019635 (first received 12 June 2019). ">CTRI/2019/06/019635</a>; <a href="./references#CD013751-bbs2-0086" title="KansagraK . Desidustat in the treatment of anemia in CKD. ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=36915&amp;EncHid=&amp;userName=CTRI/2019/12/022312 (first received 11 December 2019). ">DREAM‐D 2019</a>; <a href="./references#CD013751-bbs2-0087" title="LeeJW . A study to evaluate efficacy and safety of JTZ-951 compared to darbepoetin alfa in Korean renal anemia patients receiving hemodialysis [A multi-center, randomized, open-label, active-controlled, parallel-group, phase iii study to compare the efficacy and safety of JTZ-951 with darbepoetin alfa in anemic patients with chronic kidney disease receiving maintenance hemodialysis]. www.clinicaltrials.gov/show/NCT04027517 (first received 22 July 2019). ">NCT04027517</a>; <a href="./references#CD013751-bbs2-0088" title="LiuH . Evaluate the efficacy and safety of roxadustat for the treatment of anemia and risks of cardiovascular and cerebrovascular events in ESRD newly initiated dialysis patients [Phase 4 multicenter, randomized, open-lable, active-controlled study of the efficacy and safty of roxadustat for the treatment of anemia and risks of cardiovascular and cerebrovascular events in incident-dialysis patients]. www.clinicaltrials.gov/show/NCT04134026 (first received 21 October 2019). ">NCT04134026</a>; <a href="./references#CD013751-bbs2-0089" title="NCT04313153. Trial evaluating the efficacy and safety of oral vadadustat once daily (QD) and three times weekly (TIW) for the maintenance treatment of anemia in hemodialysis subjects converting from erythropoiesis-stimulating agents (ESAs) [Phase 3b, randomized, open-label, active-controlled trial evaluating the efficacy and safety of oral vadadustat once daily (QD) and three times weekly (TIW) for the maintenance treatment of anemia in hemodialysis subjects converting from erythropoiesis-stimulating agents (ESAs)]. www.clinicaltrials.gov/show/NCT04313153 (first received 18 March 2020). ">NCT04313153</a>; <a href="./references#CD013751-bbs2-0090" title="PER-038-14. A phase 3, multicenter, randomized, open-label active-controlled study of the efficacy and safety of FG-4592 in the treatment of anemia in incident-dialysis patients. www.ins.gob.pe/ensayosclinicos/rpec/recuperarECPBNuevoEN.asp?numec=038-14 (first received 11 December 2014). ">PER‐038‐14</a>; <a href="./references#CD013751-bbs2-0091" title="NazarAL . A randomized, active-controlled clinical trial to evaluate the efficacy and safety of desidustat versus darbepoetin for the treatment of anemia in patients with chronic kidney disease (CKD) who are not on dialysis [A phase 3, multicenter, multi-country, open-label, randomized, active-controlled clinical trial to evaluate the efficacy and safety of desidustat versus darbepoetin for the treatment of anemia in patients with chronic kidney disease (CKD) who are not on dialysis]. slctr.lk/trials/slctr-2019-032 (first received 13 August 2019). ">SLCTR‐2019‐032</a>) and one study was completed prior to publication; however, no results are as yet available (<a href="./references#CD013751-bbs2-0083" title="NCT03799627. Study of vadadustat in hemodialysis patients with anemia switching from epoetin alfa (FO2RWARD-2) [Phase 2, randomized, open-label, active-controlled, efficacy, safety, pharmacokinetics, and pharmacodynamics study of oral vadadustat for the treatment of anemia in hemodialysis subjects converting from epoetin alfa (FO2RWARD-2)]. www.clinicaltrials.gov/show/NCT03799627 (first received 10 January 2019). ">FO2RWARD‐2 2019</a>). These nine studies will be assessed in a future update of this review (<a href="#CD013751-fig-0001">Figure 1</a>). </p> <div class="figure" id="CD013751-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Flow diagram." data-id="CD013751-fig-0001" src="/cdsr/doi/10.1002/14651858.CD013751.pub2/media/CDSR/CD013751/image_n/nCD013751-FIG-01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Flow diagram.</p> </div> </div> </div> </section> <section id="CD013751-sec-0043"> <h4 class="title">Included studies</h4> <p>We included 51 studies (117 records), randomising 30,994 participants. The characteristics of the participants and the interventions used are detailed in the <a href="./references#CD013751-sec-0138" title="">Characteristics of included studies</a>. </p> <section id="CD013751-sec-0044"> <h5 class="title">Study design, setting and characteristics</h5> <p>Study duration varied from 8 to 108 weeks, with a median of 28 weeks. No study had a cross‐over or cluster‐randomised design. Studies were conducted from 2013 to 2021 in China (<a href="./references#CD013751-bbs2-0016" title="ChenN , HaoC , LiuB , LinHL , CailiW , XingCY , et al. A phase 3, randomized, open-label, active-controlled study of efficacy and safety of roxadustat for treatment of anemia in subjects with CKD on dialysis [abstract no: TH-PO1152]. Journal of the American Society of Nephrology2018;29(Abstract Suppl):B5. ChenN , HaoC , LiuBC , LinH , WangC , XingC , et al. Roxadustat treatment for anemia in patients undergoing long-term dialysis. New England Journal of Medicine2019;381(11):1011-22. [MEDLINE: 31340116]">Chen 2019</a>; <a href="./references#CD013751-bbs2-0017" title="ChenN , HaoC , PengX , LinH , YinA , HaoL , et al. Roxadustat for anemia in patients with kidney disease not receiving dialysis. New England Journal of Medicine2019;381(11):1001-10. [MEDLINE: 31340089]ChenN , HaoC , PengX , LinHL , YinA , HaoL , et al. A phase 3, randomized, double-blind, placebo-controlled study of efficacy and safety of roxadustat (FG-4592) for treatment of anemia in subjects with CKD not on dialysis [abstract no: TH-PO1153]. Journal of the American Society of Nephrology2018;29(Abstract Suppl):B5. ">Chen 2019a</a>; <a href="./references#CD013751-bbs2-0018" title="ChenN , QianJ , ChenJ , YuX , MeiC , HaoC , et al. Phase 2 studies of oral hypoxia-inducible factor prolyl hydroxylase inhibitor FG-4592 for treatment of anemia in China. Nephrology Dialysis Transplantation2017;32(8):1373-86. [MEDLINE: 28371815]">Chen DD 2017</a>; <a href="./references#CD013751-bbs2-0019" title="ChenN , QianJ , ChenJ , YuX , MeiC , HaoC , et al. Phase 2 studies of oral hypoxia-inducible factor prolyl hydroxylase inhibitor FG-4592 for treatment of anemia in China. Nephrology Dialysis Transplantation2017;32(8):1373-86. [MEDLINE: 28371815]QianJQ , ChenN , ChenJ , HaoC , LinHL , NiD , et al. A randomized, double-blind, placebo controlled trial of FG-4592 for correction of anemia in subjects with chronic kidney disease in China [abstract no: FR-OR011]. Journal of the American Society of Nephrology2013;24(Abstract Suppl):38A. ">Chen NDD 2017</a>), Japan (<a href="./references#CD013751-bbs2-0001" title="AkizawaT , TsubakiharaY , NangakuM , EndoY , NakajimaH , KohnoT , et al. Effects of daprodustat, a novel hypoxia-inducible factor prolyl hydroxylase inhibitor on anemia management in Japanese hemodialysis subjects. American Journal of Nephrology2017;45(2):127-35. [MEDLINE: 27978511]EndoY , KohnoT , ImaiY , KawaseN , HaraK , LeporeJJ , et al. A 4 -week dose response study of the hypoxia inducible factor-prolyl hydroxylase inhibitor GSK1278863 in Japanese anemic haemodialysis subjects [abstract no: SA-PO819]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):818A. NCT02019719. Study to evaluate the safety, efficacy and pharmacokinetics of GSK1278863 in Japanese hemodialysis-dependent subjects with anemia associated with chronic kidney disease [A 4-week, phase ii, randomized, double-blind, dose-ranging, placebo-controlled, parallel-group, multi-center study to evaluate the safety, efficacy and pharmacokinetics of GSK1278863 in Japanese hemodialysis-dependent subjects with anemia associated with chronic kidney disease]. clinicaltrials.gov/show/NCT02019719 (first received 24 December 2013). ">Akizawa 2017</a>; <a href="./references#CD013751-bbs2-0002" title="AkizawaT , IwasakiM , OtsukaT , ReuschM , MisumiT . Roxadustat for the treatment of chronic kidney disease-associated anemia in Japanese patients not on dialysis [abstract no: FR-PO1142]. Journal of the American Society of Nephrology2016;27(Abstract Suppl):7B. AkizawaT , IwasakiM , OtsukaT , ReuschM , MisumiT . Roxadustat treatment of chronic kidney disease-associated anemia in Japanese patients not on dialysis: a phase 2, randomized, double-blind, placebo-controlled trial. Advances in Therapy2019;36(6):1438-54. [MEDLINE: 30953333]">Akizawa 2019</a>; <a href="./references#CD013751-bbs2-0003" title="AkizawaT , IwasakiM , YamaguchiY , MajikawaY , ReuschM . Authors' Reply. Journal of the American Society of Nephrology2021;32(4):1005-7. [MEDLINE: 33649099]AkizawaT , IwasakiM , YamaguchiY , MajikawaY , ReuschM . Phase 3, randomized, double-blind, active-comparator (darbepoetin alfa) conversion study of oral roxadustat in CKD patients with anemia on hemodialysis in Japan [abstract no: TH-PO1151]. Journal of the American Society of Nephrology2018;29(Abstract Suppl):B4. AkizawaT , IwasakiM , YamaguchiY , MajikawaY , ReuschM . Phase 3, randomized, double-blind, active-comparator (darbepoetin alfa) study of oral roxadustat in CKD patients with anemia on hemodialysis in Japan. Journal of the American Society of Nephrology2020;31(7):1628-39. [MEDLINE: 32493693]AkizawaT , YamaguchiY , MajikawaY , ReuschM . Factors affecting the doses of roxadustat vs darbepoetin alfa for anemia treatment in hemodialysis patients. Therapeutic Apheresis &amp; Dialysis2021;25(5):575-85. [MEDLINE: 33200512]Astellas1517-CL-0307. A study of intermittent oral dosing of ASP1517 in hemodialysis chronic kidney disease patients with anemia [A phase 3, multi-center, randomized, 2-arm parallel, double-blind, active-comparator (darbepoetin alfa) conversion study of intermittent oral dosing of ASP1517 in hemodialysis chronic kidney disease patients with anemia]. www.clinicaltrials.astellas.com/study/?pid=1517-CL-0307 (accessed 4 May 2022). LiuF , WangJ , YeQ , FuH , MaoJ . Roxadustat for renal anemia in ESRD from PKD patients: is it safe enough?Journal of the American Society of Nephrology2021;32(4):1005. [MEDLINE: 33649100]NguyenQD , SepahYJ , YamaguchiY , OtsukaT , MajikawaY , ReuschM , et al. Ophthalmological effects of roxadustat in the treatment of anemia in dialysis-dependent and non-dialysis-dependent CKD patients: findings from two phase 3 studies [abstract no: PO0267]. Journal of the American Society of Nephrology2020;31(Abstract Suppl):134. [EMBASE: 633698979]SepahY , NguyenQD , YamaguchiY , MajikawaY , ReuschM , AkizawaT . Ophthalmological effects of roxadustat in the treatment of anaemia in chronic kidney disease patients on dialysis in a phase 3, randomised, double-blind, active-comparator conversion study [abstract no: MO002]. Nephrology Dialysis Transplantation2020;35(Suppl 3):iii102. [EMBASE: 633421367]">Akizawa 2020a</a>; <a href="./references#CD013751-bbs2-0004" title="AkizawaT , NangakuM , YonekawaT , OkudaN , KawamatsuS , OnoueT , et al. Efficacy and safety of daprodustat compared with darbepoetin alfa in Japanese hemodialysis patients with anemia: a randomized, double-blind, phase 3 trial. Clinical Journal of the American Society of Nephrology: CJASN2020;15(8):1155-65. [MEDLINE: 32723804]OzekiH , AkizawaT , NangakuM , YonekawaT , OkudaN , KawamatsuS , et al. Efficacy and safety of daprodustat compared with darbepoetin alfa in Japanese hemodialysis patients with anemia: A randomized, double-blind, phase 3 trial [abstract no: SaO036]. Nephrology Dialysis Transplantation2019;34(Suppl 1):a350. [EMBASE: 631305259]">Akizawa 2020c</a>; <a href="./references#CD013751-bbs2-0005" title="AkizawaT , IwasakiM , OtsukaT , YamaguchiY , ReuschM . A phase 3, multicenter, randomized, open-label, active comparator conversion study of roxadustat in non-dialysis-dependent (NDD) patients with anemia in chronic kidney disease (CKD) [abstract no: POS-244]. Kidney International Reports2021;6(4 Suppl):S103. [EMBASE: 2011682459]AkizawaT , IwasakiM , OtsukaT , YamaguchiY , ReuschM . A phase 3, multicenter, randomized, open-label, active comparator conversion study of roxadustat in non-dialysis-dependent (NDD) patients with anemia in CKD [abstract no: PO0269]. Journal of the American Society of Nephrology2020;31(Abstract Suppl):134. [EMBASE: 633699036]NguyenQD , SepahYJ , YamaguchiY , OtsukaT , MajikawaY , ReuschM , et al. Ophthalmological effects of roxadustat in the treatment of anemia in dialysis-dependent and non-dialysis-dependent CKD patients: findings from two phase 3 studies [abstract no: PO0267]. Journal of the American Society of Nephrology2020;31(Abstract Suppl):134. [EMBASE: 633698979]">Akizawa 2020f</a>; <a href="./references#CD013751-bbs2-0006" title="AkizawaT , IwasakiM , OtsukaT , YamaguchiY , ReuschM . Phase 3 study of roxadustat to treat anemia in non-dialysis-dependant CKD. Kidney International Reports2021;6(7):1810-28. [MEDLINE: 34307976]AkizawaT , Tanaka-AminoK , OtsukaT , YamaguchiY . Factors affecting doses of roxadustat versus darbepoetin alfa for anemia in nondialysis patients. American Journal of Nephrology2021;52(9):702-13. [MEDLINE: 34628408]">Akizawa 2021</a>; <a href="./references#CD013751-bbs2-0027" title="HouYP , MaoXY , WangC , XuZH , BuZH , XuM , et al. Roxadustat treatment for anemia in peritoneal dialysis patients: a randomized controlled trial. Journal of the Formosan Medical Association2021;121(2):529-38. [MEDLINE: 34167878]">Hou 2021</a>; <a href="./references#CD013751-bbs2-0031" title="AkizawaT , TaguchiM , MatsudaY , IekushiK , YamadaT , YamamotoH . Molidustat for the treatment of renal anaemia in patients with dialysis-dependent chronic kidney disease: Design and rationale of three phase III studies. BMJ Open2019;9(6):e026602. [MEDLINE: 31203241]AkizawaT , YamadaT , NoboriK , MatsudaY , HayashiY , HayasakiT , et al. Molidustat for Japanese patients with renal anemia receiving dialysis. Kidney International Reports2021;6(10):2604–16. [MEDLINE: 34622100]AkizawaT , YamadaT , NoboriK , MatsudaY , HayashiY , HayasakiT , et al. Results from a phase 3 study comparing the efficacy and safety of molidustat vs. Darbepoetin Alfa in patients receiving hemodialysis and treated with erythropoiesis-stimulating agents (ESAS) [abstract no: PO22623]. Journal of the American Society of Nephrology2020;31(Abstract Suppl):B4. [EMBASE: 633697376]">MIYABI HD‐M 2019</a>; <a href="./references#CD013751-bbs2-0032" title="YamamotoH , NoboriK , MatsudaY , HayashiY , HayasakiT , AkizawaT . Efficacy and safety of molidustat for anemia in ESA-naive nondialysis patients: a randomized, phase 3 trial. American Journal of Nephrology2021;52(10-11):871-83. [MEDLINE: 34569489]YamamotoH , TaguchiM , MatsudaY , IekushiK , YamadaT , AkizawaT . Molidustat for the treatment of renal anaemia in patients with non-dialysis-dependent chronic kidney disease: design and rationale of two phase III studies. BMJ Open2019;9(6):e026704. [MEDLINE: 31203242]YamamotoH , TaguchiM , NoboriK , MatsudaY , IekushiK , AkizawaT . To investigate the efficacy and safety of molidustat in non-dialysis patients with renal anemia who are not treated with erythropoiesis stimulating agents: MIYABI ND-C [abstract no: P1866]. Nephrology Dialysis Transplantation2020;35(Suppl 3):iii2177. [EMBASE: 633422996]">MIYABI ND‐C 2019</a>; <a href="./references#CD013751-bbs2-0033" title="YamamotoH , NoboriK , MatsudaY , HayashiY , HayasakiT , AkizawaT . Molidustat for renal anemia in nondialysis patients previously treated with erythropoiesis-stimulating agents: a randomized, open-label, phase 3 study. American Journal of Nephrology2021;52(10-11):884-93. [MEDLINE: 34569482]YamamotoH , TaguchiM , MatsudaY , IekushiK , YamadaT , AkizawaT . Molidustat for the treatment of renal anaemia in patients with non-dialysis-dependent chronic kidney disease: design and rationale of two phase III studies. BMJ Open2019;9(6):e026704. [MEDLINE: 31203242]YamamotoH , TaguchiM , NoboriK , MatsudaY , IekushiK , AkizawaT . To investigate the efficacy and safety of molidustat in non-dialysis patients with renal anemia who are treated with erythropoiesis stimulating agents: Miyabi ND-M [Abstract no: P1868]. Nephrology Dialysis Transplantation2020;35(Suppl 3):iii2179. [EMBASE: 633423006]">MIYABI ND‐M 2019</a>; <a href="./references#CD013751-bbs2-0034" title="NangakuM , KondoK , UetaK , KokadoY , KanekoG , MatsudaH , et al. Efficacy and safety of vadadustat compared with darbepoetin alfa in Japanese anemic patients on hemodialysis: a phase 3, multicenter, randomized, double-blind study. Nephrology Dialysis Transplantation2021;36(9):1731-41. [MEDLINE: 33650630]NangakuM , KondoK , UetaK , KokadoY , KanekoG , MatsudaH , et al. Randomized, double-blinded, active-controlled (darbepoetin alfa), phase 3 study of vadadustat in CKD patients with anemia on hemodialysis in Japan [abstract no: TH-OR024]. Journal of the American Society of Nephrology2019;30(Abstract Suppl):6. [EMBASE: 633771357]">Nangaku 2021</a>; <a href="./references#CD013751-bbs2-0035" title="NangakuM , KondoK , KokadoY , UetaK , KanekoG , ShiosakaM , et al. Randomized, open-label, active-controlled (darbepoetin alfa), phase 3 study of vadadustat for treating anemia in non-dialysis-dependent CKD patients in Japan [abstract no: SA-PO229]. Journal of the American Society of Nephrology2019;30(Abstract Suppl):823. [EMBASE: 633767995]NangakuM , KondoK , KokadoY , UetaK , KanekoG , TandaiT , et al. Phase 3 randomized study comparing vadadustat with darbepoetin alfa for anemia in Japanese patients with nondialysis-dependent CKD. Journal of the American Society of Nephrology2021;32(7):1779-90. [MEDLINE: 33883252]">Nangaku 2021a</a>; <a href="./references#CD013751-bbs2-0036" title="GSK201753. A 52-week, Phase III, open-label, multi-center study to evaluate efficacy and safety of GSK1278863 in Japanese non-dialysis and peritoneal dialysis subjects with anemia associated with chronic kidney disease [study protocol]. www.clinicaltrials.gov/ProvidedDocs/63/NCT02791763/Prot_000.pdf (accessed 9 May 2022). NangakuM , HamanoT , AkizawaT , TsubakiharaY , NagaiR , OkudaN , et al. Daprodustat compared with epoetin beta pegol for anemia in Japanese patients not on dialysis: a 52-week randomized open-label phase 3 trial. American Journal of Nephrology2021;52(1):26-35. [MEDLINE: 33561857]">Nangaku 2021b</a>; <a href="./references#CD013751-bbs2-0037" title="Astellas1517-CL-0304. A study to investigate the effect of ASP1517 after intermittent oral dosing in dialysis chronic kidney disease patients with anemia compared with darbepoetin as a reference drug [A Japanese, phase 2, multicenter, randomized, 4-arm parallel, double-blind (arms 1-3), open-label (arm 4), active-comparator (darbepoetin alfa) study of intermittent oral dosing of asp1517 in hemodialysis-dependent chronic kidney disease patients with anemia [1517-CL-0304 clinical study results report]]. www.trialsummaries.com/Study/StudyDetails?id=14175&amp;tenant=MT_AST_9011; www.clinicaltrials.gov/ct2/show/NCT01888445 (first received 6 August 2018). ">NCT01888445</a>; <a href="./references#CD013751-bbs2-0038" title="NangakuM , FaragYM , deGomaE , LuoW , VargoD , KhawajaZ . Vadadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor, for treatment of anemia of chronic kidney disease: two randomized Phase 2 trials in Japanese patients. Nephrology Dialysis Transplantation 2020 Jul 20 [epub ahead of print]. [DOI: 10.1093/ndt/gfaa060] [MEDLINE: 32719868]NangakuM , KhawajaZ , LuoW , GarafolaS , De GomaE , KomatsuY . Randomized, placebo-controlled phase 2 trials of vadadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), to treat anemia of CKD [abstract no: TH-PO228]. Journal of the American Society of Nephrology2018;29(Abstract Suppl):171. [EMBASE: 633737146]SolinskyC , FaragYM , KhawajaZ , AndersR , LuoW , ChavanA , et al. Impact of vadadustat on iron regulation in Japanese subjects with chronic kidney disease (CKD) [abstract no: 352]. American Journal of Kidney Diseases2020;75(4):638-9. [EMBASE: 2005716872]">NDD‐CKD 2020</a>; <a href="./references#CD013751-bbs2-0039" title="NangakuM , FaragYM , deGomaE , LuoW , VargoD , KhawajaZ . Vadadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor, for treatment of anemia of chronic kidney disease: two randomized Phase 2 trials in Japanese patients. Nephrology Dialysis Transplantation 2020 Jul 20 [epub ahead of print]. [DOI: 10.1093/ndt/gfaa060] [MEDLINE: 32719868]NangakuM , KhawajaZ , LuoW , GarafolaS , deGomaE , KomatsuY . Randomized, placebo-controlled phase 2 trials of vadadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), to treat anemia of CKD [abstract no: TH-PO228]. Journal of the American Society of Nephrology2018;29(Abstract Suppl):171. [EMBASE: 633737146]SolinskyC , FaragYM , KhawajaZ , AndersR , LuoW , ChavanA , et al. Impact of vadadustat on iron regulation in Japanese subjects with chronic kidney disease (CKD) [abstract no: 352]. American Journal of Kidney Diseases2020;75(4):638-9. [EMBASE: 2005716872]">NDD‐CKD 2020a</a>; <a href="./references#CD013751-bbs2-0050" title="AkizawaT , MaedaK , MiyazawaY , KoretomoR . Phase 3 study to compare the efficacy and safety of enarodustat (JTZ-951), an oral HIF-PH inhibitor, with darbepoetin alfa in anemic patients with CKD receiving maintenance hemodialysis [abstract no: TH-PO1186]. Journal of the American Society of Nephrology2019;30(Abstract Suppl):B4. AkizawaT , NangakuM , YamaguchiT , KoretomoR , MaedaK , MiyazawaY , et al. A phase 3 study of enarodustat (JTZ-951) in Japanese hemodialysis patients for treatment of anemia in chronic kidney disease: SYMPHONY HD study. Kidney Diseases2021;7(6):494-502. [EMBASE: 2013576033]">SYMPHONY HD 2021</a>; <a href="./references#CD013751-bbs2-0051" title="AkizawaT , NangakuM , YamaguchiT , KoretomoR , MaedaK , MiyazawaY , et al. A phase 3 study of enarodustat in anemic patients with CKD not requiring dialysis: the SYMPHONY ND study. Kidney International Reports2021;6(7):1840-9. [MEDLINE: 34307978]">SYMPHONY ND 2021</a>), and the USA (<a href="./references#CD013751-bbs2-0014" title="BesarabA , HutlerHN , KlausS , LeeTT , LilienfeldDE , NeffTB , et al. FG-4592, a novel oral HIF prolyl hydroxylase inhibitor, elevates hemoglobin in anemic stage 3/4 CKD patients [abstract no: SA-FC416]. Journal of the American Society of Nephrology2010;21(Abstract Suppl):95A. BesarabA , ProvenzanoR , HertelJ , ZabanehR , KlausSJ , LeeT , et al. Randomized placebo-controlled dose-ranging and pharmacodynamics study of roxadustat (FG-4592) to treat anemia in nondialysis-dependent chronic kidney disease (NDD-CKD) patients. Nephrology Dialysis Transplantation2015;30(10):1665-73. [MEDLINE: 26238121]">Besarab 2015</a>; <a href="./references#CD013751-bbs2-0041" title="HaaseVH , SpinowitzBS , PergolaPE , FarmerT , MaroniBJ , HartmanCS . AKB-6548 demonstrates controlled hemogloblin (HGB) response in a phase 2b study for the treatment of anemia in patients with chronic kidney disease not on dialysis (ND-CKD) [abstract no: TH-PO649]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):237A. HaaseVH , SpinowitzBS , PergolaPE , KhawajaZ , ChanJ , ZurawQ , et al. Efficacy and dose requirements of vadadustat are independent of systemic inflammation and prior erythropoiesis-stimulating agent(ESA) dose in patients with non-dialysis dependent chronic kidney disease (NDD-CKD) [abstract no: TH-PO907]. Journal of the American Society of Nephrology2016;27(Abstract Suppl):304A. PergolaPE , SpinowitzB , HaaseVH , HartmanCS , FarmerTM , PoluKR , et al. AKB-6548, a novel hypoxia-inducible factor prolyl-hydroxylase inhibitor (HIF-PHI) for the treatment of anemia in patients with chronic kidney disease not on dialysis (ND-CKD) [abstract no: FO015]. Nephrology Dialysis Transplantation2015;30(Suppl 3):iii8. [EMBASE: 72206296]PergolaPE , SpinowitzBS , HartmanCS , MaroniBJ , HaaseVH . Vadadustat, a novel oral HIF stabilizer, provides effective anemia treatment in nondialysis-dependent chronic kidney disease. Kidney International2016;90(5):1115-22. [MEDLINE: 27650732]SpinowitzBS , PergolaPE , HaaseVH , FarmerTM , HartmanCS , MaroniBJ . Hemoglobin (HGB) response in a phase 2b study of AKB-6548 for the treatment of anemia in patients with non-dialysis dependant chronic kidney disease (NDD-CKD). [abstract no: TH-OR038]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):11A. ">Pergola 2016</a>; <a href="./references#CD013751-bbs2-0044" title="ProvenzanoR , FaddaG , BernardoM , JamesC , KochendoerferG , LeeT , et al. FG2216, a novel oral HIF-PHI, stimulates erythropoiesis and increases hemoglobin concentration in patients with non-dialysis CKD [abstract no: 212]. American Journal of Kidney Diseases2008;51(4):A80. ProvenzanoR , HulterH , AgarwalA , KlausS , LeeT , YuP , et al. Hypoxia-inducible factor (HIF) prolyl hydroxylase inhibitor FG-2216 increases Hb without FE depletion in the absence of IV Fe [abstract no: 249]. American Journal of Kidney Diseases2013;61(4):A78. [EMBASE: 71024073]">Provenzano 2008</a>; <a href="./references#CD013751-bbs2-0045" title="ProvenzanoR , BesarabA , DuaSL , NguyenPV , WrightSH , ZeigS , et al. FG-4592, a novel oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), maintains hemoglobin levels and lowers cholesterol in hemodialysis patients: phase 2 comparison with epoetin alfa [abstract no: FR-PO257]. Journal of the American Society of Nephrology2012;23(Abstract Suppl):428A. ProvenzanoR , BesarabA , WrightS , DuaS , ZeigS , NguyenP , et al. Roxadustat (FG-4592) versus epoetin alfa for anemia in patients receiving maintenance hemodialysis: a phase 2, randomized, 6- to 19-week, open-label, active-comparator, dose-ranging, safety and exploratory efficacy study. American Journal of Kidney Diseases2016;67(6):912-24. [MEDLINE: 26846333]">Provenzano 2016</a>; <a href="./references#CD013751-bbs2-0046" title="ProvenzanoR , BesarabA , DuaSL , NguyenPV , WrightSH , ZeigS , et al. FG-4592, a novel oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), maintains hemoglobin levels and lowers cholesterol in hemodialysis patients: phase 2 comparison with epoetin alfa [abstract no: FR-PO257]. Journal of the American Society of Nephrology2012;23(Abstract Suppl):428A. ProvenzanoR , BesarabA , WrightS , DuaS , ZeigS , NguyenP , et al. Roxadustat (FG-4592) versus epoetin alfa for anemia in patients receiving maintenance hemodialysis: a phase 2, randomized, 6- to 19-week, open-label, active-comparator, dose-ranging, safety and exploratory efficacy study. American Journal of Kidney Diseases2016;67(6):912-24. [MEDLINE: 26846333]">Provenzano 2016a</a>), or were multinational (<a href="./references#CD013751-bbs2-0009" title="SinghAK , BlackorbyA , CizmanB , CarrollK , CobitzAR , DaviesR , et al. Study design and baseline characteristics of patients on dialysis in the ASCEND-D trial. Nephrology Dialysis Transplantation2021;37(5):960-72. [MEDLINE: 33744933] [MEDLINE: 33744933]SinghAK , BlackorbyA , CizmanB , CobitzAR , GodoySA , JhaV , et al. Regional variation of erythropoietin-stimulating agent hyporesponsiveness in the global daprodustat dialysis study (ASCEND-D) [abstract no: TH-OR08]. Journal of the American Society of Nephrology2020;31(Abstract Suppl):3. [EMBASE: 633698062]SinghAK , CarrollK , PerkovicV , SolomonS , JhaV , JohansenKL , et al. Daprodustat for the treatment of anemia in patients undergoing dialysis. New England Journal of Medicine2021;385(25):2325-35. [MEDLINE: 34739194]">ASCEND‐D 2021</a>; <a href="./references#CD013751-bbs2-0010" title="SinghAK . Daprodustat is noninferior to darbepoetin alfa in treating anemia in incident dialysis patients [abstract no: PO0465]. Journal of the American Society of Nephrology2021;32(Abstract Suppl):184-5. [EMBASE: 636331207]">ASCEND‐ID 2021</a>; <a href="./references#CD013751-bbs2-0011" title="PerkovicV , BlackorbyA , CizmanB , CarrollK , CobitzA , DaviesR , et al. ASCEND-ND: Study design and baseline characteristics. Nephrology Dialysis Transplantation2021;36(Suppl 1):i334-5. [EMBASE: 635918331]SinghAK , CarrollK , McMurrayJJ , SolomonS , JhaV , JohansenKL , et al. Daprodustat for the treatment of anemia in patients not undergoing dialysis. New England Journal of Medicine2021;385(25):2313-24. [MEDLINE: 34739196]">ASCEND‐ND 2021</a>; <a href="./references#CD013751-bbs2-0012" title="JohansenKL , CobitzAR , LopesRD , SinghAK , ObradorGT , CizmanB , et al. Effects of daprodustat on hemoglobin and quality of life in patients with CKD: results of the ascend-NHQ randomized, double-blind, placebo-controlled trial [abstract no: FR-OR53]. Journal of the American Society of Nephrology2021;32(Abstract Suppl):36. [EMBASE: 636330656]">ASCEND‐NHQ 2021</a>; <a href="./references#CD013751-bbs2-0013" title="CoyneDW , SinghAK , LopesRD , BaileyCK , DiminoTL , HuangC , et al. ASCEND-TD: A randomized, double-blind, active-controlled study of daprodustat administered three times weekly in hemodialysis patients [abstract no: PO0487]. Journal of the American Society of Nephrology2021;32(Abstract Suppl):191. [EMBASE: 636329480]">ASCEND‐TD 2021</a>; <a href="./references#CD013751-bbs2-0007" title="Astellas 1517-CL-0608. Roxadustat in the treatment of anemia in chronic kidney disease patients not requiring dialysis [A phase 3, randomized, double-blind, placebo controlled study of the efficacy and safety of roxadustat for the treatment of anemia in chronic kidney disease patients not on dialysis]. www.trialsummaries.com/Study/StudyDetails?id=14384&amp;tenant=MT_AST_90112019. EspositoC , CsikyB , TataradzeA , ReuschM , HanC , SulowiczW . Two phase 3, multicenter, randomized studies of intermittent oral roxadustat in anemic CKD patients on (PYRENEES) and not on (ALPS) dialysis [abstract no: SA-PO225]. Journal of the American Society of Nephrology2019;30(Abstract Suppl):822. [EMBASE: 633767739]Pecoits-FilhoR , ChanTM , HardyE , YuKH , FishbaneS . Roxadustat treatment results in consistent improvements in hemoglobin (Hb) vs. placebo: an analysis of three multinational randomized clinical trials in patients with non-dialysis-dependent CKD (NDD-CKD) [abstract no: TH-OR05]. Journal of the American Society of Nephrology2020;31(Abstract Suppl):2. [EMBASE: 633697943]RastogiA , Pecoits-FilhoR , FishbaneS , LittleDJ , HardyE , YuKH , et al. Roxadustat treatment corrects anemia to hemoglobin (HB) values ≥10 g/dL in the majority of patients with non-dialysis-dependent chronic kidney disease (NDD-CKD) [abstract no: PO0264]. Journal of the American Society of Nephrology2020;31(Abstract Suppl):133. [EMBASE: 633698803]ShutovE , SulowiczW , EspositoC , TataradzeA , AndricB , ReuschM , et al. Roxadustat for the treatment of anemia in chronic kidney disease patients not on dialysis: a phase 3, randomized, double-blind, placebo-controlled study (ALPS). Nephrology Dialysis Transplantation2021;36(9):1629-39. [MEDLINE: 33630072]">ALPS 2021</a>; <a href="./references#CD013751-bbs2-0008" title="CoyneDW , RogerSD , ChouW , BesarabA , LeongR , LeeTT , et al. Roxadustat favorably modifies iron indices in patients with non-dialysis-dependent CKD-related anemia [abstract no: PO0262]. Journal of the American Society of Nephrology2020;31(Abstract Suppl):132. [EMBASE: 633698686]CoyneDW , RogerSD , ShinS , KimSG , CadenaAA , MoustafaMA , et al. Roxadustat for CKD-related anemia in non-dialysis patients. Kidney International Reports2021;6(3):624-35. [MEDLINE: 33732977]CoyneDW , RogerSD , ShinSK , KimSG , CadenaAA , MoustafaMA , et al. ANDES: A phase 3, randomized, double-blind, placebo controlled study of the efficacy and safety of roxadustat for the treatment of anemia in CKD patients not on dialysis [abstract no: SA-PO0228]. Journal of the American Society of Nephrology2019;30(Abstract Suppl):822-3. [EMBASE: 633767955]Pecoits-FilhoR , ChanTM , HardyE , YuKHP , FishbaneS . Roxadustat treatment results in consistent improvements in hemoglobin (Hb) vs. placebo: an analysis of three multinational randomized clinical trials in patients with non-dialysis-dependent CKD (NDD-CKD) [abstract no: TH-OR05]. Journal of the American Society of Nephrology2020;31(Abstract Suppl):2. [EMBASE: 633697943]RastogiA , Pecoits-FilhoR , FishbaneS , LittleDJ , HardyE , YuKH , et al. Roxadustat treatment corrects anemia to hemoglobin (HB) values ≥10 g/dL in the majority of patients with non-dialysis-dependent chronic kidney disease (NDD-CKD) [abstract no: PO0264]. Journal of the American Society of Nephrology2020;31(Abstract Suppl):133. [EMBASE: 633698803]">ANDES 2021</a>; <a href="./references#CD013751-bbs2-0015" title="BrigandiRA , JohnsonB , OeiC , WestermanM , OlbinaG , deZoysaJ , et al. A novel hypoxia-inducible factor-prolyl hydroxylase inhibitor (GSK1278863) for anemia in CKD: a 28-day, phase 2a randomized trial. American Journal of Kidney Diseases2016;67(6):861-71. [MEDLINE: 26827289]BrigandiRA , JohnsonB , OeiC , WestermanME , OlbinaG , KumarS , et al. Induction of erythropoiesis in anemic patients by prolylhydroxylase inhibitor in a repeat dose, randomized placebo controlled trial [abstract no: SA-PO117]. Journal of the American Society of Nephrology2012;23(Abstract Suppl):662A. BrigandiRA , WestermanME , OlbinaG , OeiC , RussSF , KumarS . Modulation of hepcidin by prolylhydroxylase inhibitor in randomized trials [abstract no: SA-PO118]. Journal of the American Society of Nephrology2012;23(Abstract Suppl):662A. ">Brigandi 2016</a>; <a href="./references#CD013751-bbs2-0020" title="AkizawaT , MacdougallIC , BernsJS , BernhardtT , TaguchiM , OguraE , et al. Iron regulation by molidustat, bay 85-3934, a daily oral hypoxia-inducible factor prolyl hydroxylase inhibitor in patients with chronic kidney disease [abstract no: SP334]. Nephrology Dialysis Transplantation2018;33(Suppl 1):i457. [EMBASE: 622606520]AkizawaT , MacdougallIC , BernsJS , YamamotoH , TaguchiM , IekushiK , et al. Iron regulation by molidustat, a daily oral hypoxia-inducible factor prolyl hydroxylase inhibitor, in patients with chronic kidney disease. Nephron2019;143(4):243-54. [MEDLINE: 31387097]MacdougallIC , AkizawaT , BernsJ , LentiniS , BernhardtT . Molidustat increases haemoglobin in erythropoiesis stimulating agents (ESA)-naive anaemic patients with chronic kidney disease not on dialysis (CKD-ND) [abstract no: SO036]. Nephrology Dialysis Transplantation2016;31(Suppl 1):i16. [EMBASE: 72325954]MacdougallIC , AkizawaT , BernsJS , BernhardtT , KruegerT . Effects of molidustat in the treatment of anemia in CKD [Erratum in: Clin J Am Soc Nephrol. 2019 Oct 7;14(10):1524]. Clinical Journal of the American Society of Nephrology: CJASN2019;14(1):28-39. [MEDLINE: 30559105]MacdougallIC , BernsJS , AkizawaT , FishbaneS , BernhardtT . DIALOGUE phase 2 program for BAY85-3934 a HIF-PH inhibitor with daily oral treatment in anemic patients suffering from CKD/ESRD [abstract no: FR-PO219]. Journal of the American Society of Nephrology2013;24(Abstract Suppl):413A. ">DIALOGUE 1 2019</a>; <a href="./references#CD013751-bbs2-0021" title="AkizawaT , MacdougallIC , BernsJS , YamamotoH , TaguchiM , IekushiK , et al. Iron regulation by molidustat, a daily oral hypoxia-inducible factor prolyl hydroxylase inhibitor, in patients with chronic kidney disease. Nephron2019;143(4):243-54. [MEDLINE: 31387097]MacdougallIC , AkizawaT , BernsJ , LentiniS , BernhardtT , KrugerT . Safety and efficacy of molidustat in erythropoiesis stimulating agents (ESA) pre-treated anaemic patients with chronic kidney disease not on dialysis (CKD-ND) [abstract no: SP309]. Nephrology Dialysis Transplantation2016;31(Suppl 1):i193. [EMBASE: 72326411]MacdougallIC , AkizawaT , BernsJ , LentiniS , BernhardtT . Molidustat increases haemoglobin in erythropoiesis stimulating agents (ESA)-naive anaemic patients with chronic kidney disease not on dialysis (CKD-ND) [abstract no: SO036]]. Nephrology Dialysis Transplantation2016;31(Suppl 1):i16. [EMBASE: 72325954]MacdougallIC , AkizawaT , BernsJS , BernhardtT , KruegerT . Effects of molidustat in the treatment of anemia in CKD [Erratum in: Clin J Am Soc Nephrol. 2019 Oct 7;14(10):1524]. Clinical Journal of the American Society of Nephrology: CJASN2019;14(1):28-39. [MEDLINE: 30559105]MacdougallIC , BernsJS , AkizawaT , FishbaneS , BernhardtT . DIALOGUE phase 2 program for BAY85-3934 a HIF-PH inhibitor with daily oral treatment in anemic patients suffering from CKD/ESRD [abstract no: FR-PO219]. Journal of the American Society of Nephrology2013;24(Abstract Suppl):413A. ">DIALOGUE 2 2019</a>; <a href="./references#CD013751-bbs2-0022" title="AkizawaT , MacdougallIC , BernsJS , YamamotoH , TaguchiM , IekushiK , et al. Iron regulation by molidustat, a daily oral hypoxia-inducible factor prolyl hydroxylase inhibitor, in patients with chronic kidney disease. Nephron2019;143(4):243-54. [MEDLINE: 31387097]MacdougallIC , AkizawaT , BernsJ , LentiniS , BernhardtT . Molidustat increases haemoglobin in erythropoiesis stimulating agents (ESA)-naive anaemic patients with chronic kidney disease not on dialysis (CKD-ND) [abstract no: SO036]. Nephrology Dialysis Transplantation2016;31(Suppl 1):i16. [EMBASE: 72325954]MacdougallIC , AkizawaT , BernsJS , BernhardtT , KruegerT . Effects of molidustat in the treatment of anemia in CKD [Erratum in: Clin J Am Soc Nephrol. 2019 Oct 7;14(10):1524]. Clinical Journal of the American Society of Nephrology: CJASN2019;14(1):28-39. [MEDLINE: 30559105]MacdougallIC , BernsJS , AkizawaT , FishbaneS , BernhardtT . DIALOGUE phase 2 program for BAY85-3934 a HIF-PH inhibitor with daily oral treatment in anemic patients suffering from CKD/ESRD [abstract no: FR-PO219]. Journal of the American Society of Nephrology2013;24(Abstract Suppl):413A. ">DIALOGUE 4 2019</a>; <a href="./references#CD013751-bbs2-0023" title="BarrattJ , AndricB , TataradzeA , SchoemigM , ReuschM , ValluriU , et al. Roxadustat for the treatment of anemia in CKD patients not on dialysis (NDD): a phase 3, randomized, open-label, active-controlled study [abstract no: TH-OR02]. Journal of the American Society of Nephrology2020;31(Abstract Suppl):1. [EMBASE: 633697812]BarrattJ , AndricB , TataradzeA , SchomigM , ReuschM , ValluriU , et al. Roxadustat for the treatment of anaemia in chronic kidney disease patients not on dialysis: a phase 3, randomised, open-label, active-controlled study (DOLOMITES). Nephrology Dialysis Transplantation2021;36(9):1616-28. [MEDLINE: 34077510]BarrattJ , AndricB , TataradzeA , SchomigM , ReuschM , ValluriU , et al. Roxadustat for the treatment of anaemia in chronic kidney disease patients not on dialysis: a phase 3, randomised, open-label, active controlled study [abstract no: MO001]. Nephrology Dialysis Transplantation2020;35(Suppl 3):iii101. [EMBASE: 633423023]BarrattJ , AndricB , TataradzeA , SchomigM , ReuschM , ValluriU , et al. Roxadustat for the treatment of anemia in chronic kidney disease (CKD) patients not on dialysis (NDD): a phase 3, randomized, open-label, active-controlled study [abstract no: Pos-247]. Kidney International Reports2021;6(4 Suppl):S104. [EMBASE: 2011683542]">DOLOMITES 2021</a>; <a href="./references#CD013751-bbs2-0024" title="ProvenzanoM , EvgenyS , LiubovE , KorneyevaS , KathresalAA , PooleL , et al. HIMALAYAS: a phase 3, randomized, open-label, active-controlled study of the efficacy and safety of roxadustat in the treatment of anemia in incident-dialysis patients [abstract no: TH-OR021]. Journal of the American Society of Nephrology2019;30(Abstract Suppl):5. [EMBASE: 633771140]ProvenzanoR , ShutovE , EremeevaL , KorneyevaS , PooleL , SahaG , et al. Roxadustat for anemia in patients with end-stage renal disease incident to dialysis. Nephrology Dialysis Transplantation2021;36(9):1717-30. [MEDLINE: 33629100]">HIMALAYAS 2021</a>; <a href="./references#CD013751-bbs2-0025" title="CizmanB , AckertJ , MeadowcroftA , BiswasN , KellyD , KleinmanD , et al. Ocular safety profile of daprodustat: results of two 24 week studies [abstract no: SAO004]. Nephrology Dialysis Transplantation2018;33(Suppl 1):i316. [EMBASE: 622604997]HoldstockL , CizmanB , MeadowcroftAM , BiswasN , JohnsonBM , JonesD , et al. Daprodustat for anemia: a 24-week, open-label, randomized controlled trial in participants with chronic kidney disease. Clinical Kidney Journal2019;12(1):129-38. [MEDLINE: 30746140]HoldstockL , CizmanB , MeadowcroftAM , BiswasN , JonesD , JohnsonBM , et al. Daprodustat, a HIF-prolyl-hydroxylase inhibitor, increases and maintains hemoglobin over 24 weeks in anemic chronic kidney disease subjects [abstract no: TH-PO908]. Journal of the American Society of Nephrology2016;27(Abstract Suppl):304A. ">Holdstock 2019</a>; <a href="./references#CD013751-bbs2-0026" title="CizmanB , AckertJ , MeadowcroftA , BiswasN , KellyD , KleinmanD , et al. Ocular safety profile of daprodustat: results of two 24 week studies [abstract no: SAO004]. Nephrology Dialysis Transplantation2018;33(Suppl 1):i316. [EMBASE: 622604997]HoldstockL , CizmanB , MeadowcroftAM , BiswasN , JohnsonBM , JonesD , et al. Daprodustat for anemia: a 24-week, open-label, randomized controlled trial in participants with chronic kidney disease. Clinical Kidney Journal2019;12(1):129-38. [MEDLINE: 30746140]HoldstockL , CizmanB , MeadowcroftAM , BiswasN , JonesD , JohnsonBM , et al. Daprodustat, a HIF-prolyl-hydroxylase inhibitor, increases and maintains hemoglobin over 24 weeks in anemic chronic kidney disease subjects [abstract no: TH-PO908]. Journal of the American Society of Nephrology2016;27(Abstract Suppl):304A. ">Holdstock 2019a</a>; <a href="./references#CD013751-bbs2-0028" title="ChertowGM , BoudvilleN , ChowdhuryP , GonzalezC , KooiengaL , LuoW , et al. Vadadustat for treatment of anemia in patients with dialysis-dependent CKD receiving peritoneal dialysis [abstract no: PO0464]. Journal of the American Society of Nephrology2021;32(Abstract Suppl):184. [EMBASE: 636331136]EckardtKU , AgarwalR , AswadA , AwadA , BlockGA , BacciMR , et al. Safety and efficacy of vadadustat for anemia in patients undergoing dialysis. New England Journal of Medicine2021;384(17):1601-12. [MEDLINE: 33913638]EckardtKU , AgarwalR , FaragYM , JardineAG , KhawajaZ , KouryMJ , et al. Global Phase 3 programme of vadadustat for treatment of anaemia of chronic kidney disease: rationale, study design and baseline characteristics of dialysis-dependent patients in the INNO2VATE trials. Nephrology Dialysis Transplantation2020;36(11):2039-48. [MEDLINE: 33188693]EckardtKU . Global phase 3 clinical trials of vadadustat vs. darbepoetin alfa for treatment of anemia in patients with dialysis-dependent CKD [abstract no: TH-OR01]. Journal of the American Society of Nephrology2020;31(Abstract Suppl):1. [EMBASE: 633697781]ParfreyPS , LuoW , MaroniB , AndersR , VargoD , McCulloughPA . Thromboembolic events with vadadustat vs. darbepoetin alfa for anemia treatment in patients with dialysis-dependent CKD [abstract no: PO0463]. Journal of the American Society of Nephrology2021;32(Abstract Suppl):184. [EMBASE: 636331080]WinkelmayerW , TumlinJA , FishbaneS , FaragY , VargoD , LuoW , et al. Hematologic efficacy of vadadustat for anemia in patients with kidney failure on dialysis [abstract no: MO529]. Nephrology Dialysis Transplantation2021;36(Suppl 1):i325-6. [EMBASE: 635917983]WinkelmayerWC , FishbaneS , TumlinJA , FaragYM , LuoW , AndersR , et al. Iron-related outcomes in patients with dialysis-dependent CKD randomized to vadadustat vs. darbepoetin alfa [abstract no: PO0457]. Journal of the American Society of Nephrology2021;32(Abstract Suppl):182. [EMBASE: 636330773]">INNO2VATE 2020</a>; <a href="./references#CD013751-bbs2-0029" title="EckardtKU , AgarwalR , AswadA , AwadA , BlockGA , BacciMR , et al. Safety and efficacy of vadadustat for anemia in patients undergoing dialysis. New England Journal of Medicine2021;384(17):1601-12. [MEDLINE: 33913638]EckardtKU , AgarwalR , FaragYM , JardineAG , KhawajaZ , KouryMJ , et al. Global Phase 3 programme of vadadustat for treatment of anaemia of chronic kidney disease: rationale, study design and baseline characteristics of dialysis-dependent patients in the INNO2VATE trials. Nephrology Dialysis Transplantation2020;36(11):2039-48. [MEDLINE: 33188693]EckardtKU . Global phase 3 clinical trials of vadadustat vs. darbepoetin alfa for treatment of anemia in patients with dialysis-dependent CKD [abstract no: TH-OR01]. Journal of the American Society of Nephrology2020;31(Abstract Suppl):1. [EMBASE: 633697781]WinkelmayerWC , FishbaneS , TumlinJA , FaragYM , LuoW , AndersR , et al. Iron-related outcomes in patients with dialysis-dependent CKD randomized to vadadustat vs. darbepoetin alfa [abstract no: PO0457]. Journal of the American Society of Nephrology2021;32(Abstract Suppl):182. [EMBASE: 636330773]">INNO2VATE 2020a</a>; <a href="./references#CD013751-bbs2-0030" title="CizmanB , AckertJ , MeadowcroftA , BiswasN , KellyD , KleinmanD , et al. Ocular safety profile of daprodustat: results of two 24 week studies [abstract no: SAO004]. Nephrology Dialysis Transplantation2018;33(Suppl 1):i316. [EMBASE: 622604997]CobitzAR , MeadowcroftAM , CizmanB , HoldstockL , BiswasN , JonesD , et al. Daprodustat, a HIF-prolyl-hydroxylase inhibitor, maintains hemoglobin levels over 24 weeks in anemic hemodialysis subjects switching from recombinant human erythropoietin. [abstract no: SA-OR114]. Journal of the American Society of Nephrology2016;27(Abstract Suppl):93A. MeadowcroftAM , CizmanB , HoldstockL , BiswasN , JohnsonBM , JonesD , et al. Daprodustat for anemia: a 24-week, open-label, randomized controlled trial in participants on hemodialysis. Clinical Kidney Journal2019;12(1):139-48. [MEDLINE: 30746141]">Meadowcroft 2019</a>; <a href="./references#CD013751-bbs2-0040" title="AstraZeneca. A phase 3, multicenter, randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of roxadustat for the treatment of anemia in chronic kidney disease patients not on dialysis [clinical study protocol V6; 31 August 2018]. www.clinicaltrials.gov/ProvidedDocs/27/NCT02174627/Prot_000.pdf (accessed 9 May 2022). EleftheriadisT , PissasG , LiakopoulosV , StefanidisI . On the increased event rate of urinary tract infection and pneumonia in CKD patients treated with roxadustat for anemia. Journal of the American Society of Nephrology2021;32(6):1537. [MEDLINE: 33849917]FishbaneS , El-ShahawyMA , Pecoits-FilhoR , VanBP , HouserMT , FrisonL , et al. OLYMPUS: a phase 3, randomized, double-blind, placebo-controlled, international study of roxadustat efficacy in patients with non-dialysis-dependent (NDD) CKD and anemia [abstract no: TH-OR023]. Journal of the American Society of Nephrology2019;30(Abstract Suppl):6. [EMBASE: 633771285]FishbaneS , El-ShahawyMA , Pecoits-FilhoR , VanBP , HouserMT , FrisonL , et al. Roxadustat for treating anemia in patients with CKD not on dialysis: results from a randomized phase 3 study. Journal of the American Society of Nephrology2021;32(3):737-55. [MEDLINE: 33568383]FishbaneS , El-ShahawyMA , VanBP , LittleDJ . Authors' Reply. Journal of the American Society of Nephrology2021;32(6):1537-8. [MEDLINE: 33849916]Pecoits-FilhoR , ChanTM , HardyE , YuKH , FishbaneS . Roxadustat treatment results in consistent improvements in hemoglobin (Hb) vs. placebo: an analysis of three multinational randomized clinical trials in patients with non-dialysis-dependent CKD (NDD-CKD) [abstract no: TH-OR05]. Journal of the American Society of Nephrology2020;31(Abstract Suppl):2. [EMBASE: 633697943]RastogiA , Pecoits-FilhoR , FishbaneS , LittleDJ , HardyE , YuKH , et al. Roxadustat treatment corrects anemia to hemoglobin (HB) values ≥10 g/dL in the majority of patients with non-dialysis-dependent chronic kidney disease (NDD-CKD) [abstract no: PO0264]. Journal of the American Society of Nephrology2020;31(Abstract Suppl):133. [EMBASE: 633698803]">OLYMPUS 2021</a>; <a href="./references#CD013751-bbs2-0042" title="BunnHF . Vadadustat for anemia in patients with dialysis-dependent or non-dialysis-dependent chronic kidney disease. New England Journal of Medicine2021;385(16):e56. [MEDLINE: 34644481]ChertowGM , PergolaPE , AgarwalR , BlockGA , FaragYM , JardineAG , et al. Cardiovascular safety and efficacy of vadadustat for the treatment of anemia in non-dialysis-dependent CKD: design and baseline characteristics. American Heart Journal2021;235(5):1-11. [MEDLINE: 33129989]ChertowGM , PergolaPE , FaragYM , AgarwalR , ArnoldS , BakoG , et al. Vadadustat in patients with anemia and non-dialysis-dependent CKD. New England Journal of Medicine2021;384(17):1589-600. [MEDLINE: 33913637]ChertowGM . Global phase 3 clinical trials of vadadustat vs. darbepoetin alfa for treatment of anemia in patients with non-dialysis-dependent CKD [abstract no: FR-OR54]. Journal of the American Society of Nephrology2020;31(Abstract Suppl):B2. [EMBASE: 633697273]KouryM , PergolaPE , Roy-ChaudhuryP , FaragYM , LuoW , AndersR , et al. Iron-related outcomes in patients with non-dialysis-dependent CKD randomized to vadadustat vs. darbepoetin Alfa [abstract no: PO0482]. Journal of the American Society of Nephrology2021;32(Abstract Suppl):190. [EMBASE: 636329134]McCulloughPA , LuoW , AndersR , VargoD , ParfreyPS . Assessment of thromboembolic events with vadadustat vs. darbepoetin alfa for treatment of anemia in patients with non-dialysis-dependent CKD [abstract no: PO0462]. Journal of the American Society of Nephrology2021;32(Abstract Suppl):184. [EMBASE: 636331039]">PRO2TECT‐CONVERSION 2021</a>; <a href="./references#CD013751-bbs2-0043" title="BunnHF . Vadadustat for anemia in patients with dialysis-dependent or non-dialysis-dependent chronic kidney disease. New England Journal of Medicine2021;385(16):e56. [MEDLINE: 34644481]ChertowGM , PergolaPE , AgarwalR , BlockGA , FaragYM , JardineAG , et al. Cardiovascular safety and efficacy of vadadustat for the treatment of anemia in non-dialysis-dependent CKD: design and baseline characteristics. American Heart Journal2021;235(5):1-11. [MEDLINE: 33129989]ChertowGM , PergolaPE , FaragYM , AgarwalR , ArnoldS , BakoG , et al. Vadadustat in patients with anemia and non-dialysis-dependent CKD. New England Journal of Medicine2021;384(17):1589-600. [MEDLINE: 33913637]ChertowGM . Global phase 3 clinical trials of vadadustat vs. darbepoetin alfa for treatment of anemia in patients with non-dialysis-dependent CKD [abstract no: FR-OR5]. Journal of the American Society of Nephrology2020;31(Abstract Suppl):B2. [EMBASE: 633697273]KouryM , PergolaPE , Roy-ChaudhuryP , FaragYM , LuoW , AndersR , et al. Iron-related outcomes in patients with non-dialysis-dependent CKD randomized to vadadustat vs. darbepoetin alfa [abstract no: PO0482]. Journal of the American Society of Nephrology2021;32(Abstract Suppl):190. [EMBASE: 636329134]McCulloughPA , LuoW , AndersR , VargoD , ParfreyPS . Assessment of thromboembolic events with vadadustat vs. darbepoetin alfa for treatment of anemia in patients with non-dialysis-dependent CKD [abstract no: PO0462]. Journal of the American Society of Nephrology2021;32(Abstract Suppl):184. [EMBASE: 636331039]">PRO2TECT‐CORRECTION 2021</a>; <a href="./references#CD013751-bbs2-0047" title="Astellas 1517-CL-0613. Roxadustat in the treatment of anemia in end stage renal disease (ESRD) patients on stable dialysis [A phase 3, randomized, open-label, active-controlled study to evaluate the efficacy and safety of roxadustat in the maintenance treatment of anemia in end stage renal disease patients on stable dialysis]. www.trialsummaries.com/Study/StudyDetails?id=14380&amp;tenant=MT_AST_9011 (accessed 9 May 2022). CsikyB , SchomigM , EspositoC , BarrattJ , ReuschM , ValluriU , et al. Roxadustat for the maintenance treatment of anemia in patients with end-stage kidney disease on stable dialysis: a European phase 3, randomized, open-label, active-controlled study (PYRENEES). Advances in Therapy2021;38(10):5361-80. [MEDLINE: 34537926]EspositoC , CsikyB , TataradzeA , ReuschM , HanC , SulowiczW . Two phase 3, multicenter, randomized studies of intermittent oral roxadustat in anemic CKD patients on (PYRENEES) and not on (ALPS) dialysis. Swiss Medical Weekly2020;150(Suppl 248):21-2S. [EMBASE: 634241523]EspositoC , CsikyB , TataradzeA , ReuschM , HanC , SulowiczW . Two phase 3, multicenter, randomized studies of intermittent oral roxadustat in anemic CKD patients on (PYRENEES) and not on (ALPS) dialysis [abstract no: SA-PO225]. Journal of the American Society of Nephrology2019;30(Abstract Suppl):822. [EMBASE: 633767739]">PYRENEES 2021</a>; <a href="./references#CD013751-bbs2-0048" title="AstraZeneca. A phase 3, multicenter, randomized, open-label, active-controlled study of the safety and efficacy of roxadustat in the treatment of anemia in dialysis patients [Clinical study protocol v8.0 19 September 2018]. www.clinicaltrials.gov/ProvidedDocs/31/NCT02174731/Prot_000.pdf (accessed 10 May 2022). FishbaneS , PollockCA , El-ShahawyMA , EscuderoET , RastogiA , VanBP , et al. ROCKIES: an international, phase 3, randomized, open-label, active-controlled study of roxadustat for anemia in dialysis-dependent CKD patients [abstract no: TH-OR022]. Journal of the American Society of Nephrology2019;30(Abstract Suppl):6. [EMBASE: 633771219]">ROCKIES 2019</a>; <a href="./references#CD013751-bbs2-0049" title="CharytanC , Manllo-KarimR , MartinER , SteerD , BernardoM , DuaSL , et al. A randomized trial of roxadustat in anemia of kidney failure: SIERRAS study. Kidney International Reports2021;6(7):1829-39. [MEDLINE: 34307977]CharytanC , Manllo-KarimR , MartinER , SteerD , BernardoM , DuaSL , et al. SIERRAS: A phase 3, open-label, randomized, active-controlled study of the efficacy and safety of roxadustat in the maintenance treatment of anemia in subjects with ESRD on stable dialysis [abstract no: SA-PO227]. Journal of the American Society of Nephrology2019;30(Abstract Suppl):822. [EMBASE: 633767862]">SIERRAS 2021</a>). All but three studies (<a href="./references#CD013751-bbs2-0005" title="AkizawaT , IwasakiM , OtsukaT , YamaguchiY , ReuschM . A phase 3, multicenter, randomized, open-label, active comparator conversion study of roxadustat in non-dialysis-dependent (NDD) patients with anemia in chronic kidney disease (CKD) [abstract no: POS-244]. Kidney International Reports2021;6(4 Suppl):S103. [EMBASE: 2011682459]AkizawaT , IwasakiM , OtsukaT , YamaguchiY , ReuschM . A phase 3, multicenter, randomized, open-label, active comparator conversion study of roxadustat in non-dialysis-dependent (NDD) patients with anemia in CKD [abstract no: PO0269]. Journal of the American Society of Nephrology2020;31(Abstract Suppl):134. [EMBASE: 633699036]NguyenQD , SepahYJ , YamaguchiY , OtsukaT , MajikawaY , ReuschM , et al. Ophthalmological effects of roxadustat in the treatment of anemia in dialysis-dependent and non-dialysis-dependent CKD patients: findings from two phase 3 studies [abstract no: PO0267]. Journal of the American Society of Nephrology2020;31(Abstract Suppl):134. [EMBASE: 633698979]">Akizawa 2020f</a>; <a href="./references#CD013751-bbs2-0027" title="HouYP , MaoXY , WangC , XuZH , BuZH , XuM , et al. Roxadustat treatment for anemia in peritoneal dialysis patients: a randomized controlled trial. Journal of the Formosan Medical Association2021;121(2):529-38. [MEDLINE: 34167878]">Hou 2021</a>; <a href="./references#CD013751-bbs2-0051" title="AkizawaT , NangakuM , YamaguchiT , KoretomoR , MaedaK , MiyazawaY , et al. A phase 3 study of enarodustat in anemic patients with CKD not requiring dialysis: the SYMPHONY ND study. Kidney International Reports2021;6(7):1840-9. [MEDLINE: 34307978]">SYMPHONY ND 2021</a>) received at least some funding from pharmaceutical companies. No studies were phase 1 studies, 19 studies (<a href="./references#CD013751-bbs2-0001" title="AkizawaT , TsubakiharaY , NangakuM , EndoY , NakajimaH , KohnoT , et al. Effects of daprodustat, a novel hypoxia-inducible factor prolyl hydroxylase inhibitor on anemia management in Japanese hemodialysis subjects. American Journal of Nephrology2017;45(2):127-35. [MEDLINE: 27978511]EndoY , KohnoT , ImaiY , KawaseN , HaraK , LeporeJJ , et al. A 4 -week dose response study of the hypoxia inducible factor-prolyl hydroxylase inhibitor GSK1278863 in Japanese anemic haemodialysis subjects [abstract no: SA-PO819]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):818A. NCT02019719. Study to evaluate the safety, efficacy and pharmacokinetics of GSK1278863 in Japanese hemodialysis-dependent subjects with anemia associated with chronic kidney disease [A 4-week, phase ii, randomized, double-blind, dose-ranging, placebo-controlled, parallel-group, multi-center study to evaluate the safety, efficacy and pharmacokinetics of GSK1278863 in Japanese hemodialysis-dependent subjects with anemia associated with chronic kidney disease]. clinicaltrials.gov/show/NCT02019719 (first received 24 December 2013). ">Akizawa 2017</a>; <a href="./references#CD013751-bbs2-0002" title="AkizawaT , IwasakiM , OtsukaT , ReuschM , MisumiT . Roxadustat for the treatment of chronic kidney disease-associated anemia in Japanese patients not on dialysis [abstract no: FR-PO1142]. Journal of the American Society of Nephrology2016;27(Abstract Suppl):7B. AkizawaT , IwasakiM , OtsukaT , ReuschM , MisumiT . Roxadustat treatment of chronic kidney disease-associated anemia in Japanese patients not on dialysis: a phase 2, randomized, double-blind, placebo-controlled trial. Advances in Therapy2019;36(6):1438-54. [MEDLINE: 30953333]">Akizawa 2019</a>; <a href="./references#CD013751-bbs2-0014" title="BesarabA , HutlerHN , KlausS , LeeTT , LilienfeldDE , NeffTB , et al. FG-4592, a novel oral HIF prolyl hydroxylase inhibitor, elevates hemoglobin in anemic stage 3/4 CKD patients [abstract no: SA-FC416]. Journal of the American Society of Nephrology2010;21(Abstract Suppl):95A. BesarabA , ProvenzanoR , HertelJ , ZabanehR , KlausSJ , LeeT , et al. Randomized placebo-controlled dose-ranging and pharmacodynamics study of roxadustat (FG-4592) to treat anemia in nondialysis-dependent chronic kidney disease (NDD-CKD) patients. Nephrology Dialysis Transplantation2015;30(10):1665-73. [MEDLINE: 26238121]">Besarab 2015</a>; <a href="./references#CD013751-bbs2-0015" title="BrigandiRA , JohnsonB , OeiC , WestermanM , OlbinaG , deZoysaJ , et al. A novel hypoxia-inducible factor-prolyl hydroxylase inhibitor (GSK1278863) for anemia in CKD: a 28-day, phase 2a randomized trial. American Journal of Kidney Diseases2016;67(6):861-71. [MEDLINE: 26827289]BrigandiRA , JohnsonB , OeiC , WestermanME , OlbinaG , KumarS , et al. Induction of erythropoiesis in anemic patients by prolylhydroxylase inhibitor in a repeat dose, randomized placebo controlled trial [abstract no: SA-PO117]. Journal of the American Society of Nephrology2012;23(Abstract Suppl):662A. BrigandiRA , WestermanME , OlbinaG , OeiC , RussSF , KumarS . Modulation of hepcidin by prolylhydroxylase inhibitor in randomized trials [abstract no: SA-PO118]. Journal of the American Society of Nephrology2012;23(Abstract Suppl):662A. ">Brigandi 2016</a>; <a href="./references#CD013751-bbs2-0018" title="ChenN , QianJ , ChenJ , YuX , MeiC , HaoC , et al. Phase 2 studies of oral hypoxia-inducible factor prolyl hydroxylase inhibitor FG-4592 for treatment of anemia in China. Nephrology Dialysis Transplantation2017;32(8):1373-86. [MEDLINE: 28371815]">Chen DD 2017</a>; <a href="./references#CD013751-bbs2-0019" title="ChenN , QianJ , ChenJ , YuX , MeiC , HaoC , et al. Phase 2 studies of oral hypoxia-inducible factor prolyl hydroxylase inhibitor FG-4592 for treatment of anemia in China. Nephrology Dialysis Transplantation2017;32(8):1373-86. [MEDLINE: 28371815]QianJQ , ChenN , ChenJ , HaoC , LinHL , NiD , et al. A randomized, double-blind, placebo controlled trial of FG-4592 for correction of anemia in subjects with chronic kidney disease in China [abstract no: FR-OR011]. Journal of the American Society of Nephrology2013;24(Abstract Suppl):38A. ">Chen NDD 2017</a>; <a href="./references#CD013751-bbs2-0020" title="AkizawaT , MacdougallIC , BernsJS , BernhardtT , TaguchiM , OguraE , et al. Iron regulation by molidustat, bay 85-3934, a daily oral hypoxia-inducible factor prolyl hydroxylase inhibitor in patients with chronic kidney disease [abstract no: SP334]. Nephrology Dialysis Transplantation2018;33(Suppl 1):i457. [EMBASE: 622606520]AkizawaT , MacdougallIC , BernsJS , YamamotoH , TaguchiM , IekushiK , et al. Iron regulation by molidustat, a daily oral hypoxia-inducible factor prolyl hydroxylase inhibitor, in patients with chronic kidney disease. Nephron2019;143(4):243-54. [MEDLINE: 31387097]MacdougallIC , AkizawaT , BernsJ , LentiniS , BernhardtT . Molidustat increases haemoglobin in erythropoiesis stimulating agents (ESA)-naive anaemic patients with chronic kidney disease not on dialysis (CKD-ND) [abstract no: SO036]. Nephrology Dialysis Transplantation2016;31(Suppl 1):i16. [EMBASE: 72325954]MacdougallIC , AkizawaT , BernsJS , BernhardtT , KruegerT . Effects of molidustat in the treatment of anemia in CKD [Erratum in: Clin J Am Soc Nephrol. 2019 Oct 7;14(10):1524]. Clinical Journal of the American Society of Nephrology: CJASN2019;14(1):28-39. [MEDLINE: 30559105]MacdougallIC , BernsJS , AkizawaT , FishbaneS , BernhardtT . DIALOGUE phase 2 program for BAY85-3934 a HIF-PH inhibitor with daily oral treatment in anemic patients suffering from CKD/ESRD [abstract no: FR-PO219]. Journal of the American Society of Nephrology2013;24(Abstract Suppl):413A. ">DIALOGUE 1 2019</a>; <a href="./references#CD013751-bbs2-0021" title="AkizawaT , MacdougallIC , BernsJS , YamamotoH , TaguchiM , IekushiK , et al. Iron regulation by molidustat, a daily oral hypoxia-inducible factor prolyl hydroxylase inhibitor, in patients with chronic kidney disease. Nephron2019;143(4):243-54. [MEDLINE: 31387097]MacdougallIC , AkizawaT , BernsJ , LentiniS , BernhardtT , KrugerT . Safety and efficacy of molidustat in erythropoiesis stimulating agents (ESA) pre-treated anaemic patients with chronic kidney disease not on dialysis (CKD-ND) [abstract no: SP309]. Nephrology Dialysis Transplantation2016;31(Suppl 1):i193. [EMBASE: 72326411]MacdougallIC , AkizawaT , BernsJ , LentiniS , BernhardtT . Molidustat increases haemoglobin in erythropoiesis stimulating agents (ESA)-naive anaemic patients with chronic kidney disease not on dialysis (CKD-ND) [abstract no: SO036]]. Nephrology Dialysis Transplantation2016;31(Suppl 1):i16. [EMBASE: 72325954]MacdougallIC , AkizawaT , BernsJS , BernhardtT , KruegerT . Effects of molidustat in the treatment of anemia in CKD [Erratum in: Clin J Am Soc Nephrol. 2019 Oct 7;14(10):1524]. Clinical Journal of the American Society of Nephrology: CJASN2019;14(1):28-39. [MEDLINE: 30559105]MacdougallIC , BernsJS , AkizawaT , FishbaneS , BernhardtT . DIALOGUE phase 2 program for BAY85-3934 a HIF-PH inhibitor with daily oral treatment in anemic patients suffering from CKD/ESRD [abstract no: FR-PO219]. Journal of the American Society of Nephrology2013;24(Abstract Suppl):413A. ">DIALOGUE 2 2019</a>; <a href="./references#CD013751-bbs2-0022" title="AkizawaT , MacdougallIC , BernsJS , YamamotoH , TaguchiM , IekushiK , et al. Iron regulation by molidustat, a daily oral hypoxia-inducible factor prolyl hydroxylase inhibitor, in patients with chronic kidney disease. Nephron2019;143(4):243-54. [MEDLINE: 31387097]MacdougallIC , AkizawaT , BernsJ , LentiniS , BernhardtT . Molidustat increases haemoglobin in erythropoiesis stimulating agents (ESA)-naive anaemic patients with chronic kidney disease not on dialysis (CKD-ND) [abstract no: SO036]. Nephrology Dialysis Transplantation2016;31(Suppl 1):i16. [EMBASE: 72325954]MacdougallIC , AkizawaT , BernsJS , BernhardtT , KruegerT . Effects of molidustat in the treatment of anemia in CKD [Erratum in: Clin J Am Soc Nephrol. 2019 Oct 7;14(10):1524]. Clinical Journal of the American Society of Nephrology: CJASN2019;14(1):28-39. [MEDLINE: 30559105]MacdougallIC , BernsJS , AkizawaT , FishbaneS , BernhardtT . DIALOGUE phase 2 program for BAY85-3934 a HIF-PH inhibitor with daily oral treatment in anemic patients suffering from CKD/ESRD [abstract no: FR-PO219]. Journal of the American Society of Nephrology2013;24(Abstract Suppl):413A. ">DIALOGUE 4 2019</a>; <a href="./references#CD013751-bbs2-0025" title="CizmanB , AckertJ , MeadowcroftA , BiswasN , KellyD , KleinmanD , et al. Ocular safety profile of daprodustat: results of two 24 week studies [abstract no: SAO004]. Nephrology Dialysis Transplantation2018;33(Suppl 1):i316. [EMBASE: 622604997]HoldstockL , CizmanB , MeadowcroftAM , BiswasN , JohnsonBM , JonesD , et al. Daprodustat for anemia: a 24-week, open-label, randomized controlled trial in participants with chronic kidney disease. Clinical Kidney Journal2019;12(1):129-38. [MEDLINE: 30746140]HoldstockL , CizmanB , MeadowcroftAM , BiswasN , JonesD , JohnsonBM , et al. Daprodustat, a HIF-prolyl-hydroxylase inhibitor, increases and maintains hemoglobin over 24 weeks in anemic chronic kidney disease subjects [abstract no: TH-PO908]. Journal of the American Society of Nephrology2016;27(Abstract Suppl):304A. ">Holdstock 2019</a>; <a href="./references#CD013751-bbs2-0026" title="CizmanB , AckertJ , MeadowcroftA , BiswasN , KellyD , KleinmanD , et al. Ocular safety profile of daprodustat: results of two 24 week studies [abstract no: SAO004]. Nephrology Dialysis Transplantation2018;33(Suppl 1):i316. [EMBASE: 622604997]HoldstockL , CizmanB , MeadowcroftAM , BiswasN , JohnsonBM , JonesD , et al. Daprodustat for anemia: a 24-week, open-label, randomized controlled trial in participants with chronic kidney disease. Clinical Kidney Journal2019;12(1):129-38. [MEDLINE: 30746140]HoldstockL , CizmanB , MeadowcroftAM , BiswasN , JonesD , JohnsonBM , et al. Daprodustat, a HIF-prolyl-hydroxylase inhibitor, increases and maintains hemoglobin over 24 weeks in anemic chronic kidney disease subjects [abstract no: TH-PO908]. Journal of the American Society of Nephrology2016;27(Abstract Suppl):304A. ">Holdstock 2019a</a>; <a href="./references#CD013751-bbs2-0037" title="Astellas1517-CL-0304. A study to investigate the effect of ASP1517 after intermittent oral dosing in dialysis chronic kidney disease patients with anemia compared with darbepoetin as a reference drug [A Japanese, phase 2, multicenter, randomized, 4-arm parallel, double-blind (arms 1-3), open-label (arm 4), active-comparator (darbepoetin alfa) study of intermittent oral dosing of asp1517 in hemodialysis-dependent chronic kidney disease patients with anemia [1517-CL-0304 clinical study results report]]. www.trialsummaries.com/Study/StudyDetails?id=14175&amp;tenant=MT_AST_9011; www.clinicaltrials.gov/ct2/show/NCT01888445 (first received 6 August 2018). ">NCT01888445</a>; <a href="./references#CD013751-bbs2-0038" title="NangakuM , FaragYM , deGomaE , LuoW , VargoD , KhawajaZ . Vadadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor, for treatment of anemia of chronic kidney disease: two randomized Phase 2 trials in Japanese patients. Nephrology Dialysis Transplantation 2020 Jul 20 [epub ahead of print]. [DOI: 10.1093/ndt/gfaa060] [MEDLINE: 32719868]NangakuM , KhawajaZ , LuoW , GarafolaS , De GomaE , KomatsuY . Randomized, placebo-controlled phase 2 trials of vadadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), to treat anemia of CKD [abstract no: TH-PO228]. Journal of the American Society of Nephrology2018;29(Abstract Suppl):171. [EMBASE: 633737146]SolinskyC , FaragYM , KhawajaZ , AndersR , LuoW , ChavanA , et al. Impact of vadadustat on iron regulation in Japanese subjects with chronic kidney disease (CKD) [abstract no: 352]. American Journal of Kidney Diseases2020;75(4):638-9. [EMBASE: 2005716872]">NDD‐CKD 2020</a>; <a href="./references#CD013751-bbs2-0039" title="NangakuM , FaragYM , deGomaE , LuoW , VargoD , KhawajaZ . Vadadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor, for treatment of anemia of chronic kidney disease: two randomized Phase 2 trials in Japanese patients. Nephrology Dialysis Transplantation 2020 Jul 20 [epub ahead of print]. [DOI: 10.1093/ndt/gfaa060] [MEDLINE: 32719868]NangakuM , KhawajaZ , LuoW , GarafolaS , deGomaE , KomatsuY . Randomized, placebo-controlled phase 2 trials of vadadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), to treat anemia of CKD [abstract no: TH-PO228]. Journal of the American Society of Nephrology2018;29(Abstract Suppl):171. [EMBASE: 633737146]SolinskyC , FaragYM , KhawajaZ , AndersR , LuoW , ChavanA , et al. Impact of vadadustat on iron regulation in Japanese subjects with chronic kidney disease (CKD) [abstract no: 352]. American Journal of Kidney Diseases2020;75(4):638-9. [EMBASE: 2005716872]">NDD‐CKD 2020a</a>; <a href="./references#CD013751-bbs2-0041" title="HaaseVH , SpinowitzBS , PergolaPE , FarmerT , MaroniBJ , HartmanCS . AKB-6548 demonstrates controlled hemogloblin (HGB) response in a phase 2b study for the treatment of anemia in patients with chronic kidney disease not on dialysis (ND-CKD) [abstract no: TH-PO649]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):237A. HaaseVH , SpinowitzBS , PergolaPE , KhawajaZ , ChanJ , ZurawQ , et al. Efficacy and dose requirements of vadadustat are independent of systemic inflammation and prior erythropoiesis-stimulating agent(ESA) dose in patients with non-dialysis dependent chronic kidney disease (NDD-CKD) [abstract no: TH-PO907]. Journal of the American Society of Nephrology2016;27(Abstract Suppl):304A. PergolaPE , SpinowitzB , HaaseVH , HartmanCS , FarmerTM , PoluKR , et al. AKB-6548, a novel hypoxia-inducible factor prolyl-hydroxylase inhibitor (HIF-PHI) for the treatment of anemia in patients with chronic kidney disease not on dialysis (ND-CKD) [abstract no: FO015]. Nephrology Dialysis Transplantation2015;30(Suppl 3):iii8. [EMBASE: 72206296]PergolaPE , SpinowitzBS , HartmanCS , MaroniBJ , HaaseVH . Vadadustat, a novel oral HIF stabilizer, provides effective anemia treatment in nondialysis-dependent chronic kidney disease. Kidney International2016;90(5):1115-22. [MEDLINE: 27650732]SpinowitzBS , PergolaPE , HaaseVH , FarmerTM , HartmanCS , MaroniBJ . Hemoglobin (HGB) response in a phase 2b study of AKB-6548 for the treatment of anemia in patients with non-dialysis dependant chronic kidney disease (NDD-CKD). [abstract no: TH-OR038]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):11A. ">Pergola 2016</a>; <a href="./references#CD013751-bbs2-0044" title="ProvenzanoR , FaddaG , BernardoM , JamesC , KochendoerferG , LeeT , et al. FG2216, a novel oral HIF-PHI, stimulates erythropoiesis and increases hemoglobin concentration in patients with non-dialysis CKD [abstract no: 212]. American Journal of Kidney Diseases2008;51(4):A80. ProvenzanoR , HulterH , AgarwalA , KlausS , LeeT , YuP , et al. Hypoxia-inducible factor (HIF) prolyl hydroxylase inhibitor FG-2216 increases Hb without FE depletion in the absence of IV Fe [abstract no: 249]. American Journal of Kidney Diseases2013;61(4):A78. [EMBASE: 71024073]">Provenzano 2008</a>; <a href="./references#CD013751-bbs2-0045" title="ProvenzanoR , BesarabA , DuaSL , NguyenPV , WrightSH , ZeigS , et al. FG-4592, a novel oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), maintains hemoglobin levels and lowers cholesterol in hemodialysis patients: phase 2 comparison with epoetin alfa [abstract no: FR-PO257]. Journal of the American Society of Nephrology2012;23(Abstract Suppl):428A. ProvenzanoR , BesarabA , WrightS , DuaS , ZeigS , NguyenP , et al. Roxadustat (FG-4592) versus epoetin alfa for anemia in patients receiving maintenance hemodialysis: a phase 2, randomized, 6- to 19-week, open-label, active-comparator, dose-ranging, safety and exploratory efficacy study. American Journal of Kidney Diseases2016;67(6):912-24. [MEDLINE: 26846333]">Provenzano 2016</a>; <a href="./references#CD013751-bbs2-0046" title="ProvenzanoR , BesarabA , DuaSL , NguyenPV , WrightSH , ZeigS , et al. FG-4592, a novel oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), maintains hemoglobin levels and lowers cholesterol in hemodialysis patients: phase 2 comparison with epoetin alfa [abstract no: FR-PO257]. Journal of the American Society of Nephrology2012;23(Abstract Suppl):428A. ProvenzanoR , BesarabA , WrightS , DuaS , ZeigS , NguyenP , et al. Roxadustat (FG-4592) versus epoetin alfa for anemia in patients receiving maintenance hemodialysis: a phase 2, randomized, 6- to 19-week, open-label, active-comparator, dose-ranging, safety and exploratory efficacy study. American Journal of Kidney Diseases2016;67(6):912-24. [MEDLINE: 26846333]">Provenzano 2016a</a>; <a href="./references#CD013751-bbs2-0049" title="CharytanC , Manllo-KarimR , MartinER , SteerD , BernardoM , DuaSL , et al. A randomized trial of roxadustat in anemia of kidney failure: SIERRAS study. Kidney International Reports2021;6(7):1829-39. [MEDLINE: 34307977]CharytanC , Manllo-KarimR , MartinER , SteerD , BernardoM , DuaSL , et al. SIERRAS: A phase 3, open-label, randomized, active-controlled study of the efficacy and safety of roxadustat in the maintenance treatment of anemia in subjects with ESRD on stable dialysis [abstract no: SA-PO227]. Journal of the American Society of Nephrology2019;30(Abstract Suppl):822. [EMBASE: 633767862]">SIERRAS 2021</a>) were phase 2 studies, and 32 studies were phase 3 studies. </p> </section> <section id="CD013751-sec-0045"> <h5 class="title">Study participants</h5> <p>The sample size varied from 51 (<a href="./references#CD013751-bbs2-0038" title="NangakuM , FaragYM , deGomaE , LuoW , VargoD , KhawajaZ . Vadadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor, for treatment of anemia of chronic kidney disease: two randomized Phase 2 trials in Japanese patients. Nephrology Dialysis Transplantation 2020 Jul 20 [epub ahead of print]. [DOI: 10.1093/ndt/gfaa060] [MEDLINE: 32719868]NangakuM , KhawajaZ , LuoW , GarafolaS , De GomaE , KomatsuY . Randomized, placebo-controlled phase 2 trials of vadadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), to treat anemia of CKD [abstract no: TH-PO228]. Journal of the American Society of Nephrology2018;29(Abstract Suppl):171. [EMBASE: 633737146]SolinskyC , FaragYM , KhawajaZ , AndersR , LuoW , ChavanA , et al. Impact of vadadustat on iron regulation in Japanese subjects with chronic kidney disease (CKD) [abstract no: 352]. American Journal of Kidney Diseases2020;75(4):638-9. [EMBASE: 2005716872]">NDD‐CKD 2020</a>) to 3872 participants (<a href="./references#CD013751-bbs2-0011" title="PerkovicV , BlackorbyA , CizmanB , CarrollK , CobitzA , DaviesR , et al. ASCEND-ND: Study design and baseline characteristics. Nephrology Dialysis Transplantation2021;36(Suppl 1):i334-5. [EMBASE: 635918331]SinghAK , CarrollK , McMurrayJJ , SolomonS , JhaV , JohansenKL , et al. Daprodustat for the treatment of anemia in patients not undergoing dialysis. New England Journal of Medicine2021;385(25):2313-24. [MEDLINE: 34739196]">ASCEND‐ND 2021</a>) (median of 223 participants). The mean study age ranged from 48 years (<a href="./references#CD013751-bbs2-0016" title="ChenN , HaoC , LiuB , LinHL , CailiW , XingCY , et al. A phase 3, randomized, open-label, active-controlled study of efficacy and safety of roxadustat for treatment of anemia in subjects with CKD on dialysis [abstract no: TH-PO1152]. Journal of the American Society of Nephrology2018;29(Abstract Suppl):B5. ChenN , HaoC , LiuBC , LinH , WangC , XingC , et al. Roxadustat treatment for anemia in patients undergoing long-term dialysis. New England Journal of Medicine2019;381(11):1011-22. [MEDLINE: 31340116]">Chen 2019</a>) to 72 years (<a href="./references#CD013751-bbs2-0032" title="YamamotoH , NoboriK , MatsudaY , HayashiY , HayasakiT , AkizawaT . Efficacy and safety of molidustat for anemia in ESA-naive nondialysis patients: a randomized, phase 3 trial. American Journal of Nephrology2021;52(10-11):871-83. [MEDLINE: 34569489]YamamotoH , TaguchiM , MatsudaY , IekushiK , YamadaT , AkizawaT . Molidustat for the treatment of renal anaemia in patients with non-dialysis-dependent chronic kidney disease: design and rationale of two phase III studies. BMJ Open2019;9(6):e026704. [MEDLINE: 31203242]YamamotoH , TaguchiM , NoboriK , MatsudaY , IekushiK , AkizawaT . To investigate the efficacy and safety of molidustat in non-dialysis patients with renal anemia who are not treated with erythropoiesis stimulating agents: MIYABI ND-C [abstract no: P1866]. Nephrology Dialysis Transplantation2020;35(Suppl 3):iii2177. [EMBASE: 633422996]">MIYABI ND‐C 2019</a>; <a href="./references#CD013751-bbs2-0035" title="NangakuM , KondoK , KokadoY , UetaK , KanekoG , ShiosakaM , et al. Randomized, open-label, active-controlled (darbepoetin alfa), phase 3 study of vadadustat for treating anemia in non-dialysis-dependent CKD patients in Japan [abstract no: SA-PO229]. Journal of the American Society of Nephrology2019;30(Abstract Suppl):823. [EMBASE: 633767995]NangakuM , KondoK , KokadoY , UetaK , KanekoG , TandaiT , et al. Phase 3 randomized study comparing vadadustat with darbepoetin alfa for anemia in Japanese patients with nondialysis-dependent CKD. Journal of the American Society of Nephrology2021;32(7):1779-90. [MEDLINE: 33883252]">Nangaku 2021a</a>) (median 63 years). No studies evaluated treatment in children or in recipients of a kidney transplant. </p> <p>Twenty‐five studies in people with CKD stages 3 to 5 not treated with dialysis (<a href="./references#CD013751-bbs2-0002" title="AkizawaT , IwasakiM , OtsukaT , ReuschM , MisumiT . Roxadustat for the treatment of chronic kidney disease-associated anemia in Japanese patients not on dialysis [abstract no: FR-PO1142]. Journal of the American Society of Nephrology2016;27(Abstract Suppl):7B. AkizawaT , IwasakiM , OtsukaT , ReuschM , MisumiT . Roxadustat treatment of chronic kidney disease-associated anemia in Japanese patients not on dialysis: a phase 2, randomized, double-blind, placebo-controlled trial. Advances in Therapy2019;36(6):1438-54. [MEDLINE: 30953333]">Akizawa 2019</a>; <a href="./references#CD013751-bbs2-0005" title="AkizawaT , IwasakiM , OtsukaT , YamaguchiY , ReuschM . A phase 3, multicenter, randomized, open-label, active comparator conversion study of roxadustat in non-dialysis-dependent (NDD) patients with anemia in chronic kidney disease (CKD) [abstract no: POS-244]. Kidney International Reports2021;6(4 Suppl):S103. [EMBASE: 2011682459]AkizawaT , IwasakiM , OtsukaT , YamaguchiY , ReuschM . A phase 3, multicenter, randomized, open-label, active comparator conversion study of roxadustat in non-dialysis-dependent (NDD) patients with anemia in CKD [abstract no: PO0269]. Journal of the American Society of Nephrology2020;31(Abstract Suppl):134. [EMBASE: 633699036]NguyenQD , SepahYJ , YamaguchiY , OtsukaT , MajikawaY , ReuschM , et al. Ophthalmological effects of roxadustat in the treatment of anemia in dialysis-dependent and non-dialysis-dependent CKD patients: findings from two phase 3 studies [abstract no: PO0267]. Journal of the American Society of Nephrology2020;31(Abstract Suppl):134. [EMBASE: 633698979]">Akizawa 2020f</a>; <a href="./references#CD013751-bbs2-0007" title="Astellas 1517-CL-0608. Roxadustat in the treatment of anemia in chronic kidney disease patients not requiring dialysis [A phase 3, randomized, double-blind, placebo controlled study of the efficacy and safety of roxadustat for the treatment of anemia in chronic kidney disease patients not on dialysis]. www.trialsummaries.com/Study/StudyDetails?id=14384&amp;tenant=MT_AST_90112019. EspositoC , CsikyB , TataradzeA , ReuschM , HanC , SulowiczW . Two phase 3, multicenter, randomized studies of intermittent oral roxadustat in anemic CKD patients on (PYRENEES) and not on (ALPS) dialysis [abstract no: SA-PO225]. Journal of the American Society of Nephrology2019;30(Abstract Suppl):822. [EMBASE: 633767739]Pecoits-FilhoR , ChanTM , HardyE , YuKH , FishbaneS . Roxadustat treatment results in consistent improvements in hemoglobin (Hb) vs. placebo: an analysis of three multinational randomized clinical trials in patients with non-dialysis-dependent CKD (NDD-CKD) [abstract no: TH-OR05]. Journal of the American Society of Nephrology2020;31(Abstract Suppl):2. [EMBASE: 633697943]RastogiA , Pecoits-FilhoR , FishbaneS , LittleDJ , HardyE , YuKH , et al. Roxadustat treatment corrects anemia to hemoglobin (HB) values ≥10 g/dL in the majority of patients with non-dialysis-dependent chronic kidney disease (NDD-CKD) [abstract no: PO0264]. Journal of the American Society of Nephrology2020;31(Abstract Suppl):133. [EMBASE: 633698803]ShutovE , SulowiczW , EspositoC , TataradzeA , AndricB , ReuschM , et al. Roxadustat for the treatment of anemia in chronic kidney disease patients not on dialysis: a phase 3, randomized, double-blind, placebo-controlled study (ALPS). Nephrology Dialysis Transplantation2021;36(9):1629-39. [MEDLINE: 33630072]">ALPS 2021</a>; <a href="./references#CD013751-bbs2-0008" title="CoyneDW , RogerSD , ChouW , BesarabA , LeongR , LeeTT , et al. Roxadustat favorably modifies iron indices in patients with non-dialysis-dependent CKD-related anemia [abstract no: PO0262]. Journal of the American Society of Nephrology2020;31(Abstract Suppl):132. [EMBASE: 633698686]CoyneDW , RogerSD , ShinS , KimSG , CadenaAA , MoustafaMA , et al. Roxadustat for CKD-related anemia in non-dialysis patients. Kidney International Reports2021;6(3):624-35. [MEDLINE: 33732977]CoyneDW , RogerSD , ShinSK , KimSG , CadenaAA , MoustafaMA , et al. ANDES: A phase 3, randomized, double-blind, placebo controlled study of the efficacy and safety of roxadustat for the treatment of anemia in CKD patients not on dialysis [abstract no: SA-PO0228]. Journal of the American Society of Nephrology2019;30(Abstract Suppl):822-3. [EMBASE: 633767955]Pecoits-FilhoR , ChanTM , HardyE , YuKHP , FishbaneS . Roxadustat treatment results in consistent improvements in hemoglobin (Hb) vs. placebo: an analysis of three multinational randomized clinical trials in patients with non-dialysis-dependent CKD (NDD-CKD) [abstract no: TH-OR05]. Journal of the American Society of Nephrology2020;31(Abstract Suppl):2. [EMBASE: 633697943]RastogiA , Pecoits-FilhoR , FishbaneS , LittleDJ , HardyE , YuKH , et al. Roxadustat treatment corrects anemia to hemoglobin (HB) values ≥10 g/dL in the majority of patients with non-dialysis-dependent chronic kidney disease (NDD-CKD) [abstract no: PO0264]. Journal of the American Society of Nephrology2020;31(Abstract Suppl):133. [EMBASE: 633698803]">ANDES 2021</a>; <a href="./references#CD013751-bbs2-0011" title="PerkovicV , BlackorbyA , CizmanB , CarrollK , CobitzA , DaviesR , et al. ASCEND-ND: Study design and baseline characteristics. Nephrology Dialysis Transplantation2021;36(Suppl 1):i334-5. [EMBASE: 635918331]SinghAK , CarrollK , McMurrayJJ , SolomonS , JhaV , JohansenKL , et al. Daprodustat for the treatment of anemia in patients not undergoing dialysis. New England Journal of Medicine2021;385(25):2313-24. [MEDLINE: 34739196]">ASCEND‐ND 2021</a>; <a href="./references#CD013751-bbs2-0012" title="JohansenKL , CobitzAR , LopesRD , SinghAK , ObradorGT , CizmanB , et al. Effects of daprodustat on hemoglobin and quality of life in patients with CKD: results of the ascend-NHQ randomized, double-blind, placebo-controlled trial [abstract no: FR-OR53]. Journal of the American Society of Nephrology2021;32(Abstract Suppl):36. [EMBASE: 636330656]">ASCEND‐NHQ 2021</a>; <a href="./references#CD013751-bbs2-0014" title="BesarabA , HutlerHN , KlausS , LeeTT , LilienfeldDE , NeffTB , et al. FG-4592, a novel oral HIF prolyl hydroxylase inhibitor, elevates hemoglobin in anemic stage 3/4 CKD patients [abstract no: SA-FC416]. Journal of the American Society of Nephrology2010;21(Abstract Suppl):95A. BesarabA , ProvenzanoR , HertelJ , ZabanehR , KlausSJ , LeeT , et al. Randomized placebo-controlled dose-ranging and pharmacodynamics study of roxadustat (FG-4592) to treat anemia in nondialysis-dependent chronic kidney disease (NDD-CKD) patients. Nephrology Dialysis Transplantation2015;30(10):1665-73. [MEDLINE: 26238121]">Besarab 2015</a>; <a href="./references#CD013751-bbs2-0017" title="ChenN , HaoC , PengX , LinH , YinA , HaoL , et al. Roxadustat for anemia in patients with kidney disease not receiving dialysis. New England Journal of Medicine2019;381(11):1001-10. [MEDLINE: 31340089]ChenN , HaoC , PengX , LinHL , YinA , HaoL , et al. A phase 3, randomized, double-blind, placebo-controlled study of efficacy and safety of roxadustat (FG-4592) for treatment of anemia in subjects with CKD not on dialysis [abstract no: TH-PO1153]. Journal of the American Society of Nephrology2018;29(Abstract Suppl):B5. ">Chen 2019a</a>; <a href="./references#CD013751-bbs2-0018" title="ChenN , QianJ , ChenJ , YuX , MeiC , HaoC , et al. Phase 2 studies of oral hypoxia-inducible factor prolyl hydroxylase inhibitor FG-4592 for treatment of anemia in China. Nephrology Dialysis Transplantation2017;32(8):1373-86. [MEDLINE: 28371815]">Chen DD 2017</a>; <a href="./references#CD013751-bbs2-0020" title="AkizawaT , MacdougallIC , BernsJS , BernhardtT , TaguchiM , OguraE , et al. Iron regulation by molidustat, bay 85-3934, a daily oral hypoxia-inducible factor prolyl hydroxylase inhibitor in patients with chronic kidney disease [abstract no: SP334]. Nephrology Dialysis Transplantation2018;33(Suppl 1):i457. [EMBASE: 622606520]AkizawaT , MacdougallIC , BernsJS , YamamotoH , TaguchiM , IekushiK , et al. Iron regulation by molidustat, a daily oral hypoxia-inducible factor prolyl hydroxylase inhibitor, in patients with chronic kidney disease. Nephron2019;143(4):243-54. [MEDLINE: 31387097]MacdougallIC , AkizawaT , BernsJ , LentiniS , BernhardtT . Molidustat increases haemoglobin in erythropoiesis stimulating agents (ESA)-naive anaemic patients with chronic kidney disease not on dialysis (CKD-ND) [abstract no: SO036]. Nephrology Dialysis Transplantation2016;31(Suppl 1):i16. [EMBASE: 72325954]MacdougallIC , AkizawaT , BernsJS , BernhardtT , KruegerT . Effects of molidustat in the treatment of anemia in CKD [Erratum in: Clin J Am Soc Nephrol. 2019 Oct 7;14(10):1524]. Clinical Journal of the American Society of Nephrology: CJASN2019;14(1):28-39. [MEDLINE: 30559105]MacdougallIC , BernsJS , AkizawaT , FishbaneS , BernhardtT . DIALOGUE phase 2 program for BAY85-3934 a HIF-PH inhibitor with daily oral treatment in anemic patients suffering from CKD/ESRD [abstract no: FR-PO219]. Journal of the American Society of Nephrology2013;24(Abstract Suppl):413A. ">DIALOGUE 1 2019</a>; <a href="./references#CD013751-bbs2-0021" title="AkizawaT , MacdougallIC , BernsJS , YamamotoH , TaguchiM , IekushiK , et al. Iron regulation by molidustat, a daily oral hypoxia-inducible factor prolyl hydroxylase inhibitor, in patients with chronic kidney disease. Nephron2019;143(4):243-54. [MEDLINE: 31387097]MacdougallIC , AkizawaT , BernsJ , LentiniS , BernhardtT , KrugerT . Safety and efficacy of molidustat in erythropoiesis stimulating agents (ESA) pre-treated anaemic patients with chronic kidney disease not on dialysis (CKD-ND) [abstract no: SP309]. Nephrology Dialysis Transplantation2016;31(Suppl 1):i193. [EMBASE: 72326411]MacdougallIC , AkizawaT , BernsJ , LentiniS , BernhardtT . Molidustat increases haemoglobin in erythropoiesis stimulating agents (ESA)-naive anaemic patients with chronic kidney disease not on dialysis (CKD-ND) [abstract no: SO036]]. Nephrology Dialysis Transplantation2016;31(Suppl 1):i16. [EMBASE: 72325954]MacdougallIC , AkizawaT , BernsJS , BernhardtT , KruegerT . Effects of molidustat in the treatment of anemia in CKD [Erratum in: Clin J Am Soc Nephrol. 2019 Oct 7;14(10):1524]. Clinical Journal of the American Society of Nephrology: CJASN2019;14(1):28-39. [MEDLINE: 30559105]MacdougallIC , BernsJS , AkizawaT , FishbaneS , BernhardtT . DIALOGUE phase 2 program for BAY85-3934 a HIF-PH inhibitor with daily oral treatment in anemic patients suffering from CKD/ESRD [abstract no: FR-PO219]. Journal of the American Society of Nephrology2013;24(Abstract Suppl):413A. ">DIALOGUE 2 2019</a>; <a href="./references#CD013751-bbs2-0023" title="BarrattJ , AndricB , TataradzeA , SchoemigM , ReuschM , ValluriU , et al. Roxadustat for the treatment of anemia in CKD patients not on dialysis (NDD): a phase 3, randomized, open-label, active-controlled study [abstract no: TH-OR02]. Journal of the American Society of Nephrology2020;31(Abstract Suppl):1. [EMBASE: 633697812]BarrattJ , AndricB , TataradzeA , SchomigM , ReuschM , ValluriU , et al. Roxadustat for the treatment of anaemia in chronic kidney disease patients not on dialysis: a phase 3, randomised, open-label, active-controlled study (DOLOMITES). Nephrology Dialysis Transplantation2021;36(9):1616-28. [MEDLINE: 34077510]BarrattJ , AndricB , TataradzeA , SchomigM , ReuschM , ValluriU , et al. Roxadustat for the treatment of anaemia in chronic kidney disease patients not on dialysis: a phase 3, randomised, open-label, active controlled study [abstract no: MO001]. Nephrology Dialysis Transplantation2020;35(Suppl 3):iii101. [EMBASE: 633423023]BarrattJ , AndricB , TataradzeA , SchomigM , ReuschM , ValluriU , et al. Roxadustat for the treatment of anemia in chronic kidney disease (CKD) patients not on dialysis (NDD): a phase 3, randomized, open-label, active-controlled study [abstract no: Pos-247]. Kidney International Reports2021;6(4 Suppl):S104. [EMBASE: 2011683542]">DOLOMITES 2021</a>; <a href="./references#CD013751-bbs2-0025" title="CizmanB , AckertJ , MeadowcroftA , BiswasN , KellyD , KleinmanD , et al. Ocular safety profile of daprodustat: results of two 24 week studies [abstract no: SAO004]. Nephrology Dialysis Transplantation2018;33(Suppl 1):i316. [EMBASE: 622604997]HoldstockL , CizmanB , MeadowcroftAM , BiswasN , JohnsonBM , JonesD , et al. Daprodustat for anemia: a 24-week, open-label, randomized controlled trial in participants with chronic kidney disease. Clinical Kidney Journal2019;12(1):129-38. [MEDLINE: 30746140]HoldstockL , CizmanB , MeadowcroftAM , BiswasN , JonesD , JohnsonBM , et al. Daprodustat, a HIF-prolyl-hydroxylase inhibitor, increases and maintains hemoglobin over 24 weeks in anemic chronic kidney disease subjects [abstract no: TH-PO908]. Journal of the American Society of Nephrology2016;27(Abstract Suppl):304A. ">Holdstock 2019</a>; <a href="./references#CD013751-bbs2-0026" title="CizmanB , AckertJ , MeadowcroftA , BiswasN , KellyD , KleinmanD , et al. Ocular safety profile of daprodustat: results of two 24 week studies [abstract no: SAO004]. Nephrology Dialysis Transplantation2018;33(Suppl 1):i316. [EMBASE: 622604997]HoldstockL , CizmanB , MeadowcroftAM , BiswasN , JohnsonBM , JonesD , et al. Daprodustat for anemia: a 24-week, open-label, randomized controlled trial in participants with chronic kidney disease. Clinical Kidney Journal2019;12(1):129-38. [MEDLINE: 30746140]HoldstockL , CizmanB , MeadowcroftAM , BiswasN , JonesD , JohnsonBM , et al. Daprodustat, a HIF-prolyl-hydroxylase inhibitor, increases and maintains hemoglobin over 24 weeks in anemic chronic kidney disease subjects [abstract no: TH-PO908]. Journal of the American Society of Nephrology2016;27(Abstract Suppl):304A. ">Holdstock 2019a</a>; <a href="./references#CD013751-bbs2-0032" title="YamamotoH , NoboriK , MatsudaY , HayashiY , HayasakiT , AkizawaT . Efficacy and safety of molidustat for anemia in ESA-naive nondialysis patients: a randomized, phase 3 trial. American Journal of Nephrology2021;52(10-11):871-83. [MEDLINE: 34569489]YamamotoH , TaguchiM , MatsudaY , IekushiK , YamadaT , AkizawaT . Molidustat for the treatment of renal anaemia in patients with non-dialysis-dependent chronic kidney disease: design and rationale of two phase III studies. BMJ Open2019;9(6):e026704. [MEDLINE: 31203242]YamamotoH , TaguchiM , NoboriK , MatsudaY , IekushiK , AkizawaT . To investigate the efficacy and safety of molidustat in non-dialysis patients with renal anemia who are not treated with erythropoiesis stimulating agents: MIYABI ND-C [abstract no: P1866]. Nephrology Dialysis Transplantation2020;35(Suppl 3):iii2177. [EMBASE: 633422996]">MIYABI ND‐C 2019</a>; <a href="./references#CD013751-bbs2-0033" title="YamamotoH , NoboriK , MatsudaY , HayashiY , HayasakiT , AkizawaT . Molidustat for renal anemia in nondialysis patients previously treated with erythropoiesis-stimulating agents: a randomized, open-label, phase 3 study. American Journal of Nephrology2021;52(10-11):884-93. [MEDLINE: 34569482]YamamotoH , TaguchiM , MatsudaY , IekushiK , YamadaT , AkizawaT . Molidustat for the treatment of renal anaemia in patients with non-dialysis-dependent chronic kidney disease: design and rationale of two phase III studies. BMJ Open2019;9(6):e026704. [MEDLINE: 31203242]YamamotoH , TaguchiM , NoboriK , MatsudaY , IekushiK , AkizawaT . To investigate the efficacy and safety of molidustat in non-dialysis patients with renal anemia who are treated with erythropoiesis stimulating agents: Miyabi ND-M [Abstract no: P1868]. Nephrology Dialysis Transplantation2020;35(Suppl 3):iii2179. [EMBASE: 633423006]">MIYABI ND‐M 2019</a>; <a href="./references#CD013751-bbs2-0035" title="NangakuM , KondoK , KokadoY , UetaK , KanekoG , ShiosakaM , et al. Randomized, open-label, active-controlled (darbepoetin alfa), phase 3 study of vadadustat for treating anemia in non-dialysis-dependent CKD patients in Japan [abstract no: SA-PO229]. Journal of the American Society of Nephrology2019;30(Abstract Suppl):823. [EMBASE: 633767995]NangakuM , KondoK , KokadoY , UetaK , KanekoG , TandaiT , et al. Phase 3 randomized study comparing vadadustat with darbepoetin alfa for anemia in Japanese patients with nondialysis-dependent CKD. Journal of the American Society of Nephrology2021;32(7):1779-90. [MEDLINE: 33883252]">Nangaku 2021a</a>; <a href="./references#CD013751-bbs2-0036" title="GSK201753. A 52-week, Phase III, open-label, multi-center study to evaluate efficacy and safety of GSK1278863 in Japanese non-dialysis and peritoneal dialysis subjects with anemia associated with chronic kidney disease [study protocol]. www.clinicaltrials.gov/ProvidedDocs/63/NCT02791763/Prot_000.pdf (accessed 9 May 2022). NangakuM , HamanoT , AkizawaT , TsubakiharaY , NagaiR , OkudaN , et al. Daprodustat compared with epoetin beta pegol for anemia in Japanese patients not on dialysis: a 52-week randomized open-label phase 3 trial. American Journal of Nephrology2021;52(1):26-35. [MEDLINE: 33561857]">Nangaku 2021b</a>; <a href="./references#CD013751-bbs2-0038" title="NangakuM , FaragYM , deGomaE , LuoW , VargoD , KhawajaZ . Vadadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor, for treatment of anemia of chronic kidney disease: two randomized Phase 2 trials in Japanese patients. Nephrology Dialysis Transplantation 2020 Jul 20 [epub ahead of print]. [DOI: 10.1093/ndt/gfaa060] [MEDLINE: 32719868]NangakuM , KhawajaZ , LuoW , GarafolaS , De GomaE , KomatsuY . Randomized, placebo-controlled phase 2 trials of vadadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), to treat anemia of CKD [abstract no: TH-PO228]. Journal of the American Society of Nephrology2018;29(Abstract Suppl):171. [EMBASE: 633737146]SolinskyC , FaragYM , KhawajaZ , AndersR , LuoW , ChavanA , et al. Impact of vadadustat on iron regulation in Japanese subjects with chronic kidney disease (CKD) [abstract no: 352]. American Journal of Kidney Diseases2020;75(4):638-9. [EMBASE: 2005716872]">NDD‐CKD 2020</a>; <a href="./references#CD013751-bbs2-0040" title="AstraZeneca. A phase 3, multicenter, randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of roxadustat for the treatment of anemia in chronic kidney disease patients not on dialysis [clinical study protocol V6; 31 August 2018]. www.clinicaltrials.gov/ProvidedDocs/27/NCT02174627/Prot_000.pdf (accessed 9 May 2022). EleftheriadisT , PissasG , LiakopoulosV , StefanidisI . On the increased event rate of urinary tract infection and pneumonia in CKD patients treated with roxadustat for anemia. Journal of the American Society of Nephrology2021;32(6):1537. [MEDLINE: 33849917]FishbaneS , El-ShahawyMA , Pecoits-FilhoR , VanBP , HouserMT , FrisonL , et al. OLYMPUS: a phase 3, randomized, double-blind, placebo-controlled, international study of roxadustat efficacy in patients with non-dialysis-dependent (NDD) CKD and anemia [abstract no: TH-OR023]. Journal of the American Society of Nephrology2019;30(Abstract Suppl):6. [EMBASE: 633771285]FishbaneS , El-ShahawyMA , Pecoits-FilhoR , VanBP , HouserMT , FrisonL , et al. Roxadustat for treating anemia in patients with CKD not on dialysis: results from a randomized phase 3 study. Journal of the American Society of Nephrology2021;32(3):737-55. [MEDLINE: 33568383]FishbaneS , El-ShahawyMA , VanBP , LittleDJ . Authors' Reply. Journal of the American Society of Nephrology2021;32(6):1537-8. [MEDLINE: 33849916]Pecoits-FilhoR , ChanTM , HardyE , YuKH , FishbaneS . Roxadustat treatment results in consistent improvements in hemoglobin (Hb) vs. placebo: an analysis of three multinational randomized clinical trials in patients with non-dialysis-dependent CKD (NDD-CKD) [abstract no: TH-OR05]. Journal of the American Society of Nephrology2020;31(Abstract Suppl):2. [EMBASE: 633697943]RastogiA , Pecoits-FilhoR , FishbaneS , LittleDJ , HardyE , YuKH , et al. Roxadustat treatment corrects anemia to hemoglobin (HB) values ≥10 g/dL in the majority of patients with non-dialysis-dependent chronic kidney disease (NDD-CKD) [abstract no: PO0264]. Journal of the American Society of Nephrology2020;31(Abstract Suppl):133. [EMBASE: 633698803]">OLYMPUS 2021</a>; <a href="./references#CD013751-bbs2-0041" title="HaaseVH , SpinowitzBS , PergolaPE , FarmerT , MaroniBJ , HartmanCS . AKB-6548 demonstrates controlled hemogloblin (HGB) response in a phase 2b study for the treatment of anemia in patients with chronic kidney disease not on dialysis (ND-CKD) [abstract no: TH-PO649]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):237A. HaaseVH , SpinowitzBS , PergolaPE , KhawajaZ , ChanJ , ZurawQ , et al. Efficacy and dose requirements of vadadustat are independent of systemic inflammation and prior erythropoiesis-stimulating agent(ESA) dose in patients with non-dialysis dependent chronic kidney disease (NDD-CKD) [abstract no: TH-PO907]. Journal of the American Society of Nephrology2016;27(Abstract Suppl):304A. PergolaPE , SpinowitzB , HaaseVH , HartmanCS , FarmerTM , PoluKR , et al. AKB-6548, a novel hypoxia-inducible factor prolyl-hydroxylase inhibitor (HIF-PHI) for the treatment of anemia in patients with chronic kidney disease not on dialysis (ND-CKD) [abstract no: FO015]. Nephrology Dialysis Transplantation2015;30(Suppl 3):iii8. [EMBASE: 72206296]PergolaPE , SpinowitzBS , HartmanCS , MaroniBJ , HaaseVH . Vadadustat, a novel oral HIF stabilizer, provides effective anemia treatment in nondialysis-dependent chronic kidney disease. Kidney International2016;90(5):1115-22. [MEDLINE: 27650732]SpinowitzBS , PergolaPE , HaaseVH , FarmerTM , HartmanCS , MaroniBJ . Hemoglobin (HGB) response in a phase 2b study of AKB-6548 for the treatment of anemia in patients with non-dialysis dependant chronic kidney disease (NDD-CKD). [abstract no: TH-OR038]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):11A. ">Pergola 2016</a>; <a href="./references#CD013751-bbs2-0042" title="BunnHF . Vadadustat for anemia in patients with dialysis-dependent or non-dialysis-dependent chronic kidney disease. New England Journal of Medicine2021;385(16):e56. [MEDLINE: 34644481]ChertowGM , PergolaPE , AgarwalR , BlockGA , FaragYM , JardineAG , et al. Cardiovascular safety and efficacy of vadadustat for the treatment of anemia in non-dialysis-dependent CKD: design and baseline characteristics. American Heart Journal2021;235(5):1-11. [MEDLINE: 33129989]ChertowGM , PergolaPE , FaragYM , AgarwalR , ArnoldS , BakoG , et al. Vadadustat in patients with anemia and non-dialysis-dependent CKD. New England Journal of Medicine2021;384(17):1589-600. [MEDLINE: 33913637]ChertowGM . Global phase 3 clinical trials of vadadustat vs. darbepoetin alfa for treatment of anemia in patients with non-dialysis-dependent CKD [abstract no: FR-OR54]. Journal of the American Society of Nephrology2020;31(Abstract Suppl):B2. [EMBASE: 633697273]KouryM , PergolaPE , Roy-ChaudhuryP , FaragYM , LuoW , AndersR , et al. Iron-related outcomes in patients with non-dialysis-dependent CKD randomized to vadadustat vs. darbepoetin Alfa [abstract no: PO0482]. Journal of the American Society of Nephrology2021;32(Abstract Suppl):190. [EMBASE: 636329134]McCulloughPA , LuoW , AndersR , VargoD , ParfreyPS . Assessment of thromboembolic events with vadadustat vs. darbepoetin alfa for treatment of anemia in patients with non-dialysis-dependent CKD [abstract no: PO0462]. Journal of the American Society of Nephrology2021;32(Abstract Suppl):184. [EMBASE: 636331039]">PRO2TECT‐CONVERSION 2021</a>; <a href="./references#CD013751-bbs2-0043" title="BunnHF . Vadadustat for anemia in patients with dialysis-dependent or non-dialysis-dependent chronic kidney disease. New England Journal of Medicine2021;385(16):e56. [MEDLINE: 34644481]ChertowGM , PergolaPE , AgarwalR , BlockGA , FaragYM , JardineAG , et al. Cardiovascular safety and efficacy of vadadustat for the treatment of anemia in non-dialysis-dependent CKD: design and baseline characteristics. American Heart Journal2021;235(5):1-11. [MEDLINE: 33129989]ChertowGM , PergolaPE , FaragYM , AgarwalR , ArnoldS , BakoG , et al. Vadadustat in patients with anemia and non-dialysis-dependent CKD. New England Journal of Medicine2021;384(17):1589-600. [MEDLINE: 33913637]ChertowGM . Global phase 3 clinical trials of vadadustat vs. darbepoetin alfa for treatment of anemia in patients with non-dialysis-dependent CKD [abstract no: FR-OR5]. Journal of the American Society of Nephrology2020;31(Abstract Suppl):B2. [EMBASE: 633697273]KouryM , PergolaPE , Roy-ChaudhuryP , FaragYM , LuoW , AndersR , et al. Iron-related outcomes in patients with non-dialysis-dependent CKD randomized to vadadustat vs. darbepoetin alfa [abstract no: PO0482]. Journal of the American Society of Nephrology2021;32(Abstract Suppl):190. [EMBASE: 636329134]McCulloughPA , LuoW , AndersR , VargoD , ParfreyPS . Assessment of thromboembolic events with vadadustat vs. darbepoetin alfa for treatment of anemia in patients with non-dialysis-dependent CKD [abstract no: PO0462]. Journal of the American Society of Nephrology2021;32(Abstract Suppl):184. [EMBASE: 636331039]">PRO2TECT‐CORRECTION 2021</a>; <a href="./references#CD013751-bbs2-0044" title="ProvenzanoR , FaddaG , BernardoM , JamesC , KochendoerferG , LeeT , et al. FG2216, a novel oral HIF-PHI, stimulates erythropoiesis and increases hemoglobin concentration in patients with non-dialysis CKD [abstract no: 212]. American Journal of Kidney Diseases2008;51(4):A80. ProvenzanoR , HulterH , AgarwalA , KlausS , LeeT , YuP , et al. Hypoxia-inducible factor (HIF) prolyl hydroxylase inhibitor FG-2216 increases Hb without FE depletion in the absence of IV Fe [abstract no: 249]. American Journal of Kidney Diseases2013;61(4):A78. [EMBASE: 71024073]">Provenzano 2008</a>; <a href="./references#CD013751-bbs2-0051" title="AkizawaT , NangakuM , YamaguchiT , KoretomoR , MaedaK , MiyazawaY , et al. A phase 3 study of enarodustat in anemic patients with CKD not requiring dialysis: the SYMPHONY ND study. Kidney International Reports2021;6(7):1840-9. [MEDLINE: 34307978]">SYMPHONY ND 2021</a>), one study in people with CKD stages 3‐5 including 5D (<a href="./references#CD013751-bbs2-0015" title="BrigandiRA , JohnsonB , OeiC , WestermanM , OlbinaG , deZoysaJ , et al. A novel hypoxia-inducible factor-prolyl hydroxylase inhibitor (GSK1278863) for anemia in CKD: a 28-day, phase 2a randomized trial. American Journal of Kidney Diseases2016;67(6):861-71. [MEDLINE: 26827289]BrigandiRA , JohnsonB , OeiC , WestermanME , OlbinaG , KumarS , et al. Induction of erythropoiesis in anemic patients by prolylhydroxylase inhibitor in a repeat dose, randomized placebo controlled trial [abstract no: SA-PO117]. Journal of the American Society of Nephrology2012;23(Abstract Suppl):662A. BrigandiRA , WestermanME , OlbinaG , OeiC , RussSF , KumarS . Modulation of hepcidin by prolylhydroxylase inhibitor in randomized trials [abstract no: SA-PO118]. Journal of the American Society of Nephrology2012;23(Abstract Suppl):662A. ">Brigandi 2016</a>), 14 studies in people treated with haemodialysis (HD) (<a href="./references#CD013751-bbs2-0001" title="AkizawaT , TsubakiharaY , NangakuM , EndoY , NakajimaH , KohnoT , et al. Effects of daprodustat, a novel hypoxia-inducible factor prolyl hydroxylase inhibitor on anemia management in Japanese hemodialysis subjects. American Journal of Nephrology2017;45(2):127-35. [MEDLINE: 27978511]EndoY , KohnoT , ImaiY , KawaseN , HaraK , LeporeJJ , et al. A 4 -week dose response study of the hypoxia inducible factor-prolyl hydroxylase inhibitor GSK1278863 in Japanese anemic haemodialysis subjects [abstract no: SA-PO819]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):818A. NCT02019719. Study to evaluate the safety, efficacy and pharmacokinetics of GSK1278863 in Japanese hemodialysis-dependent subjects with anemia associated with chronic kidney disease [A 4-week, phase ii, randomized, double-blind, dose-ranging, placebo-controlled, parallel-group, multi-center study to evaluate the safety, efficacy and pharmacokinetics of GSK1278863 in Japanese hemodialysis-dependent subjects with anemia associated with chronic kidney disease]. clinicaltrials.gov/show/NCT02019719 (first received 24 December 2013). ">Akizawa 2017</a>; <a href="./references#CD013751-bbs2-0003" title="AkizawaT , IwasakiM , YamaguchiY , MajikawaY , ReuschM . Authors' Reply. Journal of the American Society of Nephrology2021;32(4):1005-7. [MEDLINE: 33649099]AkizawaT , IwasakiM , YamaguchiY , MajikawaY , ReuschM . Phase 3, randomized, double-blind, active-comparator (darbepoetin alfa) conversion study of oral roxadustat in CKD patients with anemia on hemodialysis in Japan [abstract no: TH-PO1151]. Journal of the American Society of Nephrology2018;29(Abstract Suppl):B4. AkizawaT , IwasakiM , YamaguchiY , MajikawaY , ReuschM . Phase 3, randomized, double-blind, active-comparator (darbepoetin alfa) study of oral roxadustat in CKD patients with anemia on hemodialysis in Japan. Journal of the American Society of Nephrology2020;31(7):1628-39. [MEDLINE: 32493693]AkizawaT , YamaguchiY , MajikawaY , ReuschM . Factors affecting the doses of roxadustat vs darbepoetin alfa for anemia treatment in hemodialysis patients. Therapeutic Apheresis &amp; Dialysis2021;25(5):575-85. [MEDLINE: 33200512]Astellas1517-CL-0307. A study of intermittent oral dosing of ASP1517 in hemodialysis chronic kidney disease patients with anemia [A phase 3, multi-center, randomized, 2-arm parallel, double-blind, active-comparator (darbepoetin alfa) conversion study of intermittent oral dosing of ASP1517 in hemodialysis chronic kidney disease patients with anemia]. www.clinicaltrials.astellas.com/study/?pid=1517-CL-0307 (accessed 4 May 2022). LiuF , WangJ , YeQ , FuH , MaoJ . Roxadustat for renal anemia in ESRD from PKD patients: is it safe enough?Journal of the American Society of Nephrology2021;32(4):1005. [MEDLINE: 33649100]NguyenQD , SepahYJ , YamaguchiY , OtsukaT , MajikawaY , ReuschM , et al. Ophthalmological effects of roxadustat in the treatment of anemia in dialysis-dependent and non-dialysis-dependent CKD patients: findings from two phase 3 studies [abstract no: PO0267]. Journal of the American Society of Nephrology2020;31(Abstract Suppl):134. [EMBASE: 633698979]SepahY , NguyenQD , YamaguchiY , MajikawaY , ReuschM , AkizawaT . Ophthalmological effects of roxadustat in the treatment of anaemia in chronic kidney disease patients on dialysis in a phase 3, randomised, double-blind, active-comparator conversion study [abstract no: MO002]. Nephrology Dialysis Transplantation2020;35(Suppl 3):iii102. [EMBASE: 633421367]">Akizawa 2020a</a>; <a href="./references#CD013751-bbs2-0004" title="AkizawaT , NangakuM , YonekawaT , OkudaN , KawamatsuS , OnoueT , et al. Efficacy and safety of daprodustat compared with darbepoetin alfa in Japanese hemodialysis patients with anemia: a randomized, double-blind, phase 3 trial. Clinical Journal of the American Society of Nephrology: CJASN2020;15(8):1155-65. [MEDLINE: 32723804]OzekiH , AkizawaT , NangakuM , YonekawaT , OkudaN , KawamatsuS , et al. Efficacy and safety of daprodustat compared with darbepoetin alfa in Japanese hemodialysis patients with anemia: A randomized, double-blind, phase 3 trial [abstract no: SaO036]. Nephrology Dialysis Transplantation2019;34(Suppl 1):a350. [EMBASE: 631305259]">Akizawa 2020c</a>; <a href="./references#CD013751-bbs2-0013" title="CoyneDW , SinghAK , LopesRD , BaileyCK , DiminoTL , HuangC , et al. ASCEND-TD: A randomized, double-blind, active-controlled study of daprodustat administered three times weekly in hemodialysis patients [abstract no: PO0487]. Journal of the American Society of Nephrology2021;32(Abstract Suppl):191. [EMBASE: 636329480]">ASCEND‐TD 2021</a>; <a href="./references#CD013751-bbs2-0018" title="ChenN , QianJ , ChenJ , YuX , MeiC , HaoC , et al. Phase 2 studies of oral hypoxia-inducible factor prolyl hydroxylase inhibitor FG-4592 for treatment of anemia in China. Nephrology Dialysis Transplantation2017;32(8):1373-86. [MEDLINE: 28371815]">Chen DD 2017</a>; <a href="./references#CD013751-bbs2-0022" title="AkizawaT , MacdougallIC , BernsJS , YamamotoH , TaguchiM , IekushiK , et al. Iron regulation by molidustat, a daily oral hypoxia-inducible factor prolyl hydroxylase inhibitor, in patients with chronic kidney disease. Nephron2019;143(4):243-54. [MEDLINE: 31387097]MacdougallIC , AkizawaT , BernsJ , LentiniS , BernhardtT . Molidustat increases haemoglobin in erythropoiesis stimulating agents (ESA)-naive anaemic patients with chronic kidney disease not on dialysis (CKD-ND) [abstract no: SO036]. Nephrology Dialysis Transplantation2016;31(Suppl 1):i16. [EMBASE: 72325954]MacdougallIC , AkizawaT , BernsJS , BernhardtT , KruegerT . Effects of molidustat in the treatment of anemia in CKD [Erratum in: Clin J Am Soc Nephrol. 2019 Oct 7;14(10):1524]. Clinical Journal of the American Society of Nephrology: CJASN2019;14(1):28-39. [MEDLINE: 30559105]MacdougallIC , BernsJS , AkizawaT , FishbaneS , BernhardtT . DIALOGUE phase 2 program for BAY85-3934 a HIF-PH inhibitor with daily oral treatment in anemic patients suffering from CKD/ESRD [abstract no: FR-PO219]. Journal of the American Society of Nephrology2013;24(Abstract Suppl):413A. ">DIALOGUE 4 2019</a>; <a href="./references#CD013751-bbs2-0030" title="CizmanB , AckertJ , MeadowcroftA , BiswasN , KellyD , KleinmanD , et al. Ocular safety profile of daprodustat: results of two 24 week studies [abstract no: SAO004]. Nephrology Dialysis Transplantation2018;33(Suppl 1):i316. [EMBASE: 622604997]CobitzAR , MeadowcroftAM , CizmanB , HoldstockL , BiswasN , JonesD , et al. Daprodustat, a HIF-prolyl-hydroxylase inhibitor, maintains hemoglobin levels over 24 weeks in anemic hemodialysis subjects switching from recombinant human erythropoietin. [abstract no: SA-OR114]. Journal of the American Society of Nephrology2016;27(Abstract Suppl):93A. MeadowcroftAM , CizmanB , HoldstockL , BiswasN , JohnsonBM , JonesD , et al. Daprodustat for anemia: a 24-week, open-label, randomized controlled trial in participants on hemodialysis. Clinical Kidney Journal2019;12(1):139-48. [MEDLINE: 30746141]">Meadowcroft 2019</a>; <a href="./references#CD013751-bbs2-0031" title="AkizawaT , TaguchiM , MatsudaY , IekushiK , YamadaT , YamamotoH . Molidustat for the treatment of renal anaemia in patients with dialysis-dependent chronic kidney disease: Design and rationale of three phase III studies. BMJ Open2019;9(6):e026602. [MEDLINE: 31203241]AkizawaT , YamadaT , NoboriK , MatsudaY , HayashiY , HayasakiT , et al. Molidustat for Japanese patients with renal anemia receiving dialysis. Kidney International Reports2021;6(10):2604–16. [MEDLINE: 34622100]AkizawaT , YamadaT , NoboriK , MatsudaY , HayashiY , HayasakiT , et al. Results from a phase 3 study comparing the efficacy and safety of molidustat vs. Darbepoetin Alfa in patients receiving hemodialysis and treated with erythropoiesis-stimulating agents (ESAS) [abstract no: PO22623]. Journal of the American Society of Nephrology2020;31(Abstract Suppl):B4. [EMBASE: 633697376]">MIYABI HD‐M 2019</a>; <a href="./references#CD013751-bbs2-0034" title="NangakuM , KondoK , UetaK , KokadoY , KanekoG , MatsudaH , et al. Efficacy and safety of vadadustat compared with darbepoetin alfa in Japanese anemic patients on hemodialysis: a phase 3, multicenter, randomized, double-blind study. Nephrology Dialysis Transplantation2021;36(9):1731-41. [MEDLINE: 33650630]NangakuM , KondoK , UetaK , KokadoY , KanekoG , MatsudaH , et al. Randomized, double-blinded, active-controlled (darbepoetin alfa), phase 3 study of vadadustat in CKD patients with anemia on hemodialysis in Japan [abstract no: TH-OR024]. Journal of the American Society of Nephrology2019;30(Abstract Suppl):6. [EMBASE: 633771357]">Nangaku 2021</a>; <a href="./references#CD013751-bbs2-0037" title="Astellas1517-CL-0304. A study to investigate the effect of ASP1517 after intermittent oral dosing in dialysis chronic kidney disease patients with anemia compared with darbepoetin as a reference drug [A Japanese, phase 2, multicenter, randomized, 4-arm parallel, double-blind (arms 1-3), open-label (arm 4), active-comparator (darbepoetin alfa) study of intermittent oral dosing of asp1517 in hemodialysis-dependent chronic kidney disease patients with anemia [1517-CL-0304 clinical study results report]]. www.trialsummaries.com/Study/StudyDetails?id=14175&amp;tenant=MT_AST_9011; www.clinicaltrials.gov/ct2/show/NCT01888445 (first received 6 August 2018). ">NCT01888445</a>; <a href="./references#CD013751-bbs2-0039" title="NangakuM , FaragYM , deGomaE , LuoW , VargoD , KhawajaZ . Vadadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor, for treatment of anemia of chronic kidney disease: two randomized Phase 2 trials in Japanese patients. Nephrology Dialysis Transplantation 2020 Jul 20 [epub ahead of print]. [DOI: 10.1093/ndt/gfaa060] [MEDLINE: 32719868]NangakuM , KhawajaZ , LuoW , GarafolaS , deGomaE , KomatsuY . Randomized, placebo-controlled phase 2 trials of vadadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), to treat anemia of CKD [abstract no: TH-PO228]. Journal of the American Society of Nephrology2018;29(Abstract Suppl):171. [EMBASE: 633737146]SolinskyC , FaragYM , KhawajaZ , AndersR , LuoW , ChavanA , et al. Impact of vadadustat on iron regulation in Japanese subjects with chronic kidney disease (CKD) [abstract no: 352]. American Journal of Kidney Diseases2020;75(4):638-9. [EMBASE: 2005716872]">NDD‐CKD 2020a</a>; <a href="./references#CD013751-bbs2-0045" title="ProvenzanoR , BesarabA , DuaSL , NguyenPV , WrightSH , ZeigS , et al. FG-4592, a novel oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), maintains hemoglobin levels and lowers cholesterol in hemodialysis patients: phase 2 comparison with epoetin alfa [abstract no: FR-PO257]. Journal of the American Society of Nephrology2012;23(Abstract Suppl):428A. ProvenzanoR , BesarabA , WrightS , DuaS , ZeigS , NguyenP , et al. Roxadustat (FG-4592) versus epoetin alfa for anemia in patients receiving maintenance hemodialysis: a phase 2, randomized, 6- to 19-week, open-label, active-comparator, dose-ranging, safety and exploratory efficacy study. American Journal of Kidney Diseases2016;67(6):912-24. [MEDLINE: 26846333]">Provenzano 2016</a>; <a href="./references#CD013751-bbs2-0046" title="ProvenzanoR , BesarabA , DuaSL , NguyenPV , WrightSH , ZeigS , et al. FG-4592, a novel oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), maintains hemoglobin levels and lowers cholesterol in hemodialysis patients: phase 2 comparison with epoetin alfa [abstract no: FR-PO257]. Journal of the American Society of Nephrology2012;23(Abstract Suppl):428A. ProvenzanoR , BesarabA , WrightS , DuaS , ZeigS , NguyenP , et al. Roxadustat (FG-4592) versus epoetin alfa for anemia in patients receiving maintenance hemodialysis: a phase 2, randomized, 6- to 19-week, open-label, active-comparator, dose-ranging, safety and exploratory efficacy study. American Journal of Kidney Diseases2016;67(6):912-24. [MEDLINE: 26846333]">Provenzano 2016a</a>; <a href="./references#CD013751-bbs2-0050" title="AkizawaT , MaedaK , MiyazawaY , KoretomoR . Phase 3 study to compare the efficacy and safety of enarodustat (JTZ-951), an oral HIF-PH inhibitor, with darbepoetin alfa in anemic patients with CKD receiving maintenance hemodialysis [abstract no: TH-PO1186]. Journal of the American Society of Nephrology2019;30(Abstract Suppl):B4. AkizawaT , NangakuM , YamaguchiT , KoretomoR , MaedaK , MiyazawaY , et al. A phase 3 study of enarodustat (JTZ-951) in Japanese hemodialysis patients for treatment of anemia in chronic kidney disease: SYMPHONY HD study. Kidney Diseases2021;7(6):494-502. [EMBASE: 2013576033]">SYMPHONY HD 2021</a>), one study in people with PD (<a href="./references#CD013751-bbs2-0027" title="HouYP , MaoXY , WangC , XuZH , BuZH , XuM , et al. Roxadustat treatment for anemia in peritoneal dialysis patients: a randomized controlled trial. Journal of the Formosan Medical Association2021;121(2):529-38. [MEDLINE: 34167878]">Hou 2021</a>), and 10 studies (<a href="./references#CD013751-bbs2-0009" title="SinghAK , BlackorbyA , CizmanB , CarrollK , CobitzAR , DaviesR , et al. Study design and baseline characteristics of patients on dialysis in the ASCEND-D trial. Nephrology Dialysis Transplantation2021;37(5):960-72. [MEDLINE: 33744933] [MEDLINE: 33744933]SinghAK , BlackorbyA , CizmanB , CobitzAR , GodoySA , JhaV , et al. Regional variation of erythropoietin-stimulating agent hyporesponsiveness in the global daprodustat dialysis study (ASCEND-D) [abstract no: TH-OR08]. Journal of the American Society of Nephrology2020;31(Abstract Suppl):3. [EMBASE: 633698062]SinghAK , CarrollK , PerkovicV , SolomonS , JhaV , JohansenKL , et al. Daprodustat for the treatment of anemia in patients undergoing dialysis. New England Journal of Medicine2021;385(25):2325-35. [MEDLINE: 34739194]">ASCEND‐D 2021</a>; <a href="./references#CD013751-bbs2-0010" title="SinghAK . Daprodustat is noninferior to darbepoetin alfa in treating anemia in incident dialysis patients [abstract no: PO0465]. Journal of the American Society of Nephrology2021;32(Abstract Suppl):184-5. [EMBASE: 636331207]">ASCEND‐ID 2021</a>; <a href="./references#CD013751-bbs2-0016" title="ChenN , HaoC , LiuB , LinHL , CailiW , XingCY , et al. A phase 3, randomized, open-label, active-controlled study of efficacy and safety of roxadustat for treatment of anemia in subjects with CKD on dialysis [abstract no: TH-PO1152]. Journal of the American Society of Nephrology2018;29(Abstract Suppl):B5. ChenN , HaoC , LiuBC , LinH , WangC , XingC , et al. Roxadustat treatment for anemia in patients undergoing long-term dialysis. New England Journal of Medicine2019;381(11):1011-22. [MEDLINE: 31340116]">Chen 2019</a>; <a href="./references#CD013751-bbs2-0024" title="ProvenzanoM , EvgenyS , LiubovE , KorneyevaS , KathresalAA , PooleL , et al. HIMALAYAS: a phase 3, randomized, open-label, active-controlled study of the efficacy and safety of roxadustat in the treatment of anemia in incident-dialysis patients [abstract no: TH-OR021]. Journal of the American Society of Nephrology2019;30(Abstract Suppl):5. [EMBASE: 633771140]ProvenzanoR , ShutovE , EremeevaL , KorneyevaS , PooleL , SahaG , et al. Roxadustat for anemia in patients with end-stage renal disease incident to dialysis. Nephrology Dialysis Transplantation2021;36(9):1717-30. [MEDLINE: 33629100]">HIMALAYAS 2021</a>; <a href="./references#CD013751-bbs2-0028" title="ChertowGM , BoudvilleN , ChowdhuryP , GonzalezC , KooiengaL , LuoW , et al. Vadadustat for treatment of anemia in patients with dialysis-dependent CKD receiving peritoneal dialysis [abstract no: PO0464]. Journal of the American Society of Nephrology2021;32(Abstract Suppl):184. [EMBASE: 636331136]EckardtKU , AgarwalR , AswadA , AwadA , BlockGA , BacciMR , et al. Safety and efficacy of vadadustat for anemia in patients undergoing dialysis. New England Journal of Medicine2021;384(17):1601-12. [MEDLINE: 33913638]EckardtKU , AgarwalR , FaragYM , JardineAG , KhawajaZ , KouryMJ , et al. Global Phase 3 programme of vadadustat for treatment of anaemia of chronic kidney disease: rationale, study design and baseline characteristics of dialysis-dependent patients in the INNO2VATE trials. Nephrology Dialysis Transplantation2020;36(11):2039-48. [MEDLINE: 33188693]EckardtKU . Global phase 3 clinical trials of vadadustat vs. darbepoetin alfa for treatment of anemia in patients with dialysis-dependent CKD [abstract no: TH-OR01]. Journal of the American Society of Nephrology2020;31(Abstract Suppl):1. [EMBASE: 633697781]ParfreyPS , LuoW , MaroniB , AndersR , VargoD , McCulloughPA . Thromboembolic events with vadadustat vs. darbepoetin alfa for anemia treatment in patients with dialysis-dependent CKD [abstract no: PO0463]. Journal of the American Society of Nephrology2021;32(Abstract Suppl):184. [EMBASE: 636331080]WinkelmayerW , TumlinJA , FishbaneS , FaragY , VargoD , LuoW , et al. Hematologic efficacy of vadadustat for anemia in patients with kidney failure on dialysis [abstract no: MO529]. Nephrology Dialysis Transplantation2021;36(Suppl 1):i325-6. [EMBASE: 635917983]WinkelmayerWC , FishbaneS , TumlinJA , FaragYM , LuoW , AndersR , et al. Iron-related outcomes in patients with dialysis-dependent CKD randomized to vadadustat vs. darbepoetin alfa [abstract no: PO0457]. Journal of the American Society of Nephrology2021;32(Abstract Suppl):182. [EMBASE: 636330773]">INNO2VATE 2020</a>; <a href="./references#CD013751-bbs2-0029" title="EckardtKU , AgarwalR , AswadA , AwadA , BlockGA , BacciMR , et al. Safety and efficacy of vadadustat for anemia in patients undergoing dialysis. New England Journal of Medicine2021;384(17):1601-12. [MEDLINE: 33913638]EckardtKU , AgarwalR , FaragYM , JardineAG , KhawajaZ , KouryMJ , et al. Global Phase 3 programme of vadadustat for treatment of anaemia of chronic kidney disease: rationale, study design and baseline characteristics of dialysis-dependent patients in the INNO2VATE trials. Nephrology Dialysis Transplantation2020;36(11):2039-48. [MEDLINE: 33188693]EckardtKU . Global phase 3 clinical trials of vadadustat vs. darbepoetin alfa for treatment of anemia in patients with dialysis-dependent CKD [abstract no: TH-OR01]. Journal of the American Society of Nephrology2020;31(Abstract Suppl):1. [EMBASE: 633697781]WinkelmayerWC , FishbaneS , TumlinJA , FaragYM , LuoW , AndersR , et al. Iron-related outcomes in patients with dialysis-dependent CKD randomized to vadadustat vs. darbepoetin alfa [abstract no: PO0457]. Journal of the American Society of Nephrology2021;32(Abstract Suppl):182. [EMBASE: 636330773]">INNO2VATE 2020a</a>; <a href="./references#CD013751-bbs2-0024" title="ProvenzanoM , EvgenyS , LiubovE , KorneyevaS , KathresalAA , PooleL , et al. HIMALAYAS: a phase 3, randomized, open-label, active-controlled study of the efficacy and safety of roxadustat in the treatment of anemia in incident-dialysis patients [abstract no: TH-OR021]. Journal of the American Society of Nephrology2019;30(Abstract Suppl):5. [EMBASE: 633771140]ProvenzanoR , ShutovE , EremeevaL , KorneyevaS , PooleL , SahaG , et al. Roxadustat for anemia in patients with end-stage renal disease incident to dialysis. Nephrology Dialysis Transplantation2021;36(9):1717-30. [MEDLINE: 33629100]">HIMALAYAS 2021</a>; <a href="./references#CD013751-bbs2-0047" title="Astellas 1517-CL-0613. Roxadustat in the treatment of anemia in end stage renal disease (ESRD) patients on stable dialysis [A phase 3, randomized, open-label, active-controlled study to evaluate the efficacy and safety of roxadustat in the maintenance treatment of anemia in end stage renal disease patients on stable dialysis]. www.trialsummaries.com/Study/StudyDetails?id=14380&amp;tenant=MT_AST_9011 (accessed 9 May 2022). CsikyB , SchomigM , EspositoC , BarrattJ , ReuschM , ValluriU , et al. Roxadustat for the maintenance treatment of anemia in patients with end-stage kidney disease on stable dialysis: a European phase 3, randomized, open-label, active-controlled study (PYRENEES). Advances in Therapy2021;38(10):5361-80. [MEDLINE: 34537926]EspositoC , CsikyB , TataradzeA , ReuschM , HanC , SulowiczW . Two phase 3, multicenter, randomized studies of intermittent oral roxadustat in anemic CKD patients on (PYRENEES) and not on (ALPS) dialysis. Swiss Medical Weekly2020;150(Suppl 248):21-2S. [EMBASE: 634241523]EspositoC , CsikyB , TataradzeA , ReuschM , HanC , SulowiczW . Two phase 3, multicenter, randomized studies of intermittent oral roxadustat in anemic CKD patients on (PYRENEES) and not on (ALPS) dialysis [abstract no: SA-PO225]. Journal of the American Society of Nephrology2019;30(Abstract Suppl):822. [EMBASE: 633767739]">PYRENEES 2021</a>; <a href="./references#CD013751-bbs2-0048" title="AstraZeneca. A phase 3, multicenter, randomized, open-label, active-controlled study of the safety and efficacy of roxadustat in the treatment of anemia in dialysis patients [Clinical study protocol v8.0 19 September 2018]. www.clinicaltrials.gov/ProvidedDocs/31/NCT02174731/Prot_000.pdf (accessed 10 May 2022). FishbaneS , PollockCA , El-ShahawyMA , EscuderoET , RastogiA , VanBP , et al. ROCKIES: an international, phase 3, randomized, open-label, active-controlled study of roxadustat for anemia in dialysis-dependent CKD patients [abstract no: TH-OR022]. Journal of the American Society of Nephrology2019;30(Abstract Suppl):6. [EMBASE: 633771219]">ROCKIES 2019</a>; <a href="./references#CD013751-bbs2-0049" title="CharytanC , Manllo-KarimR , MartinER , SteerD , BernardoM , DuaSL , et al. A randomized trial of roxadustat in anemia of kidney failure: SIERRAS study. Kidney International Reports2021;6(7):1829-39. [MEDLINE: 34307977]CharytanC , Manllo-KarimR , MartinER , SteerD , BernardoM , DuaSL , et al. SIERRAS: A phase 3, open-label, randomized, active-controlled study of the efficacy and safety of roxadustat in the maintenance treatment of anemia in subjects with ESRD on stable dialysis [abstract no: SA-PO227]. Journal of the American Society of Nephrology2019;30(Abstract Suppl):822. [EMBASE: 633767862]">SIERRAS 2021</a>) included people treated with HD and PD. </p> <p>Seventeen studies reported information regarding the baseline eGFR in participants (<a href="./references#CD013751-bbs2-0002" title="AkizawaT , IwasakiM , OtsukaT , ReuschM , MisumiT . Roxadustat for the treatment of chronic kidney disease-associated anemia in Japanese patients not on dialysis [abstract no: FR-PO1142]. Journal of the American Society of Nephrology2016;27(Abstract Suppl):7B. AkizawaT , IwasakiM , OtsukaT , ReuschM , MisumiT . Roxadustat treatment of chronic kidney disease-associated anemia in Japanese patients not on dialysis: a phase 2, randomized, double-blind, placebo-controlled trial. Advances in Therapy2019;36(6):1438-54. [MEDLINE: 30953333]">Akizawa 2019</a>; <a href="./references#CD013751-bbs2-0006" title="AkizawaT , IwasakiM , OtsukaT , YamaguchiY , ReuschM . Phase 3 study of roxadustat to treat anemia in non-dialysis-dependant CKD. Kidney International Reports2021;6(7):1810-28. [MEDLINE: 34307976]AkizawaT , Tanaka-AminoK , OtsukaT , YamaguchiY . Factors affecting doses of roxadustat versus darbepoetin alfa for anemia in nondialysis patients. American Journal of Nephrology2021;52(9):702-13. [MEDLINE: 34628408]">Akizawa 2021</a>; <a href="./references#CD013751-bbs2-0008" title="CoyneDW , RogerSD , ChouW , BesarabA , LeongR , LeeTT , et al. Roxadustat favorably modifies iron indices in patients with non-dialysis-dependent CKD-related anemia [abstract no: PO0262]. Journal of the American Society of Nephrology2020;31(Abstract Suppl):132. [EMBASE: 633698686]CoyneDW , RogerSD , ShinS , KimSG , CadenaAA , MoustafaMA , et al. Roxadustat for CKD-related anemia in non-dialysis patients. Kidney International Reports2021;6(3):624-35. [MEDLINE: 33732977]CoyneDW , RogerSD , ShinSK , KimSG , CadenaAA , MoustafaMA , et al. ANDES: A phase 3, randomized, double-blind, placebo controlled study of the efficacy and safety of roxadustat for the treatment of anemia in CKD patients not on dialysis [abstract no: SA-PO0228]. Journal of the American Society of Nephrology2019;30(Abstract Suppl):822-3. [EMBASE: 633767955]Pecoits-FilhoR , ChanTM , HardyE , YuKHP , FishbaneS . Roxadustat treatment results in consistent improvements in hemoglobin (Hb) vs. placebo: an analysis of three multinational randomized clinical trials in patients with non-dialysis-dependent CKD (NDD-CKD) [abstract no: TH-OR05]. Journal of the American Society of Nephrology2020;31(Abstract Suppl):2. [EMBASE: 633697943]RastogiA , Pecoits-FilhoR , FishbaneS , LittleDJ , HardyE , YuKH , et al. Roxadustat treatment corrects anemia to hemoglobin (HB) values ≥10 g/dL in the majority of patients with non-dialysis-dependent chronic kidney disease (NDD-CKD) [abstract no: PO0264]. Journal of the American Society of Nephrology2020;31(Abstract Suppl):133. [EMBASE: 633698803]">ANDES 2021</a>; <a href="./references#CD013751-bbs2-0014" title="BesarabA , HutlerHN , KlausS , LeeTT , LilienfeldDE , NeffTB , et al. FG-4592, a novel oral HIF prolyl hydroxylase inhibitor, elevates hemoglobin in anemic stage 3/4 CKD patients [abstract no: SA-FC416]. Journal of the American Society of Nephrology2010;21(Abstract Suppl):95A. BesarabA , ProvenzanoR , HertelJ , ZabanehR , KlausSJ , LeeT , et al. Randomized placebo-controlled dose-ranging and pharmacodynamics study of roxadustat (FG-4592) to treat anemia in nondialysis-dependent chronic kidney disease (NDD-CKD) patients. Nephrology Dialysis Transplantation2015;30(10):1665-73. [MEDLINE: 26238121]">Besarab 2015</a>; <a href="./references#CD013751-bbs2-0017" title="ChenN , HaoC , PengX , LinH , YinA , HaoL , et al. Roxadustat for anemia in patients with kidney disease not receiving dialysis. New England Journal of Medicine2019;381(11):1001-10. [MEDLINE: 31340089]ChenN , HaoC , PengX , LinHL , YinA , HaoL , et al. A phase 3, randomized, double-blind, placebo-controlled study of efficacy and safety of roxadustat (FG-4592) for treatment of anemia in subjects with CKD not on dialysis [abstract no: TH-PO1153]. Journal of the American Society of Nephrology2018;29(Abstract Suppl):B5. ">Chen 2019a</a>; <a href="./references#CD013751-bbs2-0019" title="ChenN , QianJ , ChenJ , YuX , MeiC , HaoC , et al. Phase 2 studies of oral hypoxia-inducible factor prolyl hydroxylase inhibitor FG-4592 for treatment of anemia in China. Nephrology Dialysis Transplantation2017;32(8):1373-86. [MEDLINE: 28371815]QianJQ , ChenN , ChenJ , HaoC , LinHL , NiD , et al. A randomized, double-blind, placebo controlled trial of FG-4592 for correction of anemia in subjects with chronic kidney disease in China [abstract no: FR-OR011]. Journal of the American Society of Nephrology2013;24(Abstract Suppl):38A. ">Chen NDD 2017</a>; <a href="./references#CD013751-bbs2-0020" title="AkizawaT , MacdougallIC , BernsJS , BernhardtT , TaguchiM , OguraE , et al. Iron regulation by molidustat, bay 85-3934, a daily oral hypoxia-inducible factor prolyl hydroxylase inhibitor in patients with chronic kidney disease [abstract no: SP334]. Nephrology Dialysis Transplantation2018;33(Suppl 1):i457. [EMBASE: 622606520]AkizawaT , MacdougallIC , BernsJS , YamamotoH , TaguchiM , IekushiK , et al. Iron regulation by molidustat, a daily oral hypoxia-inducible factor prolyl hydroxylase inhibitor, in patients with chronic kidney disease. Nephron2019;143(4):243-54. [MEDLINE: 31387097]MacdougallIC , AkizawaT , BernsJ , LentiniS , BernhardtT . Molidustat increases haemoglobin in erythropoiesis stimulating agents (ESA)-naive anaemic patients with chronic kidney disease not on dialysis (CKD-ND) [abstract no: SO036]. Nephrology Dialysis Transplantation2016;31(Suppl 1):i16. [EMBASE: 72325954]MacdougallIC , AkizawaT , BernsJS , BernhardtT , KruegerT . Effects of molidustat in the treatment of anemia in CKD [Erratum in: Clin J Am Soc Nephrol. 2019 Oct 7;14(10):1524]. Clinical Journal of the American Society of Nephrology: CJASN2019;14(1):28-39. [MEDLINE: 30559105]MacdougallIC , BernsJS , AkizawaT , FishbaneS , BernhardtT . DIALOGUE phase 2 program for BAY85-3934 a HIF-PH inhibitor with daily oral treatment in anemic patients suffering from CKD/ESRD [abstract no: FR-PO219]. Journal of the American Society of Nephrology2013;24(Abstract Suppl):413A. ">DIALOGUE 1 2019</a>; <a href="./references#CD013751-bbs2-0021" title="AkizawaT , MacdougallIC , BernsJS , YamamotoH , TaguchiM , IekushiK , et al. Iron regulation by molidustat, a daily oral hypoxia-inducible factor prolyl hydroxylase inhibitor, in patients with chronic kidney disease. Nephron2019;143(4):243-54. [MEDLINE: 31387097]MacdougallIC , AkizawaT , BernsJ , LentiniS , BernhardtT , KrugerT . Safety and efficacy of molidustat in erythropoiesis stimulating agents (ESA) pre-treated anaemic patients with chronic kidney disease not on dialysis (CKD-ND) [abstract no: SP309]. Nephrology Dialysis Transplantation2016;31(Suppl 1):i193. [EMBASE: 72326411]MacdougallIC , AkizawaT , BernsJ , LentiniS , BernhardtT . Molidustat increases haemoglobin in erythropoiesis stimulating agents (ESA)-naive anaemic patients with chronic kidney disease not on dialysis (CKD-ND) [abstract no: SO036]]. Nephrology Dialysis Transplantation2016;31(Suppl 1):i16. [EMBASE: 72325954]MacdougallIC , AkizawaT , BernsJS , BernhardtT , KruegerT . Effects of molidustat in the treatment of anemia in CKD [Erratum in: Clin J Am Soc Nephrol. 2019 Oct 7;14(10):1524]. Clinical Journal of the American Society of Nephrology: CJASN2019;14(1):28-39. [MEDLINE: 30559105]MacdougallIC , BernsJS , AkizawaT , FishbaneS , BernhardtT . DIALOGUE phase 2 program for BAY85-3934 a HIF-PH inhibitor with daily oral treatment in anemic patients suffering from CKD/ESRD [abstract no: FR-PO219]. Journal of the American Society of Nephrology2013;24(Abstract Suppl):413A. ">DIALOGUE 2 2019</a>; <a href="./references#CD013751-bbs2-0025" title="CizmanB , AckertJ , MeadowcroftA , BiswasN , KellyD , KleinmanD , et al. Ocular safety profile of daprodustat: results of two 24 week studies [abstract no: SAO004]. Nephrology Dialysis Transplantation2018;33(Suppl 1):i316. [EMBASE: 622604997]HoldstockL , CizmanB , MeadowcroftAM , BiswasN , JohnsonBM , JonesD , et al. Daprodustat for anemia: a 24-week, open-label, randomized controlled trial in participants with chronic kidney disease. Clinical Kidney Journal2019;12(1):129-38. [MEDLINE: 30746140]HoldstockL , CizmanB , MeadowcroftAM , BiswasN , JonesD , JohnsonBM , et al. Daprodustat, a HIF-prolyl-hydroxylase inhibitor, increases and maintains hemoglobin over 24 weeks in anemic chronic kidney disease subjects [abstract no: TH-PO908]. Journal of the American Society of Nephrology2016;27(Abstract Suppl):304A. ">Holdstock 2019</a>; <a href="./references#CD013751-bbs2-0026" title="CizmanB , AckertJ , MeadowcroftA , BiswasN , KellyD , KleinmanD , et al. Ocular safety profile of daprodustat: results of two 24 week studies [abstract no: SAO004]. Nephrology Dialysis Transplantation2018;33(Suppl 1):i316. [EMBASE: 622604997]HoldstockL , CizmanB , MeadowcroftAM , BiswasN , JohnsonBM , JonesD , et al. Daprodustat for anemia: a 24-week, open-label, randomized controlled trial in participants with chronic kidney disease. Clinical Kidney Journal2019;12(1):129-38. [MEDLINE: 30746140]HoldstockL , CizmanB , MeadowcroftAM , BiswasN , JonesD , JohnsonBM , et al. Daprodustat, a HIF-prolyl-hydroxylase inhibitor, increases and maintains hemoglobin over 24 weeks in anemic chronic kidney disease subjects [abstract no: TH-PO908]. Journal of the American Society of Nephrology2016;27(Abstract Suppl):304A. ">Holdstock 2019a</a>; <a href="./references#CD013751-bbs2-0035" title="NangakuM , KondoK , KokadoY , UetaK , KanekoG , ShiosakaM , et al. Randomized, open-label, active-controlled (darbepoetin alfa), phase 3 study of vadadustat for treating anemia in non-dialysis-dependent CKD patients in Japan [abstract no: SA-PO229]. Journal of the American Society of Nephrology2019;30(Abstract Suppl):823. [EMBASE: 633767995]NangakuM , KondoK , KokadoY , UetaK , KanekoG , TandaiT , et al. Phase 3 randomized study comparing vadadustat with darbepoetin alfa for anemia in Japanese patients with nondialysis-dependent CKD. Journal of the American Society of Nephrology2021;32(7):1779-90. [MEDLINE: 33883252]">Nangaku 2021a</a>; <a href="./references#CD013751-bbs2-0038" title="NangakuM , FaragYM , deGomaE , LuoW , VargoD , KhawajaZ . Vadadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor, for treatment of anemia of chronic kidney disease: two randomized Phase 2 trials in Japanese patients. Nephrology Dialysis Transplantation 2020 Jul 20 [epub ahead of print]. [DOI: 10.1093/ndt/gfaa060] [MEDLINE: 32719868]NangakuM , KhawajaZ , LuoW , GarafolaS , De GomaE , KomatsuY . Randomized, placebo-controlled phase 2 trials of vadadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), to treat anemia of CKD [abstract no: TH-PO228]. Journal of the American Society of Nephrology2018;29(Abstract Suppl):171. [EMBASE: 633737146]SolinskyC , FaragYM , KhawajaZ , AndersR , LuoW , ChavanA , et al. Impact of vadadustat on iron regulation in Japanese subjects with chronic kidney disease (CKD) [abstract no: 352]. American Journal of Kidney Diseases2020;75(4):638-9. [EMBASE: 2005716872]">NDD‐CKD 2020</a>; <a href="./references#CD013751-bbs2-0040" title="AstraZeneca. A phase 3, multicenter, randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of roxadustat for the treatment of anemia in chronic kidney disease patients not on dialysis [clinical study protocol V6; 31 August 2018]. www.clinicaltrials.gov/ProvidedDocs/27/NCT02174627/Prot_000.pdf (accessed 9 May 2022). EleftheriadisT , PissasG , LiakopoulosV , StefanidisI . On the increased event rate of urinary tract infection and pneumonia in CKD patients treated with roxadustat for anemia. Journal of the American Society of Nephrology2021;32(6):1537. [MEDLINE: 33849917]FishbaneS , El-ShahawyMA , Pecoits-FilhoR , VanBP , HouserMT , FrisonL , et al. OLYMPUS: a phase 3, randomized, double-blind, placebo-controlled, international study of roxadustat efficacy in patients with non-dialysis-dependent (NDD) CKD and anemia [abstract no: TH-OR023]. Journal of the American Society of Nephrology2019;30(Abstract Suppl):6. [EMBASE: 633771285]FishbaneS , El-ShahawyMA , Pecoits-FilhoR , VanBP , HouserMT , FrisonL , et al. Roxadustat for treating anemia in patients with CKD not on dialysis: results from a randomized phase 3 study. Journal of the American Society of Nephrology2021;32(3):737-55. [MEDLINE: 33568383]FishbaneS , El-ShahawyMA , VanBP , LittleDJ . Authors' Reply. Journal of the American Society of Nephrology2021;32(6):1537-8. [MEDLINE: 33849916]Pecoits-FilhoR , ChanTM , HardyE , YuKH , FishbaneS . Roxadustat treatment results in consistent improvements in hemoglobin (Hb) vs. placebo: an analysis of three multinational randomized clinical trials in patients with non-dialysis-dependent CKD (NDD-CKD) [abstract no: TH-OR05]. Journal of the American Society of Nephrology2020;31(Abstract Suppl):2. [EMBASE: 633697943]RastogiA , Pecoits-FilhoR , FishbaneS , LittleDJ , HardyE , YuKH , et al. Roxadustat treatment corrects anemia to hemoglobin (HB) values ≥10 g/dL in the majority of patients with non-dialysis-dependent chronic kidney disease (NDD-CKD) [abstract no: PO0264]. Journal of the American Society of Nephrology2020;31(Abstract Suppl):133. [EMBASE: 633698803]">OLYMPUS 2021</a>; <a href="./references#CD013751-bbs2-0041" title="HaaseVH , SpinowitzBS , PergolaPE , FarmerT , MaroniBJ , HartmanCS . AKB-6548 demonstrates controlled hemogloblin (HGB) response in a phase 2b study for the treatment of anemia in patients with chronic kidney disease not on dialysis (ND-CKD) [abstract no: TH-PO649]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):237A. HaaseVH , SpinowitzBS , PergolaPE , KhawajaZ , ChanJ , ZurawQ , et al. Efficacy and dose requirements of vadadustat are independent of systemic inflammation and prior erythropoiesis-stimulating agent(ESA) dose in patients with non-dialysis dependent chronic kidney disease (NDD-CKD) [abstract no: TH-PO907]. Journal of the American Society of Nephrology2016;27(Abstract Suppl):304A. PergolaPE , SpinowitzB , HaaseVH , HartmanCS , FarmerTM , PoluKR , et al. AKB-6548, a novel hypoxia-inducible factor prolyl-hydroxylase inhibitor (HIF-PHI) for the treatment of anemia in patients with chronic kidney disease not on dialysis (ND-CKD) [abstract no: FO015]. Nephrology Dialysis Transplantation2015;30(Suppl 3):iii8. [EMBASE: 72206296]PergolaPE , SpinowitzBS , HartmanCS , MaroniBJ , HaaseVH . Vadadustat, a novel oral HIF stabilizer, provides effective anemia treatment in nondialysis-dependent chronic kidney disease. Kidney International2016;90(5):1115-22. [MEDLINE: 27650732]SpinowitzBS , PergolaPE , HaaseVH , FarmerTM , HartmanCS , MaroniBJ . Hemoglobin (HGB) response in a phase 2b study of AKB-6548 for the treatment of anemia in patients with non-dialysis dependant chronic kidney disease (NDD-CKD). [abstract no: TH-OR038]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):11A. ">Pergola 2016</a>; <a href="./references#CD013751-bbs2-0042" title="BunnHF . Vadadustat for anemia in patients with dialysis-dependent or non-dialysis-dependent chronic kidney disease. New England Journal of Medicine2021;385(16):e56. [MEDLINE: 34644481]ChertowGM , PergolaPE , AgarwalR , BlockGA , FaragYM , JardineAG , et al. Cardiovascular safety and efficacy of vadadustat for the treatment of anemia in non-dialysis-dependent CKD: design and baseline characteristics. American Heart Journal2021;235(5):1-11. [MEDLINE: 33129989]ChertowGM , PergolaPE , FaragYM , AgarwalR , ArnoldS , BakoG , et al. Vadadustat in patients with anemia and non-dialysis-dependent CKD. New England Journal of Medicine2021;384(17):1589-600. [MEDLINE: 33913637]ChertowGM . Global phase 3 clinical trials of vadadustat vs. darbepoetin alfa for treatment of anemia in patients with non-dialysis-dependent CKD [abstract no: FR-OR54]. Journal of the American Society of Nephrology2020;31(Abstract Suppl):B2. [EMBASE: 633697273]KouryM , PergolaPE , Roy-ChaudhuryP , FaragYM , LuoW , AndersR , et al. Iron-related outcomes in patients with non-dialysis-dependent CKD randomized to vadadustat vs. darbepoetin Alfa [abstract no: PO0482]. Journal of the American Society of Nephrology2021;32(Abstract Suppl):190. [EMBASE: 636329134]McCulloughPA , LuoW , AndersR , VargoD , ParfreyPS . Assessment of thromboembolic events with vadadustat vs. darbepoetin alfa for treatment of anemia in patients with non-dialysis-dependent CKD [abstract no: PO0462]. Journal of the American Society of Nephrology2021;32(Abstract Suppl):184. [EMBASE: 636331039]">PRO2TECT‐CONVERSION 2021</a>; <a href="./references#CD013751-bbs2-0043" title="BunnHF . Vadadustat for anemia in patients with dialysis-dependent or non-dialysis-dependent chronic kidney disease. New England Journal of Medicine2021;385(16):e56. [MEDLINE: 34644481]ChertowGM , PergolaPE , AgarwalR , BlockGA , FaragYM , JardineAG , et al. Cardiovascular safety and efficacy of vadadustat for the treatment of anemia in non-dialysis-dependent CKD: design and baseline characteristics. American Heart Journal2021;235(5):1-11. [MEDLINE: 33129989]ChertowGM , PergolaPE , FaragYM , AgarwalR , ArnoldS , BakoG , et al. Vadadustat in patients with anemia and non-dialysis-dependent CKD. New England Journal of Medicine2021;384(17):1589-600. [MEDLINE: 33913637]ChertowGM . Global phase 3 clinical trials of vadadustat vs. darbepoetin alfa for treatment of anemia in patients with non-dialysis-dependent CKD [abstract no: FR-OR5]. Journal of the American Society of Nephrology2020;31(Abstract Suppl):B2. [EMBASE: 633697273]KouryM , PergolaPE , Roy-ChaudhuryP , FaragYM , LuoW , AndersR , et al. Iron-related outcomes in patients with non-dialysis-dependent CKD randomized to vadadustat vs. darbepoetin alfa [abstract no: PO0482]. Journal of the American Society of Nephrology2021;32(Abstract Suppl):190. [EMBASE: 636329134]McCulloughPA , LuoW , AndersR , VargoD , ParfreyPS . Assessment of thromboembolic events with vadadustat vs. darbepoetin alfa for treatment of anemia in patients with non-dialysis-dependent CKD [abstract no: PO0462]. Journal of the American Society of Nephrology2021;32(Abstract Suppl):184. [EMBASE: 636331039]">PRO2TECT‐CORRECTION 2021</a>; <a href="./references#CD013751-bbs2-0051" title="AkizawaT , NangakuM , YamaguchiT , KoretomoR , MaedaK , MiyazawaY , et al. A phase 3 study of enarodustat in anemic patients with CKD not requiring dialysis: the SYMPHONY ND study. Kidney International Reports2021;6(7):1840-9. [MEDLINE: 34307978]">SYMPHONY ND 2021</a>). </p> <p>Fourteen studies enrolled people who were prescribed concomitant ESA (<a href="./references#CD013751-bbs2-0003" title="AkizawaT , IwasakiM , YamaguchiY , MajikawaY , ReuschM . Authors' Reply. Journal of the American Society of Nephrology2021;32(4):1005-7. [MEDLINE: 33649099]AkizawaT , IwasakiM , YamaguchiY , MajikawaY , ReuschM . Phase 3, randomized, double-blind, active-comparator (darbepoetin alfa) conversion study of oral roxadustat in CKD patients with anemia on hemodialysis in Japan [abstract no: TH-PO1151]. Journal of the American Society of Nephrology2018;29(Abstract Suppl):B4. AkizawaT , IwasakiM , YamaguchiY , MajikawaY , ReuschM . Phase 3, randomized, double-blind, active-comparator (darbepoetin alfa) study of oral roxadustat in CKD patients with anemia on hemodialysis in Japan. Journal of the American Society of Nephrology2020;31(7):1628-39. [MEDLINE: 32493693]AkizawaT , YamaguchiY , MajikawaY , ReuschM . Factors affecting the doses of roxadustat vs darbepoetin alfa for anemia treatment in hemodialysis patients. Therapeutic Apheresis &amp; Dialysis2021;25(5):575-85. [MEDLINE: 33200512]Astellas1517-CL-0307. A study of intermittent oral dosing of ASP1517 in hemodialysis chronic kidney disease patients with anemia [A phase 3, multi-center, randomized, 2-arm parallel, double-blind, active-comparator (darbepoetin alfa) conversion study of intermittent oral dosing of ASP1517 in hemodialysis chronic kidney disease patients with anemia]. www.clinicaltrials.astellas.com/study/?pid=1517-CL-0307 (accessed 4 May 2022). LiuF , WangJ , YeQ , FuH , MaoJ . Roxadustat for renal anemia in ESRD from PKD patients: is it safe enough?Journal of the American Society of Nephrology2021;32(4):1005. [MEDLINE: 33649100]NguyenQD , SepahYJ , YamaguchiY , OtsukaT , MajikawaY , ReuschM , et al. Ophthalmological effects of roxadustat in the treatment of anemia in dialysis-dependent and non-dialysis-dependent CKD patients: findings from two phase 3 studies [abstract no: PO0267]. Journal of the American Society of Nephrology2020;31(Abstract Suppl):134. [EMBASE: 633698979]SepahY , NguyenQD , YamaguchiY , MajikawaY , ReuschM , AkizawaT . Ophthalmological effects of roxadustat in the treatment of anaemia in chronic kidney disease patients on dialysis in a phase 3, randomised, double-blind, active-comparator conversion study [abstract no: MO002]. Nephrology Dialysis Transplantation2020;35(Suppl 3):iii102. [EMBASE: 633421367]">Akizawa 2020a</a>; <a href="./references#CD013751-bbs2-0004" title="AkizawaT , NangakuM , YonekawaT , OkudaN , KawamatsuS , OnoueT , et al. Efficacy and safety of daprodustat compared with darbepoetin alfa in Japanese hemodialysis patients with anemia: a randomized, double-blind, phase 3 trial. Clinical Journal of the American Society of Nephrology: CJASN2020;15(8):1155-65. [MEDLINE: 32723804]OzekiH , AkizawaT , NangakuM , YonekawaT , OkudaN , KawamatsuS , et al. Efficacy and safety of daprodustat compared with darbepoetin alfa in Japanese hemodialysis patients with anemia: A randomized, double-blind, phase 3 trial [abstract no: SaO036]. Nephrology Dialysis Transplantation2019;34(Suppl 1):a350. [EMBASE: 631305259]">Akizawa 2020c</a>; <a href="./references#CD013751-bbs2-0005" title="AkizawaT , IwasakiM , OtsukaT , YamaguchiY , ReuschM . A phase 3, multicenter, randomized, open-label, active comparator conversion study of roxadustat in non-dialysis-dependent (NDD) patients with anemia in chronic kidney disease (CKD) [abstract no: POS-244]. Kidney International Reports2021;6(4 Suppl):S103. [EMBASE: 2011682459]AkizawaT , IwasakiM , OtsukaT , YamaguchiY , ReuschM . A phase 3, multicenter, randomized, open-label, active comparator conversion study of roxadustat in non-dialysis-dependent (NDD) patients with anemia in CKD [abstract no: PO0269]. Journal of the American Society of Nephrology2020;31(Abstract Suppl):134. [EMBASE: 633699036]NguyenQD , SepahYJ , YamaguchiY , OtsukaT , MajikawaY , ReuschM , et al. Ophthalmological effects of roxadustat in the treatment of anemia in dialysis-dependent and non-dialysis-dependent CKD patients: findings from two phase 3 studies [abstract no: PO0267]. Journal of the American Society of Nephrology2020;31(Abstract Suppl):134. [EMBASE: 633698979]">Akizawa 2020f</a>; <a href="./references#CD013751-bbs2-0009" title="SinghAK , BlackorbyA , CizmanB , CarrollK , CobitzAR , DaviesR , et al. Study design and baseline characteristics of patients on dialysis in the ASCEND-D trial. Nephrology Dialysis Transplantation2021;37(5):960-72. [MEDLINE: 33744933] [MEDLINE: 33744933]SinghAK , BlackorbyA , CizmanB , CobitzAR , GodoySA , JhaV , et al. Regional variation of erythropoietin-stimulating agent hyporesponsiveness in the global daprodustat dialysis study (ASCEND-D) [abstract no: TH-OR08]. Journal of the American Society of Nephrology2020;31(Abstract Suppl):3. [EMBASE: 633698062]SinghAK , CarrollK , PerkovicV , SolomonS , JhaV , JohansenKL , et al. Daprodustat for the treatment of anemia in patients undergoing dialysis. New England Journal of Medicine2021;385(25):2325-35. [MEDLINE: 34739194]">ASCEND‐D 2021</a>; <a href="./references#CD013751-bbs2-0010" title="SinghAK . Daprodustat is noninferior to darbepoetin alfa in treating anemia in incident dialysis patients [abstract no: PO0465]. Journal of the American Society of Nephrology2021;32(Abstract Suppl):184-5. [EMBASE: 636331207]">ASCEND‐ID 2021</a>; <a href="./references#CD013751-bbs2-0011" title="PerkovicV , BlackorbyA , CizmanB , CarrollK , CobitzA , DaviesR , et al. ASCEND-ND: Study design and baseline characteristics. Nephrology Dialysis Transplantation2021;36(Suppl 1):i334-5. [EMBASE: 635918331]SinghAK , CarrollK , McMurrayJJ , SolomonS , JhaV , JohansenKL , et al. Daprodustat for the treatment of anemia in patients not undergoing dialysis. New England Journal of Medicine2021;385(25):2313-24. [MEDLINE: 34739196]">ASCEND‐ND 2021</a>; <a href="./references#CD013751-bbs2-0013" title="CoyneDW , SinghAK , LopesRD , BaileyCK , DiminoTL , HuangC , et al. ASCEND-TD: A randomized, double-blind, active-controlled study of daprodustat administered three times weekly in hemodialysis patients [abstract no: PO0487]. Journal of the American Society of Nephrology2021;32(Abstract Suppl):191. [EMBASE: 636329480]">ASCEND‐TD 2021</a>; <a href="./references#CD013751-bbs2-0021" title="AkizawaT , MacdougallIC , BernsJS , YamamotoH , TaguchiM , IekushiK , et al. Iron regulation by molidustat, a daily oral hypoxia-inducible factor prolyl hydroxylase inhibitor, in patients with chronic kidney disease. Nephron2019;143(4):243-54. [MEDLINE: 31387097]MacdougallIC , AkizawaT , BernsJ , LentiniS , BernhardtT , KrugerT . Safety and efficacy of molidustat in erythropoiesis stimulating agents (ESA) pre-treated anaemic patients with chronic kidney disease not on dialysis (CKD-ND) [abstract no: SP309]. Nephrology Dialysis Transplantation2016;31(Suppl 1):i193. [EMBASE: 72326411]MacdougallIC , AkizawaT , BernsJ , LentiniS , BernhardtT . Molidustat increases haemoglobin in erythropoiesis stimulating agents (ESA)-naive anaemic patients with chronic kidney disease not on dialysis (CKD-ND) [abstract no: SO036]]. Nephrology Dialysis Transplantation2016;31(Suppl 1):i16. [EMBASE: 72325954]MacdougallIC , AkizawaT , BernsJS , BernhardtT , KruegerT . Effects of molidustat in the treatment of anemia in CKD [Erratum in: Clin J Am Soc Nephrol. 2019 Oct 7;14(10):1524]. Clinical Journal of the American Society of Nephrology: CJASN2019;14(1):28-39. [MEDLINE: 30559105]MacdougallIC , BernsJS , AkizawaT , FishbaneS , BernhardtT . DIALOGUE phase 2 program for BAY85-3934 a HIF-PH inhibitor with daily oral treatment in anemic patients suffering from CKD/ESRD [abstract no: FR-PO219]. Journal of the American Society of Nephrology2013;24(Abstract Suppl):413A. ">DIALOGUE 2 2019</a>; <a href="./references#CD013751-bbs2-0022" title="AkizawaT , MacdougallIC , BernsJS , YamamotoH , TaguchiM , IekushiK , et al. Iron regulation by molidustat, a daily oral hypoxia-inducible factor prolyl hydroxylase inhibitor, in patients with chronic kidney disease. Nephron2019;143(4):243-54. [MEDLINE: 31387097]MacdougallIC , AkizawaT , BernsJ , LentiniS , BernhardtT . Molidustat increases haemoglobin in erythropoiesis stimulating agents (ESA)-naive anaemic patients with chronic kidney disease not on dialysis (CKD-ND) [abstract no: SO036]. Nephrology Dialysis Transplantation2016;31(Suppl 1):i16. [EMBASE: 72325954]MacdougallIC , AkizawaT , BernsJS , BernhardtT , KruegerT . Effects of molidustat in the treatment of anemia in CKD [Erratum in: Clin J Am Soc Nephrol. 2019 Oct 7;14(10):1524]. Clinical Journal of the American Society of Nephrology: CJASN2019;14(1):28-39. [MEDLINE: 30559105]MacdougallIC , BernsJS , AkizawaT , FishbaneS , BernhardtT . DIALOGUE phase 2 program for BAY85-3934 a HIF-PH inhibitor with daily oral treatment in anemic patients suffering from CKD/ESRD [abstract no: FR-PO219]. Journal of the American Society of Nephrology2013;24(Abstract Suppl):413A. ">DIALOGUE 4 2019</a>; <a href="./references#CD013751-bbs2-0027" title="HouYP , MaoXY , WangC , XuZH , BuZH , XuM , et al. Roxadustat treatment for anemia in peritoneal dialysis patients: a randomized controlled trial. Journal of the Formosan Medical Association2021;121(2):529-38. [MEDLINE: 34167878]">Hou 2021</a>; <a href="./references#CD013751-bbs2-0034" title="NangakuM , KondoK , UetaK , KokadoY , KanekoG , MatsudaH , et al. Efficacy and safety of vadadustat compared with darbepoetin alfa in Japanese anemic patients on hemodialysis: a phase 3, multicenter, randomized, double-blind study. Nephrology Dialysis Transplantation2021;36(9):1731-41. [MEDLINE: 33650630]NangakuM , KondoK , UetaK , KokadoY , KanekoG , MatsudaH , et al. Randomized, double-blinded, active-controlled (darbepoetin alfa), phase 3 study of vadadustat in CKD patients with anemia on hemodialysis in Japan [abstract no: TH-OR024]. Journal of the American Society of Nephrology2019;30(Abstract Suppl):6. [EMBASE: 633771357]">Nangaku 2021</a>; <a href="./references#CD013751-bbs2-0035" title="NangakuM , KondoK , KokadoY , UetaK , KanekoG , ShiosakaM , et al. Randomized, open-label, active-controlled (darbepoetin alfa), phase 3 study of vadadustat for treating anemia in non-dialysis-dependent CKD patients in Japan [abstract no: SA-PO229]. Journal of the American Society of Nephrology2019;30(Abstract Suppl):823. [EMBASE: 633767995]NangakuM , KondoK , KokadoY , UetaK , KanekoG , TandaiT , et al. Phase 3 randomized study comparing vadadustat with darbepoetin alfa for anemia in Japanese patients with nondialysis-dependent CKD. Journal of the American Society of Nephrology2021;32(7):1779-90. [MEDLINE: 33883252]">Nangaku 2021a</a>; <a href="./references#CD013751-bbs2-0036" title="GSK201753. A 52-week, Phase III, open-label, multi-center study to evaluate efficacy and safety of GSK1278863 in Japanese non-dialysis and peritoneal dialysis subjects with anemia associated with chronic kidney disease [study protocol]. www.clinicaltrials.gov/ProvidedDocs/63/NCT02791763/Prot_000.pdf (accessed 9 May 2022). NangakuM , HamanoT , AkizawaT , TsubakiharaY , NagaiR , OkudaN , et al. Daprodustat compared with epoetin beta pegol for anemia in Japanese patients not on dialysis: a 52-week randomized open-label phase 3 trial. American Journal of Nephrology2021;52(1):26-35. [MEDLINE: 33561857]">Nangaku 2021b</a>; <a href="./references#CD013751-bbs2-0049" title="CharytanC , Manllo-KarimR , MartinER , SteerD , BernardoM , DuaSL , et al. A randomized trial of roxadustat in anemia of kidney failure: SIERRAS study. Kidney International Reports2021;6(7):1829-39. [MEDLINE: 34307977]CharytanC , Manllo-KarimR , MartinER , SteerD , BernardoM , DuaSL , et al. SIERRAS: A phase 3, open-label, randomized, active-controlled study of the efficacy and safety of roxadustat in the maintenance treatment of anemia in subjects with ESRD on stable dialysis [abstract no: SA-PO227]. Journal of the American Society of Nephrology2019;30(Abstract Suppl):822. [EMBASE: 633767862]">SIERRAS 2021</a>), three studies enrolled people who were prescribed iron supplements (<a href="./references#CD013751-bbs2-0014" title="BesarabA , HutlerHN , KlausS , LeeTT , LilienfeldDE , NeffTB , et al. FG-4592, a novel oral HIF prolyl hydroxylase inhibitor, elevates hemoglobin in anemic stage 3/4 CKD patients [abstract no: SA-FC416]. Journal of the American Society of Nephrology2010;21(Abstract Suppl):95A. BesarabA , ProvenzanoR , HertelJ , ZabanehR , KlausSJ , LeeT , et al. Randomized placebo-controlled dose-ranging and pharmacodynamics study of roxadustat (FG-4592) to treat anemia in nondialysis-dependent chronic kidney disease (NDD-CKD) patients. Nephrology Dialysis Transplantation2015;30(10):1665-73. [MEDLINE: 26238121]">Besarab 2015</a>; <a href="./references#CD013751-bbs2-0017" title="ChenN , HaoC , PengX , LinH , YinA , HaoL , et al. Roxadustat for anemia in patients with kidney disease not receiving dialysis. New England Journal of Medicine2019;381(11):1001-10. [MEDLINE: 31340089]ChenN , HaoC , PengX , LinHL , YinA , HaoL , et al. A phase 3, randomized, double-blind, placebo-controlled study of efficacy and safety of roxadustat (FG-4592) for treatment of anemia in subjects with CKD not on dialysis [abstract no: TH-PO1153]. Journal of the American Society of Nephrology2018;29(Abstract Suppl):B5. ">Chen 2019a</a>; <a href="./references#CD013751-bbs2-0037" title="Astellas1517-CL-0304. A study to investigate the effect of ASP1517 after intermittent oral dosing in dialysis chronic kidney disease patients with anemia compared with darbepoetin as a reference drug [A Japanese, phase 2, multicenter, randomized, 4-arm parallel, double-blind (arms 1-3), open-label (arm 4), active-comparator (darbepoetin alfa) study of intermittent oral dosing of asp1517 in hemodialysis-dependent chronic kidney disease patients with anemia [1517-CL-0304 clinical study results report]]. www.trialsummaries.com/Study/StudyDetails?id=14175&amp;tenant=MT_AST_9011; www.clinicaltrials.gov/ct2/show/NCT01888445 (first received 6 August 2018). ">NCT01888445</a>), and four studies enrolled people who were also prescribed ESA, iron supplements or both (<a href="./references#CD013751-bbs2-0001" title="AkizawaT , TsubakiharaY , NangakuM , EndoY , NakajimaH , KohnoT , et al. Effects of daprodustat, a novel hypoxia-inducible factor prolyl hydroxylase inhibitor on anemia management in Japanese hemodialysis subjects. American Journal of Nephrology2017;45(2):127-35. [MEDLINE: 27978511]EndoY , KohnoT , ImaiY , KawaseN , HaraK , LeporeJJ , et al. A 4 -week dose response study of the hypoxia inducible factor-prolyl hydroxylase inhibitor GSK1278863 in Japanese anemic haemodialysis subjects [abstract no: SA-PO819]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):818A. NCT02019719. Study to evaluate the safety, efficacy and pharmacokinetics of GSK1278863 in Japanese hemodialysis-dependent subjects with anemia associated with chronic kidney disease [A 4-week, phase ii, randomized, double-blind, dose-ranging, placebo-controlled, parallel-group, multi-center study to evaluate the safety, efficacy and pharmacokinetics of GSK1278863 in Japanese hemodialysis-dependent subjects with anemia associated with chronic kidney disease]. clinicaltrials.gov/show/NCT02019719 (first received 24 December 2013). ">Akizawa 2017</a>; <a href="./references#CD013751-bbs2-0043" title="BunnHF . Vadadustat for anemia in patients with dialysis-dependent or non-dialysis-dependent chronic kidney disease. New England Journal of Medicine2021;385(16):e56. [MEDLINE: 34644481]ChertowGM , PergolaPE , AgarwalR , BlockGA , FaragYM , JardineAG , et al. Cardiovascular safety and efficacy of vadadustat for the treatment of anemia in non-dialysis-dependent CKD: design and baseline characteristics. American Heart Journal2021;235(5):1-11. [MEDLINE: 33129989]ChertowGM , PergolaPE , FaragYM , AgarwalR , ArnoldS , BakoG , et al. Vadadustat in patients with anemia and non-dialysis-dependent CKD. New England Journal of Medicine2021;384(17):1589-600. [MEDLINE: 33913637]ChertowGM . Global phase 3 clinical trials of vadadustat vs. darbepoetin alfa for treatment of anemia in patients with non-dialysis-dependent CKD [abstract no: FR-OR5]. Journal of the American Society of Nephrology2020;31(Abstract Suppl):B2. [EMBASE: 633697273]KouryM , PergolaPE , Roy-ChaudhuryP , FaragYM , LuoW , AndersR , et al. Iron-related outcomes in patients with non-dialysis-dependent CKD randomized to vadadustat vs. darbepoetin alfa [abstract no: PO0482]. Journal of the American Society of Nephrology2021;32(Abstract Suppl):190. [EMBASE: 636329134]McCulloughPA , LuoW , AndersR , VargoD , ParfreyPS . Assessment of thromboembolic events with vadadustat vs. darbepoetin alfa for treatment of anemia in patients with non-dialysis-dependent CKD [abstract no: PO0462]. Journal of the American Society of Nephrology2021;32(Abstract Suppl):184. [EMBASE: 636331039]">PRO2TECT‐CORRECTION 2021</a>; <a href="./references#CD013751-bbs2-0050" title="AkizawaT , MaedaK , MiyazawaY , KoretomoR . Phase 3 study to compare the efficacy and safety of enarodustat (JTZ-951), an oral HIF-PH inhibitor, with darbepoetin alfa in anemic patients with CKD receiving maintenance hemodialysis [abstract no: TH-PO1186]. Journal of the American Society of Nephrology2019;30(Abstract Suppl):B4. AkizawaT , NangakuM , YamaguchiT , KoretomoR , MaedaK , MiyazawaY , et al. A phase 3 study of enarodustat (JTZ-951) in Japanese hemodialysis patients for treatment of anemia in chronic kidney disease: SYMPHONY HD study. Kidney Diseases2021;7(6):494-502. [EMBASE: 2013576033]">SYMPHONY HD 2021</a>; <a href="./references#CD013751-bbs2-0051" title="AkizawaT , NangakuM , YamaguchiT , KoretomoR , MaedaK , MiyazawaY , et al. A phase 3 study of enarodustat in anemic patients with CKD not requiring dialysis: the SYMPHONY ND study. Kidney International Reports2021;6(7):1840-9. [MEDLINE: 34307978]">SYMPHONY ND 2021</a>). One study enrolled people who did not receive ESA (<a href="./references#CD013751-bbs2-0012" title="JohansenKL , CobitzAR , LopesRD , SinghAK , ObradorGT , CizmanB , et al. Effects of daprodustat on hemoglobin and quality of life in patients with CKD: results of the ascend-NHQ randomized, double-blind, placebo-controlled trial [abstract no: FR-OR53]. Journal of the American Society of Nephrology2021;32(Abstract Suppl):36. [EMBASE: 636330656]">ASCEND‐NHQ 2021</a>). </p> <p>The target Hb levels in the included studies were as follows:</p> <p> <ul id="CD013751-list-0011"> <li> <p>One study reported the Hb target level ≥ 10 g/dL or an increase of at least 1.0 g/dL in people with a baseline Hb of 8.0 g/dL or more or an increase of at least 2.0 g/dL in people with a baseline Hb of less than 8.0 g/dL (<a href="./references#CD013751-bbs2-0017" title="ChenN , HaoC , PengX , LinH , YinA , HaoL , et al. Roxadustat for anemia in patients with kidney disease not receiving dialysis. New England Journal of Medicine2019;381(11):1001-10. [MEDLINE: 31340089]ChenN , HaoC , PengX , LinHL , YinA , HaoL , et al. A phase 3, randomized, double-blind, placebo-controlled study of efficacy and safety of roxadustat (FG-4592) for treatment of anemia in subjects with CKD not on dialysis [abstract no: TH-PO1153]. Journal of the American Society of Nephrology2018;29(Abstract Suppl):B5. ">Chen 2019a</a>) </p> </li> <li> <p>Four studies reported the Hb target increase ≥ 1 g/dL (<a href="./references#CD013751-bbs2-0014" title="BesarabA , HutlerHN , KlausS , LeeTT , LilienfeldDE , NeffTB , et al. FG-4592, a novel oral HIF prolyl hydroxylase inhibitor, elevates hemoglobin in anemic stage 3/4 CKD patients [abstract no: SA-FC416]. Journal of the American Society of Nephrology2010;21(Abstract Suppl):95A. BesarabA , ProvenzanoR , HertelJ , ZabanehR , KlausSJ , LeeT , et al. Randomized placebo-controlled dose-ranging and pharmacodynamics study of roxadustat (FG-4592) to treat anemia in nondialysis-dependent chronic kidney disease (NDD-CKD) patients. Nephrology Dialysis Transplantation2015;30(10):1665-73. [MEDLINE: 26238121]">Besarab 2015</a>; <a href="./references#CD013751-bbs2-0016" title="ChenN , HaoC , LiuB , LinHL , CailiW , XingCY , et al. A phase 3, randomized, open-label, active-controlled study of efficacy and safety of roxadustat for treatment of anemia in subjects with CKD on dialysis [abstract no: TH-PO1152]. Journal of the American Society of Nephrology2018;29(Abstract Suppl):B5. ChenN , HaoC , LiuBC , LinH , WangC , XingC , et al. Roxadustat treatment for anemia in patients undergoing long-term dialysis. New England Journal of Medicine2019;381(11):1011-22. [MEDLINE: 31340116]">Chen 2019</a>; <a href="./references#CD013751-bbs2-0018" title="ChenN , QianJ , ChenJ , YuX , MeiC , HaoC , et al. Phase 2 studies of oral hypoxia-inducible factor prolyl hydroxylase inhibitor FG-4592 for treatment of anemia in China. Nephrology Dialysis Transplantation2017;32(8):1373-86. [MEDLINE: 28371815]">Chen DD 2017</a>; <a href="./references#CD013751-bbs2-0044" title="ProvenzanoR , FaddaG , BernardoM , JamesC , KochendoerferG , LeeT , et al. FG2216, a novel oral HIF-PHI, stimulates erythropoiesis and increases hemoglobin concentration in patients with non-dialysis CKD [abstract no: 212]. American Journal of Kidney Diseases2008;51(4):A80. ProvenzanoR , HulterH , AgarwalA , KlausS , LeeT , YuP , et al. Hypoxia-inducible factor (HIF) prolyl hydroxylase inhibitor FG-2216 increases Hb without FE depletion in the absence of IV Fe [abstract no: 249]. American Journal of Kidney Diseases2013;61(4):A78. [EMBASE: 71024073]">Provenzano 2008</a>) </p> </li> <li> <p>One study reported either an increase in Hb ≥ 1 g/dL or Hb target ≥ 11.0 g/dL (<a href="./references#CD013751-bbs2-0019" title="ChenN , QianJ , ChenJ , YuX , MeiC , HaoC , et al. Phase 2 studies of oral hypoxia-inducible factor prolyl hydroxylase inhibitor FG-4592 for treatment of anemia in China. Nephrology Dialysis Transplantation2017;32(8):1373-86. [MEDLINE: 28371815]QianJQ , ChenN , ChenJ , HaoC , LinHL , NiD , et al. A randomized, double-blind, placebo controlled trial of FG-4592 for correction of anemia in subjects with chronic kidney disease in China [abstract no: FR-OR011]. Journal of the American Society of Nephrology2013;24(Abstract Suppl):38A. ">Chen NDD 2017</a>) </p> </li> <li> <p>One study reported an increase in Hb of 0.5 to 1.0 g/dL (<a href="./references#CD013751-bbs2-0015" title="BrigandiRA , JohnsonB , OeiC , WestermanM , OlbinaG , deZoysaJ , et al. A novel hypoxia-inducible factor-prolyl hydroxylase inhibitor (GSK1278863) for anemia in CKD: a 28-day, phase 2a randomized trial. American Journal of Kidney Diseases2016;67(6):861-71. [MEDLINE: 26827289]BrigandiRA , JohnsonB , OeiC , WestermanME , OlbinaG , KumarS , et al. Induction of erythropoiesis in anemic patients by prolylhydroxylase inhibitor in a repeat dose, randomized placebo controlled trial [abstract no: SA-PO117]. Journal of the American Society of Nephrology2012;23(Abstract Suppl):662A. BrigandiRA , WestermanME , OlbinaG , OeiC , RussSF , KumarS . Modulation of hepcidin by prolylhydroxylase inhibitor in randomized trials [abstract no: SA-PO118]. Journal of the American Society of Nephrology2012;23(Abstract Suppl):662A. ">Brigandi 2016</a>) </p> </li> <li> <p>One study reported the Hb target increase of at least 0.5 to 2.0 g/dL (<a href="./references#CD013751-bbs2-0001" title="AkizawaT , TsubakiharaY , NangakuM , EndoY , NakajimaH , KohnoT , et al. Effects of daprodustat, a novel hypoxia-inducible factor prolyl hydroxylase inhibitor on anemia management in Japanese hemodialysis subjects. American Journal of Nephrology2017;45(2):127-35. [MEDLINE: 27978511]EndoY , KohnoT , ImaiY , KawaseN , HaraK , LeporeJJ , et al. A 4 -week dose response study of the hypoxia inducible factor-prolyl hydroxylase inhibitor GSK1278863 in Japanese anemic haemodialysis subjects [abstract no: SA-PO819]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):818A. NCT02019719. Study to evaluate the safety, efficacy and pharmacokinetics of GSK1278863 in Japanese hemodialysis-dependent subjects with anemia associated with chronic kidney disease [A 4-week, phase ii, randomized, double-blind, dose-ranging, placebo-controlled, parallel-group, multi-center study to evaluate the safety, efficacy and pharmacokinetics of GSK1278863 in Japanese hemodialysis-dependent subjects with anemia associated with chronic kidney disease]. clinicaltrials.gov/show/NCT02019719 (first received 24 December 2013). ">Akizawa 2017</a>) </p> </li> <li> <p>Five studies reported the Hb target  was10 to 11 g/dL (<a href="./references#CD013751-bbs2-0009" title="SinghAK , BlackorbyA , CizmanB , CarrollK , CobitzAR , DaviesR , et al. Study design and baseline characteristics of patients on dialysis in the ASCEND-D trial. Nephrology Dialysis Transplantation2021;37(5):960-72. [MEDLINE: 33744933] [MEDLINE: 33744933]SinghAK , BlackorbyA , CizmanB , CobitzAR , GodoySA , JhaV , et al. Regional variation of erythropoietin-stimulating agent hyporesponsiveness in the global daprodustat dialysis study (ASCEND-D) [abstract no: TH-OR08]. Journal of the American Society of Nephrology2020;31(Abstract Suppl):3. [EMBASE: 633698062]SinghAK , CarrollK , PerkovicV , SolomonS , JhaV , JohansenKL , et al. Daprodustat for the treatment of anemia in patients undergoing dialysis. New England Journal of Medicine2021;385(25):2325-35. [MEDLINE: 34739194]">ASCEND‐D 2021</a>; <a href="./references#CD013751-bbs2-0010" title="SinghAK . Daprodustat is noninferior to darbepoetin alfa in treating anemia in incident dialysis patients [abstract no: PO0465]. Journal of the American Society of Nephrology2021;32(Abstract Suppl):184-5. [EMBASE: 636331207]">ASCEND‐ID 2021</a>; <a href="./references#CD013751-bbs2-0011" title="PerkovicV , BlackorbyA , CizmanB , CarrollK , CobitzA , DaviesR , et al. ASCEND-ND: Study design and baseline characteristics. Nephrology Dialysis Transplantation2021;36(Suppl 1):i334-5. [EMBASE: 635918331]SinghAK , CarrollK , McMurrayJJ , SolomonS , JhaV , JohansenKL , et al. Daprodustat for the treatment of anemia in patients not undergoing dialysis. New England Journal of Medicine2021;385(25):2313-24. [MEDLINE: 34739196]">ASCEND‐ND 2021</a>; <a href="./references#CD013751-bbs2-0013" title="CoyneDW , SinghAK , LopesRD , BaileyCK , DiminoTL , HuangC , et al. ASCEND-TD: A randomized, double-blind, active-controlled study of daprodustat administered three times weekly in hemodialysis patients [abstract no: PO0487]. Journal of the American Society of Nephrology2021;32(Abstract Suppl):191. [EMBASE: 636329480]">ASCEND‐TD 2021</a>; <a href="./references#CD013751-bbs2-0022" title="AkizawaT , MacdougallIC , BernsJS , YamamotoH , TaguchiM , IekushiK , et al. Iron regulation by molidustat, a daily oral hypoxia-inducible factor prolyl hydroxylase inhibitor, in patients with chronic kidney disease. Nephron2019;143(4):243-54. [MEDLINE: 31387097]MacdougallIC , AkizawaT , BernsJ , LentiniS , BernhardtT . Molidustat increases haemoglobin in erythropoiesis stimulating agents (ESA)-naive anaemic patients with chronic kidney disease not on dialysis (CKD-ND) [abstract no: SO036]. Nephrology Dialysis Transplantation2016;31(Suppl 1):i16. [EMBASE: 72325954]MacdougallIC , AkizawaT , BernsJS , BernhardtT , KruegerT . Effects of molidustat in the treatment of anemia in CKD [Erratum in: Clin J Am Soc Nephrol. 2019 Oct 7;14(10):1524]. Clinical Journal of the American Society of Nephrology: CJASN2019;14(1):28-39. [MEDLINE: 30559105]MacdougallIC , BernsJS , AkizawaT , FishbaneS , BernhardtT . DIALOGUE phase 2 program for BAY85-3934 a HIF-PH inhibitor with daily oral treatment in anemic patients suffering from CKD/ESRD [abstract no: FR-PO219]. Journal of the American Society of Nephrology2013;24(Abstract Suppl):413A. ">DIALOGUE 4 2019</a>) </p> </li> <li> <p>Two studies reported the Hb target was 10 to 11.5 g/dL (<a href="./references#CD013751-bbs2-0028" title="ChertowGM , BoudvilleN , ChowdhuryP , GonzalezC , KooiengaL , LuoW , et al. Vadadustat for treatment of anemia in patients with dialysis-dependent CKD receiving peritoneal dialysis [abstract no: PO0464]. Journal of the American Society of Nephrology2021;32(Abstract Suppl):184. [EMBASE: 636331136]EckardtKU , AgarwalR , AswadA , AwadA , BlockGA , BacciMR , et al. Safety and efficacy of vadadustat for anemia in patients undergoing dialysis. New England Journal of Medicine2021;384(17):1601-12. [MEDLINE: 33913638]EckardtKU , AgarwalR , FaragYM , JardineAG , KhawajaZ , KouryMJ , et al. Global Phase 3 programme of vadadustat for treatment of anaemia of chronic kidney disease: rationale, study design and baseline characteristics of dialysis-dependent patients in the INNO2VATE trials. Nephrology Dialysis Transplantation2020;36(11):2039-48. [MEDLINE: 33188693]EckardtKU . Global phase 3 clinical trials of vadadustat vs. darbepoetin alfa for treatment of anemia in patients with dialysis-dependent CKD [abstract no: TH-OR01]. Journal of the American Society of Nephrology2020;31(Abstract Suppl):1. [EMBASE: 633697781]ParfreyPS , LuoW , MaroniB , AndersR , VargoD , McCulloughPA . Thromboembolic events with vadadustat vs. darbepoetin alfa for anemia treatment in patients with dialysis-dependent CKD [abstract no: PO0463]. Journal of the American Society of Nephrology2021;32(Abstract Suppl):184. [EMBASE: 636331080]WinkelmayerW , TumlinJA , FishbaneS , FaragY , VargoD , LuoW , et al. Hematologic efficacy of vadadustat for anemia in patients with kidney failure on dialysis [abstract no: MO529]. Nephrology Dialysis Transplantation2021;36(Suppl 1):i325-6. [EMBASE: 635917983]WinkelmayerWC , FishbaneS , TumlinJA , FaragYM , LuoW , AndersR , et al. Iron-related outcomes in patients with dialysis-dependent CKD randomized to vadadustat vs. darbepoetin alfa [abstract no: PO0457]. Journal of the American Society of Nephrology2021;32(Abstract Suppl):182. [EMBASE: 636330773]">INNO2VATE 2020</a>; <a href="./references#CD013751-bbs2-0030" title="CizmanB , AckertJ , MeadowcroftA , BiswasN , KellyD , KleinmanD , et al. Ocular safety profile of daprodustat: results of two 24 week studies [abstract no: SAO004]. Nephrology Dialysis Transplantation2018;33(Suppl 1):i316. [EMBASE: 622604997]CobitzAR , MeadowcroftAM , CizmanB , HoldstockL , BiswasN , JonesD , et al. Daprodustat, a HIF-prolyl-hydroxylase inhibitor, maintains hemoglobin levels over 24 weeks in anemic hemodialysis subjects switching from recombinant human erythropoietin. [abstract no: SA-OR114]. Journal of the American Society of Nephrology2016;27(Abstract Suppl):93A. MeadowcroftAM , CizmanB , HoldstockL , BiswasN , JohnsonBM , JonesD , et al. Daprodustat for anemia: a 24-week, open-label, randomized controlled trial in participants on hemodialysis. Clinical Kidney Journal2019;12(1):139-48. [MEDLINE: 30746141]">Meadowcroft 2019</a>) </p> </li> <li> <p>Seventeen studies reported the Hb target was 10 to 12 g/dL (<a href="./references#CD013751-bbs2-0002" title="AkizawaT , IwasakiM , OtsukaT , ReuschM , MisumiT . Roxadustat for the treatment of chronic kidney disease-associated anemia in Japanese patients not on dialysis [abstract no: FR-PO1142]. Journal of the American Society of Nephrology2016;27(Abstract Suppl):7B. AkizawaT , IwasakiM , OtsukaT , ReuschM , MisumiT . Roxadustat treatment of chronic kidney disease-associated anemia in Japanese patients not on dialysis: a phase 2, randomized, double-blind, placebo-controlled trial. Advances in Therapy2019;36(6):1438-54. [MEDLINE: 30953333]">Akizawa 2019</a>; <a href="./references#CD013751-bbs2-0003" title="AkizawaT , IwasakiM , YamaguchiY , MajikawaY , ReuschM . Authors' Reply. Journal of the American Society of Nephrology2021;32(4):1005-7. [MEDLINE: 33649099]AkizawaT , IwasakiM , YamaguchiY , MajikawaY , ReuschM . Phase 3, randomized, double-blind, active-comparator (darbepoetin alfa) conversion study of oral roxadustat in CKD patients with anemia on hemodialysis in Japan [abstract no: TH-PO1151]. Journal of the American Society of Nephrology2018;29(Abstract Suppl):B4. AkizawaT , IwasakiM , YamaguchiY , MajikawaY , ReuschM . Phase 3, randomized, double-blind, active-comparator (darbepoetin alfa) study of oral roxadustat in CKD patients with anemia on hemodialysis in Japan. Journal of the American Society of Nephrology2020;31(7):1628-39. [MEDLINE: 32493693]AkizawaT , YamaguchiY , MajikawaY , ReuschM . Factors affecting the doses of roxadustat vs darbepoetin alfa for anemia treatment in hemodialysis patients. Therapeutic Apheresis &amp; Dialysis2021;25(5):575-85. [MEDLINE: 33200512]Astellas1517-CL-0307. A study of intermittent oral dosing of ASP1517 in hemodialysis chronic kidney disease patients with anemia [A phase 3, multi-center, randomized, 2-arm parallel, double-blind, active-comparator (darbepoetin alfa) conversion study of intermittent oral dosing of ASP1517 in hemodialysis chronic kidney disease patients with anemia]. www.clinicaltrials.astellas.com/study/?pid=1517-CL-0307 (accessed 4 May 2022). LiuF , WangJ , YeQ , FuH , MaoJ . Roxadustat for renal anemia in ESRD from PKD patients: is it safe enough?Journal of the American Society of Nephrology2021;32(4):1005. [MEDLINE: 33649100]NguyenQD , SepahYJ , YamaguchiY , OtsukaT , MajikawaY , ReuschM , et al. Ophthalmological effects of roxadustat in the treatment of anemia in dialysis-dependent and non-dialysis-dependent CKD patients: findings from two phase 3 studies [abstract no: PO0267]. Journal of the American Society of Nephrology2020;31(Abstract Suppl):134. [EMBASE: 633698979]SepahY , NguyenQD , YamaguchiY , MajikawaY , ReuschM , AkizawaT . Ophthalmological effects of roxadustat in the treatment of anaemia in chronic kidney disease patients on dialysis in a phase 3, randomised, double-blind, active-comparator conversion study [abstract no: MO002]. Nephrology Dialysis Transplantation2020;35(Suppl 3):iii102. [EMBASE: 633421367]">Akizawa 2020a</a>; <a href="./references#CD013751-bbs2-0004" title="AkizawaT , NangakuM , YonekawaT , OkudaN , KawamatsuS , OnoueT , et al. Efficacy and safety of daprodustat compared with darbepoetin alfa in Japanese hemodialysis patients with anemia: a randomized, double-blind, phase 3 trial. Clinical Journal of the American Society of Nephrology: CJASN2020;15(8):1155-65. [MEDLINE: 32723804]OzekiH , AkizawaT , NangakuM , YonekawaT , OkudaN , KawamatsuS , et al. Efficacy and safety of daprodustat compared with darbepoetin alfa in Japanese hemodialysis patients with anemia: A randomized, double-blind, phase 3 trial [abstract no: SaO036]. Nephrology Dialysis Transplantation2019;34(Suppl 1):a350. [EMBASE: 631305259]">Akizawa 2020c</a>; <a href="./references#CD013751-bbs2-0006" title="AkizawaT , IwasakiM , OtsukaT , YamaguchiY , ReuschM . Phase 3 study of roxadustat to treat anemia in non-dialysis-dependant CKD. Kidney International Reports2021;6(7):1810-28. [MEDLINE: 34307976]AkizawaT , Tanaka-AminoK , OtsukaT , YamaguchiY . Factors affecting doses of roxadustat versus darbepoetin alfa for anemia in nondialysis patients. American Journal of Nephrology2021;52(9):702-13. [MEDLINE: 34628408]">Akizawa 2021</a>; <a href="./references#CD013751-bbs2-0021" title="AkizawaT , MacdougallIC , BernsJS , YamamotoH , TaguchiM , IekushiK , et al. Iron regulation by molidustat, a daily oral hypoxia-inducible factor prolyl hydroxylase inhibitor, in patients with chronic kidney disease. Nephron2019;143(4):243-54. [MEDLINE: 31387097]MacdougallIC , AkizawaT , BernsJ , LentiniS , BernhardtT , KrugerT . Safety and efficacy of molidustat in erythropoiesis stimulating agents (ESA) pre-treated anaemic patients with chronic kidney disease not on dialysis (CKD-ND) [abstract no: SP309]. Nephrology Dialysis Transplantation2016;31(Suppl 1):i193. [EMBASE: 72326411]MacdougallIC , AkizawaT , BernsJ , LentiniS , BernhardtT . Molidustat increases haemoglobin in erythropoiesis stimulating agents (ESA)-naive anaemic patients with chronic kidney disease not on dialysis (CKD-ND) [abstract no: SO036]]. Nephrology Dialysis Transplantation2016;31(Suppl 1):i16. [EMBASE: 72325954]MacdougallIC , AkizawaT , BernsJS , BernhardtT , KruegerT . Effects of molidustat in the treatment of anemia in CKD [Erratum in: Clin J Am Soc Nephrol. 2019 Oct 7;14(10):1524]. Clinical Journal of the American Society of Nephrology: CJASN2019;14(1):28-39. [MEDLINE: 30559105]MacdougallIC , BernsJS , AkizawaT , FishbaneS , BernhardtT . DIALOGUE phase 2 program for BAY85-3934 a HIF-PH inhibitor with daily oral treatment in anemic patients suffering from CKD/ESRD [abstract no: FR-PO219]. Journal of the American Society of Nephrology2013;24(Abstract Suppl):413A. ">DIALOGUE 2 2019</a>; <a href="./references#CD013751-bbs2-0023" title="BarrattJ , AndricB , TataradzeA , SchoemigM , ReuschM , ValluriU , et al. Roxadustat for the treatment of anemia in CKD patients not on dialysis (NDD): a phase 3, randomized, open-label, active-controlled study [abstract no: TH-OR02]. Journal of the American Society of Nephrology2020;31(Abstract Suppl):1. [EMBASE: 633697812]BarrattJ , AndricB , TataradzeA , SchomigM , ReuschM , ValluriU , et al. Roxadustat for the treatment of anaemia in chronic kidney disease patients not on dialysis: a phase 3, randomised, open-label, active-controlled study (DOLOMITES). Nephrology Dialysis Transplantation2021;36(9):1616-28. [MEDLINE: 34077510]BarrattJ , AndricB , TataradzeA , SchomigM , ReuschM , ValluriU , et al. Roxadustat for the treatment of anaemia in chronic kidney disease patients not on dialysis: a phase 3, randomised, open-label, active controlled study [abstract no: MO001]. Nephrology Dialysis Transplantation2020;35(Suppl 3):iii101. [EMBASE: 633423023]BarrattJ , AndricB , TataradzeA , SchomigM , ReuschM , ValluriU , et al. Roxadustat for the treatment of anemia in chronic kidney disease (CKD) patients not on dialysis (NDD): a phase 3, randomized, open-label, active-controlled study [abstract no: Pos-247]. Kidney International Reports2021;6(4 Suppl):S104. [EMBASE: 2011683542]">DOLOMITES 2021</a>; <a href="./references#CD013751-bbs2-0031" title="AkizawaT , TaguchiM , MatsudaY , IekushiK , YamadaT , YamamotoH . Molidustat for the treatment of renal anaemia in patients with dialysis-dependent chronic kidney disease: Design and rationale of three phase III studies. BMJ Open2019;9(6):e026602. [MEDLINE: 31203241]AkizawaT , YamadaT , NoboriK , MatsudaY , HayashiY , HayasakiT , et al. Molidustat for Japanese patients with renal anemia receiving dialysis. Kidney International Reports2021;6(10):2604–16. [MEDLINE: 34622100]AkizawaT , YamadaT , NoboriK , MatsudaY , HayashiY , HayasakiT , et al. Results from a phase 3 study comparing the efficacy and safety of molidustat vs. Darbepoetin Alfa in patients receiving hemodialysis and treated with erythropoiesis-stimulating agents (ESAS) [abstract no: PO22623]. Journal of the American Society of Nephrology2020;31(Abstract Suppl):B4. [EMBASE: 633697376]">MIYABI HD‐M 2019</a>; <a href="./references#CD013751-bbs2-0033" title="YamamotoH , NoboriK , MatsudaY , HayashiY , HayasakiT , AkizawaT . Molidustat for renal anemia in nondialysis patients previously treated with erythropoiesis-stimulating agents: a randomized, open-label, phase 3 study. American Journal of Nephrology2021;52(10-11):884-93. [MEDLINE: 34569482]YamamotoH , TaguchiM , MatsudaY , IekushiK , YamadaT , AkizawaT . Molidustat for the treatment of renal anaemia in patients with non-dialysis-dependent chronic kidney disease: design and rationale of two phase III studies. BMJ Open2019;9(6):e026704. [MEDLINE: 31203242]YamamotoH , TaguchiM , NoboriK , MatsudaY , IekushiK , AkizawaT . To investigate the efficacy and safety of molidustat in non-dialysis patients with renal anemia who are treated with erythropoiesis stimulating agents: Miyabi ND-M [Abstract no: P1868]. Nephrology Dialysis Transplantation2020;35(Suppl 3):iii2179. [EMBASE: 633423006]">MIYABI ND‐M 2019</a>; <a href="./references#CD013751-bbs2-0034" title="NangakuM , KondoK , UetaK , KokadoY , KanekoG , MatsudaH , et al. Efficacy and safety of vadadustat compared with darbepoetin alfa in Japanese anemic patients on hemodialysis: a phase 3, multicenter, randomized, double-blind study. Nephrology Dialysis Transplantation2021;36(9):1731-41. [MEDLINE: 33650630]NangakuM , KondoK , UetaK , KokadoY , KanekoG , MatsudaH , et al. Randomized, double-blinded, active-controlled (darbepoetin alfa), phase 3 study of vadadustat in CKD patients with anemia on hemodialysis in Japan [abstract no: TH-OR024]. Journal of the American Society of Nephrology2019;30(Abstract Suppl):6. [EMBASE: 633771357]">Nangaku 2021</a>; <a href="./references#CD013751-bbs2-0037" title="Astellas1517-CL-0304. A study to investigate the effect of ASP1517 after intermittent oral dosing in dialysis chronic kidney disease patients with anemia compared with darbepoetin as a reference drug [A Japanese, phase 2, multicenter, randomized, 4-arm parallel, double-blind (arms 1-3), open-label (arm 4), active-comparator (darbepoetin alfa) study of intermittent oral dosing of asp1517 in hemodialysis-dependent chronic kidney disease patients with anemia [1517-CL-0304 clinical study results report]]. www.trialsummaries.com/Study/StudyDetails?id=14175&amp;tenant=MT_AST_9011; www.clinicaltrials.gov/ct2/show/NCT01888445 (first received 6 August 2018). ">NCT01888445</a>; <a href="./references#CD013751-bbs2-0038" title="NangakuM , FaragYM , deGomaE , LuoW , VargoD , KhawajaZ . Vadadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor, for treatment of anemia of chronic kidney disease: two randomized Phase 2 trials in Japanese patients. Nephrology Dialysis Transplantation 2020 Jul 20 [epub ahead of print]. [DOI: 10.1093/ndt/gfaa060] [MEDLINE: 32719868]NangakuM , KhawajaZ , LuoW , GarafolaS , De GomaE , KomatsuY . Randomized, placebo-controlled phase 2 trials of vadadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), to treat anemia of CKD [abstract no: TH-PO228]. Journal of the American Society of Nephrology2018;29(Abstract Suppl):171. [EMBASE: 633737146]SolinskyC , FaragYM , KhawajaZ , AndersR , LuoW , ChavanA , et al. Impact of vadadustat on iron regulation in Japanese subjects with chronic kidney disease (CKD) [abstract no: 352]. American Journal of Kidney Diseases2020;75(4):638-9. [EMBASE: 2005716872]">NDD‐CKD 2020</a>; <a href="./references#CD013751-bbs2-0039" title="NangakuM , FaragYM , deGomaE , LuoW , VargoD , KhawajaZ . Vadadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor, for treatment of anemia of chronic kidney disease: two randomized Phase 2 trials in Japanese patients. Nephrology Dialysis Transplantation 2020 Jul 20 [epub ahead of print]. [DOI: 10.1093/ndt/gfaa060] [MEDLINE: 32719868]NangakuM , KhawajaZ , LuoW , GarafolaS , deGomaE , KomatsuY . Randomized, placebo-controlled phase 2 trials of vadadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), to treat anemia of CKD [abstract no: TH-PO228]. Journal of the American Society of Nephrology2018;29(Abstract Suppl):171. [EMBASE: 633737146]SolinskyC , FaragYM , KhawajaZ , AndersR , LuoW , ChavanA , et al. Impact of vadadustat on iron regulation in Japanese subjects with chronic kidney disease (CKD) [abstract no: 352]. American Journal of Kidney Diseases2020;75(4):638-9. [EMBASE: 2005716872]">NDD‐CKD 2020a</a>; <a href="./references#CD013751-bbs2-0040" title="AstraZeneca. A phase 3, multicenter, randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of roxadustat for the treatment of anemia in chronic kidney disease patients not on dialysis [clinical study protocol V6; 31 August 2018]. www.clinicaltrials.gov/ProvidedDocs/27/NCT02174627/Prot_000.pdf (accessed 9 May 2022). EleftheriadisT , PissasG , LiakopoulosV , StefanidisI . On the increased event rate of urinary tract infection and pneumonia in CKD patients treated with roxadustat for anemia. Journal of the American Society of Nephrology2021;32(6):1537. [MEDLINE: 33849917]FishbaneS , El-ShahawyMA , Pecoits-FilhoR , VanBP , HouserMT , FrisonL , et al. OLYMPUS: a phase 3, randomized, double-blind, placebo-controlled, international study of roxadustat efficacy in patients with non-dialysis-dependent (NDD) CKD and anemia [abstract no: TH-OR023]. Journal of the American Society of Nephrology2019;30(Abstract Suppl):6. [EMBASE: 633771285]FishbaneS , El-ShahawyMA , Pecoits-FilhoR , VanBP , HouserMT , FrisonL , et al. Roxadustat for treating anemia in patients with CKD not on dialysis: results from a randomized phase 3 study. Journal of the American Society of Nephrology2021;32(3):737-55. [MEDLINE: 33568383]FishbaneS , El-ShahawyMA , VanBP , LittleDJ . Authors' Reply. Journal of the American Society of Nephrology2021;32(6):1537-8. [MEDLINE: 33849916]Pecoits-FilhoR , ChanTM , HardyE , YuKH , FishbaneS . Roxadustat treatment results in consistent improvements in hemoglobin (Hb) vs. placebo: an analysis of three multinational randomized clinical trials in patients with non-dialysis-dependent CKD (NDD-CKD) [abstract no: TH-OR05]. Journal of the American Society of Nephrology2020;31(Abstract Suppl):2. [EMBASE: 633697943]RastogiA , Pecoits-FilhoR , FishbaneS , LittleDJ , HardyE , YuKH , et al. Roxadustat treatment corrects anemia to hemoglobin (HB) values ≥10 g/dL in the majority of patients with non-dialysis-dependent chronic kidney disease (NDD-CKD) [abstract no: PO0264]. Journal of the American Society of Nephrology2020;31(Abstract Suppl):133. [EMBASE: 633698803]">OLYMPUS 2021</a>; <a href="./references#CD013751-bbs2-0047" title="Astellas 1517-CL-0613. Roxadustat in the treatment of anemia in end stage renal disease (ESRD) patients on stable dialysis [A phase 3, randomized, open-label, active-controlled study to evaluate the efficacy and safety of roxadustat in the maintenance treatment of anemia in end stage renal disease patients on stable dialysis]. www.trialsummaries.com/Study/StudyDetails?id=14380&amp;tenant=MT_AST_9011 (accessed 9 May 2022). CsikyB , SchomigM , EspositoC , BarrattJ , ReuschM , ValluriU , et al. Roxadustat for the maintenance treatment of anemia in patients with end-stage kidney disease on stable dialysis: a European phase 3, randomized, open-label, active-controlled study (PYRENEES). Advances in Therapy2021;38(10):5361-80. [MEDLINE: 34537926]EspositoC , CsikyB , TataradzeA , ReuschM , HanC , SulowiczW . Two phase 3, multicenter, randomized studies of intermittent oral roxadustat in anemic CKD patients on (PYRENEES) and not on (ALPS) dialysis. Swiss Medical Weekly2020;150(Suppl 248):21-2S. [EMBASE: 634241523]EspositoC , CsikyB , TataradzeA , ReuschM , HanC , SulowiczW . Two phase 3, multicenter, randomized studies of intermittent oral roxadustat in anemic CKD patients on (PYRENEES) and not on (ALPS) dialysis [abstract no: SA-PO225]. Journal of the American Society of Nephrology2019;30(Abstract Suppl):822. [EMBASE: 633767739]">PYRENEES 2021</a>; <a href="./references#CD013751-bbs2-0048" title="AstraZeneca. A phase 3, multicenter, randomized, open-label, active-controlled study of the safety and efficacy of roxadustat in the treatment of anemia in dialysis patients [Clinical study protocol v8.0 19 September 2018]. www.clinicaltrials.gov/ProvidedDocs/31/NCT02174731/Prot_000.pdf (accessed 10 May 2022). FishbaneS , PollockCA , El-ShahawyMA , EscuderoET , RastogiA , VanBP , et al. ROCKIES: an international, phase 3, randomized, open-label, active-controlled study of roxadustat for anemia in dialysis-dependent CKD patients [abstract no: TH-OR022]. Journal of the American Society of Nephrology2019;30(Abstract Suppl):6. [EMBASE: 633771219]">ROCKIES 2019</a>; <a href="./references#CD013751-bbs2-0050" title="AkizawaT , MaedaK , MiyazawaY , KoretomoR . Phase 3 study to compare the efficacy and safety of enarodustat (JTZ-951), an oral HIF-PH inhibitor, with darbepoetin alfa in anemic patients with CKD receiving maintenance hemodialysis [abstract no: TH-PO1186]. Journal of the American Society of Nephrology2019;30(Abstract Suppl):B4. AkizawaT , NangakuM , YamaguchiT , KoretomoR , MaedaK , MiyazawaY , et al. A phase 3 study of enarodustat (JTZ-951) in Japanese hemodialysis patients for treatment of anemia in chronic kidney disease: SYMPHONY HD study. Kidney Diseases2021;7(6):494-502. [EMBASE: 2013576033]">SYMPHONY HD 2021</a>; <a href="./references#CD013751-bbs2-0051" title="AkizawaT , NangakuM , YamaguchiT , KoretomoR , MaedaK , MiyazawaY , et al. A phase 3 study of enarodustat in anemic patients with CKD not requiring dialysis: the SYMPHONY ND study. Kidney International Reports2021;6(7):1840-9. [MEDLINE: 34307978]">SYMPHONY ND 2021</a>) </p> </li> <li> <p>One study reported the Hb target was 10 to 12 g/dL but also an increase of at least 1 g/dL (<a href="./references#CD013751-bbs2-0049" title="CharytanC , Manllo-KarimR , MartinER , SteerD , BernardoM , DuaSL , et al. A randomized trial of roxadustat in anemia of kidney failure: SIERRAS study. Kidney International Reports2021;6(7):1829-39. [MEDLINE: 34307977]CharytanC , Manllo-KarimR , MartinER , SteerD , BernardoM , DuaSL , et al. SIERRAS: A phase 3, open-label, randomized, active-controlled study of the efficacy and safety of roxadustat in the maintenance treatment of anemia in subjects with ESRD on stable dialysis [abstract no: SA-PO227]. Journal of the American Society of Nephrology2019;30(Abstract Suppl):822. [EMBASE: 633767862]">SIERRAS 2021</a>) </p> </li> <li> <p>Two studies reported the Hb target was 11 g/dL and an increase of 1 g/dL if baseline Hb was &gt; 8 g/dL or an increase of 2 g/dL if baseline Hb was &lt; 8 g/dL (<a href="./references#CD013751-bbs2-0008" title="CoyneDW , RogerSD , ChouW , BesarabA , LeongR , LeeTT , et al. Roxadustat favorably modifies iron indices in patients with non-dialysis-dependent CKD-related anemia [abstract no: PO0262]. Journal of the American Society of Nephrology2020;31(Abstract Suppl):132. [EMBASE: 633698686]CoyneDW , RogerSD , ShinS , KimSG , CadenaAA , MoustafaMA , et al. Roxadustat for CKD-related anemia in non-dialysis patients. Kidney International Reports2021;6(3):624-35. [MEDLINE: 33732977]CoyneDW , RogerSD , ShinSK , KimSG , CadenaAA , MoustafaMA , et al. ANDES: A phase 3, randomized, double-blind, placebo controlled study of the efficacy and safety of roxadustat for the treatment of anemia in CKD patients not on dialysis [abstract no: SA-PO0228]. Journal of the American Society of Nephrology2019;30(Abstract Suppl):822-3. [EMBASE: 633767955]Pecoits-FilhoR , ChanTM , HardyE , YuKHP , FishbaneS . Roxadustat treatment results in consistent improvements in hemoglobin (Hb) vs. placebo: an analysis of three multinational randomized clinical trials in patients with non-dialysis-dependent CKD (NDD-CKD) [abstract no: TH-OR05]. Journal of the American Society of Nephrology2020;31(Abstract Suppl):2. [EMBASE: 633697943]RastogiA , Pecoits-FilhoR , FishbaneS , LittleDJ , HardyE , YuKH , et al. Roxadustat treatment corrects anemia to hemoglobin (HB) values ≥10 g/dL in the majority of patients with non-dialysis-dependent chronic kidney disease (NDD-CKD) [abstract no: PO0264]. Journal of the American Society of Nephrology2020;31(Abstract Suppl):133. [EMBASE: 633698803]">ANDES 2021</a>; <a href="./references#CD013751-bbs2-0024" title="ProvenzanoM , EvgenyS , LiubovE , KorneyevaS , KathresalAA , PooleL , et al. HIMALAYAS: a phase 3, randomized, open-label, active-controlled study of the efficacy and safety of roxadustat in the treatment of anemia in incident-dialysis patients [abstract no: TH-OR021]. Journal of the American Society of Nephrology2019;30(Abstract Suppl):5. [EMBASE: 633771140]ProvenzanoR , ShutovE , EremeevaL , KorneyevaS , PooleL , SahaG , et al. Roxadustat for anemia in patients with end-stage renal disease incident to dialysis. Nephrology Dialysis Transplantation2021;36(9):1717-30. [MEDLINE: 33629100]">HIMALAYAS 2021</a>) </p> </li> <li> <p>One study reported both an increase in Hb ≥ 1 g/dL or Hb target ≥ 11.0 g/dL (<a href="./references#CD013751-bbs2-0007" title="Astellas 1517-CL-0608. Roxadustat in the treatment of anemia in chronic kidney disease patients not requiring dialysis [A phase 3, randomized, double-blind, placebo controlled study of the efficacy and safety of roxadustat for the treatment of anemia in chronic kidney disease patients not on dialysis]. www.trialsummaries.com/Study/StudyDetails?id=14384&amp;tenant=MT_AST_90112019. EspositoC , CsikyB , TataradzeA , ReuschM , HanC , SulowiczW . Two phase 3, multicenter, randomized studies of intermittent oral roxadustat in anemic CKD patients on (PYRENEES) and not on (ALPS) dialysis [abstract no: SA-PO225]. Journal of the American Society of Nephrology2019;30(Abstract Suppl):822. [EMBASE: 633767739]Pecoits-FilhoR , ChanTM , HardyE , YuKH , FishbaneS . Roxadustat treatment results in consistent improvements in hemoglobin (Hb) vs. placebo: an analysis of three multinational randomized clinical trials in patients with non-dialysis-dependent CKD (NDD-CKD) [abstract no: TH-OR05]. Journal of the American Society of Nephrology2020;31(Abstract Suppl):2. [EMBASE: 633697943]RastogiA , Pecoits-FilhoR , FishbaneS , LittleDJ , HardyE , YuKH , et al. Roxadustat treatment corrects anemia to hemoglobin (HB) values ≥10 g/dL in the majority of patients with non-dialysis-dependent chronic kidney disease (NDD-CKD) [abstract no: PO0264]. Journal of the American Society of Nephrology2020;31(Abstract Suppl):133. [EMBASE: 633698803]ShutovE , SulowiczW , EspositoC , TataradzeA , AndricB , ReuschM , et al. Roxadustat for the treatment of anemia in chronic kidney disease patients not on dialysis: a phase 3, randomized, double-blind, placebo-controlled study (ALPS). Nephrology Dialysis Transplantation2021;36(9):1629-39. [MEDLINE: 33630072]">ALPS 2021</a>) </p> </li> <li> <p>Five studies reported the Hb target 11 to 13 g/dL (<a href="./references#CD013751-bbs2-0033" title="YamamotoH , NoboriK , MatsudaY , HayashiY , HayasakiT , AkizawaT . Molidustat for renal anemia in nondialysis patients previously treated with erythropoiesis-stimulating agents: a randomized, open-label, phase 3 study. American Journal of Nephrology2021;52(10-11):884-93. [MEDLINE: 34569482]YamamotoH , TaguchiM , MatsudaY , IekushiK , YamadaT , AkizawaT . Molidustat for the treatment of renal anaemia in patients with non-dialysis-dependent chronic kidney disease: design and rationale of two phase III studies. BMJ Open2019;9(6):e026704. [MEDLINE: 31203242]YamamotoH , TaguchiM , NoboriK , MatsudaY , IekushiK , AkizawaT . To investigate the efficacy and safety of molidustat in non-dialysis patients with renal anemia who are treated with erythropoiesis stimulating agents: Miyabi ND-M [Abstract no: P1868]. Nephrology Dialysis Transplantation2020;35(Suppl 3):iii2179. [EMBASE: 633423006]">MIYABI ND‐M 2019</a>; <a href="./references#CD013751-bbs2-0035" title="NangakuM , KondoK , KokadoY , UetaK , KanekoG , ShiosakaM , et al. Randomized, open-label, active-controlled (darbepoetin alfa), phase 3 study of vadadustat for treating anemia in non-dialysis-dependent CKD patients in Japan [abstract no: SA-PO229]. Journal of the American Society of Nephrology2019;30(Abstract Suppl):823. [EMBASE: 633767995]NangakuM , KondoK , KokadoY , UetaK , KanekoG , TandaiT , et al. Phase 3 randomized study comparing vadadustat with darbepoetin alfa for anemia in Japanese patients with nondialysis-dependent CKD. Journal of the American Society of Nephrology2021;32(7):1779-90. [MEDLINE: 33883252]">Nangaku 2021a</a>; <a href="./references#CD013751-bbs2-0036" title="GSK201753. A 52-week, Phase III, open-label, multi-center study to evaluate efficacy and safety of GSK1278863 in Japanese non-dialysis and peritoneal dialysis subjects with anemia associated with chronic kidney disease [study protocol]. www.clinicaltrials.gov/ProvidedDocs/63/NCT02791763/Prot_000.pdf (accessed 9 May 2022). NangakuM , HamanoT , AkizawaT , TsubakiharaY , NagaiR , OkudaN , et al. Daprodustat compared with epoetin beta pegol for anemia in Japanese patients not on dialysis: a 52-week randomized open-label phase 3 trial. American Journal of Nephrology2021;52(1):26-35. [MEDLINE: 33561857]">Nangaku 2021b</a>; <a href="./references#CD013751-bbs2-0045" title="ProvenzanoR , BesarabA , DuaSL , NguyenPV , WrightSH , ZeigS , et al. FG-4592, a novel oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), maintains hemoglobin levels and lowers cholesterol in hemodialysis patients: phase 2 comparison with epoetin alfa [abstract no: FR-PO257]. Journal of the American Society of Nephrology2012;23(Abstract Suppl):428A. ProvenzanoR , BesarabA , WrightS , DuaS , ZeigS , NguyenP , et al. Roxadustat (FG-4592) versus epoetin alfa for anemia in patients receiving maintenance hemodialysis: a phase 2, randomized, 6- to 19-week, open-label, active-comparator, dose-ranging, safety and exploratory efficacy study. American Journal of Kidney Diseases2016;67(6):912-24. [MEDLINE: 26846333]">Provenzano 2016</a>; <a href="./references#CD013751-bbs2-0046" title="ProvenzanoR , BesarabA , DuaSL , NguyenPV , WrightSH , ZeigS , et al. FG-4592, a novel oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), maintains hemoglobin levels and lowers cholesterol in hemodialysis patients: phase 2 comparison with epoetin alfa [abstract no: FR-PO257]. Journal of the American Society of Nephrology2012;23(Abstract Suppl):428A. ProvenzanoR , BesarabA , WrightS , DuaS , ZeigS , NguyenP , et al. Roxadustat (FG-4592) versus epoetin alfa for anemia in patients receiving maintenance hemodialysis: a phase 2, randomized, 6- to 19-week, open-label, active-comparator, dose-ranging, safety and exploratory efficacy study. American Journal of Kidney Diseases2016;67(6):912-24. [MEDLINE: 26846333]">Provenzano 2016a</a>) </p> </li> <li> <p>One study reported the Hb target was 11 to 12 g/dL and an increase of 1 g/dL (<a href="./references#CD013751-bbs2-0012" title="JohansenKL , CobitzAR , LopesRD , SinghAK , ObradorGT , CizmanB , et al. Effects of daprodustat on hemoglobin and quality of life in patients with CKD: results of the ascend-NHQ randomized, double-blind, placebo-controlled trial [abstract no: FR-OR53]. Journal of the American Society of Nephrology2021;32(Abstract Suppl):36. [EMBASE: 636330656]">ASCEND‐NHQ 2021</a>) </p> </li> <li> <p>One study reported the Hb target was 8 to 11 g/dL (<a href="./references#CD013751-bbs2-0026" title="CizmanB , AckertJ , MeadowcroftA , BiswasN , KellyD , KleinmanD , et al. Ocular safety profile of daprodustat: results of two 24 week studies [abstract no: SAO004]. Nephrology Dialysis Transplantation2018;33(Suppl 1):i316. [EMBASE: 622604997]HoldstockL , CizmanB , MeadowcroftAM , BiswasN , JohnsonBM , JonesD , et al. Daprodustat for anemia: a 24-week, open-label, randomized controlled trial in participants with chronic kidney disease. Clinical Kidney Journal2019;12(1):129-38. [MEDLINE: 30746140]HoldstockL , CizmanB , MeadowcroftAM , BiswasN , JonesD , JohnsonBM , et al. Daprodustat, a HIF-prolyl-hydroxylase inhibitor, increases and maintains hemoglobin over 24 weeks in anemic chronic kidney disease subjects [abstract no: TH-PO908]. Journal of the American Society of Nephrology2016;27(Abstract Suppl):304A. ">Holdstock 2019a</a>) </p> </li> <li> <p>One study reported the Hb target was 9 to 10.5 g/dL (<a href="./references#CD013751-bbs2-0025" title="CizmanB , AckertJ , MeadowcroftA , BiswasN , KellyD , KleinmanD , et al. Ocular safety profile of daprodustat: results of two 24 week studies [abstract no: SAO004]. Nephrology Dialysis Transplantation2018;33(Suppl 1):i316. [EMBASE: 622604997]HoldstockL , CizmanB , MeadowcroftAM , BiswasN , JohnsonBM , JonesD , et al. Daprodustat for anemia: a 24-week, open-label, randomized controlled trial in participants with chronic kidney disease. Clinical Kidney Journal2019;12(1):129-38. [MEDLINE: 30746140]HoldstockL , CizmanB , MeadowcroftAM , BiswasN , JonesD , JohnsonBM , et al. Daprodustat, a HIF-prolyl-hydroxylase inhibitor, increases and maintains hemoglobin over 24 weeks in anemic chronic kidney disease subjects [abstract no: TH-PO908]. Journal of the American Society of Nephrology2016;27(Abstract Suppl):304A. ">Holdstock 2019</a>) </p> </li> <li> <p>One study reported the Hb target was ≥ 11.0 g/dL (<a href="./references#CD013751-bbs2-0041" title="HaaseVH , SpinowitzBS , PergolaPE , FarmerT , MaroniBJ , HartmanCS . AKB-6548 demonstrates controlled hemogloblin (HGB) response in a phase 2b study for the treatment of anemia in patients with chronic kidney disease not on dialysis (ND-CKD) [abstract no: TH-PO649]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):237A. HaaseVH , SpinowitzBS , PergolaPE , KhawajaZ , ChanJ , ZurawQ , et al. Efficacy and dose requirements of vadadustat are independent of systemic inflammation and prior erythropoiesis-stimulating agent(ESA) dose in patients with non-dialysis dependent chronic kidney disease (NDD-CKD) [abstract no: TH-PO907]. Journal of the American Society of Nephrology2016;27(Abstract Suppl):304A. PergolaPE , SpinowitzB , HaaseVH , HartmanCS , FarmerTM , PoluKR , et al. AKB-6548, a novel hypoxia-inducible factor prolyl-hydroxylase inhibitor (HIF-PHI) for the treatment of anemia in patients with chronic kidney disease not on dialysis (ND-CKD) [abstract no: FO015]. Nephrology Dialysis Transplantation2015;30(Suppl 3):iii8. [EMBASE: 72206296]PergolaPE , SpinowitzBS , HartmanCS , MaroniBJ , HaaseVH . Vadadustat, a novel oral HIF stabilizer, provides effective anemia treatment in nondialysis-dependent chronic kidney disease. Kidney International2016;90(5):1115-22. [MEDLINE: 27650732]SpinowitzBS , PergolaPE , HaaseVH , FarmerTM , HartmanCS , MaroniBJ . Hemoglobin (HGB) response in a phase 2b study of AKB-6548 for the treatment of anemia in patients with non-dialysis dependant chronic kidney disease (NDD-CKD). [abstract no: TH-OR038]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):11A. ">Pergola 2016</a>) </p> </li> <li> <p>Three studies reported the Hb target in the USA was ≥ 10 to 11 g/dL and in the non‐USA countries was ≥ 10 to 12 g/dL (<a href="./references#CD013751-bbs2-0029" title="EckardtKU , AgarwalR , AswadA , AwadA , BlockGA , BacciMR , et al. Safety and efficacy of vadadustat for anemia in patients undergoing dialysis. New England Journal of Medicine2021;384(17):1601-12. [MEDLINE: 33913638]EckardtKU , AgarwalR , FaragYM , JardineAG , KhawajaZ , KouryMJ , et al. Global Phase 3 programme of vadadustat for treatment of anaemia of chronic kidney disease: rationale, study design and baseline characteristics of dialysis-dependent patients in the INNO2VATE trials. Nephrology Dialysis Transplantation2020;36(11):2039-48. [MEDLINE: 33188693]EckardtKU . Global phase 3 clinical trials of vadadustat vs. darbepoetin alfa for treatment of anemia in patients with dialysis-dependent CKD [abstract no: TH-OR01]. Journal of the American Society of Nephrology2020;31(Abstract Suppl):1. [EMBASE: 633697781]WinkelmayerWC , FishbaneS , TumlinJA , FaragYM , LuoW , AndersR , et al. Iron-related outcomes in patients with dialysis-dependent CKD randomized to vadadustat vs. darbepoetin alfa [abstract no: PO0457]. Journal of the American Society of Nephrology2021;32(Abstract Suppl):182. [EMBASE: 636330773]">INNO2VATE 2020a</a>; <a href="./references#CD013751-bbs2-0042" title="BunnHF . Vadadustat for anemia in patients with dialysis-dependent or non-dialysis-dependent chronic kidney disease. New England Journal of Medicine2021;385(16):e56. [MEDLINE: 34644481]ChertowGM , PergolaPE , AgarwalR , BlockGA , FaragYM , JardineAG , et al. Cardiovascular safety and efficacy of vadadustat for the treatment of anemia in non-dialysis-dependent CKD: design and baseline characteristics. American Heart Journal2021;235(5):1-11. [MEDLINE: 33129989]ChertowGM , PergolaPE , FaragYM , AgarwalR , ArnoldS , BakoG , et al. Vadadustat in patients with anemia and non-dialysis-dependent CKD. New England Journal of Medicine2021;384(17):1589-600. [MEDLINE: 33913637]ChertowGM . Global phase 3 clinical trials of vadadustat vs. darbepoetin alfa for treatment of anemia in patients with non-dialysis-dependent CKD [abstract no: FR-OR54]. Journal of the American Society of Nephrology2020;31(Abstract Suppl):B2. [EMBASE: 633697273]KouryM , PergolaPE , Roy-ChaudhuryP , FaragYM , LuoW , AndersR , et al. Iron-related outcomes in patients with non-dialysis-dependent CKD randomized to vadadustat vs. darbepoetin Alfa [abstract no: PO0482]. Journal of the American Society of Nephrology2021;32(Abstract Suppl):190. [EMBASE: 636329134]McCulloughPA , LuoW , AndersR , VargoD , ParfreyPS . Assessment of thromboembolic events with vadadustat vs. darbepoetin alfa for treatment of anemia in patients with non-dialysis-dependent CKD [abstract no: PO0462]. Journal of the American Society of Nephrology2021;32(Abstract Suppl):184. [EMBASE: 636331039]">PRO2TECT‐CONVERSION 2021</a>; <a href="./references#CD013751-bbs2-0043" title="BunnHF . Vadadustat for anemia in patients with dialysis-dependent or non-dialysis-dependent chronic kidney disease. New England Journal of Medicine2021;385(16):e56. [MEDLINE: 34644481]ChertowGM , PergolaPE , AgarwalR , BlockGA , FaragYM , JardineAG , et al. Cardiovascular safety and efficacy of vadadustat for the treatment of anemia in non-dialysis-dependent CKD: design and baseline characteristics. American Heart Journal2021;235(5):1-11. [MEDLINE: 33129989]ChertowGM , PergolaPE , FaragYM , AgarwalR , ArnoldS , BakoG , et al. Vadadustat in patients with anemia and non-dialysis-dependent CKD. New England Journal of Medicine2021;384(17):1589-600. [MEDLINE: 33913637]ChertowGM . Global phase 3 clinical trials of vadadustat vs. darbepoetin alfa for treatment of anemia in patients with non-dialysis-dependent CKD [abstract no: FR-OR5]. Journal of the American Society of Nephrology2020;31(Abstract Suppl):B2. [EMBASE: 633697273]KouryM , PergolaPE , Roy-ChaudhuryP , FaragYM , LuoW , AndersR , et al. Iron-related outcomes in patients with non-dialysis-dependent CKD randomized to vadadustat vs. darbepoetin alfa [abstract no: PO0482]. Journal of the American Society of Nephrology2021;32(Abstract Suppl):190. [EMBASE: 636329134]McCulloughPA , LuoW , AndersR , VargoD , ParfreyPS . Assessment of thromboembolic events with vadadustat vs. darbepoetin alfa for treatment of anemia in patients with non-dialysis-dependent CKD [abstract no: PO0462]. Journal of the American Society of Nephrology2021;32(Abstract Suppl):184. [EMBASE: 636331039]">PRO2TECT‐CORRECTION 2021</a>) </p> </li> <li> <p>Three studies did not report a Hb target (<a href="./references#CD013751-bbs2-0005" title="AkizawaT , IwasakiM , OtsukaT , YamaguchiY , ReuschM . A phase 3, multicenter, randomized, open-label, active comparator conversion study of roxadustat in non-dialysis-dependent (NDD) patients with anemia in chronic kidney disease (CKD) [abstract no: POS-244]. Kidney International Reports2021;6(4 Suppl):S103. [EMBASE: 2011682459]AkizawaT , IwasakiM , OtsukaT , YamaguchiY , ReuschM . A phase 3, multicenter, randomized, open-label, active comparator conversion study of roxadustat in non-dialysis-dependent (NDD) patients with anemia in CKD [abstract no: PO0269]. Journal of the American Society of Nephrology2020;31(Abstract Suppl):134. [EMBASE: 633699036]NguyenQD , SepahYJ , YamaguchiY , OtsukaT , MajikawaY , ReuschM , et al. Ophthalmological effects of roxadustat in the treatment of anemia in dialysis-dependent and non-dialysis-dependent CKD patients: findings from two phase 3 studies [abstract no: PO0267]. Journal of the American Society of Nephrology2020;31(Abstract Suppl):134. [EMBASE: 633698979]">Akizawa 2020f</a>; <a href="./references#CD013751-bbs2-0009" title="SinghAK , BlackorbyA , CizmanB , CarrollK , CobitzAR , DaviesR , et al. Study design and baseline characteristics of patients on dialysis in the ASCEND-D trial. Nephrology Dialysis Transplantation2021;37(5):960-72. [MEDLINE: 33744933] [MEDLINE: 33744933]SinghAK , BlackorbyA , CizmanB , CobitzAR , GodoySA , JhaV , et al. Regional variation of erythropoietin-stimulating agent hyporesponsiveness in the global daprodustat dialysis study (ASCEND-D) [abstract no: TH-OR08]. Journal of the American Society of Nephrology2020;31(Abstract Suppl):3. [EMBASE: 633698062]SinghAK , CarrollK , PerkovicV , SolomonS , JhaV , JohansenKL , et al. Daprodustat for the treatment of anemia in patients undergoing dialysis. New England Journal of Medicine2021;385(25):2325-35. [MEDLINE: 34739194]">ASCEND‐D 2021</a>; <a href="./references#CD013751-bbs2-0020" title="AkizawaT , MacdougallIC , BernsJS , BernhardtT , TaguchiM , OguraE , et al. Iron regulation by molidustat, bay 85-3934, a daily oral hypoxia-inducible factor prolyl hydroxylase inhibitor in patients with chronic kidney disease [abstract no: SP334]. Nephrology Dialysis Transplantation2018;33(Suppl 1):i457. [EMBASE: 622606520]AkizawaT , MacdougallIC , BernsJS , YamamotoH , TaguchiM , IekushiK , et al. Iron regulation by molidustat, a daily oral hypoxia-inducible factor prolyl hydroxylase inhibitor, in patients with chronic kidney disease. Nephron2019;143(4):243-54. [MEDLINE: 31387097]MacdougallIC , AkizawaT , BernsJ , LentiniS , BernhardtT . Molidustat increases haemoglobin in erythropoiesis stimulating agents (ESA)-naive anaemic patients with chronic kidney disease not on dialysis (CKD-ND) [abstract no: SO036]. Nephrology Dialysis Transplantation2016;31(Suppl 1):i16. [EMBASE: 72325954]MacdougallIC , AkizawaT , BernsJS , BernhardtT , KruegerT . Effects of molidustat in the treatment of anemia in CKD [Erratum in: Clin J Am Soc Nephrol. 2019 Oct 7;14(10):1524]. Clinical Journal of the American Society of Nephrology: CJASN2019;14(1):28-39. [MEDLINE: 30559105]MacdougallIC , BernsJS , AkizawaT , FishbaneS , BernhardtT . DIALOGUE phase 2 program for BAY85-3934 a HIF-PH inhibitor with daily oral treatment in anemic patients suffering from CKD/ESRD [abstract no: FR-PO219]. Journal of the American Society of Nephrology2013;24(Abstract Suppl):413A. ">DIALOGUE 1 2019</a>). </p> </li> </ul> </p> </section> <section id="CD013751-sec-0046"> <h5 class="title">Interventions</h5> <p> <ul id="CD013751-list-0012"> <li> <p>One study (<a href="./references#CD013751-bbs2-0019" title="ChenN , QianJ , ChenJ , YuX , MeiC , HaoC , et al. Phase 2 studies of oral hypoxia-inducible factor prolyl hydroxylase inhibitor FG-4592 for treatment of anemia in China. Nephrology Dialysis Transplantation2017;32(8):1373-86. [MEDLINE: 28371815]QianJQ , ChenN , ChenJ , HaoC , LinHL , NiD , et al. A randomized, double-blind, placebo controlled trial of FG-4592 for correction of anemia in subjects with chronic kidney disease in China [abstract no: FR-OR011]. Journal of the American Society of Nephrology2013;24(Abstract Suppl):38A. ">Chen NDD 2017</a>) compared three arms, including different doses of HIF stabiliser and placebo </p> </li> <li> <p>Seven studies (<a href="./references#CD013751-bbs2-0002" title="AkizawaT , IwasakiM , OtsukaT , ReuschM , MisumiT . Roxadustat for the treatment of chronic kidney disease-associated anemia in Japanese patients not on dialysis [abstract no: FR-PO1142]. Journal of the American Society of Nephrology2016;27(Abstract Suppl):7B. AkizawaT , IwasakiM , OtsukaT , ReuschM , MisumiT . Roxadustat treatment of chronic kidney disease-associated anemia in Japanese patients not on dialysis: a phase 2, randomized, double-blind, placebo-controlled trial. Advances in Therapy2019;36(6):1438-54. [MEDLINE: 30953333]">Akizawa 2019</a>; <a href="./references#CD013751-bbs2-0018" title="ChenN , QianJ , ChenJ , YuX , MeiC , HaoC , et al. Phase 2 studies of oral hypoxia-inducible factor prolyl hydroxylase inhibitor FG-4592 for treatment of anemia in China. Nephrology Dialysis Transplantation2017;32(8):1373-86. [MEDLINE: 28371815]">Chen DD 2017</a>; <a href="./references#CD013751-bbs2-0021" title="AkizawaT , MacdougallIC , BernsJS , YamamotoH , TaguchiM , IekushiK , et al. Iron regulation by molidustat, a daily oral hypoxia-inducible factor prolyl hydroxylase inhibitor, in patients with chronic kidney disease. Nephron2019;143(4):243-54. [MEDLINE: 31387097]MacdougallIC , AkizawaT , BernsJ , LentiniS , BernhardtT , KrugerT . Safety and efficacy of molidustat in erythropoiesis stimulating agents (ESA) pre-treated anaemic patients with chronic kidney disease not on dialysis (CKD-ND) [abstract no: SP309]. Nephrology Dialysis Transplantation2016;31(Suppl 1):i193. [EMBASE: 72326411]MacdougallIC , AkizawaT , BernsJ , LentiniS , BernhardtT . Molidustat increases haemoglobin in erythropoiesis stimulating agents (ESA)-naive anaemic patients with chronic kidney disease not on dialysis (CKD-ND) [abstract no: SO036]]. Nephrology Dialysis Transplantation2016;31(Suppl 1):i16. [EMBASE: 72325954]MacdougallIC , AkizawaT , BernsJS , BernhardtT , KruegerT . Effects of molidustat in the treatment of anemia in CKD [Erratum in: Clin J Am Soc Nephrol. 2019 Oct 7;14(10):1524]. Clinical Journal of the American Society of Nephrology: CJASN2019;14(1):28-39. [MEDLINE: 30559105]MacdougallIC , BernsJS , AkizawaT , FishbaneS , BernhardtT . DIALOGUE phase 2 program for BAY85-3934 a HIF-PH inhibitor with daily oral treatment in anemic patients suffering from CKD/ESRD [abstract no: FR-PO219]. Journal of the American Society of Nephrology2013;24(Abstract Suppl):413A. ">DIALOGUE 2 2019</a>; <a href="./references#CD013751-bbs2-0025" title="CizmanB , AckertJ , MeadowcroftA , BiswasN , KellyD , KleinmanD , et al. Ocular safety profile of daprodustat: results of two 24 week studies [abstract no: SAO004]. Nephrology Dialysis Transplantation2018;33(Suppl 1):i316. [EMBASE: 622604997]HoldstockL , CizmanB , MeadowcroftAM , BiswasN , JohnsonBM , JonesD , et al. Daprodustat for anemia: a 24-week, open-label, randomized controlled trial in participants with chronic kidney disease. Clinical Kidney Journal2019;12(1):129-38. [MEDLINE: 30746140]HoldstockL , CizmanB , MeadowcroftAM , BiswasN , JonesD , JohnsonBM , et al. Daprodustat, a HIF-prolyl-hydroxylase inhibitor, increases and maintains hemoglobin over 24 weeks in anemic chronic kidney disease subjects [abstract no: TH-PO908]. Journal of the American Society of Nephrology2016;27(Abstract Suppl):304A. ">Holdstock 2019</a>; <a href="./references#CD013751-bbs2-0037" title="Astellas1517-CL-0304. A study to investigate the effect of ASP1517 after intermittent oral dosing in dialysis chronic kidney disease patients with anemia compared with darbepoetin as a reference drug [A Japanese, phase 2, multicenter, randomized, 4-arm parallel, double-blind (arms 1-3), open-label (arm 4), active-comparator (darbepoetin alfa) study of intermittent oral dosing of asp1517 in hemodialysis-dependent chronic kidney disease patients with anemia [1517-CL-0304 clinical study results report]]. www.trialsummaries.com/Study/StudyDetails?id=14175&amp;tenant=MT_AST_9011; www.clinicaltrials.gov/ct2/show/NCT01888445 (first received 6 August 2018). ">NCT01888445</a>; <a href="./references#CD013751-bbs2-0038" title="NangakuM , FaragYM , deGomaE , LuoW , VargoD , KhawajaZ . Vadadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor, for treatment of anemia of chronic kidney disease: two randomized Phase 2 trials in Japanese patients. Nephrology Dialysis Transplantation 2020 Jul 20 [epub ahead of print]. [DOI: 10.1093/ndt/gfaa060] [MEDLINE: 32719868]NangakuM , KhawajaZ , LuoW , GarafolaS , De GomaE , KomatsuY . Randomized, placebo-controlled phase 2 trials of vadadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), to treat anemia of CKD [abstract no: TH-PO228]. Journal of the American Society of Nephrology2018;29(Abstract Suppl):171. [EMBASE: 633737146]SolinskyC , FaragYM , KhawajaZ , AndersR , LuoW , ChavanA , et al. Impact of vadadustat on iron regulation in Japanese subjects with chronic kidney disease (CKD) [abstract no: 352]. American Journal of Kidney Diseases2020;75(4):638-9. [EMBASE: 2005716872]">NDD‐CKD 2020</a>; <a href="./references#CD013751-bbs2-0039" title="NangakuM , FaragYM , deGomaE , LuoW , VargoD , KhawajaZ . Vadadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor, for treatment of anemia of chronic kidney disease: two randomized Phase 2 trials in Japanese patients. Nephrology Dialysis Transplantation 2020 Jul 20 [epub ahead of print]. [DOI: 10.1093/ndt/gfaa060] [MEDLINE: 32719868]NangakuM , KhawajaZ , LuoW , GarafolaS , deGomaE , KomatsuY . Randomized, placebo-controlled phase 2 trials of vadadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), to treat anemia of CKD [abstract no: TH-PO228]. Journal of the American Society of Nephrology2018;29(Abstract Suppl):171. [EMBASE: 633737146]SolinskyC , FaragYM , KhawajaZ , AndersR , LuoW , ChavanA , et al. Impact of vadadustat on iron regulation in Japanese subjects with chronic kidney disease (CKD) [abstract no: 352]. American Journal of Kidney Diseases2020;75(4):638-9. [EMBASE: 2005716872]">NDD‐CKD 2020a</a>) included different doses of HIF stabiliser and ESA (<a href="./references#CD013751-bbs2-0018" title="ChenN , QianJ , ChenJ , YuX , MeiC , HaoC , et al. Phase 2 studies of oral hypoxia-inducible factor prolyl hydroxylase inhibitor FG-4592 for treatment of anemia in China. Nephrology Dialysis Transplantation2017;32(8):1373-86. [MEDLINE: 28371815]">Chen DD 2017</a>; <a href="./references#CD013751-bbs2-0021" title="AkizawaT , MacdougallIC , BernsJS , YamamotoH , TaguchiM , IekushiK , et al. Iron regulation by molidustat, a daily oral hypoxia-inducible factor prolyl hydroxylase inhibitor, in patients with chronic kidney disease. Nephron2019;143(4):243-54. [MEDLINE: 31387097]MacdougallIC , AkizawaT , BernsJ , LentiniS , BernhardtT , KrugerT . Safety and efficacy of molidustat in erythropoiesis stimulating agents (ESA) pre-treated anaemic patients with chronic kidney disease not on dialysis (CKD-ND) [abstract no: SP309]. Nephrology Dialysis Transplantation2016;31(Suppl 1):i193. [EMBASE: 72326411]MacdougallIC , AkizawaT , BernsJ , LentiniS , BernhardtT . Molidustat increases haemoglobin in erythropoiesis stimulating agents (ESA)-naive anaemic patients with chronic kidney disease not on dialysis (CKD-ND) [abstract no: SO036]]. Nephrology Dialysis Transplantation2016;31(Suppl 1):i16. [EMBASE: 72325954]MacdougallIC , AkizawaT , BernsJS , BernhardtT , KruegerT . Effects of molidustat in the treatment of anemia in CKD [Erratum in: Clin J Am Soc Nephrol. 2019 Oct 7;14(10):1524]. Clinical Journal of the American Society of Nephrology: CJASN2019;14(1):28-39. [MEDLINE: 30559105]MacdougallIC , BernsJS , AkizawaT , FishbaneS , BernhardtT . DIALOGUE phase 2 program for BAY85-3934 a HIF-PH inhibitor with daily oral treatment in anemic patients suffering from CKD/ESRD [abstract no: FR-PO219]. Journal of the American Society of Nephrology2013;24(Abstract Suppl):413A. ">DIALOGUE 2 2019</a>; <a href="./references#CD013751-bbs2-0025" title="CizmanB , AckertJ , MeadowcroftA , BiswasN , KellyD , KleinmanD , et al. Ocular safety profile of daprodustat: results of two 24 week studies [abstract no: SAO004]. Nephrology Dialysis Transplantation2018;33(Suppl 1):i316. [EMBASE: 622604997]HoldstockL , CizmanB , MeadowcroftAM , BiswasN , JohnsonBM , JonesD , et al. Daprodustat for anemia: a 24-week, open-label, randomized controlled trial in participants with chronic kidney disease. Clinical Kidney Journal2019;12(1):129-38. [MEDLINE: 30746140]HoldstockL , CizmanB , MeadowcroftAM , BiswasN , JonesD , JohnsonBM , et al. Daprodustat, a HIF-prolyl-hydroxylase inhibitor, increases and maintains hemoglobin over 24 weeks in anemic chronic kidney disease subjects [abstract no: TH-PO908]. Journal of the American Society of Nephrology2016;27(Abstract Suppl):304A. ">Holdstock 2019</a>; <a href="./references#CD013751-bbs2-0037" title="Astellas1517-CL-0304. A study to investigate the effect of ASP1517 after intermittent oral dosing in dialysis chronic kidney disease patients with anemia compared with darbepoetin as a reference drug [A Japanese, phase 2, multicenter, randomized, 4-arm parallel, double-blind (arms 1-3), open-label (arm 4), active-comparator (darbepoetin alfa) study of intermittent oral dosing of asp1517 in hemodialysis-dependent chronic kidney disease patients with anemia [1517-CL-0304 clinical study results report]]. www.trialsummaries.com/Study/StudyDetails?id=14175&amp;tenant=MT_AST_9011; www.clinicaltrials.gov/ct2/show/NCT01888445 (first received 6 August 2018). ">NCT01888445</a>), or different doses of HIF stabiliser and placebo (<a href="./references#CD013751-bbs2-0002" title="AkizawaT , IwasakiM , OtsukaT , ReuschM , MisumiT . Roxadustat for the treatment of chronic kidney disease-associated anemia in Japanese patients not on dialysis [abstract no: FR-PO1142]. Journal of the American Society of Nephrology2016;27(Abstract Suppl):7B. AkizawaT , IwasakiM , OtsukaT , ReuschM , MisumiT . Roxadustat treatment of chronic kidney disease-associated anemia in Japanese patients not on dialysis: a phase 2, randomized, double-blind, placebo-controlled trial. Advances in Therapy2019;36(6):1438-54. [MEDLINE: 30953333]">Akizawa 2019</a>; <a href="./references#CD013751-bbs2-0038" title="NangakuM , FaragYM , deGomaE , LuoW , VargoD , KhawajaZ . Vadadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor, for treatment of anemia of chronic kidney disease: two randomized Phase 2 trials in Japanese patients. Nephrology Dialysis Transplantation 2020 Jul 20 [epub ahead of print]. [DOI: 10.1093/ndt/gfaa060] [MEDLINE: 32719868]NangakuM , KhawajaZ , LuoW , GarafolaS , De GomaE , KomatsuY . Randomized, placebo-controlled phase 2 trials of vadadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), to treat anemia of CKD [abstract no: TH-PO228]. Journal of the American Society of Nephrology2018;29(Abstract Suppl):171. [EMBASE: 633737146]SolinskyC , FaragYM , KhawajaZ , AndersR , LuoW , ChavanA , et al. Impact of vadadustat on iron regulation in Japanese subjects with chronic kidney disease (CKD) [abstract no: 352]. American Journal of Kidney Diseases2020;75(4):638-9. [EMBASE: 2005716872]">NDD‐CKD 2020</a>; <a href="./references#CD013751-bbs2-0039" title="NangakuM , FaragYM , deGomaE , LuoW , VargoD , KhawajaZ . Vadadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor, for treatment of anemia of chronic kidney disease: two randomized Phase 2 trials in Japanese patients. Nephrology Dialysis Transplantation 2020 Jul 20 [epub ahead of print]. [DOI: 10.1093/ndt/gfaa060] [MEDLINE: 32719868]NangakuM , KhawajaZ , LuoW , GarafolaS , deGomaE , KomatsuY . Randomized, placebo-controlled phase 2 trials of vadadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), to treat anemia of CKD [abstract no: TH-PO228]. Journal of the American Society of Nephrology2018;29(Abstract Suppl):171. [EMBASE: 633737146]SolinskyC , FaragYM , KhawajaZ , AndersR , LuoW , ChavanA , et al. Impact of vadadustat on iron regulation in Japanese subjects with chronic kidney disease (CKD) [abstract no: 352]. American Journal of Kidney Diseases2020;75(4):638-9. [EMBASE: 2005716872]">NDD‐CKD 2020a</a>) </p> </li> <li> <p>Five studies (<a href="./references#CD013751-bbs2-0001" title="AkizawaT , TsubakiharaY , NangakuM , EndoY , NakajimaH , KohnoT , et al. Effects of daprodustat, a novel hypoxia-inducible factor prolyl hydroxylase inhibitor on anemia management in Japanese hemodialysis subjects. American Journal of Nephrology2017;45(2):127-35. [MEDLINE: 27978511]EndoY , KohnoT , ImaiY , KawaseN , HaraK , LeporeJJ , et al. A 4 -week dose response study of the hypoxia inducible factor-prolyl hydroxylase inhibitor GSK1278863 in Japanese anemic haemodialysis subjects [abstract no: SA-PO819]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):818A. NCT02019719. Study to evaluate the safety, efficacy and pharmacokinetics of GSK1278863 in Japanese hemodialysis-dependent subjects with anemia associated with chronic kidney disease [A 4-week, phase ii, randomized, double-blind, dose-ranging, placebo-controlled, parallel-group, multi-center study to evaluate the safety, efficacy and pharmacokinetics of GSK1278863 in Japanese hemodialysis-dependent subjects with anemia associated with chronic kidney disease]. clinicaltrials.gov/show/NCT02019719 (first received 24 December 2013). ">Akizawa 2017</a>; <a href="./references#CD013751-bbs2-0014" title="BesarabA , HutlerHN , KlausS , LeeTT , LilienfeldDE , NeffTB , et al. FG-4592, a novel oral HIF prolyl hydroxylase inhibitor, elevates hemoglobin in anemic stage 3/4 CKD patients [abstract no: SA-FC416]. Journal of the American Society of Nephrology2010;21(Abstract Suppl):95A. BesarabA , ProvenzanoR , HertelJ , ZabanehR , KlausSJ , LeeT , et al. Randomized placebo-controlled dose-ranging and pharmacodynamics study of roxadustat (FG-4592) to treat anemia in nondialysis-dependent chronic kidney disease (NDD-CKD) patients. Nephrology Dialysis Transplantation2015;30(10):1665-73. [MEDLINE: 26238121]">Besarab 2015</a>; <a href="./references#CD013751-bbs2-0015" title="BrigandiRA , JohnsonB , OeiC , WestermanM , OlbinaG , deZoysaJ , et al. A novel hypoxia-inducible factor-prolyl hydroxylase inhibitor (GSK1278863) for anemia in CKD: a 28-day, phase 2a randomized trial. American Journal of Kidney Diseases2016;67(6):861-71. [MEDLINE: 26827289]BrigandiRA , JohnsonB , OeiC , WestermanME , OlbinaG , KumarS , et al. Induction of erythropoiesis in anemic patients by prolylhydroxylase inhibitor in a repeat dose, randomized placebo controlled trial [abstract no: SA-PO117]. Journal of the American Society of Nephrology2012;23(Abstract Suppl):662A. BrigandiRA , WestermanME , OlbinaG , OeiC , RussSF , KumarS . Modulation of hepcidin by prolylhydroxylase inhibitor in randomized trials [abstract no: SA-PO118]. Journal of the American Society of Nephrology2012;23(Abstract Suppl):662A. ">Brigandi 2016</a>; <a href="./references#CD013751-bbs2-0022" title="AkizawaT , MacdougallIC , BernsJS , YamamotoH , TaguchiM , IekushiK , et al. Iron regulation by molidustat, a daily oral hypoxia-inducible factor prolyl hydroxylase inhibitor, in patients with chronic kidney disease. Nephron2019;143(4):243-54. [MEDLINE: 31387097]MacdougallIC , AkizawaT , BernsJ , LentiniS , BernhardtT . Molidustat increases haemoglobin in erythropoiesis stimulating agents (ESA)-naive anaemic patients with chronic kidney disease not on dialysis (CKD-ND) [abstract no: SO036]. Nephrology Dialysis Transplantation2016;31(Suppl 1):i16. [EMBASE: 72325954]MacdougallIC , AkizawaT , BernsJS , BernhardtT , KruegerT . Effects of molidustat in the treatment of anemia in CKD [Erratum in: Clin J Am Soc Nephrol. 2019 Oct 7;14(10):1524]. Clinical Journal of the American Society of Nephrology: CJASN2019;14(1):28-39. [MEDLINE: 30559105]MacdougallIC , BernsJS , AkizawaT , FishbaneS , BernhardtT . DIALOGUE phase 2 program for BAY85-3934 a HIF-PH inhibitor with daily oral treatment in anemic patients suffering from CKD/ESRD [abstract no: FR-PO219]. Journal of the American Society of Nephrology2013;24(Abstract Suppl):413A. ">DIALOGUE 4 2019</a>; <a href="./references#CD013751-bbs2-0045" title="ProvenzanoR , BesarabA , DuaSL , NguyenPV , WrightSH , ZeigS , et al. FG-4592, a novel oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), maintains hemoglobin levels and lowers cholesterol in hemodialysis patients: phase 2 comparison with epoetin alfa [abstract no: FR-PO257]. Journal of the American Society of Nephrology2012;23(Abstract Suppl):428A. ProvenzanoR , BesarabA , WrightS , DuaS , ZeigS , NguyenP , et al. Roxadustat (FG-4592) versus epoetin alfa for anemia in patients receiving maintenance hemodialysis: a phase 2, randomized, 6- to 19-week, open-label, active-comparator, dose-ranging, safety and exploratory efficacy study. American Journal of Kidney Diseases2016;67(6):912-24. [MEDLINE: 26846333]">Provenzano 2016</a>) compared five arms, including different doses of HIF stabiliser and ESA (<a href="./references#CD013751-bbs2-0022" title="AkizawaT , MacdougallIC , BernsJS , YamamotoH , TaguchiM , IekushiK , et al. Iron regulation by molidustat, a daily oral hypoxia-inducible factor prolyl hydroxylase inhibitor, in patients with chronic kidney disease. Nephron2019;143(4):243-54. [MEDLINE: 31387097]MacdougallIC , AkizawaT , BernsJ , LentiniS , BernhardtT . Molidustat increases haemoglobin in erythropoiesis stimulating agents (ESA)-naive anaemic patients with chronic kidney disease not on dialysis (CKD-ND) [abstract no: SO036]. Nephrology Dialysis Transplantation2016;31(Suppl 1):i16. [EMBASE: 72325954]MacdougallIC , AkizawaT , BernsJS , BernhardtT , KruegerT . Effects of molidustat in the treatment of anemia in CKD [Erratum in: Clin J Am Soc Nephrol. 2019 Oct 7;14(10):1524]. Clinical Journal of the American Society of Nephrology: CJASN2019;14(1):28-39. [MEDLINE: 30559105]MacdougallIC , BernsJS , AkizawaT , FishbaneS , BernhardtT . DIALOGUE phase 2 program for BAY85-3934 a HIF-PH inhibitor with daily oral treatment in anemic patients suffering from CKD/ESRD [abstract no: FR-PO219]. Journal of the American Society of Nephrology2013;24(Abstract Suppl):413A. ">DIALOGUE 4 2019</a>; <a href="./references#CD013751-bbs2-0045" title="ProvenzanoR , BesarabA , DuaSL , NguyenPV , WrightSH , ZeigS , et al. FG-4592, a novel oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), maintains hemoglobin levels and lowers cholesterol in hemodialysis patients: phase 2 comparison with epoetin alfa [abstract no: FR-PO257]. Journal of the American Society of Nephrology2012;23(Abstract Suppl):428A. ProvenzanoR , BesarabA , WrightS , DuaS , ZeigS , NguyenP , et al. Roxadustat (FG-4592) versus epoetin alfa for anemia in patients receiving maintenance hemodialysis: a phase 2, randomized, 6- to 19-week, open-label, active-comparator, dose-ranging, safety and exploratory efficacy study. American Journal of Kidney Diseases2016;67(6):912-24. [MEDLINE: 26846333]">Provenzano 2016</a>), or different doses of HIF stabiliser and placebo (<a href="./references#CD013751-bbs2-0001" title="AkizawaT , TsubakiharaY , NangakuM , EndoY , NakajimaH , KohnoT , et al. Effects of daprodustat, a novel hypoxia-inducible factor prolyl hydroxylase inhibitor on anemia management in Japanese hemodialysis subjects. American Journal of Nephrology2017;45(2):127-35. [MEDLINE: 27978511]EndoY , KohnoT , ImaiY , KawaseN , HaraK , LeporeJJ , et al. A 4 -week dose response study of the hypoxia inducible factor-prolyl hydroxylase inhibitor GSK1278863 in Japanese anemic haemodialysis subjects [abstract no: SA-PO819]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):818A. NCT02019719. Study to evaluate the safety, efficacy and pharmacokinetics of GSK1278863 in Japanese hemodialysis-dependent subjects with anemia associated with chronic kidney disease [A 4-week, phase ii, randomized, double-blind, dose-ranging, placebo-controlled, parallel-group, multi-center study to evaluate the safety, efficacy and pharmacokinetics of GSK1278863 in Japanese hemodialysis-dependent subjects with anemia associated with chronic kidney disease]. clinicaltrials.gov/show/NCT02019719 (first received 24 December 2013). ">Akizawa 2017</a>; <a href="./references#CD013751-bbs2-0014" title="BesarabA , HutlerHN , KlausS , LeeTT , LilienfeldDE , NeffTB , et al. FG-4592, a novel oral HIF prolyl hydroxylase inhibitor, elevates hemoglobin in anemic stage 3/4 CKD patients [abstract no: SA-FC416]. Journal of the American Society of Nephrology2010;21(Abstract Suppl):95A. BesarabA , ProvenzanoR , HertelJ , ZabanehR , KlausSJ , LeeT , et al. Randomized placebo-controlled dose-ranging and pharmacodynamics study of roxadustat (FG-4592) to treat anemia in nondialysis-dependent chronic kidney disease (NDD-CKD) patients. Nephrology Dialysis Transplantation2015;30(10):1665-73. [MEDLINE: 26238121]">Besarab 2015</a>; <a href="./references#CD013751-bbs2-0015" title="BrigandiRA , JohnsonB , OeiC , WestermanM , OlbinaG , deZoysaJ , et al. A novel hypoxia-inducible factor-prolyl hydroxylase inhibitor (GSK1278863) for anemia in CKD: a 28-day, phase 2a randomized trial. American Journal of Kidney Diseases2016;67(6):861-71. [MEDLINE: 26827289]BrigandiRA , JohnsonB , OeiC , WestermanME , OlbinaG , KumarS , et al. Induction of erythropoiesis in anemic patients by prolylhydroxylase inhibitor in a repeat dose, randomized placebo controlled trial [abstract no: SA-PO117]. Journal of the American Society of Nephrology2012;23(Abstract Suppl):662A. BrigandiRA , WestermanME , OlbinaG , OeiC , RussSF , KumarS . Modulation of hepcidin by prolylhydroxylase inhibitor in randomized trials [abstract no: SA-PO118]. Journal of the American Society of Nephrology2012;23(Abstract Suppl):662A. ">Brigandi 2016</a>) </p> </li> <li> <p>One study (<a href="./references#CD013751-bbs2-0020" title="AkizawaT , MacdougallIC , BernsJS , BernhardtT , TaguchiM , OguraE , et al. Iron regulation by molidustat, bay 85-3934, a daily oral hypoxia-inducible factor prolyl hydroxylase inhibitor in patients with chronic kidney disease [abstract no: SP334]. Nephrology Dialysis Transplantation2018;33(Suppl 1):i457. [EMBASE: 622606520]AkizawaT , MacdougallIC , BernsJS , YamamotoH , TaguchiM , IekushiK , et al. Iron regulation by molidustat, a daily oral hypoxia-inducible factor prolyl hydroxylase inhibitor, in patients with chronic kidney disease. Nephron2019;143(4):243-54. [MEDLINE: 31387097]MacdougallIC , AkizawaT , BernsJ , LentiniS , BernhardtT . Molidustat increases haemoglobin in erythropoiesis stimulating agents (ESA)-naive anaemic patients with chronic kidney disease not on dialysis (CKD-ND) [abstract no: SO036]. Nephrology Dialysis Transplantation2016;31(Suppl 1):i16. [EMBASE: 72325954]MacdougallIC , AkizawaT , BernsJS , BernhardtT , KruegerT . Effects of molidustat in the treatment of anemia in CKD [Erratum in: Clin J Am Soc Nephrol. 2019 Oct 7;14(10):1524]. Clinical Journal of the American Society of Nephrology: CJASN2019;14(1):28-39. [MEDLINE: 30559105]MacdougallIC , BernsJS , AkizawaT , FishbaneS , BernhardtT . DIALOGUE phase 2 program for BAY85-3934 a HIF-PH inhibitor with daily oral treatment in anemic patients suffering from CKD/ESRD [abstract no: FR-PO219]. Journal of the American Society of Nephrology2013;24(Abstract Suppl):413A. ">DIALOGUE 1 2019</a>) compared six arms, including different doses of HIF stabiliser and placebo </p> </li> <li> <p>One study (<a href="./references#CD013751-bbs2-0046" title="ProvenzanoR , BesarabA , DuaSL , NguyenPV , WrightSH , ZeigS , et al. FG-4592, a novel oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), maintains hemoglobin levels and lowers cholesterol in hemodialysis patients: phase 2 comparison with epoetin alfa [abstract no: FR-PO257]. Journal of the American Society of Nephrology2012;23(Abstract Suppl):428A. ProvenzanoR , BesarabA , WrightS , DuaS , ZeigS , NguyenP , et al. Roxadustat (FG-4592) versus epoetin alfa for anemia in patients receiving maintenance hemodialysis: a phase 2, randomized, 6- to 19-week, open-label, active-comparator, dose-ranging, safety and exploratory efficacy study. American Journal of Kidney Diseases2016;67(6):912-24. [MEDLINE: 26846333]">Provenzano 2016a</a>) compared seven arms, including different doses of HIF stabiliser and ESA </p> </li> </ul> </p> <p>Forty‐three studies (<a href="./references#CD013751-bbs2-0001" title="AkizawaT , TsubakiharaY , NangakuM , EndoY , NakajimaH , KohnoT , et al. Effects of daprodustat, a novel hypoxia-inducible factor prolyl hydroxylase inhibitor on anemia management in Japanese hemodialysis subjects. American Journal of Nephrology2017;45(2):127-35. [MEDLINE: 27978511]EndoY , KohnoT , ImaiY , KawaseN , HaraK , LeporeJJ , et al. A 4 -week dose response study of the hypoxia inducible factor-prolyl hydroxylase inhibitor GSK1278863 in Japanese anemic haemodialysis subjects [abstract no: SA-PO819]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):818A. NCT02019719. Study to evaluate the safety, efficacy and pharmacokinetics of GSK1278863 in Japanese hemodialysis-dependent subjects with anemia associated with chronic kidney disease [A 4-week, phase ii, randomized, double-blind, dose-ranging, placebo-controlled, parallel-group, multi-center study to evaluate the safety, efficacy and pharmacokinetics of GSK1278863 in Japanese hemodialysis-dependent subjects with anemia associated with chronic kidney disease]. clinicaltrials.gov/show/NCT02019719 (first received 24 December 2013). ">Akizawa 2017</a>; <a href="./references#CD013751-bbs2-0002" title="AkizawaT , IwasakiM , OtsukaT , ReuschM , MisumiT . Roxadustat for the treatment of chronic kidney disease-associated anemia in Japanese patients not on dialysis [abstract no: FR-PO1142]. Journal of the American Society of Nephrology2016;27(Abstract Suppl):7B. AkizawaT , IwasakiM , OtsukaT , ReuschM , MisumiT . Roxadustat treatment of chronic kidney disease-associated anemia in Japanese patients not on dialysis: a phase 2, randomized, double-blind, placebo-controlled trial. Advances in Therapy2019;36(6):1438-54. [MEDLINE: 30953333]">Akizawa 2019</a>; <a href="./references#CD013751-bbs2-0003" title="AkizawaT , IwasakiM , YamaguchiY , MajikawaY , ReuschM . Authors' Reply. Journal of the American Society of Nephrology2021;32(4):1005-7. [MEDLINE: 33649099]AkizawaT , IwasakiM , YamaguchiY , MajikawaY , ReuschM . Phase 3, randomized, double-blind, active-comparator (darbepoetin alfa) conversion study of oral roxadustat in CKD patients with anemia on hemodialysis in Japan [abstract no: TH-PO1151]. Journal of the American Society of Nephrology2018;29(Abstract Suppl):B4. AkizawaT , IwasakiM , YamaguchiY , MajikawaY , ReuschM . Phase 3, randomized, double-blind, active-comparator (darbepoetin alfa) study of oral roxadustat in CKD patients with anemia on hemodialysis in Japan. Journal of the American Society of Nephrology2020;31(7):1628-39. [MEDLINE: 32493693]AkizawaT , YamaguchiY , MajikawaY , ReuschM . Factors affecting the doses of roxadustat vs darbepoetin alfa for anemia treatment in hemodialysis patients. Therapeutic Apheresis &amp; Dialysis2021;25(5):575-85. [MEDLINE: 33200512]Astellas1517-CL-0307. A study of intermittent oral dosing of ASP1517 in hemodialysis chronic kidney disease patients with anemia [A phase 3, multi-center, randomized, 2-arm parallel, double-blind, active-comparator (darbepoetin alfa) conversion study of intermittent oral dosing of ASP1517 in hemodialysis chronic kidney disease patients with anemia]. www.clinicaltrials.astellas.com/study/?pid=1517-CL-0307 (accessed 4 May 2022). LiuF , WangJ , YeQ , FuH , MaoJ . Roxadustat for renal anemia in ESRD from PKD patients: is it safe enough?Journal of the American Society of Nephrology2021;32(4):1005. [MEDLINE: 33649100]NguyenQD , SepahYJ , YamaguchiY , OtsukaT , MajikawaY , ReuschM , et al. Ophthalmological effects of roxadustat in the treatment of anemia in dialysis-dependent and non-dialysis-dependent CKD patients: findings from two phase 3 studies [abstract no: PO0267]. Journal of the American Society of Nephrology2020;31(Abstract Suppl):134. [EMBASE: 633698979]SepahY , NguyenQD , YamaguchiY , MajikawaY , ReuschM , AkizawaT . Ophthalmological effects of roxadustat in the treatment of anaemia in chronic kidney disease patients on dialysis in a phase 3, randomised, double-blind, active-comparator conversion study [abstract no: MO002]. Nephrology Dialysis Transplantation2020;35(Suppl 3):iii102. [EMBASE: 633421367]">Akizawa 2020a</a>; <a href="./references#CD013751-bbs2-0004" title="AkizawaT , NangakuM , YonekawaT , OkudaN , KawamatsuS , OnoueT , et al. Efficacy and safety of daprodustat compared with darbepoetin alfa in Japanese hemodialysis patients with anemia: a randomized, double-blind, phase 3 trial. Clinical Journal of the American Society of Nephrology: CJASN2020;15(8):1155-65. [MEDLINE: 32723804]OzekiH , AkizawaT , NangakuM , YonekawaT , OkudaN , KawamatsuS , et al. Efficacy and safety of daprodustat compared with darbepoetin alfa in Japanese hemodialysis patients with anemia: A randomized, double-blind, phase 3 trial [abstract no: SaO036]. Nephrology Dialysis Transplantation2019;34(Suppl 1):a350. [EMBASE: 631305259]">Akizawa 2020c</a>; <a href="./references#CD013751-bbs2-0006" title="AkizawaT , IwasakiM , OtsukaT , YamaguchiY , ReuschM . Phase 3 study of roxadustat to treat anemia in non-dialysis-dependant CKD. Kidney International Reports2021;6(7):1810-28. [MEDLINE: 34307976]AkizawaT , Tanaka-AminoK , OtsukaT , YamaguchiY . Factors affecting doses of roxadustat versus darbepoetin alfa for anemia in nondialysis patients. American Journal of Nephrology2021;52(9):702-13. [MEDLINE: 34628408]">Akizawa 2021</a>; <a href="./references#CD013751-bbs2-0009" title="SinghAK , BlackorbyA , CizmanB , CarrollK , CobitzAR , DaviesR , et al. Study design and baseline characteristics of patients on dialysis in the ASCEND-D trial. Nephrology Dialysis Transplantation2021;37(5):960-72. [MEDLINE: 33744933] [MEDLINE: 33744933]SinghAK , BlackorbyA , CizmanB , CobitzAR , GodoySA , JhaV , et al. Regional variation of erythropoietin-stimulating agent hyporesponsiveness in the global daprodustat dialysis study (ASCEND-D) [abstract no: TH-OR08]. Journal of the American Society of Nephrology2020;31(Abstract Suppl):3. [EMBASE: 633698062]SinghAK , CarrollK , PerkovicV , SolomonS , JhaV , JohansenKL , et al. Daprodustat for the treatment of anemia in patients undergoing dialysis. New England Journal of Medicine2021;385(25):2325-35. [MEDLINE: 34739194]">ASCEND‐D 2021</a>; <a href="./references#CD013751-bbs2-0011" title="PerkovicV , BlackorbyA , CizmanB , CarrollK , CobitzA , DaviesR , et al. ASCEND-ND: Study design and baseline characteristics. Nephrology Dialysis Transplantation2021;36(Suppl 1):i334-5. [EMBASE: 635918331]SinghAK , CarrollK , McMurrayJJ , SolomonS , JhaV , JohansenKL , et al. Daprodustat for the treatment of anemia in patients not undergoing dialysis. New England Journal of Medicine2021;385(25):2313-24. [MEDLINE: 34739196]">ASCEND‐ND 2021</a>; <a href="./references#CD013751-bbs2-0007" title="Astellas 1517-CL-0608. Roxadustat in the treatment of anemia in chronic kidney disease patients not requiring dialysis [A phase 3, randomized, double-blind, placebo controlled study of the efficacy and safety of roxadustat for the treatment of anemia in chronic kidney disease patients not on dialysis]. www.trialsummaries.com/Study/StudyDetails?id=14384&amp;tenant=MT_AST_90112019. EspositoC , CsikyB , TataradzeA , ReuschM , HanC , SulowiczW . Two phase 3, multicenter, randomized studies of intermittent oral roxadustat in anemic CKD patients on (PYRENEES) and not on (ALPS) dialysis [abstract no: SA-PO225]. Journal of the American Society of Nephrology2019;30(Abstract Suppl):822. [EMBASE: 633767739]Pecoits-FilhoR , ChanTM , HardyE , YuKH , FishbaneS . Roxadustat treatment results in consistent improvements in hemoglobin (Hb) vs. placebo: an analysis of three multinational randomized clinical trials in patients with non-dialysis-dependent CKD (NDD-CKD) [abstract no: TH-OR05]. Journal of the American Society of Nephrology2020;31(Abstract Suppl):2. [EMBASE: 633697943]RastogiA , Pecoits-FilhoR , FishbaneS , LittleDJ , HardyE , YuKH , et al. Roxadustat treatment corrects anemia to hemoglobin (HB) values ≥10 g/dL in the majority of patients with non-dialysis-dependent chronic kidney disease (NDD-CKD) [abstract no: PO0264]. Journal of the American Society of Nephrology2020;31(Abstract Suppl):133. [EMBASE: 633698803]ShutovE , SulowiczW , EspositoC , TataradzeA , AndricB , ReuschM , et al. Roxadustat for the treatment of anemia in chronic kidney disease patients not on dialysis: a phase 3, randomized, double-blind, placebo-controlled study (ALPS). Nephrology Dialysis Transplantation2021;36(9):1629-39. [MEDLINE: 33630072]">ALPS 2021</a>; <a href="./references#CD013751-bbs2-0008" title="CoyneDW , RogerSD , ChouW , BesarabA , LeongR , LeeTT , et al. Roxadustat favorably modifies iron indices in patients with non-dialysis-dependent CKD-related anemia [abstract no: PO0262]. Journal of the American Society of Nephrology2020;31(Abstract Suppl):132. [EMBASE: 633698686]CoyneDW , RogerSD , ShinS , KimSG , CadenaAA , MoustafaMA , et al. Roxadustat for CKD-related anemia in non-dialysis patients. Kidney International Reports2021;6(3):624-35. [MEDLINE: 33732977]CoyneDW , RogerSD , ShinSK , KimSG , CadenaAA , MoustafaMA , et al. ANDES: A phase 3, randomized, double-blind, placebo controlled study of the efficacy and safety of roxadustat for the treatment of anemia in CKD patients not on dialysis [abstract no: SA-PO0228]. Journal of the American Society of Nephrology2019;30(Abstract Suppl):822-3. [EMBASE: 633767955]Pecoits-FilhoR , ChanTM , HardyE , YuKHP , FishbaneS . Roxadustat treatment results in consistent improvements in hemoglobin (Hb) vs. placebo: an analysis of three multinational randomized clinical trials in patients with non-dialysis-dependent CKD (NDD-CKD) [abstract no: TH-OR05]. Journal of the American Society of Nephrology2020;31(Abstract Suppl):2. [EMBASE: 633697943]RastogiA , Pecoits-FilhoR , FishbaneS , LittleDJ , HardyE , YuKH , et al. Roxadustat treatment corrects anemia to hemoglobin (HB) values ≥10 g/dL in the majority of patients with non-dialysis-dependent chronic kidney disease (NDD-CKD) [abstract no: PO0264]. Journal of the American Society of Nephrology2020;31(Abstract Suppl):133. [EMBASE: 633698803]">ANDES 2021</a>; <a href="./references#CD013751-bbs2-0014" title="BesarabA , HutlerHN , KlausS , LeeTT , LilienfeldDE , NeffTB , et al. FG-4592, a novel oral HIF prolyl hydroxylase inhibitor, elevates hemoglobin in anemic stage 3/4 CKD patients [abstract no: SA-FC416]. Journal of the American Society of Nephrology2010;21(Abstract Suppl):95A. BesarabA , ProvenzanoR , HertelJ , ZabanehR , KlausSJ , LeeT , et al. Randomized placebo-controlled dose-ranging and pharmacodynamics study of roxadustat (FG-4592) to treat anemia in nondialysis-dependent chronic kidney disease (NDD-CKD) patients. Nephrology Dialysis Transplantation2015;30(10):1665-73. [MEDLINE: 26238121]">Besarab 2015</a>; <a href="./references#CD013751-bbs2-0015" title="BrigandiRA , JohnsonB , OeiC , WestermanM , OlbinaG , deZoysaJ , et al. A novel hypoxia-inducible factor-prolyl hydroxylase inhibitor (GSK1278863) for anemia in CKD: a 28-day, phase 2a randomized trial. American Journal of Kidney Diseases2016;67(6):861-71. [MEDLINE: 26827289]BrigandiRA , JohnsonB , OeiC , WestermanME , OlbinaG , KumarS , et al. Induction of erythropoiesis in anemic patients by prolylhydroxylase inhibitor in a repeat dose, randomized placebo controlled trial [abstract no: SA-PO117]. Journal of the American Society of Nephrology2012;23(Abstract Suppl):662A. BrigandiRA , WestermanME , OlbinaG , OeiC , RussSF , KumarS . Modulation of hepcidin by prolylhydroxylase inhibitor in randomized trials [abstract no: SA-PO118]. Journal of the American Society of Nephrology2012;23(Abstract Suppl):662A. ">Brigandi 2016</a>; <a href="./references#CD013751-bbs2-0016" title="ChenN , HaoC , LiuB , LinHL , CailiW , XingCY , et al. A phase 3, randomized, open-label, active-controlled study of efficacy and safety of roxadustat for treatment of anemia in subjects with CKD on dialysis [abstract no: TH-PO1152]. Journal of the American Society of Nephrology2018;29(Abstract Suppl):B5. ChenN , HaoC , LiuBC , LinH , WangC , XingC , et al. Roxadustat treatment for anemia in patients undergoing long-term dialysis. New England Journal of Medicine2019;381(11):1011-22. [MEDLINE: 31340116]">Chen 2019</a>; <a href="./references#CD013751-bbs2-0017" title="ChenN , HaoC , PengX , LinH , YinA , HaoL , et al. Roxadustat for anemia in patients with kidney disease not receiving dialysis. New England Journal of Medicine2019;381(11):1001-10. [MEDLINE: 31340089]ChenN , HaoC , PengX , LinHL , YinA , HaoL , et al. A phase 3, randomized, double-blind, placebo-controlled study of efficacy and safety of roxadustat (FG-4592) for treatment of anemia in subjects with CKD not on dialysis [abstract no: TH-PO1153]. Journal of the American Society of Nephrology2018;29(Abstract Suppl):B5. ">Chen 2019a</a>; <a href="./references#CD013751-bbs2-0018" title="ChenN , QianJ , ChenJ , YuX , MeiC , HaoC , et al. Phase 2 studies of oral hypoxia-inducible factor prolyl hydroxylase inhibitor FG-4592 for treatment of anemia in China. Nephrology Dialysis Transplantation2017;32(8):1373-86. [MEDLINE: 28371815]">Chen DD 2017</a>; <a href="./references#CD013751-bbs2-0019" title="ChenN , QianJ , ChenJ , YuX , MeiC , HaoC , et al. Phase 2 studies of oral hypoxia-inducible factor prolyl hydroxylase inhibitor FG-4592 for treatment of anemia in China. Nephrology Dialysis Transplantation2017;32(8):1373-86. [MEDLINE: 28371815]QianJQ , ChenN , ChenJ , HaoC , LinHL , NiD , et al. A randomized, double-blind, placebo controlled trial of FG-4592 for correction of anemia in subjects with chronic kidney disease in China [abstract no: FR-OR011]. Journal of the American Society of Nephrology2013;24(Abstract Suppl):38A. ">Chen NDD 2017</a>; <a href="./references#CD013751-bbs2-0020" title="AkizawaT , MacdougallIC , BernsJS , BernhardtT , TaguchiM , OguraE , et al. Iron regulation by molidustat, bay 85-3934, a daily oral hypoxia-inducible factor prolyl hydroxylase inhibitor in patients with chronic kidney disease [abstract no: SP334]. Nephrology Dialysis Transplantation2018;33(Suppl 1):i457. [EMBASE: 622606520]AkizawaT , MacdougallIC , BernsJS , YamamotoH , TaguchiM , IekushiK , et al. Iron regulation by molidustat, a daily oral hypoxia-inducible factor prolyl hydroxylase inhibitor, in patients with chronic kidney disease. Nephron2019;143(4):243-54. [MEDLINE: 31387097]MacdougallIC , AkizawaT , BernsJ , LentiniS , BernhardtT . Molidustat increases haemoglobin in erythropoiesis stimulating agents (ESA)-naive anaemic patients with chronic kidney disease not on dialysis (CKD-ND) [abstract no: SO036]. Nephrology Dialysis Transplantation2016;31(Suppl 1):i16. [EMBASE: 72325954]MacdougallIC , AkizawaT , BernsJS , BernhardtT , KruegerT . Effects of molidustat in the treatment of anemia in CKD [Erratum in: Clin J Am Soc Nephrol. 2019 Oct 7;14(10):1524]. Clinical Journal of the American Society of Nephrology: CJASN2019;14(1):28-39. [MEDLINE: 30559105]MacdougallIC , BernsJS , AkizawaT , FishbaneS , BernhardtT . DIALOGUE phase 2 program for BAY85-3934 a HIF-PH inhibitor with daily oral treatment in anemic patients suffering from CKD/ESRD [abstract no: FR-PO219]. Journal of the American Society of Nephrology2013;24(Abstract Suppl):413A. ">DIALOGUE 1 2019</a>; <a href="./references#CD013751-bbs2-0021" title="AkizawaT , MacdougallIC , BernsJS , YamamotoH , TaguchiM , IekushiK , et al. Iron regulation by molidustat, a daily oral hypoxia-inducible factor prolyl hydroxylase inhibitor, in patients with chronic kidney disease. Nephron2019;143(4):243-54. [MEDLINE: 31387097]MacdougallIC , AkizawaT , BernsJ , LentiniS , BernhardtT , KrugerT . Safety and efficacy of molidustat in erythropoiesis stimulating agents (ESA) pre-treated anaemic patients with chronic kidney disease not on dialysis (CKD-ND) [abstract no: SP309]. Nephrology Dialysis Transplantation2016;31(Suppl 1):i193. [EMBASE: 72326411]MacdougallIC , AkizawaT , BernsJ , LentiniS , BernhardtT . Molidustat increases haemoglobin in erythropoiesis stimulating agents (ESA)-naive anaemic patients with chronic kidney disease not on dialysis (CKD-ND) [abstract no: SO036]]. Nephrology Dialysis Transplantation2016;31(Suppl 1):i16. [EMBASE: 72325954]MacdougallIC , AkizawaT , BernsJS , BernhardtT , KruegerT . Effects of molidustat in the treatment of anemia in CKD [Erratum in: Clin J Am Soc Nephrol. 2019 Oct 7;14(10):1524]. Clinical Journal of the American Society of Nephrology: CJASN2019;14(1):28-39. [MEDLINE: 30559105]MacdougallIC , BernsJS , AkizawaT , FishbaneS , BernhardtT . DIALOGUE phase 2 program for BAY85-3934 a HIF-PH inhibitor with daily oral treatment in anemic patients suffering from CKD/ESRD [abstract no: FR-PO219]. Journal of the American Society of Nephrology2013;24(Abstract Suppl):413A. ">DIALOGUE 2 2019</a>; <a href="./references#CD013751-bbs2-0022" title="AkizawaT , MacdougallIC , BernsJS , YamamotoH , TaguchiM , IekushiK , et al. Iron regulation by molidustat, a daily oral hypoxia-inducible factor prolyl hydroxylase inhibitor, in patients with chronic kidney disease. Nephron2019;143(4):243-54. [MEDLINE: 31387097]MacdougallIC , AkizawaT , BernsJ , LentiniS , BernhardtT . Molidustat increases haemoglobin in erythropoiesis stimulating agents (ESA)-naive anaemic patients with chronic kidney disease not on dialysis (CKD-ND) [abstract no: SO036]. Nephrology Dialysis Transplantation2016;31(Suppl 1):i16. [EMBASE: 72325954]MacdougallIC , AkizawaT , BernsJS , BernhardtT , KruegerT . Effects of molidustat in the treatment of anemia in CKD [Erratum in: Clin J Am Soc Nephrol. 2019 Oct 7;14(10):1524]. Clinical Journal of the American Society of Nephrology: CJASN2019;14(1):28-39. [MEDLINE: 30559105]MacdougallIC , BernsJS , AkizawaT , FishbaneS , BernhardtT . DIALOGUE phase 2 program for BAY85-3934 a HIF-PH inhibitor with daily oral treatment in anemic patients suffering from CKD/ESRD [abstract no: FR-PO219]. Journal of the American Society of Nephrology2013;24(Abstract Suppl):413A. ">DIALOGUE 4 2019</a>; <a href="./references#CD013751-bbs2-0023" title="BarrattJ , AndricB , TataradzeA , SchoemigM , ReuschM , ValluriU , et al. Roxadustat for the treatment of anemia in CKD patients not on dialysis (NDD): a phase 3, randomized, open-label, active-controlled study [abstract no: TH-OR02]. Journal of the American Society of Nephrology2020;31(Abstract Suppl):1. [EMBASE: 633697812]BarrattJ , AndricB , TataradzeA , SchomigM , ReuschM , ValluriU , et al. Roxadustat for the treatment of anaemia in chronic kidney disease patients not on dialysis: a phase 3, randomised, open-label, active-controlled study (DOLOMITES). Nephrology Dialysis Transplantation2021;36(9):1616-28. [MEDLINE: 34077510]BarrattJ , AndricB , TataradzeA , SchomigM , ReuschM , ValluriU , et al. Roxadustat for the treatment of anaemia in chronic kidney disease patients not on dialysis: a phase 3, randomised, open-label, active controlled study [abstract no: MO001]. Nephrology Dialysis Transplantation2020;35(Suppl 3):iii101. [EMBASE: 633423023]BarrattJ , AndricB , TataradzeA , SchomigM , ReuschM , ValluriU , et al. Roxadustat for the treatment of anemia in chronic kidney disease (CKD) patients not on dialysis (NDD): a phase 3, randomized, open-label, active-controlled study [abstract no: Pos-247]. Kidney International Reports2021;6(4 Suppl):S104. [EMBASE: 2011683542]">DOLOMITES 2021</a>; <a href="./references#CD013751-bbs2-0024" title="ProvenzanoM , EvgenyS , LiubovE , KorneyevaS , KathresalAA , PooleL , et al. HIMALAYAS: a phase 3, randomized, open-label, active-controlled study of the efficacy and safety of roxadustat in the treatment of anemia in incident-dialysis patients [abstract no: TH-OR021]. Journal of the American Society of Nephrology2019;30(Abstract Suppl):5. [EMBASE: 633771140]ProvenzanoR , ShutovE , EremeevaL , KorneyevaS , PooleL , SahaG , et al. Roxadustat for anemia in patients with end-stage renal disease incident to dialysis. Nephrology Dialysis Transplantation2021;36(9):1717-30. [MEDLINE: 33629100]">HIMALAYAS 2021</a>; <a href="./references#CD013751-bbs2-0025" title="CizmanB , AckertJ , MeadowcroftA , BiswasN , KellyD , KleinmanD , et al. Ocular safety profile of daprodustat: results of two 24 week studies [abstract no: SAO004]. Nephrology Dialysis Transplantation2018;33(Suppl 1):i316. [EMBASE: 622604997]HoldstockL , CizmanB , MeadowcroftAM , BiswasN , JohnsonBM , JonesD , et al. Daprodustat for anemia: a 24-week, open-label, randomized controlled trial in participants with chronic kidney disease. Clinical Kidney Journal2019;12(1):129-38. [MEDLINE: 30746140]HoldstockL , CizmanB , MeadowcroftAM , BiswasN , JonesD , JohnsonBM , et al. Daprodustat, a HIF-prolyl-hydroxylase inhibitor, increases and maintains hemoglobin over 24 weeks in anemic chronic kidney disease subjects [abstract no: TH-PO908]. Journal of the American Society of Nephrology2016;27(Abstract Suppl):304A. ">Holdstock 2019</a>; <a href="./references#CD013751-bbs2-0026" title="CizmanB , AckertJ , MeadowcroftA , BiswasN , KellyD , KleinmanD , et al. Ocular safety profile of daprodustat: results of two 24 week studies [abstract no: SAO004]. Nephrology Dialysis Transplantation2018;33(Suppl 1):i316. [EMBASE: 622604997]HoldstockL , CizmanB , MeadowcroftAM , BiswasN , JohnsonBM , JonesD , et al. Daprodustat for anemia: a 24-week, open-label, randomized controlled trial in participants with chronic kidney disease. Clinical Kidney Journal2019;12(1):129-38. [MEDLINE: 30746140]HoldstockL , CizmanB , MeadowcroftAM , BiswasN , JonesD , JohnsonBM , et al. Daprodustat, a HIF-prolyl-hydroxylase inhibitor, increases and maintains hemoglobin over 24 weeks in anemic chronic kidney disease subjects [abstract no: TH-PO908]. Journal of the American Society of Nephrology2016;27(Abstract Suppl):304A. ">Holdstock 2019a</a>; <a href="./references#CD013751-bbs2-0027" title="HouYP , MaoXY , WangC , XuZH , BuZH , XuM , et al. Roxadustat treatment for anemia in peritoneal dialysis patients: a randomized controlled trial. Journal of the Formosan Medical Association2021;121(2):529-38. [MEDLINE: 34167878]">Hou 2021</a>; <a href="./references#CD013751-bbs2-0028" title="ChertowGM , BoudvilleN , ChowdhuryP , GonzalezC , KooiengaL , LuoW , et al. Vadadustat for treatment of anemia in patients with dialysis-dependent CKD receiving peritoneal dialysis [abstract no: PO0464]. Journal of the American Society of Nephrology2021;32(Abstract Suppl):184. [EMBASE: 636331136]EckardtKU , AgarwalR , AswadA , AwadA , BlockGA , BacciMR , et al. Safety and efficacy of vadadustat for anemia in patients undergoing dialysis. New England Journal of Medicine2021;384(17):1601-12. [MEDLINE: 33913638]EckardtKU , AgarwalR , FaragYM , JardineAG , KhawajaZ , KouryMJ , et al. Global Phase 3 programme of vadadustat for treatment of anaemia of chronic kidney disease: rationale, study design and baseline characteristics of dialysis-dependent patients in the INNO2VATE trials. Nephrology Dialysis Transplantation2020;36(11):2039-48. [MEDLINE: 33188693]EckardtKU . Global phase 3 clinical trials of vadadustat vs. darbepoetin alfa for treatment of anemia in patients with dialysis-dependent CKD [abstract no: TH-OR01]. Journal of the American Society of Nephrology2020;31(Abstract Suppl):1. [EMBASE: 633697781]ParfreyPS , LuoW , MaroniB , AndersR , VargoD , McCulloughPA . Thromboembolic events with vadadustat vs. darbepoetin alfa for anemia treatment in patients with dialysis-dependent CKD [abstract no: PO0463]. Journal of the American Society of Nephrology2021;32(Abstract Suppl):184. [EMBASE: 636331080]WinkelmayerW , TumlinJA , FishbaneS , FaragY , VargoD , LuoW , et al. Hematologic efficacy of vadadustat for anemia in patients with kidney failure on dialysis [abstract no: MO529]. Nephrology Dialysis Transplantation2021;36(Suppl 1):i325-6. [EMBASE: 635917983]WinkelmayerWC , FishbaneS , TumlinJA , FaragYM , LuoW , AndersR , et al. Iron-related outcomes in patients with dialysis-dependent CKD randomized to vadadustat vs. darbepoetin alfa [abstract no: PO0457]. Journal of the American Society of Nephrology2021;32(Abstract Suppl):182. [EMBASE: 636330773]">INNO2VATE 2020</a>; <a href="./references#CD013751-bbs2-0029" title="EckardtKU , AgarwalR , AswadA , AwadA , BlockGA , BacciMR , et al. Safety and efficacy of vadadustat for anemia in patients undergoing dialysis. New England Journal of Medicine2021;384(17):1601-12. [MEDLINE: 33913638]EckardtKU , AgarwalR , FaragYM , JardineAG , KhawajaZ , KouryMJ , et al. Global Phase 3 programme of vadadustat for treatment of anaemia of chronic kidney disease: rationale, study design and baseline characteristics of dialysis-dependent patients in the INNO2VATE trials. Nephrology Dialysis Transplantation2020;36(11):2039-48. [MEDLINE: 33188693]EckardtKU . Global phase 3 clinical trials of vadadustat vs. darbepoetin alfa for treatment of anemia in patients with dialysis-dependent CKD [abstract no: TH-OR01]. Journal of the American Society of Nephrology2020;31(Abstract Suppl):1. [EMBASE: 633697781]WinkelmayerWC , FishbaneS , TumlinJA , FaragYM , LuoW , AndersR , et al. Iron-related outcomes in patients with dialysis-dependent CKD randomized to vadadustat vs. darbepoetin alfa [abstract no: PO0457]. Journal of the American Society of Nephrology2021;32(Abstract Suppl):182. [EMBASE: 636330773]">INNO2VATE 2020a</a>; <a href="./references#CD013751-bbs2-0031" title="AkizawaT , TaguchiM , MatsudaY , IekushiK , YamadaT , YamamotoH . Molidustat for the treatment of renal anaemia in patients with dialysis-dependent chronic kidney disease: Design and rationale of three phase III studies. BMJ Open2019;9(6):e026602. [MEDLINE: 31203241]AkizawaT , YamadaT , NoboriK , MatsudaY , HayashiY , HayasakiT , et al. Molidustat for Japanese patients with renal anemia receiving dialysis. Kidney International Reports2021;6(10):2604–16. [MEDLINE: 34622100]AkizawaT , YamadaT , NoboriK , MatsudaY , HayashiY , HayasakiT , et al. Results from a phase 3 study comparing the efficacy and safety of molidustat vs. Darbepoetin Alfa in patients receiving hemodialysis and treated with erythropoiesis-stimulating agents (ESAS) [abstract no: PO22623]. Journal of the American Society of Nephrology2020;31(Abstract Suppl):B4. [EMBASE: 633697376]">MIYABI HD‐M 2019</a>; <a href="./references#CD013751-bbs2-0032" title="YamamotoH , NoboriK , MatsudaY , HayashiY , HayasakiT , AkizawaT . Efficacy and safety of molidustat for anemia in ESA-naive nondialysis patients: a randomized, phase 3 trial. American Journal of Nephrology2021;52(10-11):871-83. [MEDLINE: 34569489]YamamotoH , TaguchiM , MatsudaY , IekushiK , YamadaT , AkizawaT . Molidustat for the treatment of renal anaemia in patients with non-dialysis-dependent chronic kidney disease: design and rationale of two phase III studies. BMJ Open2019;9(6):e026704. [MEDLINE: 31203242]YamamotoH , TaguchiM , NoboriK , MatsudaY , IekushiK , AkizawaT . To investigate the efficacy and safety of molidustat in non-dialysis patients with renal anemia who are not treated with erythropoiesis stimulating agents: MIYABI ND-C [abstract no: P1866]. Nephrology Dialysis Transplantation2020;35(Suppl 3):iii2177. [EMBASE: 633422996]">MIYABI ND‐C 2019</a>; <a href="./references#CD013751-bbs2-0033" title="YamamotoH , NoboriK , MatsudaY , HayashiY , HayasakiT , AkizawaT . Molidustat for renal anemia in nondialysis patients previously treated with erythropoiesis-stimulating agents: a randomized, open-label, phase 3 study. American Journal of Nephrology2021;52(10-11):884-93. [MEDLINE: 34569482]YamamotoH , TaguchiM , MatsudaY , IekushiK , YamadaT , AkizawaT . Molidustat for the treatment of renal anaemia in patients with non-dialysis-dependent chronic kidney disease: design and rationale of two phase III studies. BMJ Open2019;9(6):e026704. [MEDLINE: 31203242]YamamotoH , TaguchiM , NoboriK , MatsudaY , IekushiK , AkizawaT . To investigate the efficacy and safety of molidustat in non-dialysis patients with renal anemia who are treated with erythropoiesis stimulating agents: Miyabi ND-M [Abstract no: P1868]. Nephrology Dialysis Transplantation2020;35(Suppl 3):iii2179. [EMBASE: 633423006]">MIYABI ND‐M 2019</a>; <a href="./references#CD013751-bbs2-0034" title="NangakuM , KondoK , UetaK , KokadoY , KanekoG , MatsudaH , et al. Efficacy and safety of vadadustat compared with darbepoetin alfa in Japanese anemic patients on hemodialysis: a phase 3, multicenter, randomized, double-blind study. Nephrology Dialysis Transplantation2021;36(9):1731-41. [MEDLINE: 33650630]NangakuM , KondoK , UetaK , KokadoY , KanekoG , MatsudaH , et al. Randomized, double-blinded, active-controlled (darbepoetin alfa), phase 3 study of vadadustat in CKD patients with anemia on hemodialysis in Japan [abstract no: TH-OR024]. Journal of the American Society of Nephrology2019;30(Abstract Suppl):6. [EMBASE: 633771357]">Nangaku 2021</a>; <a href="./references#CD013751-bbs2-0035" title="NangakuM , KondoK , KokadoY , UetaK , KanekoG , ShiosakaM , et al. Randomized, open-label, active-controlled (darbepoetin alfa), phase 3 study of vadadustat for treating anemia in non-dialysis-dependent CKD patients in Japan [abstract no: SA-PO229]. Journal of the American Society of Nephrology2019;30(Abstract Suppl):823. [EMBASE: 633767995]NangakuM , KondoK , KokadoY , UetaK , KanekoG , TandaiT , et al. Phase 3 randomized study comparing vadadustat with darbepoetin alfa for anemia in Japanese patients with nondialysis-dependent CKD. Journal of the American Society of Nephrology2021;32(7):1779-90. [MEDLINE: 33883252]">Nangaku 2021a</a>; <a href="./references#CD013751-bbs2-0036" title="GSK201753. A 52-week, Phase III, open-label, multi-center study to evaluate efficacy and safety of GSK1278863 in Japanese non-dialysis and peritoneal dialysis subjects with anemia associated with chronic kidney disease [study protocol]. www.clinicaltrials.gov/ProvidedDocs/63/NCT02791763/Prot_000.pdf (accessed 9 May 2022). NangakuM , HamanoT , AkizawaT , TsubakiharaY , NagaiR , OkudaN , et al. Daprodustat compared with epoetin beta pegol for anemia in Japanese patients not on dialysis: a 52-week randomized open-label phase 3 trial. American Journal of Nephrology2021;52(1):26-35. [MEDLINE: 33561857]">Nangaku 2021b</a>; <a href="./references#CD013751-bbs2-0037" title="Astellas1517-CL-0304. A study to investigate the effect of ASP1517 after intermittent oral dosing in dialysis chronic kidney disease patients with anemia compared with darbepoetin as a reference drug [A Japanese, phase 2, multicenter, randomized, 4-arm parallel, double-blind (arms 1-3), open-label (arm 4), active-comparator (darbepoetin alfa) study of intermittent oral dosing of asp1517 in hemodialysis-dependent chronic kidney disease patients with anemia [1517-CL-0304 clinical study results report]]. www.trialsummaries.com/Study/StudyDetails?id=14175&amp;tenant=MT_AST_9011; www.clinicaltrials.gov/ct2/show/NCT01888445 (first received 6 August 2018). ">NCT01888445</a>; <a href="./references#CD013751-bbs2-0038" title="NangakuM , FaragYM , deGomaE , LuoW , VargoD , KhawajaZ . Vadadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor, for treatment of anemia of chronic kidney disease: two randomized Phase 2 trials in Japanese patients. Nephrology Dialysis Transplantation 2020 Jul 20 [epub ahead of print]. [DOI: 10.1093/ndt/gfaa060] [MEDLINE: 32719868]NangakuM , KhawajaZ , LuoW , GarafolaS , De GomaE , KomatsuY . Randomized, placebo-controlled phase 2 trials of vadadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), to treat anemia of CKD [abstract no: TH-PO228]. Journal of the American Society of Nephrology2018;29(Abstract Suppl):171. [EMBASE: 633737146]SolinskyC , FaragYM , KhawajaZ , AndersR , LuoW , ChavanA , et al. Impact of vadadustat on iron regulation in Japanese subjects with chronic kidney disease (CKD) [abstract no: 352]. American Journal of Kidney Diseases2020;75(4):638-9. [EMBASE: 2005716872]">NDD‐CKD 2020</a>; <a href="./references#CD013751-bbs2-0039" title="NangakuM , FaragYM , deGomaE , LuoW , VargoD , KhawajaZ . Vadadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor, for treatment of anemia of chronic kidney disease: two randomized Phase 2 trials in Japanese patients. Nephrology Dialysis Transplantation 2020 Jul 20 [epub ahead of print]. [DOI: 10.1093/ndt/gfaa060] [MEDLINE: 32719868]NangakuM , KhawajaZ , LuoW , GarafolaS , deGomaE , KomatsuY . Randomized, placebo-controlled phase 2 trials of vadadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), to treat anemia of CKD [abstract no: TH-PO228]. Journal of the American Society of Nephrology2018;29(Abstract Suppl):171. [EMBASE: 633737146]SolinskyC , FaragYM , KhawajaZ , AndersR , LuoW , ChavanA , et al. Impact of vadadustat on iron regulation in Japanese subjects with chronic kidney disease (CKD) [abstract no: 352]. American Journal of Kidney Diseases2020;75(4):638-9. [EMBASE: 2005716872]">NDD‐CKD 2020a</a>; <a href="./references#CD013751-bbs2-0040" title="AstraZeneca. A phase 3, multicenter, randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of roxadustat for the treatment of anemia in chronic kidney disease patients not on dialysis [clinical study protocol V6; 31 August 2018]. www.clinicaltrials.gov/ProvidedDocs/27/NCT02174627/Prot_000.pdf (accessed 9 May 2022). EleftheriadisT , PissasG , LiakopoulosV , StefanidisI . On the increased event rate of urinary tract infection and pneumonia in CKD patients treated with roxadustat for anemia. Journal of the American Society of Nephrology2021;32(6):1537. [MEDLINE: 33849917]FishbaneS , El-ShahawyMA , Pecoits-FilhoR , VanBP , HouserMT , FrisonL , et al. OLYMPUS: a phase 3, randomized, double-blind, placebo-controlled, international study of roxadustat efficacy in patients with non-dialysis-dependent (NDD) CKD and anemia [abstract no: TH-OR023]. Journal of the American Society of Nephrology2019;30(Abstract Suppl):6. [EMBASE: 633771285]FishbaneS , El-ShahawyMA , Pecoits-FilhoR , VanBP , HouserMT , FrisonL , et al. Roxadustat for treating anemia in patients with CKD not on dialysis: results from a randomized phase 3 study. Journal of the American Society of Nephrology2021;32(3):737-55. [MEDLINE: 33568383]FishbaneS , El-ShahawyMA , VanBP , LittleDJ . Authors' Reply. Journal of the American Society of Nephrology2021;32(6):1537-8. [MEDLINE: 33849916]Pecoits-FilhoR , ChanTM , HardyE , YuKH , FishbaneS . Roxadustat treatment results in consistent improvements in hemoglobin (Hb) vs. placebo: an analysis of three multinational randomized clinical trials in patients with non-dialysis-dependent CKD (NDD-CKD) [abstract no: TH-OR05]. Journal of the American Society of Nephrology2020;31(Abstract Suppl):2. [EMBASE: 633697943]RastogiA , Pecoits-FilhoR , FishbaneS , LittleDJ , HardyE , YuKH , et al. Roxadustat treatment corrects anemia to hemoglobin (HB) values ≥10 g/dL in the majority of patients with non-dialysis-dependent chronic kidney disease (NDD-CKD) [abstract no: PO0264]. Journal of the American Society of Nephrology2020;31(Abstract Suppl):133. [EMBASE: 633698803]">OLYMPUS 2021</a>; <a href="./references#CD013751-bbs2-0041" title="HaaseVH , SpinowitzBS , PergolaPE , FarmerT , MaroniBJ , HartmanCS . AKB-6548 demonstrates controlled hemogloblin (HGB) response in a phase 2b study for the treatment of anemia in patients with chronic kidney disease not on dialysis (ND-CKD) [abstract no: TH-PO649]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):237A. HaaseVH , SpinowitzBS , PergolaPE , KhawajaZ , ChanJ , ZurawQ , et al. Efficacy and dose requirements of vadadustat are independent of systemic inflammation and prior erythropoiesis-stimulating agent(ESA) dose in patients with non-dialysis dependent chronic kidney disease (NDD-CKD) [abstract no: TH-PO907]. Journal of the American Society of Nephrology2016;27(Abstract Suppl):304A. PergolaPE , SpinowitzB , HaaseVH , HartmanCS , FarmerTM , PoluKR , et al. AKB-6548, a novel hypoxia-inducible factor prolyl-hydroxylase inhibitor (HIF-PHI) for the treatment of anemia in patients with chronic kidney disease not on dialysis (ND-CKD) [abstract no: FO015]. Nephrology Dialysis Transplantation2015;30(Suppl 3):iii8. [EMBASE: 72206296]PergolaPE , SpinowitzBS , HartmanCS , MaroniBJ , HaaseVH . Vadadustat, a novel oral HIF stabilizer, provides effective anemia treatment in nondialysis-dependent chronic kidney disease. Kidney International2016;90(5):1115-22. [MEDLINE: 27650732]SpinowitzBS , PergolaPE , HaaseVH , FarmerTM , HartmanCS , MaroniBJ . Hemoglobin (HGB) response in a phase 2b study of AKB-6548 for the treatment of anemia in patients with non-dialysis dependant chronic kidney disease (NDD-CKD). [abstract no: TH-OR038]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):11A. ">Pergola 2016</a>; <a href="./references#CD013751-bbs2-0042" title="BunnHF . Vadadustat for anemia in patients with dialysis-dependent or non-dialysis-dependent chronic kidney disease. New England Journal of Medicine2021;385(16):e56. [MEDLINE: 34644481]ChertowGM , PergolaPE , AgarwalR , BlockGA , FaragYM , JardineAG , et al. Cardiovascular safety and efficacy of vadadustat for the treatment of anemia in non-dialysis-dependent CKD: design and baseline characteristics. American Heart Journal2021;235(5):1-11. [MEDLINE: 33129989]ChertowGM , PergolaPE , FaragYM , AgarwalR , ArnoldS , BakoG , et al. Vadadustat in patients with anemia and non-dialysis-dependent CKD. New England Journal of Medicine2021;384(17):1589-600. [MEDLINE: 33913637]ChertowGM . Global phase 3 clinical trials of vadadustat vs. darbepoetin alfa for treatment of anemia in patients with non-dialysis-dependent CKD [abstract no: FR-OR54]. Journal of the American Society of Nephrology2020;31(Abstract Suppl):B2. [EMBASE: 633697273]KouryM , PergolaPE , Roy-ChaudhuryP , FaragYM , LuoW , AndersR , et al. Iron-related outcomes in patients with non-dialysis-dependent CKD randomized to vadadustat vs. darbepoetin Alfa [abstract no: PO0482]. Journal of the American Society of Nephrology2021;32(Abstract Suppl):190. [EMBASE: 636329134]McCulloughPA , LuoW , AndersR , VargoD , ParfreyPS . Assessment of thromboembolic events with vadadustat vs. darbepoetin alfa for treatment of anemia in patients with non-dialysis-dependent CKD [abstract no: PO0462]. Journal of the American Society of Nephrology2021;32(Abstract Suppl):184. [EMBASE: 636331039]">PRO2TECT‐CONVERSION 2021</a>; <a href="./references#CD013751-bbs2-0043" title="BunnHF . Vadadustat for anemia in patients with dialysis-dependent or non-dialysis-dependent chronic kidney disease. New England Journal of Medicine2021;385(16):e56. [MEDLINE: 34644481]ChertowGM , PergolaPE , AgarwalR , BlockGA , FaragYM , JardineAG , et al. Cardiovascular safety and efficacy of vadadustat for the treatment of anemia in non-dialysis-dependent CKD: design and baseline characteristics. American Heart Journal2021;235(5):1-11. [MEDLINE: 33129989]ChertowGM , PergolaPE , FaragYM , AgarwalR , ArnoldS , BakoG , et al. Vadadustat in patients with anemia and non-dialysis-dependent CKD. New England Journal of Medicine2021;384(17):1589-600. [MEDLINE: 33913637]ChertowGM . Global phase 3 clinical trials of vadadustat vs. darbepoetin alfa for treatment of anemia in patients with non-dialysis-dependent CKD [abstract no: FR-OR5]. Journal of the American Society of Nephrology2020;31(Abstract Suppl):B2. [EMBASE: 633697273]KouryM , PergolaPE , Roy-ChaudhuryP , FaragYM , LuoW , AndersR , et al. Iron-related outcomes in patients with non-dialysis-dependent CKD randomized to vadadustat vs. darbepoetin alfa [abstract no: PO0482]. Journal of the American Society of Nephrology2021;32(Abstract Suppl):190. [EMBASE: 636329134]McCulloughPA , LuoW , AndersR , VargoD , ParfreyPS . Assessment of thromboembolic events with vadadustat vs. darbepoetin alfa for treatment of anemia in patients with non-dialysis-dependent CKD [abstract no: PO0462]. Journal of the American Society of Nephrology2021;32(Abstract Suppl):184. [EMBASE: 636331039]">PRO2TECT‐CORRECTION 2021</a>; <a href="./references#CD013751-bbs2-0044" title="ProvenzanoR , FaddaG , BernardoM , JamesC , KochendoerferG , LeeT , et al. FG2216, a novel oral HIF-PHI, stimulates erythropoiesis and increases hemoglobin concentration in patients with non-dialysis CKD [abstract no: 212]. American Journal of Kidney Diseases2008;51(4):A80. ProvenzanoR , HulterH , AgarwalA , KlausS , LeeT , YuP , et al. Hypoxia-inducible factor (HIF) prolyl hydroxylase inhibitor FG-2216 increases Hb without FE depletion in the absence of IV Fe [abstract no: 249]. American Journal of Kidney Diseases2013;61(4):A78. [EMBASE: 71024073]">Provenzano 2008</a>; <a href="./references#CD013751-bbs2-0047" title="Astellas 1517-CL-0613. Roxadustat in the treatment of anemia in end stage renal disease (ESRD) patients on stable dialysis [A phase 3, randomized, open-label, active-controlled study to evaluate the efficacy and safety of roxadustat in the maintenance treatment of anemia in end stage renal disease patients on stable dialysis]. www.trialsummaries.com/Study/StudyDetails?id=14380&amp;tenant=MT_AST_9011 (accessed 9 May 2022). CsikyB , SchomigM , EspositoC , BarrattJ , ReuschM , ValluriU , et al. Roxadustat for the maintenance treatment of anemia in patients with end-stage kidney disease on stable dialysis: a European phase 3, randomized, open-label, active-controlled study (PYRENEES). Advances in Therapy2021;38(10):5361-80. [MEDLINE: 34537926]EspositoC , CsikyB , TataradzeA , ReuschM , HanC , SulowiczW . Two phase 3, multicenter, randomized studies of intermittent oral roxadustat in anemic CKD patients on (PYRENEES) and not on (ALPS) dialysis. Swiss Medical Weekly2020;150(Suppl 248):21-2S. [EMBASE: 634241523]EspositoC , CsikyB , TataradzeA , ReuschM , HanC , SulowiczW . Two phase 3, multicenter, randomized studies of intermittent oral roxadustat in anemic CKD patients on (PYRENEES) and not on (ALPS) dialysis [abstract no: SA-PO225]. Journal of the American Society of Nephrology2019;30(Abstract Suppl):822. [EMBASE: 633767739]">PYRENEES 2021</a>; <a href="./references#CD013751-bbs2-0049" title="CharytanC , Manllo-KarimR , MartinER , SteerD , BernardoM , DuaSL , et al. A randomized trial of roxadustat in anemia of kidney failure: SIERRAS study. Kidney International Reports2021;6(7):1829-39. [MEDLINE: 34307977]CharytanC , Manllo-KarimR , MartinER , SteerD , BernardoM , DuaSL , et al. SIERRAS: A phase 3, open-label, randomized, active-controlled study of the efficacy and safety of roxadustat in the maintenance treatment of anemia in subjects with ESRD on stable dialysis [abstract no: SA-PO227]. Journal of the American Society of Nephrology2019;30(Abstract Suppl):822. [EMBASE: 633767862]">SIERRAS 2021</a>; <a href="./references#CD013751-bbs2-0050" title="AkizawaT , MaedaK , MiyazawaY , KoretomoR . Phase 3 study to compare the efficacy and safety of enarodustat (JTZ-951), an oral HIF-PH inhibitor, with darbepoetin alfa in anemic patients with CKD receiving maintenance hemodialysis [abstract no: TH-PO1186]. Journal of the American Society of Nephrology2019;30(Abstract Suppl):B4. AkizawaT , NangakuM , YamaguchiT , KoretomoR , MaedaK , MiyazawaY , et al. A phase 3 study of enarodustat (JTZ-951) in Japanese hemodialysis patients for treatment of anemia in chronic kidney disease: SYMPHONY HD study. Kidney Diseases2021;7(6):494-502. [EMBASE: 2013576033]">SYMPHONY HD 2021</a>; <a href="./references#CD013751-bbs2-0051" title="AkizawaT , NangakuM , YamaguchiT , KoretomoR , MaedaK , MiyazawaY , et al. A phase 3 study of enarodustat in anemic patients with CKD not requiring dialysis: the SYMPHONY ND study. Kidney International Reports2021;6(7):1840-9. [MEDLINE: 34307978]">SYMPHONY ND 2021</a>) (26,152 participants) were included in the meta‐analyses. </p> <section id="CD013751-sec-0047"> <h6 class="title">HIF stabilisers versus placebo</h6> <p>Sixteen studies (6330 participants) compared HIF stabiliser to placebo; 14 studies (5500 participants) could be meta‐analysed. </p> <p> <ul id="CD013751-list-0013"> <li> <p>Daprodustat (2 studies, 147 participants) (<a href="./references#CD013751-bbs2-0001" title="AkizawaT , TsubakiharaY , NangakuM , EndoY , NakajimaH , KohnoT , et al. Effects of daprodustat, a novel hypoxia-inducible factor prolyl hydroxylase inhibitor on anemia management in Japanese hemodialysis subjects. American Journal of Nephrology2017;45(2):127-35. [MEDLINE: 27978511]EndoY , KohnoT , ImaiY , KawaseN , HaraK , LeporeJJ , et al. A 4 -week dose response study of the hypoxia inducible factor-prolyl hydroxylase inhibitor GSK1278863 in Japanese anemic haemodialysis subjects [abstract no: SA-PO819]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):818A. NCT02019719. Study to evaluate the safety, efficacy and pharmacokinetics of GSK1278863 in Japanese hemodialysis-dependent subjects with anemia associated with chronic kidney disease [A 4-week, phase ii, randomized, double-blind, dose-ranging, placebo-controlled, parallel-group, multi-center study to evaluate the safety, efficacy and pharmacokinetics of GSK1278863 in Japanese hemodialysis-dependent subjects with anemia associated with chronic kidney disease]. clinicaltrials.gov/show/NCT02019719 (first received 24 December 2013). ">Akizawa 2017</a>; <a href="./references#CD013751-bbs2-0015" title="BrigandiRA , JohnsonB , OeiC , WestermanM , OlbinaG , deZoysaJ , et al. A novel hypoxia-inducible factor-prolyl hydroxylase inhibitor (GSK1278863) for anemia in CKD: a 28-day, phase 2a randomized trial. American Journal of Kidney Diseases2016;67(6):861-71. [MEDLINE: 26827289]BrigandiRA , JohnsonB , OeiC , WestermanME , OlbinaG , KumarS , et al. Induction of erythropoiesis in anemic patients by prolylhydroxylase inhibitor in a repeat dose, randomized placebo controlled trial [abstract no: SA-PO117]. Journal of the American Society of Nephrology2012;23(Abstract Suppl):662A. BrigandiRA , WestermanME , OlbinaG , OeiC , RussSF , KumarS . Modulation of hepcidin by prolylhydroxylase inhibitor in randomized trials [abstract no: SA-PO118]. Journal of the American Society of Nephrology2012;23(Abstract Suppl):662A. ">Brigandi 2016</a>) </p> </li> <li> <p>FG2216 (1 study, 142 participants) (<a href="./references#CD013751-bbs2-0044" title="ProvenzanoR , FaddaG , BernardoM , JamesC , KochendoerferG , LeeT , et al. FG2216, a novel oral HIF-PHI, stimulates erythropoiesis and increases hemoglobin concentration in patients with non-dialysis CKD [abstract no: 212]. American Journal of Kidney Diseases2008;51(4):A80. ProvenzanoR , HulterH , AgarwalA , KlausS , LeeT , YuP , et al. Hypoxia-inducible factor (HIF) prolyl hydroxylase inhibitor FG-2216 increases Hb without FE depletion in the absence of IV Fe [abstract no: 249]. American Journal of Kidney Diseases2013;61(4):A78. [EMBASE: 71024073]">Provenzano 2008</a>) </p> </li> <li> <p>Molidustat (1 study, 121 participants) (<a href="./references#CD013751-bbs2-0020" title="AkizawaT , MacdougallIC , BernsJS , BernhardtT , TaguchiM , OguraE , et al. Iron regulation by molidustat, bay 85-3934, a daily oral hypoxia-inducible factor prolyl hydroxylase inhibitor in patients with chronic kidney disease [abstract no: SP334]. Nephrology Dialysis Transplantation2018;33(Suppl 1):i457. [EMBASE: 622606520]AkizawaT , MacdougallIC , BernsJS , YamamotoH , TaguchiM , IekushiK , et al. Iron regulation by molidustat, a daily oral hypoxia-inducible factor prolyl hydroxylase inhibitor, in patients with chronic kidney disease. Nephron2019;143(4):243-54. [MEDLINE: 31387097]MacdougallIC , AkizawaT , BernsJ , LentiniS , BernhardtT . Molidustat increases haemoglobin in erythropoiesis stimulating agents (ESA)-naive anaemic patients with chronic kidney disease not on dialysis (CKD-ND) [abstract no: SO036]. Nephrology Dialysis Transplantation2016;31(Suppl 1):i16. [EMBASE: 72325954]MacdougallIC , AkizawaT , BernsJS , BernhardtT , KruegerT . Effects of molidustat in the treatment of anemia in CKD [Erratum in: Clin J Am Soc Nephrol. 2019 Oct 7;14(10):1524]. Clinical Journal of the American Society of Nephrology: CJASN2019;14(1):28-39. [MEDLINE: 30559105]MacdougallIC , BernsJS , AkizawaT , FishbaneS , BernhardtT . DIALOGUE phase 2 program for BAY85-3934 a HIF-PH inhibitor with daily oral treatment in anemic patients suffering from CKD/ESRD [abstract no: FR-PO219]. Journal of the American Society of Nephrology2013;24(Abstract Suppl):413A. ">DIALOGUE 1 2019</a>) </p> </li> <li> <p>Roxadustat (7 studies, 4769 participants) (<a href="./references#CD013751-bbs2-0002" title="AkizawaT , IwasakiM , OtsukaT , ReuschM , MisumiT . Roxadustat for the treatment of chronic kidney disease-associated anemia in Japanese patients not on dialysis [abstract no: FR-PO1142]. Journal of the American Society of Nephrology2016;27(Abstract Suppl):7B. AkizawaT , IwasakiM , OtsukaT , ReuschM , MisumiT . Roxadustat treatment of chronic kidney disease-associated anemia in Japanese patients not on dialysis: a phase 2, randomized, double-blind, placebo-controlled trial. Advances in Therapy2019;36(6):1438-54. [MEDLINE: 30953333]">Akizawa 2019</a>; <a href="./references#CD013751-bbs2-0007" title="Astellas 1517-CL-0608. Roxadustat in the treatment of anemia in chronic kidney disease patients not requiring dialysis [A phase 3, randomized, double-blind, placebo controlled study of the efficacy and safety of roxadustat for the treatment of anemia in chronic kidney disease patients not on dialysis]. www.trialsummaries.com/Study/StudyDetails?id=14384&amp;tenant=MT_AST_90112019. EspositoC , CsikyB , TataradzeA , ReuschM , HanC , SulowiczW . Two phase 3, multicenter, randomized studies of intermittent oral roxadustat in anemic CKD patients on (PYRENEES) and not on (ALPS) dialysis [abstract no: SA-PO225]. Journal of the American Society of Nephrology2019;30(Abstract Suppl):822. [EMBASE: 633767739]Pecoits-FilhoR , ChanTM , HardyE , YuKH , FishbaneS . Roxadustat treatment results in consistent improvements in hemoglobin (Hb) vs. placebo: an analysis of three multinational randomized clinical trials in patients with non-dialysis-dependent CKD (NDD-CKD) [abstract no: TH-OR05]. Journal of the American Society of Nephrology2020;31(Abstract Suppl):2. [EMBASE: 633697943]RastogiA , Pecoits-FilhoR , FishbaneS , LittleDJ , HardyE , YuKH , et al. Roxadustat treatment corrects anemia to hemoglobin (HB) values ≥10 g/dL in the majority of patients with non-dialysis-dependent chronic kidney disease (NDD-CKD) [abstract no: PO0264]. Journal of the American Society of Nephrology2020;31(Abstract Suppl):133. [EMBASE: 633698803]ShutovE , SulowiczW , EspositoC , TataradzeA , AndricB , ReuschM , et al. Roxadustat for the treatment of anemia in chronic kidney disease patients not on dialysis: a phase 3, randomized, double-blind, placebo-controlled study (ALPS). Nephrology Dialysis Transplantation2021;36(9):1629-39. [MEDLINE: 33630072]">ALPS 2021</a>; <a href="./references#CD013751-bbs2-0008" title="CoyneDW , RogerSD , ChouW , BesarabA , LeongR , LeeTT , et al. Roxadustat favorably modifies iron indices in patients with non-dialysis-dependent CKD-related anemia [abstract no: PO0262]. Journal of the American Society of Nephrology2020;31(Abstract Suppl):132. [EMBASE: 633698686]CoyneDW , RogerSD , ShinS , KimSG , CadenaAA , MoustafaMA , et al. Roxadustat for CKD-related anemia in non-dialysis patients. Kidney International Reports2021;6(3):624-35. [MEDLINE: 33732977]CoyneDW , RogerSD , ShinSK , KimSG , CadenaAA , MoustafaMA , et al. ANDES: A phase 3, randomized, double-blind, placebo controlled study of the efficacy and safety of roxadustat for the treatment of anemia in CKD patients not on dialysis [abstract no: SA-PO0228]. Journal of the American Society of Nephrology2019;30(Abstract Suppl):822-3. [EMBASE: 633767955]Pecoits-FilhoR , ChanTM , HardyE , YuKHP , FishbaneS . Roxadustat treatment results in consistent improvements in hemoglobin (Hb) vs. placebo: an analysis of three multinational randomized clinical trials in patients with non-dialysis-dependent CKD (NDD-CKD) [abstract no: TH-OR05]. Journal of the American Society of Nephrology2020;31(Abstract Suppl):2. [EMBASE: 633697943]RastogiA , Pecoits-FilhoR , FishbaneS , LittleDJ , HardyE , YuKH , et al. Roxadustat treatment corrects anemia to hemoglobin (HB) values ≥10 g/dL in the majority of patients with non-dialysis-dependent chronic kidney disease (NDD-CKD) [abstract no: PO0264]. Journal of the American Society of Nephrology2020;31(Abstract Suppl):133. [EMBASE: 633698803]">ANDES 2021</a>; <a href="./references#CD013751-bbs2-0014" title="BesarabA , HutlerHN , KlausS , LeeTT , LilienfeldDE , NeffTB , et al. FG-4592, a novel oral HIF prolyl hydroxylase inhibitor, elevates hemoglobin in anemic stage 3/4 CKD patients [abstract no: SA-FC416]. Journal of the American Society of Nephrology2010;21(Abstract Suppl):95A. BesarabA , ProvenzanoR , HertelJ , ZabanehR , KlausSJ , LeeT , et al. Randomized placebo-controlled dose-ranging and pharmacodynamics study of roxadustat (FG-4592) to treat anemia in nondialysis-dependent chronic kidney disease (NDD-CKD) patients. Nephrology Dialysis Transplantation2015;30(10):1665-73. [MEDLINE: 26238121]">Besarab 2015</a>; <a href="./references#CD013751-bbs2-0017" title="ChenN , HaoC , PengX , LinH , YinA , HaoL , et al. Roxadustat for anemia in patients with kidney disease not receiving dialysis. New England Journal of Medicine2019;381(11):1001-10. [MEDLINE: 31340089]ChenN , HaoC , PengX , LinHL , YinA , HaoL , et al. A phase 3, randomized, double-blind, placebo-controlled study of efficacy and safety of roxadustat (FG-4592) for treatment of anemia in subjects with CKD not on dialysis [abstract no: TH-PO1153]. Journal of the American Society of Nephrology2018;29(Abstract Suppl):B5. ">Chen 2019a</a>; <a href="./references#CD013751-bbs2-0019" title="ChenN , QianJ , ChenJ , YuX , MeiC , HaoC , et al. Phase 2 studies of oral hypoxia-inducible factor prolyl hydroxylase inhibitor FG-4592 for treatment of anemia in China. Nephrology Dialysis Transplantation2017;32(8):1373-86. [MEDLINE: 28371815]QianJQ , ChenN , ChenJ , HaoC , LinHL , NiD , et al. A randomized, double-blind, placebo controlled trial of FG-4592 for correction of anemia in subjects with chronic kidney disease in China [abstract no: FR-OR011]. Journal of the American Society of Nephrology2013;24(Abstract Suppl):38A. ">Chen NDD 2017</a>; <a href="./references#CD013751-bbs2-0040" title="AstraZeneca. A phase 3, multicenter, randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of roxadustat for the treatment of anemia in chronic kidney disease patients not on dialysis [clinical study protocol V6; 31 August 2018]. www.clinicaltrials.gov/ProvidedDocs/27/NCT02174627/Prot_000.pdf (accessed 9 May 2022). EleftheriadisT , PissasG , LiakopoulosV , StefanidisI . On the increased event rate of urinary tract infection and pneumonia in CKD patients treated with roxadustat for anemia. Journal of the American Society of Nephrology2021;32(6):1537. [MEDLINE: 33849917]FishbaneS , El-ShahawyMA , Pecoits-FilhoR , VanBP , HouserMT , FrisonL , et al. OLYMPUS: a phase 3, randomized, double-blind, placebo-controlled, international study of roxadustat efficacy in patients with non-dialysis-dependent (NDD) CKD and anemia [abstract no: TH-OR023]. Journal of the American Society of Nephrology2019;30(Abstract Suppl):6. [EMBASE: 633771285]FishbaneS , El-ShahawyMA , Pecoits-FilhoR , VanBP , HouserMT , FrisonL , et al. Roxadustat for treating anemia in patients with CKD not on dialysis: results from a randomized phase 3 study. Journal of the American Society of Nephrology2021;32(3):737-55. [MEDLINE: 33568383]FishbaneS , El-ShahawyMA , VanBP , LittleDJ . Authors' Reply. Journal of the American Society of Nephrology2021;32(6):1537-8. [MEDLINE: 33849916]Pecoits-FilhoR , ChanTM , HardyE , YuKH , FishbaneS . Roxadustat treatment results in consistent improvements in hemoglobin (Hb) vs. placebo: an analysis of three multinational randomized clinical trials in patients with non-dialysis-dependent CKD (NDD-CKD) [abstract no: TH-OR05]. Journal of the American Society of Nephrology2020;31(Abstract Suppl):2. [EMBASE: 633697943]RastogiA , Pecoits-FilhoR , FishbaneS , LittleDJ , HardyE , YuKH , et al. Roxadustat treatment corrects anemia to hemoglobin (HB) values ≥10 g/dL in the majority of patients with non-dialysis-dependent chronic kidney disease (NDD-CKD) [abstract no: PO0264]. Journal of the American Society of Nephrology2020;31(Abstract Suppl):133. [EMBASE: 633698803]">OLYMPUS 2021</a>) </p> </li> <li> <p>Vadadustat (3 studies, 321 participants) (<a href="./references#CD013751-bbs2-0038" title="NangakuM , FaragYM , deGomaE , LuoW , VargoD , KhawajaZ . Vadadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor, for treatment of anemia of chronic kidney disease: two randomized Phase 2 trials in Japanese patients. Nephrology Dialysis Transplantation 2020 Jul 20 [epub ahead of print]. [DOI: 10.1093/ndt/gfaa060] [MEDLINE: 32719868]NangakuM , KhawajaZ , LuoW , GarafolaS , De GomaE , KomatsuY . Randomized, placebo-controlled phase 2 trials of vadadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), to treat anemia of CKD [abstract no: TH-PO228]. Journal of the American Society of Nephrology2018;29(Abstract Suppl):171. [EMBASE: 633737146]SolinskyC , FaragYM , KhawajaZ , AndersR , LuoW , ChavanA , et al. Impact of vadadustat on iron regulation in Japanese subjects with chronic kidney disease (CKD) [abstract no: 352]. American Journal of Kidney Diseases2020;75(4):638-9. [EMBASE: 2005716872]">NDD‐CKD 2020</a>; <a href="./references#CD013751-bbs2-0039" title="NangakuM , FaragYM , deGomaE , LuoW , VargoD , KhawajaZ . Vadadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor, for treatment of anemia of chronic kidney disease: two randomized Phase 2 trials in Japanese patients. Nephrology Dialysis Transplantation 2020 Jul 20 [epub ahead of print]. [DOI: 10.1093/ndt/gfaa060] [MEDLINE: 32719868]NangakuM , KhawajaZ , LuoW , GarafolaS , deGomaE , KomatsuY . Randomized, placebo-controlled phase 2 trials of vadadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), to treat anemia of CKD [abstract no: TH-PO228]. Journal of the American Society of Nephrology2018;29(Abstract Suppl):171. [EMBASE: 633737146]SolinskyC , FaragYM , KhawajaZ , AndersR , LuoW , ChavanA , et al. Impact of vadadustat on iron regulation in Japanese subjects with chronic kidney disease (CKD) [abstract no: 352]. American Journal of Kidney Diseases2020;75(4):638-9. [EMBASE: 2005716872]">NDD‐CKD 2020a</a>; <a href="./references#CD013751-bbs2-0041" title="HaaseVH , SpinowitzBS , PergolaPE , FarmerT , MaroniBJ , HartmanCS . AKB-6548 demonstrates controlled hemogloblin (HGB) response in a phase 2b study for the treatment of anemia in patients with chronic kidney disease not on dialysis (ND-CKD) [abstract no: TH-PO649]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):237A. HaaseVH , SpinowitzBS , PergolaPE , KhawajaZ , ChanJ , ZurawQ , et al. Efficacy and dose requirements of vadadustat are independent of systemic inflammation and prior erythropoiesis-stimulating agent(ESA) dose in patients with non-dialysis dependent chronic kidney disease (NDD-CKD) [abstract no: TH-PO907]. Journal of the American Society of Nephrology2016;27(Abstract Suppl):304A. PergolaPE , SpinowitzB , HaaseVH , HartmanCS , FarmerTM , PoluKR , et al. AKB-6548, a novel hypoxia-inducible factor prolyl-hydroxylase inhibitor (HIF-PHI) for the treatment of anemia in patients with chronic kidney disease not on dialysis (ND-CKD) [abstract no: FO015]. Nephrology Dialysis Transplantation2015;30(Suppl 3):iii8. [EMBASE: 72206296]PergolaPE , SpinowitzBS , HartmanCS , MaroniBJ , HaaseVH . Vadadustat, a novel oral HIF stabilizer, provides effective anemia treatment in nondialysis-dependent chronic kidney disease. Kidney International2016;90(5):1115-22. [MEDLINE: 27650732]SpinowitzBS , PergolaPE , HaaseVH , FarmerTM , HartmanCS , MaroniBJ . Hemoglobin (HGB) response in a phase 2b study of AKB-6548 for the treatment of anemia in patients with non-dialysis dependant chronic kidney disease (NDD-CKD). [abstract no: TH-OR038]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):11A. ">Pergola 2016</a>) </p> </li> </ul> </p> </section> <section id="CD013751-sec-0048"> <h6 class="title">HIF stabilisers versus standard care</h6> <p>No studies compared HIF stabilisers to standard care.</p> </section> <section id="CD013751-sec-0049"> <h6 class="title">HIF stabilisers versus erythropoiesis‐stimulating agent</h6> <p>Thirty‐four studies (23,141 participants) compared HIF stabilisers to ESA; 29 studies (21,406 participants) could be meta‐analysed. </p> <p> <ul id="CD013751-list-0014"> <li> <p>Daprodustat versus not specified EPO (2 studies, 252 participants) (<a href="./references#CD013751-bbs2-0025" title="CizmanB , AckertJ , MeadowcroftA , BiswasN , KellyD , KleinmanD , et al. Ocular safety profile of daprodustat: results of two 24 week studies [abstract no: SAO004]. Nephrology Dialysis Transplantation2018;33(Suppl 1):i316. [EMBASE: 622604997]HoldstockL , CizmanB , MeadowcroftAM , BiswasN , JohnsonBM , JonesD , et al. Daprodustat for anemia: a 24-week, open-label, randomized controlled trial in participants with chronic kidney disease. Clinical Kidney Journal2019;12(1):129-38. [MEDLINE: 30746140]HoldstockL , CizmanB , MeadowcroftAM , BiswasN , JonesD , JohnsonBM , et al. Daprodustat, a HIF-prolyl-hydroxylase inhibitor, increases and maintains hemoglobin over 24 weeks in anemic chronic kidney disease subjects [abstract no: TH-PO908]. Journal of the American Society of Nephrology2016;27(Abstract Suppl):304A. ">Holdstock 2019</a>; <a href="./references#CD013751-bbs2-0026" title="CizmanB , AckertJ , MeadowcroftA , BiswasN , KellyD , KleinmanD , et al. Ocular safety profile of daprodustat: results of two 24 week studies [abstract no: SAO004]. Nephrology Dialysis Transplantation2018;33(Suppl 1):i316. [EMBASE: 622604997]HoldstockL , CizmanB , MeadowcroftAM , BiswasN , JohnsonBM , JonesD , et al. Daprodustat for anemia: a 24-week, open-label, randomized controlled trial in participants with chronic kidney disease. Clinical Kidney Journal2019;12(1):129-38. [MEDLINE: 30746140]HoldstockL , CizmanB , MeadowcroftAM , BiswasN , JonesD , JohnsonBM , et al. Daprodustat, a HIF-prolyl-hydroxylase inhibitor, increases and maintains hemoglobin over 24 weeks in anemic chronic kidney disease subjects [abstract no: TH-PO908]. Journal of the American Society of Nephrology2016;27(Abstract Suppl):304A. ">Holdstock 2019a</a>) </p> </li> <li> <p>Daprodustat versus darbepoetin alfa (3 studies, 4759 participants) (<a href="./references#CD013751-bbs2-0004" title="AkizawaT , NangakuM , YonekawaT , OkudaN , KawamatsuS , OnoueT , et al. Efficacy and safety of daprodustat compared with darbepoetin alfa in Japanese hemodialysis patients with anemia: a randomized, double-blind, phase 3 trial. Clinical Journal of the American Society of Nephrology: CJASN2020;15(8):1155-65. [MEDLINE: 32723804]OzekiH , AkizawaT , NangakuM , YonekawaT , OkudaN , KawamatsuS , et al. Efficacy and safety of daprodustat compared with darbepoetin alfa in Japanese hemodialysis patients with anemia: A randomized, double-blind, phase 3 trial [abstract no: SaO036]. Nephrology Dialysis Transplantation2019;34(Suppl 1):a350. [EMBASE: 631305259]">Akizawa 2020c</a>; <a href="./references#CD013751-bbs2-0011" title="PerkovicV , BlackorbyA , CizmanB , CarrollK , CobitzA , DaviesR , et al. ASCEND-ND: Study design and baseline characteristics. Nephrology Dialysis Transplantation2021;36(Suppl 1):i334-5. [EMBASE: 635918331]SinghAK , CarrollK , McMurrayJJ , SolomonS , JhaV , JohansenKL , et al. Daprodustat for the treatment of anemia in patients not undergoing dialysis. New England Journal of Medicine2021;385(25):2313-24. [MEDLINE: 34739196]">ASCEND‐ND 2021</a>; <a href="./references#CD013751-bbs2-0023" title="BarrattJ , AndricB , TataradzeA , SchoemigM , ReuschM , ValluriU , et al. Roxadustat for the treatment of anemia in CKD patients not on dialysis (NDD): a phase 3, randomized, open-label, active-controlled study [abstract no: TH-OR02]. Journal of the American Society of Nephrology2020;31(Abstract Suppl):1. [EMBASE: 633697812]BarrattJ , AndricB , TataradzeA , SchomigM , ReuschM , ValluriU , et al. Roxadustat for the treatment of anaemia in chronic kidney disease patients not on dialysis: a phase 3, randomised, open-label, active-controlled study (DOLOMITES). Nephrology Dialysis Transplantation2021;36(9):1616-28. [MEDLINE: 34077510]BarrattJ , AndricB , TataradzeA , SchomigM , ReuschM , ValluriU , et al. Roxadustat for the treatment of anaemia in chronic kidney disease patients not on dialysis: a phase 3, randomised, open-label, active controlled study [abstract no: MO001]. Nephrology Dialysis Transplantation2020;35(Suppl 3):iii101. [EMBASE: 633423023]BarrattJ , AndricB , TataradzeA , SchomigM , ReuschM , ValluriU , et al. Roxadustat for the treatment of anemia in chronic kidney disease (CKD) patients not on dialysis (NDD): a phase 3, randomized, open-label, active-controlled study [abstract no: Pos-247]. Kidney International Reports2021;6(4 Suppl):S104. [EMBASE: 2011683542]">DOLOMITES 2021</a>) </p> </li> <li> <p>Daprodustat versus darbepoetin alfa or EPO alfa (1 study, 2964 participants) (<a href="./references#CD013751-bbs2-0009" title="SinghAK , BlackorbyA , CizmanB , CarrollK , CobitzAR , DaviesR , et al. Study design and baseline characteristics of patients on dialysis in the ASCEND-D trial. Nephrology Dialysis Transplantation2021;37(5):960-72. [MEDLINE: 33744933] [MEDLINE: 33744933]SinghAK , BlackorbyA , CizmanB , CobitzAR , GodoySA , JhaV , et al. Regional variation of erythropoietin-stimulating agent hyporesponsiveness in the global daprodustat dialysis study (ASCEND-D) [abstract no: TH-OR08]. Journal of the American Society of Nephrology2020;31(Abstract Suppl):3. [EMBASE: 633698062]SinghAK , CarrollK , PerkovicV , SolomonS , JhaV , JohansenKL , et al. Daprodustat for the treatment of anemia in patients undergoing dialysis. New England Journal of Medicine2021;385(25):2325-35. [MEDLINE: 34739194]">ASCEND‐D 2021</a>) </p> </li> <li> <p>Daprodustat versus mircera (1 study, 299 participants) (<a href="./references#CD013751-bbs2-0036" title="GSK201753. A 52-week, Phase III, open-label, multi-center study to evaluate efficacy and safety of GSK1278863 in Japanese non-dialysis and peritoneal dialysis subjects with anemia associated with chronic kidney disease [study protocol]. www.clinicaltrials.gov/ProvidedDocs/63/NCT02791763/Prot_000.pdf (accessed 9 May 2022). NangakuM , HamanoT , AkizawaT , TsubakiharaY , NagaiR , OkudaN , et al. Daprodustat compared with epoetin beta pegol for anemia in Japanese patients not on dialysis: a 52-week randomized open-label phase 3 trial. American Journal of Nephrology2021;52(1):26-35. [MEDLINE: 33561857]">Nangaku 2021b</a>) </p> </li> <li> <p>Enarodustat versus darbepoetin alfa (2 studies, 389 participants) (<a href="./references#CD013751-bbs2-0050" title="AkizawaT , MaedaK , MiyazawaY , KoretomoR . Phase 3 study to compare the efficacy and safety of enarodustat (JTZ-951), an oral HIF-PH inhibitor, with darbepoetin alfa in anemic patients with CKD receiving maintenance hemodialysis [abstract no: TH-PO1186]. Journal of the American Society of Nephrology2019;30(Abstract Suppl):B4. AkizawaT , NangakuM , YamaguchiT , KoretomoR , MaedaK , MiyazawaY , et al. A phase 3 study of enarodustat (JTZ-951) in Japanese hemodialysis patients for treatment of anemia in chronic kidney disease: SYMPHONY HD study. Kidney Diseases2021;7(6):494-502. [EMBASE: 2013576033]">SYMPHONY HD 2021</a>; <a href="./references#CD013751-bbs2-0051" title="AkizawaT , NangakuM , YamaguchiT , KoretomoR , MaedaK , MiyazawaY , et al. A phase 3 study of enarodustat in anemic patients with CKD not requiring dialysis: the SYMPHONY ND study. Kidney International Reports2021;6(7):1840-9. [MEDLINE: 34307978]">SYMPHONY ND 2021</a>) </p> </li> <li> <p>Molidustat versus epoetin alfa and beta (1 study, 199 participants) (<a href="./references#CD013751-bbs2-0022" title="AkizawaT , MacdougallIC , BernsJS , YamamotoH , TaguchiM , IekushiK , et al. Iron regulation by molidustat, a daily oral hypoxia-inducible factor prolyl hydroxylase inhibitor, in patients with chronic kidney disease. Nephron2019;143(4):243-54. [MEDLINE: 31387097]MacdougallIC , AkizawaT , BernsJ , LentiniS , BernhardtT . Molidustat increases haemoglobin in erythropoiesis stimulating agents (ESA)-naive anaemic patients with chronic kidney disease not on dialysis (CKD-ND) [abstract no: SO036]. Nephrology Dialysis Transplantation2016;31(Suppl 1):i16. [EMBASE: 72325954]MacdougallIC , AkizawaT , BernsJS , BernhardtT , KruegerT . Effects of molidustat in the treatment of anemia in CKD [Erratum in: Clin J Am Soc Nephrol. 2019 Oct 7;14(10):1524]. Clinical Journal of the American Society of Nephrology: CJASN2019;14(1):28-39. [MEDLINE: 30559105]MacdougallIC , BernsJS , AkizawaT , FishbaneS , BernhardtT . DIALOGUE phase 2 program for BAY85-3934 a HIF-PH inhibitor with daily oral treatment in anemic patients suffering from CKD/ESRD [abstract no: FR-PO219]. Journal of the American Society of Nephrology2013;24(Abstract Suppl):413A. ">DIALOGUE 4 2019</a>) </p> </li> <li> <p>Molidustat versus darbepoetin alfa (4 studies, 679 participants) (<a href="./references#CD013751-bbs2-0021" title="AkizawaT , MacdougallIC , BernsJS , YamamotoH , TaguchiM , IekushiK , et al. Iron regulation by molidustat, a daily oral hypoxia-inducible factor prolyl hydroxylase inhibitor, in patients with chronic kidney disease. Nephron2019;143(4):243-54. [MEDLINE: 31387097]MacdougallIC , AkizawaT , BernsJ , LentiniS , BernhardtT , KrugerT . Safety and efficacy of molidustat in erythropoiesis stimulating agents (ESA) pre-treated anaemic patients with chronic kidney disease not on dialysis (CKD-ND) [abstract no: SP309]. Nephrology Dialysis Transplantation2016;31(Suppl 1):i193. [EMBASE: 72326411]MacdougallIC , AkizawaT , BernsJ , LentiniS , BernhardtT . Molidustat increases haemoglobin in erythropoiesis stimulating agents (ESA)-naive anaemic patients with chronic kidney disease not on dialysis (CKD-ND) [abstract no: SO036]]. Nephrology Dialysis Transplantation2016;31(Suppl 1):i16. [EMBASE: 72325954]MacdougallIC , AkizawaT , BernsJS , BernhardtT , KruegerT . Effects of molidustat in the treatment of anemia in CKD [Erratum in: Clin J Am Soc Nephrol. 2019 Oct 7;14(10):1524]. Clinical Journal of the American Society of Nephrology: CJASN2019;14(1):28-39. [MEDLINE: 30559105]MacdougallIC , BernsJS , AkizawaT , FishbaneS , BernhardtT . DIALOGUE phase 2 program for BAY85-3934 a HIF-PH inhibitor with daily oral treatment in anemic patients suffering from CKD/ESRD [abstract no: FR-PO219]. Journal of the American Society of Nephrology2013;24(Abstract Suppl):413A. ">DIALOGUE 2 2019</a>; <a href="./references#CD013751-bbs2-0031" title="AkizawaT , TaguchiM , MatsudaY , IekushiK , YamadaT , YamamotoH . Molidustat for the treatment of renal anaemia in patients with dialysis-dependent chronic kidney disease: Design and rationale of three phase III studies. BMJ Open2019;9(6):e026602. [MEDLINE: 31203241]AkizawaT , YamadaT , NoboriK , MatsudaY , HayashiY , HayasakiT , et al. Molidustat for Japanese patients with renal anemia receiving dialysis. Kidney International Reports2021;6(10):2604–16. [MEDLINE: 34622100]AkizawaT , YamadaT , NoboriK , MatsudaY , HayashiY , HayasakiT , et al. Results from a phase 3 study comparing the efficacy and safety of molidustat vs. Darbepoetin Alfa in patients receiving hemodialysis and treated with erythropoiesis-stimulating agents (ESAS) [abstract no: PO22623]. Journal of the American Society of Nephrology2020;31(Abstract Suppl):B4. [EMBASE: 633697376]">MIYABI HD‐M 2019</a>; <a href="./references#CD013751-bbs2-0032" title="YamamotoH , NoboriK , MatsudaY , HayashiY , HayasakiT , AkizawaT . Efficacy and safety of molidustat for anemia in ESA-naive nondialysis patients: a randomized, phase 3 trial. American Journal of Nephrology2021;52(10-11):871-83. [MEDLINE: 34569489]YamamotoH , TaguchiM , MatsudaY , IekushiK , YamadaT , AkizawaT . Molidustat for the treatment of renal anaemia in patients with non-dialysis-dependent chronic kidney disease: design and rationale of two phase III studies. BMJ Open2019;9(6):e026704. [MEDLINE: 31203242]YamamotoH , TaguchiM , NoboriK , MatsudaY , IekushiK , AkizawaT . To investigate the efficacy and safety of molidustat in non-dialysis patients with renal anemia who are not treated with erythropoiesis stimulating agents: MIYABI ND-C [abstract no: P1866]. Nephrology Dialysis Transplantation2020;35(Suppl 3):iii2177. [EMBASE: 633422996]">MIYABI ND‐C 2019</a>; <a href="./references#CD013751-bbs2-0033" title="YamamotoH , NoboriK , MatsudaY , HayashiY , HayasakiT , AkizawaT . Molidustat for renal anemia in nondialysis patients previously treated with erythropoiesis-stimulating agents: a randomized, open-label, phase 3 study. American Journal of Nephrology2021;52(10-11):884-93. [MEDLINE: 34569482]YamamotoH , TaguchiM , MatsudaY , IekushiK , YamadaT , AkizawaT . Molidustat for the treatment of renal anaemia in patients with non-dialysis-dependent chronic kidney disease: design and rationale of two phase III studies. BMJ Open2019;9(6):e026704. [MEDLINE: 31203242]YamamotoH , TaguchiM , NoboriK , MatsudaY , IekushiK , AkizawaT . To investigate the efficacy and safety of molidustat in non-dialysis patients with renal anemia who are treated with erythropoiesis stimulating agents: Miyabi ND-M [Abstract no: P1868]. Nephrology Dialysis Transplantation2020;35(Suppl 3):iii2179. [EMBASE: 633423006]">MIYABI ND‐M 2019</a>) </p> </li> <li> <p>Roxadustat versus epoetin alfa (4 studies, 2176 participants) (<a href="./references#CD013751-bbs2-0016" title="ChenN , HaoC , LiuB , LinHL , CailiW , XingCY , et al. A phase 3, randomized, open-label, active-controlled study of efficacy and safety of roxadustat for treatment of anemia in subjects with CKD on dialysis [abstract no: TH-PO1152]. Journal of the American Society of Nephrology2018;29(Abstract Suppl):B5. ChenN , HaoC , LiuBC , LinH , WangC , XingC , et al. Roxadustat treatment for anemia in patients undergoing long-term dialysis. New England Journal of Medicine2019;381(11):1011-22. [MEDLINE: 31340116]">Chen 2019</a>; <a href="./references#CD013751-bbs2-0018" title="ChenN , QianJ , ChenJ , YuX , MeiC , HaoC , et al. Phase 2 studies of oral hypoxia-inducible factor prolyl hydroxylase inhibitor FG-4592 for treatment of anemia in China. Nephrology Dialysis Transplantation2017;32(8):1373-86. [MEDLINE: 28371815]">Chen DD 2017</a>; <a href="./references#CD013751-bbs2-0024" title="ProvenzanoM , EvgenyS , LiubovE , KorneyevaS , KathresalAA , PooleL , et al. HIMALAYAS: a phase 3, randomized, open-label, active-controlled study of the efficacy and safety of roxadustat in the treatment of anemia in incident-dialysis patients [abstract no: TH-OR021]. Journal of the American Society of Nephrology2019;30(Abstract Suppl):5. [EMBASE: 633771140]ProvenzanoR , ShutovE , EremeevaL , KorneyevaS , PooleL , SahaG , et al. Roxadustat for anemia in patients with end-stage renal disease incident to dialysis. Nephrology Dialysis Transplantation2021;36(9):1717-30. [MEDLINE: 33629100]">HIMALAYAS 2021</a>; <a href="./references#CD013751-bbs2-0049" title="CharytanC , Manllo-KarimR , MartinER , SteerD , BernardoM , DuaSL , et al. A randomized trial of roxadustat in anemia of kidney failure: SIERRAS study. Kidney International Reports2021;6(7):1829-39. [MEDLINE: 34307977]CharytanC , Manllo-KarimR , MartinER , SteerD , BernardoM , DuaSL , et al. SIERRAS: A phase 3, open-label, randomized, active-controlled study of the efficacy and safety of roxadustat in the maintenance treatment of anemia in subjects with ESRD on stable dialysis [abstract no: SA-PO227]. Journal of the American Society of Nephrology2019;30(Abstract Suppl):822. [EMBASE: 633767862]">SIERRAS 2021</a>) </p> </li> <li> <p>Roxadustat versus darbepoetin alfa (3 studies, 696 participants) (<a href="./references#CD013751-bbs2-0003" title="AkizawaT , IwasakiM , YamaguchiY , MajikawaY , ReuschM . Authors' Reply. Journal of the American Society of Nephrology2021;32(4):1005-7. [MEDLINE: 33649099]AkizawaT , IwasakiM , YamaguchiY , MajikawaY , ReuschM . Phase 3, randomized, double-blind, active-comparator (darbepoetin alfa) conversion study of oral roxadustat in CKD patients with anemia on hemodialysis in Japan [abstract no: TH-PO1151]. Journal of the American Society of Nephrology2018;29(Abstract Suppl):B4. AkizawaT , IwasakiM , YamaguchiY , MajikawaY , ReuschM . Phase 3, randomized, double-blind, active-comparator (darbepoetin alfa) study of oral roxadustat in CKD patients with anemia on hemodialysis in Japan. Journal of the American Society of Nephrology2020;31(7):1628-39. [MEDLINE: 32493693]AkizawaT , YamaguchiY , MajikawaY , ReuschM . Factors affecting the doses of roxadustat vs darbepoetin alfa for anemia treatment in hemodialysis patients. Therapeutic Apheresis &amp; Dialysis2021;25(5):575-85. [MEDLINE: 33200512]Astellas1517-CL-0307. A study of intermittent oral dosing of ASP1517 in hemodialysis chronic kidney disease patients with anemia [A phase 3, multi-center, randomized, 2-arm parallel, double-blind, active-comparator (darbepoetin alfa) conversion study of intermittent oral dosing of ASP1517 in hemodialysis chronic kidney disease patients with anemia]. www.clinicaltrials.astellas.com/study/?pid=1517-CL-0307 (accessed 4 May 2022). LiuF , WangJ , YeQ , FuH , MaoJ . Roxadustat for renal anemia in ESRD from PKD patients: is it safe enough?Journal of the American Society of Nephrology2021;32(4):1005. [MEDLINE: 33649100]NguyenQD , SepahYJ , YamaguchiY , OtsukaT , MajikawaY , ReuschM , et al. Ophthalmological effects of roxadustat in the treatment of anemia in dialysis-dependent and non-dialysis-dependent CKD patients: findings from two phase 3 studies [abstract no: PO0267]. Journal of the American Society of Nephrology2020;31(Abstract Suppl):134. [EMBASE: 633698979]SepahY , NguyenQD , YamaguchiY , MajikawaY , ReuschM , AkizawaT . Ophthalmological effects of roxadustat in the treatment of anaemia in chronic kidney disease patients on dialysis in a phase 3, randomised, double-blind, active-comparator conversion study [abstract no: MO002]. Nephrology Dialysis Transplantation2020;35(Suppl 3):iii102. [EMBASE: 633421367]">Akizawa 2020a</a>; <a href="./references#CD013751-bbs2-0006" title="AkizawaT , IwasakiM , OtsukaT , YamaguchiY , ReuschM . Phase 3 study of roxadustat to treat anemia in non-dialysis-dependant CKD. Kidney International Reports2021;6(7):1810-28. [MEDLINE: 34307976]AkizawaT , Tanaka-AminoK , OtsukaT , YamaguchiY . Factors affecting doses of roxadustat versus darbepoetin alfa for anemia in nondialysis patients. American Journal of Nephrology2021;52(9):702-13. [MEDLINE: 34628408]">Akizawa 2021</a>; <a href="./references#CD013751-bbs2-0037" title="Astellas1517-CL-0304. A study to investigate the effect of ASP1517 after intermittent oral dosing in dialysis chronic kidney disease patients with anemia compared with darbepoetin as a reference drug [A Japanese, phase 2, multicenter, randomized, 4-arm parallel, double-blind (arms 1-3), open-label (arm 4), active-comparator (darbepoetin alfa) study of intermittent oral dosing of asp1517 in hemodialysis-dependent chronic kidney disease patients with anemia [1517-CL-0304 clinical study results report]]. www.trialsummaries.com/Study/StudyDetails?id=14175&amp;tenant=MT_AST_9011; www.clinicaltrials.gov/ct2/show/NCT01888445 (first received 6 August 2018). ">NCT01888445</a>) </p> </li> <li> <p>Roxadustat versus epoetin alfa and darbepoetin alfa (1 study, 838 participants) (<a href="./references#CD013751-bbs2-0047" title="Astellas 1517-CL-0613. Roxadustat in the treatment of anemia in end stage renal disease (ESRD) patients on stable dialysis [A phase 3, randomized, open-label, active-controlled study to evaluate the efficacy and safety of roxadustat in the maintenance treatment of anemia in end stage renal disease patients on stable dialysis]. www.trialsummaries.com/Study/StudyDetails?id=14380&amp;tenant=MT_AST_9011 (accessed 9 May 2022). CsikyB , SchomigM , EspositoC , BarrattJ , ReuschM , ValluriU , et al. Roxadustat for the maintenance treatment of anemia in patients with end-stage kidney disease on stable dialysis: a European phase 3, randomized, open-label, active-controlled study (PYRENEES). Advances in Therapy2021;38(10):5361-80. [MEDLINE: 34537926]EspositoC , CsikyB , TataradzeA , ReuschM , HanC , SulowiczW . Two phase 3, multicenter, randomized studies of intermittent oral roxadustat in anemic CKD patients on (PYRENEES) and not on (ALPS) dialysis. Swiss Medical Weekly2020;150(Suppl 248):21-2S. [EMBASE: 634241523]EspositoC , CsikyB , TataradzeA , ReuschM , HanC , SulowiczW . Two phase 3, multicenter, randomized studies of intermittent oral roxadustat in anemic CKD patients on (PYRENEES) and not on (ALPS) dialysis [abstract no: SA-PO225]. Journal of the American Society of Nephrology2019;30(Abstract Suppl):822. [EMBASE: 633767739]">PYRENEES 2021</a>) </p> </li> <li> <p>Roxadustat versus not specified ESA (1 study, 129 participants) (<a href="./references#CD013751-bbs2-0027" title="HouYP , MaoXY , WangC , XuZH , BuZH , XuM , et al. Roxadustat treatment for anemia in peritoneal dialysis patients: a randomized controlled trial. Journal of the Formosan Medical Association2021;121(2):529-38. [MEDLINE: 34167878]">Hou 2021</a>) </p> </li> <li> <p>Vadadustat versus darbepoetin alfa (6 studies, 8026 participants) (<a href="./references#CD013751-bbs2-0028" title="ChertowGM , BoudvilleN , ChowdhuryP , GonzalezC , KooiengaL , LuoW , et al. Vadadustat for treatment of anemia in patients with dialysis-dependent CKD receiving peritoneal dialysis [abstract no: PO0464]. Journal of the American Society of Nephrology2021;32(Abstract Suppl):184. [EMBASE: 636331136]EckardtKU , AgarwalR , AswadA , AwadA , BlockGA , BacciMR , et al. Safety and efficacy of vadadustat for anemia in patients undergoing dialysis. New England Journal of Medicine2021;384(17):1601-12. [MEDLINE: 33913638]EckardtKU , AgarwalR , FaragYM , JardineAG , KhawajaZ , KouryMJ , et al. Global Phase 3 programme of vadadustat for treatment of anaemia of chronic kidney disease: rationale, study design and baseline characteristics of dialysis-dependent patients in the INNO2VATE trials. Nephrology Dialysis Transplantation2020;36(11):2039-48. [MEDLINE: 33188693]EckardtKU . Global phase 3 clinical trials of vadadustat vs. darbepoetin alfa for treatment of anemia in patients with dialysis-dependent CKD [abstract no: TH-OR01]. Journal of the American Society of Nephrology2020;31(Abstract Suppl):1. [EMBASE: 633697781]ParfreyPS , LuoW , MaroniB , AndersR , VargoD , McCulloughPA . Thromboembolic events with vadadustat vs. darbepoetin alfa for anemia treatment in patients with dialysis-dependent CKD [abstract no: PO0463]. Journal of the American Society of Nephrology2021;32(Abstract Suppl):184. [EMBASE: 636331080]WinkelmayerW , TumlinJA , FishbaneS , FaragY , VargoD , LuoW , et al. Hematologic efficacy of vadadustat for anemia in patients with kidney failure on dialysis [abstract no: MO529]. Nephrology Dialysis Transplantation2021;36(Suppl 1):i325-6. [EMBASE: 635917983]WinkelmayerWC , FishbaneS , TumlinJA , FaragYM , LuoW , AndersR , et al. Iron-related outcomes in patients with dialysis-dependent CKD randomized to vadadustat vs. darbepoetin alfa [abstract no: PO0457]. Journal of the American Society of Nephrology2021;32(Abstract Suppl):182. [EMBASE: 636330773]">INNO2VATE 2020</a>; <a href="./references#CD013751-bbs2-0029" title="EckardtKU , AgarwalR , AswadA , AwadA , BlockGA , BacciMR , et al. Safety and efficacy of vadadustat for anemia in patients undergoing dialysis. New England Journal of Medicine2021;384(17):1601-12. [MEDLINE: 33913638]EckardtKU , AgarwalR , FaragYM , JardineAG , KhawajaZ , KouryMJ , et al. Global Phase 3 programme of vadadustat for treatment of anaemia of chronic kidney disease: rationale, study design and baseline characteristics of dialysis-dependent patients in the INNO2VATE trials. Nephrology Dialysis Transplantation2020;36(11):2039-48. [MEDLINE: 33188693]EckardtKU . Global phase 3 clinical trials of vadadustat vs. darbepoetin alfa for treatment of anemia in patients with dialysis-dependent CKD [abstract no: TH-OR01]. Journal of the American Society of Nephrology2020;31(Abstract Suppl):1. [EMBASE: 633697781]WinkelmayerWC , FishbaneS , TumlinJA , FaragYM , LuoW , AndersR , et al. Iron-related outcomes in patients with dialysis-dependent CKD randomized to vadadustat vs. darbepoetin alfa [abstract no: PO0457]. Journal of the American Society of Nephrology2021;32(Abstract Suppl):182. [EMBASE: 636330773]">INNO2VATE 2020a</a>; <a href="./references#CD013751-bbs2-0034" title="NangakuM , KondoK , UetaK , KokadoY , KanekoG , MatsudaH , et al. Efficacy and safety of vadadustat compared with darbepoetin alfa in Japanese anemic patients on hemodialysis: a phase 3, multicenter, randomized, double-blind study. Nephrology Dialysis Transplantation2021;36(9):1731-41. [MEDLINE: 33650630]NangakuM , KondoK , UetaK , KokadoY , KanekoG , MatsudaH , et al. Randomized, double-blinded, active-controlled (darbepoetin alfa), phase 3 study of vadadustat in CKD patients with anemia on hemodialysis in Japan [abstract no: TH-OR024]. Journal of the American Society of Nephrology2019;30(Abstract Suppl):6. [EMBASE: 633771357]">Nangaku 2021</a>; <a href="./references#CD013751-bbs2-0035" title="NangakuM , KondoK , KokadoY , UetaK , KanekoG , ShiosakaM , et al. Randomized, open-label, active-controlled (darbepoetin alfa), phase 3 study of vadadustat for treating anemia in non-dialysis-dependent CKD patients in Japan [abstract no: SA-PO229]. Journal of the American Society of Nephrology2019;30(Abstract Suppl):823. [EMBASE: 633767995]NangakuM , KondoK , KokadoY , UetaK , KanekoG , TandaiT , et al. Phase 3 randomized study comparing vadadustat with darbepoetin alfa for anemia in Japanese patients with nondialysis-dependent CKD. Journal of the American Society of Nephrology2021;32(7):1779-90. [MEDLINE: 33883252]">Nangaku 2021a</a>; <a href="./references#CD013751-bbs2-0042" title="BunnHF . Vadadustat for anemia in patients with dialysis-dependent or non-dialysis-dependent chronic kidney disease. New England Journal of Medicine2021;385(16):e56. [MEDLINE: 34644481]ChertowGM , PergolaPE , AgarwalR , BlockGA , FaragYM , JardineAG , et al. Cardiovascular safety and efficacy of vadadustat for the treatment of anemia in non-dialysis-dependent CKD: design and baseline characteristics. American Heart Journal2021;235(5):1-11. [MEDLINE: 33129989]ChertowGM , PergolaPE , FaragYM , AgarwalR , ArnoldS , BakoG , et al. Vadadustat in patients with anemia and non-dialysis-dependent CKD. New England Journal of Medicine2021;384(17):1589-600. [MEDLINE: 33913637]ChertowGM . Global phase 3 clinical trials of vadadustat vs. darbepoetin alfa for treatment of anemia in patients with non-dialysis-dependent CKD [abstract no: FR-OR54]. Journal of the American Society of Nephrology2020;31(Abstract Suppl):B2. [EMBASE: 633697273]KouryM , PergolaPE , Roy-ChaudhuryP , FaragYM , LuoW , AndersR , et al. Iron-related outcomes in patients with non-dialysis-dependent CKD randomized to vadadustat vs. darbepoetin Alfa [abstract no: PO0482]. Journal of the American Society of Nephrology2021;32(Abstract Suppl):190. [EMBASE: 636329134]McCulloughPA , LuoW , AndersR , VargoD , ParfreyPS . Assessment of thromboembolic events with vadadustat vs. darbepoetin alfa for treatment of anemia in patients with non-dialysis-dependent CKD [abstract no: PO0462]. Journal of the American Society of Nephrology2021;32(Abstract Suppl):184. [EMBASE: 636331039]">PRO2TECT‐CONVERSION 2021</a>; <a href="./references#CD013751-bbs2-0043" title="BunnHF . Vadadustat for anemia in patients with dialysis-dependent or non-dialysis-dependent chronic kidney disease. New England Journal of Medicine2021;385(16):e56. [MEDLINE: 34644481]ChertowGM , PergolaPE , AgarwalR , BlockGA , FaragYM , JardineAG , et al. Cardiovascular safety and efficacy of vadadustat for the treatment of anemia in non-dialysis-dependent CKD: design and baseline characteristics. American Heart Journal2021;235(5):1-11. [MEDLINE: 33129989]ChertowGM , PergolaPE , FaragYM , AgarwalR , ArnoldS , BakoG , et al. Vadadustat in patients with anemia and non-dialysis-dependent CKD. New England Journal of Medicine2021;384(17):1589-600. [MEDLINE: 33913637]ChertowGM . Global phase 3 clinical trials of vadadustat vs. darbepoetin alfa for treatment of anemia in patients with non-dialysis-dependent CKD [abstract no: FR-OR5]. Journal of the American Society of Nephrology2020;31(Abstract Suppl):B2. [EMBASE: 633697273]KouryM , PergolaPE , Roy-ChaudhuryP , FaragYM , LuoW , AndersR , et al. Iron-related outcomes in patients with non-dialysis-dependent CKD randomized to vadadustat vs. darbepoetin alfa [abstract no: PO0482]. Journal of the American Society of Nephrology2021;32(Abstract Suppl):190. [EMBASE: 636329134]McCulloughPA , LuoW , AndersR , VargoD , ParfreyPS . Assessment of thromboembolic events with vadadustat vs. darbepoetin alfa for treatment of anemia in patients with non-dialysis-dependent CKD [abstract no: PO0462]. Journal of the American Society of Nephrology2021;32(Abstract Suppl):184. [EMBASE: 636331039]">PRO2TECT‐CORRECTION 2021</a>). </p> </li> </ul> </p> </section> <section id="CD013751-sec-0050"> <h6 class="title">HIF stabilisers versus iron supplementation</h6> <p>No studies compared HIF stabilisers with iron supplementation.</p> </section> </section> </section> <section id="CD013751-sec-0051"> <h4 class="title">Excluded studies</h4> <p>We excluded 31 studies. The reasons for exclusion were:</p> <p> <ul id="CD013751-list-0015"> <li> <p>Follow‐up less than eight weeks (22 studies: <a href="./references#CD013751-bbs2-0053" title="AkizawaT , MiyazawaY , MatsuiA , KoretomoR , AraiM . Enarodustat (JTZ-951) , an oral HIF-PH inhibitor, elevates and maintains hemoglobin levels over 30 weeks in Japanese anemic patients with CKD not on dialysis [abstract no: TH-PO225]. Journal of the American Society of Nephrology2018;29(Abstract Suppl):171. [EMBASE: 633737010]AkizawaT , NangakuM , YamaguchiT , AraiM , KoretomoR , MatsuiA , et al. A placebo-controlled, randomized trial of enarodustat in patients with chronic kidney disease followed by long-term trial. American Journal of Nephrology2019;49(2):165-74. [MEDLINE: 30699415]">Akizawa 2019a</a>; <a href="./references#CD013751-bbs2-0054" title="AkizawaT , MiyazawaY , MaedaK , KoretomoR , AraiM . Enarodustat (JTZ-951), an oral HIF-PH inhibitor, maintains hemoglobin levels switching from ESAs over 30 weeks in Japanese anemic patients with CKD receiving maintenance hemodialysis [abstract no: TH-PO226]. Journal of the American Society of Nephrology2018;29(Abstract Suppl):171. [EMBASE: 633737068]AkizawaT , NangakuM , YamaguchiT , AraiM , KoretomoR , MaedaK , et al. Enarodustat, conversion and maintenance therapy for anemia in hemodialysis patients: a randomized, placebo-controlled phase 2b trial followed by long-term trial. Nephron2019;143(2):77-85. [MEDLINE: 31117088]">Akizawa 2019b</a>; <a href="./references#CD013751-bbs2-0058" title="NCT03457701. Anemia studies in CKD: erythropoiesis via a novel prolyl hydroxylase inhibitor (PHI) daprodustat- iron (ASCEND: Fe) [A repeat dose, open label, two period, randomized, cross over study to compare the effect of daprodustat to recombinant, human erythropoietin (rhEPO) on oral iron absorption in adult participants with anemia associated with chronic kidney disease who are not on dialysis]. www.clinicaltrials.gov/show/NCT03457701 (first received 7 March 2018). ">ASCEND:Fe 2018</a>; <a href="./references#CD013751-bbs2-0059" title="NCT03029247. Anemia study in chronic kidney disease (CKD): erythropoiesis via a novel prolyl hydroxylase inhibitor (PHI) daprodustat-blood pressure (ASCEND-BP) [A randomized, open-label study to evaluate the effect of daprodustat on blood pressure in subjects with anemia associated with chronic kidney disease on hemodialysis switched from a stable dose of an erythropoiesis-stimulating agent]. www.clinicaltrials.gov/show/NCT03029247 (first received 24 January 2017). ">ASCEND‐BP 2017</a>; <a href="./references#CD013751-bbs2-0060" title="BaileyCK , CaltabianoS , CobitzAR , HuangC , MaharKM , PatelV , et al. A 29-day safety, efficacy, and pharmacodynamic study of a hypoxia-inducible factor prolyl hydroxylase inhibitor, daprodustat, administered TIW in anemic subjects on hemodialysis (HD) [abstract no: SA-PO811]. Journal of the American Society of Nephrology2017;28(Abstract Suppl):889. [EMBASE: 633698132]BaileyCK , CaltabianoS , CobitzAR , HuangC , MaharKM , PatelVV . A randomized, 29-day, dose-ranging, efficacy and safety study of daprodustat, administered three times weekly in patients with anemia on hemodialysis. BMC Nephrology2019;20(1):372. [MEDLINE: 31619187]">Bailey 2019</a>; <a href="./references#CD013751-bbs2-0062" title="BuchA , FarmerTM , HartmanC , AlcornH , ShalwitzR . Hemodialysis has minimal impact on the pharmacokinetics of AKB-6548, a once-daily oral inhibitor of hypoxia inducible factor prolyl-hydroxylases (HIFPHs) for the treatment of anemia related to chronic kidney disease (CKD) [abstract no: FR-PO952]. Journal of the American Society of Nephrology2014;25(Abstract Suppl):590A. ">Buch 2014</a>; <a href="./references#CD013751-bbs2-0063" title="NangakuM , FaragYM , deGomaE , LuoW , VargoD , KhawajaZ . Vadadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor, for treatment of anemia of chronic kidney disease: two randomized Phase 2 trials in Japanese patients. Nephrology Dialysis Transplantation 2020 Jul 28 [epub ahead of print]. [MEDLINE: 32719868]NangakuM , KhawajaZ , LuoW , GarafolaS , deGomaE , KomatsuY . Randomized, placebo-controlled phase 2 trials of vadadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), to treat anemia of CKD [abstract no: TH-PO228]. Journal of the American Society of Nephrology2018;29(Abstract Suppl):171. [EMBASE: 633737146]SolinskyC , FaragYM , KhawajaZ , AndersR , LuoW , ChavanA , et al. Impact of vadadustat on iron regulation in Japanese subjects with chronic kidney disease (CKD) [abstract no: 352]. American Journal of Kidney Diseases2020;75(4):638-9. [EMBASE: 2005716872]">DD‐CKD 2020</a>; <a href="./references#CD013751-bbs2-0064" title="2012-004049-34. A four-week, phase IIa, randomized, active-controlled, parallel-group, multi-center study to evaluate the safety, efficacy and pharmacokinetics of switching subjects from a stable dose of recombinant human erythropoietin to GSK1278863 in hemodialysis-dependent subjects with anaemia associated with chronic kidney disease - 4 week switch study in HD subjects. www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2012-004049-342013. GSK116582. A 4 week phase IIa, randomized, active-controlled, parallel-group, multi-center study to evaluate the safety, efficacy and pharmacokinetics of switching subjects from a stable dose of recombinant human erythropoietin to GSK1278863 in hemodialysis-dependent subjects with anemia associated with chronic kidney disease. www.clinicaltrialsregister.eu/ctr-search/trial/2012-004049-34/results2013. ">EudraCT2012‐004049‐34</a>; <a href="./references#CD013751-bbs2-0065" title="GSK116581. A four-week phase IIa, randomized, double-blind, placebo controlled, parallel-group, multi-center study to evaluate the safety, efficacy and pharmacokinetics of GSK1278863 in subjects with anemia associated with chronic kidney disease who are not taking recombinant human erythropoietin and are not undergoing dialysis. www.clinicaltrialsregister.eu/ctr-search/trial/2012-004050-29/results2012. ">EudraCT2012‐004050‐29</a>; <a href="./references#CD013751-bbs2-0066" title="2015-004790-32. A 29-day, randomized, double-blinded, placebo-controlled, parallel-group, multi-center study to evaluate the efficacy, safety and pharmacokinetics of three-times weekly dosing of GSK1278863 in hemodialysis-dependent subjects with anemia associated with chronic kidney disease who are switched from a stable dose of an erythropoiesis-stimulating agent. www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2015-004790-32 2016 Jan 13. ">EudraCT2015‐004790‐32</a>; <a href="./references#CD013751-bbs2-0067" title="FrohnaPA , MilweeS , PinkettJ , LeeT , Moore-PerryK , ChouJ , et al. Preliminary results from a randomized, single-blind, placebo-controlled trial of FG-4592, a novel hypoxia inducible factor prolyl hydroxylase inhibitor, in CKD anemia [abstract no: SU-PO806]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):763A. ">Frohna 2007</a>; <a href="./references#CD013751-bbs2-0069" title="HartmanCS , ShalwitzIR , ShalwitzRA . Controlled hemoglobin response in a double-blind, placebo-controlled trial of AKB-6548 in subjects with chronic kidney disease [abstract no: SO051]. Nephrology Dialysis Transplantation2014;29(Suppl 3):iii22. [EMBASE: 71491516]ShalwitzR , HartmanC , FlinnC , ShalwitzI , PetersKG , BesarabA , et al. AKB-6548, a new hypoxia-inducible factor prolyl hydroxylase inhibitor, increases hemoglobin in chronic kidney disease patients without increasing basal erythropoietin levels [abstract no: FR-OR116]. Journal of the American Society of Nephrology2012;23(Abstract Suppl):56A. ">Hartman 2014</a>; <a href="./references#CD013751-bbs2-0070" title="HoldstockL , MeadowcroftAM , MaierR , JohnsonBM , JonesD , RastogiA , et al. Four-week studies of oral hypoxia-inducible factor-prolyl hydroxylase inhibitor GSK1278863 for treatment of anemia. Journal of the American Society of Nephrology2016;27(4):1234-44. [MEDLINE: 26494831]">Holdstock CKD 2016</a>; <a href="./references#CD013751-bbs2-0071" title="HoldstockL , MeadowcroftAM , MaierR , JohnsonBM , JonesD , RastogiA , et al. Four-week studies of oral hypoxia-inducible factor-prolyl hydroxylase inhibitor GSK1278863 for treatment of anemia. Journal of the American Society of Nephrology2016;27(4):1234-44. [MEDLINE: 26494831]MeadowcroftAM , HoldstockL , MaierR , JonesD , JohnsonB , CobitzAR , et al. Four-week safety, efficacy and pharmacodynamic study of hypoxia-inducible factor (HIF)-prolyl inhibitor GSK1278863 in anemic hemodialysis subjects switching from recombinant human erythropoietin [abstract no: SA-PO1092]. Journal of the American Society of Nephrology2013;24(Abstract Suppl):6B. ">Holdstock HD 2016</a>; <a href="./references#CD013751-bbs2-0072" title="MartinER , SmithMT , MaroniBJ , ZurawQC , deGomaEM . Clinical trial of vadadustat in patients with anemia secondary to stage 3 or 4 chronic kidney disease. American Journal of Nephrology2017;45(5):380-8. [MEDLINE: 28343225]">Martin 2017</a>; <a href="./references#CD013751-bbs2-0074" title="YamamotoH . Safety, tolerability, PK &amp; PD study of JTZ-951 in anemic subjects with end-stage renal disease [Randomized, single-blind, placebo-controlled, multiple ascending dose study to evaluate safety, tolerability, pharmacokinetics &amp; pharmacodynamics of JTZ-951 administered once daily for 15 days in anemic subjects with end-stage renal disease]. www.clinicaltrials.gov/show/NCT01971164 (first received 29 October 2013). ">NCT01971164</a>; <a href="./references#CD013751-bbs2-0075" title="NCT03992066. Study to evaluate the pharmacokinetics, pharmacodynamics, and safety of vadadustat in hemodialysis subjects with anemia associated with chronic kidney disease [A phase 1b, randomized, open-label study to evaluate the pharmacokinetics, pharmacodynamics, and safety of vadadustat in hemodialysis subjects with anemia associated with chronic kidney disease]. www.clinicaltrials.gov/show/NCT03992066 (first received 19 June 2019). ">NCT03992066</a>; <a href="./references#CD013751-bbs2-0077" title="PaiS , KoretomoR , TamakiS , BergJ , MarburyT , GallowayC , et al. JTZ-951, a novel HIF-PHD inhibitor, demonstrates increases in hemoglobin, iron mobilization, reproducible pharmacokinetics, and safety following once daily administration for 15 days in patients with anemia receiving hemodialysis [abstract no: FP658]. Nephrology Dialysis Transplantation2015;30:iii293-4. [EMBASE: 72207075]">Pai 2015</a>; <a href="./references#CD013751-bbs2-0078" title="ParmarD , KansagraK . A phase II trial to assess safety, tolerability and efficacy of phd-2 inhibitor (desidustat-zyan1) in the treatment of anemia in pre-dialysis chronic kidney disease patients [abstract no: MON-318]. Kidney International Reports2019;4(7 Suppl):S430. [EMBASE: 2002179966]ParmarDV , KansagraKA , PatelJC , JoshiSN , SharmaNS , ShelatAD , et al. Outcomes of desidustat treatment in people with anemia and chronic kidney disease: a phase 2 study. American Journal of Nephrology2019;49(6):470-8. [MEDLINE: 31112954]">Parmar 2019</a>; <a href="./references#CD013751-bbs2-0079" title="ProvenzanoR , GoodkinD , KlausS , LindeP , KazaziF , LeeT , et al. Evaluation of FG-4592, a novel oral hypoxia-inducible factor prolyl hydroxylase inhibitor, to treat anemia in hemodialysis patients [abstract no: 253]. American Journal of Kidney Diseases2011;57(4):A80. [EMBASE: 70379812]">Provenzano 2011</a>; <a href="./references#CD013751-bbs2-0080" title="ProvenzanoR , TumlinJ , ZabanehR , ChouJ , HemmerichS , NeffTB , et al. Oral hypoxia-inducible factor prolyl hydroxylase inhibitor roxadustat (FG-4592) for treatment of anemia in chronic kidney disease: a placebo-controlled study of pharmacokinetic and pharmacodynamic profiles in hemodialysis patients. Journal of Clinical Pharmacology2020;60(11):1432-40. [MEDLINE: 32603526]ProvenzanoR , TumlinJ , ZabanehR , LindeP , ChouJ , ZhongM , et al. Pharmacokinetics of oral FG-4592 to treat anemia in hemodialysis (HD) patients (PTS) [abstract no: 254]. American Journal of Kidney Diseases2011;57(4):A80. [EMBASE: 70379813]">Provenzano 2011a</a>; <a href="./references#CD013751-bbs2-0082" title="WiecekA , PiechaG , IgnacyW , SchmidtR , NeumayerHH , ScigallaP , et al. Pharmacological stabilization of HIF increased hemoglobin concentration in anemic patients with chronic kidney disease [abstract no: MO24]. Nephrology Dialysis Transplantation2005;20(Suppl 5):v195. ">Wiecek 2005</a>) </p> </li> <li> <p>Wrong interventions (9 studies: <a href="./references#CD013751-bbs2-0052" title="AkizawaT , HanakiK , AraiM . JTZ-951, an oral novel HIF-PHD inhibitor, elevates hemoglobin in Japanese anemic patients with chronic kidney disease receiving maintenance hemodialysis [abstract no: FO019]. Nephrology Dialysis Transplantation2015;30(Suppl 3):iii10. [EMBASE: 72206300]">Akizawa 2015a</a>; <a href="./references#CD013751-bbs2-0057" title="AkizawaT , UenoM , ShigaT , ReuschM . Oral roxadustat three times weekly in ESA-naive and ESA-converted patients with anemia of chronic kidney disease on hemodialysis: Results from two phase 3 studies. Therapeutic Apheresis &amp; Dialysis2020;24(6):628-41. [MEDLINE: 31891449]">Akizawa 2020g</a>; <a href="./references#CD013751-bbs2-0055" title="AkizawaT , OtsukaT , ReuschM , UenoM . Intermittent oral dosing of roxadustat in peritoneal dialysis chronic kidney disease patients with anemia: a randomized, phase 3, multicenter, open-label study. Therapeutic Apheresis &amp; Dialysis2020;24(2):115-25. [MEDLINE: 31222951]AkizawaT , OtsukaT , ReuschM , UenoM . Phase 3, multicenter, open-label study of intermittent oral roxadustat in peritoneal dialysis CKD patients with anemia [abstract no: SA-OR075]. Journal of the American Society of Nephrology2018;29(Abstract Suppl):99. [EMBASE: 633736837]">Akizawa 2020</a>; <a href="./references#CD013751-bbs2-0056" title="AkizawaT , OtsukaT , YamaguchiY , ReuschM . Phase 3, multicenter, randomized, open-label, non-comparative study of intermittent oral roxadustat in ESA-naive CKD patients not on dialysis in Japan [abstract no: SA-PO226]. Journal of the American Society of Nephrology2019;30(Abstract Suppl):822. [EMBASE: 633767826]AkizawaT , YamaguchiY , OtsukaT , ReuschM . A phase 3, multicenter, randomized, two-arm, open-label study of intermittent oral dosing of roxadustat for the treatment of anemia in Japanese erythropoiesis-stimulating agent-naive chronic kidney disease patients not on dialysis. Nephron2020;144(8):372-82. [MEDLINE: 32580188]">Akizawa 2020b</a>; <a href="./references#CD013751-bbs2-0061" title="BesarabA , ChanDT , DuaSL , FrancoM , HenryE , LeongR , et al. Hypoxia inducing factor prolyl hydroxylase inhibitor FG-4592 corrects anemia in peritoneal dialysis [abstract no: SA-OR087]. Journal of the American Society of Nephrology2013;24(Abstract Suppl):91A. BesarabA , ChernyavskayaE , MotylevI , ShutovE , KumbarLM , GurevichK , et al. Roxadustat (FG-4592): correction of anemia in incident dialysis patients. Journal of the American Society of Nephrology2016;27(4):1225-33. [MEDLINE: 26494833]BesarabA , ChernyavskayaEN , MotylevI , EvgenyS , YampolskiyAF , KumbarLM , et al. FG-4592, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor, corrects anemia without iron supplementation in incident dialysis patients [abstract no: TH-OR096]. Journal of the American Society of Nephrology2012;23(Abstract Suppl):21A. BesarabA , SzczechL , YuKH , NeffTB . Impact of iron regimen on iron indices and hepcidin during roxadustat anemia correction in incident dialysis patients [abstract no: TH-PO847]. Journal of the American Society of Nephrology2014;25(Abstract Suppl):304a. ">Besarab 2016</a>; <a href="./references#CD013751-bbs2-0068" title="HaaseVH , KhawajaZ , ChanJ , ZurawQ , Farzaneh-FarR , MaroniBJ , et al. Vadadustat maintains hemoglobin (Hb) levels in dialysis-dependent chronic kidney disease (DD-CKD) patients independent of systemic inflammation or prior dose of erythropoiesis-stimulating agent (ESA) [abstract no: TH-PO960]. Journal of the American Society of Nephrology2016;27(Abstract Suppl):318A. ">Haase 2016</a>; <a href="./references#CD013751-bbs2-0073" title="NCT01679587. Dose escalation study to investigate safety, tolerability, pharmacodynamics, and pharmacokinetics of BAY85-3934 in subjects with chronic kidney disease (CKD) [A multicenter, randomized, single-blind, placebo-controlled, combined 2-fold cross-over and group-comparison, dose-escalation study to investigate safety, tolerability, pharmacodynamics, and pharmacokinetics of single oral doses of BAY 85-3934 in subjects with chronic kidney disease (CKD)]. www.clinicaltrials.gov/show/NCT01679587 (first received 6 September 2012). ">NCT01679587</a>; <a href="./references#CD013751-bbs2-0076" title="NCT04059913. Evaluate the efficacy and safety of multiple roxadustat dosing regimens for the treatment of anemia in dialysis subjects with chronic kidney disease [A prospective, randomized, open-label, multi-center study to evaluate the efficacy and safety of multiple roxadustat dosing regimens for the treatment of anemia in dialysis subjects with chronic kidney disease]. www.clinicaltrials.gov/show/NCT04059913 (first received 16 August 2019). ">NCT04059913</a>; <a href="./references#CD013751-bbs2-0081" title="BesarabA , BeloD , DiamondS , MartinE , SunC , LeeT , et al. Evaluation of hypoxia-inducible factor prolyl hydroxylase inhibitor FG-4592 for hemoglobin correction and maintenance in nondialysis chronic kidney disease patients for 16 and 24 weeks [abstract no: FP215]. Nephrology Dialysis Transplantation2012;27(Suppl 2):ii144-5. [EMBASE: 70765709]BesarabA , ProvenzanoR , FishbaneS , SunCH , BeloDS , NeffTB , et al. FG-4592 oral hypoxia-inducible factor prolyl hydroxylase inhibitor corrects anemia in nondialysis CKD patients without IV iron [abstract no: TH-PO364]. Journal of the American Society of Nephrology2011;22(Abstract Suppl):196A. ProvenzanoR , BesarabA , SunCH , DiamondSA , DurhamJH , CangianoJL , et al. Oral hypoxia-inducible factor prolyl hydroxylase inhibitor roxadustat (FG-4592) for the treatment of anemia in patients with CKD. Clinical Journal of the American Society of Nephrology: CJASN2016;11(6):982-91. [MEDLINE: 27094610]">Provenzano 2016b</a>). </p> </li> </ul> </p> <section id="CD013751-sec-0052"> <h5 class="title">Ongoing studies</h5> <p>Our search identified eight studies that have yet to be completed.</p> <p> <ul id="CD013751-list-0016"> <li> <p>Daprodustat versus darbepoetin alfa (<a href="./references#CD013751-bbs2-0084" title="NCT03446612. Anemia study in chronic kidney disease (CKD) : erythropoiesis via a novel prolyl hydroxylase inhibitor (PHI) daprodustat -forearm blood flow (ASCEND-FBF) [A randomized, repeat dose, open label, parallel group, multi-center study to evaluate the effect of daprodustat compared to darbepoetin alfa on forearm blood flow in participants with anemia of chronic kidney disease that are not dialysis dependent]. www.clinicaltrials.gov/show/NCT03446612 (first received 27 February 2018). ">ASCEND‐FBF 2018</a>) </p> </li> <li> <p>Desidustat versus darbepoetin (<a href="./references#CD013751-bbs2-0085" title="KansagraK . Desidustat in the treatment of anemia in chronic kidney disease (CKD) [A phase 3, multicenter, multicountry, open-label, randomized, active-controlled clinical trial to evaluate the efficacy and safety of desidustat versus darbepoetin for the treatment of anemia in patients with chronic kidney disease (CKD) who are not on dialysis.]. ctri.nic.in/Clinicaltrials/showallp.php?mid1=33329&amp;EncHid=&amp;userName=CTRI/2019/06/019635 (first received 12 June 2019). ">CTRI/2019/06/019635</a>; <a href="./references#CD013751-bbs2-0091" title="NazarAL . A randomized, active-controlled clinical trial to evaluate the efficacy and safety of desidustat versus darbepoetin for the treatment of anemia in patients with chronic kidney disease (CKD) who are not on dialysis [A phase 3, multicenter, multi-country, open-label, randomized, active-controlled clinical trial to evaluate the efficacy and safety of desidustat versus darbepoetin for the treatment of anemia in patients with chronic kidney disease (CKD) who are not on dialysis]. slctr.lk/trials/slctr-2019-032 (first received 13 August 2019). ">SLCTR‐2019‐032</a>) </p> </li> <li> <p>Desidustat versus epoetin alfa (<a href="./references#CD013751-bbs2-0086" title="KansagraK . Desidustat in the treatment of anemia in CKD. ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=36915&amp;EncHid=&amp;userName=CTRI/2019/12/022312 (first received 11 December 2019). ">DREAM‐D 2019</a>) </p> </li> <li> <p>Enarodustat versus darbepoetin alfa (<a href="./references#CD013751-bbs2-0087" title="LeeJW . A study to evaluate efficacy and safety of JTZ-951 compared to darbepoetin alfa in Korean renal anemia patients receiving hemodialysis [A multi-center, randomized, open-label, active-controlled, parallel-group, phase iii study to compare the efficacy and safety of JTZ-951 with darbepoetin alfa in anemic patients with chronic kidney disease receiving maintenance hemodialysis]. www.clinicaltrials.gov/show/NCT04027517 (first received 22 July 2019). ">NCT04027517</a>) </p> </li> <li> <p>Roxadustat versus epoetin alfa (<a href="./references#CD013751-bbs2-0088" title="LiuH . Evaluate the efficacy and safety of roxadustat for the treatment of anemia and risks of cardiovascular and cerebrovascular events in ESRD newly initiated dialysis patients [Phase 4 multicenter, randomized, open-lable, active-controlled study of the efficacy and safty of roxadustat for the treatment of anemia and risks of cardiovascular and cerebrovascular events in incident-dialysis patients]. www.clinicaltrials.gov/show/NCT04134026 (first received 21 October 2019). ">NCT04134026</a>; <a href="./references#CD013751-bbs2-0090" title="PER-038-14. A phase 3, multicenter, randomized, open-label active-controlled study of the efficacy and safety of FG-4592 in the treatment of anemia in incident-dialysis patients. www.ins.gob.pe/ensayosclinicos/rpec/recuperarECPBNuevoEN.asp?numec=038-14 (first received 11 December 2014). ">PER‐038‐14</a>) </p> </li> <li> <p>Vadadustat versus darbepoetin alfa (<a href="./references#CD013751-bbs2-0089" title="NCT04313153. Trial evaluating the efficacy and safety of oral vadadustat once daily (QD) and three times weekly (TIW) for the maintenance treatment of anemia in hemodialysis subjects converting from erythropoiesis-stimulating agents (ESAs) [Phase 3b, randomized, open-label, active-controlled trial evaluating the efficacy and safety of oral vadadustat once daily (QD) and three times weekly (TIW) for the maintenance treatment of anemia in hemodialysis subjects converting from erythropoiesis-stimulating agents (ESAs)]. www.clinicaltrials.gov/show/NCT04313153 (first received 18 March 2020). ">NCT04313153</a>) </p> </li> </ul> </p> </section> </section> </section> <section id="CD013751-sec-0053"> <h3 class="title">Risk of bias in included studies</h3> <p>The risk of bias for studies overall are summarised in <a href="#CD013751-fig-0002">Figure 2</a> and the risk of bias in each study is shown in <a href="#CD013751-fig-0003">Figure 3</a>. </p> <div class="figure" id="CD013751-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD013751-fig-0002" src="/cdsr/doi/10.1002/14651858.CD013751.pub2/media/CDSR/CD013751/image_n/nCD013751-FIG-02.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <div class="figure" id="CD013751-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD013751-fig-0003" src="/cdsr/doi/10.1002/14651858.CD013751.pub2/media/CDSR/CD013751/image_n/nCD013751-FIG-03.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD013751-sec-0054"> <h4 class="title">Allocation</h4> <section id="CD013751-sec-0055"> <h5 class="title">Random sequence generation</h5> <p>Methods for generating the random sequence were at low risk of bias in 22 studies (<a href="./references#CD013751-bbs2-0002" title="AkizawaT , IwasakiM , OtsukaT , ReuschM , MisumiT . Roxadustat for the treatment of chronic kidney disease-associated anemia in Japanese patients not on dialysis [abstract no: FR-PO1142]. Journal of the American Society of Nephrology2016;27(Abstract Suppl):7B. AkizawaT , IwasakiM , OtsukaT , ReuschM , MisumiT . Roxadustat treatment of chronic kidney disease-associated anemia in Japanese patients not on dialysis: a phase 2, randomized, double-blind, placebo-controlled trial. Advances in Therapy2019;36(6):1438-54. [MEDLINE: 30953333]">Akizawa 2019</a>; <a href="./references#CD013751-bbs2-0003" title="AkizawaT , IwasakiM , YamaguchiY , MajikawaY , ReuschM . Authors' Reply. Journal of the American Society of Nephrology2021;32(4):1005-7. [MEDLINE: 33649099]AkizawaT , IwasakiM , YamaguchiY , MajikawaY , ReuschM . Phase 3, randomized, double-blind, active-comparator (darbepoetin alfa) conversion study of oral roxadustat in CKD patients with anemia on hemodialysis in Japan [abstract no: TH-PO1151]. Journal of the American Society of Nephrology2018;29(Abstract Suppl):B4. AkizawaT , IwasakiM , YamaguchiY , MajikawaY , ReuschM . Phase 3, randomized, double-blind, active-comparator (darbepoetin alfa) study of oral roxadustat in CKD patients with anemia on hemodialysis in Japan. Journal of the American Society of Nephrology2020;31(7):1628-39. [MEDLINE: 32493693]AkizawaT , YamaguchiY , MajikawaY , ReuschM . Factors affecting the doses of roxadustat vs darbepoetin alfa for anemia treatment in hemodialysis patients. Therapeutic Apheresis &amp; Dialysis2021;25(5):575-85. [MEDLINE: 33200512]Astellas1517-CL-0307. A study of intermittent oral dosing of ASP1517 in hemodialysis chronic kidney disease patients with anemia [A phase 3, multi-center, randomized, 2-arm parallel, double-blind, active-comparator (darbepoetin alfa) conversion study of intermittent oral dosing of ASP1517 in hemodialysis chronic kidney disease patients with anemia]. www.clinicaltrials.astellas.com/study/?pid=1517-CL-0307 (accessed 4 May 2022). LiuF , WangJ , YeQ , FuH , MaoJ . Roxadustat for renal anemia in ESRD from PKD patients: is it safe enough?Journal of the American Society of Nephrology2021;32(4):1005. [MEDLINE: 33649100]NguyenQD , SepahYJ , YamaguchiY , OtsukaT , MajikawaY , ReuschM , et al. Ophthalmological effects of roxadustat in the treatment of anemia in dialysis-dependent and non-dialysis-dependent CKD patients: findings from two phase 3 studies [abstract no: PO0267]. Journal of the American Society of Nephrology2020;31(Abstract Suppl):134. [EMBASE: 633698979]SepahY , NguyenQD , YamaguchiY , MajikawaY , ReuschM , AkizawaT . Ophthalmological effects of roxadustat in the treatment of anaemia in chronic kidney disease patients on dialysis in a phase 3, randomised, double-blind, active-comparator conversion study [abstract no: MO002]. Nephrology Dialysis Transplantation2020;35(Suppl 3):iii102. [EMBASE: 633421367]">Akizawa 2020a</a>; <a href="./references#CD013751-bbs2-0004" title="AkizawaT , NangakuM , YonekawaT , OkudaN , KawamatsuS , OnoueT , et al. Efficacy and safety of daprodustat compared with darbepoetin alfa in Japanese hemodialysis patients with anemia: a randomized, double-blind, phase 3 trial. Clinical Journal of the American Society of Nephrology: CJASN2020;15(8):1155-65. [MEDLINE: 32723804]OzekiH , AkizawaT , NangakuM , YonekawaT , OkudaN , KawamatsuS , et al. Efficacy and safety of daprodustat compared with darbepoetin alfa in Japanese hemodialysis patients with anemia: A randomized, double-blind, phase 3 trial [abstract no: SaO036]. Nephrology Dialysis Transplantation2019;34(Suppl 1):a350. [EMBASE: 631305259]">Akizawa 2020c</a>; <a href="./references#CD013751-bbs2-0008" title="CoyneDW , RogerSD , ChouW , BesarabA , LeongR , LeeTT , et al. Roxadustat favorably modifies iron indices in patients with non-dialysis-dependent CKD-related anemia [abstract no: PO0262]. Journal of the American Society of Nephrology2020;31(Abstract Suppl):132. [EMBASE: 633698686]CoyneDW , RogerSD , ShinS , KimSG , CadenaAA , MoustafaMA , et al. Roxadustat for CKD-related anemia in non-dialysis patients. Kidney International Reports2021;6(3):624-35. [MEDLINE: 33732977]CoyneDW , RogerSD , ShinSK , KimSG , CadenaAA , MoustafaMA , et al. ANDES: A phase 3, randomized, double-blind, placebo controlled study of the efficacy and safety of roxadustat for the treatment of anemia in CKD patients not on dialysis [abstract no: SA-PO0228]. Journal of the American Society of Nephrology2019;30(Abstract Suppl):822-3. [EMBASE: 633767955]Pecoits-FilhoR , ChanTM , HardyE , YuKHP , FishbaneS . Roxadustat treatment results in consistent improvements in hemoglobin (Hb) vs. placebo: an analysis of three multinational randomized clinical trials in patients with non-dialysis-dependent CKD (NDD-CKD) [abstract no: TH-OR05]. Journal of the American Society of Nephrology2020;31(Abstract Suppl):2. [EMBASE: 633697943]RastogiA , Pecoits-FilhoR , FishbaneS , LittleDJ , HardyE , YuKH , et al. Roxadustat treatment corrects anemia to hemoglobin (HB) values ≥10 g/dL in the majority of patients with non-dialysis-dependent chronic kidney disease (NDD-CKD) [abstract no: PO0264]. Journal of the American Society of Nephrology2020;31(Abstract Suppl):133. [EMBASE: 633698803]">ANDES 2021</a>; <a href="./references#CD013751-bbs2-0009" title="SinghAK , BlackorbyA , CizmanB , CarrollK , CobitzAR , DaviesR , et al. Study design and baseline characteristics of patients on dialysis in the ASCEND-D trial. Nephrology Dialysis Transplantation2021;37(5):960-72. [MEDLINE: 33744933] [MEDLINE: 33744933]SinghAK , BlackorbyA , CizmanB , CobitzAR , GodoySA , JhaV , et al. Regional variation of erythropoietin-stimulating agent hyporesponsiveness in the global daprodustat dialysis study (ASCEND-D) [abstract no: TH-OR08]. Journal of the American Society of Nephrology2020;31(Abstract Suppl):3. [EMBASE: 633698062]SinghAK , CarrollK , PerkovicV , SolomonS , JhaV , JohansenKL , et al. Daprodustat for the treatment of anemia in patients undergoing dialysis. New England Journal of Medicine2021;385(25):2325-35. [MEDLINE: 34739194]">ASCEND‐D 2021</a>; <a href="./references#CD013751-bbs2-0011" title="PerkovicV , BlackorbyA , CizmanB , CarrollK , CobitzA , DaviesR , et al. ASCEND-ND: Study design and baseline characteristics. Nephrology Dialysis Transplantation2021;36(Suppl 1):i334-5. [EMBASE: 635918331]SinghAK , CarrollK , McMurrayJJ , SolomonS , JhaV , JohansenKL , et al. Daprodustat for the treatment of anemia in patients not undergoing dialysis. New England Journal of Medicine2021;385(25):2313-24. [MEDLINE: 34739196]">ASCEND‐ND 2021</a>; <a href="./references#CD013751-bbs2-0020" title="AkizawaT , MacdougallIC , BernsJS , BernhardtT , TaguchiM , OguraE , et al. Iron regulation by molidustat, bay 85-3934, a daily oral hypoxia-inducible factor prolyl hydroxylase inhibitor in patients with chronic kidney disease [abstract no: SP334]. Nephrology Dialysis Transplantation2018;33(Suppl 1):i457. [EMBASE: 622606520]AkizawaT , MacdougallIC , BernsJS , YamamotoH , TaguchiM , IekushiK , et al. Iron regulation by molidustat, a daily oral hypoxia-inducible factor prolyl hydroxylase inhibitor, in patients with chronic kidney disease. Nephron2019;143(4):243-54. [MEDLINE: 31387097]MacdougallIC , AkizawaT , BernsJ , LentiniS , BernhardtT . Molidustat increases haemoglobin in erythropoiesis stimulating agents (ESA)-naive anaemic patients with chronic kidney disease not on dialysis (CKD-ND) [abstract no: SO036]. Nephrology Dialysis Transplantation2016;31(Suppl 1):i16. [EMBASE: 72325954]MacdougallIC , AkizawaT , BernsJS , BernhardtT , KruegerT . Effects of molidustat in the treatment of anemia in CKD [Erratum in: Clin J Am Soc Nephrol. 2019 Oct 7;14(10):1524]. Clinical Journal of the American Society of Nephrology: CJASN2019;14(1):28-39. [MEDLINE: 30559105]MacdougallIC , BernsJS , AkizawaT , FishbaneS , BernhardtT . DIALOGUE phase 2 program for BAY85-3934 a HIF-PH inhibitor with daily oral treatment in anemic patients suffering from CKD/ESRD [abstract no: FR-PO219]. Journal of the American Society of Nephrology2013;24(Abstract Suppl):413A. ">DIALOGUE 1 2019</a>; <a href="./references#CD013751-bbs2-0021" title="AkizawaT , MacdougallIC , BernsJS , YamamotoH , TaguchiM , IekushiK , et al. Iron regulation by molidustat, a daily oral hypoxia-inducible factor prolyl hydroxylase inhibitor, in patients with chronic kidney disease. Nephron2019;143(4):243-54. [MEDLINE: 31387097]MacdougallIC , AkizawaT , BernsJ , LentiniS , BernhardtT , KrugerT . Safety and efficacy of molidustat in erythropoiesis stimulating agents (ESA) pre-treated anaemic patients with chronic kidney disease not on dialysis (CKD-ND) [abstract no: SP309]. Nephrology Dialysis Transplantation2016;31(Suppl 1):i193. [EMBASE: 72326411]MacdougallIC , AkizawaT , BernsJ , LentiniS , BernhardtT . Molidustat increases haemoglobin in erythropoiesis stimulating agents (ESA)-naive anaemic patients with chronic kidney disease not on dialysis (CKD-ND) [abstract no: SO036]]. Nephrology Dialysis Transplantation2016;31(Suppl 1):i16. [EMBASE: 72325954]MacdougallIC , AkizawaT , BernsJS , BernhardtT , KruegerT . Effects of molidustat in the treatment of anemia in CKD [Erratum in: Clin J Am Soc Nephrol. 2019 Oct 7;14(10):1524]. Clinical Journal of the American Society of Nephrology: CJASN2019;14(1):28-39. [MEDLINE: 30559105]MacdougallIC , BernsJS , AkizawaT , FishbaneS , BernhardtT . DIALOGUE phase 2 program for BAY85-3934 a HIF-PH inhibitor with daily oral treatment in anemic patients suffering from CKD/ESRD [abstract no: FR-PO219]. Journal of the American Society of Nephrology2013;24(Abstract Suppl):413A. ">DIALOGUE 2 2019</a>; <a href="./references#CD013751-bbs2-0022" title="AkizawaT , MacdougallIC , BernsJS , YamamotoH , TaguchiM , IekushiK , et al. Iron regulation by molidustat, a daily oral hypoxia-inducible factor prolyl hydroxylase inhibitor, in patients with chronic kidney disease. Nephron2019;143(4):243-54. [MEDLINE: 31387097]MacdougallIC , AkizawaT , BernsJ , LentiniS , BernhardtT . Molidustat increases haemoglobin in erythropoiesis stimulating agents (ESA)-naive anaemic patients with chronic kidney disease not on dialysis (CKD-ND) [abstract no: SO036]. Nephrology Dialysis Transplantation2016;31(Suppl 1):i16. [EMBASE: 72325954]MacdougallIC , AkizawaT , BernsJS , BernhardtT , KruegerT . Effects of molidustat in the treatment of anemia in CKD [Erratum in: Clin J Am Soc Nephrol. 2019 Oct 7;14(10):1524]. Clinical Journal of the American Society of Nephrology: CJASN2019;14(1):28-39. [MEDLINE: 30559105]MacdougallIC , BernsJS , AkizawaT , FishbaneS , BernhardtT . DIALOGUE phase 2 program for BAY85-3934 a HIF-PH inhibitor with daily oral treatment in anemic patients suffering from CKD/ESRD [abstract no: FR-PO219]. Journal of the American Society of Nephrology2013;24(Abstract Suppl):413A. ">DIALOGUE 4 2019</a>; <a href="./references#CD013751-bbs2-0024" title="ProvenzanoM , EvgenyS , LiubovE , KorneyevaS , KathresalAA , PooleL , et al. HIMALAYAS: a phase 3, randomized, open-label, active-controlled study of the efficacy and safety of roxadustat in the treatment of anemia in incident-dialysis patients [abstract no: TH-OR021]. Journal of the American Society of Nephrology2019;30(Abstract Suppl):5. [EMBASE: 633771140]ProvenzanoR , ShutovE , EremeevaL , KorneyevaS , PooleL , SahaG , et al. Roxadustat for anemia in patients with end-stage renal disease incident to dialysis. Nephrology Dialysis Transplantation2021;36(9):1717-30. [MEDLINE: 33629100]">HIMALAYAS 2021</a>; <a href="./references#CD013751-bbs2-0025" title="CizmanB , AckertJ , MeadowcroftA , BiswasN , KellyD , KleinmanD , et al. Ocular safety profile of daprodustat: results of two 24 week studies [abstract no: SAO004]. Nephrology Dialysis Transplantation2018;33(Suppl 1):i316. [EMBASE: 622604997]HoldstockL , CizmanB , MeadowcroftAM , BiswasN , JohnsonBM , JonesD , et al. Daprodustat for anemia: a 24-week, open-label, randomized controlled trial in participants with chronic kidney disease. Clinical Kidney Journal2019;12(1):129-38. [MEDLINE: 30746140]HoldstockL , CizmanB , MeadowcroftAM , BiswasN , JonesD , JohnsonBM , et al. Daprodustat, a HIF-prolyl-hydroxylase inhibitor, increases and maintains hemoglobin over 24 weeks in anemic chronic kidney disease subjects [abstract no: TH-PO908]. Journal of the American Society of Nephrology2016;27(Abstract Suppl):304A. ">Holdstock 2019</a>; <a href="./references#CD013751-bbs2-0026" title="CizmanB , AckertJ , MeadowcroftA , BiswasN , KellyD , KleinmanD , et al. Ocular safety profile of daprodustat: results of two 24 week studies [abstract no: SAO004]. Nephrology Dialysis Transplantation2018;33(Suppl 1):i316. [EMBASE: 622604997]HoldstockL , CizmanB , MeadowcroftAM , BiswasN , JohnsonBM , JonesD , et al. Daprodustat for anemia: a 24-week, open-label, randomized controlled trial in participants with chronic kidney disease. Clinical Kidney Journal2019;12(1):129-38. [MEDLINE: 30746140]HoldstockL , CizmanB , MeadowcroftAM , BiswasN , JonesD , JohnsonBM , et al. Daprodustat, a HIF-prolyl-hydroxylase inhibitor, increases and maintains hemoglobin over 24 weeks in anemic chronic kidney disease subjects [abstract no: TH-PO908]. Journal of the American Society of Nephrology2016;27(Abstract Suppl):304A. ">Holdstock 2019a</a>; <a href="./references#CD013751-bbs2-0030" title="CizmanB , AckertJ , MeadowcroftA , BiswasN , KellyD , KleinmanD , et al. Ocular safety profile of daprodustat: results of two 24 week studies [abstract no: SAO004]. Nephrology Dialysis Transplantation2018;33(Suppl 1):i316. [EMBASE: 622604997]CobitzAR , MeadowcroftAM , CizmanB , HoldstockL , BiswasN , JonesD , et al. Daprodustat, a HIF-prolyl-hydroxylase inhibitor, maintains hemoglobin levels over 24 weeks in anemic hemodialysis subjects switching from recombinant human erythropoietin. [abstract no: SA-OR114]. Journal of the American Society of Nephrology2016;27(Abstract Suppl):93A. MeadowcroftAM , CizmanB , HoldstockL , BiswasN , JohnsonBM , JonesD , et al. Daprodustat for anemia: a 24-week, open-label, randomized controlled trial in participants on hemodialysis. Clinical Kidney Journal2019;12(1):139-48. [MEDLINE: 30746141]">Meadowcroft 2019</a>; <a href="./references#CD013751-bbs2-0031" title="AkizawaT , TaguchiM , MatsudaY , IekushiK , YamadaT , YamamotoH . Molidustat for the treatment of renal anaemia in patients with dialysis-dependent chronic kidney disease: Design and rationale of three phase III studies. BMJ Open2019;9(6):e026602. [MEDLINE: 31203241]AkizawaT , YamadaT , NoboriK , MatsudaY , HayashiY , HayasakiT , et al. Molidustat for Japanese patients with renal anemia receiving dialysis. Kidney International Reports2021;6(10):2604–16. [MEDLINE: 34622100]AkizawaT , YamadaT , NoboriK , MatsudaY , HayashiY , HayasakiT , et al. Results from a phase 3 study comparing the efficacy and safety of molidustat vs. Darbepoetin Alfa in patients receiving hemodialysis and treated with erythropoiesis-stimulating agents (ESAS) [abstract no: PO22623]. Journal of the American Society of Nephrology2020;31(Abstract Suppl):B4. [EMBASE: 633697376]">MIYABI HD‐M 2019</a>; <a href="./references#CD013751-bbs2-0032" title="YamamotoH , NoboriK , MatsudaY , HayashiY , HayasakiT , AkizawaT . Efficacy and safety of molidustat for anemia in ESA-naive nondialysis patients: a randomized, phase 3 trial. American Journal of Nephrology2021;52(10-11):871-83. [MEDLINE: 34569489]YamamotoH , TaguchiM , MatsudaY , IekushiK , YamadaT , AkizawaT . Molidustat for the treatment of renal anaemia in patients with non-dialysis-dependent chronic kidney disease: design and rationale of two phase III studies. BMJ Open2019;9(6):e026704. [MEDLINE: 31203242]YamamotoH , TaguchiM , NoboriK , MatsudaY , IekushiK , AkizawaT . To investigate the efficacy and safety of molidustat in non-dialysis patients with renal anemia who are not treated with erythropoiesis stimulating agents: MIYABI ND-C [abstract no: P1866]. Nephrology Dialysis Transplantation2020;35(Suppl 3):iii2177. [EMBASE: 633422996]">MIYABI ND‐C 2019</a>; <a href="./references#CD013751-bbs2-0033" title="YamamotoH , NoboriK , MatsudaY , HayashiY , HayasakiT , AkizawaT . Molidustat for renal anemia in nondialysis patients previously treated with erythropoiesis-stimulating agents: a randomized, open-label, phase 3 study. American Journal of Nephrology2021;52(10-11):884-93. [MEDLINE: 34569482]YamamotoH , TaguchiM , MatsudaY , IekushiK , YamadaT , AkizawaT . Molidustat for the treatment of renal anaemia in patients with non-dialysis-dependent chronic kidney disease: design and rationale of two phase III studies. BMJ Open2019;9(6):e026704. [MEDLINE: 31203242]YamamotoH , TaguchiM , NoboriK , MatsudaY , IekushiK , AkizawaT . To investigate the efficacy and safety of molidustat in non-dialysis patients with renal anemia who are treated with erythropoiesis stimulating agents: Miyabi ND-M [Abstract no: P1868]. Nephrology Dialysis Transplantation2020;35(Suppl 3):iii2179. [EMBASE: 633423006]">MIYABI ND‐M 2019</a>; <a href="./references#CD013751-bbs2-0035" title="NangakuM , KondoK , KokadoY , UetaK , KanekoG , ShiosakaM , et al. Randomized, open-label, active-controlled (darbepoetin alfa), phase 3 study of vadadustat for treating anemia in non-dialysis-dependent CKD patients in Japan [abstract no: SA-PO229]. Journal of the American Society of Nephrology2019;30(Abstract Suppl):823. [EMBASE: 633767995]NangakuM , KondoK , KokadoY , UetaK , KanekoG , TandaiT , et al. Phase 3 randomized study comparing vadadustat with darbepoetin alfa for anemia in Japanese patients with nondialysis-dependent CKD. Journal of the American Society of Nephrology2021;32(7):1779-90. [MEDLINE: 33883252]">Nangaku 2021a</a>; <a href="./references#CD013751-bbs2-0036" title="GSK201753. A 52-week, Phase III, open-label, multi-center study to evaluate efficacy and safety of GSK1278863 in Japanese non-dialysis and peritoneal dialysis subjects with anemia associated with chronic kidney disease [study protocol]. www.clinicaltrials.gov/ProvidedDocs/63/NCT02791763/Prot_000.pdf (accessed 9 May 2022). NangakuM , HamanoT , AkizawaT , TsubakiharaY , NagaiR , OkudaN , et al. Daprodustat compared with epoetin beta pegol for anemia in Japanese patients not on dialysis: a 52-week randomized open-label phase 3 trial. American Journal of Nephrology2021;52(1):26-35. [MEDLINE: 33561857]">Nangaku 2021b</a>; <a href="./references#CD013751-bbs2-0037" title="Astellas1517-CL-0304. A study to investigate the effect of ASP1517 after intermittent oral dosing in dialysis chronic kidney disease patients with anemia compared with darbepoetin as a reference drug [A Japanese, phase 2, multicenter, randomized, 4-arm parallel, double-blind (arms 1-3), open-label (arm 4), active-comparator (darbepoetin alfa) study of intermittent oral dosing of asp1517 in hemodialysis-dependent chronic kidney disease patients with anemia [1517-CL-0304 clinical study results report]]. www.trialsummaries.com/Study/StudyDetails?id=14175&amp;tenant=MT_AST_9011; www.clinicaltrials.gov/ct2/show/NCT01888445 (first received 6 August 2018). ">NCT01888445</a>; <a href="./references#CD013751-bbs2-0040" title="AstraZeneca. A phase 3, multicenter, randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of roxadustat for the treatment of anemia in chronic kidney disease patients not on dialysis [clinical study protocol V6; 31 August 2018]. www.clinicaltrials.gov/ProvidedDocs/27/NCT02174627/Prot_000.pdf (accessed 9 May 2022). EleftheriadisT , PissasG , LiakopoulosV , StefanidisI . On the increased event rate of urinary tract infection and pneumonia in CKD patients treated with roxadustat for anemia. Journal of the American Society of Nephrology2021;32(6):1537. [MEDLINE: 33849917]FishbaneS , El-ShahawyMA , Pecoits-FilhoR , VanBP , HouserMT , FrisonL , et al. OLYMPUS: a phase 3, randomized, double-blind, placebo-controlled, international study of roxadustat efficacy in patients with non-dialysis-dependent (NDD) CKD and anemia [abstract no: TH-OR023]. Journal of the American Society of Nephrology2019;30(Abstract Suppl):6. [EMBASE: 633771285]FishbaneS , El-ShahawyMA , Pecoits-FilhoR , VanBP , HouserMT , FrisonL , et al. Roxadustat for treating anemia in patients with CKD not on dialysis: results from a randomized phase 3 study. Journal of the American Society of Nephrology2021;32(3):737-55. [MEDLINE: 33568383]FishbaneS , El-ShahawyMA , VanBP , LittleDJ . Authors' Reply. Journal of the American Society of Nephrology2021;32(6):1537-8. [MEDLINE: 33849916]Pecoits-FilhoR , ChanTM , HardyE , YuKH , FishbaneS . Roxadustat treatment results in consistent improvements in hemoglobin (Hb) vs. placebo: an analysis of three multinational randomized clinical trials in patients with non-dialysis-dependent CKD (NDD-CKD) [abstract no: TH-OR05]. Journal of the American Society of Nephrology2020;31(Abstract Suppl):2. [EMBASE: 633697943]RastogiA , Pecoits-FilhoR , FishbaneS , LittleDJ , HardyE , YuKH , et al. Roxadustat treatment corrects anemia to hemoglobin (HB) values ≥10 g/dL in the majority of patients with non-dialysis-dependent chronic kidney disease (NDD-CKD) [abstract no: PO0264]. Journal of the American Society of Nephrology2020;31(Abstract Suppl):133. [EMBASE: 633698803]">OLYMPUS 2021</a>; <a href="./references#CD013751-bbs2-0049" title="CharytanC , Manllo-KarimR , MartinER , SteerD , BernardoM , DuaSL , et al. A randomized trial of roxadustat in anemia of kidney failure: SIERRAS study. Kidney International Reports2021;6(7):1829-39. [MEDLINE: 34307977]CharytanC , Manllo-KarimR , MartinER , SteerD , BernardoM , DuaSL , et al. SIERRAS: A phase 3, open-label, randomized, active-controlled study of the efficacy and safety of roxadustat in the maintenance treatment of anemia in subjects with ESRD on stable dialysis [abstract no: SA-PO227]. Journal of the American Society of Nephrology2019;30(Abstract Suppl):822. [EMBASE: 633767862]">SIERRAS 2021</a>; <a href="./references#CD013751-bbs2-0051" title="AkizawaT , NangakuM , YamaguchiT , KoretomoR , MaedaK , MiyazawaY , et al. A phase 3 study of enarodustat in anemic patients with CKD not requiring dialysis: the SYMPHONY ND study. Kidney International Reports2021;6(7):1840-9. [MEDLINE: 34307978]">SYMPHONY ND 2021</a>). The method for generating the random sequence was unclear in 29 studies. </p> </section> <section id="CD013751-sec-0056"> <h5 class="title">Allocation concealment</h5> <p>Allocation concealment was at low risk of bias in 19 studies (<a href="./references#CD013751-bbs2-0003" title="AkizawaT , IwasakiM , YamaguchiY , MajikawaY , ReuschM . Authors' Reply. Journal of the American Society of Nephrology2021;32(4):1005-7. [MEDLINE: 33649099]AkizawaT , IwasakiM , YamaguchiY , MajikawaY , ReuschM . Phase 3, randomized, double-blind, active-comparator (darbepoetin alfa) conversion study of oral roxadustat in CKD patients with anemia on hemodialysis in Japan [abstract no: TH-PO1151]. Journal of the American Society of Nephrology2018;29(Abstract Suppl):B4. AkizawaT , IwasakiM , YamaguchiY , MajikawaY , ReuschM . Phase 3, randomized, double-blind, active-comparator (darbepoetin alfa) study of oral roxadustat in CKD patients with anemia on hemodialysis in Japan. Journal of the American Society of Nephrology2020;31(7):1628-39. [MEDLINE: 32493693]AkizawaT , YamaguchiY , MajikawaY , ReuschM . Factors affecting the doses of roxadustat vs darbepoetin alfa for anemia treatment in hemodialysis patients. Therapeutic Apheresis &amp; Dialysis2021;25(5):575-85. [MEDLINE: 33200512]Astellas1517-CL-0307. A study of intermittent oral dosing of ASP1517 in hemodialysis chronic kidney disease patients with anemia [A phase 3, multi-center, randomized, 2-arm parallel, double-blind, active-comparator (darbepoetin alfa) conversion study of intermittent oral dosing of ASP1517 in hemodialysis chronic kidney disease patients with anemia]. www.clinicaltrials.astellas.com/study/?pid=1517-CL-0307 (accessed 4 May 2022). LiuF , WangJ , YeQ , FuH , MaoJ . Roxadustat for renal anemia in ESRD from PKD patients: is it safe enough?Journal of the American Society of Nephrology2021;32(4):1005. [MEDLINE: 33649100]NguyenQD , SepahYJ , YamaguchiY , OtsukaT , MajikawaY , ReuschM , et al. Ophthalmological effects of roxadustat in the treatment of anemia in dialysis-dependent and non-dialysis-dependent CKD patients: findings from two phase 3 studies [abstract no: PO0267]. Journal of the American Society of Nephrology2020;31(Abstract Suppl):134. [EMBASE: 633698979]SepahY , NguyenQD , YamaguchiY , MajikawaY , ReuschM , AkizawaT . Ophthalmological effects of roxadustat in the treatment of anaemia in chronic kidney disease patients on dialysis in a phase 3, randomised, double-blind, active-comparator conversion study [abstract no: MO002]. Nephrology Dialysis Transplantation2020;35(Suppl 3):iii102. [EMBASE: 633421367]">Akizawa 2020a</a>; <a href="./references#CD013751-bbs2-0004" title="AkizawaT , NangakuM , YonekawaT , OkudaN , KawamatsuS , OnoueT , et al. Efficacy and safety of daprodustat compared with darbepoetin alfa in Japanese hemodialysis patients with anemia: a randomized, double-blind, phase 3 trial. Clinical Journal of the American Society of Nephrology: CJASN2020;15(8):1155-65. [MEDLINE: 32723804]OzekiH , AkizawaT , NangakuM , YonekawaT , OkudaN , KawamatsuS , et al. Efficacy and safety of daprodustat compared with darbepoetin alfa in Japanese hemodialysis patients with anemia: A randomized, double-blind, phase 3 trial [abstract no: SaO036]. Nephrology Dialysis Transplantation2019;34(Suppl 1):a350. [EMBASE: 631305259]">Akizawa 2020c</a>; <a href="./references#CD013751-bbs2-0008" title="CoyneDW , RogerSD , ChouW , BesarabA , LeongR , LeeTT , et al. Roxadustat favorably modifies iron indices in patients with non-dialysis-dependent CKD-related anemia [abstract no: PO0262]. Journal of the American Society of Nephrology2020;31(Abstract Suppl):132. [EMBASE: 633698686]CoyneDW , RogerSD , ShinS , KimSG , CadenaAA , MoustafaMA , et al. Roxadustat for CKD-related anemia in non-dialysis patients. Kidney International Reports2021;6(3):624-35. [MEDLINE: 33732977]CoyneDW , RogerSD , ShinSK , KimSG , CadenaAA , MoustafaMA , et al. ANDES: A phase 3, randomized, double-blind, placebo controlled study of the efficacy and safety of roxadustat for the treatment of anemia in CKD patients not on dialysis [abstract no: SA-PO0228]. Journal of the American Society of Nephrology2019;30(Abstract Suppl):822-3. [EMBASE: 633767955]Pecoits-FilhoR , ChanTM , HardyE , YuKHP , FishbaneS . Roxadustat treatment results in consistent improvements in hemoglobin (Hb) vs. placebo: an analysis of three multinational randomized clinical trials in patients with non-dialysis-dependent CKD (NDD-CKD) [abstract no: TH-OR05]. Journal of the American Society of Nephrology2020;31(Abstract Suppl):2. [EMBASE: 633697943]RastogiA , Pecoits-FilhoR , FishbaneS , LittleDJ , HardyE , YuKH , et al. Roxadustat treatment corrects anemia to hemoglobin (HB) values ≥10 g/dL in the majority of patients with non-dialysis-dependent chronic kidney disease (NDD-CKD) [abstract no: PO0264]. Journal of the American Society of Nephrology2020;31(Abstract Suppl):133. [EMBASE: 633698803]">ANDES 2021</a>; <a href="./references#CD013751-bbs2-0009" title="SinghAK , BlackorbyA , CizmanB , CarrollK , CobitzAR , DaviesR , et al. Study design and baseline characteristics of patients on dialysis in the ASCEND-D trial. Nephrology Dialysis Transplantation2021;37(5):960-72. [MEDLINE: 33744933] [MEDLINE: 33744933]SinghAK , BlackorbyA , CizmanB , CobitzAR , GodoySA , JhaV , et al. Regional variation of erythropoietin-stimulating agent hyporesponsiveness in the global daprodustat dialysis study (ASCEND-D) [abstract no: TH-OR08]. Journal of the American Society of Nephrology2020;31(Abstract Suppl):3. [EMBASE: 633698062]SinghAK , CarrollK , PerkovicV , SolomonS , JhaV , JohansenKL , et al. Daprodustat for the treatment of anemia in patients undergoing dialysis. New England Journal of Medicine2021;385(25):2325-35. [MEDLINE: 34739194]">ASCEND‐D 2021</a>; <a href="./references#CD013751-bbs2-0011" title="PerkovicV , BlackorbyA , CizmanB , CarrollK , CobitzA , DaviesR , et al. ASCEND-ND: Study design and baseline characteristics. Nephrology Dialysis Transplantation2021;36(Suppl 1):i334-5. [EMBASE: 635918331]SinghAK , CarrollK , McMurrayJJ , SolomonS , JhaV , JohansenKL , et al. Daprodustat for the treatment of anemia in patients not undergoing dialysis. New England Journal of Medicine2021;385(25):2313-24. [MEDLINE: 34739196]">ASCEND‐ND 2021</a>; <a href="./references#CD013751-bbs2-0020" title="AkizawaT , MacdougallIC , BernsJS , BernhardtT , TaguchiM , OguraE , et al. Iron regulation by molidustat, bay 85-3934, a daily oral hypoxia-inducible factor prolyl hydroxylase inhibitor in patients with chronic kidney disease [abstract no: SP334]. Nephrology Dialysis Transplantation2018;33(Suppl 1):i457. [EMBASE: 622606520]AkizawaT , MacdougallIC , BernsJS , YamamotoH , TaguchiM , IekushiK , et al. Iron regulation by molidustat, a daily oral hypoxia-inducible factor prolyl hydroxylase inhibitor, in patients with chronic kidney disease. Nephron2019;143(4):243-54. [MEDLINE: 31387097]MacdougallIC , AkizawaT , BernsJ , LentiniS , BernhardtT . Molidustat increases haemoglobin in erythropoiesis stimulating agents (ESA)-naive anaemic patients with chronic kidney disease not on dialysis (CKD-ND) [abstract no: SO036]. Nephrology Dialysis Transplantation2016;31(Suppl 1):i16. [EMBASE: 72325954]MacdougallIC , AkizawaT , BernsJS , BernhardtT , KruegerT . Effects of molidustat in the treatment of anemia in CKD [Erratum in: Clin J Am Soc Nephrol. 2019 Oct 7;14(10):1524]. Clinical Journal of the American Society of Nephrology: CJASN2019;14(1):28-39. [MEDLINE: 30559105]MacdougallIC , BernsJS , AkizawaT , FishbaneS , BernhardtT . DIALOGUE phase 2 program for BAY85-3934 a HIF-PH inhibitor with daily oral treatment in anemic patients suffering from CKD/ESRD [abstract no: FR-PO219]. Journal of the American Society of Nephrology2013;24(Abstract Suppl):413A. ">DIALOGUE 1 2019</a>; <a href="./references#CD013751-bbs2-0021" title="AkizawaT , MacdougallIC , BernsJS , YamamotoH , TaguchiM , IekushiK , et al. Iron regulation by molidustat, a daily oral hypoxia-inducible factor prolyl hydroxylase inhibitor, in patients with chronic kidney disease. Nephron2019;143(4):243-54. [MEDLINE: 31387097]MacdougallIC , AkizawaT , BernsJ , LentiniS , BernhardtT , KrugerT . Safety and efficacy of molidustat in erythropoiesis stimulating agents (ESA) pre-treated anaemic patients with chronic kidney disease not on dialysis (CKD-ND) [abstract no: SP309]. Nephrology Dialysis Transplantation2016;31(Suppl 1):i193. [EMBASE: 72326411]MacdougallIC , AkizawaT , BernsJ , LentiniS , BernhardtT . Molidustat increases haemoglobin in erythropoiesis stimulating agents (ESA)-naive anaemic patients with chronic kidney disease not on dialysis (CKD-ND) [abstract no: SO036]]. Nephrology Dialysis Transplantation2016;31(Suppl 1):i16. [EMBASE: 72325954]MacdougallIC , AkizawaT , BernsJS , BernhardtT , KruegerT . Effects of molidustat in the treatment of anemia in CKD [Erratum in: Clin J Am Soc Nephrol. 2019 Oct 7;14(10):1524]. Clinical Journal of the American Society of Nephrology: CJASN2019;14(1):28-39. [MEDLINE: 30559105]MacdougallIC , BernsJS , AkizawaT , FishbaneS , BernhardtT . DIALOGUE phase 2 program for BAY85-3934 a HIF-PH inhibitor with daily oral treatment in anemic patients suffering from CKD/ESRD [abstract no: FR-PO219]. Journal of the American Society of Nephrology2013;24(Abstract Suppl):413A. ">DIALOGUE 2 2019</a>; <a href="./references#CD013751-bbs2-0022" title="AkizawaT , MacdougallIC , BernsJS , YamamotoH , TaguchiM , IekushiK , et al. Iron regulation by molidustat, a daily oral hypoxia-inducible factor prolyl hydroxylase inhibitor, in patients with chronic kidney disease. Nephron2019;143(4):243-54. [MEDLINE: 31387097]MacdougallIC , AkizawaT , BernsJ , LentiniS , BernhardtT . Molidustat increases haemoglobin in erythropoiesis stimulating agents (ESA)-naive anaemic patients with chronic kidney disease not on dialysis (CKD-ND) [abstract no: SO036]. Nephrology Dialysis Transplantation2016;31(Suppl 1):i16. [EMBASE: 72325954]MacdougallIC , AkizawaT , BernsJS , BernhardtT , KruegerT . Effects of molidustat in the treatment of anemia in CKD [Erratum in: Clin J Am Soc Nephrol. 2019 Oct 7;14(10):1524]. Clinical Journal of the American Society of Nephrology: CJASN2019;14(1):28-39. [MEDLINE: 30559105]MacdougallIC , BernsJS , AkizawaT , FishbaneS , BernhardtT . DIALOGUE phase 2 program for BAY85-3934 a HIF-PH inhibitor with daily oral treatment in anemic patients suffering from CKD/ESRD [abstract no: FR-PO219]. Journal of the American Society of Nephrology2013;24(Abstract Suppl):413A. ">DIALOGUE 4 2019</a>; <a href="./references#CD013751-bbs2-0024" title="ProvenzanoM , EvgenyS , LiubovE , KorneyevaS , KathresalAA , PooleL , et al. HIMALAYAS: a phase 3, randomized, open-label, active-controlled study of the efficacy and safety of roxadustat in the treatment of anemia in incident-dialysis patients [abstract no: TH-OR021]. Journal of the American Society of Nephrology2019;30(Abstract Suppl):5. [EMBASE: 633771140]ProvenzanoR , ShutovE , EremeevaL , KorneyevaS , PooleL , SahaG , et al. Roxadustat for anemia in patients with end-stage renal disease incident to dialysis. Nephrology Dialysis Transplantation2021;36(9):1717-30. [MEDLINE: 33629100]">HIMALAYAS 2021</a>; <a href="./references#CD013751-bbs2-0025" title="CizmanB , AckertJ , MeadowcroftA , BiswasN , KellyD , KleinmanD , et al. Ocular safety profile of daprodustat: results of two 24 week studies [abstract no: SAO004]. Nephrology Dialysis Transplantation2018;33(Suppl 1):i316. [EMBASE: 622604997]HoldstockL , CizmanB , MeadowcroftAM , BiswasN , JohnsonBM , JonesD , et al. Daprodustat for anemia: a 24-week, open-label, randomized controlled trial in participants with chronic kidney disease. Clinical Kidney Journal2019;12(1):129-38. [MEDLINE: 30746140]HoldstockL , CizmanB , MeadowcroftAM , BiswasN , JonesD , JohnsonBM , et al. Daprodustat, a HIF-prolyl-hydroxylase inhibitor, increases and maintains hemoglobin over 24 weeks in anemic chronic kidney disease subjects [abstract no: TH-PO908]. Journal of the American Society of Nephrology2016;27(Abstract Suppl):304A. ">Holdstock 2019</a>; <a href="./references#CD013751-bbs2-0026" title="CizmanB , AckertJ , MeadowcroftA , BiswasN , KellyD , KleinmanD , et al. Ocular safety profile of daprodustat: results of two 24 week studies [abstract no: SAO004]. Nephrology Dialysis Transplantation2018;33(Suppl 1):i316. [EMBASE: 622604997]HoldstockL , CizmanB , MeadowcroftAM , BiswasN , JohnsonBM , JonesD , et al. Daprodustat for anemia: a 24-week, open-label, randomized controlled trial in participants with chronic kidney disease. Clinical Kidney Journal2019;12(1):129-38. [MEDLINE: 30746140]HoldstockL , CizmanB , MeadowcroftAM , BiswasN , JonesD , JohnsonBM , et al. Daprodustat, a HIF-prolyl-hydroxylase inhibitor, increases and maintains hemoglobin over 24 weeks in anemic chronic kidney disease subjects [abstract no: TH-PO908]. Journal of the American Society of Nephrology2016;27(Abstract Suppl):304A. ">Holdstock 2019a</a>; <a href="./references#CD013751-bbs2-0030" title="CizmanB , AckertJ , MeadowcroftA , BiswasN , KellyD , KleinmanD , et al. Ocular safety profile of daprodustat: results of two 24 week studies [abstract no: SAO004]. Nephrology Dialysis Transplantation2018;33(Suppl 1):i316. [EMBASE: 622604997]CobitzAR , MeadowcroftAM , CizmanB , HoldstockL , BiswasN , JonesD , et al. Daprodustat, a HIF-prolyl-hydroxylase inhibitor, maintains hemoglobin levels over 24 weeks in anemic hemodialysis subjects switching from recombinant human erythropoietin. [abstract no: SA-OR114]. Journal of the American Society of Nephrology2016;27(Abstract Suppl):93A. MeadowcroftAM , CizmanB , HoldstockL , BiswasN , JohnsonBM , JonesD , et al. Daprodustat for anemia: a 24-week, open-label, randomized controlled trial in participants on hemodialysis. Clinical Kidney Journal2019;12(1):139-48. [MEDLINE: 30746141]">Meadowcroft 2019</a>; <a href="./references#CD013751-bbs2-0031" title="AkizawaT , TaguchiM , MatsudaY , IekushiK , YamadaT , YamamotoH . Molidustat for the treatment of renal anaemia in patients with dialysis-dependent chronic kidney disease: Design and rationale of three phase III studies. BMJ Open2019;9(6):e026602. [MEDLINE: 31203241]AkizawaT , YamadaT , NoboriK , MatsudaY , HayashiY , HayasakiT , et al. Molidustat for Japanese patients with renal anemia receiving dialysis. Kidney International Reports2021;6(10):2604–16. [MEDLINE: 34622100]AkizawaT , YamadaT , NoboriK , MatsudaY , HayashiY , HayasakiT , et al. Results from a phase 3 study comparing the efficacy and safety of molidustat vs. Darbepoetin Alfa in patients receiving hemodialysis and treated with erythropoiesis-stimulating agents (ESAS) [abstract no: PO22623]. Journal of the American Society of Nephrology2020;31(Abstract Suppl):B4. [EMBASE: 633697376]">MIYABI HD‐M 2019</a>; <a href="./references#CD013751-bbs2-0032" title="YamamotoH , NoboriK , MatsudaY , HayashiY , HayasakiT , AkizawaT . Efficacy and safety of molidustat for anemia in ESA-naive nondialysis patients: a randomized, phase 3 trial. American Journal of Nephrology2021;52(10-11):871-83. [MEDLINE: 34569489]YamamotoH , TaguchiM , MatsudaY , IekushiK , YamadaT , AkizawaT . Molidustat for the treatment of renal anaemia in patients with non-dialysis-dependent chronic kidney disease: design and rationale of two phase III studies. BMJ Open2019;9(6):e026704. [MEDLINE: 31203242]YamamotoH , TaguchiM , NoboriK , MatsudaY , IekushiK , AkizawaT . To investigate the efficacy and safety of molidustat in non-dialysis patients with renal anemia who are not treated with erythropoiesis stimulating agents: MIYABI ND-C [abstract no: P1866]. Nephrology Dialysis Transplantation2020;35(Suppl 3):iii2177. [EMBASE: 633422996]">MIYABI ND‐C 2019</a>; <a href="./references#CD013751-bbs2-0033" title="YamamotoH , NoboriK , MatsudaY , HayashiY , HayasakiT , AkizawaT . Molidustat for renal anemia in nondialysis patients previously treated with erythropoiesis-stimulating agents: a randomized, open-label, phase 3 study. American Journal of Nephrology2021;52(10-11):884-93. [MEDLINE: 34569482]YamamotoH , TaguchiM , MatsudaY , IekushiK , YamadaT , AkizawaT . Molidustat for the treatment of renal anaemia in patients with non-dialysis-dependent chronic kidney disease: design and rationale of two phase III studies. BMJ Open2019;9(6):e026704. [MEDLINE: 31203242]YamamotoH , TaguchiM , NoboriK , MatsudaY , IekushiK , AkizawaT . To investigate the efficacy and safety of molidustat in non-dialysis patients with renal anemia who are treated with erythropoiesis stimulating agents: Miyabi ND-M [Abstract no: P1868]. Nephrology Dialysis Transplantation2020;35(Suppl 3):iii2179. [EMBASE: 633423006]">MIYABI ND‐M 2019</a>; <a href="./references#CD013751-bbs2-0036" title="GSK201753. A 52-week, Phase III, open-label, multi-center study to evaluate efficacy and safety of GSK1278863 in Japanese non-dialysis and peritoneal dialysis subjects with anemia associated with chronic kidney disease [study protocol]. www.clinicaltrials.gov/ProvidedDocs/63/NCT02791763/Prot_000.pdf (accessed 9 May 2022). NangakuM , HamanoT , AkizawaT , TsubakiharaY , NagaiR , OkudaN , et al. Daprodustat compared with epoetin beta pegol for anemia in Japanese patients not on dialysis: a 52-week randomized open-label phase 3 trial. American Journal of Nephrology2021;52(1):26-35. [MEDLINE: 33561857]">Nangaku 2021b</a>; <a href="./references#CD013751-bbs2-0040" title="AstraZeneca. A phase 3, multicenter, randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of roxadustat for the treatment of anemia in chronic kidney disease patients not on dialysis [clinical study protocol V6; 31 August 2018]. www.clinicaltrials.gov/ProvidedDocs/27/NCT02174627/Prot_000.pdf (accessed 9 May 2022). EleftheriadisT , PissasG , LiakopoulosV , StefanidisI . On the increased event rate of urinary tract infection and pneumonia in CKD patients treated with roxadustat for anemia. Journal of the American Society of Nephrology2021;32(6):1537. [MEDLINE: 33849917]FishbaneS , El-ShahawyMA , Pecoits-FilhoR , VanBP , HouserMT , FrisonL , et al. OLYMPUS: a phase 3, randomized, double-blind, placebo-controlled, international study of roxadustat efficacy in patients with non-dialysis-dependent (NDD) CKD and anemia [abstract no: TH-OR023]. Journal of the American Society of Nephrology2019;30(Abstract Suppl):6. [EMBASE: 633771285]FishbaneS , El-ShahawyMA , Pecoits-FilhoR , VanBP , HouserMT , FrisonL , et al. Roxadustat for treating anemia in patients with CKD not on dialysis: results from a randomized phase 3 study. Journal of the American Society of Nephrology2021;32(3):737-55. [MEDLINE: 33568383]FishbaneS , El-ShahawyMA , VanBP , LittleDJ . Authors' Reply. Journal of the American Society of Nephrology2021;32(6):1537-8. [MEDLINE: 33849916]Pecoits-FilhoR , ChanTM , HardyE , YuKH , FishbaneS . Roxadustat treatment results in consistent improvements in hemoglobin (Hb) vs. placebo: an analysis of three multinational randomized clinical trials in patients with non-dialysis-dependent CKD (NDD-CKD) [abstract no: TH-OR05]. Journal of the American Society of Nephrology2020;31(Abstract Suppl):2. [EMBASE: 633697943]RastogiA , Pecoits-FilhoR , FishbaneS , LittleDJ , HardyE , YuKH , et al. Roxadustat treatment corrects anemia to hemoglobin (HB) values ≥10 g/dL in the majority of patients with non-dialysis-dependent chronic kidney disease (NDD-CKD) [abstract no: PO0264]. Journal of the American Society of Nephrology2020;31(Abstract Suppl):133. [EMBASE: 633698803]">OLYMPUS 2021</a>; <a href="./references#CD013751-bbs2-0049" title="CharytanC , Manllo-KarimR , MartinER , SteerD , BernardoM , DuaSL , et al. A randomized trial of roxadustat in anemia of kidney failure: SIERRAS study. Kidney International Reports2021;6(7):1829-39. [MEDLINE: 34307977]CharytanC , Manllo-KarimR , MartinER , SteerD , BernardoM , DuaSL , et al. SIERRAS: A phase 3, open-label, randomized, active-controlled study of the efficacy and safety of roxadustat in the maintenance treatment of anemia in subjects with ESRD on stable dialysis [abstract no: SA-PO227]. Journal of the American Society of Nephrology2019;30(Abstract Suppl):822. [EMBASE: 633767862]">SIERRAS 2021</a>; <a href="./references#CD013751-bbs2-0051" title="AkizawaT , NangakuM , YamaguchiT , KoretomoR , MaedaK , MiyazawaY , et al. A phase 3 study of enarodustat in anemic patients with CKD not requiring dialysis: the SYMPHONY ND study. Kidney International Reports2021;6(7):1840-9. [MEDLINE: 34307978]">SYMPHONY ND 2021</a>). The risk of bias for allocation concealment was unclear in 32 studies. </p> </section> </section> <section id="CD013751-sec-0057"> <h4 class="title">Blinding</h4> <section id="CD013751-sec-0058"> <h5 class="title">Performance bias</h5> <p>Six studies (<a href="./references#CD013751-bbs2-0002" title="AkizawaT , IwasakiM , OtsukaT , ReuschM , MisumiT . Roxadustat for the treatment of chronic kidney disease-associated anemia in Japanese patients not on dialysis [abstract no: FR-PO1142]. Journal of the American Society of Nephrology2016;27(Abstract Suppl):7B. AkizawaT , IwasakiM , OtsukaT , ReuschM , MisumiT . Roxadustat treatment of chronic kidney disease-associated anemia in Japanese patients not on dialysis: a phase 2, randomized, double-blind, placebo-controlled trial. Advances in Therapy2019;36(6):1438-54. [MEDLINE: 30953333]">Akizawa 2019</a>; <a href="./references#CD013751-bbs2-0008" title="CoyneDW , RogerSD , ChouW , BesarabA , LeongR , LeeTT , et al. Roxadustat favorably modifies iron indices in patients with non-dialysis-dependent CKD-related anemia [abstract no: PO0262]. Journal of the American Society of Nephrology2020;31(Abstract Suppl):132. [EMBASE: 633698686]CoyneDW , RogerSD , ShinS , KimSG , CadenaAA , MoustafaMA , et al. Roxadustat for CKD-related anemia in non-dialysis patients. Kidney International Reports2021;6(3):624-35. [MEDLINE: 33732977]CoyneDW , RogerSD , ShinSK , KimSG , CadenaAA , MoustafaMA , et al. ANDES: A phase 3, randomized, double-blind, placebo controlled study of the efficacy and safety of roxadustat for the treatment of anemia in CKD patients not on dialysis [abstract no: SA-PO0228]. Journal of the American Society of Nephrology2019;30(Abstract Suppl):822-3. [EMBASE: 633767955]Pecoits-FilhoR , ChanTM , HardyE , YuKHP , FishbaneS . Roxadustat treatment results in consistent improvements in hemoglobin (Hb) vs. placebo: an analysis of three multinational randomized clinical trials in patients with non-dialysis-dependent CKD (NDD-CKD) [abstract no: TH-OR05]. Journal of the American Society of Nephrology2020;31(Abstract Suppl):2. [EMBASE: 633697943]RastogiA , Pecoits-FilhoR , FishbaneS , LittleDJ , HardyE , YuKH , et al. Roxadustat treatment corrects anemia to hemoglobin (HB) values ≥10 g/dL in the majority of patients with non-dialysis-dependent chronic kidney disease (NDD-CKD) [abstract no: PO0264]. Journal of the American Society of Nephrology2020;31(Abstract Suppl):133. [EMBASE: 633698803]">ANDES 2021</a>; <a href="./references#CD013751-bbs2-0020" title="AkizawaT , MacdougallIC , BernsJS , BernhardtT , TaguchiM , OguraE , et al. Iron regulation by molidustat, bay 85-3934, a daily oral hypoxia-inducible factor prolyl hydroxylase inhibitor in patients with chronic kidney disease [abstract no: SP334]. Nephrology Dialysis Transplantation2018;33(Suppl 1):i457. [EMBASE: 622606520]AkizawaT , MacdougallIC , BernsJS , YamamotoH , TaguchiM , IekushiK , et al. Iron regulation by molidustat, a daily oral hypoxia-inducible factor prolyl hydroxylase inhibitor, in patients with chronic kidney disease. Nephron2019;143(4):243-54. [MEDLINE: 31387097]MacdougallIC , AkizawaT , BernsJ , LentiniS , BernhardtT . Molidustat increases haemoglobin in erythropoiesis stimulating agents (ESA)-naive anaemic patients with chronic kidney disease not on dialysis (CKD-ND) [abstract no: SO036]. Nephrology Dialysis Transplantation2016;31(Suppl 1):i16. [EMBASE: 72325954]MacdougallIC , AkizawaT , BernsJS , BernhardtT , KruegerT . Effects of molidustat in the treatment of anemia in CKD [Erratum in: Clin J Am Soc Nephrol. 2019 Oct 7;14(10):1524]. Clinical Journal of the American Society of Nephrology: CJASN2019;14(1):28-39. [MEDLINE: 30559105]MacdougallIC , BernsJS , AkizawaT , FishbaneS , BernhardtT . DIALOGUE phase 2 program for BAY85-3934 a HIF-PH inhibitor with daily oral treatment in anemic patients suffering from CKD/ESRD [abstract no: FR-PO219]. Journal of the American Society of Nephrology2013;24(Abstract Suppl):413A. ">DIALOGUE 1 2019</a>; <a href="./references#CD013751-bbs2-0030" title="CizmanB , AckertJ , MeadowcroftA , BiswasN , KellyD , KleinmanD , et al. Ocular safety profile of daprodustat: results of two 24 week studies [abstract no: SAO004]. Nephrology Dialysis Transplantation2018;33(Suppl 1):i316. [EMBASE: 622604997]CobitzAR , MeadowcroftAM , CizmanB , HoldstockL , BiswasN , JonesD , et al. Daprodustat, a HIF-prolyl-hydroxylase inhibitor, maintains hemoglobin levels over 24 weeks in anemic hemodialysis subjects switching from recombinant human erythropoietin. [abstract no: SA-OR114]. Journal of the American Society of Nephrology2016;27(Abstract Suppl):93A. MeadowcroftAM , CizmanB , HoldstockL , BiswasN , JohnsonBM , JonesD , et al. Daprodustat for anemia: a 24-week, open-label, randomized controlled trial in participants on hemodialysis. Clinical Kidney Journal2019;12(1):139-48. [MEDLINE: 30746141]">Meadowcroft 2019</a>; <a href="./references#CD013751-bbs2-0031" title="AkizawaT , TaguchiM , MatsudaY , IekushiK , YamadaT , YamamotoH . Molidustat for the treatment of renal anaemia in patients with dialysis-dependent chronic kidney disease: Design and rationale of three phase III studies. BMJ Open2019;9(6):e026602. [MEDLINE: 31203241]AkizawaT , YamadaT , NoboriK , MatsudaY , HayashiY , HayasakiT , et al. Molidustat for Japanese patients with renal anemia receiving dialysis. Kidney International Reports2021;6(10):2604–16. [MEDLINE: 34622100]AkizawaT , YamadaT , NoboriK , MatsudaY , HayashiY , HayasakiT , et al. Results from a phase 3 study comparing the efficacy and safety of molidustat vs. Darbepoetin Alfa in patients receiving hemodialysis and treated with erythropoiesis-stimulating agents (ESAS) [abstract no: PO22623]. Journal of the American Society of Nephrology2020;31(Abstract Suppl):B4. [EMBASE: 633697376]">MIYABI HD‐M 2019</a>; <a href="./references#CD013751-bbs2-0040" title="AstraZeneca. A phase 3, multicenter, randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of roxadustat for the treatment of anemia in chronic kidney disease patients not on dialysis [clinical study protocol V6; 31 August 2018]. www.clinicaltrials.gov/ProvidedDocs/27/NCT02174627/Prot_000.pdf (accessed 9 May 2022). EleftheriadisT , PissasG , LiakopoulosV , StefanidisI . On the increased event rate of urinary tract infection and pneumonia in CKD patients treated with roxadustat for anemia. Journal of the American Society of Nephrology2021;32(6):1537. [MEDLINE: 33849917]FishbaneS , El-ShahawyMA , Pecoits-FilhoR , VanBP , HouserMT , FrisonL , et al. OLYMPUS: a phase 3, randomized, double-blind, placebo-controlled, international study of roxadustat efficacy in patients with non-dialysis-dependent (NDD) CKD and anemia [abstract no: TH-OR023]. Journal of the American Society of Nephrology2019;30(Abstract Suppl):6. [EMBASE: 633771285]FishbaneS , El-ShahawyMA , Pecoits-FilhoR , VanBP , HouserMT , FrisonL , et al. Roxadustat for treating anemia in patients with CKD not on dialysis: results from a randomized phase 3 study. Journal of the American Society of Nephrology2021;32(3):737-55. [MEDLINE: 33568383]FishbaneS , El-ShahawyMA , VanBP , LittleDJ . Authors' Reply. Journal of the American Society of Nephrology2021;32(6):1537-8. [MEDLINE: 33849916]Pecoits-FilhoR , ChanTM , HardyE , YuKH , FishbaneS . Roxadustat treatment results in consistent improvements in hemoglobin (Hb) vs. placebo: an analysis of three multinational randomized clinical trials in patients with non-dialysis-dependent CKD (NDD-CKD) [abstract no: TH-OR05]. Journal of the American Society of Nephrology2020;31(Abstract Suppl):2. [EMBASE: 633697943]RastogiA , Pecoits-FilhoR , FishbaneS , LittleDJ , HardyE , YuKH , et al. Roxadustat treatment corrects anemia to hemoglobin (HB) values ≥10 g/dL in the majority of patients with non-dialysis-dependent chronic kidney disease (NDD-CKD) [abstract no: PO0264]. Journal of the American Society of Nephrology2020;31(Abstract Suppl):133. [EMBASE: 633698803]">OLYMPUS 2021</a>) included blinding to treatment allocation for participants and investigators. Thirty‐two studies (<a href="./references#CD013751-bbs2-0005" title="AkizawaT , IwasakiM , OtsukaT , YamaguchiY , ReuschM . A phase 3, multicenter, randomized, open-label, active comparator conversion study of roxadustat in non-dialysis-dependent (NDD) patients with anemia in chronic kidney disease (CKD) [abstract no: POS-244]. Kidney International Reports2021;6(4 Suppl):S103. [EMBASE: 2011682459]AkizawaT , IwasakiM , OtsukaT , YamaguchiY , ReuschM . A phase 3, multicenter, randomized, open-label, active comparator conversion study of roxadustat in non-dialysis-dependent (NDD) patients with anemia in CKD [abstract no: PO0269]. Journal of the American Society of Nephrology2020;31(Abstract Suppl):134. [EMBASE: 633699036]NguyenQD , SepahYJ , YamaguchiY , OtsukaT , MajikawaY , ReuschM , et al. Ophthalmological effects of roxadustat in the treatment of anemia in dialysis-dependent and non-dialysis-dependent CKD patients: findings from two phase 3 studies [abstract no: PO0267]. Journal of the American Society of Nephrology2020;31(Abstract Suppl):134. [EMBASE: 633698979]">Akizawa 2020f</a>; <a href="./references#CD013751-bbs2-0006" title="AkizawaT , IwasakiM , OtsukaT , YamaguchiY , ReuschM . Phase 3 study of roxadustat to treat anemia in non-dialysis-dependant CKD. Kidney International Reports2021;6(7):1810-28. [MEDLINE: 34307976]AkizawaT , Tanaka-AminoK , OtsukaT , YamaguchiY . Factors affecting doses of roxadustat versus darbepoetin alfa for anemia in nondialysis patients. American Journal of Nephrology2021;52(9):702-13. [MEDLINE: 34628408]">Akizawa 2021</a>; <a href="./references#CD013751-bbs2-0009" title="SinghAK , BlackorbyA , CizmanB , CarrollK , CobitzAR , DaviesR , et al. Study design and baseline characteristics of patients on dialysis in the ASCEND-D trial. Nephrology Dialysis Transplantation2021;37(5):960-72. [MEDLINE: 33744933] [MEDLINE: 33744933]SinghAK , BlackorbyA , CizmanB , CobitzAR , GodoySA , JhaV , et al. Regional variation of erythropoietin-stimulating agent hyporesponsiveness in the global daprodustat dialysis study (ASCEND-D) [abstract no: TH-OR08]. Journal of the American Society of Nephrology2020;31(Abstract Suppl):3. [EMBASE: 633698062]SinghAK , CarrollK , PerkovicV , SolomonS , JhaV , JohansenKL , et al. Daprodustat for the treatment of anemia in patients undergoing dialysis. New England Journal of Medicine2021;385(25):2325-35. [MEDLINE: 34739194]">ASCEND‐D 2021</a>; <a href="./references#CD013751-bbs2-0010" title="SinghAK . Daprodustat is noninferior to darbepoetin alfa in treating anemia in incident dialysis patients [abstract no: PO0465]. Journal of the American Society of Nephrology2021;32(Abstract Suppl):184-5. [EMBASE: 636331207]">ASCEND‐ID 2021</a>; <a href="./references#CD013751-bbs2-0011" title="PerkovicV , BlackorbyA , CizmanB , CarrollK , CobitzA , DaviesR , et al. ASCEND-ND: Study design and baseline characteristics. Nephrology Dialysis Transplantation2021;36(Suppl 1):i334-5. [EMBASE: 635918331]SinghAK , CarrollK , McMurrayJJ , SolomonS , JhaV , JohansenKL , et al. Daprodustat for the treatment of anemia in patients not undergoing dialysis. New England Journal of Medicine2021;385(25):2313-24. [MEDLINE: 34739196]">ASCEND‐ND 2021</a>; <a href="./references#CD013751-bbs2-0014" title="BesarabA , HutlerHN , KlausS , LeeTT , LilienfeldDE , NeffTB , et al. FG-4592, a novel oral HIF prolyl hydroxylase inhibitor, elevates hemoglobin in anemic stage 3/4 CKD patients [abstract no: SA-FC416]. Journal of the American Society of Nephrology2010;21(Abstract Suppl):95A. BesarabA , ProvenzanoR , HertelJ , ZabanehR , KlausSJ , LeeT , et al. Randomized placebo-controlled dose-ranging and pharmacodynamics study of roxadustat (FG-4592) to treat anemia in nondialysis-dependent chronic kidney disease (NDD-CKD) patients. Nephrology Dialysis Transplantation2015;30(10):1665-73. [MEDLINE: 26238121]">Besarab 2015</a>; <a href="./references#CD013751-bbs2-0015" title="BrigandiRA , JohnsonB , OeiC , WestermanM , OlbinaG , deZoysaJ , et al. A novel hypoxia-inducible factor-prolyl hydroxylase inhibitor (GSK1278863) for anemia in CKD: a 28-day, phase 2a randomized trial. American Journal of Kidney Diseases2016;67(6):861-71. [MEDLINE: 26827289]BrigandiRA , JohnsonB , OeiC , WestermanME , OlbinaG , KumarS , et al. Induction of erythropoiesis in anemic patients by prolylhydroxylase inhibitor in a repeat dose, randomized placebo controlled trial [abstract no: SA-PO117]. Journal of the American Society of Nephrology2012;23(Abstract Suppl):662A. BrigandiRA , WestermanME , OlbinaG , OeiC , RussSF , KumarS . Modulation of hepcidin by prolylhydroxylase inhibitor in randomized trials [abstract no: SA-PO118]. Journal of the American Society of Nephrology2012;23(Abstract Suppl):662A. ">Brigandi 2016</a>; <a href="./references#CD013751-bbs2-0016" title="ChenN , HaoC , LiuB , LinHL , CailiW , XingCY , et al. A phase 3, randomized, open-label, active-controlled study of efficacy and safety of roxadustat for treatment of anemia in subjects with CKD on dialysis [abstract no: TH-PO1152]. Journal of the American Society of Nephrology2018;29(Abstract Suppl):B5. ChenN , HaoC , LiuBC , LinH , WangC , XingC , et al. Roxadustat treatment for anemia in patients undergoing long-term dialysis. New England Journal of Medicine2019;381(11):1011-22. [MEDLINE: 31340116]">Chen 2019</a>; <a href="./references#CD013751-bbs2-0018" title="ChenN , QianJ , ChenJ , YuX , MeiC , HaoC , et al. Phase 2 studies of oral hypoxia-inducible factor prolyl hydroxylase inhibitor FG-4592 for treatment of anemia in China. Nephrology Dialysis Transplantation2017;32(8):1373-86. [MEDLINE: 28371815]">Chen DD 2017</a>; <a href="./references#CD013751-bbs2-0021" title="AkizawaT , MacdougallIC , BernsJS , YamamotoH , TaguchiM , IekushiK , et al. Iron regulation by molidustat, a daily oral hypoxia-inducible factor prolyl hydroxylase inhibitor, in patients with chronic kidney disease. Nephron2019;143(4):243-54. [MEDLINE: 31387097]MacdougallIC , AkizawaT , BernsJ , LentiniS , BernhardtT , KrugerT . Safety and efficacy of molidustat in erythropoiesis stimulating agents (ESA) pre-treated anaemic patients with chronic kidney disease not on dialysis (CKD-ND) [abstract no: SP309]. Nephrology Dialysis Transplantation2016;31(Suppl 1):i193. [EMBASE: 72326411]MacdougallIC , AkizawaT , BernsJ , LentiniS , BernhardtT . Molidustat increases haemoglobin in erythropoiesis stimulating agents (ESA)-naive anaemic patients with chronic kidney disease not on dialysis (CKD-ND) [abstract no: SO036]]. Nephrology Dialysis Transplantation2016;31(Suppl 1):i16. [EMBASE: 72325954]MacdougallIC , AkizawaT , BernsJS , BernhardtT , KruegerT . Effects of molidustat in the treatment of anemia in CKD [Erratum in: Clin J Am Soc Nephrol. 2019 Oct 7;14(10):1524]. Clinical Journal of the American Society of Nephrology: CJASN2019;14(1):28-39. [MEDLINE: 30559105]MacdougallIC , BernsJS , AkizawaT , FishbaneS , BernhardtT . DIALOGUE phase 2 program for BAY85-3934 a HIF-PH inhibitor with daily oral treatment in anemic patients suffering from CKD/ESRD [abstract no: FR-PO219]. Journal of the American Society of Nephrology2013;24(Abstract Suppl):413A. ">DIALOGUE 2 2019</a>; <a href="./references#CD013751-bbs2-0022" title="AkizawaT , MacdougallIC , BernsJS , YamamotoH , TaguchiM , IekushiK , et al. Iron regulation by molidustat, a daily oral hypoxia-inducible factor prolyl hydroxylase inhibitor, in patients with chronic kidney disease. Nephron2019;143(4):243-54. [MEDLINE: 31387097]MacdougallIC , AkizawaT , BernsJ , LentiniS , BernhardtT . Molidustat increases haemoglobin in erythropoiesis stimulating agents (ESA)-naive anaemic patients with chronic kidney disease not on dialysis (CKD-ND) [abstract no: SO036]. Nephrology Dialysis Transplantation2016;31(Suppl 1):i16. [EMBASE: 72325954]MacdougallIC , AkizawaT , BernsJS , BernhardtT , KruegerT . Effects of molidustat in the treatment of anemia in CKD [Erratum in: Clin J Am Soc Nephrol. 2019 Oct 7;14(10):1524]. Clinical Journal of the American Society of Nephrology: CJASN2019;14(1):28-39. [MEDLINE: 30559105]MacdougallIC , BernsJS , AkizawaT , FishbaneS , BernhardtT . DIALOGUE phase 2 program for BAY85-3934 a HIF-PH inhibitor with daily oral treatment in anemic patients suffering from CKD/ESRD [abstract no: FR-PO219]. Journal of the American Society of Nephrology2013;24(Abstract Suppl):413A. ">DIALOGUE 4 2019</a>; <a href="./references#CD013751-bbs2-0023" title="BarrattJ , AndricB , TataradzeA , SchoemigM , ReuschM , ValluriU , et al. Roxadustat for the treatment of anemia in CKD patients not on dialysis (NDD): a phase 3, randomized, open-label, active-controlled study [abstract no: TH-OR02]. Journal of the American Society of Nephrology2020;31(Abstract Suppl):1. [EMBASE: 633697812]BarrattJ , AndricB , TataradzeA , SchomigM , ReuschM , ValluriU , et al. Roxadustat for the treatment of anaemia in chronic kidney disease patients not on dialysis: a phase 3, randomised, open-label, active-controlled study (DOLOMITES). Nephrology Dialysis Transplantation2021;36(9):1616-28. [MEDLINE: 34077510]BarrattJ , AndricB , TataradzeA , SchomigM , ReuschM , ValluriU , et al. Roxadustat for the treatment of anaemia in chronic kidney disease patients not on dialysis: a phase 3, randomised, open-label, active controlled study [abstract no: MO001]. Nephrology Dialysis Transplantation2020;35(Suppl 3):iii101. [EMBASE: 633423023]BarrattJ , AndricB , TataradzeA , SchomigM , ReuschM , ValluriU , et al. Roxadustat for the treatment of anemia in chronic kidney disease (CKD) patients not on dialysis (NDD): a phase 3, randomized, open-label, active-controlled study [abstract no: Pos-247]. Kidney International Reports2021;6(4 Suppl):S104. [EMBASE: 2011683542]">DOLOMITES 2021</a>; <a href="./references#CD013751-bbs2-0024" title="ProvenzanoM , EvgenyS , LiubovE , KorneyevaS , KathresalAA , PooleL , et al. HIMALAYAS: a phase 3, randomized, open-label, active-controlled study of the efficacy and safety of roxadustat in the treatment of anemia in incident-dialysis patients [abstract no: TH-OR021]. Journal of the American Society of Nephrology2019;30(Abstract Suppl):5. [EMBASE: 633771140]ProvenzanoR , ShutovE , EremeevaL , KorneyevaS , PooleL , SahaG , et al. Roxadustat for anemia in patients with end-stage renal disease incident to dialysis. Nephrology Dialysis Transplantation2021;36(9):1717-30. [MEDLINE: 33629100]">HIMALAYAS 2021</a>; <a href="./references#CD013751-bbs2-0025" title="CizmanB , AckertJ , MeadowcroftA , BiswasN , KellyD , KleinmanD , et al. Ocular safety profile of daprodustat: results of two 24 week studies [abstract no: SAO004]. Nephrology Dialysis Transplantation2018;33(Suppl 1):i316. [EMBASE: 622604997]HoldstockL , CizmanB , MeadowcroftAM , BiswasN , JohnsonBM , JonesD , et al. Daprodustat for anemia: a 24-week, open-label, randomized controlled trial in participants with chronic kidney disease. Clinical Kidney Journal2019;12(1):129-38. [MEDLINE: 30746140]HoldstockL , CizmanB , MeadowcroftAM , BiswasN , JonesD , JohnsonBM , et al. Daprodustat, a HIF-prolyl-hydroxylase inhibitor, increases and maintains hemoglobin over 24 weeks in anemic chronic kidney disease subjects [abstract no: TH-PO908]. Journal of the American Society of Nephrology2016;27(Abstract Suppl):304A. ">Holdstock 2019</a>; <a href="./references#CD013751-bbs2-0026" title="CizmanB , AckertJ , MeadowcroftA , BiswasN , KellyD , KleinmanD , et al. Ocular safety profile of daprodustat: results of two 24 week studies [abstract no: SAO004]. Nephrology Dialysis Transplantation2018;33(Suppl 1):i316. [EMBASE: 622604997]HoldstockL , CizmanB , MeadowcroftAM , BiswasN , JohnsonBM , JonesD , et al. Daprodustat for anemia: a 24-week, open-label, randomized controlled trial in participants with chronic kidney disease. Clinical Kidney Journal2019;12(1):129-38. [MEDLINE: 30746140]HoldstockL , CizmanB , MeadowcroftAM , BiswasN , JonesD , JohnsonBM , et al. Daprodustat, a HIF-prolyl-hydroxylase inhibitor, increases and maintains hemoglobin over 24 weeks in anemic chronic kidney disease subjects [abstract no: TH-PO908]. Journal of the American Society of Nephrology2016;27(Abstract Suppl):304A. ">Holdstock 2019a</a>; <a href="./references#CD013751-bbs2-0027" title="HouYP , MaoXY , WangC , XuZH , BuZH , XuM , et al. Roxadustat treatment for anemia in peritoneal dialysis patients: a randomized controlled trial. Journal of the Formosan Medical Association2021;121(2):529-38. [MEDLINE: 34167878]">Hou 2021</a>; <a href="./references#CD013751-bbs2-0028" title="ChertowGM , BoudvilleN , ChowdhuryP , GonzalezC , KooiengaL , LuoW , et al. Vadadustat for treatment of anemia in patients with dialysis-dependent CKD receiving peritoneal dialysis [abstract no: PO0464]. Journal of the American Society of Nephrology2021;32(Abstract Suppl):184. [EMBASE: 636331136]EckardtKU , AgarwalR , AswadA , AwadA , BlockGA , BacciMR , et al. Safety and efficacy of vadadustat for anemia in patients undergoing dialysis. New England Journal of Medicine2021;384(17):1601-12. [MEDLINE: 33913638]EckardtKU , AgarwalR , FaragYM , JardineAG , KhawajaZ , KouryMJ , et al. Global Phase 3 programme of vadadustat for treatment of anaemia of chronic kidney disease: rationale, study design and baseline characteristics of dialysis-dependent patients in the INNO2VATE trials. Nephrology Dialysis Transplantation2020;36(11):2039-48. [MEDLINE: 33188693]EckardtKU . Global phase 3 clinical trials of vadadustat vs. darbepoetin alfa for treatment of anemia in patients with dialysis-dependent CKD [abstract no: TH-OR01]. Journal of the American Society of Nephrology2020;31(Abstract Suppl):1. [EMBASE: 633697781]ParfreyPS , LuoW , MaroniB , AndersR , VargoD , McCulloughPA . Thromboembolic events with vadadustat vs. darbepoetin alfa for anemia treatment in patients with dialysis-dependent CKD [abstract no: PO0463]. Journal of the American Society of Nephrology2021;32(Abstract Suppl):184. [EMBASE: 636331080]WinkelmayerW , TumlinJA , FishbaneS , FaragY , VargoD , LuoW , et al. Hematologic efficacy of vadadustat for anemia in patients with kidney failure on dialysis [abstract no: MO529]. Nephrology Dialysis Transplantation2021;36(Suppl 1):i325-6. [EMBASE: 635917983]WinkelmayerWC , FishbaneS , TumlinJA , FaragYM , LuoW , AndersR , et al. Iron-related outcomes in patients with dialysis-dependent CKD randomized to vadadustat vs. darbepoetin alfa [abstract no: PO0457]. Journal of the American Society of Nephrology2021;32(Abstract Suppl):182. [EMBASE: 636330773]">INNO2VATE 2020</a>; <a href="./references#CD013751-bbs2-0029" title="EckardtKU , AgarwalR , AswadA , AwadA , BlockGA , BacciMR , et al. Safety and efficacy of vadadustat for anemia in patients undergoing dialysis. New England Journal of Medicine2021;384(17):1601-12. [MEDLINE: 33913638]EckardtKU , AgarwalR , FaragYM , JardineAG , KhawajaZ , KouryMJ , et al. Global Phase 3 programme of vadadustat for treatment of anaemia of chronic kidney disease: rationale, study design and baseline characteristics of dialysis-dependent patients in the INNO2VATE trials. Nephrology Dialysis Transplantation2020;36(11):2039-48. [MEDLINE: 33188693]EckardtKU . Global phase 3 clinical trials of vadadustat vs. darbepoetin alfa for treatment of anemia in patients with dialysis-dependent CKD [abstract no: TH-OR01]. Journal of the American Society of Nephrology2020;31(Abstract Suppl):1. [EMBASE: 633697781]WinkelmayerWC , FishbaneS , TumlinJA , FaragYM , LuoW , AndersR , et al. Iron-related outcomes in patients with dialysis-dependent CKD randomized to vadadustat vs. darbepoetin alfa [abstract no: PO0457]. Journal of the American Society of Nephrology2021;32(Abstract Suppl):182. [EMBASE: 636330773]">INNO2VATE 2020a</a>; <a href="./references#CD013751-bbs2-0032" title="YamamotoH , NoboriK , MatsudaY , HayashiY , HayasakiT , AkizawaT . Efficacy and safety of molidustat for anemia in ESA-naive nondialysis patients: a randomized, phase 3 trial. American Journal of Nephrology2021;52(10-11):871-83. [MEDLINE: 34569489]YamamotoH , TaguchiM , MatsudaY , IekushiK , YamadaT , AkizawaT . Molidustat for the treatment of renal anaemia in patients with non-dialysis-dependent chronic kidney disease: design and rationale of two phase III studies. BMJ Open2019;9(6):e026704. [MEDLINE: 31203242]YamamotoH , TaguchiM , NoboriK , MatsudaY , IekushiK , AkizawaT . To investigate the efficacy and safety of molidustat in non-dialysis patients with renal anemia who are not treated with erythropoiesis stimulating agents: MIYABI ND-C [abstract no: P1866]. Nephrology Dialysis Transplantation2020;35(Suppl 3):iii2177. [EMBASE: 633422996]">MIYABI ND‐C 2019</a>; <a href="./references#CD013751-bbs2-0033" title="YamamotoH , NoboriK , MatsudaY , HayashiY , HayasakiT , AkizawaT . Molidustat for renal anemia in nondialysis patients previously treated with erythropoiesis-stimulating agents: a randomized, open-label, phase 3 study. American Journal of Nephrology2021;52(10-11):884-93. [MEDLINE: 34569482]YamamotoH , TaguchiM , MatsudaY , IekushiK , YamadaT , AkizawaT . Molidustat for the treatment of renal anaemia in patients with non-dialysis-dependent chronic kidney disease: design and rationale of two phase III studies. BMJ Open2019;9(6):e026704. [MEDLINE: 31203242]YamamotoH , TaguchiM , NoboriK , MatsudaY , IekushiK , AkizawaT . To investigate the efficacy and safety of molidustat in non-dialysis patients with renal anemia who are treated with erythropoiesis stimulating agents: Miyabi ND-M [Abstract no: P1868]. Nephrology Dialysis Transplantation2020;35(Suppl 3):iii2179. [EMBASE: 633423006]">MIYABI ND‐M 2019</a>; <a href="./references#CD013751-bbs2-0035" title="NangakuM , KondoK , KokadoY , UetaK , KanekoG , ShiosakaM , et al. Randomized, open-label, active-controlled (darbepoetin alfa), phase 3 study of vadadustat for treating anemia in non-dialysis-dependent CKD patients in Japan [abstract no: SA-PO229]. Journal of the American Society of Nephrology2019;30(Abstract Suppl):823. [EMBASE: 633767995]NangakuM , KondoK , KokadoY , UetaK , KanekoG , TandaiT , et al. Phase 3 randomized study comparing vadadustat with darbepoetin alfa for anemia in Japanese patients with nondialysis-dependent CKD. Journal of the American Society of Nephrology2021;32(7):1779-90. [MEDLINE: 33883252]">Nangaku 2021a</a>; <a href="./references#CD013751-bbs2-0036" title="GSK201753. A 52-week, Phase III, open-label, multi-center study to evaluate efficacy and safety of GSK1278863 in Japanese non-dialysis and peritoneal dialysis subjects with anemia associated with chronic kidney disease [study protocol]. www.clinicaltrials.gov/ProvidedDocs/63/NCT02791763/Prot_000.pdf (accessed 9 May 2022). NangakuM , HamanoT , AkizawaT , TsubakiharaY , NagaiR , OkudaN , et al. Daprodustat compared with epoetin beta pegol for anemia in Japanese patients not on dialysis: a 52-week randomized open-label phase 3 trial. American Journal of Nephrology2021;52(1):26-35. [MEDLINE: 33561857]">Nangaku 2021b</a>; <a href="./references#CD013751-bbs2-0037" title="Astellas1517-CL-0304. A study to investigate the effect of ASP1517 after intermittent oral dosing in dialysis chronic kidney disease patients with anemia compared with darbepoetin as a reference drug [A Japanese, phase 2, multicenter, randomized, 4-arm parallel, double-blind (arms 1-3), open-label (arm 4), active-comparator (darbepoetin alfa) study of intermittent oral dosing of asp1517 in hemodialysis-dependent chronic kidney disease patients with anemia [1517-CL-0304 clinical study results report]]. www.trialsummaries.com/Study/StudyDetails?id=14175&amp;tenant=MT_AST_9011; www.clinicaltrials.gov/ct2/show/NCT01888445 (first received 6 August 2018). ">NCT01888445</a>; <a href="./references#CD013751-bbs2-0042" title="BunnHF . Vadadustat for anemia in patients with dialysis-dependent or non-dialysis-dependent chronic kidney disease. New England Journal of Medicine2021;385(16):e56. [MEDLINE: 34644481]ChertowGM , PergolaPE , AgarwalR , BlockGA , FaragYM , JardineAG , et al. Cardiovascular safety and efficacy of vadadustat for the treatment of anemia in non-dialysis-dependent CKD: design and baseline characteristics. American Heart Journal2021;235(5):1-11. [MEDLINE: 33129989]ChertowGM , PergolaPE , FaragYM , AgarwalR , ArnoldS , BakoG , et al. Vadadustat in patients with anemia and non-dialysis-dependent CKD. New England Journal of Medicine2021;384(17):1589-600. [MEDLINE: 33913637]ChertowGM . Global phase 3 clinical trials of vadadustat vs. darbepoetin alfa for treatment of anemia in patients with non-dialysis-dependent CKD [abstract no: FR-OR54]. Journal of the American Society of Nephrology2020;31(Abstract Suppl):B2. [EMBASE: 633697273]KouryM , PergolaPE , Roy-ChaudhuryP , FaragYM , LuoW , AndersR , et al. Iron-related outcomes in patients with non-dialysis-dependent CKD randomized to vadadustat vs. darbepoetin Alfa [abstract no: PO0482]. Journal of the American Society of Nephrology2021;32(Abstract Suppl):190. [EMBASE: 636329134]McCulloughPA , LuoW , AndersR , VargoD , ParfreyPS . Assessment of thromboembolic events with vadadustat vs. darbepoetin alfa for treatment of anemia in patients with non-dialysis-dependent CKD [abstract no: PO0462]. Journal of the American Society of Nephrology2021;32(Abstract Suppl):184. [EMBASE: 636331039]">PRO2TECT‐CONVERSION 2021</a>; <a href="./references#CD013751-bbs2-0043" title="BunnHF . Vadadustat for anemia in patients with dialysis-dependent or non-dialysis-dependent chronic kidney disease. New England Journal of Medicine2021;385(16):e56. [MEDLINE: 34644481]ChertowGM , PergolaPE , AgarwalR , BlockGA , FaragYM , JardineAG , et al. Cardiovascular safety and efficacy of vadadustat for the treatment of anemia in non-dialysis-dependent CKD: design and baseline characteristics. American Heart Journal2021;235(5):1-11. [MEDLINE: 33129989]ChertowGM , PergolaPE , FaragYM , AgarwalR , ArnoldS , BakoG , et al. Vadadustat in patients with anemia and non-dialysis-dependent CKD. New England Journal of Medicine2021;384(17):1589-600. [MEDLINE: 33913637]ChertowGM . Global phase 3 clinical trials of vadadustat vs. darbepoetin alfa for treatment of anemia in patients with non-dialysis-dependent CKD [abstract no: FR-OR5]. Journal of the American Society of Nephrology2020;31(Abstract Suppl):B2. [EMBASE: 633697273]KouryM , PergolaPE , Roy-ChaudhuryP , FaragYM , LuoW , AndersR , et al. Iron-related outcomes in patients with non-dialysis-dependent CKD randomized to vadadustat vs. darbepoetin alfa [abstract no: PO0482]. Journal of the American Society of Nephrology2021;32(Abstract Suppl):190. [EMBASE: 636329134]McCulloughPA , LuoW , AndersR , VargoD , ParfreyPS . Assessment of thromboembolic events with vadadustat vs. darbepoetin alfa for treatment of anemia in patients with non-dialysis-dependent CKD [abstract no: PO0462]. Journal of the American Society of Nephrology2021;32(Abstract Suppl):184. [EMBASE: 636331039]">PRO2TECT‐CORRECTION 2021</a>; <a href="./references#CD013751-bbs2-0044" title="ProvenzanoR , FaddaG , BernardoM , JamesC , KochendoerferG , LeeT , et al. FG2216, a novel oral HIF-PHI, stimulates erythropoiesis and increases hemoglobin concentration in patients with non-dialysis CKD [abstract no: 212]. American Journal of Kidney Diseases2008;51(4):A80. ProvenzanoR , HulterH , AgarwalA , KlausS , LeeT , YuP , et al. Hypoxia-inducible factor (HIF) prolyl hydroxylase inhibitor FG-2216 increases Hb without FE depletion in the absence of IV Fe [abstract no: 249]. American Journal of Kidney Diseases2013;61(4):A78. [EMBASE: 71024073]">Provenzano 2008</a>; <a href="./references#CD013751-bbs2-0045" title="ProvenzanoR , BesarabA , DuaSL , NguyenPV , WrightSH , ZeigS , et al. FG-4592, a novel oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), maintains hemoglobin levels and lowers cholesterol in hemodialysis patients: phase 2 comparison with epoetin alfa [abstract no: FR-PO257]. Journal of the American Society of Nephrology2012;23(Abstract Suppl):428A. ProvenzanoR , BesarabA , WrightS , DuaS , ZeigS , NguyenP , et al. Roxadustat (FG-4592) versus epoetin alfa for anemia in patients receiving maintenance hemodialysis: a phase 2, randomized, 6- to 19-week, open-label, active-comparator, dose-ranging, safety and exploratory efficacy study. American Journal of Kidney Diseases2016;67(6):912-24. [MEDLINE: 26846333]">Provenzano 2016</a>; <a href="./references#CD013751-bbs2-0046" title="ProvenzanoR , BesarabA , DuaSL , NguyenPV , WrightSH , ZeigS , et al. FG-4592, a novel oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), maintains hemoglobin levels and lowers cholesterol in hemodialysis patients: phase 2 comparison with epoetin alfa [abstract no: FR-PO257]. Journal of the American Society of Nephrology2012;23(Abstract Suppl):428A. ProvenzanoR , BesarabA , WrightS , DuaS , ZeigS , NguyenP , et al. Roxadustat (FG-4592) versus epoetin alfa for anemia in patients receiving maintenance hemodialysis: a phase 2, randomized, 6- to 19-week, open-label, active-comparator, dose-ranging, safety and exploratory efficacy study. American Journal of Kidney Diseases2016;67(6):912-24. [MEDLINE: 26846333]">Provenzano 2016a</a>; <a href="./references#CD013751-bbs2-0047" title="Astellas 1517-CL-0613. Roxadustat in the treatment of anemia in end stage renal disease (ESRD) patients on stable dialysis [A phase 3, randomized, open-label, active-controlled study to evaluate the efficacy and safety of roxadustat in the maintenance treatment of anemia in end stage renal disease patients on stable dialysis]. www.trialsummaries.com/Study/StudyDetails?id=14380&amp;tenant=MT_AST_9011 (accessed 9 May 2022). CsikyB , SchomigM , EspositoC , BarrattJ , ReuschM , ValluriU , et al. Roxadustat for the maintenance treatment of anemia in patients with end-stage kidney disease on stable dialysis: a European phase 3, randomized, open-label, active-controlled study (PYRENEES). Advances in Therapy2021;38(10):5361-80. [MEDLINE: 34537926]EspositoC , CsikyB , TataradzeA , ReuschM , HanC , SulowiczW . Two phase 3, multicenter, randomized studies of intermittent oral roxadustat in anemic CKD patients on (PYRENEES) and not on (ALPS) dialysis. Swiss Medical Weekly2020;150(Suppl 248):21-2S. [EMBASE: 634241523]EspositoC , CsikyB , TataradzeA , ReuschM , HanC , SulowiczW . Two phase 3, multicenter, randomized studies of intermittent oral roxadustat in anemic CKD patients on (PYRENEES) and not on (ALPS) dialysis [abstract no: SA-PO225]. Journal of the American Society of Nephrology2019;30(Abstract Suppl):822. [EMBASE: 633767739]">PYRENEES 2021</a>; <a href="./references#CD013751-bbs2-0048" title="AstraZeneca. A phase 3, multicenter, randomized, open-label, active-controlled study of the safety and efficacy of roxadustat in the treatment of anemia in dialysis patients [Clinical study protocol v8.0 19 September 2018]. www.clinicaltrials.gov/ProvidedDocs/31/NCT02174731/Prot_000.pdf (accessed 10 May 2022). FishbaneS , PollockCA , El-ShahawyMA , EscuderoET , RastogiA , VanBP , et al. ROCKIES: an international, phase 3, randomized, open-label, active-controlled study of roxadustat for anemia in dialysis-dependent CKD patients [abstract no: TH-OR022]. Journal of the American Society of Nephrology2019;30(Abstract Suppl):6. [EMBASE: 633771219]">ROCKIES 2019</a>; <a href="./references#CD013751-bbs2-0049" title="CharytanC , Manllo-KarimR , MartinER , SteerD , BernardoM , DuaSL , et al. A randomized trial of roxadustat in anemia of kidney failure: SIERRAS study. Kidney International Reports2021;6(7):1829-39. [MEDLINE: 34307977]CharytanC , Manllo-KarimR , MartinER , SteerD , BernardoM , DuaSL , et al. SIERRAS: A phase 3, open-label, randomized, active-controlled study of the efficacy and safety of roxadustat in the maintenance treatment of anemia in subjects with ESRD on stable dialysis [abstract no: SA-PO227]. Journal of the American Society of Nephrology2019;30(Abstract Suppl):822. [EMBASE: 633767862]">SIERRAS 2021</a>; <a href="./references#CD013751-bbs2-0051" title="AkizawaT , NangakuM , YamaguchiT , KoretomoR , MaedaK , MiyazawaY , et al. A phase 3 study of enarodustat in anemic patients with CKD not requiring dialysis: the SYMPHONY ND study. Kidney International Reports2021;6(7):1840-9. [MEDLINE: 34307978]">SYMPHONY ND 2021</a>) were not blinded to treatment allocation for participants and investigators. The risk of performance bias was unclear in 13 studies. </p> </section> <section id="CD013751-sec-0059"> <h5 class="title">Detection bias</h5> <p>Eight studies (<a href="./references#CD013751-bbs2-0011" title="PerkovicV , BlackorbyA , CizmanB , CarrollK , CobitzA , DaviesR , et al. ASCEND-ND: Study design and baseline characteristics. Nephrology Dialysis Transplantation2021;36(Suppl 1):i334-5. [EMBASE: 635918331]SinghAK , CarrollK , McMurrayJJ , SolomonS , JhaV , JohansenKL , et al. Daprodustat for the treatment of anemia in patients not undergoing dialysis. New England Journal of Medicine2021;385(25):2313-24. [MEDLINE: 34739196]">ASCEND‐ND 2021</a>; <a href="./references#CD013751-bbs2-0023" title="BarrattJ , AndricB , TataradzeA , SchoemigM , ReuschM , ValluriU , et al. Roxadustat for the treatment of anemia in CKD patients not on dialysis (NDD): a phase 3, randomized, open-label, active-controlled study [abstract no: TH-OR02]. Journal of the American Society of Nephrology2020;31(Abstract Suppl):1. [EMBASE: 633697812]BarrattJ , AndricB , TataradzeA , SchomigM , ReuschM , ValluriU , et al. Roxadustat for the treatment of anaemia in chronic kidney disease patients not on dialysis: a phase 3, randomised, open-label, active-controlled study (DOLOMITES). Nephrology Dialysis Transplantation2021;36(9):1616-28. [MEDLINE: 34077510]BarrattJ , AndricB , TataradzeA , SchomigM , ReuschM , ValluriU , et al. Roxadustat for the treatment of anaemia in chronic kidney disease patients not on dialysis: a phase 3, randomised, open-label, active controlled study [abstract no: MO001]. Nephrology Dialysis Transplantation2020;35(Suppl 3):iii101. [EMBASE: 633423023]BarrattJ , AndricB , TataradzeA , SchomigM , ReuschM , ValluriU , et al. Roxadustat for the treatment of anemia in chronic kidney disease (CKD) patients not on dialysis (NDD): a phase 3, randomized, open-label, active-controlled study [abstract no: Pos-247]. Kidney International Reports2021;6(4 Suppl):S104. [EMBASE: 2011683542]">DOLOMITES 2021</a>; <a href="./references#CD013751-bbs2-0025" title="CizmanB , AckertJ , MeadowcroftA , BiswasN , KellyD , KleinmanD , et al. Ocular safety profile of daprodustat: results of two 24 week studies [abstract no: SAO004]. Nephrology Dialysis Transplantation2018;33(Suppl 1):i316. [EMBASE: 622604997]HoldstockL , CizmanB , MeadowcroftAM , BiswasN , JohnsonBM , JonesD , et al. Daprodustat for anemia: a 24-week, open-label, randomized controlled trial in participants with chronic kidney disease. Clinical Kidney Journal2019;12(1):129-38. [MEDLINE: 30746140]HoldstockL , CizmanB , MeadowcroftAM , BiswasN , JonesD , JohnsonBM , et al. Daprodustat, a HIF-prolyl-hydroxylase inhibitor, increases and maintains hemoglobin over 24 weeks in anemic chronic kidney disease subjects [abstract no: TH-PO908]. Journal of the American Society of Nephrology2016;27(Abstract Suppl):304A. ">Holdstock 2019</a>; <a href="./references#CD013751-bbs2-0026" title="CizmanB , AckertJ , MeadowcroftA , BiswasN , KellyD , KleinmanD , et al. Ocular safety profile of daprodustat: results of two 24 week studies [abstract no: SAO004]. Nephrology Dialysis Transplantation2018;33(Suppl 1):i316. [EMBASE: 622604997]HoldstockL , CizmanB , MeadowcroftAM , BiswasN , JohnsonBM , JonesD , et al. Daprodustat for anemia: a 24-week, open-label, randomized controlled trial in participants with chronic kidney disease. Clinical Kidney Journal2019;12(1):129-38. [MEDLINE: 30746140]HoldstockL , CizmanB , MeadowcroftAM , BiswasN , JonesD , JohnsonBM , et al. Daprodustat, a HIF-prolyl-hydroxylase inhibitor, increases and maintains hemoglobin over 24 weeks in anemic chronic kidney disease subjects [abstract no: TH-PO908]. Journal of the American Society of Nephrology2016;27(Abstract Suppl):304A. ">Holdstock 2019a</a>; <a href="./references#CD013751-bbs2-0030" title="CizmanB , AckertJ , MeadowcroftA , BiswasN , KellyD , KleinmanD , et al. Ocular safety profile of daprodustat: results of two 24 week studies [abstract no: SAO004]. Nephrology Dialysis Transplantation2018;33(Suppl 1):i316. [EMBASE: 622604997]CobitzAR , MeadowcroftAM , CizmanB , HoldstockL , BiswasN , JonesD , et al. Daprodustat, a HIF-prolyl-hydroxylase inhibitor, maintains hemoglobin levels over 24 weeks in anemic hemodialysis subjects switching from recombinant human erythropoietin. [abstract no: SA-OR114]. Journal of the American Society of Nephrology2016;27(Abstract Suppl):93A. MeadowcroftAM , CizmanB , HoldstockL , BiswasN , JohnsonBM , JonesD , et al. Daprodustat for anemia: a 24-week, open-label, randomized controlled trial in participants on hemodialysis. Clinical Kidney Journal2019;12(1):139-48. [MEDLINE: 30746141]">Meadowcroft 2019</a>; <a href="./references#CD013751-bbs2-0036" title="GSK201753. A 52-week, Phase III, open-label, multi-center study to evaluate efficacy and safety of GSK1278863 in Japanese non-dialysis and peritoneal dialysis subjects with anemia associated with chronic kidney disease [study protocol]. www.clinicaltrials.gov/ProvidedDocs/63/NCT02791763/Prot_000.pdf (accessed 9 May 2022). NangakuM , HamanoT , AkizawaT , TsubakiharaY , NagaiR , OkudaN , et al. Daprodustat compared with epoetin beta pegol for anemia in Japanese patients not on dialysis: a 52-week randomized open-label phase 3 trial. American Journal of Nephrology2021;52(1):26-35. [MEDLINE: 33561857]">Nangaku 2021b</a>; <a href="./references#CD013751-bbs2-0042" title="BunnHF . Vadadustat for anemia in patients with dialysis-dependent or non-dialysis-dependent chronic kidney disease. New England Journal of Medicine2021;385(16):e56. [MEDLINE: 34644481]ChertowGM , PergolaPE , AgarwalR , BlockGA , FaragYM , JardineAG , et al. Cardiovascular safety and efficacy of vadadustat for the treatment of anemia in non-dialysis-dependent CKD: design and baseline characteristics. American Heart Journal2021;235(5):1-11. [MEDLINE: 33129989]ChertowGM , PergolaPE , FaragYM , AgarwalR , ArnoldS , BakoG , et al. Vadadustat in patients with anemia and non-dialysis-dependent CKD. New England Journal of Medicine2021;384(17):1589-600. [MEDLINE: 33913637]ChertowGM . Global phase 3 clinical trials of vadadustat vs. darbepoetin alfa for treatment of anemia in patients with non-dialysis-dependent CKD [abstract no: FR-OR54]. Journal of the American Society of Nephrology2020;31(Abstract Suppl):B2. [EMBASE: 633697273]KouryM , PergolaPE , Roy-ChaudhuryP , FaragYM , LuoW , AndersR , et al. Iron-related outcomes in patients with non-dialysis-dependent CKD randomized to vadadustat vs. darbepoetin Alfa [abstract no: PO0482]. Journal of the American Society of Nephrology2021;32(Abstract Suppl):190. [EMBASE: 636329134]McCulloughPA , LuoW , AndersR , VargoD , ParfreyPS . Assessment of thromboembolic events with vadadustat vs. darbepoetin alfa for treatment of anemia in patients with non-dialysis-dependent CKD [abstract no: PO0462]. Journal of the American Society of Nephrology2021;32(Abstract Suppl):184. [EMBASE: 636331039]">PRO2TECT‐CONVERSION 2021</a>; <a href="./references#CD013751-bbs2-0043" title="BunnHF . Vadadustat for anemia in patients with dialysis-dependent or non-dialysis-dependent chronic kidney disease. New England Journal of Medicine2021;385(16):e56. [MEDLINE: 34644481]ChertowGM , PergolaPE , AgarwalR , BlockGA , FaragYM , JardineAG , et al. Cardiovascular safety and efficacy of vadadustat for the treatment of anemia in non-dialysis-dependent CKD: design and baseline characteristics. American Heart Journal2021;235(5):1-11. [MEDLINE: 33129989]ChertowGM , PergolaPE , FaragYM , AgarwalR , ArnoldS , BakoG , et al. Vadadustat in patients with anemia and non-dialysis-dependent CKD. New England Journal of Medicine2021;384(17):1589-600. [MEDLINE: 33913637]ChertowGM . Global phase 3 clinical trials of vadadustat vs. darbepoetin alfa for treatment of anemia in patients with non-dialysis-dependent CKD [abstract no: FR-OR5]. Journal of the American Society of Nephrology2020;31(Abstract Suppl):B2. [EMBASE: 633697273]KouryM , PergolaPE , Roy-ChaudhuryP , FaragYM , LuoW , AndersR , et al. Iron-related outcomes in patients with non-dialysis-dependent CKD randomized to vadadustat vs. darbepoetin alfa [abstract no: PO0482]. Journal of the American Society of Nephrology2021;32(Abstract Suppl):190. [EMBASE: 636329134]McCulloughPA , LuoW , AndersR , VargoD , ParfreyPS . Assessment of thromboembolic events with vadadustat vs. darbepoetin alfa for treatment of anemia in patients with non-dialysis-dependent CKD [abstract no: PO0462]. Journal of the American Society of Nephrology2021;32(Abstract Suppl):184. [EMBASE: 636331039]">PRO2TECT‐CORRECTION 2021</a>) assessed outcomes based on objective laboratory assessments and were at low risk of bias. Thirty‐seven studies (<a href="./references#CD013751-bbs2-0001" title="AkizawaT , TsubakiharaY , NangakuM , EndoY , NakajimaH , KohnoT , et al. Effects of daprodustat, a novel hypoxia-inducible factor prolyl hydroxylase inhibitor on anemia management in Japanese hemodialysis subjects. American Journal of Nephrology2017;45(2):127-35. [MEDLINE: 27978511]EndoY , KohnoT , ImaiY , KawaseN , HaraK , LeporeJJ , et al. A 4 -week dose response study of the hypoxia inducible factor-prolyl hydroxylase inhibitor GSK1278863 in Japanese anemic haemodialysis subjects [abstract no: SA-PO819]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):818A. NCT02019719. Study to evaluate the safety, efficacy and pharmacokinetics of GSK1278863 in Japanese hemodialysis-dependent subjects with anemia associated with chronic kidney disease [A 4-week, phase ii, randomized, double-blind, dose-ranging, placebo-controlled, parallel-group, multi-center study to evaluate the safety, efficacy and pharmacokinetics of GSK1278863 in Japanese hemodialysis-dependent subjects with anemia associated with chronic kidney disease]. clinicaltrials.gov/show/NCT02019719 (first received 24 December 2013). ">Akizawa 2017</a>; <a href="./references#CD013751-bbs2-0002" title="AkizawaT , IwasakiM , OtsukaT , ReuschM , MisumiT . Roxadustat for the treatment of chronic kidney disease-associated anemia in Japanese patients not on dialysis [abstract no: FR-PO1142]. Journal of the American Society of Nephrology2016;27(Abstract Suppl):7B. AkizawaT , IwasakiM , OtsukaT , ReuschM , MisumiT . Roxadustat treatment of chronic kidney disease-associated anemia in Japanese patients not on dialysis: a phase 2, randomized, double-blind, placebo-controlled trial. Advances in Therapy2019;36(6):1438-54. [MEDLINE: 30953333]">Akizawa 2019</a>; <a href="./references#CD013751-bbs2-0003" title="AkizawaT , IwasakiM , YamaguchiY , MajikawaY , ReuschM . Authors' Reply. Journal of the American Society of Nephrology2021;32(4):1005-7. [MEDLINE: 33649099]AkizawaT , IwasakiM , YamaguchiY , MajikawaY , ReuschM . Phase 3, randomized, double-blind, active-comparator (darbepoetin alfa) conversion study of oral roxadustat in CKD patients with anemia on hemodialysis in Japan [abstract no: TH-PO1151]. Journal of the American Society of Nephrology2018;29(Abstract Suppl):B4. AkizawaT , IwasakiM , YamaguchiY , MajikawaY , ReuschM . Phase 3, randomized, double-blind, active-comparator (darbepoetin alfa) study of oral roxadustat in CKD patients with anemia on hemodialysis in Japan. Journal of the American Society of Nephrology2020;31(7):1628-39. [MEDLINE: 32493693]AkizawaT , YamaguchiY , MajikawaY , ReuschM . Factors affecting the doses of roxadustat vs darbepoetin alfa for anemia treatment in hemodialysis patients. Therapeutic Apheresis &amp; Dialysis2021;25(5):575-85. [MEDLINE: 33200512]Astellas1517-CL-0307. A study of intermittent oral dosing of ASP1517 in hemodialysis chronic kidney disease patients with anemia [A phase 3, multi-center, randomized, 2-arm parallel, double-blind, active-comparator (darbepoetin alfa) conversion study of intermittent oral dosing of ASP1517 in hemodialysis chronic kidney disease patients with anemia]. www.clinicaltrials.astellas.com/study/?pid=1517-CL-0307 (accessed 4 May 2022). LiuF , WangJ , YeQ , FuH , MaoJ . Roxadustat for renal anemia in ESRD from PKD patients: is it safe enough?Journal of the American Society of Nephrology2021;32(4):1005. [MEDLINE: 33649100]NguyenQD , SepahYJ , YamaguchiY , OtsukaT , MajikawaY , ReuschM , et al. Ophthalmological effects of roxadustat in the treatment of anemia in dialysis-dependent and non-dialysis-dependent CKD patients: findings from two phase 3 studies [abstract no: PO0267]. Journal of the American Society of Nephrology2020;31(Abstract Suppl):134. [EMBASE: 633698979]SepahY , NguyenQD , YamaguchiY , MajikawaY , ReuschM , AkizawaT . Ophthalmological effects of roxadustat in the treatment of anaemia in chronic kidney disease patients on dialysis in a phase 3, randomised, double-blind, active-comparator conversion study [abstract no: MO002]. Nephrology Dialysis Transplantation2020;35(Suppl 3):iii102. [EMBASE: 633421367]">Akizawa 2020a</a>; <a href="./references#CD013751-bbs2-0004" title="AkizawaT , NangakuM , YonekawaT , OkudaN , KawamatsuS , OnoueT , et al. Efficacy and safety of daprodustat compared with darbepoetin alfa in Japanese hemodialysis patients with anemia: a randomized, double-blind, phase 3 trial. Clinical Journal of the American Society of Nephrology: CJASN2020;15(8):1155-65. [MEDLINE: 32723804]OzekiH , AkizawaT , NangakuM , YonekawaT , OkudaN , KawamatsuS , et al. Efficacy and safety of daprodustat compared with darbepoetin alfa in Japanese hemodialysis patients with anemia: A randomized, double-blind, phase 3 trial [abstract no: SaO036]. Nephrology Dialysis Transplantation2019;34(Suppl 1):a350. [EMBASE: 631305259]">Akizawa 2020c</a>; <a href="./references#CD013751-bbs2-0005" title="AkizawaT , IwasakiM , OtsukaT , YamaguchiY , ReuschM . A phase 3, multicenter, randomized, open-label, active comparator conversion study of roxadustat in non-dialysis-dependent (NDD) patients with anemia in chronic kidney disease (CKD) [abstract no: POS-244]. Kidney International Reports2021;6(4 Suppl):S103. [EMBASE: 2011682459]AkizawaT , IwasakiM , OtsukaT , YamaguchiY , ReuschM . A phase 3, multicenter, randomized, open-label, active comparator conversion study of roxadustat in non-dialysis-dependent (NDD) patients with anemia in CKD [abstract no: PO0269]. Journal of the American Society of Nephrology2020;31(Abstract Suppl):134. [EMBASE: 633699036]NguyenQD , SepahYJ , YamaguchiY , OtsukaT , MajikawaY , ReuschM , et al. Ophthalmological effects of roxadustat in the treatment of anemia in dialysis-dependent and non-dialysis-dependent CKD patients: findings from two phase 3 studies [abstract no: PO0267]. Journal of the American Society of Nephrology2020;31(Abstract Suppl):134. [EMBASE: 633698979]">Akizawa 2020f</a>; <a href="./references#CD013751-bbs2-0006" title="AkizawaT , IwasakiM , OtsukaT , YamaguchiY , ReuschM . Phase 3 study of roxadustat to treat anemia in non-dialysis-dependant CKD. Kidney International Reports2021;6(7):1810-28. [MEDLINE: 34307976]AkizawaT , Tanaka-AminoK , OtsukaT , YamaguchiY . Factors affecting doses of roxadustat versus darbepoetin alfa for anemia in nondialysis patients. American Journal of Nephrology2021;52(9):702-13. [MEDLINE: 34628408]">Akizawa 2021</a>; <a href="./references#CD013751-bbs2-0007" title="Astellas 1517-CL-0608. Roxadustat in the treatment of anemia in chronic kidney disease patients not requiring dialysis [A phase 3, randomized, double-blind, placebo controlled study of the efficacy and safety of roxadustat for the treatment of anemia in chronic kidney disease patients not on dialysis]. www.trialsummaries.com/Study/StudyDetails?id=14384&amp;tenant=MT_AST_90112019. EspositoC , CsikyB , TataradzeA , ReuschM , HanC , SulowiczW . Two phase 3, multicenter, randomized studies of intermittent oral roxadustat in anemic CKD patients on (PYRENEES) and not on (ALPS) dialysis [abstract no: SA-PO225]. Journal of the American Society of Nephrology2019;30(Abstract Suppl):822. [EMBASE: 633767739]Pecoits-FilhoR , ChanTM , HardyE , YuKH , FishbaneS . Roxadustat treatment results in consistent improvements in hemoglobin (Hb) vs. placebo: an analysis of three multinational randomized clinical trials in patients with non-dialysis-dependent CKD (NDD-CKD) [abstract no: TH-OR05]. Journal of the American Society of Nephrology2020;31(Abstract Suppl):2. [EMBASE: 633697943]RastogiA , Pecoits-FilhoR , FishbaneS , LittleDJ , HardyE , YuKH , et al. Roxadustat treatment corrects anemia to hemoglobin (HB) values ≥10 g/dL in the majority of patients with non-dialysis-dependent chronic kidney disease (NDD-CKD) [abstract no: PO0264]. Journal of the American Society of Nephrology2020;31(Abstract Suppl):133. [EMBASE: 633698803]ShutovE , SulowiczW , EspositoC , TataradzeA , AndricB , ReuschM , et al. Roxadustat for the treatment of anemia in chronic kidney disease patients not on dialysis: a phase 3, randomized, double-blind, placebo-controlled study (ALPS). Nephrology Dialysis Transplantation2021;36(9):1629-39. [MEDLINE: 33630072]">ALPS 2021</a>; <a href="./references#CD013751-bbs2-0008" title="CoyneDW , RogerSD , ChouW , BesarabA , LeongR , LeeTT , et al. Roxadustat favorably modifies iron indices in patients with non-dialysis-dependent CKD-related anemia [abstract no: PO0262]. Journal of the American Society of Nephrology2020;31(Abstract Suppl):132. [EMBASE: 633698686]CoyneDW , RogerSD , ShinS , KimSG , CadenaAA , MoustafaMA , et al. Roxadustat for CKD-related anemia in non-dialysis patients. Kidney International Reports2021;6(3):624-35. [MEDLINE: 33732977]CoyneDW , RogerSD , ShinSK , KimSG , CadenaAA , MoustafaMA , et al. ANDES: A phase 3, randomized, double-blind, placebo controlled study of the efficacy and safety of roxadustat for the treatment of anemia in CKD patients not on dialysis [abstract no: SA-PO0228]. Journal of the American Society of Nephrology2019;30(Abstract Suppl):822-3. [EMBASE: 633767955]Pecoits-FilhoR , ChanTM , HardyE , YuKHP , FishbaneS . Roxadustat treatment results in consistent improvements in hemoglobin (Hb) vs. placebo: an analysis of three multinational randomized clinical trials in patients with non-dialysis-dependent CKD (NDD-CKD) [abstract no: TH-OR05]. Journal of the American Society of Nephrology2020;31(Abstract Suppl):2. [EMBASE: 633697943]RastogiA , Pecoits-FilhoR , FishbaneS , LittleDJ , HardyE , YuKH , et al. Roxadustat treatment corrects anemia to hemoglobin (HB) values ≥10 g/dL in the majority of patients with non-dialysis-dependent chronic kidney disease (NDD-CKD) [abstract no: PO0264]. Journal of the American Society of Nephrology2020;31(Abstract Suppl):133. [EMBASE: 633698803]">ANDES 2021</a>; <a href="./references#CD013751-bbs2-0010" title="SinghAK . Daprodustat is noninferior to darbepoetin alfa in treating anemia in incident dialysis patients [abstract no: PO0465]. Journal of the American Society of Nephrology2021;32(Abstract Suppl):184-5. [EMBASE: 636331207]">ASCEND‐ID 2021</a>; <a href="./references#CD013751-bbs2-0012" title="JohansenKL , CobitzAR , LopesRD , SinghAK , ObradorGT , CizmanB , et al. Effects of daprodustat on hemoglobin and quality of life in patients with CKD: results of the ascend-NHQ randomized, double-blind, placebo-controlled trial [abstract no: FR-OR53]. Journal of the American Society of Nephrology2021;32(Abstract Suppl):36. [EMBASE: 636330656]">ASCEND‐NHQ 2021</a>; <a href="./references#CD013751-bbs2-0013" title="CoyneDW , SinghAK , LopesRD , BaileyCK , DiminoTL , HuangC , et al. ASCEND-TD: A randomized, double-blind, active-controlled study of daprodustat administered three times weekly in hemodialysis patients [abstract no: PO0487]. Journal of the American Society of Nephrology2021;32(Abstract Suppl):191. [EMBASE: 636329480]">ASCEND‐TD 2021</a>; <a href="./references#CD013751-bbs2-0014" title="BesarabA , HutlerHN , KlausS , LeeTT , LilienfeldDE , NeffTB , et al. FG-4592, a novel oral HIF prolyl hydroxylase inhibitor, elevates hemoglobin in anemic stage 3/4 CKD patients [abstract no: SA-FC416]. Journal of the American Society of Nephrology2010;21(Abstract Suppl):95A. BesarabA , ProvenzanoR , HertelJ , ZabanehR , KlausSJ , LeeT , et al. Randomized placebo-controlled dose-ranging and pharmacodynamics study of roxadustat (FG-4592) to treat anemia in nondialysis-dependent chronic kidney disease (NDD-CKD) patients. Nephrology Dialysis Transplantation2015;30(10):1665-73. [MEDLINE: 26238121]">Besarab 2015</a>; <a href="./references#CD013751-bbs2-0015" title="BrigandiRA , JohnsonB , OeiC , WestermanM , OlbinaG , deZoysaJ , et al. A novel hypoxia-inducible factor-prolyl hydroxylase inhibitor (GSK1278863) for anemia in CKD: a 28-day, phase 2a randomized trial. American Journal of Kidney Diseases2016;67(6):861-71. [MEDLINE: 26827289]BrigandiRA , JohnsonB , OeiC , WestermanME , OlbinaG , KumarS , et al. Induction of erythropoiesis in anemic patients by prolylhydroxylase inhibitor in a repeat dose, randomized placebo controlled trial [abstract no: SA-PO117]. Journal of the American Society of Nephrology2012;23(Abstract Suppl):662A. BrigandiRA , WestermanME , OlbinaG , OeiC , RussSF , KumarS . Modulation of hepcidin by prolylhydroxylase inhibitor in randomized trials [abstract no: SA-PO118]. Journal of the American Society of Nephrology2012;23(Abstract Suppl):662A. ">Brigandi 2016</a>; <a href="./references#CD013751-bbs2-0016" title="ChenN , HaoC , LiuB , LinHL , CailiW , XingCY , et al. A phase 3, randomized, open-label, active-controlled study of efficacy and safety of roxadustat for treatment of anemia in subjects with CKD on dialysis [abstract no: TH-PO1152]. Journal of the American Society of Nephrology2018;29(Abstract Suppl):B5. ChenN , HaoC , LiuBC , LinH , WangC , XingC , et al. Roxadustat treatment for anemia in patients undergoing long-term dialysis. New England Journal of Medicine2019;381(11):1011-22. [MEDLINE: 31340116]">Chen 2019</a>; <a href="./references#CD013751-bbs2-0017" title="ChenN , HaoC , PengX , LinH , YinA , HaoL , et al. Roxadustat for anemia in patients with kidney disease not receiving dialysis. New England Journal of Medicine2019;381(11):1001-10. [MEDLINE: 31340089]ChenN , HaoC , PengX , LinHL , YinA , HaoL , et al. A phase 3, randomized, double-blind, placebo-controlled study of efficacy and safety of roxadustat (FG-4592) for treatment of anemia in subjects with CKD not on dialysis [abstract no: TH-PO1153]. Journal of the American Society of Nephrology2018;29(Abstract Suppl):B5. ">Chen 2019a</a>; <a href="./references#CD013751-bbs2-0018" title="ChenN , QianJ , ChenJ , YuX , MeiC , HaoC , et al. Phase 2 studies of oral hypoxia-inducible factor prolyl hydroxylase inhibitor FG-4592 for treatment of anemia in China. Nephrology Dialysis Transplantation2017;32(8):1373-86. [MEDLINE: 28371815]">Chen DD 2017</a>; <a href="./references#CD013751-bbs2-0019" title="ChenN , QianJ , ChenJ , YuX , MeiC , HaoC , et al. Phase 2 studies of oral hypoxia-inducible factor prolyl hydroxylase inhibitor FG-4592 for treatment of anemia in China. Nephrology Dialysis Transplantation2017;32(8):1373-86. [MEDLINE: 28371815]QianJQ , ChenN , ChenJ , HaoC , LinHL , NiD , et al. A randomized, double-blind, placebo controlled trial of FG-4592 for correction of anemia in subjects with chronic kidney disease in China [abstract no: FR-OR011]. Journal of the American Society of Nephrology2013;24(Abstract Suppl):38A. ">Chen NDD 2017</a>; <a href="./references#CD013751-bbs2-0024" title="ProvenzanoM , EvgenyS , LiubovE , KorneyevaS , KathresalAA , PooleL , et al. HIMALAYAS: a phase 3, randomized, open-label, active-controlled study of the efficacy and safety of roxadustat in the treatment of anemia in incident-dialysis patients [abstract no: TH-OR021]. Journal of the American Society of Nephrology2019;30(Abstract Suppl):5. [EMBASE: 633771140]ProvenzanoR , ShutovE , EremeevaL , KorneyevaS , PooleL , SahaG , et al. Roxadustat for anemia in patients with end-stage renal disease incident to dialysis. Nephrology Dialysis Transplantation2021;36(9):1717-30. [MEDLINE: 33629100]">HIMALAYAS 2021</a>; <a href="./references#CD013751-bbs2-0027" title="HouYP , MaoXY , WangC , XuZH , BuZH , XuM , et al. Roxadustat treatment for anemia in peritoneal dialysis patients: a randomized controlled trial. Journal of the Formosan Medical Association2021;121(2):529-38. [MEDLINE: 34167878]">Hou 2021</a>; <a href="./references#CD013751-bbs2-0028" title="ChertowGM , BoudvilleN , ChowdhuryP , GonzalezC , KooiengaL , LuoW , et al. Vadadustat for treatment of anemia in patients with dialysis-dependent CKD receiving peritoneal dialysis [abstract no: PO0464]. Journal of the American Society of Nephrology2021;32(Abstract Suppl):184. [EMBASE: 636331136]EckardtKU , AgarwalR , AswadA , AwadA , BlockGA , BacciMR , et al. Safety and efficacy of vadadustat for anemia in patients undergoing dialysis. New England Journal of Medicine2021;384(17):1601-12. [MEDLINE: 33913638]EckardtKU , AgarwalR , FaragYM , JardineAG , KhawajaZ , KouryMJ , et al. Global Phase 3 programme of vadadustat for treatment of anaemia of chronic kidney disease: rationale, study design and baseline characteristics of dialysis-dependent patients in the INNO2VATE trials. Nephrology Dialysis Transplantation2020;36(11):2039-48. [MEDLINE: 33188693]EckardtKU . Global phase 3 clinical trials of vadadustat vs. darbepoetin alfa for treatment of anemia in patients with dialysis-dependent CKD [abstract no: TH-OR01]. Journal of the American Society of Nephrology2020;31(Abstract Suppl):1. [EMBASE: 633697781]ParfreyPS , LuoW , MaroniB , AndersR , VargoD , McCulloughPA . Thromboembolic events with vadadustat vs. darbepoetin alfa for anemia treatment in patients with dialysis-dependent CKD [abstract no: PO0463]. Journal of the American Society of Nephrology2021;32(Abstract Suppl):184. [EMBASE: 636331080]WinkelmayerW , TumlinJA , FishbaneS , FaragY , VargoD , LuoW , et al. Hematologic efficacy of vadadustat for anemia in patients with kidney failure on dialysis [abstract no: MO529]. Nephrology Dialysis Transplantation2021;36(Suppl 1):i325-6. [EMBASE: 635917983]WinkelmayerWC , FishbaneS , TumlinJA , FaragYM , LuoW , AndersR , et al. Iron-related outcomes in patients with dialysis-dependent CKD randomized to vadadustat vs. darbepoetin alfa [abstract no: PO0457]. Journal of the American Society of Nephrology2021;32(Abstract Suppl):182. [EMBASE: 636330773]">INNO2VATE 2020</a>; <a href="./references#CD013751-bbs2-0029" title="EckardtKU , AgarwalR , AswadA , AwadA , BlockGA , BacciMR , et al. Safety and efficacy of vadadustat for anemia in patients undergoing dialysis. New England Journal of Medicine2021;384(17):1601-12. [MEDLINE: 33913638]EckardtKU , AgarwalR , FaragYM , JardineAG , KhawajaZ , KouryMJ , et al. Global Phase 3 programme of vadadustat for treatment of anaemia of chronic kidney disease: rationale, study design and baseline characteristics of dialysis-dependent patients in the INNO2VATE trials. Nephrology Dialysis Transplantation2020;36(11):2039-48. [MEDLINE: 33188693]EckardtKU . Global phase 3 clinical trials of vadadustat vs. darbepoetin alfa for treatment of anemia in patients with dialysis-dependent CKD [abstract no: TH-OR01]. Journal of the American Society of Nephrology2020;31(Abstract Suppl):1. [EMBASE: 633697781]WinkelmayerWC , FishbaneS , TumlinJA , FaragYM , LuoW , AndersR , et al. Iron-related outcomes in patients with dialysis-dependent CKD randomized to vadadustat vs. darbepoetin alfa [abstract no: PO0457]. Journal of the American Society of Nephrology2021;32(Abstract Suppl):182. [EMBASE: 636330773]">INNO2VATE 2020a</a>; <a href="./references#CD013751-bbs2-0031" title="AkizawaT , TaguchiM , MatsudaY , IekushiK , YamadaT , YamamotoH . Molidustat for the treatment of renal anaemia in patients with dialysis-dependent chronic kidney disease: Design and rationale of three phase III studies. BMJ Open2019;9(6):e026602. [MEDLINE: 31203241]AkizawaT , YamadaT , NoboriK , MatsudaY , HayashiY , HayasakiT , et al. Molidustat for Japanese patients with renal anemia receiving dialysis. Kidney International Reports2021;6(10):2604–16. [MEDLINE: 34622100]AkizawaT , YamadaT , NoboriK , MatsudaY , HayashiY , HayasakiT , et al. Results from a phase 3 study comparing the efficacy and safety of molidustat vs. Darbepoetin Alfa in patients receiving hemodialysis and treated with erythropoiesis-stimulating agents (ESAS) [abstract no: PO22623]. Journal of the American Society of Nephrology2020;31(Abstract Suppl):B4. [EMBASE: 633697376]">MIYABI HD‐M 2019</a>; <a href="./references#CD013751-bbs2-0032" title="YamamotoH , NoboriK , MatsudaY , HayashiY , HayasakiT , AkizawaT . Efficacy and safety of molidustat for anemia in ESA-naive nondialysis patients: a randomized, phase 3 trial. American Journal of Nephrology2021;52(10-11):871-83. [MEDLINE: 34569489]YamamotoH , TaguchiM , MatsudaY , IekushiK , YamadaT , AkizawaT . Molidustat for the treatment of renal anaemia in patients with non-dialysis-dependent chronic kidney disease: design and rationale of two phase III studies. BMJ Open2019;9(6):e026704. [MEDLINE: 31203242]YamamotoH , TaguchiM , NoboriK , MatsudaY , IekushiK , AkizawaT . To investigate the efficacy and safety of molidustat in non-dialysis patients with renal anemia who are not treated with erythropoiesis stimulating agents: MIYABI ND-C [abstract no: P1866]. Nephrology Dialysis Transplantation2020;35(Suppl 3):iii2177. [EMBASE: 633422996]">MIYABI ND‐C 2019</a>; <a href="./references#CD013751-bbs2-0033" title="YamamotoH , NoboriK , MatsudaY , HayashiY , HayasakiT , AkizawaT . Molidustat for renal anemia in nondialysis patients previously treated with erythropoiesis-stimulating agents: a randomized, open-label, phase 3 study. American Journal of Nephrology2021;52(10-11):884-93. [MEDLINE: 34569482]YamamotoH , TaguchiM , MatsudaY , IekushiK , YamadaT , AkizawaT . Molidustat for the treatment of renal anaemia in patients with non-dialysis-dependent chronic kidney disease: design and rationale of two phase III studies. BMJ Open2019;9(6):e026704. [MEDLINE: 31203242]YamamotoH , TaguchiM , NoboriK , MatsudaY , IekushiK , AkizawaT . To investigate the efficacy and safety of molidustat in non-dialysis patients with renal anemia who are treated with erythropoiesis stimulating agents: Miyabi ND-M [Abstract no: P1868]. Nephrology Dialysis Transplantation2020;35(Suppl 3):iii2179. [EMBASE: 633423006]">MIYABI ND‐M 2019</a>; <a href="./references#CD013751-bbs2-0034" title="NangakuM , KondoK , UetaK , KokadoY , KanekoG , MatsudaH , et al. Efficacy and safety of vadadustat compared with darbepoetin alfa in Japanese anemic patients on hemodialysis: a phase 3, multicenter, randomized, double-blind study. Nephrology Dialysis Transplantation2021;36(9):1731-41. [MEDLINE: 33650630]NangakuM , KondoK , UetaK , KokadoY , KanekoG , MatsudaH , et al. Randomized, double-blinded, active-controlled (darbepoetin alfa), phase 3 study of vadadustat in CKD patients with anemia on hemodialysis in Japan [abstract no: TH-OR024]. Journal of the American Society of Nephrology2019;30(Abstract Suppl):6. [EMBASE: 633771357]">Nangaku 2021</a>; <a href="./references#CD013751-bbs2-0035" title="NangakuM , KondoK , KokadoY , UetaK , KanekoG , ShiosakaM , et al. Randomized, open-label, active-controlled (darbepoetin alfa), phase 3 study of vadadustat for treating anemia in non-dialysis-dependent CKD patients in Japan [abstract no: SA-PO229]. Journal of the American Society of Nephrology2019;30(Abstract Suppl):823. [EMBASE: 633767995]NangakuM , KondoK , KokadoY , UetaK , KanekoG , TandaiT , et al. Phase 3 randomized study comparing vadadustat with darbepoetin alfa for anemia in Japanese patients with nondialysis-dependent CKD. Journal of the American Society of Nephrology2021;32(7):1779-90. [MEDLINE: 33883252]">Nangaku 2021a</a>; <a href="./references#CD013751-bbs2-0037" title="Astellas1517-CL-0304. A study to investigate the effect of ASP1517 after intermittent oral dosing in dialysis chronic kidney disease patients with anemia compared with darbepoetin as a reference drug [A Japanese, phase 2, multicenter, randomized, 4-arm parallel, double-blind (arms 1-3), open-label (arm 4), active-comparator (darbepoetin alfa) study of intermittent oral dosing of asp1517 in hemodialysis-dependent chronic kidney disease patients with anemia [1517-CL-0304 clinical study results report]]. www.trialsummaries.com/Study/StudyDetails?id=14175&amp;tenant=MT_AST_9011; www.clinicaltrials.gov/ct2/show/NCT01888445 (first received 6 August 2018). ">NCT01888445</a>; <a href="./references#CD013751-bbs2-0038" title="NangakuM , FaragYM , deGomaE , LuoW , VargoD , KhawajaZ . Vadadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor, for treatment of anemia of chronic kidney disease: two randomized Phase 2 trials in Japanese patients. Nephrology Dialysis Transplantation 2020 Jul 20 [epub ahead of print]. [DOI: 10.1093/ndt/gfaa060] [MEDLINE: 32719868]NangakuM , KhawajaZ , LuoW , GarafolaS , De GomaE , KomatsuY . Randomized, placebo-controlled phase 2 trials of vadadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), to treat anemia of CKD [abstract no: TH-PO228]. Journal of the American Society of Nephrology2018;29(Abstract Suppl):171. [EMBASE: 633737146]SolinskyC , FaragYM , KhawajaZ , AndersR , LuoW , ChavanA , et al. Impact of vadadustat on iron regulation in Japanese subjects with chronic kidney disease (CKD) [abstract no: 352]. American Journal of Kidney Diseases2020;75(4):638-9. [EMBASE: 2005716872]">NDD‐CKD 2020</a>; <a href="./references#CD013751-bbs2-0039" title="NangakuM , FaragYM , deGomaE , LuoW , VargoD , KhawajaZ . Vadadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor, for treatment of anemia of chronic kidney disease: two randomized Phase 2 trials in Japanese patients. Nephrology Dialysis Transplantation 2020 Jul 20 [epub ahead of print]. [DOI: 10.1093/ndt/gfaa060] [MEDLINE: 32719868]NangakuM , KhawajaZ , LuoW , GarafolaS , deGomaE , KomatsuY . Randomized, placebo-controlled phase 2 trials of vadadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), to treat anemia of CKD [abstract no: TH-PO228]. Journal of the American Society of Nephrology2018;29(Abstract Suppl):171. [EMBASE: 633737146]SolinskyC , FaragYM , KhawajaZ , AndersR , LuoW , ChavanA , et al. Impact of vadadustat on iron regulation in Japanese subjects with chronic kidney disease (CKD) [abstract no: 352]. American Journal of Kidney Diseases2020;75(4):638-9. [EMBASE: 2005716872]">NDD‐CKD 2020a</a>; <a href="./references#CD013751-bbs2-0040" title="AstraZeneca. A phase 3, multicenter, randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of roxadustat for the treatment of anemia in chronic kidney disease patients not on dialysis [clinical study protocol V6; 31 August 2018]. www.clinicaltrials.gov/ProvidedDocs/27/NCT02174627/Prot_000.pdf (accessed 9 May 2022). EleftheriadisT , PissasG , LiakopoulosV , StefanidisI . On the increased event rate of urinary tract infection and pneumonia in CKD patients treated with roxadustat for anemia. Journal of the American Society of Nephrology2021;32(6):1537. [MEDLINE: 33849917]FishbaneS , El-ShahawyMA , Pecoits-FilhoR , VanBP , HouserMT , FrisonL , et al. OLYMPUS: a phase 3, randomized, double-blind, placebo-controlled, international study of roxadustat efficacy in patients with non-dialysis-dependent (NDD) CKD and anemia [abstract no: TH-OR023]. Journal of the American Society of Nephrology2019;30(Abstract Suppl):6. [EMBASE: 633771285]FishbaneS , El-ShahawyMA , Pecoits-FilhoR , VanBP , HouserMT , FrisonL , et al. Roxadustat for treating anemia in patients with CKD not on dialysis: results from a randomized phase 3 study. Journal of the American Society of Nephrology2021;32(3):737-55. [MEDLINE: 33568383]FishbaneS , El-ShahawyMA , VanBP , LittleDJ . Authors' Reply. Journal of the American Society of Nephrology2021;32(6):1537-8. [MEDLINE: 33849916]Pecoits-FilhoR , ChanTM , HardyE , YuKH , FishbaneS . Roxadustat treatment results in consistent improvements in hemoglobin (Hb) vs. placebo: an analysis of three multinational randomized clinical trials in patients with non-dialysis-dependent CKD (NDD-CKD) [abstract no: TH-OR05]. Journal of the American Society of Nephrology2020;31(Abstract Suppl):2. [EMBASE: 633697943]RastogiA , Pecoits-FilhoR , FishbaneS , LittleDJ , HardyE , YuKH , et al. Roxadustat treatment corrects anemia to hemoglobin (HB) values ≥10 g/dL in the majority of patients with non-dialysis-dependent chronic kidney disease (NDD-CKD) [abstract no: PO0264]. Journal of the American Society of Nephrology2020;31(Abstract Suppl):133. [EMBASE: 633698803]">OLYMPUS 2021</a>; <a href="./references#CD013751-bbs2-0041" title="HaaseVH , SpinowitzBS , PergolaPE , FarmerT , MaroniBJ , HartmanCS . AKB-6548 demonstrates controlled hemogloblin (HGB) response in a phase 2b study for the treatment of anemia in patients with chronic kidney disease not on dialysis (ND-CKD) [abstract no: TH-PO649]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):237A. HaaseVH , SpinowitzBS , PergolaPE , KhawajaZ , ChanJ , ZurawQ , et al. Efficacy and dose requirements of vadadustat are independent of systemic inflammation and prior erythropoiesis-stimulating agent(ESA) dose in patients with non-dialysis dependent chronic kidney disease (NDD-CKD) [abstract no: TH-PO907]. Journal of the American Society of Nephrology2016;27(Abstract Suppl):304A. PergolaPE , SpinowitzB , HaaseVH , HartmanCS , FarmerTM , PoluKR , et al. AKB-6548, a novel hypoxia-inducible factor prolyl-hydroxylase inhibitor (HIF-PHI) for the treatment of anemia in patients with chronic kidney disease not on dialysis (ND-CKD) [abstract no: FO015]. Nephrology Dialysis Transplantation2015;30(Suppl 3):iii8. [EMBASE: 72206296]PergolaPE , SpinowitzBS , HartmanCS , MaroniBJ , HaaseVH . Vadadustat, a novel oral HIF stabilizer, provides effective anemia treatment in nondialysis-dependent chronic kidney disease. Kidney International2016;90(5):1115-22. [MEDLINE: 27650732]SpinowitzBS , PergolaPE , HaaseVH , FarmerTM , HartmanCS , MaroniBJ . Hemoglobin (HGB) response in a phase 2b study of AKB-6548 for the treatment of anemia in patients with non-dialysis dependant chronic kidney disease (NDD-CKD). [abstract no: TH-OR038]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):11A. ">Pergola 2016</a>; <a href="./references#CD013751-bbs2-0044" title="ProvenzanoR , FaddaG , BernardoM , JamesC , KochendoerferG , LeeT , et al. FG2216, a novel oral HIF-PHI, stimulates erythropoiesis and increases hemoglobin concentration in patients with non-dialysis CKD [abstract no: 212]. American Journal of Kidney Diseases2008;51(4):A80. ProvenzanoR , HulterH , AgarwalA , KlausS , LeeT , YuP , et al. Hypoxia-inducible factor (HIF) prolyl hydroxylase inhibitor FG-2216 increases Hb without FE depletion in the absence of IV Fe [abstract no: 249]. American Journal of Kidney Diseases2013;61(4):A78. [EMBASE: 71024073]">Provenzano 2008</a>; <a href="./references#CD013751-bbs2-0047" title="Astellas 1517-CL-0613. Roxadustat in the treatment of anemia in end stage renal disease (ESRD) patients on stable dialysis [A phase 3, randomized, open-label, active-controlled study to evaluate the efficacy and safety of roxadustat in the maintenance treatment of anemia in end stage renal disease patients on stable dialysis]. www.trialsummaries.com/Study/StudyDetails?id=14380&amp;tenant=MT_AST_9011 (accessed 9 May 2022). CsikyB , SchomigM , EspositoC , BarrattJ , ReuschM , ValluriU , et al. Roxadustat for the maintenance treatment of anemia in patients with end-stage kidney disease on stable dialysis: a European phase 3, randomized, open-label, active-controlled study (PYRENEES). Advances in Therapy2021;38(10):5361-80. [MEDLINE: 34537926]EspositoC , CsikyB , TataradzeA , ReuschM , HanC , SulowiczW . Two phase 3, multicenter, randomized studies of intermittent oral roxadustat in anemic CKD patients on (PYRENEES) and not on (ALPS) dialysis. Swiss Medical Weekly2020;150(Suppl 248):21-2S. [EMBASE: 634241523]EspositoC , CsikyB , TataradzeA , ReuschM , HanC , SulowiczW . Two phase 3, multicenter, randomized studies of intermittent oral roxadustat in anemic CKD patients on (PYRENEES) and not on (ALPS) dialysis [abstract no: SA-PO225]. Journal of the American Society of Nephrology2019;30(Abstract Suppl):822. [EMBASE: 633767739]">PYRENEES 2021</a>; <a href="./references#CD013751-bbs2-0048" title="AstraZeneca. A phase 3, multicenter, randomized, open-label, active-controlled study of the safety and efficacy of roxadustat in the treatment of anemia in dialysis patients [Clinical study protocol v8.0 19 September 2018]. www.clinicaltrials.gov/ProvidedDocs/31/NCT02174731/Prot_000.pdf (accessed 10 May 2022). FishbaneS , PollockCA , El-ShahawyMA , EscuderoET , RastogiA , VanBP , et al. ROCKIES: an international, phase 3, randomized, open-label, active-controlled study of roxadustat for anemia in dialysis-dependent CKD patients [abstract no: TH-OR022]. Journal of the American Society of Nephrology2019;30(Abstract Suppl):6. [EMBASE: 633771219]">ROCKIES 2019</a>; <a href="./references#CD013751-bbs2-0049" title="CharytanC , Manllo-KarimR , MartinER , SteerD , BernardoM , DuaSL , et al. A randomized trial of roxadustat in anemia of kidney failure: SIERRAS study. Kidney International Reports2021;6(7):1829-39. [MEDLINE: 34307977]CharytanC , Manllo-KarimR , MartinER , SteerD , BernardoM , DuaSL , et al. SIERRAS: A phase 3, open-label, randomized, active-controlled study of the efficacy and safety of roxadustat in the maintenance treatment of anemia in subjects with ESRD on stable dialysis [abstract no: SA-PO227]. Journal of the American Society of Nephrology2019;30(Abstract Suppl):822. [EMBASE: 633767862]">SIERRAS 2021</a>; <a href="./references#CD013751-bbs2-0050" title="AkizawaT , MaedaK , MiyazawaY , KoretomoR . Phase 3 study to compare the efficacy and safety of enarodustat (JTZ-951), an oral HIF-PH inhibitor, with darbepoetin alfa in anemic patients with CKD receiving maintenance hemodialysis [abstract no: TH-PO1186]. Journal of the American Society of Nephrology2019;30(Abstract Suppl):B4. AkizawaT , NangakuM , YamaguchiT , KoretomoR , MaedaK , MiyazawaY , et al. A phase 3 study of enarodustat (JTZ-951) in Japanese hemodialysis patients for treatment of anemia in chronic kidney disease: SYMPHONY HD study. Kidney Diseases2021;7(6):494-502. [EMBASE: 2013576033]">SYMPHONY HD 2021</a>; <a href="./references#CD013751-bbs2-0051" title="AkizawaT , NangakuM , YamaguchiT , KoretomoR , MaedaK , MiyazawaY , et al. A phase 3 study of enarodustat in anemic patients with CKD not requiring dialysis: the SYMPHONY ND study. Kidney International Reports2021;6(7):1840-9. [MEDLINE: 34307978]">SYMPHONY ND 2021</a>) were at high risk of bias for blinding of outcome assessment in reporting patient‐centred outcomes, including adverse events. Six studies were considered at unclear risk of bias. </p> </section> </section> <section id="CD013751-sec-0060"> <h4 class="title">Incomplete outcome data</h4> <p>Twelve studies (<a href="./references#CD013751-bbs2-0004" title="AkizawaT , NangakuM , YonekawaT , OkudaN , KawamatsuS , OnoueT , et al. Efficacy and safety of daprodustat compared with darbepoetin alfa in Japanese hemodialysis patients with anemia: a randomized, double-blind, phase 3 trial. Clinical Journal of the American Society of Nephrology: CJASN2020;15(8):1155-65. [MEDLINE: 32723804]OzekiH , AkizawaT , NangakuM , YonekawaT , OkudaN , KawamatsuS , et al. Efficacy and safety of daprodustat compared with darbepoetin alfa in Japanese hemodialysis patients with anemia: A randomized, double-blind, phase 3 trial [abstract no: SaO036]. Nephrology Dialysis Transplantation2019;34(Suppl 1):a350. [EMBASE: 631305259]">Akizawa 2020c</a>; <a href="./references#CD013751-bbs2-0008" title="CoyneDW , RogerSD , ChouW , BesarabA , LeongR , LeeTT , et al. Roxadustat favorably modifies iron indices in patients with non-dialysis-dependent CKD-related anemia [abstract no: PO0262]. Journal of the American Society of Nephrology2020;31(Abstract Suppl):132. [EMBASE: 633698686]CoyneDW , RogerSD , ShinS , KimSG , CadenaAA , MoustafaMA , et al. Roxadustat for CKD-related anemia in non-dialysis patients. Kidney International Reports2021;6(3):624-35. [MEDLINE: 33732977]CoyneDW , RogerSD , ShinSK , KimSG , CadenaAA , MoustafaMA , et al. ANDES: A phase 3, randomized, double-blind, placebo controlled study of the efficacy and safety of roxadustat for the treatment of anemia in CKD patients not on dialysis [abstract no: SA-PO0228]. Journal of the American Society of Nephrology2019;30(Abstract Suppl):822-3. [EMBASE: 633767955]Pecoits-FilhoR , ChanTM , HardyE , YuKHP , FishbaneS . Roxadustat treatment results in consistent improvements in hemoglobin (Hb) vs. placebo: an analysis of three multinational randomized clinical trials in patients with non-dialysis-dependent CKD (NDD-CKD) [abstract no: TH-OR05]. Journal of the American Society of Nephrology2020;31(Abstract Suppl):2. [EMBASE: 633697943]RastogiA , Pecoits-FilhoR , FishbaneS , LittleDJ , HardyE , YuKH , et al. Roxadustat treatment corrects anemia to hemoglobin (HB) values ≥10 g/dL in the majority of patients with non-dialysis-dependent chronic kidney disease (NDD-CKD) [abstract no: PO0264]. Journal of the American Society of Nephrology2020;31(Abstract Suppl):133. [EMBASE: 633698803]">ANDES 2021</a>; <a href="./references#CD013751-bbs2-0010" title="SinghAK . Daprodustat is noninferior to darbepoetin alfa in treating anemia in incident dialysis patients [abstract no: PO0465]. Journal of the American Society of Nephrology2021;32(Abstract Suppl):184-5. [EMBASE: 636331207]">ASCEND‐ID 2021</a>; <a href="./references#CD013751-bbs2-0014" title="BesarabA , HutlerHN , KlausS , LeeTT , LilienfeldDE , NeffTB , et al. FG-4592, a novel oral HIF prolyl hydroxylase inhibitor, elevates hemoglobin in anemic stage 3/4 CKD patients [abstract no: SA-FC416]. Journal of the American Society of Nephrology2010;21(Abstract Suppl):95A. BesarabA , ProvenzanoR , HertelJ , ZabanehR , KlausSJ , LeeT , et al. Randomized placebo-controlled dose-ranging and pharmacodynamics study of roxadustat (FG-4592) to treat anemia in nondialysis-dependent chronic kidney disease (NDD-CKD) patients. Nephrology Dialysis Transplantation2015;30(10):1665-73. [MEDLINE: 26238121]">Besarab 2015</a>; <a href="./references#CD013751-bbs2-0015" title="BrigandiRA , JohnsonB , OeiC , WestermanM , OlbinaG , deZoysaJ , et al. A novel hypoxia-inducible factor-prolyl hydroxylase inhibitor (GSK1278863) for anemia in CKD: a 28-day, phase 2a randomized trial. American Journal of Kidney Diseases2016;67(6):861-71. [MEDLINE: 26827289]BrigandiRA , JohnsonB , OeiC , WestermanME , OlbinaG , KumarS , et al. Induction of erythropoiesis in anemic patients by prolylhydroxylase inhibitor in a repeat dose, randomized placebo controlled trial [abstract no: SA-PO117]. Journal of the American Society of Nephrology2012;23(Abstract Suppl):662A. BrigandiRA , WestermanME , OlbinaG , OeiC , RussSF , KumarS . Modulation of hepcidin by prolylhydroxylase inhibitor in randomized trials [abstract no: SA-PO118]. Journal of the American Society of Nephrology2012;23(Abstract Suppl):662A. ">Brigandi 2016</a>; <a href="./references#CD013751-bbs2-0016" title="ChenN , HaoC , LiuB , LinHL , CailiW , XingCY , et al. A phase 3, randomized, open-label, active-controlled study of efficacy and safety of roxadustat for treatment of anemia in subjects with CKD on dialysis [abstract no: TH-PO1152]. Journal of the American Society of Nephrology2018;29(Abstract Suppl):B5. ChenN , HaoC , LiuBC , LinH , WangC , XingC , et al. Roxadustat treatment for anemia in patients undergoing long-term dialysis. New England Journal of Medicine2019;381(11):1011-22. [MEDLINE: 31340116]">Chen 2019</a>; <a href="./references#CD013751-bbs2-0017" title="ChenN , HaoC , PengX , LinH , YinA , HaoL , et al. Roxadustat for anemia in patients with kidney disease not receiving dialysis. New England Journal of Medicine2019;381(11):1001-10. [MEDLINE: 31340089]ChenN , HaoC , PengX , LinHL , YinA , HaoL , et al. A phase 3, randomized, double-blind, placebo-controlled study of efficacy and safety of roxadustat (FG-4592) for treatment of anemia in subjects with CKD not on dialysis [abstract no: TH-PO1153]. Journal of the American Society of Nephrology2018;29(Abstract Suppl):B5. ">Chen 2019a</a>; <a href="./references#CD013751-bbs2-0019" title="ChenN , QianJ , ChenJ , YuX , MeiC , HaoC , et al. Phase 2 studies of oral hypoxia-inducible factor prolyl hydroxylase inhibitor FG-4592 for treatment of anemia in China. Nephrology Dialysis Transplantation2017;32(8):1373-86. [MEDLINE: 28371815]QianJQ , ChenN , ChenJ , HaoC , LinHL , NiD , et al. A randomized, double-blind, placebo controlled trial of FG-4592 for correction of anemia in subjects with chronic kidney disease in China [abstract no: FR-OR011]. Journal of the American Society of Nephrology2013;24(Abstract Suppl):38A. ">Chen NDD 2017</a>; <a href="./references#CD013751-bbs2-0020" title="AkizawaT , MacdougallIC , BernsJS , BernhardtT , TaguchiM , OguraE , et al. Iron regulation by molidustat, bay 85-3934, a daily oral hypoxia-inducible factor prolyl hydroxylase inhibitor in patients with chronic kidney disease [abstract no: SP334]. Nephrology Dialysis Transplantation2018;33(Suppl 1):i457. [EMBASE: 622606520]AkizawaT , MacdougallIC , BernsJS , YamamotoH , TaguchiM , IekushiK , et al. Iron regulation by molidustat, a daily oral hypoxia-inducible factor prolyl hydroxylase inhibitor, in patients with chronic kidney disease. Nephron2019;143(4):243-54. [MEDLINE: 31387097]MacdougallIC , AkizawaT , BernsJ , LentiniS , BernhardtT . Molidustat increases haemoglobin in erythropoiesis stimulating agents (ESA)-naive anaemic patients with chronic kidney disease not on dialysis (CKD-ND) [abstract no: SO036]. Nephrology Dialysis Transplantation2016;31(Suppl 1):i16. [EMBASE: 72325954]MacdougallIC , AkizawaT , BernsJS , BernhardtT , KruegerT . Effects of molidustat in the treatment of anemia in CKD [Erratum in: Clin J Am Soc Nephrol. 2019 Oct 7;14(10):1524]. Clinical Journal of the American Society of Nephrology: CJASN2019;14(1):28-39. [MEDLINE: 30559105]MacdougallIC , BernsJS , AkizawaT , FishbaneS , BernhardtT . DIALOGUE phase 2 program for BAY85-3934 a HIF-PH inhibitor with daily oral treatment in anemic patients suffering from CKD/ESRD [abstract no: FR-PO219]. Journal of the American Society of Nephrology2013;24(Abstract Suppl):413A. ">DIALOGUE 1 2019</a>; <a href="./references#CD013751-bbs2-0021" title="AkizawaT , MacdougallIC , BernsJS , YamamotoH , TaguchiM , IekushiK , et al. Iron regulation by molidustat, a daily oral hypoxia-inducible factor prolyl hydroxylase inhibitor, in patients with chronic kidney disease. Nephron2019;143(4):243-54. [MEDLINE: 31387097]MacdougallIC , AkizawaT , BernsJ , LentiniS , BernhardtT , KrugerT . Safety and efficacy of molidustat in erythropoiesis stimulating agents (ESA) pre-treated anaemic patients with chronic kidney disease not on dialysis (CKD-ND) [abstract no: SP309]. Nephrology Dialysis Transplantation2016;31(Suppl 1):i193. [EMBASE: 72326411]MacdougallIC , AkizawaT , BernsJ , LentiniS , BernhardtT . Molidustat increases haemoglobin in erythropoiesis stimulating agents (ESA)-naive anaemic patients with chronic kidney disease not on dialysis (CKD-ND) [abstract no: SO036]]. Nephrology Dialysis Transplantation2016;31(Suppl 1):i16. [EMBASE: 72325954]MacdougallIC , AkizawaT , BernsJS , BernhardtT , KruegerT . Effects of molidustat in the treatment of anemia in CKD [Erratum in: Clin J Am Soc Nephrol. 2019 Oct 7;14(10):1524]. Clinical Journal of the American Society of Nephrology: CJASN2019;14(1):28-39. [MEDLINE: 30559105]MacdougallIC , BernsJS , AkizawaT , FishbaneS , BernhardtT . DIALOGUE phase 2 program for BAY85-3934 a HIF-PH inhibitor with daily oral treatment in anemic patients suffering from CKD/ESRD [abstract no: FR-PO219]. Journal of the American Society of Nephrology2013;24(Abstract Suppl):413A. ">DIALOGUE 2 2019</a>; <a href="./references#CD013751-bbs2-0022" title="AkizawaT , MacdougallIC , BernsJS , YamamotoH , TaguchiM , IekushiK , et al. Iron regulation by molidustat, a daily oral hypoxia-inducible factor prolyl hydroxylase inhibitor, in patients with chronic kidney disease. Nephron2019;143(4):243-54. [MEDLINE: 31387097]MacdougallIC , AkizawaT , BernsJ , LentiniS , BernhardtT . Molidustat increases haemoglobin in erythropoiesis stimulating agents (ESA)-naive anaemic patients with chronic kidney disease not on dialysis (CKD-ND) [abstract no: SO036]. Nephrology Dialysis Transplantation2016;31(Suppl 1):i16. [EMBASE: 72325954]MacdougallIC , AkizawaT , BernsJS , BernhardtT , KruegerT . Effects of molidustat in the treatment of anemia in CKD [Erratum in: Clin J Am Soc Nephrol. 2019 Oct 7;14(10):1524]. Clinical Journal of the American Society of Nephrology: CJASN2019;14(1):28-39. [MEDLINE: 30559105]MacdougallIC , BernsJS , AkizawaT , FishbaneS , BernhardtT . DIALOGUE phase 2 program for BAY85-3934 a HIF-PH inhibitor with daily oral treatment in anemic patients suffering from CKD/ESRD [abstract no: FR-PO219]. Journal of the American Society of Nephrology2013;24(Abstract Suppl):413A. ">DIALOGUE 4 2019</a>; <a href="./references#CD013751-bbs2-0038" title="NangakuM , FaragYM , deGomaE , LuoW , VargoD , KhawajaZ . Vadadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor, for treatment of anemia of chronic kidney disease: two randomized Phase 2 trials in Japanese patients. Nephrology Dialysis Transplantation 2020 Jul 20 [epub ahead of print]. [DOI: 10.1093/ndt/gfaa060] [MEDLINE: 32719868]NangakuM , KhawajaZ , LuoW , GarafolaS , De GomaE , KomatsuY . Randomized, placebo-controlled phase 2 trials of vadadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), to treat anemia of CKD [abstract no: TH-PO228]. Journal of the American Society of Nephrology2018;29(Abstract Suppl):171. [EMBASE: 633737146]SolinskyC , FaragYM , KhawajaZ , AndersR , LuoW , ChavanA , et al. Impact of vadadustat on iron regulation in Japanese subjects with chronic kidney disease (CKD) [abstract no: 352]. American Journal of Kidney Diseases2020;75(4):638-9. [EMBASE: 2005716872]">NDD‐CKD 2020</a>) were at low risk of attrition bias. Seventeen studies (<a href="./references#CD013751-bbs2-0002" title="AkizawaT , IwasakiM , OtsukaT , ReuschM , MisumiT . Roxadustat for the treatment of chronic kidney disease-associated anemia in Japanese patients not on dialysis [abstract no: FR-PO1142]. Journal of the American Society of Nephrology2016;27(Abstract Suppl):7B. AkizawaT , IwasakiM , OtsukaT , ReuschM , MisumiT . Roxadustat treatment of chronic kidney disease-associated anemia in Japanese patients not on dialysis: a phase 2, randomized, double-blind, placebo-controlled trial. Advances in Therapy2019;36(6):1438-54. [MEDLINE: 30953333]">Akizawa 2019</a>; <a href="./references#CD013751-bbs2-0005" title="AkizawaT , IwasakiM , OtsukaT , YamaguchiY , ReuschM . A phase 3, multicenter, randomized, open-label, active comparator conversion study of roxadustat in non-dialysis-dependent (NDD) patients with anemia in chronic kidney disease (CKD) [abstract no: POS-244]. Kidney International Reports2021;6(4 Suppl):S103. [EMBASE: 2011682459]AkizawaT , IwasakiM , OtsukaT , YamaguchiY , ReuschM . A phase 3, multicenter, randomized, open-label, active comparator conversion study of roxadustat in non-dialysis-dependent (NDD) patients with anemia in CKD [abstract no: PO0269]. Journal of the American Society of Nephrology2020;31(Abstract Suppl):134. [EMBASE: 633699036]NguyenQD , SepahYJ , YamaguchiY , OtsukaT , MajikawaY , ReuschM , et al. Ophthalmological effects of roxadustat in the treatment of anemia in dialysis-dependent and non-dialysis-dependent CKD patients: findings from two phase 3 studies [abstract no: PO0267]. Journal of the American Society of Nephrology2020;31(Abstract Suppl):134. [EMBASE: 633698979]">Akizawa 2020f</a>; <a href="./references#CD013751-bbs2-0006" title="AkizawaT , IwasakiM , OtsukaT , YamaguchiY , ReuschM . Phase 3 study of roxadustat to treat anemia in non-dialysis-dependant CKD. Kidney International Reports2021;6(7):1810-28. [MEDLINE: 34307976]AkizawaT , Tanaka-AminoK , OtsukaT , YamaguchiY . Factors affecting doses of roxadustat versus darbepoetin alfa for anemia in nondialysis patients. American Journal of Nephrology2021;52(9):702-13. [MEDLINE: 34628408]">Akizawa 2021</a>; <a href="./references#CD013751-bbs2-0007" title="Astellas 1517-CL-0608. Roxadustat in the treatment of anemia in chronic kidney disease patients not requiring dialysis [A phase 3, randomized, double-blind, placebo controlled study of the efficacy and safety of roxadustat for the treatment of anemia in chronic kidney disease patients not on dialysis]. www.trialsummaries.com/Study/StudyDetails?id=14384&amp;tenant=MT_AST_90112019. EspositoC , CsikyB , TataradzeA , ReuschM , HanC , SulowiczW . Two phase 3, multicenter, randomized studies of intermittent oral roxadustat in anemic CKD patients on (PYRENEES) and not on (ALPS) dialysis [abstract no: SA-PO225]. Journal of the American Society of Nephrology2019;30(Abstract Suppl):822. [EMBASE: 633767739]Pecoits-FilhoR , ChanTM , HardyE , YuKH , FishbaneS . Roxadustat treatment results in consistent improvements in hemoglobin (Hb) vs. placebo: an analysis of three multinational randomized clinical trials in patients with non-dialysis-dependent CKD (NDD-CKD) [abstract no: TH-OR05]. Journal of the American Society of Nephrology2020;31(Abstract Suppl):2. [EMBASE: 633697943]RastogiA , Pecoits-FilhoR , FishbaneS , LittleDJ , HardyE , YuKH , et al. Roxadustat treatment corrects anemia to hemoglobin (HB) values ≥10 g/dL in the majority of patients with non-dialysis-dependent chronic kidney disease (NDD-CKD) [abstract no: PO0264]. Journal of the American Society of Nephrology2020;31(Abstract Suppl):133. [EMBASE: 633698803]ShutovE , SulowiczW , EspositoC , TataradzeA , AndricB , ReuschM , et al. Roxadustat for the treatment of anemia in chronic kidney disease patients not on dialysis: a phase 3, randomized, double-blind, placebo-controlled study (ALPS). Nephrology Dialysis Transplantation2021;36(9):1629-39. [MEDLINE: 33630072]">ALPS 2021</a>; <a href="./references#CD013751-bbs2-0012" title="JohansenKL , CobitzAR , LopesRD , SinghAK , ObradorGT , CizmanB , et al. Effects of daprodustat on hemoglobin and quality of life in patients with CKD: results of the ascend-NHQ randomized, double-blind, placebo-controlled trial [abstract no: FR-OR53]. Journal of the American Society of Nephrology2021;32(Abstract Suppl):36. [EMBASE: 636330656]">ASCEND‐NHQ 2021</a>; <a href="./references#CD013751-bbs2-0013" title="CoyneDW , SinghAK , LopesRD , BaileyCK , DiminoTL , HuangC , et al. ASCEND-TD: A randomized, double-blind, active-controlled study of daprodustat administered three times weekly in hemodialysis patients [abstract no: PO0487]. Journal of the American Society of Nephrology2021;32(Abstract Suppl):191. [EMBASE: 636329480]">ASCEND‐TD 2021</a>; <a href="./references#CD013751-bbs2-0018" title="ChenN , QianJ , ChenJ , YuX , MeiC , HaoC , et al. Phase 2 studies of oral hypoxia-inducible factor prolyl hydroxylase inhibitor FG-4592 for treatment of anemia in China. Nephrology Dialysis Transplantation2017;32(8):1373-86. [MEDLINE: 28371815]">Chen DD 2017</a>; <a href="./references#CD013751-bbs2-0025" title="CizmanB , AckertJ , MeadowcroftA , BiswasN , KellyD , KleinmanD , et al. Ocular safety profile of daprodustat: results of two 24 week studies [abstract no: SAO004]. Nephrology Dialysis Transplantation2018;33(Suppl 1):i316. [EMBASE: 622604997]HoldstockL , CizmanB , MeadowcroftAM , BiswasN , JohnsonBM , JonesD , et al. Daprodustat for anemia: a 24-week, open-label, randomized controlled trial in participants with chronic kidney disease. Clinical Kidney Journal2019;12(1):129-38. [MEDLINE: 30746140]HoldstockL , CizmanB , MeadowcroftAM , BiswasN , JonesD , JohnsonBM , et al. Daprodustat, a HIF-prolyl-hydroxylase inhibitor, increases and maintains hemoglobin over 24 weeks in anemic chronic kidney disease subjects [abstract no: TH-PO908]. Journal of the American Society of Nephrology2016;27(Abstract Suppl):304A. ">Holdstock 2019</a>; <a href="./references#CD013751-bbs2-0026" title="CizmanB , AckertJ , MeadowcroftA , BiswasN , KellyD , KleinmanD , et al. Ocular safety profile of daprodustat: results of two 24 week studies [abstract no: SAO004]. Nephrology Dialysis Transplantation2018;33(Suppl 1):i316. [EMBASE: 622604997]HoldstockL , CizmanB , MeadowcroftAM , BiswasN , JohnsonBM , JonesD , et al. Daprodustat for anemia: a 24-week, open-label, randomized controlled trial in participants with chronic kidney disease. Clinical Kidney Journal2019;12(1):129-38. [MEDLINE: 30746140]HoldstockL , CizmanB , MeadowcroftAM , BiswasN , JonesD , JohnsonBM , et al. Daprodustat, a HIF-prolyl-hydroxylase inhibitor, increases and maintains hemoglobin over 24 weeks in anemic chronic kidney disease subjects [abstract no: TH-PO908]. Journal of the American Society of Nephrology2016;27(Abstract Suppl):304A. ">Holdstock 2019a</a>; <a href="./references#CD013751-bbs2-0030" title="CizmanB , AckertJ , MeadowcroftA , BiswasN , KellyD , KleinmanD , et al. Ocular safety profile of daprodustat: results of two 24 week studies [abstract no: SAO004]. Nephrology Dialysis Transplantation2018;33(Suppl 1):i316. [EMBASE: 622604997]CobitzAR , MeadowcroftAM , CizmanB , HoldstockL , BiswasN , JonesD , et al. Daprodustat, a HIF-prolyl-hydroxylase inhibitor, maintains hemoglobin levels over 24 weeks in anemic hemodialysis subjects switching from recombinant human erythropoietin. [abstract no: SA-OR114]. Journal of the American Society of Nephrology2016;27(Abstract Suppl):93A. MeadowcroftAM , CizmanB , HoldstockL , BiswasN , JohnsonBM , JonesD , et al. Daprodustat for anemia: a 24-week, open-label, randomized controlled trial in participants on hemodialysis. Clinical Kidney Journal2019;12(1):139-48. [MEDLINE: 30746141]">Meadowcroft 2019</a>; <a href="./references#CD013751-bbs2-0037" title="Astellas1517-CL-0304. A study to investigate the effect of ASP1517 after intermittent oral dosing in dialysis chronic kidney disease patients with anemia compared with darbepoetin as a reference drug [A Japanese, phase 2, multicenter, randomized, 4-arm parallel, double-blind (arms 1-3), open-label (arm 4), active-comparator (darbepoetin alfa) study of intermittent oral dosing of asp1517 in hemodialysis-dependent chronic kidney disease patients with anemia [1517-CL-0304 clinical study results report]]. www.trialsummaries.com/Study/StudyDetails?id=14175&amp;tenant=MT_AST_9011; www.clinicaltrials.gov/ct2/show/NCT01888445 (first received 6 August 2018). ">NCT01888445</a>; <a href="./references#CD013751-bbs2-0039" title="NangakuM , FaragYM , deGomaE , LuoW , VargoD , KhawajaZ . Vadadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor, for treatment of anemia of chronic kidney disease: two randomized Phase 2 trials in Japanese patients. Nephrology Dialysis Transplantation 2020 Jul 20 [epub ahead of print]. [DOI: 10.1093/ndt/gfaa060] [MEDLINE: 32719868]NangakuM , KhawajaZ , LuoW , GarafolaS , deGomaE , KomatsuY . Randomized, placebo-controlled phase 2 trials of vadadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), to treat anemia of CKD [abstract no: TH-PO228]. Journal of the American Society of Nephrology2018;29(Abstract Suppl):171. [EMBASE: 633737146]SolinskyC , FaragYM , KhawajaZ , AndersR , LuoW , ChavanA , et al. Impact of vadadustat on iron regulation in Japanese subjects with chronic kidney disease (CKD) [abstract no: 352]. American Journal of Kidney Diseases2020;75(4):638-9. [EMBASE: 2005716872]">NDD‐CKD 2020a</a>; <a href="./references#CD013751-bbs2-0044" title="ProvenzanoR , FaddaG , BernardoM , JamesC , KochendoerferG , LeeT , et al. FG2216, a novel oral HIF-PHI, stimulates erythropoiesis and increases hemoglobin concentration in patients with non-dialysis CKD [abstract no: 212]. American Journal of Kidney Diseases2008;51(4):A80. ProvenzanoR , HulterH , AgarwalA , KlausS , LeeT , YuP , et al. Hypoxia-inducible factor (HIF) prolyl hydroxylase inhibitor FG-2216 increases Hb without FE depletion in the absence of IV Fe [abstract no: 249]. American Journal of Kidney Diseases2013;61(4):A78. [EMBASE: 71024073]">Provenzano 2008</a>; <a href="./references#CD013751-bbs2-0045" title="ProvenzanoR , BesarabA , DuaSL , NguyenPV , WrightSH , ZeigS , et al. FG-4592, a novel oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), maintains hemoglobin levels and lowers cholesterol in hemodialysis patients: phase 2 comparison with epoetin alfa [abstract no: FR-PO257]. Journal of the American Society of Nephrology2012;23(Abstract Suppl):428A. ProvenzanoR , BesarabA , WrightS , DuaS , ZeigS , NguyenP , et al. Roxadustat (FG-4592) versus epoetin alfa for anemia in patients receiving maintenance hemodialysis: a phase 2, randomized, 6- to 19-week, open-label, active-comparator, dose-ranging, safety and exploratory efficacy study. American Journal of Kidney Diseases2016;67(6):912-24. [MEDLINE: 26846333]">Provenzano 2016</a>; <a href="./references#CD013751-bbs2-0046" title="ProvenzanoR , BesarabA , DuaSL , NguyenPV , WrightSH , ZeigS , et al. FG-4592, a novel oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), maintains hemoglobin levels and lowers cholesterol in hemodialysis patients: phase 2 comparison with epoetin alfa [abstract no: FR-PO257]. Journal of the American Society of Nephrology2012;23(Abstract Suppl):428A. ProvenzanoR , BesarabA , WrightS , DuaS , ZeigS , NguyenP , et al. Roxadustat (FG-4592) versus epoetin alfa for anemia in patients receiving maintenance hemodialysis: a phase 2, randomized, 6- to 19-week, open-label, active-comparator, dose-ranging, safety and exploratory efficacy study. American Journal of Kidney Diseases2016;67(6):912-24. [MEDLINE: 26846333]">Provenzano 2016a</a>; <a href="./references#CD013751-bbs2-0047" title="Astellas 1517-CL-0613. Roxadustat in the treatment of anemia in end stage renal disease (ESRD) patients on stable dialysis [A phase 3, randomized, open-label, active-controlled study to evaluate the efficacy and safety of roxadustat in the maintenance treatment of anemia in end stage renal disease patients on stable dialysis]. www.trialsummaries.com/Study/StudyDetails?id=14380&amp;tenant=MT_AST_9011 (accessed 9 May 2022). CsikyB , SchomigM , EspositoC , BarrattJ , ReuschM , ValluriU , et al. Roxadustat for the maintenance treatment of anemia in patients with end-stage kidney disease on stable dialysis: a European phase 3, randomized, open-label, active-controlled study (PYRENEES). Advances in Therapy2021;38(10):5361-80. [MEDLINE: 34537926]EspositoC , CsikyB , TataradzeA , ReuschM , HanC , SulowiczW . Two phase 3, multicenter, randomized studies of intermittent oral roxadustat in anemic CKD patients on (PYRENEES) and not on (ALPS) dialysis. Swiss Medical Weekly2020;150(Suppl 248):21-2S. [EMBASE: 634241523]EspositoC , CsikyB , TataradzeA , ReuschM , HanC , SulowiczW . Two phase 3, multicenter, randomized studies of intermittent oral roxadustat in anemic CKD patients on (PYRENEES) and not on (ALPS) dialysis [abstract no: SA-PO225]. Journal of the American Society of Nephrology2019;30(Abstract Suppl):822. [EMBASE: 633767739]">PYRENEES 2021</a>; <a href="./references#CD013751-bbs2-0048" title="AstraZeneca. A phase 3, multicenter, randomized, open-label, active-controlled study of the safety and efficacy of roxadustat in the treatment of anemia in dialysis patients [Clinical study protocol v8.0 19 September 2018]. www.clinicaltrials.gov/ProvidedDocs/31/NCT02174731/Prot_000.pdf (accessed 10 May 2022). FishbaneS , PollockCA , El-ShahawyMA , EscuderoET , RastogiA , VanBP , et al. ROCKIES: an international, phase 3, randomized, open-label, active-controlled study of roxadustat for anemia in dialysis-dependent CKD patients [abstract no: TH-OR022]. Journal of the American Society of Nephrology2019;30(Abstract Suppl):6. [EMBASE: 633771219]">ROCKIES 2019</a>) were at high risk of attrition bias as there was a differential loss to follow‐up between treatment groups and/or high attrition rates in both treatment groups. Loss to follow‐up was commonly due to withdrawal from the study or adverse events. The risk of attrition bias was unclear in 22 studies. </p> </section> <section id="CD013751-sec-0061"> <h4 class="title">Selective reporting</h4> <p>Twenty studies (<a href="./references#CD013751-bbs2-0002" title="AkizawaT , IwasakiM , OtsukaT , ReuschM , MisumiT . Roxadustat for the treatment of chronic kidney disease-associated anemia in Japanese patients not on dialysis [abstract no: FR-PO1142]. Journal of the American Society of Nephrology2016;27(Abstract Suppl):7B. AkizawaT , IwasakiM , OtsukaT , ReuschM , MisumiT . Roxadustat treatment of chronic kidney disease-associated anemia in Japanese patients not on dialysis: a phase 2, randomized, double-blind, placebo-controlled trial. Advances in Therapy2019;36(6):1438-54. [MEDLINE: 30953333]">Akizawa 2019</a>; <a href="./references#CD013751-bbs2-0003" title="AkizawaT , IwasakiM , YamaguchiY , MajikawaY , ReuschM . Authors' Reply. Journal of the American Society of Nephrology2021;32(4):1005-7. [MEDLINE: 33649099]AkizawaT , IwasakiM , YamaguchiY , MajikawaY , ReuschM . Phase 3, randomized, double-blind, active-comparator (darbepoetin alfa) conversion study of oral roxadustat in CKD patients with anemia on hemodialysis in Japan [abstract no: TH-PO1151]. Journal of the American Society of Nephrology2018;29(Abstract Suppl):B4. AkizawaT , IwasakiM , YamaguchiY , MajikawaY , ReuschM . Phase 3, randomized, double-blind, active-comparator (darbepoetin alfa) study of oral roxadustat in CKD patients with anemia on hemodialysis in Japan. Journal of the American Society of Nephrology2020;31(7):1628-39. [MEDLINE: 32493693]AkizawaT , YamaguchiY , MajikawaY , ReuschM . Factors affecting the doses of roxadustat vs darbepoetin alfa for anemia treatment in hemodialysis patients. Therapeutic Apheresis &amp; Dialysis2021;25(5):575-85. [MEDLINE: 33200512]Astellas1517-CL-0307. A study of intermittent oral dosing of ASP1517 in hemodialysis chronic kidney disease patients with anemia [A phase 3, multi-center, randomized, 2-arm parallel, double-blind, active-comparator (darbepoetin alfa) conversion study of intermittent oral dosing of ASP1517 in hemodialysis chronic kidney disease patients with anemia]. www.clinicaltrials.astellas.com/study/?pid=1517-CL-0307 (accessed 4 May 2022). LiuF , WangJ , YeQ , FuH , MaoJ . Roxadustat for renal anemia in ESRD from PKD patients: is it safe enough?Journal of the American Society of Nephrology2021;32(4):1005. [MEDLINE: 33649100]NguyenQD , SepahYJ , YamaguchiY , OtsukaT , MajikawaY , ReuschM , et al. Ophthalmological effects of roxadustat in the treatment of anemia in dialysis-dependent and non-dialysis-dependent CKD patients: findings from two phase 3 studies [abstract no: PO0267]. Journal of the American Society of Nephrology2020;31(Abstract Suppl):134. [EMBASE: 633698979]SepahY , NguyenQD , YamaguchiY , MajikawaY , ReuschM , AkizawaT . Ophthalmological effects of roxadustat in the treatment of anaemia in chronic kidney disease patients on dialysis in a phase 3, randomised, double-blind, active-comparator conversion study [abstract no: MO002]. Nephrology Dialysis Transplantation2020;35(Suppl 3):iii102. [EMBASE: 633421367]">Akizawa 2020a</a>; <a href="./references#CD013751-bbs2-0009" title="SinghAK , BlackorbyA , CizmanB , CarrollK , CobitzAR , DaviesR , et al. Study design and baseline characteristics of patients on dialysis in the ASCEND-D trial. Nephrology Dialysis Transplantation2021;37(5):960-72. [MEDLINE: 33744933] [MEDLINE: 33744933]SinghAK , BlackorbyA , CizmanB , CobitzAR , GodoySA , JhaV , et al. Regional variation of erythropoietin-stimulating agent hyporesponsiveness in the global daprodustat dialysis study (ASCEND-D) [abstract no: TH-OR08]. Journal of the American Society of Nephrology2020;31(Abstract Suppl):3. [EMBASE: 633698062]SinghAK , CarrollK , PerkovicV , SolomonS , JhaV , JohansenKL , et al. Daprodustat for the treatment of anemia in patients undergoing dialysis. New England Journal of Medicine2021;385(25):2325-35. [MEDLINE: 34739194]">ASCEND‐D 2021</a>; <a href="./references#CD013751-bbs2-0011" title="PerkovicV , BlackorbyA , CizmanB , CarrollK , CobitzA , DaviesR , et al. ASCEND-ND: Study design and baseline characteristics. Nephrology Dialysis Transplantation2021;36(Suppl 1):i334-5. [EMBASE: 635918331]SinghAK , CarrollK , McMurrayJJ , SolomonS , JhaV , JohansenKL , et al. Daprodustat for the treatment of anemia in patients not undergoing dialysis. New England Journal of Medicine2021;385(25):2313-24. [MEDLINE: 34739196]">ASCEND‐ND 2021</a>; <a href="./references#CD013751-bbs2-0016" title="ChenN , HaoC , LiuB , LinHL , CailiW , XingCY , et al. A phase 3, randomized, open-label, active-controlled study of efficacy and safety of roxadustat for treatment of anemia in subjects with CKD on dialysis [abstract no: TH-PO1152]. Journal of the American Society of Nephrology2018;29(Abstract Suppl):B5. ChenN , HaoC , LiuBC , LinH , WangC , XingC , et al. Roxadustat treatment for anemia in patients undergoing long-term dialysis. New England Journal of Medicine2019;381(11):1011-22. [MEDLINE: 31340116]">Chen 2019</a>; <a href="./references#CD013751-bbs2-0020" title="AkizawaT , MacdougallIC , BernsJS , BernhardtT , TaguchiM , OguraE , et al. Iron regulation by molidustat, bay 85-3934, a daily oral hypoxia-inducible factor prolyl hydroxylase inhibitor in patients with chronic kidney disease [abstract no: SP334]. Nephrology Dialysis Transplantation2018;33(Suppl 1):i457. [EMBASE: 622606520]AkizawaT , MacdougallIC , BernsJS , YamamotoH , TaguchiM , IekushiK , et al. Iron regulation by molidustat, a daily oral hypoxia-inducible factor prolyl hydroxylase inhibitor, in patients with chronic kidney disease. Nephron2019;143(4):243-54. [MEDLINE: 31387097]MacdougallIC , AkizawaT , BernsJ , LentiniS , BernhardtT . Molidustat increases haemoglobin in erythropoiesis stimulating agents (ESA)-naive anaemic patients with chronic kidney disease not on dialysis (CKD-ND) [abstract no: SO036]. Nephrology Dialysis Transplantation2016;31(Suppl 1):i16. [EMBASE: 72325954]MacdougallIC , AkizawaT , BernsJS , BernhardtT , KruegerT . Effects of molidustat in the treatment of anemia in CKD [Erratum in: Clin J Am Soc Nephrol. 2019 Oct 7;14(10):1524]. Clinical Journal of the American Society of Nephrology: CJASN2019;14(1):28-39. [MEDLINE: 30559105]MacdougallIC , BernsJS , AkizawaT , FishbaneS , BernhardtT . DIALOGUE phase 2 program for BAY85-3934 a HIF-PH inhibitor with daily oral treatment in anemic patients suffering from CKD/ESRD [abstract no: FR-PO219]. Journal of the American Society of Nephrology2013;24(Abstract Suppl):413A. ">DIALOGUE 1 2019</a>; <a href="./references#CD013751-bbs2-0021" title="AkizawaT , MacdougallIC , BernsJS , YamamotoH , TaguchiM , IekushiK , et al. Iron regulation by molidustat, a daily oral hypoxia-inducible factor prolyl hydroxylase inhibitor, in patients with chronic kidney disease. Nephron2019;143(4):243-54. [MEDLINE: 31387097]MacdougallIC , AkizawaT , BernsJ , LentiniS , BernhardtT , KrugerT . Safety and efficacy of molidustat in erythropoiesis stimulating agents (ESA) pre-treated anaemic patients with chronic kidney disease not on dialysis (CKD-ND) [abstract no: SP309]. Nephrology Dialysis Transplantation2016;31(Suppl 1):i193. [EMBASE: 72326411]MacdougallIC , AkizawaT , BernsJ , LentiniS , BernhardtT . Molidustat increases haemoglobin in erythropoiesis stimulating agents (ESA)-naive anaemic patients with chronic kidney disease not on dialysis (CKD-ND) [abstract no: SO036]]. Nephrology Dialysis Transplantation2016;31(Suppl 1):i16. [EMBASE: 72325954]MacdougallIC , AkizawaT , BernsJS , BernhardtT , KruegerT . Effects of molidustat in the treatment of anemia in CKD [Erratum in: Clin J Am Soc Nephrol. 2019 Oct 7;14(10):1524]. Clinical Journal of the American Society of Nephrology: CJASN2019;14(1):28-39. [MEDLINE: 30559105]MacdougallIC , BernsJS , AkizawaT , FishbaneS , BernhardtT . DIALOGUE phase 2 program for BAY85-3934 a HIF-PH inhibitor with daily oral treatment in anemic patients suffering from CKD/ESRD [abstract no: FR-PO219]. Journal of the American Society of Nephrology2013;24(Abstract Suppl):413A. ">DIALOGUE 2 2019</a>; <a href="./references#CD013751-bbs2-0022" title="AkizawaT , MacdougallIC , BernsJS , YamamotoH , TaguchiM , IekushiK , et al. Iron regulation by molidustat, a daily oral hypoxia-inducible factor prolyl hydroxylase inhibitor, in patients with chronic kidney disease. Nephron2019;143(4):243-54. [MEDLINE: 31387097]MacdougallIC , AkizawaT , BernsJ , LentiniS , BernhardtT . Molidustat increases haemoglobin in erythropoiesis stimulating agents (ESA)-naive anaemic patients with chronic kidney disease not on dialysis (CKD-ND) [abstract no: SO036]. Nephrology Dialysis Transplantation2016;31(Suppl 1):i16. [EMBASE: 72325954]MacdougallIC , AkizawaT , BernsJS , BernhardtT , KruegerT . Effects of molidustat in the treatment of anemia in CKD [Erratum in: Clin J Am Soc Nephrol. 2019 Oct 7;14(10):1524]. Clinical Journal of the American Society of Nephrology: CJASN2019;14(1):28-39. [MEDLINE: 30559105]MacdougallIC , BernsJS , AkizawaT , FishbaneS , BernhardtT . DIALOGUE phase 2 program for BAY85-3934 a HIF-PH inhibitor with daily oral treatment in anemic patients suffering from CKD/ESRD [abstract no: FR-PO219]. Journal of the American Society of Nephrology2013;24(Abstract Suppl):413A. ">DIALOGUE 4 2019</a>; <a href="./references#CD013751-bbs2-0023" title="BarrattJ , AndricB , TataradzeA , SchoemigM , ReuschM , ValluriU , et al. Roxadustat for the treatment of anemia in CKD patients not on dialysis (NDD): a phase 3, randomized, open-label, active-controlled study [abstract no: TH-OR02]. Journal of the American Society of Nephrology2020;31(Abstract Suppl):1. [EMBASE: 633697812]BarrattJ , AndricB , TataradzeA , SchomigM , ReuschM , ValluriU , et al. Roxadustat for the treatment of anaemia in chronic kidney disease patients not on dialysis: a phase 3, randomised, open-label, active-controlled study (DOLOMITES). Nephrology Dialysis Transplantation2021;36(9):1616-28. [MEDLINE: 34077510]BarrattJ , AndricB , TataradzeA , SchomigM , ReuschM , ValluriU , et al. Roxadustat for the treatment of anaemia in chronic kidney disease patients not on dialysis: a phase 3, randomised, open-label, active controlled study [abstract no: MO001]. Nephrology Dialysis Transplantation2020;35(Suppl 3):iii101. [EMBASE: 633423023]BarrattJ , AndricB , TataradzeA , SchomigM , ReuschM , ValluriU , et al. Roxadustat for the treatment of anemia in chronic kidney disease (CKD) patients not on dialysis (NDD): a phase 3, randomized, open-label, active-controlled study [abstract no: Pos-247]. Kidney International Reports2021;6(4 Suppl):S104. [EMBASE: 2011683542]">DOLOMITES 2021</a>; <a href="./references#CD013751-bbs2-0025" title="CizmanB , AckertJ , MeadowcroftA , BiswasN , KellyD , KleinmanD , et al. Ocular safety profile of daprodustat: results of two 24 week studies [abstract no: SAO004]. Nephrology Dialysis Transplantation2018;33(Suppl 1):i316. [EMBASE: 622604997]HoldstockL , CizmanB , MeadowcroftAM , BiswasN , JohnsonBM , JonesD , et al. Daprodustat for anemia: a 24-week, open-label, randomized controlled trial in participants with chronic kidney disease. Clinical Kidney Journal2019;12(1):129-38. [MEDLINE: 30746140]HoldstockL , CizmanB , MeadowcroftAM , BiswasN , JonesD , JohnsonBM , et al. Daprodustat, a HIF-prolyl-hydroxylase inhibitor, increases and maintains hemoglobin over 24 weeks in anemic chronic kidney disease subjects [abstract no: TH-PO908]. Journal of the American Society of Nephrology2016;27(Abstract Suppl):304A. ">Holdstock 2019</a>; <a href="./references#CD013751-bbs2-0026" title="CizmanB , AckertJ , MeadowcroftA , BiswasN , KellyD , KleinmanD , et al. Ocular safety profile of daprodustat: results of two 24 week studies [abstract no: SAO004]. Nephrology Dialysis Transplantation2018;33(Suppl 1):i316. [EMBASE: 622604997]HoldstockL , CizmanB , MeadowcroftAM , BiswasN , JohnsonBM , JonesD , et al. Daprodustat for anemia: a 24-week, open-label, randomized controlled trial in participants with chronic kidney disease. Clinical Kidney Journal2019;12(1):129-38. [MEDLINE: 30746140]HoldstockL , CizmanB , MeadowcroftAM , BiswasN , JonesD , JohnsonBM , et al. Daprodustat, a HIF-prolyl-hydroxylase inhibitor, increases and maintains hemoglobin over 24 weeks in anemic chronic kidney disease subjects [abstract no: TH-PO908]. Journal of the American Society of Nephrology2016;27(Abstract Suppl):304A. ">Holdstock 2019a</a>; <a href="./references#CD013751-bbs2-0027" title="HouYP , MaoXY , WangC , XuZH , BuZH , XuM , et al. Roxadustat treatment for anemia in peritoneal dialysis patients: a randomized controlled trial. Journal of the Formosan Medical Association2021;121(2):529-38. [MEDLINE: 34167878]">Hou 2021</a>; <a href="./references#CD013751-bbs2-0031" title="AkizawaT , TaguchiM , MatsudaY , IekushiK , YamadaT , YamamotoH . Molidustat for the treatment of renal anaemia in patients with dialysis-dependent chronic kidney disease: Design and rationale of three phase III studies. BMJ Open2019;9(6):e026602. [MEDLINE: 31203241]AkizawaT , YamadaT , NoboriK , MatsudaY , HayashiY , HayasakiT , et al. Molidustat for Japanese patients with renal anemia receiving dialysis. Kidney International Reports2021;6(10):2604–16. [MEDLINE: 34622100]AkizawaT , YamadaT , NoboriK , MatsudaY , HayashiY , HayasakiT , et al. Results from a phase 3 study comparing the efficacy and safety of molidustat vs. Darbepoetin Alfa in patients receiving hemodialysis and treated with erythropoiesis-stimulating agents (ESAS) [abstract no: PO22623]. Journal of the American Society of Nephrology2020;31(Abstract Suppl):B4. [EMBASE: 633697376]">MIYABI HD‐M 2019</a>; <a href="./references#CD013751-bbs2-0032" title="YamamotoH , NoboriK , MatsudaY , HayashiY , HayasakiT , AkizawaT . Efficacy and safety of molidustat for anemia in ESA-naive nondialysis patients: a randomized, phase 3 trial. American Journal of Nephrology2021;52(10-11):871-83. [MEDLINE: 34569489]YamamotoH , TaguchiM , MatsudaY , IekushiK , YamadaT , AkizawaT . Molidustat for the treatment of renal anaemia in patients with non-dialysis-dependent chronic kidney disease: design and rationale of two phase III studies. BMJ Open2019;9(6):e026704. [MEDLINE: 31203242]YamamotoH , TaguchiM , NoboriK , MatsudaY , IekushiK , AkizawaT . To investigate the efficacy and safety of molidustat in non-dialysis patients with renal anemia who are not treated with erythropoiesis stimulating agents: MIYABI ND-C [abstract no: P1866]. Nephrology Dialysis Transplantation2020;35(Suppl 3):iii2177. [EMBASE: 633422996]">MIYABI ND‐C 2019</a>; <a href="./references#CD013751-bbs2-0033" title="YamamotoH , NoboriK , MatsudaY , HayashiY , HayasakiT , AkizawaT . Molidustat for renal anemia in nondialysis patients previously treated with erythropoiesis-stimulating agents: a randomized, open-label, phase 3 study. American Journal of Nephrology2021;52(10-11):884-93. [MEDLINE: 34569482]YamamotoH , TaguchiM , MatsudaY , IekushiK , YamadaT , AkizawaT . Molidustat for the treatment of renal anaemia in patients with non-dialysis-dependent chronic kidney disease: design and rationale of two phase III studies. BMJ Open2019;9(6):e026704. [MEDLINE: 31203242]YamamotoH , TaguchiM , NoboriK , MatsudaY , IekushiK , AkizawaT . To investigate the efficacy and safety of molidustat in non-dialysis patients with renal anemia who are treated with erythropoiesis stimulating agents: Miyabi ND-M [Abstract no: P1868]. Nephrology Dialysis Transplantation2020;35(Suppl 3):iii2179. [EMBASE: 633423006]">MIYABI ND‐M 2019</a>; <a href="./references#CD013751-bbs2-0035" title="NangakuM , KondoK , KokadoY , UetaK , KanekoG , ShiosakaM , et al. Randomized, open-label, active-controlled (darbepoetin alfa), phase 3 study of vadadustat for treating anemia in non-dialysis-dependent CKD patients in Japan [abstract no: SA-PO229]. Journal of the American Society of Nephrology2019;30(Abstract Suppl):823. [EMBASE: 633767995]NangakuM , KondoK , KokadoY , UetaK , KanekoG , TandaiT , et al. Phase 3 randomized study comparing vadadustat with darbepoetin alfa for anemia in Japanese patients with nondialysis-dependent CKD. Journal of the American Society of Nephrology2021;32(7):1779-90. [MEDLINE: 33883252]">Nangaku 2021a</a>; <a href="./references#CD013751-bbs2-0037" title="Astellas1517-CL-0304. A study to investigate the effect of ASP1517 after intermittent oral dosing in dialysis chronic kidney disease patients with anemia compared with darbepoetin as a reference drug [A Japanese, phase 2, multicenter, randomized, 4-arm parallel, double-blind (arms 1-3), open-label (arm 4), active-comparator (darbepoetin alfa) study of intermittent oral dosing of asp1517 in hemodialysis-dependent chronic kidney disease patients with anemia [1517-CL-0304 clinical study results report]]. www.trialsummaries.com/Study/StudyDetails?id=14175&amp;tenant=MT_AST_9011; www.clinicaltrials.gov/ct2/show/NCT01888445 (first received 6 August 2018). ">NCT01888445</a>; <a href="./references#CD013751-bbs2-0042" title="BunnHF . Vadadustat for anemia in patients with dialysis-dependent or non-dialysis-dependent chronic kidney disease. New England Journal of Medicine2021;385(16):e56. [MEDLINE: 34644481]ChertowGM , PergolaPE , AgarwalR , BlockGA , FaragYM , JardineAG , et al. Cardiovascular safety and efficacy of vadadustat for the treatment of anemia in non-dialysis-dependent CKD: design and baseline characteristics. American Heart Journal2021;235(5):1-11. [MEDLINE: 33129989]ChertowGM , PergolaPE , FaragYM , AgarwalR , ArnoldS , BakoG , et al. Vadadustat in patients with anemia and non-dialysis-dependent CKD. New England Journal of Medicine2021;384(17):1589-600. [MEDLINE: 33913637]ChertowGM . Global phase 3 clinical trials of vadadustat vs. darbepoetin alfa for treatment of anemia in patients with non-dialysis-dependent CKD [abstract no: FR-OR54]. Journal of the American Society of Nephrology2020;31(Abstract Suppl):B2. [EMBASE: 633697273]KouryM , PergolaPE , Roy-ChaudhuryP , FaragYM , LuoW , AndersR , et al. Iron-related outcomes in patients with non-dialysis-dependent CKD randomized to vadadustat vs. darbepoetin Alfa [abstract no: PO0482]. Journal of the American Society of Nephrology2021;32(Abstract Suppl):190. [EMBASE: 636329134]McCulloughPA , LuoW , AndersR , VargoD , ParfreyPS . Assessment of thromboembolic events with vadadustat vs. darbepoetin alfa for treatment of anemia in patients with non-dialysis-dependent CKD [abstract no: PO0462]. Journal of the American Society of Nephrology2021;32(Abstract Suppl):184. [EMBASE: 636331039]">PRO2TECT‐CONVERSION 2021</a>; <a href="./references#CD013751-bbs2-0043" title="BunnHF . Vadadustat for anemia in patients with dialysis-dependent or non-dialysis-dependent chronic kidney disease. New England Journal of Medicine2021;385(16):e56. [MEDLINE: 34644481]ChertowGM , PergolaPE , AgarwalR , BlockGA , FaragYM , JardineAG , et al. Cardiovascular safety and efficacy of vadadustat for the treatment of anemia in non-dialysis-dependent CKD: design and baseline characteristics. American Heart Journal2021;235(5):1-11. [MEDLINE: 33129989]ChertowGM , PergolaPE , FaragYM , AgarwalR , ArnoldS , BakoG , et al. Vadadustat in patients with anemia and non-dialysis-dependent CKD. New England Journal of Medicine2021;384(17):1589-600. [MEDLINE: 33913637]ChertowGM . Global phase 3 clinical trials of vadadustat vs. darbepoetin alfa for treatment of anemia in patients with non-dialysis-dependent CKD [abstract no: FR-OR5]. Journal of the American Society of Nephrology2020;31(Abstract Suppl):B2. [EMBASE: 633697273]KouryM , PergolaPE , Roy-ChaudhuryP , FaragYM , LuoW , AndersR , et al. Iron-related outcomes in patients with non-dialysis-dependent CKD randomized to vadadustat vs. darbepoetin alfa [abstract no: PO0482]. Journal of the American Society of Nephrology2021;32(Abstract Suppl):190. [EMBASE: 636329134]McCulloughPA , LuoW , AndersR , VargoD , ParfreyPS . Assessment of thromboembolic events with vadadustat vs. darbepoetin alfa for treatment of anemia in patients with non-dialysis-dependent CKD [abstract no: PO0462]. Journal of the American Society of Nephrology2021;32(Abstract Suppl):184. [EMBASE: 636331039]">PRO2TECT‐CORRECTION 2021</a>; <a href="./references#CD013751-bbs2-0049" title="CharytanC , Manllo-KarimR , MartinER , SteerD , BernardoM , DuaSL , et al. A randomized trial of roxadustat in anemia of kidney failure: SIERRAS study. Kidney International Reports2021;6(7):1829-39. [MEDLINE: 34307977]CharytanC , Manllo-KarimR , MartinER , SteerD , BernardoM , DuaSL , et al. SIERRAS: A phase 3, open-label, randomized, active-controlled study of the efficacy and safety of roxadustat in the maintenance treatment of anemia in subjects with ESRD on stable dialysis [abstract no: SA-PO227]. Journal of the American Society of Nephrology2019;30(Abstract Suppl):822. [EMBASE: 633767862]">SIERRAS 2021</a>) reported expected and clinically‐relevant outcomes and were at low risk of bias. Thirty‐one studies did not report patient‐centred outcomes of death or adverse events. </p> </section> <section id="CD013751-sec-0062"> <h4 class="title">Other potential sources of bias</h4> <p>One study (<a href="./references#CD013751-bbs2-0027" title="HouYP , MaoXY , WangC , XuZH , BuZH , XuM , et al. Roxadustat treatment for anemia in peritoneal dialysis patients: a randomized controlled trial. Journal of the Formosan Medical Association2021;121(2):529-38. [MEDLINE: 34167878]">Hou 2021</a>) was assessed to be at low risk of bias, 49 studies (<a href="./references#CD013751-bbs2-0001" title="AkizawaT , TsubakiharaY , NangakuM , EndoY , NakajimaH , KohnoT , et al. Effects of daprodustat, a novel hypoxia-inducible factor prolyl hydroxylase inhibitor on anemia management in Japanese hemodialysis subjects. American Journal of Nephrology2017;45(2):127-35. [MEDLINE: 27978511]EndoY , KohnoT , ImaiY , KawaseN , HaraK , LeporeJJ , et al. A 4 -week dose response study of the hypoxia inducible factor-prolyl hydroxylase inhibitor GSK1278863 in Japanese anemic haemodialysis subjects [abstract no: SA-PO819]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):818A. NCT02019719. Study to evaluate the safety, efficacy and pharmacokinetics of GSK1278863 in Japanese hemodialysis-dependent subjects with anemia associated with chronic kidney disease [A 4-week, phase ii, randomized, double-blind, dose-ranging, placebo-controlled, parallel-group, multi-center study to evaluate the safety, efficacy and pharmacokinetics of GSK1278863 in Japanese hemodialysis-dependent subjects with anemia associated with chronic kidney disease]. clinicaltrials.gov/show/NCT02019719 (first received 24 December 2013). ">Akizawa 2017</a>; <a href="./references#CD013751-bbs2-0002" title="AkizawaT , IwasakiM , OtsukaT , ReuschM , MisumiT . Roxadustat for the treatment of chronic kidney disease-associated anemia in Japanese patients not on dialysis [abstract no: FR-PO1142]. Journal of the American Society of Nephrology2016;27(Abstract Suppl):7B. AkizawaT , IwasakiM , OtsukaT , ReuschM , MisumiT . Roxadustat treatment of chronic kidney disease-associated anemia in Japanese patients not on dialysis: a phase 2, randomized, double-blind, placebo-controlled trial. Advances in Therapy2019;36(6):1438-54. [MEDLINE: 30953333]">Akizawa 2019</a>; <a href="./references#CD013751-bbs2-0003" title="AkizawaT , IwasakiM , YamaguchiY , MajikawaY , ReuschM . Authors' Reply. Journal of the American Society of Nephrology2021;32(4):1005-7. [MEDLINE: 33649099]AkizawaT , IwasakiM , YamaguchiY , MajikawaY , ReuschM . Phase 3, randomized, double-blind, active-comparator (darbepoetin alfa) conversion study of oral roxadustat in CKD patients with anemia on hemodialysis in Japan [abstract no: TH-PO1151]. Journal of the American Society of Nephrology2018;29(Abstract Suppl):B4. AkizawaT , IwasakiM , YamaguchiY , MajikawaY , ReuschM . Phase 3, randomized, double-blind, active-comparator (darbepoetin alfa) study of oral roxadustat in CKD patients with anemia on hemodialysis in Japan. Journal of the American Society of Nephrology2020;31(7):1628-39. [MEDLINE: 32493693]AkizawaT , YamaguchiY , MajikawaY , ReuschM . Factors affecting the doses of roxadustat vs darbepoetin alfa for anemia treatment in hemodialysis patients. Therapeutic Apheresis &amp; Dialysis2021;25(5):575-85. [MEDLINE: 33200512]Astellas1517-CL-0307. A study of intermittent oral dosing of ASP1517 in hemodialysis chronic kidney disease patients with anemia [A phase 3, multi-center, randomized, 2-arm parallel, double-blind, active-comparator (darbepoetin alfa) conversion study of intermittent oral dosing of ASP1517 in hemodialysis chronic kidney disease patients with anemia]. www.clinicaltrials.astellas.com/study/?pid=1517-CL-0307 (accessed 4 May 2022). LiuF , WangJ , YeQ , FuH , MaoJ . Roxadustat for renal anemia in ESRD from PKD patients: is it safe enough?Journal of the American Society of Nephrology2021;32(4):1005. [MEDLINE: 33649100]NguyenQD , SepahYJ , YamaguchiY , OtsukaT , MajikawaY , ReuschM , et al. Ophthalmological effects of roxadustat in the treatment of anemia in dialysis-dependent and non-dialysis-dependent CKD patients: findings from two phase 3 studies [abstract no: PO0267]. Journal of the American Society of Nephrology2020;31(Abstract Suppl):134. [EMBASE: 633698979]SepahY , NguyenQD , YamaguchiY , MajikawaY , ReuschM , AkizawaT . Ophthalmological effects of roxadustat in the treatment of anaemia in chronic kidney disease patients on dialysis in a phase 3, randomised, double-blind, active-comparator conversion study [abstract no: MO002]. Nephrology Dialysis Transplantation2020;35(Suppl 3):iii102. [EMBASE: 633421367]">Akizawa 2020a</a>; <a href="./references#CD013751-bbs2-0004" title="AkizawaT , NangakuM , YonekawaT , OkudaN , KawamatsuS , OnoueT , et al. Efficacy and safety of daprodustat compared with darbepoetin alfa in Japanese hemodialysis patients with anemia: a randomized, double-blind, phase 3 trial. Clinical Journal of the American Society of Nephrology: CJASN2020;15(8):1155-65. [MEDLINE: 32723804]OzekiH , AkizawaT , NangakuM , YonekawaT , OkudaN , KawamatsuS , et al. Efficacy and safety of daprodustat compared with darbepoetin alfa in Japanese hemodialysis patients with anemia: A randomized, double-blind, phase 3 trial [abstract no: SaO036]. Nephrology Dialysis Transplantation2019;34(Suppl 1):a350. [EMBASE: 631305259]">Akizawa 2020c</a>; <a href="./references#CD013751-bbs2-0006" title="AkizawaT , IwasakiM , OtsukaT , YamaguchiY , ReuschM . Phase 3 study of roxadustat to treat anemia in non-dialysis-dependant CKD. Kidney International Reports2021;6(7):1810-28. [MEDLINE: 34307976]AkizawaT , Tanaka-AminoK , OtsukaT , YamaguchiY . Factors affecting doses of roxadustat versus darbepoetin alfa for anemia in nondialysis patients. American Journal of Nephrology2021;52(9):702-13. [MEDLINE: 34628408]">Akizawa 2021</a>; <a href="./references#CD013751-bbs2-0007" title="Astellas 1517-CL-0608. Roxadustat in the treatment of anemia in chronic kidney disease patients not requiring dialysis [A phase 3, randomized, double-blind, placebo controlled study of the efficacy and safety of roxadustat for the treatment of anemia in chronic kidney disease patients not on dialysis]. www.trialsummaries.com/Study/StudyDetails?id=14384&amp;tenant=MT_AST_90112019. EspositoC , CsikyB , TataradzeA , ReuschM , HanC , SulowiczW . Two phase 3, multicenter, randomized studies of intermittent oral roxadustat in anemic CKD patients on (PYRENEES) and not on (ALPS) dialysis [abstract no: SA-PO225]. Journal of the American Society of Nephrology2019;30(Abstract Suppl):822. [EMBASE: 633767739]Pecoits-FilhoR , ChanTM , HardyE , YuKH , FishbaneS . Roxadustat treatment results in consistent improvements in hemoglobin (Hb) vs. placebo: an analysis of three multinational randomized clinical trials in patients with non-dialysis-dependent CKD (NDD-CKD) [abstract no: TH-OR05]. Journal of the American Society of Nephrology2020;31(Abstract Suppl):2. [EMBASE: 633697943]RastogiA , Pecoits-FilhoR , FishbaneS , LittleDJ , HardyE , YuKH , et al. Roxadustat treatment corrects anemia to hemoglobin (HB) values ≥10 g/dL in the majority of patients with non-dialysis-dependent chronic kidney disease (NDD-CKD) [abstract no: PO0264]. Journal of the American Society of Nephrology2020;31(Abstract Suppl):133. [EMBASE: 633698803]ShutovE , SulowiczW , EspositoC , TataradzeA , AndricB , ReuschM , et al. Roxadustat for the treatment of anemia in chronic kidney disease patients not on dialysis: a phase 3, randomized, double-blind, placebo-controlled study (ALPS). Nephrology Dialysis Transplantation2021;36(9):1629-39. [MEDLINE: 33630072]">ALPS 2021</a>; <a href="./references#CD013751-bbs2-0008" title="CoyneDW , RogerSD , ChouW , BesarabA , LeongR , LeeTT , et al. Roxadustat favorably modifies iron indices in patients with non-dialysis-dependent CKD-related anemia [abstract no: PO0262]. Journal of the American Society of Nephrology2020;31(Abstract Suppl):132. [EMBASE: 633698686]CoyneDW , RogerSD , ShinS , KimSG , CadenaAA , MoustafaMA , et al. Roxadustat for CKD-related anemia in non-dialysis patients. Kidney International Reports2021;6(3):624-35. [MEDLINE: 33732977]CoyneDW , RogerSD , ShinSK , KimSG , CadenaAA , MoustafaMA , et al. ANDES: A phase 3, randomized, double-blind, placebo controlled study of the efficacy and safety of roxadustat for the treatment of anemia in CKD patients not on dialysis [abstract no: SA-PO0228]. Journal of the American Society of Nephrology2019;30(Abstract Suppl):822-3. [EMBASE: 633767955]Pecoits-FilhoR , ChanTM , HardyE , YuKHP , FishbaneS . Roxadustat treatment results in consistent improvements in hemoglobin (Hb) vs. placebo: an analysis of three multinational randomized clinical trials in patients with non-dialysis-dependent CKD (NDD-CKD) [abstract no: TH-OR05]. Journal of the American Society of Nephrology2020;31(Abstract Suppl):2. [EMBASE: 633697943]RastogiA , Pecoits-FilhoR , FishbaneS , LittleDJ , HardyE , YuKH , et al. Roxadustat treatment corrects anemia to hemoglobin (HB) values ≥10 g/dL in the majority of patients with non-dialysis-dependent chronic kidney disease (NDD-CKD) [abstract no: PO0264]. Journal of the American Society of Nephrology2020;31(Abstract Suppl):133. [EMBASE: 633698803]">ANDES 2021</a>; <a href="./references#CD013751-bbs2-0009" title="SinghAK , BlackorbyA , CizmanB , CarrollK , CobitzAR , DaviesR , et al. Study design and baseline characteristics of patients on dialysis in the ASCEND-D trial. Nephrology Dialysis Transplantation2021;37(5):960-72. [MEDLINE: 33744933] [MEDLINE: 33744933]SinghAK , BlackorbyA , CizmanB , CobitzAR , GodoySA , JhaV , et al. Regional variation of erythropoietin-stimulating agent hyporesponsiveness in the global daprodustat dialysis study (ASCEND-D) [abstract no: TH-OR08]. Journal of the American Society of Nephrology2020;31(Abstract Suppl):3. [EMBASE: 633698062]SinghAK , CarrollK , PerkovicV , SolomonS , JhaV , JohansenKL , et al. Daprodustat for the treatment of anemia in patients undergoing dialysis. New England Journal of Medicine2021;385(25):2325-35. [MEDLINE: 34739194]">ASCEND‐D 2021</a>; <a href="./references#CD013751-bbs2-0010" title="SinghAK . Daprodustat is noninferior to darbepoetin alfa in treating anemia in incident dialysis patients [abstract no: PO0465]. Journal of the American Society of Nephrology2021;32(Abstract Suppl):184-5. [EMBASE: 636331207]">ASCEND‐ID 2021</a>; <a href="./references#CD013751-bbs2-0011" title="PerkovicV , BlackorbyA , CizmanB , CarrollK , CobitzA , DaviesR , et al. ASCEND-ND: Study design and baseline characteristics. Nephrology Dialysis Transplantation2021;36(Suppl 1):i334-5. [EMBASE: 635918331]SinghAK , CarrollK , McMurrayJJ , SolomonS , JhaV , JohansenKL , et al. Daprodustat for the treatment of anemia in patients not undergoing dialysis. New England Journal of Medicine2021;385(25):2313-24. [MEDLINE: 34739196]">ASCEND‐ND 2021</a>; <a href="./references#CD013751-bbs2-0012" title="JohansenKL , CobitzAR , LopesRD , SinghAK , ObradorGT , CizmanB , et al. Effects of daprodustat on hemoglobin and quality of life in patients with CKD: results of the ascend-NHQ randomized, double-blind, placebo-controlled trial [abstract no: FR-OR53]. Journal of the American Society of Nephrology2021;32(Abstract Suppl):36. [EMBASE: 636330656]">ASCEND‐NHQ 2021</a>; <a href="./references#CD013751-bbs2-0013" title="CoyneDW , SinghAK , LopesRD , BaileyCK , DiminoTL , HuangC , et al. ASCEND-TD: A randomized, double-blind, active-controlled study of daprodustat administered three times weekly in hemodialysis patients [abstract no: PO0487]. Journal of the American Society of Nephrology2021;32(Abstract Suppl):191. [EMBASE: 636329480]">ASCEND‐TD 2021</a>; <a href="./references#CD013751-bbs2-0014" title="BesarabA , HutlerHN , KlausS , LeeTT , LilienfeldDE , NeffTB , et al. FG-4592, a novel oral HIF prolyl hydroxylase inhibitor, elevates hemoglobin in anemic stage 3/4 CKD patients [abstract no: SA-FC416]. Journal of the American Society of Nephrology2010;21(Abstract Suppl):95A. BesarabA , ProvenzanoR , HertelJ , ZabanehR , KlausSJ , LeeT , et al. Randomized placebo-controlled dose-ranging and pharmacodynamics study of roxadustat (FG-4592) to treat anemia in nondialysis-dependent chronic kidney disease (NDD-CKD) patients. Nephrology Dialysis Transplantation2015;30(10):1665-73. [MEDLINE: 26238121]">Besarab 2015</a>; <a href="./references#CD013751-bbs2-0015" title="BrigandiRA , JohnsonB , OeiC , WestermanM , OlbinaG , deZoysaJ , et al. A novel hypoxia-inducible factor-prolyl hydroxylase inhibitor (GSK1278863) for anemia in CKD: a 28-day, phase 2a randomized trial. American Journal of Kidney Diseases2016;67(6):861-71. [MEDLINE: 26827289]BrigandiRA , JohnsonB , OeiC , WestermanME , OlbinaG , KumarS , et al. Induction of erythropoiesis in anemic patients by prolylhydroxylase inhibitor in a repeat dose, randomized placebo controlled trial [abstract no: SA-PO117]. Journal of the American Society of Nephrology2012;23(Abstract Suppl):662A. BrigandiRA , WestermanME , OlbinaG , OeiC , RussSF , KumarS . Modulation of hepcidin by prolylhydroxylase inhibitor in randomized trials [abstract no: SA-PO118]. Journal of the American Society of Nephrology2012;23(Abstract Suppl):662A. ">Brigandi 2016</a>; <a href="./references#CD013751-bbs2-0016" title="ChenN , HaoC , LiuB , LinHL , CailiW , XingCY , et al. A phase 3, randomized, open-label, active-controlled study of efficacy and safety of roxadustat for treatment of anemia in subjects with CKD on dialysis [abstract no: TH-PO1152]. Journal of the American Society of Nephrology2018;29(Abstract Suppl):B5. ChenN , HaoC , LiuBC , LinH , WangC , XingC , et al. Roxadustat treatment for anemia in patients undergoing long-term dialysis. New England Journal of Medicine2019;381(11):1011-22. [MEDLINE: 31340116]">Chen 2019</a>; <a href="./references#CD013751-bbs2-0017" title="ChenN , HaoC , PengX , LinH , YinA , HaoL , et al. Roxadustat for anemia in patients with kidney disease not receiving dialysis. New England Journal of Medicine2019;381(11):1001-10. [MEDLINE: 31340089]ChenN , HaoC , PengX , LinHL , YinA , HaoL , et al. A phase 3, randomized, double-blind, placebo-controlled study of efficacy and safety of roxadustat (FG-4592) for treatment of anemia in subjects with CKD not on dialysis [abstract no: TH-PO1153]. Journal of the American Society of Nephrology2018;29(Abstract Suppl):B5. ">Chen 2019a</a>; <a href="./references#CD013751-bbs2-0018" title="ChenN , QianJ , ChenJ , YuX , MeiC , HaoC , et al. Phase 2 studies of oral hypoxia-inducible factor prolyl hydroxylase inhibitor FG-4592 for treatment of anemia in China. Nephrology Dialysis Transplantation2017;32(8):1373-86. [MEDLINE: 28371815]">Chen DD 2017</a>; <a href="./references#CD013751-bbs2-0019" title="ChenN , QianJ , ChenJ , YuX , MeiC , HaoC , et al. Phase 2 studies of oral hypoxia-inducible factor prolyl hydroxylase inhibitor FG-4592 for treatment of anemia in China. Nephrology Dialysis Transplantation2017;32(8):1373-86. [MEDLINE: 28371815]QianJQ , ChenN , ChenJ , HaoC , LinHL , NiD , et al. A randomized, double-blind, placebo controlled trial of FG-4592 for correction of anemia in subjects with chronic kidney disease in China [abstract no: FR-OR011]. Journal of the American Society of Nephrology2013;24(Abstract Suppl):38A. ">Chen NDD 2017</a>; <a href="./references#CD013751-bbs2-0020" title="AkizawaT , MacdougallIC , BernsJS , BernhardtT , TaguchiM , OguraE , et al. Iron regulation by molidustat, bay 85-3934, a daily oral hypoxia-inducible factor prolyl hydroxylase inhibitor in patients with chronic kidney disease [abstract no: SP334]. Nephrology Dialysis Transplantation2018;33(Suppl 1):i457. [EMBASE: 622606520]AkizawaT , MacdougallIC , BernsJS , YamamotoH , TaguchiM , IekushiK , et al. Iron regulation by molidustat, a daily oral hypoxia-inducible factor prolyl hydroxylase inhibitor, in patients with chronic kidney disease. Nephron2019;143(4):243-54. [MEDLINE: 31387097]MacdougallIC , AkizawaT , BernsJ , LentiniS , BernhardtT . Molidustat increases haemoglobin in erythropoiesis stimulating agents (ESA)-naive anaemic patients with chronic kidney disease not on dialysis (CKD-ND) [abstract no: SO036]. Nephrology Dialysis Transplantation2016;31(Suppl 1):i16. [EMBASE: 72325954]MacdougallIC , AkizawaT , BernsJS , BernhardtT , KruegerT . Effects of molidustat in the treatment of anemia in CKD [Erratum in: Clin J Am Soc Nephrol. 2019 Oct 7;14(10):1524]. Clinical Journal of the American Society of Nephrology: CJASN2019;14(1):28-39. [MEDLINE: 30559105]MacdougallIC , BernsJS , AkizawaT , FishbaneS , BernhardtT . DIALOGUE phase 2 program for BAY85-3934 a HIF-PH inhibitor with daily oral treatment in anemic patients suffering from CKD/ESRD [abstract no: FR-PO219]. Journal of the American Society of Nephrology2013;24(Abstract Suppl):413A. ">DIALOGUE 1 2019</a>; <a href="./references#CD013751-bbs2-0021" title="AkizawaT , MacdougallIC , BernsJS , YamamotoH , TaguchiM , IekushiK , et al. Iron regulation by molidustat, a daily oral hypoxia-inducible factor prolyl hydroxylase inhibitor, in patients with chronic kidney disease. Nephron2019;143(4):243-54. [MEDLINE: 31387097]MacdougallIC , AkizawaT , BernsJ , LentiniS , BernhardtT , KrugerT . Safety and efficacy of molidustat in erythropoiesis stimulating agents (ESA) pre-treated anaemic patients with chronic kidney disease not on dialysis (CKD-ND) [abstract no: SP309]. Nephrology Dialysis Transplantation2016;31(Suppl 1):i193. [EMBASE: 72326411]MacdougallIC , AkizawaT , BernsJ , LentiniS , BernhardtT . Molidustat increases haemoglobin in erythropoiesis stimulating agents (ESA)-naive anaemic patients with chronic kidney disease not on dialysis (CKD-ND) [abstract no: SO036]]. Nephrology Dialysis Transplantation2016;31(Suppl 1):i16. [EMBASE: 72325954]MacdougallIC , AkizawaT , BernsJS , BernhardtT , KruegerT . Effects of molidustat in the treatment of anemia in CKD [Erratum in: Clin J Am Soc Nephrol. 2019 Oct 7;14(10):1524]. Clinical Journal of the American Society of Nephrology: CJASN2019;14(1):28-39. [MEDLINE: 30559105]MacdougallIC , BernsJS , AkizawaT , FishbaneS , BernhardtT . DIALOGUE phase 2 program for BAY85-3934 a HIF-PH inhibitor with daily oral treatment in anemic patients suffering from CKD/ESRD [abstract no: FR-PO219]. Journal of the American Society of Nephrology2013;24(Abstract Suppl):413A. ">DIALOGUE 2 2019</a>; <a href="./references#CD013751-bbs2-0022" title="AkizawaT , MacdougallIC , BernsJS , YamamotoH , TaguchiM , IekushiK , et al. Iron regulation by molidustat, a daily oral hypoxia-inducible factor prolyl hydroxylase inhibitor, in patients with chronic kidney disease. Nephron2019;143(4):243-54. [MEDLINE: 31387097]MacdougallIC , AkizawaT , BernsJ , LentiniS , BernhardtT . Molidustat increases haemoglobin in erythropoiesis stimulating agents (ESA)-naive anaemic patients with chronic kidney disease not on dialysis (CKD-ND) [abstract no: SO036]. Nephrology Dialysis Transplantation2016;31(Suppl 1):i16. [EMBASE: 72325954]MacdougallIC , AkizawaT , BernsJS , BernhardtT , KruegerT . Effects of molidustat in the treatment of anemia in CKD [Erratum in: Clin J Am Soc Nephrol. 2019 Oct 7;14(10):1524]. Clinical Journal of the American Society of Nephrology: CJASN2019;14(1):28-39. [MEDLINE: 30559105]MacdougallIC , BernsJS , AkizawaT , FishbaneS , BernhardtT . DIALOGUE phase 2 program for BAY85-3934 a HIF-PH inhibitor with daily oral treatment in anemic patients suffering from CKD/ESRD [abstract no: FR-PO219]. Journal of the American Society of Nephrology2013;24(Abstract Suppl):413A. ">DIALOGUE 4 2019</a>; <a href="./references#CD013751-bbs2-0023" title="BarrattJ , AndricB , TataradzeA , SchoemigM , ReuschM , ValluriU , et al. Roxadustat for the treatment of anemia in CKD patients not on dialysis (NDD): a phase 3, randomized, open-label, active-controlled study [abstract no: TH-OR02]. Journal of the American Society of Nephrology2020;31(Abstract Suppl):1. [EMBASE: 633697812]BarrattJ , AndricB , TataradzeA , SchomigM , ReuschM , ValluriU , et al. Roxadustat for the treatment of anaemia in chronic kidney disease patients not on dialysis: a phase 3, randomised, open-label, active-controlled study (DOLOMITES). Nephrology Dialysis Transplantation2021;36(9):1616-28. [MEDLINE: 34077510]BarrattJ , AndricB , TataradzeA , SchomigM , ReuschM , ValluriU , et al. Roxadustat for the treatment of anaemia in chronic kidney disease patients not on dialysis: a phase 3, randomised, open-label, active controlled study [abstract no: MO001]. Nephrology Dialysis Transplantation2020;35(Suppl 3):iii101. [EMBASE: 633423023]BarrattJ , AndricB , TataradzeA , SchomigM , ReuschM , ValluriU , et al. Roxadustat for the treatment of anemia in chronic kidney disease (CKD) patients not on dialysis (NDD): a phase 3, randomized, open-label, active-controlled study [abstract no: Pos-247]. Kidney International Reports2021;6(4 Suppl):S104. [EMBASE: 2011683542]">DOLOMITES 2021</a>; <a href="./references#CD013751-bbs2-0024" title="ProvenzanoM , EvgenyS , LiubovE , KorneyevaS , KathresalAA , PooleL , et al. HIMALAYAS: a phase 3, randomized, open-label, active-controlled study of the efficacy and safety of roxadustat in the treatment of anemia in incident-dialysis patients [abstract no: TH-OR021]. Journal of the American Society of Nephrology2019;30(Abstract Suppl):5. [EMBASE: 633771140]ProvenzanoR , ShutovE , EremeevaL , KorneyevaS , PooleL , SahaG , et al. Roxadustat for anemia in patients with end-stage renal disease incident to dialysis. Nephrology Dialysis Transplantation2021;36(9):1717-30. [MEDLINE: 33629100]">HIMALAYAS 2021</a>; <a href="./references#CD013751-bbs2-0025" title="CizmanB , AckertJ , MeadowcroftA , BiswasN , KellyD , KleinmanD , et al. Ocular safety profile of daprodustat: results of two 24 week studies [abstract no: SAO004]. Nephrology Dialysis Transplantation2018;33(Suppl 1):i316. [EMBASE: 622604997]HoldstockL , CizmanB , MeadowcroftAM , BiswasN , JohnsonBM , JonesD , et al. Daprodustat for anemia: a 24-week, open-label, randomized controlled trial in participants with chronic kidney disease. Clinical Kidney Journal2019;12(1):129-38. [MEDLINE: 30746140]HoldstockL , CizmanB , MeadowcroftAM , BiswasN , JonesD , JohnsonBM , et al. Daprodustat, a HIF-prolyl-hydroxylase inhibitor, increases and maintains hemoglobin over 24 weeks in anemic chronic kidney disease subjects [abstract no: TH-PO908]. Journal of the American Society of Nephrology2016;27(Abstract Suppl):304A. ">Holdstock 2019</a>; <a href="./references#CD013751-bbs2-0026" title="CizmanB , AckertJ , MeadowcroftA , BiswasN , KellyD , KleinmanD , et al. Ocular safety profile of daprodustat: results of two 24 week studies [abstract no: SAO004]. Nephrology Dialysis Transplantation2018;33(Suppl 1):i316. [EMBASE: 622604997]HoldstockL , CizmanB , MeadowcroftAM , BiswasN , JohnsonBM , JonesD , et al. Daprodustat for anemia: a 24-week, open-label, randomized controlled trial in participants with chronic kidney disease. Clinical Kidney Journal2019;12(1):129-38. [MEDLINE: 30746140]HoldstockL , CizmanB , MeadowcroftAM , BiswasN , JonesD , JohnsonBM , et al. Daprodustat, a HIF-prolyl-hydroxylase inhibitor, increases and maintains hemoglobin over 24 weeks in anemic chronic kidney disease subjects [abstract no: TH-PO908]. Journal of the American Society of Nephrology2016;27(Abstract Suppl):304A. ">Holdstock 2019a</a>; <a href="./references#CD013751-bbs2-0028" title="ChertowGM , BoudvilleN , ChowdhuryP , GonzalezC , KooiengaL , LuoW , et al. Vadadustat for treatment of anemia in patients with dialysis-dependent CKD receiving peritoneal dialysis [abstract no: PO0464]. Journal of the American Society of Nephrology2021;32(Abstract Suppl):184. [EMBASE: 636331136]EckardtKU , AgarwalR , AswadA , AwadA , BlockGA , BacciMR , et al. Safety and efficacy of vadadustat for anemia in patients undergoing dialysis. New England Journal of Medicine2021;384(17):1601-12. [MEDLINE: 33913638]EckardtKU , AgarwalR , FaragYM , JardineAG , KhawajaZ , KouryMJ , et al. Global Phase 3 programme of vadadustat for treatment of anaemia of chronic kidney disease: rationale, study design and baseline characteristics of dialysis-dependent patients in the INNO2VATE trials. Nephrology Dialysis Transplantation2020;36(11):2039-48. [MEDLINE: 33188693]EckardtKU . Global phase 3 clinical trials of vadadustat vs. darbepoetin alfa for treatment of anemia in patients with dialysis-dependent CKD [abstract no: TH-OR01]. Journal of the American Society of Nephrology2020;31(Abstract Suppl):1. [EMBASE: 633697781]ParfreyPS , LuoW , MaroniB , AndersR , VargoD , McCulloughPA . Thromboembolic events with vadadustat vs. darbepoetin alfa for anemia treatment in patients with dialysis-dependent CKD [abstract no: PO0463]. Journal of the American Society of Nephrology2021;32(Abstract Suppl):184. [EMBASE: 636331080]WinkelmayerW , TumlinJA , FishbaneS , FaragY , VargoD , LuoW , et al. Hematologic efficacy of vadadustat for anemia in patients with kidney failure on dialysis [abstract no: MO529]. Nephrology Dialysis Transplantation2021;36(Suppl 1):i325-6. [EMBASE: 635917983]WinkelmayerWC , FishbaneS , TumlinJA , FaragYM , LuoW , AndersR , et al. Iron-related outcomes in patients with dialysis-dependent CKD randomized to vadadustat vs. darbepoetin alfa [abstract no: PO0457]. Journal of the American Society of Nephrology2021;32(Abstract Suppl):182. [EMBASE: 636330773]">INNO2VATE 2020</a>; <a href="./references#CD013751-bbs2-0029" title="EckardtKU , AgarwalR , AswadA , AwadA , BlockGA , BacciMR , et al. Safety and efficacy of vadadustat for anemia in patients undergoing dialysis. New England Journal of Medicine2021;384(17):1601-12. [MEDLINE: 33913638]EckardtKU , AgarwalR , FaragYM , JardineAG , KhawajaZ , KouryMJ , et al. Global Phase 3 programme of vadadustat for treatment of anaemia of chronic kidney disease: rationale, study design and baseline characteristics of dialysis-dependent patients in the INNO2VATE trials. Nephrology Dialysis Transplantation2020;36(11):2039-48. [MEDLINE: 33188693]EckardtKU . Global phase 3 clinical trials of vadadustat vs. darbepoetin alfa for treatment of anemia in patients with dialysis-dependent CKD [abstract no: TH-OR01]. Journal of the American Society of Nephrology2020;31(Abstract Suppl):1. [EMBASE: 633697781]WinkelmayerWC , FishbaneS , TumlinJA , FaragYM , LuoW , AndersR , et al. Iron-related outcomes in patients with dialysis-dependent CKD randomized to vadadustat vs. darbepoetin alfa [abstract no: PO0457]. Journal of the American Society of Nephrology2021;32(Abstract Suppl):182. [EMBASE: 636330773]">INNO2VATE 2020a</a>; <a href="./references#CD013751-bbs2-0030" title="CizmanB , AckertJ , MeadowcroftA , BiswasN , KellyD , KleinmanD , et al. Ocular safety profile of daprodustat: results of two 24 week studies [abstract no: SAO004]. Nephrology Dialysis Transplantation2018;33(Suppl 1):i316. [EMBASE: 622604997]CobitzAR , MeadowcroftAM , CizmanB , HoldstockL , BiswasN , JonesD , et al. Daprodustat, a HIF-prolyl-hydroxylase inhibitor, maintains hemoglobin levels over 24 weeks in anemic hemodialysis subjects switching from recombinant human erythropoietin. [abstract no: SA-OR114]. Journal of the American Society of Nephrology2016;27(Abstract Suppl):93A. MeadowcroftAM , CizmanB , HoldstockL , BiswasN , JohnsonBM , JonesD , et al. Daprodustat for anemia: a 24-week, open-label, randomized controlled trial in participants on hemodialysis. Clinical Kidney Journal2019;12(1):139-48. [MEDLINE: 30746141]">Meadowcroft 2019</a>; <a href="./references#CD013751-bbs2-0031" title="AkizawaT , TaguchiM , MatsudaY , IekushiK , YamadaT , YamamotoH . Molidustat for the treatment of renal anaemia in patients with dialysis-dependent chronic kidney disease: Design and rationale of three phase III studies. BMJ Open2019;9(6):e026602. [MEDLINE: 31203241]AkizawaT , YamadaT , NoboriK , MatsudaY , HayashiY , HayasakiT , et al. Molidustat for Japanese patients with renal anemia receiving dialysis. Kidney International Reports2021;6(10):2604–16. [MEDLINE: 34622100]AkizawaT , YamadaT , NoboriK , MatsudaY , HayashiY , HayasakiT , et al. Results from a phase 3 study comparing the efficacy and safety of molidustat vs. Darbepoetin Alfa in patients receiving hemodialysis and treated with erythropoiesis-stimulating agents (ESAS) [abstract no: PO22623]. Journal of the American Society of Nephrology2020;31(Abstract Suppl):B4. [EMBASE: 633697376]">MIYABI HD‐M 2019</a>; <a href="./references#CD013751-bbs2-0032" title="YamamotoH , NoboriK , MatsudaY , HayashiY , HayasakiT , AkizawaT . Efficacy and safety of molidustat for anemia in ESA-naive nondialysis patients: a randomized, phase 3 trial. American Journal of Nephrology2021;52(10-11):871-83. [MEDLINE: 34569489]YamamotoH , TaguchiM , MatsudaY , IekushiK , YamadaT , AkizawaT . Molidustat for the treatment of renal anaemia in patients with non-dialysis-dependent chronic kidney disease: design and rationale of two phase III studies. BMJ Open2019;9(6):e026704. [MEDLINE: 31203242]YamamotoH , TaguchiM , NoboriK , MatsudaY , IekushiK , AkizawaT . To investigate the efficacy and safety of molidustat in non-dialysis patients with renal anemia who are not treated with erythropoiesis stimulating agents: MIYABI ND-C [abstract no: P1866]. Nephrology Dialysis Transplantation2020;35(Suppl 3):iii2177. [EMBASE: 633422996]">MIYABI ND‐C 2019</a>; <a href="./references#CD013751-bbs2-0033" title="YamamotoH , NoboriK , MatsudaY , HayashiY , HayasakiT , AkizawaT . Molidustat for renal anemia in nondialysis patients previously treated with erythropoiesis-stimulating agents: a randomized, open-label, phase 3 study. American Journal of Nephrology2021;52(10-11):884-93. [MEDLINE: 34569482]YamamotoH , TaguchiM , MatsudaY , IekushiK , YamadaT , AkizawaT . Molidustat for the treatment of renal anaemia in patients with non-dialysis-dependent chronic kidney disease: design and rationale of two phase III studies. BMJ Open2019;9(6):e026704. [MEDLINE: 31203242]YamamotoH , TaguchiM , NoboriK , MatsudaY , IekushiK , AkizawaT . To investigate the efficacy and safety of molidustat in non-dialysis patients with renal anemia who are treated with erythropoiesis stimulating agents: Miyabi ND-M [Abstract no: P1868]. Nephrology Dialysis Transplantation2020;35(Suppl 3):iii2179. [EMBASE: 633423006]">MIYABI ND‐M 2019</a>; <a href="./references#CD013751-bbs2-0034" title="NangakuM , KondoK , UetaK , KokadoY , KanekoG , MatsudaH , et al. Efficacy and safety of vadadustat compared with darbepoetin alfa in Japanese anemic patients on hemodialysis: a phase 3, multicenter, randomized, double-blind study. Nephrology Dialysis Transplantation2021;36(9):1731-41. [MEDLINE: 33650630]NangakuM , KondoK , UetaK , KokadoY , KanekoG , MatsudaH , et al. Randomized, double-blinded, active-controlled (darbepoetin alfa), phase 3 study of vadadustat in CKD patients with anemia on hemodialysis in Japan [abstract no: TH-OR024]. Journal of the American Society of Nephrology2019;30(Abstract Suppl):6. [EMBASE: 633771357]">Nangaku 2021</a>; <a href="./references#CD013751-bbs2-0035" title="NangakuM , KondoK , KokadoY , UetaK , KanekoG , ShiosakaM , et al. Randomized, open-label, active-controlled (darbepoetin alfa), phase 3 study of vadadustat for treating anemia in non-dialysis-dependent CKD patients in Japan [abstract no: SA-PO229]. Journal of the American Society of Nephrology2019;30(Abstract Suppl):823. [EMBASE: 633767995]NangakuM , KondoK , KokadoY , UetaK , KanekoG , TandaiT , et al. Phase 3 randomized study comparing vadadustat with darbepoetin alfa for anemia in Japanese patients with nondialysis-dependent CKD. Journal of the American Society of Nephrology2021;32(7):1779-90. [MEDLINE: 33883252]">Nangaku 2021a</a>; <a href="./references#CD013751-bbs2-0036" title="GSK201753. A 52-week, Phase III, open-label, multi-center study to evaluate efficacy and safety of GSK1278863 in Japanese non-dialysis and peritoneal dialysis subjects with anemia associated with chronic kidney disease [study protocol]. www.clinicaltrials.gov/ProvidedDocs/63/NCT02791763/Prot_000.pdf (accessed 9 May 2022). NangakuM , HamanoT , AkizawaT , TsubakiharaY , NagaiR , OkudaN , et al. Daprodustat compared with epoetin beta pegol for anemia in Japanese patients not on dialysis: a 52-week randomized open-label phase 3 trial. American Journal of Nephrology2021;52(1):26-35. [MEDLINE: 33561857]">Nangaku 2021b</a>; <a href="./references#CD013751-bbs2-0037" title="Astellas1517-CL-0304. A study to investigate the effect of ASP1517 after intermittent oral dosing in dialysis chronic kidney disease patients with anemia compared with darbepoetin as a reference drug [A Japanese, phase 2, multicenter, randomized, 4-arm parallel, double-blind (arms 1-3), open-label (arm 4), active-comparator (darbepoetin alfa) study of intermittent oral dosing of asp1517 in hemodialysis-dependent chronic kidney disease patients with anemia [1517-CL-0304 clinical study results report]]. www.trialsummaries.com/Study/StudyDetails?id=14175&amp;tenant=MT_AST_9011; www.clinicaltrials.gov/ct2/show/NCT01888445 (first received 6 August 2018). ">NCT01888445</a>; <a href="./references#CD013751-bbs2-0038" title="NangakuM , FaragYM , deGomaE , LuoW , VargoD , KhawajaZ . Vadadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor, for treatment of anemia of chronic kidney disease: two randomized Phase 2 trials in Japanese patients. Nephrology Dialysis Transplantation 2020 Jul 20 [epub ahead of print]. [DOI: 10.1093/ndt/gfaa060] [MEDLINE: 32719868]NangakuM , KhawajaZ , LuoW , GarafolaS , De GomaE , KomatsuY . Randomized, placebo-controlled phase 2 trials of vadadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), to treat anemia of CKD [abstract no: TH-PO228]. Journal of the American Society of Nephrology2018;29(Abstract Suppl):171. [EMBASE: 633737146]SolinskyC , FaragYM , KhawajaZ , AndersR , LuoW , ChavanA , et al. Impact of vadadustat on iron regulation in Japanese subjects with chronic kidney disease (CKD) [abstract no: 352]. American Journal of Kidney Diseases2020;75(4):638-9. [EMBASE: 2005716872]">NDD‐CKD 2020</a>; <a href="./references#CD013751-bbs2-0039" title="NangakuM , FaragYM , deGomaE , LuoW , VargoD , KhawajaZ . Vadadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor, for treatment of anemia of chronic kidney disease: two randomized Phase 2 trials in Japanese patients. Nephrology Dialysis Transplantation 2020 Jul 20 [epub ahead of print]. [DOI: 10.1093/ndt/gfaa060] [MEDLINE: 32719868]NangakuM , KhawajaZ , LuoW , GarafolaS , deGomaE , KomatsuY . Randomized, placebo-controlled phase 2 trials of vadadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), to treat anemia of CKD [abstract no: TH-PO228]. Journal of the American Society of Nephrology2018;29(Abstract Suppl):171. [EMBASE: 633737146]SolinskyC , FaragYM , KhawajaZ , AndersR , LuoW , ChavanA , et al. Impact of vadadustat on iron regulation in Japanese subjects with chronic kidney disease (CKD) [abstract no: 352]. American Journal of Kidney Diseases2020;75(4):638-9. [EMBASE: 2005716872]">NDD‐CKD 2020a</a>; <a href="./references#CD013751-bbs2-0040" title="AstraZeneca. A phase 3, multicenter, randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of roxadustat for the treatment of anemia in chronic kidney disease patients not on dialysis [clinical study protocol V6; 31 August 2018]. www.clinicaltrials.gov/ProvidedDocs/27/NCT02174627/Prot_000.pdf (accessed 9 May 2022). EleftheriadisT , PissasG , LiakopoulosV , StefanidisI . On the increased event rate of urinary tract infection and pneumonia in CKD patients treated with roxadustat for anemia. Journal of the American Society of Nephrology2021;32(6):1537. [MEDLINE: 33849917]FishbaneS , El-ShahawyMA , Pecoits-FilhoR , VanBP , HouserMT , FrisonL , et al. OLYMPUS: a phase 3, randomized, double-blind, placebo-controlled, international study of roxadustat efficacy in patients with non-dialysis-dependent (NDD) CKD and anemia [abstract no: TH-OR023]. Journal of the American Society of Nephrology2019;30(Abstract Suppl):6. [EMBASE: 633771285]FishbaneS , El-ShahawyMA , Pecoits-FilhoR , VanBP , HouserMT , FrisonL , et al. Roxadustat for treating anemia in patients with CKD not on dialysis: results from a randomized phase 3 study. Journal of the American Society of Nephrology2021;32(3):737-55. [MEDLINE: 33568383]FishbaneS , El-ShahawyMA , VanBP , LittleDJ . Authors' Reply. Journal of the American Society of Nephrology2021;32(6):1537-8. [MEDLINE: 33849916]Pecoits-FilhoR , ChanTM , HardyE , YuKH , FishbaneS . Roxadustat treatment results in consistent improvements in hemoglobin (Hb) vs. placebo: an analysis of three multinational randomized clinical trials in patients with non-dialysis-dependent CKD (NDD-CKD) [abstract no: TH-OR05]. Journal of the American Society of Nephrology2020;31(Abstract Suppl):2. [EMBASE: 633697943]RastogiA , Pecoits-FilhoR , FishbaneS , LittleDJ , HardyE , YuKH , et al. Roxadustat treatment corrects anemia to hemoglobin (HB) values ≥10 g/dL in the majority of patients with non-dialysis-dependent chronic kidney disease (NDD-CKD) [abstract no: PO0264]. Journal of the American Society of Nephrology2020;31(Abstract Suppl):133. [EMBASE: 633698803]">OLYMPUS 2021</a>; <a href="./references#CD013751-bbs2-0041" title="HaaseVH , SpinowitzBS , PergolaPE , FarmerT , MaroniBJ , HartmanCS . AKB-6548 demonstrates controlled hemogloblin (HGB) response in a phase 2b study for the treatment of anemia in patients with chronic kidney disease not on dialysis (ND-CKD) [abstract no: TH-PO649]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):237A. HaaseVH , SpinowitzBS , PergolaPE , KhawajaZ , ChanJ , ZurawQ , et al. Efficacy and dose requirements of vadadustat are independent of systemic inflammation and prior erythropoiesis-stimulating agent(ESA) dose in patients with non-dialysis dependent chronic kidney disease (NDD-CKD) [abstract no: TH-PO907]. Journal of the American Society of Nephrology2016;27(Abstract Suppl):304A. PergolaPE , SpinowitzB , HaaseVH , HartmanCS , FarmerTM , PoluKR , et al. AKB-6548, a novel hypoxia-inducible factor prolyl-hydroxylase inhibitor (HIF-PHI) for the treatment of anemia in patients with chronic kidney disease not on dialysis (ND-CKD) [abstract no: FO015]. Nephrology Dialysis Transplantation2015;30(Suppl 3):iii8. [EMBASE: 72206296]PergolaPE , SpinowitzBS , HartmanCS , MaroniBJ , HaaseVH . Vadadustat, a novel oral HIF stabilizer, provides effective anemia treatment in nondialysis-dependent chronic kidney disease. Kidney International2016;90(5):1115-22. [MEDLINE: 27650732]SpinowitzBS , PergolaPE , HaaseVH , FarmerTM , HartmanCS , MaroniBJ . Hemoglobin (HGB) response in a phase 2b study of AKB-6548 for the treatment of anemia in patients with non-dialysis dependant chronic kidney disease (NDD-CKD). [abstract no: TH-OR038]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):11A. ">Pergola 2016</a>; <a href="./references#CD013751-bbs2-0042" title="BunnHF . Vadadustat for anemia in patients with dialysis-dependent or non-dialysis-dependent chronic kidney disease. New England Journal of Medicine2021;385(16):e56. [MEDLINE: 34644481]ChertowGM , PergolaPE , AgarwalR , BlockGA , FaragYM , JardineAG , et al. Cardiovascular safety and efficacy of vadadustat for the treatment of anemia in non-dialysis-dependent CKD: design and baseline characteristics. American Heart Journal2021;235(5):1-11. [MEDLINE: 33129989]ChertowGM , PergolaPE , FaragYM , AgarwalR , ArnoldS , BakoG , et al. Vadadustat in patients with anemia and non-dialysis-dependent CKD. New England Journal of Medicine2021;384(17):1589-600. [MEDLINE: 33913637]ChertowGM . Global phase 3 clinical trials of vadadustat vs. darbepoetin alfa for treatment of anemia in patients with non-dialysis-dependent CKD [abstract no: FR-OR54]. Journal of the American Society of Nephrology2020;31(Abstract Suppl):B2. [EMBASE: 633697273]KouryM , PergolaPE , Roy-ChaudhuryP , FaragYM , LuoW , AndersR , et al. Iron-related outcomes in patients with non-dialysis-dependent CKD randomized to vadadustat vs. darbepoetin Alfa [abstract no: PO0482]. Journal of the American Society of Nephrology2021;32(Abstract Suppl):190. [EMBASE: 636329134]McCulloughPA , LuoW , AndersR , VargoD , ParfreyPS . Assessment of thromboembolic events with vadadustat vs. darbepoetin alfa for treatment of anemia in patients with non-dialysis-dependent CKD [abstract no: PO0462]. Journal of the American Society of Nephrology2021;32(Abstract Suppl):184. [EMBASE: 636331039]">PRO2TECT‐CONVERSION 2021</a>; <a href="./references#CD013751-bbs2-0043" title="BunnHF . Vadadustat for anemia in patients with dialysis-dependent or non-dialysis-dependent chronic kidney disease. New England Journal of Medicine2021;385(16):e56. [MEDLINE: 34644481]ChertowGM , PergolaPE , AgarwalR , BlockGA , FaragYM , JardineAG , et al. Cardiovascular safety and efficacy of vadadustat for the treatment of anemia in non-dialysis-dependent CKD: design and baseline characteristics. American Heart Journal2021;235(5):1-11. [MEDLINE: 33129989]ChertowGM , PergolaPE , FaragYM , AgarwalR , ArnoldS , BakoG , et al. Vadadustat in patients with anemia and non-dialysis-dependent CKD. New England Journal of Medicine2021;384(17):1589-600. [MEDLINE: 33913637]ChertowGM . Global phase 3 clinical trials of vadadustat vs. darbepoetin alfa for treatment of anemia in patients with non-dialysis-dependent CKD [abstract no: FR-OR5]. Journal of the American Society of Nephrology2020;31(Abstract Suppl):B2. [EMBASE: 633697273]KouryM , PergolaPE , Roy-ChaudhuryP , FaragYM , LuoW , AndersR , et al. Iron-related outcomes in patients with non-dialysis-dependent CKD randomized to vadadustat vs. darbepoetin alfa [abstract no: PO0482]. Journal of the American Society of Nephrology2021;32(Abstract Suppl):190. [EMBASE: 636329134]McCulloughPA , LuoW , AndersR , VargoD , ParfreyPS . Assessment of thromboembolic events with vadadustat vs. darbepoetin alfa for treatment of anemia in patients with non-dialysis-dependent CKD [abstract no: PO0462]. Journal of the American Society of Nephrology2021;32(Abstract Suppl):184. [EMBASE: 636331039]">PRO2TECT‐CORRECTION 2021</a>; <a href="./references#CD013751-bbs2-0044" title="ProvenzanoR , FaddaG , BernardoM , JamesC , KochendoerferG , LeeT , et al. FG2216, a novel oral HIF-PHI, stimulates erythropoiesis and increases hemoglobin concentration in patients with non-dialysis CKD [abstract no: 212]. American Journal of Kidney Diseases2008;51(4):A80. ProvenzanoR , HulterH , AgarwalA , KlausS , LeeT , YuP , et al. Hypoxia-inducible factor (HIF) prolyl hydroxylase inhibitor FG-2216 increases Hb without FE depletion in the absence of IV Fe [abstract no: 249]. American Journal of Kidney Diseases2013;61(4):A78. [EMBASE: 71024073]">Provenzano 2008</a>; <a href="./references#CD013751-bbs2-0045" title="ProvenzanoR , BesarabA , DuaSL , NguyenPV , WrightSH , ZeigS , et al. FG-4592, a novel oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), maintains hemoglobin levels and lowers cholesterol in hemodialysis patients: phase 2 comparison with epoetin alfa [abstract no: FR-PO257]. Journal of the American Society of Nephrology2012;23(Abstract Suppl):428A. ProvenzanoR , BesarabA , WrightS , DuaS , ZeigS , NguyenP , et al. Roxadustat (FG-4592) versus epoetin alfa for anemia in patients receiving maintenance hemodialysis: a phase 2, randomized, 6- to 19-week, open-label, active-comparator, dose-ranging, safety and exploratory efficacy study. American Journal of Kidney Diseases2016;67(6):912-24. [MEDLINE: 26846333]">Provenzano 2016</a>; <a href="./references#CD013751-bbs2-0046" title="ProvenzanoR , BesarabA , DuaSL , NguyenPV , WrightSH , ZeigS , et al. FG-4592, a novel oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), maintains hemoglobin levels and lowers cholesterol in hemodialysis patients: phase 2 comparison with epoetin alfa [abstract no: FR-PO257]. Journal of the American Society of Nephrology2012;23(Abstract Suppl):428A. ProvenzanoR , BesarabA , WrightS , DuaS , ZeigS , NguyenP , et al. Roxadustat (FG-4592) versus epoetin alfa for anemia in patients receiving maintenance hemodialysis: a phase 2, randomized, 6- to 19-week, open-label, active-comparator, dose-ranging, safety and exploratory efficacy study. American Journal of Kidney Diseases2016;67(6):912-24. [MEDLINE: 26846333]">Provenzano 2016a</a>; <a href="./references#CD013751-bbs2-0047" title="Astellas 1517-CL-0613. Roxadustat in the treatment of anemia in end stage renal disease (ESRD) patients on stable dialysis [A phase 3, randomized, open-label, active-controlled study to evaluate the efficacy and safety of roxadustat in the maintenance treatment of anemia in end stage renal disease patients on stable dialysis]. www.trialsummaries.com/Study/StudyDetails?id=14380&amp;tenant=MT_AST_9011 (accessed 9 May 2022). CsikyB , SchomigM , EspositoC , BarrattJ , ReuschM , ValluriU , et al. Roxadustat for the maintenance treatment of anemia in patients with end-stage kidney disease on stable dialysis: a European phase 3, randomized, open-label, active-controlled study (PYRENEES). Advances in Therapy2021;38(10):5361-80. [MEDLINE: 34537926]EspositoC , CsikyB , TataradzeA , ReuschM , HanC , SulowiczW . Two phase 3, multicenter, randomized studies of intermittent oral roxadustat in anemic CKD patients on (PYRENEES) and not on (ALPS) dialysis. Swiss Medical Weekly2020;150(Suppl 248):21-2S. [EMBASE: 634241523]EspositoC , CsikyB , TataradzeA , ReuschM , HanC , SulowiczW . Two phase 3, multicenter, randomized studies of intermittent oral roxadustat in anemic CKD patients on (PYRENEES) and not on (ALPS) dialysis [abstract no: SA-PO225]. Journal of the American Society of Nephrology2019;30(Abstract Suppl):822. [EMBASE: 633767739]">PYRENEES 2021</a>; <a href="./references#CD013751-bbs2-0048" title="AstraZeneca. A phase 3, multicenter, randomized, open-label, active-controlled study of the safety and efficacy of roxadustat in the treatment of anemia in dialysis patients [Clinical study protocol v8.0 19 September 2018]. www.clinicaltrials.gov/ProvidedDocs/31/NCT02174731/Prot_000.pdf (accessed 10 May 2022). FishbaneS , PollockCA , El-ShahawyMA , EscuderoET , RastogiA , VanBP , et al. ROCKIES: an international, phase 3, randomized, open-label, active-controlled study of roxadustat for anemia in dialysis-dependent CKD patients [abstract no: TH-OR022]. Journal of the American Society of Nephrology2019;30(Abstract Suppl):6. [EMBASE: 633771219]">ROCKIES 2019</a>; <a href="./references#CD013751-bbs2-0049" title="CharytanC , Manllo-KarimR , MartinER , SteerD , BernardoM , DuaSL , et al. A randomized trial of roxadustat in anemia of kidney failure: SIERRAS study. Kidney International Reports2021;6(7):1829-39. [MEDLINE: 34307977]CharytanC , Manllo-KarimR , MartinER , SteerD , BernardoM , DuaSL , et al. SIERRAS: A phase 3, open-label, randomized, active-controlled study of the efficacy and safety of roxadustat in the maintenance treatment of anemia in subjects with ESRD on stable dialysis [abstract no: SA-PO227]. Journal of the American Society of Nephrology2019;30(Abstract Suppl):822. [EMBASE: 633767862]">SIERRAS 2021</a>; <a href="./references#CD013751-bbs2-0050" title="AkizawaT , MaedaK , MiyazawaY , KoretomoR . Phase 3 study to compare the efficacy and safety of enarodustat (JTZ-951), an oral HIF-PH inhibitor, with darbepoetin alfa in anemic patients with CKD receiving maintenance hemodialysis [abstract no: TH-PO1186]. Journal of the American Society of Nephrology2019;30(Abstract Suppl):B4. AkizawaT , NangakuM , YamaguchiT , KoretomoR , MaedaK , MiyazawaY , et al. A phase 3 study of enarodustat (JTZ-951) in Japanese hemodialysis patients for treatment of anemia in chronic kidney disease: SYMPHONY HD study. Kidney Diseases2021;7(6):494-502. [EMBASE: 2013576033]">SYMPHONY HD 2021</a>; <a href="./references#CD013751-bbs2-0051" title="AkizawaT , NangakuM , YamaguchiT , KoretomoR , MaedaK , MiyazawaY , et al. A phase 3 study of enarodustat in anemic patients with CKD not requiring dialysis: the SYMPHONY ND study. Kidney International Reports2021;6(7):1840-9. [MEDLINE: 34307978]">SYMPHONY ND 2021</a>) were assessed to be at high risk of bias due to the potential role of funding, and one study was assessed as unclear risk of bias for this domain (<a href="./references#CD013751-bbs2-0005" title="AkizawaT , IwasakiM , OtsukaT , YamaguchiY , ReuschM . A phase 3, multicenter, randomized, open-label, active comparator conversion study of roxadustat in non-dialysis-dependent (NDD) patients with anemia in chronic kidney disease (CKD) [abstract no: POS-244]. Kidney International Reports2021;6(4 Suppl):S103. [EMBASE: 2011682459]AkizawaT , IwasakiM , OtsukaT , YamaguchiY , ReuschM . A phase 3, multicenter, randomized, open-label, active comparator conversion study of roxadustat in non-dialysis-dependent (NDD) patients with anemia in CKD [abstract no: PO0269]. Journal of the American Society of Nephrology2020;31(Abstract Suppl):134. [EMBASE: 633699036]NguyenQD , SepahYJ , YamaguchiY , OtsukaT , MajikawaY , ReuschM , et al. Ophthalmological effects of roxadustat in the treatment of anemia in dialysis-dependent and non-dialysis-dependent CKD patients: findings from two phase 3 studies [abstract no: PO0267]. Journal of the American Society of Nephrology2020;31(Abstract Suppl):134. [EMBASE: 633698979]">Akizawa 2020f</a>). </p> </section> </section> <section id="CD013751-sec-0063"> <h3 class="title" id="CD013751-sec-0063">Effects of interventions</h3> <p>See: <a href="./full#CD013751-tbl-0001"><b>Summary of findings 1</b> Hypoxia‐inducible factor (HIF) stabilisers versus placebo for people with chronic kidney disease (CKD)</a>; <a href="./full#CD013751-tbl-0002"><b>Summary of findings 2</b> Hypoxia‐inducible factor (HIF) stabilisers versus erythropoiesis‐stimulating agent (ESA) for people with chronic kidney disease (CKD)</a> </p> <p>See <a href="./full#CD013751-tbl-0001">summary of findings Table 1</a> and <a href="./full#CD013751-tbl-0002">summary of findings Table 2</a>. </p> <section id="CD013751-sec-0064"> <h4 class="title">HIF stabiliser versus placebo</h4> <p>Fourteen studies (<a href="./references#CD013751-bbs2-0001" title="AkizawaT , TsubakiharaY , NangakuM , EndoY , NakajimaH , KohnoT , et al. Effects of daprodustat, a novel hypoxia-inducible factor prolyl hydroxylase inhibitor on anemia management in Japanese hemodialysis subjects. American Journal of Nephrology2017;45(2):127-35. [MEDLINE: 27978511]EndoY , KohnoT , ImaiY , KawaseN , HaraK , LeporeJJ , et al. A 4 -week dose response study of the hypoxia inducible factor-prolyl hydroxylase inhibitor GSK1278863 in Japanese anemic haemodialysis subjects [abstract no: SA-PO819]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):818A. NCT02019719. Study to evaluate the safety, efficacy and pharmacokinetics of GSK1278863 in Japanese hemodialysis-dependent subjects with anemia associated with chronic kidney disease [A 4-week, phase ii, randomized, double-blind, dose-ranging, placebo-controlled, parallel-group, multi-center study to evaluate the safety, efficacy and pharmacokinetics of GSK1278863 in Japanese hemodialysis-dependent subjects with anemia associated with chronic kidney disease]. clinicaltrials.gov/show/NCT02019719 (first received 24 December 2013). ">Akizawa 2017</a>; <a href="./references#CD013751-bbs2-0002" title="AkizawaT , IwasakiM , OtsukaT , ReuschM , MisumiT . Roxadustat for the treatment of chronic kidney disease-associated anemia in Japanese patients not on dialysis [abstract no: FR-PO1142]. Journal of the American Society of Nephrology2016;27(Abstract Suppl):7B. AkizawaT , IwasakiM , OtsukaT , ReuschM , MisumiT . Roxadustat treatment of chronic kidney disease-associated anemia in Japanese patients not on dialysis: a phase 2, randomized, double-blind, placebo-controlled trial. Advances in Therapy2019;36(6):1438-54. [MEDLINE: 30953333]">Akizawa 2019</a>; <a href="./references#CD013751-bbs2-0007" title="Astellas 1517-CL-0608. Roxadustat in the treatment of anemia in chronic kidney disease patients not requiring dialysis [A phase 3, randomized, double-blind, placebo controlled study of the efficacy and safety of roxadustat for the treatment of anemia in chronic kidney disease patients not on dialysis]. www.trialsummaries.com/Study/StudyDetails?id=14384&amp;tenant=MT_AST_90112019. EspositoC , CsikyB , TataradzeA , ReuschM , HanC , SulowiczW . Two phase 3, multicenter, randomized studies of intermittent oral roxadustat in anemic CKD patients on (PYRENEES) and not on (ALPS) dialysis [abstract no: SA-PO225]. Journal of the American Society of Nephrology2019;30(Abstract Suppl):822. [EMBASE: 633767739]Pecoits-FilhoR , ChanTM , HardyE , YuKH , FishbaneS . Roxadustat treatment results in consistent improvements in hemoglobin (Hb) vs. placebo: an analysis of three multinational randomized clinical trials in patients with non-dialysis-dependent CKD (NDD-CKD) [abstract no: TH-OR05]. Journal of the American Society of Nephrology2020;31(Abstract Suppl):2. [EMBASE: 633697943]RastogiA , Pecoits-FilhoR , FishbaneS , LittleDJ , HardyE , YuKH , et al. Roxadustat treatment corrects anemia to hemoglobin (HB) values ≥10 g/dL in the majority of patients with non-dialysis-dependent chronic kidney disease (NDD-CKD) [abstract no: PO0264]. Journal of the American Society of Nephrology2020;31(Abstract Suppl):133. [EMBASE: 633698803]ShutovE , SulowiczW , EspositoC , TataradzeA , AndricB , ReuschM , et al. Roxadustat for the treatment of anemia in chronic kidney disease patients not on dialysis: a phase 3, randomized, double-blind, placebo-controlled study (ALPS). Nephrology Dialysis Transplantation2021;36(9):1629-39. [MEDLINE: 33630072]">ALPS 2021</a>; <a href="./references#CD013751-bbs2-0008" title="CoyneDW , RogerSD , ChouW , BesarabA , LeongR , LeeTT , et al. Roxadustat favorably modifies iron indices in patients with non-dialysis-dependent CKD-related anemia [abstract no: PO0262]. Journal of the American Society of Nephrology2020;31(Abstract Suppl):132. [EMBASE: 633698686]CoyneDW , RogerSD , ShinS , KimSG , CadenaAA , MoustafaMA , et al. Roxadustat for CKD-related anemia in non-dialysis patients. Kidney International Reports2021;6(3):624-35. [MEDLINE: 33732977]CoyneDW , RogerSD , ShinSK , KimSG , CadenaAA , MoustafaMA , et al. ANDES: A phase 3, randomized, double-blind, placebo controlled study of the efficacy and safety of roxadustat for the treatment of anemia in CKD patients not on dialysis [abstract no: SA-PO0228]. Journal of the American Society of Nephrology2019;30(Abstract Suppl):822-3. [EMBASE: 633767955]Pecoits-FilhoR , ChanTM , HardyE , YuKHP , FishbaneS . Roxadustat treatment results in consistent improvements in hemoglobin (Hb) vs. placebo: an analysis of three multinational randomized clinical trials in patients with non-dialysis-dependent CKD (NDD-CKD) [abstract no: TH-OR05]. Journal of the American Society of Nephrology2020;31(Abstract Suppl):2. [EMBASE: 633697943]RastogiA , Pecoits-FilhoR , FishbaneS , LittleDJ , HardyE , YuKH , et al. Roxadustat treatment corrects anemia to hemoglobin (HB) values ≥10 g/dL in the majority of patients with non-dialysis-dependent chronic kidney disease (NDD-CKD) [abstract no: PO0264]. Journal of the American Society of Nephrology2020;31(Abstract Suppl):133. [EMBASE: 633698803]">ANDES 2021</a>; <a href="./references#CD013751-bbs2-0014" title="BesarabA , HutlerHN , KlausS , LeeTT , LilienfeldDE , NeffTB , et al. FG-4592, a novel oral HIF prolyl hydroxylase inhibitor, elevates hemoglobin in anemic stage 3/4 CKD patients [abstract no: SA-FC416]. Journal of the American Society of Nephrology2010;21(Abstract Suppl):95A. BesarabA , ProvenzanoR , HertelJ , ZabanehR , KlausSJ , LeeT , et al. Randomized placebo-controlled dose-ranging and pharmacodynamics study of roxadustat (FG-4592) to treat anemia in nondialysis-dependent chronic kidney disease (NDD-CKD) patients. Nephrology Dialysis Transplantation2015;30(10):1665-73. [MEDLINE: 26238121]">Besarab 2015</a>; <a href="./references#CD013751-bbs2-0015" title="BrigandiRA , JohnsonB , OeiC , WestermanM , OlbinaG , deZoysaJ , et al. A novel hypoxia-inducible factor-prolyl hydroxylase inhibitor (GSK1278863) for anemia in CKD: a 28-day, phase 2a randomized trial. American Journal of Kidney Diseases2016;67(6):861-71. [MEDLINE: 26827289]BrigandiRA , JohnsonB , OeiC , WestermanME , OlbinaG , KumarS , et al. Induction of erythropoiesis in anemic patients by prolylhydroxylase inhibitor in a repeat dose, randomized placebo controlled trial [abstract no: SA-PO117]. Journal of the American Society of Nephrology2012;23(Abstract Suppl):662A. BrigandiRA , WestermanME , OlbinaG , OeiC , RussSF , KumarS . Modulation of hepcidin by prolylhydroxylase inhibitor in randomized trials [abstract no: SA-PO118]. Journal of the American Society of Nephrology2012;23(Abstract Suppl):662A. ">Brigandi 2016</a>; <a href="./references#CD013751-bbs2-0017" title="ChenN , HaoC , PengX , LinH , YinA , HaoL , et al. Roxadustat for anemia in patients with kidney disease not receiving dialysis. New England Journal of Medicine2019;381(11):1001-10. [MEDLINE: 31340089]ChenN , HaoC , PengX , LinHL , YinA , HaoL , et al. A phase 3, randomized, double-blind, placebo-controlled study of efficacy and safety of roxadustat (FG-4592) for treatment of anemia in subjects with CKD not on dialysis [abstract no: TH-PO1153]. Journal of the American Society of Nephrology2018;29(Abstract Suppl):B5. ">Chen 2019a</a>; <a href="./references#CD013751-bbs2-0019" title="ChenN , QianJ , ChenJ , YuX , MeiC , HaoC , et al. Phase 2 studies of oral hypoxia-inducible factor prolyl hydroxylase inhibitor FG-4592 for treatment of anemia in China. Nephrology Dialysis Transplantation2017;32(8):1373-86. [MEDLINE: 28371815]QianJQ , ChenN , ChenJ , HaoC , LinHL , NiD , et al. A randomized, double-blind, placebo controlled trial of FG-4592 for correction of anemia in subjects with chronic kidney disease in China [abstract no: FR-OR011]. Journal of the American Society of Nephrology2013;24(Abstract Suppl):38A. ">Chen NDD 2017</a>; <a href="./references#CD013751-bbs2-0020" title="AkizawaT , MacdougallIC , BernsJS , BernhardtT , TaguchiM , OguraE , et al. Iron regulation by molidustat, bay 85-3934, a daily oral hypoxia-inducible factor prolyl hydroxylase inhibitor in patients with chronic kidney disease [abstract no: SP334]. Nephrology Dialysis Transplantation2018;33(Suppl 1):i457. [EMBASE: 622606520]AkizawaT , MacdougallIC , BernsJS , YamamotoH , TaguchiM , IekushiK , et al. Iron regulation by molidustat, a daily oral hypoxia-inducible factor prolyl hydroxylase inhibitor, in patients with chronic kidney disease. Nephron2019;143(4):243-54. [MEDLINE: 31387097]MacdougallIC , AkizawaT , BernsJ , LentiniS , BernhardtT . Molidustat increases haemoglobin in erythropoiesis stimulating agents (ESA)-naive anaemic patients with chronic kidney disease not on dialysis (CKD-ND) [abstract no: SO036]. Nephrology Dialysis Transplantation2016;31(Suppl 1):i16. [EMBASE: 72325954]MacdougallIC , AkizawaT , BernsJS , BernhardtT , KruegerT . Effects of molidustat in the treatment of anemia in CKD [Erratum in: Clin J Am Soc Nephrol. 2019 Oct 7;14(10):1524]. Clinical Journal of the American Society of Nephrology: CJASN2019;14(1):28-39. [MEDLINE: 30559105]MacdougallIC , BernsJS , AkizawaT , FishbaneS , BernhardtT . DIALOGUE phase 2 program for BAY85-3934 a HIF-PH inhibitor with daily oral treatment in anemic patients suffering from CKD/ESRD [abstract no: FR-PO219]. Journal of the American Society of Nephrology2013;24(Abstract Suppl):413A. ">DIALOGUE 1 2019</a>; <a href="./references#CD013751-bbs2-0038" title="NangakuM , FaragYM , deGomaE , LuoW , VargoD , KhawajaZ . Vadadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor, for treatment of anemia of chronic kidney disease: two randomized Phase 2 trials in Japanese patients. Nephrology Dialysis Transplantation 2020 Jul 20 [epub ahead of print]. [DOI: 10.1093/ndt/gfaa060] [MEDLINE: 32719868]NangakuM , KhawajaZ , LuoW , GarafolaS , De GomaE , KomatsuY . Randomized, placebo-controlled phase 2 trials of vadadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), to treat anemia of CKD [abstract no: TH-PO228]. Journal of the American Society of Nephrology2018;29(Abstract Suppl):171. [EMBASE: 633737146]SolinskyC , FaragYM , KhawajaZ , AndersR , LuoW , ChavanA , et al. Impact of vadadustat on iron regulation in Japanese subjects with chronic kidney disease (CKD) [abstract no: 352]. American Journal of Kidney Diseases2020;75(4):638-9. [EMBASE: 2005716872]">NDD‐CKD 2020</a>; <a href="./references#CD013751-bbs2-0039" title="NangakuM , FaragYM , deGomaE , LuoW , VargoD , KhawajaZ . Vadadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor, for treatment of anemia of chronic kidney disease: two randomized Phase 2 trials in Japanese patients. Nephrology Dialysis Transplantation 2020 Jul 20 [epub ahead of print]. [DOI: 10.1093/ndt/gfaa060] [MEDLINE: 32719868]NangakuM , KhawajaZ , LuoW , GarafolaS , deGomaE , KomatsuY . Randomized, placebo-controlled phase 2 trials of vadadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), to treat anemia of CKD [abstract no: TH-PO228]. Journal of the American Society of Nephrology2018;29(Abstract Suppl):171. [EMBASE: 633737146]SolinskyC , FaragYM , KhawajaZ , AndersR , LuoW , ChavanA , et al. Impact of vadadustat on iron regulation in Japanese subjects with chronic kidney disease (CKD) [abstract no: 352]. American Journal of Kidney Diseases2020;75(4):638-9. [EMBASE: 2005716872]">NDD‐CKD 2020a</a>; <a href="./references#CD013751-bbs2-0040" title="AstraZeneca. A phase 3, multicenter, randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of roxadustat for the treatment of anemia in chronic kidney disease patients not on dialysis [clinical study protocol V6; 31 August 2018]. www.clinicaltrials.gov/ProvidedDocs/27/NCT02174627/Prot_000.pdf (accessed 9 May 2022). EleftheriadisT , PissasG , LiakopoulosV , StefanidisI . On the increased event rate of urinary tract infection and pneumonia in CKD patients treated with roxadustat for anemia. Journal of the American Society of Nephrology2021;32(6):1537. [MEDLINE: 33849917]FishbaneS , El-ShahawyMA , Pecoits-FilhoR , VanBP , HouserMT , FrisonL , et al. OLYMPUS: a phase 3, randomized, double-blind, placebo-controlled, international study of roxadustat efficacy in patients with non-dialysis-dependent (NDD) CKD and anemia [abstract no: TH-OR023]. Journal of the American Society of Nephrology2019;30(Abstract Suppl):6. [EMBASE: 633771285]FishbaneS , El-ShahawyMA , Pecoits-FilhoR , VanBP , HouserMT , FrisonL , et al. Roxadustat for treating anemia in patients with CKD not on dialysis: results from a randomized phase 3 study. Journal of the American Society of Nephrology2021;32(3):737-55. [MEDLINE: 33568383]FishbaneS , El-ShahawyMA , VanBP , LittleDJ . Authors' Reply. Journal of the American Society of Nephrology2021;32(6):1537-8. [MEDLINE: 33849916]Pecoits-FilhoR , ChanTM , HardyE , YuKH , FishbaneS . Roxadustat treatment results in consistent improvements in hemoglobin (Hb) vs. placebo: an analysis of three multinational randomized clinical trials in patients with non-dialysis-dependent CKD (NDD-CKD) [abstract no: TH-OR05]. Journal of the American Society of Nephrology2020;31(Abstract Suppl):2. [EMBASE: 633697943]RastogiA , Pecoits-FilhoR , FishbaneS , LittleDJ , HardyE , YuKH , et al. Roxadustat treatment corrects anemia to hemoglobin (HB) values ≥10 g/dL in the majority of patients with non-dialysis-dependent chronic kidney disease (NDD-CKD) [abstract no: PO0264]. Journal of the American Society of Nephrology2020;31(Abstract Suppl):133. [EMBASE: 633698803]">OLYMPUS 2021</a>; <a href="./references#CD013751-bbs2-0041" title="HaaseVH , SpinowitzBS , PergolaPE , FarmerT , MaroniBJ , HartmanCS . AKB-6548 demonstrates controlled hemogloblin (HGB) response in a phase 2b study for the treatment of anemia in patients with chronic kidney disease not on dialysis (ND-CKD) [abstract no: TH-PO649]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):237A. HaaseVH , SpinowitzBS , PergolaPE , KhawajaZ , ChanJ , ZurawQ , et al. Efficacy and dose requirements of vadadustat are independent of systemic inflammation and prior erythropoiesis-stimulating agent(ESA) dose in patients with non-dialysis dependent chronic kidney disease (NDD-CKD) [abstract no: TH-PO907]. Journal of the American Society of Nephrology2016;27(Abstract Suppl):304A. PergolaPE , SpinowitzB , HaaseVH , HartmanCS , FarmerTM , PoluKR , et al. AKB-6548, a novel hypoxia-inducible factor prolyl-hydroxylase inhibitor (HIF-PHI) for the treatment of anemia in patients with chronic kidney disease not on dialysis (ND-CKD) [abstract no: FO015]. Nephrology Dialysis Transplantation2015;30(Suppl 3):iii8. [EMBASE: 72206296]PergolaPE , SpinowitzBS , HartmanCS , MaroniBJ , HaaseVH . Vadadustat, a novel oral HIF stabilizer, provides effective anemia treatment in nondialysis-dependent chronic kidney disease. Kidney International2016;90(5):1115-22. [MEDLINE: 27650732]SpinowitzBS , PergolaPE , HaaseVH , FarmerTM , HartmanCS , MaroniBJ . Hemoglobin (HGB) response in a phase 2b study of AKB-6548 for the treatment of anemia in patients with non-dialysis dependant chronic kidney disease (NDD-CKD). [abstract no: TH-OR038]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):11A. ">Pergola 2016</a>; <a href="./references#CD013751-bbs2-0044" title="ProvenzanoR , FaddaG , BernardoM , JamesC , KochendoerferG , LeeT , et al. FG2216, a novel oral HIF-PHI, stimulates erythropoiesis and increases hemoglobin concentration in patients with non-dialysis CKD [abstract no: 212]. American Journal of Kidney Diseases2008;51(4):A80. ProvenzanoR , HulterH , AgarwalA , KlausS , LeeT , YuP , et al. Hypoxia-inducible factor (HIF) prolyl hydroxylase inhibitor FG-2216 increases Hb without FE depletion in the absence of IV Fe [abstract no: 249]. American Journal of Kidney Diseases2013;61(4):A78. [EMBASE: 71024073]">Provenzano 2008</a>) compared HIF stabiliser management of anaemia versus placebo in patients with CKD (stages 3, 4 or 5), including patients undergoing HD, during a median follow‐up of 17 weeks. The certainty of the evidence was mainly low or very low (<a href="./full#CD013751-tbl-0001">summary of findings Table 1</a>). </p> <section id="CD013751-sec-0065"> <h5 class="title">Primary outcomes</h5> <section id="CD013751-sec-0066"> <h6 class="title">Cardiovascular death</h6> <p>Compared to placebo, HIF stabiliser therapy had uncertain effects on CV death (<a href="./references#CD013751-fig-0005" title="">Analysis 1.1</a> (10 studies, 1114 participants): RR 3.68, 95% CI 0.19 to 70.21; very low certainty evidence) in people with CKD or undergoing HD. </p> </section> </section> <section id="CD013751-sec-0067"> <h5 class="title">Secondary outcomes</h5> <section id="CD013751-sec-0068"> <h6 class="title">Death (any cause)</h6> <p>Compared to placebo, HIF stabiliser therapy may make little or no difference to death (any cause) (<a href="./references#CD013751-fig-0006" title="">Analysis 1.2</a> (12 studies, 4469 participants): RR 1.12, 95% CI 0.97 to 1.30; I² = 0%; low certainty evidence) in people with CKD or undergoing HD. </p> </section> <section id="CD013751-sec-0069"> <h6 class="title">Myocardial infarction</h6> <p>The effect of HIF stabiliser treatment on nonfatal MI was uncertain (<a href="./references#CD013751-fig-0007" title="">Analysis 1.3</a> (3 studies, 822 participants): RR 1.29, 95% CI 0.31 to 5.36; I² = 0%; very low certainty evidence) compared with placebo in people with CKD. </p> <p>When MI was reported as fatal or nonfatal events, HIF stabiliser therapy may make little or no difference to the numbers with fatal or nonfatal MI (<a href="./references#CD013751-fig-0008" title="">Analysis 1.4</a> (5 studies, 4499 participants): RR 1.06, 95% CI 0.59 to 1.90; I² = 0%; low certainty evidence) compared with placebo in people with CKD. </p> </section> <section id="CD013751-sec-0070"> <h6 class="title">Stroke</h6> <p>HIF stabiliser treatment had uncertain effects on nonfatal stroke (<a href="./references#CD013751-fig-0009" title="">Analysis 1.5</a>: 2 studies, 228 participants), as no events were reported in these two studies. </p> <p>When stroke was reported as a fatal or nonfatal event, the effects of HIF stabiliser therapy on fatal or nonfatal stroke were uncertain (<a href="./references#CD013751-fig-0010" title="">Analysis 1.6</a> (3 studies, 822 participants): RR 2.08, 95% CI 0.23 to 18.46; very low certainty evidence) compared with placebo in people with CKD. </p> </section> <section id="CD013751-sec-0071"> <h6 class="title">Peripheral arterial events</h6> <p><a href="./references#CD013751-bbs2-0020" title="AkizawaT , MacdougallIC , BernsJS , BernhardtT , TaguchiM , OguraE , et al. Iron regulation by molidustat, bay 85-3934, a daily oral hypoxia-inducible factor prolyl hydroxylase inhibitor in patients with chronic kidney disease [abstract no: SP334]. Nephrology Dialysis Transplantation2018;33(Suppl 1):i457. [EMBASE: 622606520]AkizawaT , MacdougallIC , BernsJS , YamamotoH , TaguchiM , IekushiK , et al. Iron regulation by molidustat, a daily oral hypoxia-inducible factor prolyl hydroxylase inhibitor, in patients with chronic kidney disease. Nephron2019;143(4):243-54. [MEDLINE: 31387097]MacdougallIC , AkizawaT , BernsJ , LentiniS , BernhardtT . Molidustat increases haemoglobin in erythropoiesis stimulating agents (ESA)-naive anaemic patients with chronic kidney disease not on dialysis (CKD-ND) [abstract no: SO036]. Nephrology Dialysis Transplantation2016;31(Suppl 1):i16. [EMBASE: 72325954]MacdougallIC , AkizawaT , BernsJS , BernhardtT , KruegerT . Effects of molidustat in the treatment of anemia in CKD [Erratum in: Clin J Am Soc Nephrol. 2019 Oct 7;14(10):1524]. Clinical Journal of the American Society of Nephrology: CJASN2019;14(1):28-39. [MEDLINE: 30559105]MacdougallIC , BernsJS , AkizawaT , FishbaneS , BernhardtT . DIALOGUE phase 2 program for BAY85-3934 a HIF-PH inhibitor with daily oral treatment in anemic patients suffering from CKD/ESRD [abstract no: FR-PO219]. Journal of the American Society of Nephrology2013;24(Abstract Suppl):413A. ">DIALOGUE 1 2019</a> reported HIF stabilisers had uncertain effects on peripheral arterial events (<a href="./references#CD013751-fig-0011" title="">Analysis 1.7</a> (1 study, 121 participants): RR 0.20, 95% CI 0.01 to 3.04) compared with placebo in people with CKD. </p> </section> <section id="CD013751-sec-0072"> <h6 class="title">Proportion of patients requiring blood transfusion</h6> <p>HIF stabiliser treatment probably decreases the proportion of patients requiring blood transfusion (<a href="./references#CD013751-fig-0012" title="">Analysis 1.8</a> (8 studies, 4329 participants): RR 0.51, 95% CI 0.44 to 0.60; I² = 0%; moderate certainty evidence) compared with placebo in people with CKD or undergoing HD. </p> </section> <section id="CD013751-sec-0073"> <h6 class="title">Proportion of patients reaching the target haemoglobin</h6> <p>HIF stabiliser therapy probably increases the proportion of patients reaching the target Hb (<a href="./references#CD013751-fig-0013" title="">Analysis 1.9</a> (10 studies, 5102 participants): RR 8.36, 95% CI 6.42 to 10.89; I² = 37%; moderate certainty evidence) compared to placebo in people with CKD or undergoing HD. </p> </section> <section id="CD013751-sec-0074"> <h6 class="title">Kidney failure</h6> <p>HIF stabiliser therapy may make little or no difference to kidney failure (<a href="./references#CD013751-fig-0014" title="">Analysis 1.10</a> (8 studies, 2228 participants): RR 1.22, 95% CI 0.98 to 1.51; I² = 0%; low certainty evidence) compared to placebo in people with CKD. </p> </section> <section id="CD013751-sec-0075"> <h6 class="title">Thrombosis</h6> <p>HIF stabiliser therapy may increase thrombosis (<a href="./references#CD013751-fig-0015" title="">Analysis 1.11</a> (3 studies, 3452 participants): RR 2.36, 95% CI 1.19 to 4.66; I² = 0%; low certainty evidence) compared to placebo in people with CKD or undergoing HD. </p> </section> <section id="CD013751-sec-0076"> <h6 class="title">Loss of unassisted dialysis vascular access patency</h6> <p>The effect of HIF stabiliser therapy on the loss of unassisted dialysis vascular access patency was uncertain (<a href="./references#CD013751-fig-0016" title="">Analysis 1.12</a> (2 studies, 157 participants): RR 1.18, 95% CI 0.13 to 10.31; I² = 0%; very low certainty evidence) compared to placebo in people undergoing HD. </p> </section> <section id="CD013751-sec-0077"> <h6 class="title">Hyperkalaemia</h6> <p>HIF stabiliser therapy may increase hyperkalaemia (<a href="./references#CD013751-fig-0017" title="">Analysis 1.13</a> (7 studies, 4845 participants): RR 1.29, 95% CI 1.01 to 1.64; I² = 18%; low certainty evidence) compared to placebo in people with CKD. </p> </section> </section> <section id="CD013751-sec-0078"> <h5 class="title">Subgroup analyses for HIF stabiliser versus placebo</h5> <p>Additional analyses were performed stratifying by stage of CKD.</p> <p> <ul id="CD013751-list-0017"> <li> <p>CV death</p> <ul id="CD013751-list-0018"> <li> <p>CKD: <a href="./references#CD013751-fig-0018" title="">Analysis 2.1</a>.1 (7 studies, 850 participants: RR 3.68, 95% CI 0.19 to 70.21; very low certainty evidence) </p> </li> <li> <p>HD: <a href="./references#CD013751-fig-0018" title="">Analysis 2.1</a>.2 (2 studies, 157 participants: no reported events) </p> </li> <li> <p>CKD and HD: <a href="./references#CD013751-fig-0018" title="">Analysis 2.1</a>.3 (1 study, 107 participants: no reported events) </p> </li> </ul> </li> <li> <p>Nonfatal MI</p> <ul id="CD013751-list-0019"> <li> <p>CKD: <a href="./references#CD013751-fig-0019" title="">Analysis 2.2</a>.1 (3 studies, 822 participants: RR 1.29, 95% CI 0.31 to 5.36; I² = 0%; very low certainty evidence) </p> </li> </ul> </li> <li> <p>Proportion of patients requiring blood transfusion</p> <ul id="CD013751-list-0020"> <li> <p>CKD: <a href="./references#CD013751-fig-0020" title="">Analysis 2.3</a>.1 (7 studies, 4271 participants: RR 0.52, 95% CI 0.44 to 0.60; I² = 0%; moderate certainty evidence) </p> </li> <li> <p>HD: <a href="./references#CD013751-fig-0020" title="">Analysis 2.3</a>.2 (1 study, 58 participants: RR 0.21, 95% CI 0.04 to 1.14, very low certainty evidence) </p> </li> </ul> </li> <li> <p>Proportion of patients reaching the target Hb</p> <ul id="CD013751-list-0021"> <li> <p>CKD: <a href="./references#CD013751-fig-0021" title="">Analysis 2.4</a>.1 (8 studies, 4931 participants: RR 8.18, 95% CI 6.13 to 10.93; I² = 50%, low certainty evidence) </p> </li> <li> <p>CKD and HD: <a href="./references#CD013751-fig-0021" title="">Analysis 2.4</a>.2 (2 studies, 171 participants: RR 14.35, 95% CI 2.07 to 99.61; I² = 0%, very low certainty evidence) </p> </li> </ul> </li> </ul> </p> <p>Other subgroup analyses were not possible due to the limited number of studies and data. </p> </section> <section id="CD013751-sec-0079"> <h5 class="title">Sensitivity analysis for HIF stabiliser versus placebo</h5> <p>Sensitivity analyses did not provide substantively different results or were not possible due to few data and studies. </p> </section> </section> <section id="CD013751-sec-0080"> <h4 class="title">HIF stabiliser versus erythropoiesis‐stimulating agent</h4> <p>Twenty‐nine studies (<a href="./references#CD013751-bbs2-0003" title="AkizawaT , IwasakiM , YamaguchiY , MajikawaY , ReuschM . Authors' Reply. Journal of the American Society of Nephrology2021;32(4):1005-7. [MEDLINE: 33649099]AkizawaT , IwasakiM , YamaguchiY , MajikawaY , ReuschM . Phase 3, randomized, double-blind, active-comparator (darbepoetin alfa) conversion study of oral roxadustat in CKD patients with anemia on hemodialysis in Japan [abstract no: TH-PO1151]. Journal of the American Society of Nephrology2018;29(Abstract Suppl):B4. AkizawaT , IwasakiM , YamaguchiY , MajikawaY , ReuschM . Phase 3, randomized, double-blind, active-comparator (darbepoetin alfa) study of oral roxadustat in CKD patients with anemia on hemodialysis in Japan. Journal of the American Society of Nephrology2020;31(7):1628-39. [MEDLINE: 32493693]AkizawaT , YamaguchiY , MajikawaY , ReuschM . Factors affecting the doses of roxadustat vs darbepoetin alfa for anemia treatment in hemodialysis patients. Therapeutic Apheresis &amp; Dialysis2021;25(5):575-85. [MEDLINE: 33200512]Astellas1517-CL-0307. A study of intermittent oral dosing of ASP1517 in hemodialysis chronic kidney disease patients with anemia [A phase 3, multi-center, randomized, 2-arm parallel, double-blind, active-comparator (darbepoetin alfa) conversion study of intermittent oral dosing of ASP1517 in hemodialysis chronic kidney disease patients with anemia]. www.clinicaltrials.astellas.com/study/?pid=1517-CL-0307 (accessed 4 May 2022). LiuF , WangJ , YeQ , FuH , MaoJ . Roxadustat for renal anemia in ESRD from PKD patients: is it safe enough?Journal of the American Society of Nephrology2021;32(4):1005. [MEDLINE: 33649100]NguyenQD , SepahYJ , YamaguchiY , OtsukaT , MajikawaY , ReuschM , et al. Ophthalmological effects of roxadustat in the treatment of anemia in dialysis-dependent and non-dialysis-dependent CKD patients: findings from two phase 3 studies [abstract no: PO0267]. Journal of the American Society of Nephrology2020;31(Abstract Suppl):134. [EMBASE: 633698979]SepahY , NguyenQD , YamaguchiY , MajikawaY , ReuschM , AkizawaT . Ophthalmological effects of roxadustat in the treatment of anaemia in chronic kidney disease patients on dialysis in a phase 3, randomised, double-blind, active-comparator conversion study [abstract no: MO002]. Nephrology Dialysis Transplantation2020;35(Suppl 3):iii102. [EMBASE: 633421367]">Akizawa 2020a</a>; <a href="./references#CD013751-bbs2-0004" title="AkizawaT , NangakuM , YonekawaT , OkudaN , KawamatsuS , OnoueT , et al. Efficacy and safety of daprodustat compared with darbepoetin alfa in Japanese hemodialysis patients with anemia: a randomized, double-blind, phase 3 trial. Clinical Journal of the American Society of Nephrology: CJASN2020;15(8):1155-65. [MEDLINE: 32723804]OzekiH , AkizawaT , NangakuM , YonekawaT , OkudaN , KawamatsuS , et al. Efficacy and safety of daprodustat compared with darbepoetin alfa in Japanese hemodialysis patients with anemia: A randomized, double-blind, phase 3 trial [abstract no: SaO036]. Nephrology Dialysis Transplantation2019;34(Suppl 1):a350. [EMBASE: 631305259]">Akizawa 2020c</a>; <a href="./references#CD013751-bbs2-0006" title="AkizawaT , IwasakiM , OtsukaT , YamaguchiY , ReuschM . Phase 3 study of roxadustat to treat anemia in non-dialysis-dependant CKD. Kidney International Reports2021;6(7):1810-28. [MEDLINE: 34307976]AkizawaT , Tanaka-AminoK , OtsukaT , YamaguchiY . Factors affecting doses of roxadustat versus darbepoetin alfa for anemia in nondialysis patients. American Journal of Nephrology2021;52(9):702-13. [MEDLINE: 34628408]">Akizawa 2021</a>; <a href="./references#CD013751-bbs2-0009" title="SinghAK , BlackorbyA , CizmanB , CarrollK , CobitzAR , DaviesR , et al. Study design and baseline characteristics of patients on dialysis in the ASCEND-D trial. Nephrology Dialysis Transplantation2021;37(5):960-72. [MEDLINE: 33744933] [MEDLINE: 33744933]SinghAK , BlackorbyA , CizmanB , CobitzAR , GodoySA , JhaV , et al. Regional variation of erythropoietin-stimulating agent hyporesponsiveness in the global daprodustat dialysis study (ASCEND-D) [abstract no: TH-OR08]. Journal of the American Society of Nephrology2020;31(Abstract Suppl):3. [EMBASE: 633698062]SinghAK , CarrollK , PerkovicV , SolomonS , JhaV , JohansenKL , et al. Daprodustat for the treatment of anemia in patients undergoing dialysis. New England Journal of Medicine2021;385(25):2325-35. [MEDLINE: 34739194]">ASCEND‐D 2021</a>; <a href="./references#CD013751-bbs2-0011" title="PerkovicV , BlackorbyA , CizmanB , CarrollK , CobitzA , DaviesR , et al. ASCEND-ND: Study design and baseline characteristics. Nephrology Dialysis Transplantation2021;36(Suppl 1):i334-5. [EMBASE: 635918331]SinghAK , CarrollK , McMurrayJJ , SolomonS , JhaV , JohansenKL , et al. Daprodustat for the treatment of anemia in patients not undergoing dialysis. New England Journal of Medicine2021;385(25):2313-24. [MEDLINE: 34739196]">ASCEND‐ND 2021</a>; <a href="./references#CD013751-bbs2-0016" title="ChenN , HaoC , LiuB , LinHL , CailiW , XingCY , et al. A phase 3, randomized, open-label, active-controlled study of efficacy and safety of roxadustat for treatment of anemia in subjects with CKD on dialysis [abstract no: TH-PO1152]. Journal of the American Society of Nephrology2018;29(Abstract Suppl):B5. ChenN , HaoC , LiuBC , LinH , WangC , XingC , et al. Roxadustat treatment for anemia in patients undergoing long-term dialysis. New England Journal of Medicine2019;381(11):1011-22. [MEDLINE: 31340116]">Chen 2019</a>; <a href="./references#CD013751-bbs2-0018" title="ChenN , QianJ , ChenJ , YuX , MeiC , HaoC , et al. Phase 2 studies of oral hypoxia-inducible factor prolyl hydroxylase inhibitor FG-4592 for treatment of anemia in China. Nephrology Dialysis Transplantation2017;32(8):1373-86. [MEDLINE: 28371815]">Chen DD 2017</a>; <a href="./references#CD013751-bbs2-0021" title="AkizawaT , MacdougallIC , BernsJS , YamamotoH , TaguchiM , IekushiK , et al. Iron regulation by molidustat, a daily oral hypoxia-inducible factor prolyl hydroxylase inhibitor, in patients with chronic kidney disease. Nephron2019;143(4):243-54. [MEDLINE: 31387097]MacdougallIC , AkizawaT , BernsJ , LentiniS , BernhardtT , KrugerT . Safety and efficacy of molidustat in erythropoiesis stimulating agents (ESA) pre-treated anaemic patients with chronic kidney disease not on dialysis (CKD-ND) [abstract no: SP309]. Nephrology Dialysis Transplantation2016;31(Suppl 1):i193. [EMBASE: 72326411]MacdougallIC , AkizawaT , BernsJ , LentiniS , BernhardtT . Molidustat increases haemoglobin in erythropoiesis stimulating agents (ESA)-naive anaemic patients with chronic kidney disease not on dialysis (CKD-ND) [abstract no: SO036]]. Nephrology Dialysis Transplantation2016;31(Suppl 1):i16. [EMBASE: 72325954]MacdougallIC , AkizawaT , BernsJS , BernhardtT , KruegerT . Effects of molidustat in the treatment of anemia in CKD [Erratum in: Clin J Am Soc Nephrol. 2019 Oct 7;14(10):1524]. Clinical Journal of the American Society of Nephrology: CJASN2019;14(1):28-39. [MEDLINE: 30559105]MacdougallIC , BernsJS , AkizawaT , FishbaneS , BernhardtT . DIALOGUE phase 2 program for BAY85-3934 a HIF-PH inhibitor with daily oral treatment in anemic patients suffering from CKD/ESRD [abstract no: FR-PO219]. Journal of the American Society of Nephrology2013;24(Abstract Suppl):413A. ">DIALOGUE 2 2019</a>; <a href="./references#CD013751-bbs2-0022" title="AkizawaT , MacdougallIC , BernsJS , YamamotoH , TaguchiM , IekushiK , et al. Iron regulation by molidustat, a daily oral hypoxia-inducible factor prolyl hydroxylase inhibitor, in patients with chronic kidney disease. Nephron2019;143(4):243-54. [MEDLINE: 31387097]MacdougallIC , AkizawaT , BernsJ , LentiniS , BernhardtT . Molidustat increases haemoglobin in erythropoiesis stimulating agents (ESA)-naive anaemic patients with chronic kidney disease not on dialysis (CKD-ND) [abstract no: SO036]. Nephrology Dialysis Transplantation2016;31(Suppl 1):i16. [EMBASE: 72325954]MacdougallIC , AkizawaT , BernsJS , BernhardtT , KruegerT . Effects of molidustat in the treatment of anemia in CKD [Erratum in: Clin J Am Soc Nephrol. 2019 Oct 7;14(10):1524]. Clinical Journal of the American Society of Nephrology: CJASN2019;14(1):28-39. [MEDLINE: 30559105]MacdougallIC , BernsJS , AkizawaT , FishbaneS , BernhardtT . DIALOGUE phase 2 program for BAY85-3934 a HIF-PH inhibitor with daily oral treatment in anemic patients suffering from CKD/ESRD [abstract no: FR-PO219]. Journal of the American Society of Nephrology2013;24(Abstract Suppl):413A. ">DIALOGUE 4 2019</a>; <a href="./references#CD013751-bbs2-0023" title="BarrattJ , AndricB , TataradzeA , SchoemigM , ReuschM , ValluriU , et al. Roxadustat for the treatment of anemia in CKD patients not on dialysis (NDD): a phase 3, randomized, open-label, active-controlled study [abstract no: TH-OR02]. Journal of the American Society of Nephrology2020;31(Abstract Suppl):1. [EMBASE: 633697812]BarrattJ , AndricB , TataradzeA , SchomigM , ReuschM , ValluriU , et al. Roxadustat for the treatment of anaemia in chronic kidney disease patients not on dialysis: a phase 3, randomised, open-label, active-controlled study (DOLOMITES). Nephrology Dialysis Transplantation2021;36(9):1616-28. [MEDLINE: 34077510]BarrattJ , AndricB , TataradzeA , SchomigM , ReuschM , ValluriU , et al. Roxadustat for the treatment of anaemia in chronic kidney disease patients not on dialysis: a phase 3, randomised, open-label, active controlled study [abstract no: MO001]. Nephrology Dialysis Transplantation2020;35(Suppl 3):iii101. [EMBASE: 633423023]BarrattJ , AndricB , TataradzeA , SchomigM , ReuschM , ValluriU , et al. Roxadustat for the treatment of anemia in chronic kidney disease (CKD) patients not on dialysis (NDD): a phase 3, randomized, open-label, active-controlled study [abstract no: Pos-247]. Kidney International Reports2021;6(4 Suppl):S104. [EMBASE: 2011683542]">DOLOMITES 2021</a>; <a href="./references#CD013751-bbs2-0024" title="ProvenzanoM , EvgenyS , LiubovE , KorneyevaS , KathresalAA , PooleL , et al. HIMALAYAS: a phase 3, randomized, open-label, active-controlled study of the efficacy and safety of roxadustat in the treatment of anemia in incident-dialysis patients [abstract no: TH-OR021]. Journal of the American Society of Nephrology2019;30(Abstract Suppl):5. [EMBASE: 633771140]ProvenzanoR , ShutovE , EremeevaL , KorneyevaS , PooleL , SahaG , et al. Roxadustat for anemia in patients with end-stage renal disease incident to dialysis. Nephrology Dialysis Transplantation2021;36(9):1717-30. [MEDLINE: 33629100]">HIMALAYAS 2021</a>; <a href="./references#CD013751-bbs2-0025" title="CizmanB , AckertJ , MeadowcroftA , BiswasN , KellyD , KleinmanD , et al. Ocular safety profile of daprodustat: results of two 24 week studies [abstract no: SAO004]. Nephrology Dialysis Transplantation2018;33(Suppl 1):i316. [EMBASE: 622604997]HoldstockL , CizmanB , MeadowcroftAM , BiswasN , JohnsonBM , JonesD , et al. Daprodustat for anemia: a 24-week, open-label, randomized controlled trial in participants with chronic kidney disease. Clinical Kidney Journal2019;12(1):129-38. [MEDLINE: 30746140]HoldstockL , CizmanB , MeadowcroftAM , BiswasN , JonesD , JohnsonBM , et al. Daprodustat, a HIF-prolyl-hydroxylase inhibitor, increases and maintains hemoglobin over 24 weeks in anemic chronic kidney disease subjects [abstract no: TH-PO908]. Journal of the American Society of Nephrology2016;27(Abstract Suppl):304A. ">Holdstock 2019</a>; <a href="./references#CD013751-bbs2-0026" title="CizmanB , AckertJ , MeadowcroftA , BiswasN , KellyD , KleinmanD , et al. Ocular safety profile of daprodustat: results of two 24 week studies [abstract no: SAO004]. Nephrology Dialysis Transplantation2018;33(Suppl 1):i316. [EMBASE: 622604997]HoldstockL , CizmanB , MeadowcroftAM , BiswasN , JohnsonBM , JonesD , et al. Daprodustat for anemia: a 24-week, open-label, randomized controlled trial in participants with chronic kidney disease. Clinical Kidney Journal2019;12(1):129-38. [MEDLINE: 30746140]HoldstockL , CizmanB , MeadowcroftAM , BiswasN , JonesD , JohnsonBM , et al. Daprodustat, a HIF-prolyl-hydroxylase inhibitor, increases and maintains hemoglobin over 24 weeks in anemic chronic kidney disease subjects [abstract no: TH-PO908]. Journal of the American Society of Nephrology2016;27(Abstract Suppl):304A. ">Holdstock 2019a</a>; <a href="./references#CD013751-bbs2-0027" title="HouYP , MaoXY , WangC , XuZH , BuZH , XuM , et al. Roxadustat treatment for anemia in peritoneal dialysis patients: a randomized controlled trial. Journal of the Formosan Medical Association2021;121(2):529-38. [MEDLINE: 34167878]">Hou 2021</a>; <a href="./references#CD013751-bbs2-0028" title="ChertowGM , BoudvilleN , ChowdhuryP , GonzalezC , KooiengaL , LuoW , et al. Vadadustat for treatment of anemia in patients with dialysis-dependent CKD receiving peritoneal dialysis [abstract no: PO0464]. Journal of the American Society of Nephrology2021;32(Abstract Suppl):184. [EMBASE: 636331136]EckardtKU , AgarwalR , AswadA , AwadA , BlockGA , BacciMR , et al. Safety and efficacy of vadadustat for anemia in patients undergoing dialysis. New England Journal of Medicine2021;384(17):1601-12. [MEDLINE: 33913638]EckardtKU , AgarwalR , FaragYM , JardineAG , KhawajaZ , KouryMJ , et al. Global Phase 3 programme of vadadustat for treatment of anaemia of chronic kidney disease: rationale, study design and baseline characteristics of dialysis-dependent patients in the INNO2VATE trials. Nephrology Dialysis Transplantation2020;36(11):2039-48. [MEDLINE: 33188693]EckardtKU . Global phase 3 clinical trials of vadadustat vs. darbepoetin alfa for treatment of anemia in patients with dialysis-dependent CKD [abstract no: TH-OR01]. Journal of the American Society of Nephrology2020;31(Abstract Suppl):1. [EMBASE: 633697781]ParfreyPS , LuoW , MaroniB , AndersR , VargoD , McCulloughPA . Thromboembolic events with vadadustat vs. darbepoetin alfa for anemia treatment in patients with dialysis-dependent CKD [abstract no: PO0463]. Journal of the American Society of Nephrology2021;32(Abstract Suppl):184. [EMBASE: 636331080]WinkelmayerW , TumlinJA , FishbaneS , FaragY , VargoD , LuoW , et al. Hematologic efficacy of vadadustat for anemia in patients with kidney failure on dialysis [abstract no: MO529]. Nephrology Dialysis Transplantation2021;36(Suppl 1):i325-6. [EMBASE: 635917983]WinkelmayerWC , FishbaneS , TumlinJA , FaragYM , LuoW , AndersR , et al. Iron-related outcomes in patients with dialysis-dependent CKD randomized to vadadustat vs. darbepoetin alfa [abstract no: PO0457]. Journal of the American Society of Nephrology2021;32(Abstract Suppl):182. [EMBASE: 636330773]">INNO2VATE 2020</a>; <a href="./references#CD013751-bbs2-0029" title="EckardtKU , AgarwalR , AswadA , AwadA , BlockGA , BacciMR , et al. Safety and efficacy of vadadustat for anemia in patients undergoing dialysis. New England Journal of Medicine2021;384(17):1601-12. [MEDLINE: 33913638]EckardtKU , AgarwalR , FaragYM , JardineAG , KhawajaZ , KouryMJ , et al. Global Phase 3 programme of vadadustat for treatment of anaemia of chronic kidney disease: rationale, study design and baseline characteristics of dialysis-dependent patients in the INNO2VATE trials. Nephrology Dialysis Transplantation2020;36(11):2039-48. [MEDLINE: 33188693]EckardtKU . Global phase 3 clinical trials of vadadustat vs. darbepoetin alfa for treatment of anemia in patients with dialysis-dependent CKD [abstract no: TH-OR01]. Journal of the American Society of Nephrology2020;31(Abstract Suppl):1. [EMBASE: 633697781]WinkelmayerWC , FishbaneS , TumlinJA , FaragYM , LuoW , AndersR , et al. Iron-related outcomes in patients with dialysis-dependent CKD randomized to vadadustat vs. darbepoetin alfa [abstract no: PO0457]. Journal of the American Society of Nephrology2021;32(Abstract Suppl):182. [EMBASE: 636330773]">INNO2VATE 2020a</a>; <a href="./references#CD013751-bbs2-0031" title="AkizawaT , TaguchiM , MatsudaY , IekushiK , YamadaT , YamamotoH . Molidustat for the treatment of renal anaemia in patients with dialysis-dependent chronic kidney disease: Design and rationale of three phase III studies. BMJ Open2019;9(6):e026602. [MEDLINE: 31203241]AkizawaT , YamadaT , NoboriK , MatsudaY , HayashiY , HayasakiT , et al. Molidustat for Japanese patients with renal anemia receiving dialysis. Kidney International Reports2021;6(10):2604–16. [MEDLINE: 34622100]AkizawaT , YamadaT , NoboriK , MatsudaY , HayashiY , HayasakiT , et al. Results from a phase 3 study comparing the efficacy and safety of molidustat vs. Darbepoetin Alfa in patients receiving hemodialysis and treated with erythropoiesis-stimulating agents (ESAS) [abstract no: PO22623]. Journal of the American Society of Nephrology2020;31(Abstract Suppl):B4. [EMBASE: 633697376]">MIYABI HD‐M 2019</a>; <a href="./references#CD013751-bbs2-0032" title="YamamotoH , NoboriK , MatsudaY , HayashiY , HayasakiT , AkizawaT . Efficacy and safety of molidustat for anemia in ESA-naive nondialysis patients: a randomized, phase 3 trial. American Journal of Nephrology2021;52(10-11):871-83. [MEDLINE: 34569489]YamamotoH , TaguchiM , MatsudaY , IekushiK , YamadaT , AkizawaT . Molidustat for the treatment of renal anaemia in patients with non-dialysis-dependent chronic kidney disease: design and rationale of two phase III studies. BMJ Open2019;9(6):e026704. [MEDLINE: 31203242]YamamotoH , TaguchiM , NoboriK , MatsudaY , IekushiK , AkizawaT . To investigate the efficacy and safety of molidustat in non-dialysis patients with renal anemia who are not treated with erythropoiesis stimulating agents: MIYABI ND-C [abstract no: P1866]. Nephrology Dialysis Transplantation2020;35(Suppl 3):iii2177. [EMBASE: 633422996]">MIYABI ND‐C 2019</a>; <a href="./references#CD013751-bbs2-0033" title="YamamotoH , NoboriK , MatsudaY , HayashiY , HayasakiT , AkizawaT . Molidustat for renal anemia in nondialysis patients previously treated with erythropoiesis-stimulating agents: a randomized, open-label, phase 3 study. American Journal of Nephrology2021;52(10-11):884-93. [MEDLINE: 34569482]YamamotoH , TaguchiM , MatsudaY , IekushiK , YamadaT , AkizawaT . Molidustat for the treatment of renal anaemia in patients with non-dialysis-dependent chronic kidney disease: design and rationale of two phase III studies. BMJ Open2019;9(6):e026704. [MEDLINE: 31203242]YamamotoH , TaguchiM , NoboriK , MatsudaY , IekushiK , AkizawaT . To investigate the efficacy and safety of molidustat in non-dialysis patients with renal anemia who are treated with erythropoiesis stimulating agents: Miyabi ND-M [Abstract no: P1868]. Nephrology Dialysis Transplantation2020;35(Suppl 3):iii2179. [EMBASE: 633423006]">MIYABI ND‐M 2019</a>; <a href="./references#CD013751-bbs2-0034" title="NangakuM , KondoK , UetaK , KokadoY , KanekoG , MatsudaH , et al. Efficacy and safety of vadadustat compared with darbepoetin alfa in Japanese anemic patients on hemodialysis: a phase 3, multicenter, randomized, double-blind study. Nephrology Dialysis Transplantation2021;36(9):1731-41. [MEDLINE: 33650630]NangakuM , KondoK , UetaK , KokadoY , KanekoG , MatsudaH , et al. Randomized, double-blinded, active-controlled (darbepoetin alfa), phase 3 study of vadadustat in CKD patients with anemia on hemodialysis in Japan [abstract no: TH-OR024]. Journal of the American Society of Nephrology2019;30(Abstract Suppl):6. [EMBASE: 633771357]">Nangaku 2021</a>; <a href="./references#CD013751-bbs2-0035" title="NangakuM , KondoK , KokadoY , UetaK , KanekoG , ShiosakaM , et al. Randomized, open-label, active-controlled (darbepoetin alfa), phase 3 study of vadadustat for treating anemia in non-dialysis-dependent CKD patients in Japan [abstract no: SA-PO229]. Journal of the American Society of Nephrology2019;30(Abstract Suppl):823. [EMBASE: 633767995]NangakuM , KondoK , KokadoY , UetaK , KanekoG , TandaiT , et al. Phase 3 randomized study comparing vadadustat with darbepoetin alfa for anemia in Japanese patients with nondialysis-dependent CKD. Journal of the American Society of Nephrology2021;32(7):1779-90. [MEDLINE: 33883252]">Nangaku 2021a</a>; <a href="./references#CD013751-bbs2-0036" title="GSK201753. A 52-week, Phase III, open-label, multi-center study to evaluate efficacy and safety of GSK1278863 in Japanese non-dialysis and peritoneal dialysis subjects with anemia associated with chronic kidney disease [study protocol]. www.clinicaltrials.gov/ProvidedDocs/63/NCT02791763/Prot_000.pdf (accessed 9 May 2022). NangakuM , HamanoT , AkizawaT , TsubakiharaY , NagaiR , OkudaN , et al. Daprodustat compared with epoetin beta pegol for anemia in Japanese patients not on dialysis: a 52-week randomized open-label phase 3 trial. American Journal of Nephrology2021;52(1):26-35. [MEDLINE: 33561857]">Nangaku 2021b</a>; <a href="./references#CD013751-bbs2-0037" title="Astellas1517-CL-0304. A study to investigate the effect of ASP1517 after intermittent oral dosing in dialysis chronic kidney disease patients with anemia compared with darbepoetin as a reference drug [A Japanese, phase 2, multicenter, randomized, 4-arm parallel, double-blind (arms 1-3), open-label (arm 4), active-comparator (darbepoetin alfa) study of intermittent oral dosing of asp1517 in hemodialysis-dependent chronic kidney disease patients with anemia [1517-CL-0304 clinical study results report]]. www.trialsummaries.com/Study/StudyDetails?id=14175&amp;tenant=MT_AST_9011; www.clinicaltrials.gov/ct2/show/NCT01888445 (first received 6 August 2018). ">NCT01888445</a>; <a href="./references#CD013751-bbs2-0047" title="Astellas 1517-CL-0613. Roxadustat in the treatment of anemia in end stage renal disease (ESRD) patients on stable dialysis [A phase 3, randomized, open-label, active-controlled study to evaluate the efficacy and safety of roxadustat in the maintenance treatment of anemia in end stage renal disease patients on stable dialysis]. www.trialsummaries.com/Study/StudyDetails?id=14380&amp;tenant=MT_AST_9011 (accessed 9 May 2022). CsikyB , SchomigM , EspositoC , BarrattJ , ReuschM , ValluriU , et al. Roxadustat for the maintenance treatment of anemia in patients with end-stage kidney disease on stable dialysis: a European phase 3, randomized, open-label, active-controlled study (PYRENEES). Advances in Therapy2021;38(10):5361-80. [MEDLINE: 34537926]EspositoC , CsikyB , TataradzeA , ReuschM , HanC , SulowiczW . Two phase 3, multicenter, randomized studies of intermittent oral roxadustat in anemic CKD patients on (PYRENEES) and not on (ALPS) dialysis. Swiss Medical Weekly2020;150(Suppl 248):21-2S. [EMBASE: 634241523]EspositoC , CsikyB , TataradzeA , ReuschM , HanC , SulowiczW . Two phase 3, multicenter, randomized studies of intermittent oral roxadustat in anemic CKD patients on (PYRENEES) and not on (ALPS) dialysis [abstract no: SA-PO225]. Journal of the American Society of Nephrology2019;30(Abstract Suppl):822. [EMBASE: 633767739]">PYRENEES 2021</a>; <a href="./references#CD013751-bbs2-0042" title="BunnHF . Vadadustat for anemia in patients with dialysis-dependent or non-dialysis-dependent chronic kidney disease. New England Journal of Medicine2021;385(16):e56. [MEDLINE: 34644481]ChertowGM , PergolaPE , AgarwalR , BlockGA , FaragYM , JardineAG , et al. Cardiovascular safety and efficacy of vadadustat for the treatment of anemia in non-dialysis-dependent CKD: design and baseline characteristics. American Heart Journal2021;235(5):1-11. [MEDLINE: 33129989]ChertowGM , PergolaPE , FaragYM , AgarwalR , ArnoldS , BakoG , et al. Vadadustat in patients with anemia and non-dialysis-dependent CKD. New England Journal of Medicine2021;384(17):1589-600. [MEDLINE: 33913637]ChertowGM . Global phase 3 clinical trials of vadadustat vs. darbepoetin alfa for treatment of anemia in patients with non-dialysis-dependent CKD [abstract no: FR-OR54]. Journal of the American Society of Nephrology2020;31(Abstract Suppl):B2. [EMBASE: 633697273]KouryM , PergolaPE , Roy-ChaudhuryP , FaragYM , LuoW , AndersR , et al. Iron-related outcomes in patients with non-dialysis-dependent CKD randomized to vadadustat vs. darbepoetin Alfa [abstract no: PO0482]. Journal of the American Society of Nephrology2021;32(Abstract Suppl):190. [EMBASE: 636329134]McCulloughPA , LuoW , AndersR , VargoD , ParfreyPS . Assessment of thromboembolic events with vadadustat vs. darbepoetin alfa for treatment of anemia in patients with non-dialysis-dependent CKD [abstract no: PO0462]. Journal of the American Society of Nephrology2021;32(Abstract Suppl):184. [EMBASE: 636331039]">PRO2TECT‐CONVERSION 2021</a>; <a href="./references#CD013751-bbs2-0043" title="BunnHF . Vadadustat for anemia in patients with dialysis-dependent or non-dialysis-dependent chronic kidney disease. New England Journal of Medicine2021;385(16):e56. [MEDLINE: 34644481]ChertowGM , PergolaPE , AgarwalR , BlockGA , FaragYM , JardineAG , et al. Cardiovascular safety and efficacy of vadadustat for the treatment of anemia in non-dialysis-dependent CKD: design and baseline characteristics. American Heart Journal2021;235(5):1-11. [MEDLINE: 33129989]ChertowGM , PergolaPE , FaragYM , AgarwalR , ArnoldS , BakoG , et al. Vadadustat in patients with anemia and non-dialysis-dependent CKD. New England Journal of Medicine2021;384(17):1589-600. [MEDLINE: 33913637]ChertowGM . Global phase 3 clinical trials of vadadustat vs. darbepoetin alfa for treatment of anemia in patients with non-dialysis-dependent CKD [abstract no: FR-OR5]. Journal of the American Society of Nephrology2020;31(Abstract Suppl):B2. [EMBASE: 633697273]KouryM , PergolaPE , Roy-ChaudhuryP , FaragYM , LuoW , AndersR , et al. Iron-related outcomes in patients with non-dialysis-dependent CKD randomized to vadadustat vs. darbepoetin alfa [abstract no: PO0482]. Journal of the American Society of Nephrology2021;32(Abstract Suppl):190. [EMBASE: 636329134]McCulloughPA , LuoW , AndersR , VargoD , ParfreyPS . Assessment of thromboembolic events with vadadustat vs. darbepoetin alfa for treatment of anemia in patients with non-dialysis-dependent CKD [abstract no: PO0462]. Journal of the American Society of Nephrology2021;32(Abstract Suppl):184. [EMBASE: 636331039]">PRO2TECT‐CORRECTION 2021</a>; <a href="./references#CD013751-bbs2-0049" title="CharytanC , Manllo-KarimR , MartinER , SteerD , BernardoM , DuaSL , et al. A randomized trial of roxadustat in anemia of kidney failure: SIERRAS study. Kidney International Reports2021;6(7):1829-39. [MEDLINE: 34307977]CharytanC , Manllo-KarimR , MartinER , SteerD , BernardoM , DuaSL , et al. SIERRAS: A phase 3, open-label, randomized, active-controlled study of the efficacy and safety of roxadustat in the maintenance treatment of anemia in subjects with ESRD on stable dialysis [abstract no: SA-PO227]. Journal of the American Society of Nephrology2019;30(Abstract Suppl):822. [EMBASE: 633767862]">SIERRAS 2021</a>; <a href="./references#CD013751-bbs2-0050" title="AkizawaT , MaedaK , MiyazawaY , KoretomoR . Phase 3 study to compare the efficacy and safety of enarodustat (JTZ-951), an oral HIF-PH inhibitor, with darbepoetin alfa in anemic patients with CKD receiving maintenance hemodialysis [abstract no: TH-PO1186]. Journal of the American Society of Nephrology2019;30(Abstract Suppl):B4. AkizawaT , NangakuM , YamaguchiT , KoretomoR , MaedaK , MiyazawaY , et al. A phase 3 study of enarodustat (JTZ-951) in Japanese hemodialysis patients for treatment of anemia in chronic kidney disease: SYMPHONY HD study. Kidney Diseases2021;7(6):494-502. [EMBASE: 2013576033]">SYMPHONY HD 2021</a>; <a href="./references#CD013751-bbs2-0051" title="AkizawaT , NangakuM , YamaguchiT , KoretomoR , MaedaK , MiyazawaY , et al. A phase 3 study of enarodustat in anemic patients with CKD not requiring dialysis: the SYMPHONY ND study. Kidney International Reports2021;6(7):1840-9. [MEDLINE: 34307978]">SYMPHONY ND 2021</a>) compared HIF stabiliser versus ESA management of anaemia in adults with CKD (stages 3, 4 or 5), including patients undergoing HD and PD, during a median follow‐up of 52 weeks. The certainty of the evidence was mainly moderate or low (<a href="./full#CD013751-tbl-0002">summary of findings Table 2</a>). </p> <section id="CD013751-sec-0081"> <h5 class="title">Primary outcomes</h5> <section id="CD013751-sec-0082"> <h6 class="title">Cardiovascular death</h6> <p>HIF stabiliser therapy may make little or no difference to CV death (<a href="./references#CD013751-fig-0022" title="">Analysis 3.1</a> (17 studies, 10,340 participants): RR 1.05, 95% CI 0.88 to 1.26; I² = 0%; low certainty evidence) compared to ESA in people with CKD, or those undergoing HD or PD. </p> </section> <section id="CD013751-sec-0083"> <h6 class="title">Fatigue</h6> <p>The effect of HIF stabiliser management of anaemia on fatigue was uncertain (<a href="./references#CD013751-fig-0023" title="">Analysis 3.2</a> (2 studies, 3471 participants): RR 0.80, 95% CI 0.56 to 1.16; I² = 0%; very low certainty evidence) compared with ESA in people with CKD. </p> </section> </section> <section id="CD013751-sec-0084"> <h5 class="title">Secondary outcomes</h5> <section id="CD013751-sec-0085"> <h6 class="title">Death (any cause)</h6> <p>HIF stabiliser therapy probably makes little or no difference to death (any cause) (<a href="./references#CD013751-fig-0024" title="">Analysis 3.3</a> (29 studies, 21,370 participants): RR 0.98, 95% CI 0.91 to 1.06; I² = 0%; moderate certainty evidence) compared to ESA in people with CKD, or those undergoing HD or PD. </p> </section> <section id="CD013751-sec-0086"> <h6 class="title">Myocardial infarction</h6> <p>HIF stabiliser treatment may make little or no difference to nonfatal MI (<a href="./references#CD013751-fig-0025" title="">Analysis 3.4</a> (7 studies, 7765 participants): RR 0.91, 95% CI 0.76 to 1.10; I² = 0%; low certainty evidence) compared with ESA in people with CKD, or those undergoing HD or PD. </p> <p>When MI was reported as fatal or nonfatal events, HIF stabiliser treatment probably makes little or no difference to fatal or nonfatal MI (<a href="./references#CD013751-fig-0026" title="">Analysis 3.5</a> (15 studies, 14,183 participants): RR 0.95, 95% CI 0.80 to 1.12; I² = 0%; moderate certainty evidence) compared with ESA in people with CKD, or those undergoing HD or PD. </p> </section> <section id="CD013751-sec-0087"> <h6 class="title">Stroke</h6> <p>HIF stabiliser treatment may make little or no difference to nonfatal stroke (<a href="./references#CD013751-fig-0027" title="">Analysis 3.6</a> (5 studies, 7285 participants): RR 1.06, 95% CI 0.71 to 1.56; I² = 8%; low certainty evidence) compared with ESA in people with CKD, or those undergoing HD or PD. </p> <p>When stroke was reported as a fatal or nonfatal event, HIF stabiliser treatment may make little or no difference to fatal or nonfatal stroke (<a href="./references#CD013751-fig-0028" title="">Analysis 3.7</a> (7 studies, 8025 participants): RR 0.95, 95% CI 0.64 to 1.40; I² = 23%; low certainty evidence) compared with ESA in people with CKD, or those undergoing HD or PD. </p> </section> <section id="CD013751-sec-0088"> <h6 class="title">Hospitalisation for heart failure</h6> <p>The effect of HIF stabiliser therapy on nonfatal hospitalisation for heart failure was uncertain (<a href="./references#CD013751-fig-0029" title="">Analysis 3.8</a> (2 studies, 6836 participants): RR 1.23, 95% CI 1.00 to 1.52; I² = 0%; very low certainty evidence) compared with ESA in people with CKD, or those undergoing HD or PD. </p> <p>The effect of HIF stabiliser therapy on fatal or nonfatal hospitalisation for heart failure was uncertain (<a href="./references#CD013751-fig-0030" title="">Analysis 3.9</a> (3 studies, 7452 participants): RR 1.15, 95% CI 0.97 to 1.36; I² = 0%; very low certainty evidence) compared with ESA in people with CKD, or those undergoing HD or PD. </p> </section> <section id="CD013751-sec-0089"> <h6 class="title">Peripheral arterial events</h6> <p>HIF stabiliser management of anaemia had uncertain effects on peripheral arterial events (<a href="./references#CD013751-fig-0031" title="">Analysis 3.10</a>: 2 studies, 323 participants), as no events were reported in the included studies. </p> </section> <section id="CD013751-sec-0090"> <h6 class="title">Proportion of patients requiring blood transfusion</h6> <p>HIF stabiliser treatment probably decreases the proportion of patients requiring blood transfusion (<a href="./references#CD013751-fig-0032" title="">Analysis 3.11</a> (11 studies, 10,786 participants): RR 0.87, 95% CI 0.76 to 1.00; I² = 25%; moderate certainty evidence) compared with ESA in people with CKD, or those undergoing HD or PD. </p> </section> <section id="CD013751-sec-0091"> <h6 class="title">Proportion of patients reaching the target haemoglobin</h6> <p>HIF stabiliser treatment may make little or no difference to the proportion of patients reaching the target Hb (<a href="./references#CD013751-fig-0033" title="">Analysis 3.12</a> (14 studies, 4601 participants): RR 1.00, 95% CI 0.93 to 1.07; I² = 70%; low certainty evidence) compared with ESA in people with CKD, or those undergoing HD or PD. There was moderate to high heterogeneity among the studies. </p> </section> <section id="CD013751-sec-0092"> <h6 class="title">Kidney failure</h6> <p>HIF stabiliser treatment may make little or no difference to kidney failure (<a href="./references#CD013751-fig-0034" title="">Analysis 3.13</a> (9 studies, 7312 participants): RR 1.02, 95% CI 0.91 to 1.15; I² = 0%; low certainty evidence) compared with ESA in people with CKD. </p> </section> <section id="CD013751-sec-0093"> <h6 class="title">Thrombosis</h6> <p>HIF stabiliser therapy may make little or no difference to thrombosis (<a href="./references#CD013751-fig-0035" title="">Analysis 3.14</a> (11 studies, 17,026 participants): RR 1.09, 95% CI 0.86 to 1.39; I² = 46%; low certainty evidence) compared with ESA in people with CKD, HD and PD. There was moderate heterogeneity among the studies. </p> </section> <section id="CD013751-sec-0094"> <h6 class="title">Loss of unassisted dialysis access patency</h6> <p>HIF stabiliser therapy may have little or no difference on the loss of unassisted dialysis access patency (including stenosis and occlusions) (<a href="./references#CD013751-fig-0036" title="">Analysis 3.15</a> (8 studies, 2945 participants): RR 1.16, 95% CI 0.85 to 1.59; I² = 0%; low certainty evidence) compared with ESA in people undergoing HD. </p> </section> <section id="CD013751-sec-0095"> <h6 class="title">Access intervention</h6> <p><a href="./references#CD013751-bbs2-0032" title="YamamotoH , NoboriK , MatsudaY , HayashiY , HayasakiT , AkizawaT . Efficacy and safety of molidustat for anemia in ESA-naive nondialysis patients: a randomized, phase 3 trial. American Journal of Nephrology2021;52(10-11):871-83. [MEDLINE: 34569489]YamamotoH , TaguchiM , MatsudaY , IekushiK , YamadaT , AkizawaT . Molidustat for the treatment of renal anaemia in patients with non-dialysis-dependent chronic kidney disease: design and rationale of two phase III studies. BMJ Open2019;9(6):e026704. [MEDLINE: 31203242]YamamotoH , TaguchiM , NoboriK , MatsudaY , IekushiK , AkizawaT . To investigate the efficacy and safety of molidustat in non-dialysis patients with renal anemia who are not treated with erythropoiesis stimulating agents: MIYABI ND-C [abstract no: P1866]. Nephrology Dialysis Transplantation2020;35(Suppl 3):iii2177. [EMBASE: 633422996]">MIYABI ND‐C 2019</a> reported that HIF stabiliser therapy made no difference to access interventions (<a href="./references#CD013751-fig-0037" title="">Analysis 3.16</a> (1 study, 161 participants): RR 0.58, 95% CI 0.14 to 2.34) compared with ESA in people with CKD. </p> </section> <section id="CD013751-sec-0096"> <h6 class="title">Cancer</h6> <p>HIF stabiliser therapy may make little or no difference to the number with cancer (<a href="./references#CD013751-fig-0038" title="">Analysis 3.17</a> (7 studies, 1687 participants): RR 0.83, 95% CI 0.43 to 1.59; I² = 8%; low certainty evidence) compared with ESA in people with CKD or those undergoing HD. </p> </section> <section id="CD013751-sec-0097"> <h6 class="title">Infection</h6> <p><a href="./references#CD013751-bbs2-0016" title="ChenN , HaoC , LiuB , LinHL , CailiW , XingCY , et al. A phase 3, randomized, open-label, active-controlled study of efficacy and safety of roxadustat for treatment of anemia in subjects with CKD on dialysis [abstract no: TH-PO1152]. Journal of the American Society of Nephrology2018;29(Abstract Suppl):B5. ChenN , HaoC , LiuBC , LinH , WangC , XingC , et al. Roxadustat treatment for anemia in patients undergoing long-term dialysis. New England Journal of Medicine2019;381(11):1011-22. [MEDLINE: 31340116]">Chen 2019</a> reported that HIF stabiliser treatment made no difference in the number with infection (<a href="./references#CD013751-fig-0039" title="">Analysis 3.18</a> (1 study, 304 participants): RR 0.82, 95% CI 0.20 to 3.35) compared with ESA in people with HD and PD. </p> </section> <section id="CD013751-sec-0098"> <h6 class="title">Hyperkalaemia</h6> <p>Twenty‐one studies (<a href="./references#CD013751-bbs2-0003" title="AkizawaT , IwasakiM , YamaguchiY , MajikawaY , ReuschM . Authors' Reply. Journal of the American Society of Nephrology2021;32(4):1005-7. [MEDLINE: 33649099]AkizawaT , IwasakiM , YamaguchiY , MajikawaY , ReuschM . Phase 3, randomized, double-blind, active-comparator (darbepoetin alfa) conversion study of oral roxadustat in CKD patients with anemia on hemodialysis in Japan [abstract no: TH-PO1151]. Journal of the American Society of Nephrology2018;29(Abstract Suppl):B4. AkizawaT , IwasakiM , YamaguchiY , MajikawaY , ReuschM . Phase 3, randomized, double-blind, active-comparator (darbepoetin alfa) study of oral roxadustat in CKD patients with anemia on hemodialysis in Japan. Journal of the American Society of Nephrology2020;31(7):1628-39. [MEDLINE: 32493693]AkizawaT , YamaguchiY , MajikawaY , ReuschM . Factors affecting the doses of roxadustat vs darbepoetin alfa for anemia treatment in hemodialysis patients. Therapeutic Apheresis &amp; Dialysis2021;25(5):575-85. [MEDLINE: 33200512]Astellas1517-CL-0307. A study of intermittent oral dosing of ASP1517 in hemodialysis chronic kidney disease patients with anemia [A phase 3, multi-center, randomized, 2-arm parallel, double-blind, active-comparator (darbepoetin alfa) conversion study of intermittent oral dosing of ASP1517 in hemodialysis chronic kidney disease patients with anemia]. www.clinicaltrials.astellas.com/study/?pid=1517-CL-0307 (accessed 4 May 2022). LiuF , WangJ , YeQ , FuH , MaoJ . Roxadustat for renal anemia in ESRD from PKD patients: is it safe enough?Journal of the American Society of Nephrology2021;32(4):1005. [MEDLINE: 33649100]NguyenQD , SepahYJ , YamaguchiY , OtsukaT , MajikawaY , ReuschM , et al. Ophthalmological effects of roxadustat in the treatment of anemia in dialysis-dependent and non-dialysis-dependent CKD patients: findings from two phase 3 studies [abstract no: PO0267]. Journal of the American Society of Nephrology2020;31(Abstract Suppl):134. [EMBASE: 633698979]SepahY , NguyenQD , YamaguchiY , MajikawaY , ReuschM , AkizawaT . Ophthalmological effects of roxadustat in the treatment of anaemia in chronic kidney disease patients on dialysis in a phase 3, randomised, double-blind, active-comparator conversion study [abstract no: MO002]. Nephrology Dialysis Transplantation2020;35(Suppl 3):iii102. [EMBASE: 633421367]">Akizawa 2020a</a>; <a href="./references#CD013751-bbs2-0004" title="AkizawaT , NangakuM , YonekawaT , OkudaN , KawamatsuS , OnoueT , et al. Efficacy and safety of daprodustat compared with darbepoetin alfa in Japanese hemodialysis patients with anemia: a randomized, double-blind, phase 3 trial. Clinical Journal of the American Society of Nephrology: CJASN2020;15(8):1155-65. [MEDLINE: 32723804]OzekiH , AkizawaT , NangakuM , YonekawaT , OkudaN , KawamatsuS , et al. Efficacy and safety of daprodustat compared with darbepoetin alfa in Japanese hemodialysis patients with anemia: A randomized, double-blind, phase 3 trial [abstract no: SaO036]. Nephrology Dialysis Transplantation2019;34(Suppl 1):a350. [EMBASE: 631305259]">Akizawa 2020c</a>; <a href="./references#CD013751-bbs2-0006" title="AkizawaT , IwasakiM , OtsukaT , YamaguchiY , ReuschM . Phase 3 study of roxadustat to treat anemia in non-dialysis-dependant CKD. Kidney International Reports2021;6(7):1810-28. [MEDLINE: 34307976]AkizawaT , Tanaka-AminoK , OtsukaT , YamaguchiY . Factors affecting doses of roxadustat versus darbepoetin alfa for anemia in nondialysis patients. American Journal of Nephrology2021;52(9):702-13. [MEDLINE: 34628408]">Akizawa 2021</a>; <a href="./references#CD013751-bbs2-0009" title="SinghAK , BlackorbyA , CizmanB , CarrollK , CobitzAR , DaviesR , et al. Study design and baseline characteristics of patients on dialysis in the ASCEND-D trial. Nephrology Dialysis Transplantation2021;37(5):960-72. [MEDLINE: 33744933] [MEDLINE: 33744933]SinghAK , BlackorbyA , CizmanB , CobitzAR , GodoySA , JhaV , et al. Regional variation of erythropoietin-stimulating agent hyporesponsiveness in the global daprodustat dialysis study (ASCEND-D) [abstract no: TH-OR08]. Journal of the American Society of Nephrology2020;31(Abstract Suppl):3. [EMBASE: 633698062]SinghAK , CarrollK , PerkovicV , SolomonS , JhaV , JohansenKL , et al. Daprodustat for the treatment of anemia in patients undergoing dialysis. New England Journal of Medicine2021;385(25):2325-35. [MEDLINE: 34739194]">ASCEND‐D 2021</a>; <a href="./references#CD013751-bbs2-0011" title="PerkovicV , BlackorbyA , CizmanB , CarrollK , CobitzA , DaviesR , et al. ASCEND-ND: Study design and baseline characteristics. Nephrology Dialysis Transplantation2021;36(Suppl 1):i334-5. [EMBASE: 635918331]SinghAK , CarrollK , McMurrayJJ , SolomonS , JhaV , JohansenKL , et al. Daprodustat for the treatment of anemia in patients not undergoing dialysis. New England Journal of Medicine2021;385(25):2313-24. [MEDLINE: 34739196]">ASCEND‐ND 2021</a>; <a href="./references#CD013751-bbs2-0016" title="ChenN , HaoC , LiuB , LinHL , CailiW , XingCY , et al. A phase 3, randomized, open-label, active-controlled study of efficacy and safety of roxadustat for treatment of anemia in subjects with CKD on dialysis [abstract no: TH-PO1152]. Journal of the American Society of Nephrology2018;29(Abstract Suppl):B5. ChenN , HaoC , LiuBC , LinH , WangC , XingC , et al. Roxadustat treatment for anemia in patients undergoing long-term dialysis. New England Journal of Medicine2019;381(11):1011-22. [MEDLINE: 31340116]">Chen 2019</a>; <a href="./references#CD013751-bbs2-0023" title="BarrattJ , AndricB , TataradzeA , SchoemigM , ReuschM , ValluriU , et al. Roxadustat for the treatment of anemia in CKD patients not on dialysis (NDD): a phase 3, randomized, open-label, active-controlled study [abstract no: TH-OR02]. Journal of the American Society of Nephrology2020;31(Abstract Suppl):1. [EMBASE: 633697812]BarrattJ , AndricB , TataradzeA , SchomigM , ReuschM , ValluriU , et al. Roxadustat for the treatment of anaemia in chronic kidney disease patients not on dialysis: a phase 3, randomised, open-label, active-controlled study (DOLOMITES). Nephrology Dialysis Transplantation2021;36(9):1616-28. [MEDLINE: 34077510]BarrattJ , AndricB , TataradzeA , SchomigM , ReuschM , ValluriU , et al. Roxadustat for the treatment of anaemia in chronic kidney disease patients not on dialysis: a phase 3, randomised, open-label, active controlled study [abstract no: MO001]. Nephrology Dialysis Transplantation2020;35(Suppl 3):iii101. [EMBASE: 633423023]BarrattJ , AndricB , TataradzeA , SchomigM , ReuschM , ValluriU , et al. Roxadustat for the treatment of anemia in chronic kidney disease (CKD) patients not on dialysis (NDD): a phase 3, randomized, open-label, active-controlled study [abstract no: Pos-247]. Kidney International Reports2021;6(4 Suppl):S104. [EMBASE: 2011683542]">DOLOMITES 2021</a>; <a href="./references#CD013751-bbs2-0024" title="ProvenzanoM , EvgenyS , LiubovE , KorneyevaS , KathresalAA , PooleL , et al. HIMALAYAS: a phase 3, randomized, open-label, active-controlled study of the efficacy and safety of roxadustat in the treatment of anemia in incident-dialysis patients [abstract no: TH-OR021]. Journal of the American Society of Nephrology2019;30(Abstract Suppl):5. [EMBASE: 633771140]ProvenzanoR , ShutovE , EremeevaL , KorneyevaS , PooleL , SahaG , et al. Roxadustat for anemia in patients with end-stage renal disease incident to dialysis. Nephrology Dialysis Transplantation2021;36(9):1717-30. [MEDLINE: 33629100]">HIMALAYAS 2021</a>; <a href="./references#CD013751-bbs2-0027" title="HouYP , MaoXY , WangC , XuZH , BuZH , XuM , et al. Roxadustat treatment for anemia in peritoneal dialysis patients: a randomized controlled trial. Journal of the Formosan Medical Association2021;121(2):529-38. [MEDLINE: 34167878]">Hou 2021</a>; <a href="./references#CD013751-bbs2-0028" title="ChertowGM , BoudvilleN , ChowdhuryP , GonzalezC , KooiengaL , LuoW , et al. Vadadustat for treatment of anemia in patients with dialysis-dependent CKD receiving peritoneal dialysis [abstract no: PO0464]. Journal of the American Society of Nephrology2021;32(Abstract Suppl):184. [EMBASE: 636331136]EckardtKU , AgarwalR , AswadA , AwadA , BlockGA , BacciMR , et al. Safety and efficacy of vadadustat for anemia in patients undergoing dialysis. New England Journal of Medicine2021;384(17):1601-12. [MEDLINE: 33913638]EckardtKU , AgarwalR , FaragYM , JardineAG , KhawajaZ , KouryMJ , et al. Global Phase 3 programme of vadadustat for treatment of anaemia of chronic kidney disease: rationale, study design and baseline characteristics of dialysis-dependent patients in the INNO2VATE trials. Nephrology Dialysis Transplantation2020;36(11):2039-48. [MEDLINE: 33188693]EckardtKU . Global phase 3 clinical trials of vadadustat vs. darbepoetin alfa for treatment of anemia in patients with dialysis-dependent CKD [abstract no: TH-OR01]. Journal of the American Society of Nephrology2020;31(Abstract Suppl):1. [EMBASE: 633697781]ParfreyPS , LuoW , MaroniB , AndersR , VargoD , McCulloughPA . Thromboembolic events with vadadustat vs. darbepoetin alfa for anemia treatment in patients with dialysis-dependent CKD [abstract no: PO0463]. Journal of the American Society of Nephrology2021;32(Abstract Suppl):184. [EMBASE: 636331080]WinkelmayerW , TumlinJA , FishbaneS , FaragY , VargoD , LuoW , et al. Hematologic efficacy of vadadustat for anemia in patients with kidney failure on dialysis [abstract no: MO529]. Nephrology Dialysis Transplantation2021;36(Suppl 1):i325-6. [EMBASE: 635917983]WinkelmayerWC , FishbaneS , TumlinJA , FaragYM , LuoW , AndersR , et al. Iron-related outcomes in patients with dialysis-dependent CKD randomized to vadadustat vs. darbepoetin alfa [abstract no: PO0457]. Journal of the American Society of Nephrology2021;32(Abstract Suppl):182. [EMBASE: 636330773]">INNO2VATE 2020</a>; <a href="./references#CD013751-bbs2-0029" title="EckardtKU , AgarwalR , AswadA , AwadA , BlockGA , BacciMR , et al. Safety and efficacy of vadadustat for anemia in patients undergoing dialysis. New England Journal of Medicine2021;384(17):1601-12. [MEDLINE: 33913638]EckardtKU , AgarwalR , FaragYM , JardineAG , KhawajaZ , KouryMJ , et al. Global Phase 3 programme of vadadustat for treatment of anaemia of chronic kidney disease: rationale, study design and baseline characteristics of dialysis-dependent patients in the INNO2VATE trials. Nephrology Dialysis Transplantation2020;36(11):2039-48. [MEDLINE: 33188693]EckardtKU . Global phase 3 clinical trials of vadadustat vs. darbepoetin alfa for treatment of anemia in patients with dialysis-dependent CKD [abstract no: TH-OR01]. Journal of the American Society of Nephrology2020;31(Abstract Suppl):1. [EMBASE: 633697781]WinkelmayerWC , FishbaneS , TumlinJA , FaragYM , LuoW , AndersR , et al. Iron-related outcomes in patients with dialysis-dependent CKD randomized to vadadustat vs. darbepoetin alfa [abstract no: PO0457]. Journal of the American Society of Nephrology2021;32(Abstract Suppl):182. [EMBASE: 636330773]">INNO2VATE 2020a</a>; <a href="./references#CD013751-bbs2-0031" title="AkizawaT , TaguchiM , MatsudaY , IekushiK , YamadaT , YamamotoH . Molidustat for the treatment of renal anaemia in patients with dialysis-dependent chronic kidney disease: Design and rationale of three phase III studies. BMJ Open2019;9(6):e026602. [MEDLINE: 31203241]AkizawaT , YamadaT , NoboriK , MatsudaY , HayashiY , HayasakiT , et al. Molidustat for Japanese patients with renal anemia receiving dialysis. Kidney International Reports2021;6(10):2604–16. [MEDLINE: 34622100]AkizawaT , YamadaT , NoboriK , MatsudaY , HayashiY , HayasakiT , et al. Results from a phase 3 study comparing the efficacy and safety of molidustat vs. Darbepoetin Alfa in patients receiving hemodialysis and treated with erythropoiesis-stimulating agents (ESAS) [abstract no: PO22623]. Journal of the American Society of Nephrology2020;31(Abstract Suppl):B4. [EMBASE: 633697376]">MIYABI HD‐M 2019</a>; <a href="./references#CD013751-bbs2-0032" title="YamamotoH , NoboriK , MatsudaY , HayashiY , HayasakiT , AkizawaT . Efficacy and safety of molidustat for anemia in ESA-naive nondialysis patients: a randomized, phase 3 trial. American Journal of Nephrology2021;52(10-11):871-83. [MEDLINE: 34569489]YamamotoH , TaguchiM , MatsudaY , IekushiK , YamadaT , AkizawaT . Molidustat for the treatment of renal anaemia in patients with non-dialysis-dependent chronic kidney disease: design and rationale of two phase III studies. BMJ Open2019;9(6):e026704. [MEDLINE: 31203242]YamamotoH , TaguchiM , NoboriK , MatsudaY , IekushiK , AkizawaT . To investigate the efficacy and safety of molidustat in non-dialysis patients with renal anemia who are not treated with erythropoiesis stimulating agents: MIYABI ND-C [abstract no: P1866]. Nephrology Dialysis Transplantation2020;35(Suppl 3):iii2177. [EMBASE: 633422996]">MIYABI ND‐C 2019</a>; <a href="./references#CD013751-bbs2-0033" title="YamamotoH , NoboriK , MatsudaY , HayashiY , HayasakiT , AkizawaT . Molidustat for renal anemia in nondialysis patients previously treated with erythropoiesis-stimulating agents: a randomized, open-label, phase 3 study. American Journal of Nephrology2021;52(10-11):884-93. [MEDLINE: 34569482]YamamotoH , TaguchiM , MatsudaY , IekushiK , YamadaT , AkizawaT . Molidustat for the treatment of renal anaemia in patients with non-dialysis-dependent chronic kidney disease: design and rationale of two phase III studies. BMJ Open2019;9(6):e026704. [MEDLINE: 31203242]YamamotoH , TaguchiM , NoboriK , MatsudaY , IekushiK , AkizawaT . To investigate the efficacy and safety of molidustat in non-dialysis patients with renal anemia who are treated with erythropoiesis stimulating agents: Miyabi ND-M [Abstract no: P1868]. Nephrology Dialysis Transplantation2020;35(Suppl 3):iii2179. [EMBASE: 633423006]">MIYABI ND‐M 2019</a>; <a href="./references#CD013751-bbs2-0034" title="NangakuM , KondoK , UetaK , KokadoY , KanekoG , MatsudaH , et al. Efficacy and safety of vadadustat compared with darbepoetin alfa in Japanese anemic patients on hemodialysis: a phase 3, multicenter, randomized, double-blind study. Nephrology Dialysis Transplantation2021;36(9):1731-41. [MEDLINE: 33650630]NangakuM , KondoK , UetaK , KokadoY , KanekoG , MatsudaH , et al. Randomized, double-blinded, active-controlled (darbepoetin alfa), phase 3 study of vadadustat in CKD patients with anemia on hemodialysis in Japan [abstract no: TH-OR024]. Journal of the American Society of Nephrology2019;30(Abstract Suppl):6. [EMBASE: 633771357]">Nangaku 2021</a>; <a href="./references#CD013751-bbs2-0035" title="NangakuM , KondoK , KokadoY , UetaK , KanekoG , ShiosakaM , et al. Randomized, open-label, active-controlled (darbepoetin alfa), phase 3 study of vadadustat for treating anemia in non-dialysis-dependent CKD patients in Japan [abstract no: SA-PO229]. Journal of the American Society of Nephrology2019;30(Abstract Suppl):823. [EMBASE: 633767995]NangakuM , KondoK , KokadoY , UetaK , KanekoG , TandaiT , et al. Phase 3 randomized study comparing vadadustat with darbepoetin alfa for anemia in Japanese patients with nondialysis-dependent CKD. Journal of the American Society of Nephrology2021;32(7):1779-90. [MEDLINE: 33883252]">Nangaku 2021a</a>; <a href="./references#CD013751-bbs2-0036" title="GSK201753. A 52-week, Phase III, open-label, multi-center study to evaluate efficacy and safety of GSK1278863 in Japanese non-dialysis and peritoneal dialysis subjects with anemia associated with chronic kidney disease [study protocol]. www.clinicaltrials.gov/ProvidedDocs/63/NCT02791763/Prot_000.pdf (accessed 9 May 2022). NangakuM , HamanoT , AkizawaT , TsubakiharaY , NagaiR , OkudaN , et al. Daprodustat compared with epoetin beta pegol for anemia in Japanese patients not on dialysis: a 52-week randomized open-label phase 3 trial. American Journal of Nephrology2021;52(1):26-35. [MEDLINE: 33561857]">Nangaku 2021b</a>; <a href="./references#CD013751-bbs2-0042" title="BunnHF . Vadadustat for anemia in patients with dialysis-dependent or non-dialysis-dependent chronic kidney disease. New England Journal of Medicine2021;385(16):e56. [MEDLINE: 34644481]ChertowGM , PergolaPE , AgarwalR , BlockGA , FaragYM , JardineAG , et al. Cardiovascular safety and efficacy of vadadustat for the treatment of anemia in non-dialysis-dependent CKD: design and baseline characteristics. American Heart Journal2021;235(5):1-11. [MEDLINE: 33129989]ChertowGM , PergolaPE , FaragYM , AgarwalR , ArnoldS , BakoG , et al. Vadadustat in patients with anemia and non-dialysis-dependent CKD. New England Journal of Medicine2021;384(17):1589-600. [MEDLINE: 33913637]ChertowGM . Global phase 3 clinical trials of vadadustat vs. darbepoetin alfa for treatment of anemia in patients with non-dialysis-dependent CKD [abstract no: FR-OR54]. Journal of the American Society of Nephrology2020;31(Abstract Suppl):B2. [EMBASE: 633697273]KouryM , PergolaPE , Roy-ChaudhuryP , FaragYM , LuoW , AndersR , et al. Iron-related outcomes in patients with non-dialysis-dependent CKD randomized to vadadustat vs. darbepoetin Alfa [abstract no: PO0482]. Journal of the American Society of Nephrology2021;32(Abstract Suppl):190. [EMBASE: 636329134]McCulloughPA , LuoW , AndersR , VargoD , ParfreyPS . Assessment of thromboembolic events with vadadustat vs. darbepoetin alfa for treatment of anemia in patients with non-dialysis-dependent CKD [abstract no: PO0462]. Journal of the American Society of Nephrology2021;32(Abstract Suppl):184. [EMBASE: 636331039]">PRO2TECT‐CONVERSION 2021</a>; <a href="./references#CD013751-bbs2-0043" title="BunnHF . Vadadustat for anemia in patients with dialysis-dependent or non-dialysis-dependent chronic kidney disease. New England Journal of Medicine2021;385(16):e56. [MEDLINE: 34644481]ChertowGM , PergolaPE , AgarwalR , BlockGA , FaragYM , JardineAG , et al. Cardiovascular safety and efficacy of vadadustat for the treatment of anemia in non-dialysis-dependent CKD: design and baseline characteristics. American Heart Journal2021;235(5):1-11. [MEDLINE: 33129989]ChertowGM , PergolaPE , FaragYM , AgarwalR , ArnoldS , BakoG , et al. Vadadustat in patients with anemia and non-dialysis-dependent CKD. New England Journal of Medicine2021;384(17):1589-600. [MEDLINE: 33913637]ChertowGM . Global phase 3 clinical trials of vadadustat vs. darbepoetin alfa for treatment of anemia in patients with non-dialysis-dependent CKD [abstract no: FR-OR5]. Journal of the American Society of Nephrology2020;31(Abstract Suppl):B2. [EMBASE: 633697273]KouryM , PergolaPE , Roy-ChaudhuryP , FaragYM , LuoW , AndersR , et al. Iron-related outcomes in patients with non-dialysis-dependent CKD randomized to vadadustat vs. darbepoetin alfa [abstract no: PO0482]. Journal of the American Society of Nephrology2021;32(Abstract Suppl):190. [EMBASE: 636329134]McCulloughPA , LuoW , AndersR , VargoD , ParfreyPS . Assessment of thromboembolic events with vadadustat vs. darbepoetin alfa for treatment of anemia in patients with non-dialysis-dependent CKD [abstract no: PO0462]. Journal of the American Society of Nephrology2021;32(Abstract Suppl):184. [EMBASE: 636331039]">PRO2TECT‐CORRECTION 2021</a>; <a href="./references#CD013751-bbs2-0047" title="Astellas 1517-CL-0613. Roxadustat in the treatment of anemia in end stage renal disease (ESRD) patients on stable dialysis [A phase 3, randomized, open-label, active-controlled study to evaluate the efficacy and safety of roxadustat in the maintenance treatment of anemia in end stage renal disease patients on stable dialysis]. www.trialsummaries.com/Study/StudyDetails?id=14380&amp;tenant=MT_AST_9011 (accessed 9 May 2022). CsikyB , SchomigM , EspositoC , BarrattJ , ReuschM , ValluriU , et al. Roxadustat for the maintenance treatment of anemia in patients with end-stage kidney disease on stable dialysis: a European phase 3, randomized, open-label, active-controlled study (PYRENEES). Advances in Therapy2021;38(10):5361-80. [MEDLINE: 34537926]EspositoC , CsikyB , TataradzeA , ReuschM , HanC , SulowiczW . Two phase 3, multicenter, randomized studies of intermittent oral roxadustat in anemic CKD patients on (PYRENEES) and not on (ALPS) dialysis. Swiss Medical Weekly2020;150(Suppl 248):21-2S. [EMBASE: 634241523]EspositoC , CsikyB , TataradzeA , ReuschM , HanC , SulowiczW . Two phase 3, multicenter, randomized studies of intermittent oral roxadustat in anemic CKD patients on (PYRENEES) and not on (ALPS) dialysis [abstract no: SA-PO225]. Journal of the American Society of Nephrology2019;30(Abstract Suppl):822. [EMBASE: 633767739]">PYRENEES 2021</a>; <a href="./references#CD013751-bbs2-0049" title="CharytanC , Manllo-KarimR , MartinER , SteerD , BernardoM , DuaSL , et al. A randomized trial of roxadustat in anemia of kidney failure: SIERRAS study. Kidney International Reports2021;6(7):1829-39. [MEDLINE: 34307977]CharytanC , Manllo-KarimR , MartinER , SteerD , BernardoM , DuaSL , et al. SIERRAS: A phase 3, open-label, randomized, active-controlled study of the efficacy and safety of roxadustat in the maintenance treatment of anemia in subjects with ESRD on stable dialysis [abstract no: SA-PO227]. Journal of the American Society of Nephrology2019;30(Abstract Suppl):822. [EMBASE: 633767862]">SIERRAS 2021</a>) reported hyperkalaemia without providing a clear definition. </p> <p>HIF stabiliser treatment probably makes little or no difference to hyperkalaemia (<a href="./references#CD013751-fig-0040" title="">Analysis 3.19</a> (21 studies, 20,177 participants): RR 0.92, 95% CI 0.82 to 1.04; I² = 10%; moderate certainty evidence) compared with ESA in people with CKD or those undergoing HD or PD. </p> </section> <section id="CD013751-sec-0099"> <h6 class="title">Pulmonary hypertension</h6> <p>The effect of HIF stabiliser treatment on pulmonary hypertension was uncertain (<a href="./references#CD013751-fig-0041" title="">Analysis 3.20</a> (7 studies, 8641 participants): RR 1.06, 95% CI 0.56 to 2.01; I² = 11%; very low certainty evidence) compared with ESA in people with CKD and HD. </p> </section> <section id="CD013751-sec-0100"> <h6 class="title">Diabetic retinopathy</h6> <p>HIF stabiliser therapy may make little or no difference to the number with diabetic retinopathy (<a href="./references#CD013751-fig-0042" title="">Analysis 3.21</a> (8 studies, 5036 participants): RR 1.26, 95% CI 0.71 to 2.22; I² = 0%; low certainty evidence) compared with ESA in people with CKD or those undergoing HD. </p> </section> </section> <section id="CD013751-sec-0101"> <h5 class="title">Subgroup analyses for HIF stabiliser versus ESA</h5> <p>Additional analyses to compare HIF stabiliser management versus ESA were performed stratifying by stage of CKD. </p> <p> <ul id="CD013751-list-0022"> <li> <p>CV death</p> <ul id="CD013751-list-0023"> <li> <p>CKD: <a href="./references#CD013751-fig-0043" title="">Analysis 4.1</a>.1 (7 studies, 5591 participants: RR 1.19, 95% CI 0.91 to 1.55; I² = 0%; low certainty evidence) </p> </li> <li> <p>HD: <a href="./references#CD013751-fig-0043" title="">Analysis 4.1</a>.2 (7 studies, 1352 participants: RR 0.98, 95% CI 0.23 to 4.19; I² = 0%; low certainty evidence) </p> </li> <li> <p>PD: <a href="./references#CD013751-fig-0043" title="">Analysis 4.1</a>.3 (1 study, 129 participants: RR 0.50, 95% CI 0.03 to 7.80) </p> </li> <li> <p>HD and PD: <a href="./references#CD013751-fig-0043" title="">Analysis 4.1</a>.4 (2 studies, 3268 participants: RR 0.96, 95% CI 0.75 to 1.23; low certainty evidence) </p> </li> </ul> </li> <li> <p>Fatigue</p> <ul id="CD013751-list-0024"> <li> <p>CKD: <a href="./references#CD013751-fig-0044" title="">Analysis 4.2</a>.1 (2 studies, 3471 participants: RR 0.80, 95% CI 0.56 to 1.16; I² = 0%; very low certainty evidence) </p> </li> </ul> </li> <li> <p>Nonfatal MI</p> <ul id="CD013751-list-0025"> <li> <p>CKD: <a href="./references#CD013751-fig-0045" title="">Analysis 4.3</a>.1 (2 studies, 3996 participants: RR 1.05, 95% CI 0.80 to 1.39; low certainty evidence<i>)</i> </p> </li> <li> <p>HD: <a href="./references#CD013751-fig-0045" title="">Analysis 4.3</a>.2 (2 studies, 372 participants: RR 1.97, 95% CI 0.22 to 17.59; I² = 0%; very low certainty evidence) </p> </li> <li> <p>PD: <a href="./references#CD013751-fig-0045" title="">Analysis 4.3</a>.3 (1 study, 129 participants: RR 1.52, 95% CI 0.06 to 36.48) </p> </li> <li> <p>HD and PD: <a href="./references#CD013751-fig-0045" title="">Analysis 4.3</a>.4 (2 studies, 3268 participants: RR 0.80, 95% CI 0.62 to 1.03; I² = 0%; low certainty evidence) </p> </li> </ul> </li> <li> <p>Nonfatal stroke</p> <ul id="CD013751-list-0026"> <li> <p>CKD: <a href="./references#CD013751-fig-0046" title="">Analysis 4.4</a>.1 (3 studies, 4122 participants: RR 1.43, 95% CI 0.82 to 2.48; low certainty evidence) </p> </li> <li> <p>HD: <a href="./references#CD013751-fig-0046" title="">Analysis 4.4</a>.2 (1 study, 199 participants: RR 1.36, 95% CI 0.07 to 27.82) </p> </li> <li> <p>HD and PD: <a href="./references#CD013751-fig-0046" title="">Analysis 4.4</a>.3 (1 study, 2964 participants: RR 0.82, 95% CI 0.51 to 1.34) </p> </li> </ul> </li> <li> <p>Proportion of patients requiring blood transfusion</p> <ul id="CD013751-list-0027"> <li> <p>CKD: <a href="./references#CD013751-fig-0047" title="">Analysis 4.5</a>.1 (5 studies, 4933 participants: RR 0.97, 95% CI 0.84 to 1.13; I² = 0%; low certainty evidence) </p> </li> <li> <p>HD and PD: <a href="./references#CD013751-fig-0047" title="">Analysis 4.5</a>.2 (6 studies, 5853 participants: RR 0.80, 95% CI 0.64 to 1.01; I² = 46%; very low certainty evidence) </p> </li> </ul> </li> <li> <p>Proportion of patients reaching the target Hb</p> <ul id="CD013751-list-0028"> <li> <p>CKD: <a href="./references#CD013751-fig-0048" title="">Analysis 4.6</a>.1 (6 studies, 1369 participants: RR 1.02, 95% CI 0.90 to 1.16; I² = 79%; very low certainty evidence) </p> </li> <li> <p>HD and PD: <a href="./references#CD013751-fig-0046" title="">Analysis 4.4</a>.2 (8 studies, 3232 participants: RR 0.98, 95% CI 0.91 to 1.06; I² = 59%; very low certainty evidence). </p> </li> </ul> </li> </ul> </p> <p>Other subgroup analyses were not possible due to the limited number of studies and data. </p> </section> <section id="CD013751-sec-0102"> <h5 class="title">Subgroup analyses for proportion reaching Hb target: stratifying by stage of CKD</h5> <p>The test for subgroup differences indicates that there is no statistically significant subgroup effect (P = 0.77), suggesting that different stages of CKD do not modify the effect of HIF stabiliser management of anaemia on the proportion reaching the Hb target (<a href="./references#CD013751-fig-0049" title="">Analysis 5.1</a>). However, a smaller number of participants contributed data to CKD and HD than to HD and PD subgroups, meaning that the analysis may not be able to detect subgroup differences. </p> </section> <section id="CD013751-sec-0103"> <h5 class="title">Subgroup analyses for thrombosis: stratifying by stage of CKD</h5> <p>The test for subgroup differences indicates that there is no statistically significant subgroup effect (P = 0.99), suggesting that different stages of CKD do not modify the effect of HIF stabiliser management of anaemia on thrombosis (<a href="./references#CD013751-fig-0050" title="">Analysis 5.2</a>). However, a smaller number of participants and events contributed data to CKD and HD than to HD and PD subgroup, meaning that the analysis may not be able to detect subgroup differences. </p> </section> <section id="CD013751-sec-0104"> <h5 class="title">Subgroup analyses for proportion reaching Hb target: stratifying by the duration of therapy </h5> <p>The test for subgroup differences indicates that there is no statistically significant subgroup effect (P = 0.78), suggesting that different duration of therapy does not modify the effect of HIF stabiliser management of anaemia on the proportion reaching the Hb target (<a href="./references#CD013751-fig-0051" title="">Analysis 6.1</a>). However, a smaller number of participants and events contributed data to the duration of therapy from 8 to 23 weeks and at least 54 weeks than from the 24 to 53 weeks subgroup, meaning that the analysis may not be able to detect subgroup differences. </p> </section> <section id="CD013751-sec-0105"> <h5 class="title">Subgroup analyses for thrombosis: stratifying by the duration of therapy</h5> <p>The test for subgroup differences indicates that there is no statistically significant subgroup effect (P = 0.44), suggesting that different duration of therapy does not modify the effect of HIF stabiliser management of anaemia on thrombosis (<a href="./references#CD013751-fig-0052" title="">Analysis 6.2</a>). However, a smaller number of participants and events contributed data to the duration of therapy from 24 to 53 weeks subgroup than at least 54 weeks subgroup, meaning that the analysis may not be able to detect subgroup differences. </p> </section> <section id="CD013751-sec-0106"> <h5 class="title">Subgroup analyses for proportion reaching Hb target: stratifying by frequency of HIF stabiliser administration </h5> <p>The test for subgroup differences indicates that there is no statistically significant subgroup effect (P = 0.43), suggesting that different frequency of HIF stabiliser administration does not modify the effect of HIF stabiliser management of anaemia on proportion reaching the Hb target (<a href="./references#CD013751-fig-0053" title="">Analysis 7.1</a>). However, a smaller number of participants and events contributed data to once/day administration than to three times/week administration subgroup, meaning that the analysis may not be able to detect subgroup differences. </p> </section> <section id="CD013751-sec-0107"> <h5 class="title">Subgroup analyses for thrombosis: stratifying by frequency of HIF stabiliser administration</h5> <p>The test for subgroup differences indicates that there is no statistically significant subgroup effect (P = 0.17), suggesting that different frequency of HIF stabiliser administration does not modify the effect of HIF stabiliser management of anaemia on thrombosis (<a href="./references#CD013751-fig-0054" title="">Analysis 7.2</a>). However, a smaller number of participants and events contributed data to three times/week administration than the once/day administration subgroup, meaning that the analysis may not be able to detect subgroup differences. </p> </section> <section id="CD013751-sec-0108"> <h5 class="title">Subgroup analyses for proportion reaching Hb target<i>:</i> stratifying by type of study (phase 2 versus phase 3) </h5> <p>The test for subgroup differences indicates that there is no statistically significant subgroup effect (P = 0.26), suggesting that type of study does not modify the effect of HIF stabiliser management of anaemia on the proportion reaching the Hb target (<a href="./references#CD013751-fig-0055" title="">Analysis 8.1</a>). However, a smaller number of participants and events contributed data to phase 2 studies than phase 3 studies subgroup, meaning that the analysis may not be able to detect subgroup differences. </p> </section> <section id="CD013751-sec-0109"> <h5 class="title">Subgroup analyses for thrombosis: stratifying by type of study (phase 2 versus phase 3) </h5> <p>The test for subgroup differences indicates no statistically significant subgroup effect (P = 0.96), suggesting that type of study does not modify the effect of HIF stabiliser management of anaemia on thrombosis (<a href="./references#CD013751-fig-0056" title="">Analysis 8.2</a>). However, a smaller number of participants and events contributed data to phase 2 studies than phase 3 studies subgroup, meaning that the analysis may not be able to detect subgroup differences. </p> </section> <section id="CD013751-sec-0110"> <h5 class="title">Sensitivity analysis for HIF stabiliser versus ESA</h5> <p>Sensitivity analyses did not provide substantively different results or were not possible due to few data and studies. </p> </section> </section> <section id="CD013751-sec-0111"> <h4 class="title">HIF stabiliser versus standard care</h4> <p>No studies were designed to compare HIF stabiliser management of anaemia versus standard care. </p> </section> <section id="CD013751-sec-0112"> <h4 class="title">HIF stabiliser versus iron supplementation</h4> <p>No studies were designed to compare HIF stabiliser management of anaemia with iron supplementation. </p> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD013751-sec-0113" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD013751-sec-0113"></div> <section id="CD013751-sec-0114"> <h3 class="title" id="CD013751-sec-0114">Summary of main results</h3> <p>We identified 51 studies randomising 30,994 adults evaluating HIF stabilisers for the treatment of anaemia in CKD (stages 3‐5), including people receiving HD or PD. No studies were performed in children. No studies compared HIF stabiliser with standard care or iron supplementation. Most studies (29 studies randomising 21,622 participants) compared a HIF stabiliser management of anaemia with ESA for a median of 52 weeks. Risks of bias in the included studies were often high or unclear, and these risks combined with imprecision in effect estimates frequently led to low or very low certainty evidence. </p> <p>HIF stabiliser management of anaemia had uncertain effects on CV death, fatigue and death (any cause). It is uncertain whether HIF stabiliser management of anaemia reduces nonfatal MI or nonfatal stroke. HIF stabilise management of anaemia probably decreased the proportion of patients requiring blood transfusion compared to placebo or ESA. HIF stabiliser management of anaemia probably increased the proportion of patients reaching their Hb target compared to placebo. The effects of HIF stabiliser management of anaemia on hospitalisation for HF, kidney failure, peripheral arterial event, thrombosis, loss of unassisted dialysis access patency, cancer, infection, pulmonary hypertension, and diabetic nephropathy were very uncertain. Subgroup analyses suggested that different stages of CKD, duration of therapy, frequency of HIF stabiliser administration and type of study (phase 2 or phase 3 studies) did not modify the effects of HIF stabiliser management of anaemia either on the proportion reaching the target Hb, or thrombosis. Adverse events were rarely reported; specifically, the definition of hyperkalaemia was not clearly stated. </p> </section> <section id="CD013751-sec-0115"> <h3 class="title" id="CD013751-sec-0115">Overall completeness and applicability of evidence</h3> <p>Evidence from the existing studies was frequently of low or very low certainty and not available to inform clinical care or policy. About half of the included studies were in people with CKD not treated with dialysis. Many studies compared different treatment doses. No studies were conducted on recipients of a kidney transplant or children. </p> <p>Recently, the Food and Drug Administration (FDA) did not approve the use of roxadustat for the treatment of anaemia in people with CKD, including those requiring dialysis, due to the higher risk of thrombosis shown among HIF stabilisers compared to placebo or ESA (<a href="./references#CD013751-bbs2-0095" title="US Food &amp; Drug Administration. Cardiovascular and Renal Drugs Advisory Committee Meeting July 15, 2021 Roxadustat. www.fda.gov/media/150728/download (accessed 10 May 2022).">FDA Briefing Document 2021</a>). HIF stabilisers could be considered second‐choice drugs to treat anaemia in people undergoing dialysis who have been resistant to other drugs for anaemia (<a href="./references#CD013751-bbs2-0095" title="US Food &amp; Drug Administration. Cardiovascular and Renal Drugs Advisory Committee Meeting July 15, 2021 Roxadustat. www.fda.gov/media/150728/download (accessed 10 May 2022).">FDA Briefing Document 2021</a>). In our review, most studies compared a HIF stabiliser management of anaemia with ESA, and clinically important outcome data were rarely reported. Nineteen studies were phase 2 studies that addressed drug efficacy rather than key clinical outcomes, such as death and adverse events. The majority of studies had a small sample size, were of short‐term duration, had methodological limitations, or were primarily designed to evaluate surrogate measures of effect. Due to the included studies' short duration, no studies reported outcome data for life participation, PD infection, or PD technique longevity. Fatigue, hospitalisation due to HF, and infection were rarely reported. Adverse events related to treatment were not systematically reported (<a href="./appendices#CD013751-sec-0127">Appendix 3</a>), preventing an adequate safety evaluation between HIF stabilisers and placebo or ESA. </p> <p>No studies compared HIF stabilisers with standard care or iron supplementation.</p> <p>Future studies on HIF stabilisers for treating anaemia should evaluate treatment outcomes as prioritised by stakeholders (patients, caregivers and health professionals) (<a href="./references#CD013751-bbs2-0119" title="SONG Initiative. The SONG Handbook Version 1.0. www.songinitiative.org/reports-and-publications/2017.">SONG 2017</a>) to inform clinical practice and decision making. </p> </section> <section id="CD013751-sec-0116"> <h3 class="title" id="CD013751-sec-0116">Quality of the evidence</h3> <p>We used standard risk of bias domains within the Cochrane tool and GRADE methodology (<a href="./references#CD013751-bbs2-0099" title="GuyattGH , OxmanAD , VistGE , KunzR , Falck-YtterY , Alonso-CoelloP , et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ2008;336(7650):924-6. [MEDLINE: 18436948]">GRADE 2008</a>) to assess the quality of study evidence. Based on low or very low certainty evidence for the majority of outcomes assessed, future studies might provide different results. </p> <p>Some studies were at high or unclear risks of bias for most of the risk of bias domains assessment. The majority of studies did not report adequate allocation concealment, blinding or attrition. All but three studies received funding from pharmaceutical companies. Relevant clinical outcomes were rarely available for many of the included studies. </p> <p>Heterogeneity in the reporting methods of many outcomes constrained data synthesis by meta‐analysis. The targeted Hb values were wide heterogeneous. The limited number of studies prevented the exploration of other potential sources of heterogeneity in the analyses. Some subgroup and sensitivity analyses could not be conducted to explore for heterogeneity owing to insufficient data. Due to the limited number of studies, the assessment of adverse events was not possible. </p> </section> <section id="CD013751-sec-0117"> <h3 class="title" id="CD013751-sec-0117">Potential biases in the review process</h3> <p>Our review was carried out using standard Cochrane methods. Each step was completed independently by at least two authors including a selection of studies, data management, and risk of bias assessment to minimise the risks of misclassification and adjudication of evidence. A highly sensitive search of the Cochrane Kidney Transplant specialised register was undertaken in November 2021, without language restriction and including grey literature. Where possible, we contacted study authors to obtain further data. Many studies did not report key outcomes in a format suitable for meta‐analysis. </p> <p>Potential bias identified in our review included: 1) phase 2 studies may not be generalisable to phase 3 or real‐world experience because they were of limited duration and not adequately controlled, and tested treatment strategies that may not then be subsequently used in phase 3 studies aimed at approval from regulatory agencies; 2) we pooled different HIF stabilisers agents which have yet to be established in significance; 3) we reported different rate of rise for each HIF stabiliser agent; 4) we pooled different frequency of administration; 5) we pooled major adverse CV events (MACE)‐driven studies and not MACE‐driven studies; 6) we precluded heterogeneity between treatment interventions due to the small number of data observations; 7) we did not exclude poor quality studies due to the small number of included studies; 8) the limited number of studies was a constraint on our ability to assess for potential reporting bias and selective outcome reporting; 9) the definition of Hb target varied across the eligible studies; 10) the effects of HIF stabilisers management of anaemia on longer‐term outcomes were uncertain and the treatment endpoints were principally surrogate outcomes (e.g. blood pressure and laboratory parameters); 11) adverse events were rarely and inconsistently reported due to the short duration of the included studies; 12) no clear definition was provided for hyperkalaemia preventing the evaluation on different threshold; 13) the included studies were conducted in different geographical areas which translates to differences in underlying morbidity for patients. </p> <p>Visual inspection of funnel plots for HIF stabilisers versus ESA did not suggest any evidence of small study effects indicating possible publication bias for CV death (<a href="#CD013751-fig-0004">Figure 4</a>). </p> <div class="figure" id="CD013751-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Funnel plot of comparison: 2 Hypoxia‐inducible factor (HIF) stabiliser versus erythropoiesis‐stimulating agent (ESA), outcome: 2.1 Cardiovascular death." data-id="CD013751-fig-0004" src="/cdsr/doi/10.1002/14651858.CD013751.pub2/media/CDSR/CD013751/image_n/nCD013751-FIG-04.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison: 2 Hypoxia‐inducible factor (HIF) stabiliser versus erythropoiesis‐stimulating agent (ESA), outcome: 2.1 Cardiovascular death. </p> </div> </div> </div> </section> <section id="CD013751-sec-0118"> <h3 class="title" id="CD013751-sec-0118">Agreements and disagreements with other studies or reviews</h3> <p>Few studies have examined the efficacy of HIF stabilisers in people with CKD, and the number of meta‐analyses published in this field is limited. </p> <p><a href="./references#CD013751-bbs2-0121" title="WangB , YinQ , HanYC , WuM , LiZL , TuY , et al. Effect of hypoxia-inducible factor-prolyl hydroxylase inhibitors on anemia in patients with CKD: a meta-analysis of randomized controlled trials including 2804 patients. Renal Failure2020;42(1):912-25. [MEDLINE: 32869703]">Wang 2020</a> performed a meta‐analysis of RCTs including only 2804 patients with CKD. The outcomes assessed included mainly surrogate outcomes and adverse events (hypertension, hyperkalaemia, CV events, vascular access thrombosis, headache, vomiting, nasopharyngitis, nausea, and diarrhoea). Our findings confirmed that HIF stabiliser management of anaemia may increase the risk of hyperkalaemia compared with placebo. Compared to our review, <a href="./references#CD013751-bbs2-0121" title="WangB , YinQ , HanYC , WuM , LiZL , TuY , et al. Effect of hypoxia-inducible factor-prolyl hydroxylase inhibitors on anemia in patients with CKD: a meta-analysis of randomized controlled trials including 2804 patients. Renal Failure2020;42(1):912-25. [MEDLINE: 32869703]">Wang 2020</a> did not investigate death in the included studies, excluded non‐English studies and grey literature, and did not use GRADE to evaluate evidence certainty. </p> <p><a href="./references#CD013751-bbs2-0123" title="ZhongH , ZhouT , LiH , ZhongZ . The role of hypoxia-inducible factor stabilizers in the treatment of anemia in patients with chronic kidney disease. Drug Design, Development &amp; Therapy2018;12:3003-11. [MEDLINE: 30271115]">Zhong 2018</a> carried out a systematic review and meta‐analysis of nine RCTs to assess the efficacy of HIF stabilisers in the treatment of anaemia in CKD. However, due to the limited studies and short follow‐up, <a href="./references#CD013751-bbs2-0123" title="ZhongH , ZhouT , LiH , ZhongZ . The role of hypoxia-inducible factor stabilizers in the treatment of anemia in patients with chronic kidney disease. Drug Design, Development &amp; Therapy2018;12:3003-11. [MEDLINE: 30271115]">Zhong 2018</a> could not detect relevant clinical outcomes, including death and CV events, and focused mainly on surrogate outcomes (Hb, ferritin, hepcidin and total iron‐binding capacity), preventing comparisons with our review. In addition, <a href="./references#CD013751-bbs2-0123" title="ZhongH , ZhouT , LiH , ZhongZ . The role of hypoxia-inducible factor stabilizers in the treatment of anemia in patients with chronic kidney disease. Drug Design, Development &amp; Therapy2018;12:3003-11. [MEDLINE: 30271115]">Zhong 2018</a> did not use GRADE to evaluate evidence certainty. </p> <p><a href="./references#CD013751-bbs2-0107" title="LiZL , TuY , LiuBC . Treatment of renal anemia with roxadustat: advantages and achievement. Kidney Diseases2020;6(2):65–73. [MEDLINE: 32309288]">Li 2020</a> reviewed the findings from three clinical trials on roxadustat for treating kidney anaemia. Data were reported only for surrogate outcomes. The main differences with our review are the exclusion of other HIF stabilisers, such as daprodustat, molidustat and vadadustat, and the lack of data on mortality and safety outcomes. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD013751-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013751.pub2/media/CDSR/CD013751/urn:x-wiley:14651858:media:CD013751:CD013751-FIG-01" target="_blank"><b></b></a></p> </div><img alt="Flow diagram." data-id="CD013751-fig-0001" src="/cdsr/doi/10.1002/14651858.CD013751.pub2/media/CDSR/CD013751/image_n/nCD013751-FIG-01.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013751.pub2/media/CDSR/CD013751/image_t/tCD013751-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013751.pub2/full#CD013751-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013751.pub2/media/CDSR/CD013751/image_n/nCD013751-FIG-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013751-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013751.pub2/media/CDSR/CD013751/urn:x-wiley:14651858:media:CD013751:CD013751-FIG-02" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD013751-fig-0002" src="/cdsr/doi/10.1002/14651858.CD013751.pub2/media/CDSR/CD013751/image_n/nCD013751-FIG-02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013751.pub2/media/CDSR/CD013751/image_t/tCD013751-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013751.pub2/full#CD013751-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013751.pub2/media/CDSR/CD013751/image_n/nCD013751-FIG-02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013751-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013751.pub2/media/CDSR/CD013751/urn:x-wiley:14651858:media:CD013751:CD013751-FIG-03" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD013751-fig-0003" src="/cdsr/doi/10.1002/14651858.CD013751.pub2/media/CDSR/CD013751/image_n/nCD013751-FIG-03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013751.pub2/media/CDSR/CD013751/image_t/tCD013751-FIG-03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013751.pub2/full#CD013751-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013751.pub2/media/CDSR/CD013751/image_n/nCD013751-FIG-03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013751-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013751.pub2/media/CDSR/CD013751/urn:x-wiley:14651858:media:CD013751:CD013751-FIG-04" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison: 2 Hypoxia‐inducible factor (HIF) stabiliser versus erythropoiesis‐stimulating agent (ESA), outcome: 2.1 Cardiovascular death." data-id="CD013751-fig-0004" src="/cdsr/doi/10.1002/14651858.CD013751.pub2/media/CDSR/CD013751/image_n/nCD013751-FIG-04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013751.pub2/media/CDSR/CD013751/image_t/tCD013751-FIG-04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Funnel plot of comparison: 2 Hypoxia‐inducible factor (HIF) stabiliser versus erythropoiesis‐stimulating agent (ESA), outcome: 2.1 Cardiovascular death. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013751.pub2/full#CD013751-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013751.pub2/media/CDSR/CD013751/image_n/nCD013751-FIG-04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013751-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013751.pub2/media/CDSR/CD013751/urn:x-wiley:14651858:media:CD013751:CD013751-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Hypoxia‐inducible factor (HIF) stabiliser versus placebo, Outcome 1: Cardiovascular death" data-id="CD013751-fig-0005" src="/cdsr/doi/10.1002/14651858.CD013751.pub2/media/CDSR/CD013751/image_n/nCD013751-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013751.pub2/media/CDSR/CD013751/image_t/tCD013751-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: Hypoxia‐inducible factor (HIF) stabiliser versus placebo, Outcome 1: Cardiovascular death </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013751.pub2/references#CD013751-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013751.pub2/media/CDSR/CD013751/image_n/nCD013751-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013751-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013751.pub2/media/CDSR/CD013751/urn:x-wiley:14651858:media:CD013751:CD013751-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Hypoxia‐inducible factor (HIF) stabiliser versus placebo, Outcome 2: Death (any cause)" data-id="CD013751-fig-0006" src="/cdsr/doi/10.1002/14651858.CD013751.pub2/media/CDSR/CD013751/image_n/nCD013751-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013751.pub2/media/CDSR/CD013751/image_t/tCD013751-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: Hypoxia‐inducible factor (HIF) stabiliser versus placebo, Outcome 2: Death (any cause) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013751.pub2/references#CD013751-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013751.pub2/media/CDSR/CD013751/image_n/nCD013751-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013751-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013751.pub2/media/CDSR/CD013751/urn:x-wiley:14651858:media:CD013751:CD013751-CMP-001.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Hypoxia‐inducible factor (HIF) stabiliser versus placebo, Outcome 3: Nonfatal myocardial infarction" data-id="CD013751-fig-0007" src="/cdsr/doi/10.1002/14651858.CD013751.pub2/media/CDSR/CD013751/image_n/nCD013751-CMP-001.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013751.pub2/media/CDSR/CD013751/image_t/tCD013751-CMP-001.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1: Hypoxia‐inducible factor (HIF) stabiliser versus placebo, Outcome 3: Nonfatal myocardial infarction </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013751.pub2/references#CD013751-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013751.pub2/media/CDSR/CD013751/image_n/nCD013751-CMP-001.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013751-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013751.pub2/media/CDSR/CD013751/urn:x-wiley:14651858:media:CD013751:CD013751-CMP-001.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Hypoxia‐inducible factor (HIF) stabiliser versus placebo, Outcome 4: Fatal or nonfatal myocardial infarction (overall)" data-id="CD013751-fig-0008" src="/cdsr/doi/10.1002/14651858.CD013751.pub2/media/CDSR/CD013751/image_n/nCD013751-CMP-001.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013751.pub2/media/CDSR/CD013751/image_t/tCD013751-CMP-001.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1: Hypoxia‐inducible factor (HIF) stabiliser versus placebo, Outcome 4: Fatal or nonfatal myocardial infarction (overall) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013751.pub2/references#CD013751-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013751.pub2/media/CDSR/CD013751/image_n/nCD013751-CMP-001.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013751-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013751.pub2/media/CDSR/CD013751/urn:x-wiley:14651858:media:CD013751:CD013751-CMP-001.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Hypoxia‐inducible factor (HIF) stabiliser versus placebo, Outcome 5: Nonfatal stroke" data-id="CD013751-fig-0009" src="/cdsr/doi/10.1002/14651858.CD013751.pub2/media/CDSR/CD013751/image_n/nCD013751-CMP-001.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013751.pub2/media/CDSR/CD013751/image_t/tCD013751-CMP-001.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1: Hypoxia‐inducible factor (HIF) stabiliser versus placebo, Outcome 5: Nonfatal stroke </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013751.pub2/references#CD013751-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013751.pub2/media/CDSR/CD013751/image_n/nCD013751-CMP-001.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013751-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013751.pub2/media/CDSR/CD013751/urn:x-wiley:14651858:media:CD013751:CD013751-CMP-001.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Hypoxia‐inducible factor (HIF) stabiliser versus placebo, Outcome 6: Fatal or nonfatal stroke (overall)" data-id="CD013751-fig-0010" src="/cdsr/doi/10.1002/14651858.CD013751.pub2/media/CDSR/CD013751/image_n/nCD013751-CMP-001.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013751.pub2/media/CDSR/CD013751/image_t/tCD013751-CMP-001.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1: Hypoxia‐inducible factor (HIF) stabiliser versus placebo, Outcome 6: Fatal or nonfatal stroke (overall) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013751.pub2/references#CD013751-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013751.pub2/media/CDSR/CD013751/image_n/nCD013751-CMP-001.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013751-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013751.pub2/media/CDSR/CD013751/urn:x-wiley:14651858:media:CD013751:CD013751-CMP-001.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Hypoxia‐inducible factor (HIF) stabiliser versus placebo, Outcome 7: Peripheral arterial events" data-id="CD013751-fig-0011" src="/cdsr/doi/10.1002/14651858.CD013751.pub2/media/CDSR/CD013751/image_n/nCD013751-CMP-001.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013751.pub2/media/CDSR/CD013751/image_t/tCD013751-CMP-001.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1: Hypoxia‐inducible factor (HIF) stabiliser versus placebo, Outcome 7: Peripheral arterial events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013751.pub2/references#CD013751-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013751.pub2/media/CDSR/CD013751/image_n/nCD013751-CMP-001.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013751-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013751.pub2/media/CDSR/CD013751/urn:x-wiley:14651858:media:CD013751:CD013751-CMP-001.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Hypoxia‐inducible factor (HIF) stabiliser versus placebo, Outcome 8: Transfusion" data-id="CD013751-fig-0012" src="/cdsr/doi/10.1002/14651858.CD013751.pub2/media/CDSR/CD013751/image_n/nCD013751-CMP-001.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013751.pub2/media/CDSR/CD013751/image_t/tCD013751-CMP-001.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1: Hypoxia‐inducible factor (HIF) stabiliser versus placebo, Outcome 8: Transfusion </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013751.pub2/references#CD013751-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013751.pub2/media/CDSR/CD013751/image_n/nCD013751-CMP-001.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013751-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013751.pub2/media/CDSR/CD013751/urn:x-wiley:14651858:media:CD013751:CD013751-CMP-001.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Hypoxia‐inducible factor (HIF) stabiliser versus placebo, Outcome 9: Proportion reaching target haemoglobin" data-id="CD013751-fig-0013" src="/cdsr/doi/10.1002/14651858.CD013751.pub2/media/CDSR/CD013751/image_n/nCD013751-CMP-001.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013751.pub2/media/CDSR/CD013751/image_t/tCD013751-CMP-001.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1: Hypoxia‐inducible factor (HIF) stabiliser versus placebo, Outcome 9: Proportion reaching target haemoglobin </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013751.pub2/references#CD013751-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013751.pub2/media/CDSR/CD013751/image_n/nCD013751-CMP-001.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013751-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013751.pub2/media/CDSR/CD013751/urn:x-wiley:14651858:media:CD013751:CD013751-CMP-001.10" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Hypoxia‐inducible factor (HIF) stabiliser versus placebo, Outcome 10: Kidney failure" data-id="CD013751-fig-0014" src="/cdsr/doi/10.1002/14651858.CD013751.pub2/media/CDSR/CD013751/image_n/nCD013751-CMP-001.10.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013751.pub2/media/CDSR/CD013751/image_t/tCD013751-CMP-001.10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1: Hypoxia‐inducible factor (HIF) stabiliser versus placebo, Outcome 10: Kidney failure </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013751.pub2/references#CD013751-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013751.pub2/media/CDSR/CD013751/image_n/nCD013751-CMP-001.10.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013751-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013751.pub2/media/CDSR/CD013751/urn:x-wiley:14651858:media:CD013751:CD013751-CMP-001.11" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Hypoxia‐inducible factor (HIF) stabiliser versus placebo, Outcome 11: Thrombosis" data-id="CD013751-fig-0015" src="/cdsr/doi/10.1002/14651858.CD013751.pub2/media/CDSR/CD013751/image_n/nCD013751-CMP-001.11.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013751.pub2/media/CDSR/CD013751/image_t/tCD013751-CMP-001.11.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.11</div> <div class="figure-caption"> <p>Comparison 1: Hypoxia‐inducible factor (HIF) stabiliser versus placebo, Outcome 11: Thrombosis </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013751.pub2/references#CD013751-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013751.pub2/media/CDSR/CD013751/image_n/nCD013751-CMP-001.11.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013751-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013751.pub2/media/CDSR/CD013751/urn:x-wiley:14651858:media:CD013751:CD013751-CMP-001.12" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Hypoxia‐inducible factor (HIF) stabiliser versus placebo, Outcome 12: Loss of unassisted patency (stenosis)" data-id="CD013751-fig-0016" src="/cdsr/doi/10.1002/14651858.CD013751.pub2/media/CDSR/CD013751/image_n/nCD013751-CMP-001.12.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013751.pub2/media/CDSR/CD013751/image_t/tCD013751-CMP-001.12.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.12</div> <div class="figure-caption"> <p>Comparison 1: Hypoxia‐inducible factor (HIF) stabiliser versus placebo, Outcome 12: Loss of unassisted patency (stenosis) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013751.pub2/references#CD013751-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013751.pub2/media/CDSR/CD013751/image_n/nCD013751-CMP-001.12.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013751-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013751.pub2/media/CDSR/CD013751/urn:x-wiley:14651858:media:CD013751:CD013751-CMP-001.13" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Hypoxia‐inducible factor (HIF) stabiliser versus placebo, Outcome 13: Hyperkalaemia" data-id="CD013751-fig-0017" src="/cdsr/doi/10.1002/14651858.CD013751.pub2/media/CDSR/CD013751/image_n/nCD013751-CMP-001.13.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013751.pub2/media/CDSR/CD013751/image_t/tCD013751-CMP-001.13.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.13</div> <div class="figure-caption"> <p>Comparison 1: Hypoxia‐inducible factor (HIF) stabiliser versus placebo, Outcome 13: Hyperkalaemia </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013751.pub2/references#CD013751-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013751.pub2/media/CDSR/CD013751/image_n/nCD013751-CMP-001.13.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013751-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013751.pub2/media/CDSR/CD013751/urn:x-wiley:14651858:media:CD013751:CD013751-CMP-002.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Analyses for SOF table 1 stratifying by CKD stage (HIF versus placebo), Outcome 1: Cardiovascular death" data-id="CD013751-fig-0018" src="/cdsr/doi/10.1002/14651858.CD013751.pub2/media/CDSR/CD013751/image_n/nCD013751-CMP-002.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013751.pub2/media/CDSR/CD013751/image_t/tCD013751-CMP-002.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2: Analyses for SOF table 1 stratifying by CKD stage (HIF versus placebo), Outcome 1: Cardiovascular death </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013751.pub2/references#CD013751-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013751.pub2/media/CDSR/CD013751/image_n/nCD013751-CMP-002.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013751-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013751.pub2/media/CDSR/CD013751/urn:x-wiley:14651858:media:CD013751:CD013751-CMP-002.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Analyses for SOF table 1 stratifying by CKD stage (HIF versus placebo), Outcome 2: Nonfatal myocardial infarction" data-id="CD013751-fig-0019" src="/cdsr/doi/10.1002/14651858.CD013751.pub2/media/CDSR/CD013751/image_n/nCD013751-CMP-002.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013751.pub2/media/CDSR/CD013751/image_t/tCD013751-CMP-002.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2: Analyses for SOF table 1 stratifying by CKD stage (HIF versus placebo), Outcome 2: Nonfatal myocardial infarction </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013751.pub2/references#CD013751-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013751.pub2/media/CDSR/CD013751/image_n/nCD013751-CMP-002.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013751-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013751.pub2/media/CDSR/CD013751/urn:x-wiley:14651858:media:CD013751:CD013751-CMP-002.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Analyses for SOF table 1 stratifying by CKD stage (HIF versus placebo), Outcome 3: Transfusion" data-id="CD013751-fig-0020" src="/cdsr/doi/10.1002/14651858.CD013751.pub2/media/CDSR/CD013751/image_n/nCD013751-CMP-002.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013751.pub2/media/CDSR/CD013751/image_t/tCD013751-CMP-002.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2: Analyses for SOF table 1 stratifying by CKD stage (HIF versus placebo), Outcome 3: Transfusion </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013751.pub2/references#CD013751-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013751.pub2/media/CDSR/CD013751/image_n/nCD013751-CMP-002.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013751-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013751.pub2/media/CDSR/CD013751/urn:x-wiley:14651858:media:CD013751:CD013751-CMP-002.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Analyses for SOF table 1 stratifying by CKD stage (HIF versus placebo), Outcome 4: Proportion reaching target haemoglobin" data-id="CD013751-fig-0021" src="/cdsr/doi/10.1002/14651858.CD013751.pub2/media/CDSR/CD013751/image_n/nCD013751-CMP-002.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013751.pub2/media/CDSR/CD013751/image_t/tCD013751-CMP-002.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2: Analyses for SOF table 1 stratifying by CKD stage (HIF versus placebo), Outcome 4: Proportion reaching target haemoglobin </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013751.pub2/references#CD013751-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013751.pub2/media/CDSR/CD013751/image_n/nCD013751-CMP-002.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013751-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013751.pub2/media/CDSR/CD013751/urn:x-wiley:14651858:media:CD013751:CD013751-CMP-003.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Hypoxia‐inducible factor (HIF) stabiliser versus erythropoiesis‐stimulating agent (ESA), Outcome 1: Cardiovascular death" data-id="CD013751-fig-0022" src="/cdsr/doi/10.1002/14651858.CD013751.pub2/media/CDSR/CD013751/image_n/nCD013751-CMP-003.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013751.pub2/media/CDSR/CD013751/image_t/tCD013751-CMP-003.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3: Hypoxia‐inducible factor (HIF) stabiliser versus erythropoiesis‐stimulating agent (ESA), Outcome 1: Cardiovascular death </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013751.pub2/references#CD013751-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013751.pub2/media/CDSR/CD013751/image_n/nCD013751-CMP-003.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013751-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013751.pub2/media/CDSR/CD013751/urn:x-wiley:14651858:media:CD013751:CD013751-CMP-003.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Hypoxia‐inducible factor (HIF) stabiliser versus erythropoiesis‐stimulating agent (ESA), Outcome 2: Fatigue" data-id="CD013751-fig-0023" src="/cdsr/doi/10.1002/14651858.CD013751.pub2/media/CDSR/CD013751/image_n/nCD013751-CMP-003.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013751.pub2/media/CDSR/CD013751/image_t/tCD013751-CMP-003.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3: Hypoxia‐inducible factor (HIF) stabiliser versus erythropoiesis‐stimulating agent (ESA), Outcome 2: Fatigue </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013751.pub2/references#CD013751-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013751.pub2/media/CDSR/CD013751/image_n/nCD013751-CMP-003.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013751-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013751.pub2/media/CDSR/CD013751/urn:x-wiley:14651858:media:CD013751:CD013751-CMP-003.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Hypoxia‐inducible factor (HIF) stabiliser versus erythropoiesis‐stimulating agent (ESA), Outcome 3: Death (any cause)" data-id="CD013751-fig-0024" src="/cdsr/doi/10.1002/14651858.CD013751.pub2/media/CDSR/CD013751/image_n/nCD013751-CMP-003.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013751.pub2/media/CDSR/CD013751/image_t/tCD013751-CMP-003.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3: Hypoxia‐inducible factor (HIF) stabiliser versus erythropoiesis‐stimulating agent (ESA), Outcome 3: Death (any cause) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013751.pub2/references#CD013751-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013751.pub2/media/CDSR/CD013751/image_n/nCD013751-CMP-003.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013751-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013751.pub2/media/CDSR/CD013751/urn:x-wiley:14651858:media:CD013751:CD013751-CMP-003.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Hypoxia‐inducible factor (HIF) stabiliser versus erythropoiesis‐stimulating agent (ESA), Outcome 4: Nonfatal myocardial infarction" data-id="CD013751-fig-0025" src="/cdsr/doi/10.1002/14651858.CD013751.pub2/media/CDSR/CD013751/image_n/nCD013751-CMP-003.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013751.pub2/media/CDSR/CD013751/image_t/tCD013751-CMP-003.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.4</div> <div class="figure-caption"> <p>Comparison 3: Hypoxia‐inducible factor (HIF) stabiliser versus erythropoiesis‐stimulating agent (ESA), Outcome 4: Nonfatal myocardial infarction </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013751.pub2/references#CD013751-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013751.pub2/media/CDSR/CD013751/image_n/nCD013751-CMP-003.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013751-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013751.pub2/media/CDSR/CD013751/urn:x-wiley:14651858:media:CD013751:CD013751-CMP-003.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Hypoxia‐inducible factor (HIF) stabiliser versus erythropoiesis‐stimulating agent (ESA), Outcome 5: Fatal or nonfatal myocardial infarction (overall)" data-id="CD013751-fig-0026" src="/cdsr/doi/10.1002/14651858.CD013751.pub2/media/CDSR/CD013751/image_n/nCD013751-CMP-003.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013751.pub2/media/CDSR/CD013751/image_t/tCD013751-CMP-003.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.5</div> <div class="figure-caption"> <p>Comparison 3: Hypoxia‐inducible factor (HIF) stabiliser versus erythropoiesis‐stimulating agent (ESA), Outcome 5: Fatal or nonfatal myocardial infarction (overall) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013751.pub2/references#CD013751-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013751.pub2/media/CDSR/CD013751/image_n/nCD013751-CMP-003.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013751-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013751.pub2/media/CDSR/CD013751/urn:x-wiley:14651858:media:CD013751:CD013751-CMP-003.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Hypoxia‐inducible factor (HIF) stabiliser versus erythropoiesis‐stimulating agent (ESA), Outcome 6: Nonfatal stroke" data-id="CD013751-fig-0027" src="/cdsr/doi/10.1002/14651858.CD013751.pub2/media/CDSR/CD013751/image_n/nCD013751-CMP-003.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013751.pub2/media/CDSR/CD013751/image_t/tCD013751-CMP-003.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.6</div> <div class="figure-caption"> <p>Comparison 3: Hypoxia‐inducible factor (HIF) stabiliser versus erythropoiesis‐stimulating agent (ESA), Outcome 6: Nonfatal stroke </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013751.pub2/references#CD013751-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013751.pub2/media/CDSR/CD013751/image_n/nCD013751-CMP-003.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013751-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013751.pub2/media/CDSR/CD013751/urn:x-wiley:14651858:media:CD013751:CD013751-CMP-003.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Hypoxia‐inducible factor (HIF) stabiliser versus erythropoiesis‐stimulating agent (ESA), Outcome 7: Fatal or nonfatal stroke (overall)" data-id="CD013751-fig-0028" src="/cdsr/doi/10.1002/14651858.CD013751.pub2/media/CDSR/CD013751/image_n/nCD013751-CMP-003.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013751.pub2/media/CDSR/CD013751/image_t/tCD013751-CMP-003.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.7</div> <div class="figure-caption"> <p>Comparison 3: Hypoxia‐inducible factor (HIF) stabiliser versus erythropoiesis‐stimulating agent (ESA), Outcome 7: Fatal or nonfatal stroke (overall) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013751.pub2/references#CD013751-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013751.pub2/media/CDSR/CD013751/image_n/nCD013751-CMP-003.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013751-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013751.pub2/media/CDSR/CD013751/urn:x-wiley:14651858:media:CD013751:CD013751-CMP-003.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Hypoxia‐inducible factor (HIF) stabiliser versus erythropoiesis‐stimulating agent (ESA), Outcome 8: Nonfatal hospitalisation for heart failure" data-id="CD013751-fig-0029" src="/cdsr/doi/10.1002/14651858.CD013751.pub2/media/CDSR/CD013751/image_n/nCD013751-CMP-003.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013751.pub2/media/CDSR/CD013751/image_t/tCD013751-CMP-003.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.8</div> <div class="figure-caption"> <p>Comparison 3: Hypoxia‐inducible factor (HIF) stabiliser versus erythropoiesis‐stimulating agent (ESA), Outcome 8: Nonfatal hospitalisation for heart failure </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013751.pub2/references#CD013751-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013751.pub2/media/CDSR/CD013751/image_n/nCD013751-CMP-003.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013751-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013751.pub2/media/CDSR/CD013751/urn:x-wiley:14651858:media:CD013751:CD013751-CMP-003.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Hypoxia‐inducible factor (HIF) stabiliser versus erythropoiesis‐stimulating agent (ESA), Outcome 9: Fatal or nonfatal hospitalisation for heart failure" data-id="CD013751-fig-0030" src="/cdsr/doi/10.1002/14651858.CD013751.pub2/media/CDSR/CD013751/image_n/nCD013751-CMP-003.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013751.pub2/media/CDSR/CD013751/image_t/tCD013751-CMP-003.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.9</div> <div class="figure-caption"> <p>Comparison 3: Hypoxia‐inducible factor (HIF) stabiliser versus erythropoiesis‐stimulating agent (ESA), Outcome 9: Fatal or nonfatal hospitalisation for heart failure </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013751.pub2/references#CD013751-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013751.pub2/media/CDSR/CD013751/image_n/nCD013751-CMP-003.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013751-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013751.pub2/media/CDSR/CD013751/urn:x-wiley:14651858:media:CD013751:CD013751-CMP-003.10" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Hypoxia‐inducible factor (HIF) stabiliser versus erythropoiesis‐stimulating agent (ESA), Outcome 10: Peripheral arterial event" data-id="CD013751-fig-0031" src="/cdsr/doi/10.1002/14651858.CD013751.pub2/media/CDSR/CD013751/image_n/nCD013751-CMP-003.10.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013751.pub2/media/CDSR/CD013751/image_t/tCD013751-CMP-003.10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.10</div> <div class="figure-caption"> <p>Comparison 3: Hypoxia‐inducible factor (HIF) stabiliser versus erythropoiesis‐stimulating agent (ESA), Outcome 10: Peripheral arterial event </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013751.pub2/references#CD013751-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013751.pub2/media/CDSR/CD013751/image_n/nCD013751-CMP-003.10.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013751-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013751.pub2/media/CDSR/CD013751/urn:x-wiley:14651858:media:CD013751:CD013751-CMP-003.11" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Hypoxia‐inducible factor (HIF) stabiliser versus erythropoiesis‐stimulating agent (ESA), Outcome 11: Transfusion" data-id="CD013751-fig-0032" src="/cdsr/doi/10.1002/14651858.CD013751.pub2/media/CDSR/CD013751/image_n/nCD013751-CMP-003.11.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013751.pub2/media/CDSR/CD013751/image_t/tCD013751-CMP-003.11.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.11</div> <div class="figure-caption"> <p>Comparison 3: Hypoxia‐inducible factor (HIF) stabiliser versus erythropoiesis‐stimulating agent (ESA), Outcome 11: Transfusion </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013751.pub2/references#CD013751-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013751.pub2/media/CDSR/CD013751/image_n/nCD013751-CMP-003.11.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013751-fig-0033"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013751.pub2/media/CDSR/CD013751/urn:x-wiley:14651858:media:CD013751:CD013751-CMP-003.12" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Hypoxia‐inducible factor (HIF) stabiliser versus erythropoiesis‐stimulating agent (ESA), Outcome 12: Proportion reaching target haemoglobin" data-id="CD013751-fig-0033" src="/cdsr/doi/10.1002/14651858.CD013751.pub2/media/CDSR/CD013751/image_n/nCD013751-CMP-003.12.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013751.pub2/media/CDSR/CD013751/image_t/tCD013751-CMP-003.12.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.12</div> <div class="figure-caption"> <p>Comparison 3: Hypoxia‐inducible factor (HIF) stabiliser versus erythropoiesis‐stimulating agent (ESA), Outcome 12: Proportion reaching target haemoglobin </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013751.pub2/references#CD013751-fig-0033">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013751.pub2/media/CDSR/CD013751/image_n/nCD013751-CMP-003.12.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013751-fig-0034"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013751.pub2/media/CDSR/CD013751/urn:x-wiley:14651858:media:CD013751:CD013751-CMP-003.13" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Hypoxia‐inducible factor (HIF) stabiliser versus erythropoiesis‐stimulating agent (ESA), Outcome 13: Kidney failure" data-id="CD013751-fig-0034" src="/cdsr/doi/10.1002/14651858.CD013751.pub2/media/CDSR/CD013751/image_n/nCD013751-CMP-003.13.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013751.pub2/media/CDSR/CD013751/image_t/tCD013751-CMP-003.13.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.13</div> <div class="figure-caption"> <p>Comparison 3: Hypoxia‐inducible factor (HIF) stabiliser versus erythropoiesis‐stimulating agent (ESA), Outcome 13: Kidney failure </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013751.pub2/references#CD013751-fig-0034">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013751.pub2/media/CDSR/CD013751/image_n/nCD013751-CMP-003.13.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013751-fig-0035"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013751.pub2/media/CDSR/CD013751/urn:x-wiley:14651858:media:CD013751:CD013751-CMP-003.14" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Hypoxia‐inducible factor (HIF) stabiliser versus erythropoiesis‐stimulating agent (ESA), Outcome 14: Thrombosis" data-id="CD013751-fig-0035" src="/cdsr/doi/10.1002/14651858.CD013751.pub2/media/CDSR/CD013751/image_n/nCD013751-CMP-003.14.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013751.pub2/media/CDSR/CD013751/image_t/tCD013751-CMP-003.14.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.14</div> <div class="figure-caption"> <p>Comparison 3: Hypoxia‐inducible factor (HIF) stabiliser versus erythropoiesis‐stimulating agent (ESA), Outcome 14: Thrombosis </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013751.pub2/references#CD013751-fig-0035">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013751.pub2/media/CDSR/CD013751/image_n/nCD013751-CMP-003.14.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013751-fig-0036"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013751.pub2/media/CDSR/CD013751/urn:x-wiley:14651858:media:CD013751:CD013751-CMP-003.15" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Hypoxia‐inducible factor (HIF) stabiliser versus erythropoiesis‐stimulating agent (ESA), Outcome 15: Loss of unassisted patency (occlusion/stenosis)" data-id="CD013751-fig-0036" src="/cdsr/doi/10.1002/14651858.CD013751.pub2/media/CDSR/CD013751/image_n/nCD013751-CMP-003.15.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013751.pub2/media/CDSR/CD013751/image_t/tCD013751-CMP-003.15.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.15</div> <div class="figure-caption"> <p>Comparison 3: Hypoxia‐inducible factor (HIF) stabiliser versus erythropoiesis‐stimulating agent (ESA), Outcome 15: Loss of unassisted patency (occlusion/stenosis) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013751.pub2/references#CD013751-fig-0036">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013751.pub2/media/CDSR/CD013751/image_n/nCD013751-CMP-003.15.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013751-fig-0037"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013751.pub2/media/CDSR/CD013751/urn:x-wiley:14651858:media:CD013751:CD013751-CMP-003.16" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Hypoxia‐inducible factor (HIF) stabiliser versus erythropoiesis‐stimulating agent (ESA), Outcome 16: Access intervention" data-id="CD013751-fig-0037" src="/cdsr/doi/10.1002/14651858.CD013751.pub2/media/CDSR/CD013751/image_n/nCD013751-CMP-003.16.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013751.pub2/media/CDSR/CD013751/image_t/tCD013751-CMP-003.16.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.16</div> <div class="figure-caption"> <p>Comparison 3: Hypoxia‐inducible factor (HIF) stabiliser versus erythropoiesis‐stimulating agent (ESA), Outcome 16: Access intervention </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013751.pub2/references#CD013751-fig-0037">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013751.pub2/media/CDSR/CD013751/image_n/nCD013751-CMP-003.16.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013751-fig-0038"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013751.pub2/media/CDSR/CD013751/urn:x-wiley:14651858:media:CD013751:CD013751-CMP-003.17" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Hypoxia‐inducible factor (HIF) stabiliser versus erythropoiesis‐stimulating agent (ESA), Outcome 17: Cancer" data-id="CD013751-fig-0038" src="/cdsr/doi/10.1002/14651858.CD013751.pub2/media/CDSR/CD013751/image_n/nCD013751-CMP-003.17.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013751.pub2/media/CDSR/CD013751/image_t/tCD013751-CMP-003.17.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.17</div> <div class="figure-caption"> <p>Comparison 3: Hypoxia‐inducible factor (HIF) stabiliser versus erythropoiesis‐stimulating agent (ESA), Outcome 17: Cancer </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013751.pub2/references#CD013751-fig-0038">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013751.pub2/media/CDSR/CD013751/image_n/nCD013751-CMP-003.17.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013751-fig-0039"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013751.pub2/media/CDSR/CD013751/urn:x-wiley:14651858:media:CD013751:CD013751-CMP-003.18" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Hypoxia‐inducible factor (HIF) stabiliser versus erythropoiesis‐stimulating agent (ESA), Outcome 18: Infection" data-id="CD013751-fig-0039" src="/cdsr/doi/10.1002/14651858.CD013751.pub2/media/CDSR/CD013751/image_n/nCD013751-CMP-003.18.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013751.pub2/media/CDSR/CD013751/image_t/tCD013751-CMP-003.18.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.18</div> <div class="figure-caption"> <p>Comparison 3: Hypoxia‐inducible factor (HIF) stabiliser versus erythropoiesis‐stimulating agent (ESA), Outcome 18: Infection </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013751.pub2/references#CD013751-fig-0039">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013751.pub2/media/CDSR/CD013751/image_n/nCD013751-CMP-003.18.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013751-fig-0040"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013751.pub2/media/CDSR/CD013751/urn:x-wiley:14651858:media:CD013751:CD013751-CMP-003.19" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Hypoxia‐inducible factor (HIF) stabiliser versus erythropoiesis‐stimulating agent (ESA), Outcome 19: Hyperkalaemia" data-id="CD013751-fig-0040" src="/cdsr/doi/10.1002/14651858.CD013751.pub2/media/CDSR/CD013751/image_n/nCD013751-CMP-003.19.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013751.pub2/media/CDSR/CD013751/image_t/tCD013751-CMP-003.19.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.19</div> <div class="figure-caption"> <p>Comparison 3: Hypoxia‐inducible factor (HIF) stabiliser versus erythropoiesis‐stimulating agent (ESA), Outcome 19: Hyperkalaemia </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013751.pub2/references#CD013751-fig-0040">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013751.pub2/media/CDSR/CD013751/image_n/nCD013751-CMP-003.19.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013751-fig-0041"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013751.pub2/media/CDSR/CD013751/urn:x-wiley:14651858:media:CD013751:CD013751-CMP-003.20" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Hypoxia‐inducible factor (HIF) stabiliser versus erythropoiesis‐stimulating agent (ESA), Outcome 20: Pulmonary hypertension" data-id="CD013751-fig-0041" src="/cdsr/doi/10.1002/14651858.CD013751.pub2/media/CDSR/CD013751/image_n/nCD013751-CMP-003.20.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013751.pub2/media/CDSR/CD013751/image_t/tCD013751-CMP-003.20.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.20</div> <div class="figure-caption"> <p>Comparison 3: Hypoxia‐inducible factor (HIF) stabiliser versus erythropoiesis‐stimulating agent (ESA), Outcome 20: Pulmonary hypertension </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013751.pub2/references#CD013751-fig-0041">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013751.pub2/media/CDSR/CD013751/image_n/nCD013751-CMP-003.20.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013751-fig-0042"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013751.pub2/media/CDSR/CD013751/urn:x-wiley:14651858:media:CD013751:CD013751-CMP-003.21" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Hypoxia‐inducible factor (HIF) stabiliser versus erythropoiesis‐stimulating agent (ESA), Outcome 21: Diabetic retinopathy" data-id="CD013751-fig-0042" src="/cdsr/doi/10.1002/14651858.CD013751.pub2/media/CDSR/CD013751/image_n/nCD013751-CMP-003.21.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013751.pub2/media/CDSR/CD013751/image_t/tCD013751-CMP-003.21.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.21</div> <div class="figure-caption"> <p>Comparison 3: Hypoxia‐inducible factor (HIF) stabiliser versus erythropoiesis‐stimulating agent (ESA), Outcome 21: Diabetic retinopathy </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013751.pub2/references#CD013751-fig-0042">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013751.pub2/media/CDSR/CD013751/image_n/nCD013751-CMP-003.21.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013751-fig-0043"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013751.pub2/media/CDSR/CD013751/urn:x-wiley:14651858:media:CD013751:CD013751-CMP-004.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Analyses for SOF table 2 stratifying by CKD stage (HIF versus ESA), Outcome 1: Cardiovascular death" data-id="CD013751-fig-0043" src="/cdsr/doi/10.1002/14651858.CD013751.pub2/media/CDSR/CD013751/image_n/nCD013751-CMP-004.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013751.pub2/media/CDSR/CD013751/image_t/tCD013751-CMP-004.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4: Analyses for SOF table 2 stratifying by CKD stage (HIF versus ESA), Outcome 1: Cardiovascular death </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013751.pub2/references#CD013751-fig-0043">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013751.pub2/media/CDSR/CD013751/image_n/nCD013751-CMP-004.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013751-fig-0044"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013751.pub2/media/CDSR/CD013751/urn:x-wiley:14651858:media:CD013751:CD013751-CMP-004.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Analyses for SOF table 2 stratifying by CKD stage (HIF versus ESA), Outcome 2: Fatigue" data-id="CD013751-fig-0044" src="/cdsr/doi/10.1002/14651858.CD013751.pub2/media/CDSR/CD013751/image_n/nCD013751-CMP-004.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013751.pub2/media/CDSR/CD013751/image_t/tCD013751-CMP-004.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4: Analyses for SOF table 2 stratifying by CKD stage (HIF versus ESA), Outcome 2: Fatigue </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013751.pub2/references#CD013751-fig-0044">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013751.pub2/media/CDSR/CD013751/image_n/nCD013751-CMP-004.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013751-fig-0045"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013751.pub2/media/CDSR/CD013751/urn:x-wiley:14651858:media:CD013751:CD013751-CMP-004.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Analyses for SOF table 2 stratifying by CKD stage (HIF versus ESA), Outcome 3: Nonfatal myocardial infarction" data-id="CD013751-fig-0045" src="/cdsr/doi/10.1002/14651858.CD013751.pub2/media/CDSR/CD013751/image_n/nCD013751-CMP-004.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013751.pub2/media/CDSR/CD013751/image_t/tCD013751-CMP-004.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.3</div> <div class="figure-caption"> <p>Comparison 4: Analyses for SOF table 2 stratifying by CKD stage (HIF versus ESA), Outcome 3: Nonfatal myocardial infarction </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013751.pub2/references#CD013751-fig-0045">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013751.pub2/media/CDSR/CD013751/image_n/nCD013751-CMP-004.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013751-fig-0046"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013751.pub2/media/CDSR/CD013751/urn:x-wiley:14651858:media:CD013751:CD013751-CMP-004.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Analyses for SOF table 2 stratifying by CKD stage (HIF versus ESA), Outcome 4: Nonfatal stroke" data-id="CD013751-fig-0046" src="/cdsr/doi/10.1002/14651858.CD013751.pub2/media/CDSR/CD013751/image_n/nCD013751-CMP-004.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013751.pub2/media/CDSR/CD013751/image_t/tCD013751-CMP-004.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.4</div> <div class="figure-caption"> <p>Comparison 4: Analyses for SOF table 2 stratifying by CKD stage (HIF versus ESA), Outcome 4: Nonfatal stroke </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013751.pub2/references#CD013751-fig-0046">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013751.pub2/media/CDSR/CD013751/image_n/nCD013751-CMP-004.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013751-fig-0047"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013751.pub2/media/CDSR/CD013751/urn:x-wiley:14651858:media:CD013751:CD013751-CMP-004.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Analyses for SOF table 2 stratifying by CKD stage (HIF versus ESA), Outcome 5: Transfusion" data-id="CD013751-fig-0047" src="/cdsr/doi/10.1002/14651858.CD013751.pub2/media/CDSR/CD013751/image_n/nCD013751-CMP-004.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013751.pub2/media/CDSR/CD013751/image_t/tCD013751-CMP-004.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.5</div> <div class="figure-caption"> <p>Comparison 4: Analyses for SOF table 2 stratifying by CKD stage (HIF versus ESA), Outcome 5: Transfusion </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013751.pub2/references#CD013751-fig-0047">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013751.pub2/media/CDSR/CD013751/image_n/nCD013751-CMP-004.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013751-fig-0048"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013751.pub2/media/CDSR/CD013751/urn:x-wiley:14651858:media:CD013751:CD013751-CMP-004.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Analyses for SOF table 2 stratifying by CKD stage (HIF versus ESA), Outcome 6: Proportion reaching target haemoglobin" data-id="CD013751-fig-0048" src="/cdsr/doi/10.1002/14651858.CD013751.pub2/media/CDSR/CD013751/image_n/nCD013751-CMP-004.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013751.pub2/media/CDSR/CD013751/image_t/tCD013751-CMP-004.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.6</div> <div class="figure-caption"> <p>Comparison 4: Analyses for SOF table 2 stratifying by CKD stage (HIF versus ESA), Outcome 6: Proportion reaching target haemoglobin </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013751.pub2/references#CD013751-fig-0048">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013751.pub2/media/CDSR/CD013751/image_n/nCD013751-CMP-004.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013751-fig-0049"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013751.pub2/media/CDSR/CD013751/urn:x-wiley:14651858:media:CD013751:CD013751-CMP-005.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Subgroup analysis: stage CKD (HIF versus ESA), Outcome 1: Proportion reaching target haemoglobin" data-id="CD013751-fig-0049" src="/cdsr/doi/10.1002/14651858.CD013751.pub2/media/CDSR/CD013751/image_n/nCD013751-CMP-005.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013751.pub2/media/CDSR/CD013751/image_t/tCD013751-CMP-005.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.1</div> <div class="figure-caption"> <p>Comparison 5: Subgroup analysis: stage CKD (HIF versus ESA), Outcome 1: Proportion reaching target haemoglobin </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013751.pub2/references#CD013751-fig-0049">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013751.pub2/media/CDSR/CD013751/image_n/nCD013751-CMP-005.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013751-fig-0050"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013751.pub2/media/CDSR/CD013751/urn:x-wiley:14651858:media:CD013751:CD013751-CMP-005.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Subgroup analysis: stage CKD (HIF versus ESA), Outcome 2: Thrombosis" data-id="CD013751-fig-0050" src="/cdsr/doi/10.1002/14651858.CD013751.pub2/media/CDSR/CD013751/image_n/nCD013751-CMP-005.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013751.pub2/media/CDSR/CD013751/image_t/tCD013751-CMP-005.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.2</div> <div class="figure-caption"> <p>Comparison 5: Subgroup analysis: stage CKD (HIF versus ESA), Outcome 2: Thrombosis</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013751.pub2/references#CD013751-fig-0050">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013751.pub2/media/CDSR/CD013751/image_n/nCD013751-CMP-005.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013751-fig-0051"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013751.pub2/media/CDSR/CD013751/urn:x-wiley:14651858:media:CD013751:CD013751-CMP-006.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Subgroup analysis: duration of therapy (HIF versus ESA), Outcome 1: Proportion reaching target haemoglobin" data-id="CD013751-fig-0051" src="/cdsr/doi/10.1002/14651858.CD013751.pub2/media/CDSR/CD013751/image_n/nCD013751-CMP-006.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013751.pub2/media/CDSR/CD013751/image_t/tCD013751-CMP-006.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.1</div> <div class="figure-caption"> <p>Comparison 6: Subgroup analysis: duration of therapy (HIF versus ESA), Outcome 1: Proportion reaching target haemoglobin </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013751.pub2/references#CD013751-fig-0051">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013751.pub2/media/CDSR/CD013751/image_n/nCD013751-CMP-006.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013751-fig-0052"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013751.pub2/media/CDSR/CD013751/urn:x-wiley:14651858:media:CD013751:CD013751-CMP-006.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Subgroup analysis: duration of therapy (HIF versus ESA), Outcome 2: Thrombosis" data-id="CD013751-fig-0052" src="/cdsr/doi/10.1002/14651858.CD013751.pub2/media/CDSR/CD013751/image_n/nCD013751-CMP-006.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013751.pub2/media/CDSR/CD013751/image_t/tCD013751-CMP-006.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.2</div> <div class="figure-caption"> <p>Comparison 6: Subgroup analysis: duration of therapy (HIF versus ESA), Outcome 2: Thrombosis </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013751.pub2/references#CD013751-fig-0052">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013751.pub2/media/CDSR/CD013751/image_n/nCD013751-CMP-006.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013751-fig-0053"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013751.pub2/media/CDSR/CD013751/urn:x-wiley:14651858:media:CD013751:CD013751-CMP-007.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Subgroup analysis: frequency of administration (HIF versus ESA), Outcome 1: Proportion reaching target haemoglobin" data-id="CD013751-fig-0053" src="/cdsr/doi/10.1002/14651858.CD013751.pub2/media/CDSR/CD013751/image_n/nCD013751-CMP-007.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013751.pub2/media/CDSR/CD013751/image_t/tCD013751-CMP-007.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.1</div> <div class="figure-caption"> <p>Comparison 7: Subgroup analysis: frequency of administration (HIF versus ESA), Outcome 1: Proportion reaching target haemoglobin </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013751.pub2/references#CD013751-fig-0053">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013751.pub2/media/CDSR/CD013751/image_n/nCD013751-CMP-007.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013751-fig-0054"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013751.pub2/media/CDSR/CD013751/urn:x-wiley:14651858:media:CD013751:CD013751-CMP-007.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Subgroup analysis: frequency of administration (HIF versus ESA), Outcome 2: Thrombosis" data-id="CD013751-fig-0054" src="/cdsr/doi/10.1002/14651858.CD013751.pub2/media/CDSR/CD013751/image_n/nCD013751-CMP-007.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013751.pub2/media/CDSR/CD013751/image_t/tCD013751-CMP-007.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.2</div> <div class="figure-caption"> <p>Comparison 7: Subgroup analysis: frequency of administration (HIF versus ESA), Outcome 2: Thrombosis </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013751.pub2/references#CD013751-fig-0054">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013751.pub2/media/CDSR/CD013751/image_n/nCD013751-CMP-007.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013751-fig-0055"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013751.pub2/media/CDSR/CD013751/urn:x-wiley:14651858:media:CD013751:CD013751-CMP-008.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 8: Subgroup analysis: phase 2 versus phase 3 studies (HIF versus ESA), Outcome 1: Proportion reaching target haemoglobin" data-id="CD013751-fig-0055" src="/cdsr/doi/10.1002/14651858.CD013751.pub2/media/CDSR/CD013751/image_n/nCD013751-CMP-008.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013751.pub2/media/CDSR/CD013751/image_t/tCD013751-CMP-008.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.1</div> <div class="figure-caption"> <p>Comparison 8: Subgroup analysis: phase 2 versus phase 3 studies (HIF versus ESA), Outcome 1: Proportion reaching target haemoglobin </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013751.pub2/references#CD013751-fig-0055">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013751.pub2/media/CDSR/CD013751/image_n/nCD013751-CMP-008.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013751-fig-0056"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013751.pub2/media/CDSR/CD013751/urn:x-wiley:14651858:media:CD013751:CD013751-CMP-008.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 8: Subgroup analysis: phase 2 versus phase 3 studies (HIF versus ESA), Outcome 2: Thrombosis" data-id="CD013751-fig-0056" src="/cdsr/doi/10.1002/14651858.CD013751.pub2/media/CDSR/CD013751/image_n/nCD013751-CMP-008.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013751.pub2/media/CDSR/CD013751/image_t/tCD013751-CMP-008.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.2</div> <div class="figure-caption"> <p>Comparison 8: Subgroup analysis: phase 2 versus phase 3 studies (HIF versus ESA), Outcome 2: Thrombosis </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013751.pub2/references#CD013751-fig-0056">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013751.pub2/media/CDSR/CD013751/image_n/nCD013751-CMP-008.02.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD013751-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Hypoxia‐inducible factor (HIF) stabilisers versus placebo for people with chronic kidney disease (CKD)</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>HIF stabilisers versus placebo for people with CKD</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population</b>: people with CKD (including HD and PD) </p> <p><b>Settings</b>: multinational </p> <p><b>Intervention</b>: HIF stabilisers </p> <p><b>Comparison</b>: placebo </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>No. of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>HIF stabilisers</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Cardiovascular death</b> </p> <p>Median follow‐up:</p> <p>16 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Low risk population (CKD)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 3.68</b> </p> <p>(0.19 to 70.21)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>1114 (10)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low</b><sup>1,2,3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Studies were not designed to measure effects of HIF stabiliser management of anaemia on CV death compared with placebo in CKD and HD </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>No events</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>3/607**</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>High risk population (HD)</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>No events</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>No events</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Fatigue</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No studies reported this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Life participation</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No studies reported this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Nonfatal myocardial</b> </p> <p><b>infarction</b> </p> <p>Median follow‐up:</p> <p>24 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Low risk population (CKD)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.29</b> </p> <p>(0.31 to</p> <p>5.36)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>822 (3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low</b><sup>1,2,4</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>The effects of HIF stabiliser management of anaemia on nonfatal MI were uncertain compared with placebo in CKD </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>8 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>2 more per 1000</b> </p> <p>(from 6 fewer</p> <p>to 35 more)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Nonfatal stroke</b> </p> <p>Median follow‐up:</p> <p>21 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Low risk population (CKD)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>228 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low</b><sup>1,2,4</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Studies were not designed to measure effects of HIF stabiliser management of anaemia on nonfatal stroke compared with placebo in CKD </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>No events</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>No events</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Proportion of patients requiring blood transfusion</b> </p> <p>Median follow‐up:</p> <p>18 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Low risk population (CKD)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.51</b> (0.44 to 0.60) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>4329 (8)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝<br/><b>moderate</b><sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>HIF stabiliser management of anaemia probably decreases the proportion of patients requiring blood transfusion compared to placebo in CKD and HD </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>200 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>96 fewer per 1000</b><br/>(from 112 fewer to 80 fewer) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>High risk population (HD)</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>214 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>169 fewer per 1000</b><br/>(206 fewer to 30 more) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Proportion reaching target haemoglobin</b> </p> <p>Median follow‐up:</p> <p>16 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Low risk population (CKD)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 8.36</b> (6.42 to 10.89) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>5102 (10)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝<br/><b>moderate</b><sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>HIF stabiliser management of anaemia probably increases the proportion of patients reaching their Hb target compared to placebo in CKD and HD </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>83 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>594 more per 1000</b><br/>(424 more to 821 more) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>High risk population (CKD and HD)</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>No events</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>63/141**</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p>** Event rate derived from the raw data. A 'per thousand' rate is non‐informative in view of the scarcity of evidence and zero events in the control group </p> <p><b>HD:</b> haemodialysis; <b>PD:</b> peritoneal dialysis; <b>CI</b> : confidence interval; <b>RR</b>: risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Evidence certainty was downgraded by one level due to study limitations. Some studies had unclear risks for sequence generation and/or allocation concealment and the majority or all of them were not blinded (participant/investigator and/or outcomes assessor). All studies reported sources of funding </p> <p><sup>2</sup> Evidence certainty was downgraded by one level due to imprecision </p> <p><sup>3</sup> Evidence certainty was downgraded by one level due to indirectness in the study population </p> <p><sup>4</sup> Evidence certainty was downgraded by one level due to imprecision (optimal information size was not met and the included studies reported zero events) </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Hypoxia‐inducible factor (HIF) stabilisers versus placebo for people with chronic kidney disease (CKD)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013751.pub2/full#CD013751-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD013751-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Hypoxia‐inducible factor (HIF) stabilisers versus erythropoiesis‐stimulating agent (ESA) for people with chronic kidney disease (CKD)</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>HIF stabilisers versus ESA for people with CKD</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population</b>: people with CKD (including HD and PD) </p> <p><b>Settings</b>: multinational </p> <p><b>Intervention</b>: HIF stabilisers </p> <p><b>Comparison</b>: ESA </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>No. of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>ESA</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>HIF stabilisers</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Cardiovascular death</b> </p> <p>Median follow‐up:</p> <p>28 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Low risk population (CKD)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 1.05</b> </p> <p>(0.88 to 1.26)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>10,340 (17)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/><b>low</b><sup>1,2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>HIF stabiliser management of anaemia may have little or no difference on CV death compared with ESA in CKD </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>34 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>6 more per 1000</b><br/>(from 3 fewer </p> <p>to 18 more)</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>High risk population (HD and PD)</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>77 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>3 fewer per 1000</b><br/>(from 19 fewer </p> <p>to 17 more)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Fatigue</b> </p> <p>Median follow‐up:</p> <p>57 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Low risk population (CKD)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.80</b> </p> <p>(0.56 to 1.16)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>3471 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low</b><sup>1,2,3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>HIF stabiliser management of anaemia had uncertain effects on fatigue compared with ESA in CKD </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>36 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>7 fewer per 1000</b><br/>(from 16 fewer </p> <p>to 6 more)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Life participation</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No studies reported this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Nonfatal</b> </p> <p><b>myocardial</b> </p> <p><b>infarction</b> </p> <p>Median follow‐up:</p> <p>26 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Low risk population (CKD)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.91</b> </p> <p>(0.76 to 1.10)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>7765 (7)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/><b>low</b><sup>1,2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>HIF stabiliser management of anaemia may have little or no difference on nonfatal MI compared with ESA in CKD, HD and PD </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>46 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>3 more per 1000</b><br/>(from 9 fewer </p> <p>to 18 more)</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>High risk population (HD and PD)</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>80 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>16 fewer per 1000</b><br/>(from 30 fewer to 2 more) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Nonfatal stroke</b> </p> <p>Median follow‐up:</p> <p>28 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Low risk population (CKD)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 1.06</b> </p> <p>(0.71 to 1.56)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>7285 (5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/><b>low</b><sup>1,2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>HIF stabiliser management of anaemia may have little or no difference on nonfatal stroke compared with ESA in CKD, HD and PD </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>10 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>5 more per 1000</b><br/>(from 1 fewer </p> <p>to 16 more)</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>High risk population (HD)</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>24 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>5 fewer per 1000</b><br/>(from 12 fewer to 8 more) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Proportion of patients requiring blood transfusion</b> </p> <p>Median follow‐up:</p> <p>52 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Low risk population (CKD)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.87</b> (0.76 to 1.00) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>10786 (11)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝<br/><b>moderate</b><sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>HIF stabiliser management of anaemia probably decreases the proportion of patients requiring blood transfusion compared to ESA in CKD, HD and PD </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>121 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>4 fewer per 1000</b><br/>(19 fewer to 16 more) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>High risk population (HD)</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>154 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>31 fewer per 1000</b><br/>(55 fewer to 2 more) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Proportion reaching target haemoglobin</b> </p> <p>Median follow‐up:</p> <p>27 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Low risk population (CKD)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 1.00</b> (0.93 to 1.07) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>4601 (14)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/><b>low</b><sup>1,2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>HIF stabiliser management of anaemia may have little or no difference on the proportion of patients reaching their Hb target compared to ESA in CKD, HD and PD </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>793 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>16 more per 1000</b><br/>(79 fewer to 127 more) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>High risk population (HD and PD)</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>540 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>11 fewer per 1000</b><br/>(49 fewer to 32 more) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% CI is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>HD:</b> haemodialysis; <b>PD:</b> peritoneal dialysis; <b>CI</b> : confidence interval; <b>RR</b>: risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Evidence certainty was downgraded by one level due to study limitations. Some studies had unclear risks for sequence generation and/or allocation concealment and the majority or all of them were not blinded (participant/investigator and/or outcomes assessor). All studies reported sources of funding </p> <p><sup>2</sup> Evidence certainty was downgraded by one level due to imprecision </p> <p><sup>3</sup> Evidence certainty was downgraded by one level because similar studies assessed the outcomes </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Hypoxia‐inducible factor (HIF) stabilisers versus erythropoiesis‐stimulating agent (ESA) for people with chronic kidney disease (CKD)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013751.pub2/full#CD013751-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD013751-tbl-0003"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Hypoxia‐inducible factor (HIF) stabiliser versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 Cardiovascular death <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.1 Low‐dose HIF</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>349</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.2 Medium‐dose HIF</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>563</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.68 [0.19, 70.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.3 High‐dose HIF</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>508</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.4 Overall dose HIF</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1114</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.68 [0.19, 70.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 Death (any cause) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.1 Low‐dose HIF</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>349</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.2 Medium‐dose HIF</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3918</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.12 [0.97, 1.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.3 High‐dose HIF</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>508</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.4 Overall dose HIF</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4469</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.12 [0.97, 1.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.3 Nonfatal myocardial infarction <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.1 Low‐dose HIF</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>93</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.2 Medium‐dose HIF</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>707</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.56 [0.32, 7.65]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.3 High‐dose HIF</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>116</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.47 [0.06, 34.46]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.4 Overall dose HIF</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>822</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.29 [0.31, 5.36]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.4 Fatal or nonfatal myocardial infarction (overall) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.1 Low‐dose HIF</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>93</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.2 Medium‐dose HIF</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4384</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.08 [0.60, 1.96]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.3 High‐dose HIF</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>116</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.47 [0.06, 34.46]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.4 Overall dose HIF</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4499</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.06 [0.59, 1.90]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.5 Nonfatal stroke <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.1 Low‐dose HIF</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>93</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.2 Medium‐dose HIF</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>113</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.3 High‐dose HIF</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>116</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.4 Overall dose HIF</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>228</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.6 Fatal or nonfatal stroke (overall) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6.1 Low‐dose HIF</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>93</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6.2 Medium‐dose HIF</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>707</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.08 [0.23, 18.46]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6.3 High‐dose HIF</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>116</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6.4 Overall dose HIF</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>822</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.08 [0.23, 18.46]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.7 Peripheral arterial events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7.1 Low‐dose HIF</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.35 [0.02, 8.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7.2 Medium‐dose HIF</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.50 [0.03, 7.59]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7.3 High‐dose HIF</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>62</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.16 [0.01, 3.83]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7.4 Overall dose HIF</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>121</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.20 [0.01, 3.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.8 Transfusion <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.8.1 Low‐dose HIF</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>205</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.79 [0.23, 2.79]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.8.2 Medium‐dose HIF</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4077</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.49 [0.38, 0.62]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.8.3 High‐dose HIF</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>229</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.58 [0.15, 2.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.8.4 Overall dose HIF</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4329</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.51 [0.44, 0.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.9 Proportion reaching target haemoglobin <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.9.1 Low‐dose HIF</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>197</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.16 [2.28, 7.59]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.9.2 Medium‐dose HIF</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4698</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>9.36 [8.06, 10.86]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.9.3 High‐dose HIF</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>351</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>7.16 [3.62, 14.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.9.4 Overall dose HIF</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5102</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>8.36 [6.42, 10.89]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.10 Kidney failure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.10.1 Low‐dose HIF</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>191</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.12 [0.46, 9.82]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.10.2 Medium‐dose HIF</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1855</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.23 [0.94, 1.62]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.10.3 High‐dose HIF</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>324</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.63 [0.43, 6.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.10.4 Overall dose HIF</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2228</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.22 [0.98, 1.51]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.11 Thrombosis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3452</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.36 [1.19, 4.66]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.11.1 Medium‐dose HIF</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3452</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.36 [1.19, 4.66]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.12 Loss of unassisted patency (stenosis) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.12.1 Low‐dose HIF</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.12.2 Medium‐dose HIF</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>127</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.52 [0.16, 14.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.12.3 High‐dose HIF</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.00 [0.13, 68.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.12.4 Overall dose HIF</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>157</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.18 [0.13, 10.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.13 Hyperkalaemia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.13.1 Low‐dose HIF</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>99</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.21, 3.42]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.13.2 Medium‐dose HIF</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4541</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.28 [1.04, 1.56]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.13.3 High‐dose HIF</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>275</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.26, 3.84]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.13.4 Overall dose HIF</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4845</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.29 [1.01, 1.64]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Hypoxia‐inducible factor (HIF) stabiliser versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013751.pub2/references#CD013751-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD013751-tbl-0004"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Analyses for SOF table 1 stratifying by CKD stage (HIF versus placebo)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.1 Cardiovascular death <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1114</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.68 [0.19, 70.21]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.1 CKD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>850</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.68 [0.19, 70.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.2 HD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>157</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.3 CKD and HD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>107</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.2 Nonfatal myocardial infarction <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>822</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.29 [0.31, 5.36]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2.1 CKD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>822</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.29 [0.31, 5.36]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.3 Transfusion <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4329</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.51 [0.44, 0.60]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3.1 CKD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4271</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.52 [0.44, 0.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3.2 HD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.21 [0.04, 1.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.4 Proportion reaching target haemoglobin <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5102</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>8.36 [6.42, 10.89]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4.1 CKD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4931</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>8.18 [6.13, 10.93]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4.2 CKD and HD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>171</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>14.35 [2.07, 99.61]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Analyses for SOF table 1 stratifying by CKD stage (HIF versus placebo)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013751.pub2/references#CD013751-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD013751-tbl-0005"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Hypoxia‐inducible factor (HIF) stabiliser versus erythropoiesis‐stimulating agent (ESA)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.1 Cardiovascular death <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1.1 Low‐dose HIF</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>981</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.14, 6.41]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1.2 Medium‐dose HIF</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>7442</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.06 [0.88, 1.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1.3 High‐dose HIF</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2067</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.11 [0.31, 3.96]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1.4 Overall dose HIF</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>10340</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [0.88, 1.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.2 Fatigue <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3471</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [0.56, 1.16]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2.1 Medium‐dose HIF</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3471</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [0.56, 1.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.3 Death (any cause) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3.1 Low‐dose HIF</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1295</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.33, 2.75]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3.2 Medium‐dose HIF</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>15586</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.88, 1.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3.3 High‐dose HIF</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4745</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.63, 1.37]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3.4 Overall dose HIF</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>21370</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.91, 1.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.4 Nonfatal myocardial infarction <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.4.1 Low‐dose HIF</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>148</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.4.2 Medium‐dose HIF</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>7153</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.72, 1.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.4.3 High‐dose HIF</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>612</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.90 [0.31, 11.54]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.4.4 Overall dose HIF</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>7765</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.76, 1.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.5 Fatal or nonfatal myocardial infarction (overall) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.5.1 Low‐dose HIF</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>148</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.5.2 Medium‐dose HIF</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>10949</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.78, 1.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.5.3 High‐dose HIF</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3234</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.22 [0.68, 2.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.5.4 Overall dose HIF</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>14183</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.80, 1.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.6 Nonfatal stroke <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.6.1 Low‐dose HIF</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>336</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.78 [0.24, 96.68]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.6.2 Medium‐dose HIF</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6918</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.07 [0.62, 1.83]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.6.3 High‐dose HIF</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>115</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.6.4 Overall dose HIF</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>7285</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.06 [0.71, 1.56]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.7 Fatal or nonfatal stroke (overall) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.7.1 Low‐dose HIF</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>398</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.37 [0.11, 17.51]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.7.2 Medium‐dose HIF</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6980</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.70, 1.50]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.7.3 High‐dose HIF</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>795</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.49 [0.16, 1.53]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.7.4 Overall dose HIF</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8025</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.64, 1.40]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.8 Nonfatal hospitalisation for heart failure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6836</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.23 [1.00, 1.52]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.8.1 Medium‐dose HIF</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6836</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.23 [1.00, 1.52]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.9 Fatal or nonfatal hospitalisation for heart failure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.9.1 Medium‐dose HIF</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6836</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.16 [0.98, 1.39]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.9.2 High‐dose HIF</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>616</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.59, 1.79]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.9.3 Overall dose HIF</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>7452</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.15 [0.97, 1.36]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.10 Peripheral arterial event <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.10.1 Low‐dose HIF</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>148</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.10.2 Medium‐dose HIF</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>144</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.10.3 High‐dose HIF</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>179</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.10.4 Overall dose HIF</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>323</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.11 Transfusion <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.11.1 Low‐dose HIF</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>192</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.04 [0.23, 4.75]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.11.2 Medium‐dose HIF</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>7343</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.81, 1.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.11.3 High‐dose HIF</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3443</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.62, 1.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.11.4 Overall dose HIF</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>10786</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.76, 1.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.12 Proportion reaching target haemoglobin <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.12.1 Low‐dose HIF</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>861</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.91, 1.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.12.2 Medium‐dose HIF</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>507</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.69, 1.29]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.12.3 High‐dose HIF</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3425</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.91, 1.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.12.4 Overall dose HIF</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4601</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.93, 1.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.13 Kidney failure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.13.1 Low‐dose HIF</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>361</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.14 [0.20, 6.43]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.13.2 Medium‐dose HIF</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6647</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.91, 1.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.13.3 High‐dose HIF</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>368</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.88 [0.89, 53.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.13.4 Overall dose HIF</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>7312</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.91, 1.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.14 Thrombosis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.14.1 Medium‐dose HIF</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>14532</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.71, 1.37]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.14.2 High‐dose HIF</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2494</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.35 [0.99, 1.83]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.14.3 Overall dose HIF</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>17026</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.09 [0.86, 1.39]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.15 Loss of unassisted patency (occlusion/stenosis) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.15.1 Low‐dose HIF</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>271</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.53, 1.69]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.15.2 Medium‐dose HIF</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>800</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.65 [0.29, 1.47]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.15.3 High‐dose HIF</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1874</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.51 [0.99, 2.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.15.4 Overall dose HIF</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2945</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.16 [0.85, 1.59]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.16 Access intervention <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.16.1 High‐dose HIF</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.17 Cancer <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.17.1 Low‐dose HIF</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>515</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.57 [0.10, 3.35]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.17.2 Medium‐dose HIF</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>641</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.65 [0.24, 1.74]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.17.3 High‐dose HIF</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>531</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.13, 5.85]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.17.4 Overall dose HIF</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1687</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.83 [0.43, 1.59]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.18 Infection <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.18.1 High‐dose HIF</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.19 Hyperkalaemia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.19.1 Low‐dose HIF</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>570</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.72 [0.77, 3.85]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.19.2 Medium‐dose HIF</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>15152</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.82, 1.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.19.3 High‐dose HIF</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4455</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.68, 1.50]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.19.4 Overall dose HIF</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20177</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.82, 1.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.20 Pulmonary hypertension <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.20.1 Low‐dose HIF</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>570</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.98 [0.12, 72.46]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.20.2 Medium‐dose HIF</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>7455</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.13 [0.51, 2.47]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.20.3 High‐dose HIF</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>616</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.30 [0.03, 2.89]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.20.4 Overall dose HIF</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8641</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.06 [0.56, 2.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.21 Diabetic retinopathy <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.21.1 Low‐dose HIF</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>299</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.01 [0.18, 21.97]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.21.2 Medium‐dose HIF</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4435</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.18 [0.65, 2.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.21.3 High‐dose HIF</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>302</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.04 [0.12, 74.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.21.4 Overall dose HIF</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5036</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.26 [0.71, 2.22]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Hypoxia‐inducible factor (HIF) stabiliser versus erythropoiesis‐stimulating agent (ESA)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013751.pub2/references#CD013751-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD013751-tbl-0006"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Analyses for SOF table 2 stratifying by CKD stage (HIF versus ESA)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.1 Cardiovascular death <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>10340</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [0.88, 1.26]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1.1 CKD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5591</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.19 [0.91, 1.55]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1.2 HD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1352</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.23, 4.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1.3 PD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>129</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.50 [0.03, 7.80]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1.4 HD and PD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3268</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.75, 1.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.2 Fatigue <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3471</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [0.56, 1.16]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2.1 CKD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3471</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [0.56, 1.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.3 Nonfatal myocardial infarction <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>7765</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.76, 1.10]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3.1 CKD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3996</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [0.80, 1.39]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3.2 HD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>372</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.97 [0.22, 17.59]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3.3 PD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>129</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.52 [0.06, 36.48]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3.4 HD and PD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3268</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [0.62, 1.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.4 Nonfatal stroke <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>7285</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.06 [0.71, 1.56]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.4.1 CKD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4122</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.43 [0.82, 2.48]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.4.2 HD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>199</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.36 [0.07, 27.82]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.4.3 HD and PD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2964</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.82 [0.51, 1.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.5 Transfusion <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>10786</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.76, 1.00]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.5.1 CKD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4933</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.84, 1.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.5.2 HD and PD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5853</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [0.64, 1.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.6 Proportion reaching target haemoglobin <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4601</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.93, 1.07]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.6.1 CKD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1369</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.90, 1.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.6.2 HD and PD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3232</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.91, 1.06]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Analyses for SOF table 2 stratifying by CKD stage (HIF versus ESA)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013751.pub2/references#CD013751-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD013751-tbl-0007"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Subgroup analysis: stage CKD (HIF versus ESA)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.1 Proportion reaching target haemoglobin <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4601</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.93, 1.07]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1.1 CKD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1369</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.90, 1.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1.2 HD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1150</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.88, 1.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1.3 HD and PD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2082</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.86, 1.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.2 Thrombosis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>17026</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.09 [0.86, 1.39]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2.1 CKD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>7959</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.04 [0.59, 1.86]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2.2 HD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>323</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.06, 15.75]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2.3 HD and PD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8744</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.08 [0.81, 1.46]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Subgroup analysis: stage CKD (HIF versus ESA)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013751.pub2/references#CD013751-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD013751-tbl-0008"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Subgroup analysis: duration of therapy (HIF versus ESA)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.1 Proportion reaching target haemoglobin <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4601</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.93, 1.07]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1.1 From 8 to 23 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>405</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.67, 1.55]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1.2 From 24 to 53 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3392</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.92, 1.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1.3 At least 54 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>804</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.06 [0.89, 1.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.2 Thrombosis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>17026</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.09 [0.86, 1.39]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2.1 From 24 to 53 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5239</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.26 [0.87, 1.81]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2.2 At least 54 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>11787</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.04 [0.75, 1.43]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Subgroup analysis: duration of therapy (HIF versus ESA)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013751.pub2/references#CD013751-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD013751-tbl-0009"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">Subgroup analysis: frequency of administration (HIF versus ESA)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.1 Proportion reaching target haemoglobin <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4601</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.93, 1.07]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1.1 Once a day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1315</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.88, 1.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1.2 Three times a week</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3286</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.93, 1.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.2 Thrombosis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>17026</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.09 [0.86, 1.39]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2.1 Once daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>14532</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.71, 1.37]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2.2 Three times a week</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2494</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.35 [0.99, 1.83]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">Subgroup analysis: frequency of administration (HIF versus ESA)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013751.pub2/references#CD013751-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD013751-tbl-0010"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">Subgroup analysis: phase 2 versus phase 3 studies (HIF versus ESA)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8.1 Proportion reaching target haemoglobin <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4601</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.93, 1.07]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1.1 Phase 2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1356</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.10 [0.90, 1.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1.2 Phase 3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3245</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.91, 1.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8.2 Thrombosis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>17026</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.09 [0.86, 1.39]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2.1 Phase 2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>740</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.11 [0.60, 2.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2.2 Phase 3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>16286</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.09 [0.83, 1.42]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">Subgroup analysis: phase 2 versus phase 3 studies (HIF versus ESA)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013751.pub2/references#CD013751-tbl-0010">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD013751.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD013751-note-0014">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD013751-note-0012">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD013751-note-0013">Français</a> </li> <li class="section-language"> <a class="" href="hr#CD013751-note-0011">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ko#CD013751-note-0008">한국어</a> </li> <li class="section-language"> <a class="" href="ms#CD013751-note-0010">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pt#CD013751-note-0009">Português</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD013751-note-0007">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738735355000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738735355000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013751\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013751\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013751\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD013751\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013751\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013751\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013751\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013751\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013751\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD013751\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013751\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013751\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013751\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD013751\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013751\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013751\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013751\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD013751\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=na56WA6j&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD013751.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD013751.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD013751.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD013751.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD013751.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740724222330"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD013751.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740724222334"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD013751.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918e5d850f20f409',t:'MTc0MDcyNDIyMi4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 